Noble

Access DB# 162785

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: BEN SACKEY Examiner #: 73489 Date: 8/17/05
Art Unit: 1626 Phone Number 302-0704 Serial Number: 10/681,784
Mail Box and Bldg/Room Location: REM 5 3 3 1 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Sulfonamides having antiangiogenic & anticancer activity

Inventors (please provide full names): Comess et al.

Earliest Priority Filing Date: _____

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*



Elected Exampl:
5-ethyl-2-[(phenylsulfonyl)amino]benzoic acid

RECEIVED
AUG 17 2005
(STIC)

R^6 is H, alkyl

A is phenyl substituted

R^1 — H, alkyl, alkoxycarbonyl, amino, etc except heterocycle ....

R^2 — ; ✓ ✓ ✓ ✓ ✓

R^3 — ✓ ✓ ✓

R^4 — H, alkyl, alkenyl, alkylsulfonyl etc except the hets and NR_cR_d etc

****

STAFF USE ONLY	Type of Search		Vendors and cost where applicable	
Searcher: Noble	NA Sequence (#)		STN	[redacted]
Searcher Phone #:	AA Sequence (#)		Dialog	
Searcher Location:	Structure (#)	4 ✓	Questel/Orbit	
Date Searcher Picked Up:	Bibliographic	✓	Dr.Link	
Date Completed: 8/11/05	Litigation		Lexis/Nexis	
Searcher Prep & Review Time: 15	Fulltext		Sequence Systems	
Clerical Prep Time:	Patent Family		WWW/Internet	
Online Time: 55	Other		Other (specify)	

PTO-1590 (8-01)

STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 162735

TO: Ben Sackey **Location: 5b31 / 5c18** **Art Unit: 1626** **Thursday, September 01, 2005** **Case Serial Number: 10/681784**	**From: Noble Jarrell** **Location: Biotech-Chem Library** **Rem 1B71** **Phone: 272-2556** **Noble.jarrell@uspto.gov**

Search Notes

```
=> d his

     (FILE 'HOME' ENTERED AT 08:26:20 ON 01 SEP 2005)

     FILE 'HCAPLUS' ENTERED AT 08:26:28 ON 01 SEP 2005
L1            1 US2004167128/PN OR (US2003-681784# OR US2002-416793#)/AP,PRN

     FILE 'REGISTRY' ENTERED AT 08:27:16 ON 01 SEP 2005

     FILE 'HCAPLUS' ENTERED AT 08:27:16 ON 01 SEP 2005
L2              TRA L1 1- RN :     1111 TERMS

     FILE 'REGISTRY' ENTERED AT 08:27:17 ON 01 SEP 2005
L3          1111 SEA L2

     FILE 'WPIX' ENTERED AT 08:27:25 ON 01 SEP 2005
L4            1 L1

     FILE 'HCAPLUS' ENTERED AT 08:27:43 ON 01 SEP 2005

=> b hcap;d all l1 tot
FILE 'HCAPLUS' ENTERED AT 08:28:39 ON 01 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 1 Sep 2005  VOL 143 ISS 10
FILE LAST UPDATED: 31 Aug 2005  (20050831/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


L1   ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2005 ACS on STN
AN   2004:701804  HCAPLUS
DN   141:173972
ED   Entered STN:  27 Aug 2004
TI   Preparation of sulfonamides having antiangiogenic and anticancer activity
IN   Comess, Kenneth M.; Erickson, Scott A.; Henkin, Jack; Kalvin, Douglas M.;
     Kawai, Megumi; Kim, Ki H.; Bamaung, Nwe Y.; Park, Chang Hoon; Sheppard,
     George S.; Vasudevan, Anil; Wang, Jieyi; Barnes, David M.; Fidanze, Steve
     D.; Kolaczkowski, Lawrence; Mantei, Robert A.; Park, David C.; Sanders,
     William J.; Tedrow, Jason S.; Wang, Gary T.
PA   USA
SO   U.S. Pat. Appl. Publ., 127 pp.
     CODEN: USXXCO
DT   Patent
LA   English
IC   ICM  C07D279-12
     ICS  C07D277-04; A61K031-54; A61K031-537; A61K031-495
INCL 514227800; 514237500; 514255010; 514352000; 514370000; 514374000;
     514398000; 514423000; 544059000; 544162000
```

CC 25-17 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004167128	A1	20040826	US 2003-681784	20031008 <--
PRAI US 2002-416793P	P	20021008 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004167128	ICM	C07D279-12
	ICS	C07D277-04; A61K031-54; A61K031-537; A61K031-495
	INCL	514227800; 514237500; 514255010; 514352000; 514370000; 514374000; 514398000; 514423000; 544059000; 544162000
US 2004167128	NCL	514/227.800
	ECLA	C07D213/70B; C07D213/70C; C07D231/18 <--

OS MARPAT 141:173972
GI



I

AB The title compds. [I; A = 5-6 membered (non)aromatic ring containing 0-3 atoms selected from N, O, and S (wherein the ring is optionally fused to a second 5-7 membered (non)aromatic ring containing 0-3 atoms selected from N, O, and S); R1-R3 = H, alkenyl, alkoxy, etc.; R4 = H, alkyl, alkoxy, etc.; R5 = alkyl, NH2, aminoalkyl, aryl, etc.; R6 = H, alkyl, aryl, etc.; provided that when A = Ph, at least one of R1-R4 is other than H, alkyl, halo] having methionine aminopeptidase-2 inhibitory (MetAP2) activity, were prepared E.g., a multi-step synthesis of 5-ethyl-2-[(phenylsulfonyl)amino]benzoic acid, starting from 4-ethylaniline, was given. Representative compds. I had IC50's between about 0.005 μM and >100 μM against MetAP2. Also described are pharmaceutical compns. comprising the compds. I, methods of treatment using the compds. I, methods of inhibiting angiogenesis, and methods of treating cancer.

ST sulfonamide prepn antitumor angiogenesis inhibitor methionine aminopeptidase2 MetAP2; benzoic acid sulfonylamino prepn methionine aminopeptidase2 MetAP2 inhibitor; naphthoic acid phenylsulfonylamino prepn methionine aminopeptidase2 MetAP2 inhibitor

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(eukaryotic initiation factor-2-associated, p67; preparation of sulfonamides having antiangiogenic and anticancer activity)

IT Angiogenesis
(neovascularization, treatment of abnormal neovascularization; preparation of sulfonamides having antiangiogenic and anticancer activity)

IT Angiogenesis
Angiogenesis inhibitors
Antitumor agents
Neoplasm
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT 677290-81-2P, 2-[(Phenylsulfonyl)amino]-1-naphthoic acid 681241-27-0P, 2-[[(4-Fluorophenyl)sulfonyl]amino]-8-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681241-49-6P, 4-Bromo-2-[(phenylsulfonyl)amino]benzoic acid 681242-39-7P, 3-(3-Methoxy-3-

oxopropyl)-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoicaci
681242-51-3P 681242-97-7P, 2-[[(2-Nitrophenyl)sulfonyl]amino]-5,6,7,8-
tetrahydro-1-naphthalenecarboxylic acid 681243-18-5P,
2-[[(2-Aminophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-
naphthalenecarboxylic acid 681243-44-7P, 3-Ethyl-6-[[(2-
fluorophenyl)sulfonyl]amino]-2-methoxybenzoic acid 681243-56-1P,
2-([[2-([3-[(tert-Butoxycarbonyl)amino]propyl]amino)phenyl]sulfonyl]amino)-
5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-57-2P,
2-([[2-([3-[(tert-Butoxycarbonyl)(methyl)amino]propyl]amino)phenyl]sulfony
l]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681244-00-8P,
2-[[(2-[[2-(2-Pyridinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-
tetrahydro-1-naphthalenecarboxylic acid 681244-01-9P,
2-Ethoxy-3-ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]benzoic acid
681244-10-0P, 2-([[2-([[1-(tert-Butoxycarbonyl)-3-
piperidinyl]methyl]amino)phenyl]sulfonyl]amino]-5,6,7,8-tetrahydro-1-
naphthalenecarboxylic acid 681244-11-1P, 2-([[2-([[1-(tert-
Butoxycarbonyl)-3-pyrrolidinyl]methyl]amino)phenyl]sulfonyl]amino]-5,6,7,8-
tetrahydro-1-naphthalenecarboxylic acid 681244-12-2P,
2-([[2-([[1-(tert-Butoxycarbonyl)-4-piperidinyl]methyl]amino)phenyl]sulfon
yl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-90-9P,
3,5-Diethyl-2-[[(2-fluorophenyl)sulfonyl]amino]-6-methoxybenzoic acid
681246-19-5P, 2-([[2-([3-[4-(tert-Butoxycarbonyl)-1-piperazinyl]-3-
oxopropyl]amino)phenyl]sulfonyl]amino)-8-methyl-5,6,7,8-tetrahydro-1-
naphthalenecarboxylic acid 681246-20-8P, 2-([[2-([3-[4-(tert-
Butoxycarbonyl)-1-piperazinyl]-2,2-dimethyl-3-
oxopropyl]amino)phenyl]sulfonyl]amino)-8-methyl-5,6,7,8-tetrahydro-1-
naphthalenecarboxylic acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT 107143-76-0P, 5-Chloro-2-[[(3,4-dichlorophenyl)sulfonyl]amino]benzoic acid
134864-08-7P, 2-[[(4-Methylphenyl)sulfonyl]amino]-1-naphthoic acid
254878-25-6P, 2-[[(4-Chlorophenyl)sulfonyl]amino]-4,5-dimethoxybenzoic
acid 562078-23-3P, 5-Bromo-2-[(1-naphthylsulfonyl)amino]benzoic acid
677290-35-6P 677290-36-7P, 5-Isopropyl-2-[(phenylsulfonyl)amino]benzoic
acid 677290-37-8P, 5-Isobutyl-2-[(phenylsulfonyl)amino]benzoic acid
677290-38-9P, 2-[(Phenylsulfonyl)amino]-5-propylbenzoic acid
677290-39-0P, 5-Cyclopentyl-2-[(phenylsulfonyl)amino]benzoic acid
677290-40-3P, 5-Cyclohexyl-2-[(phenylsulfonyl)amino]benzoic acid
677290-41-4P, 5-Butyl-2-[(phenylsulfonyl)amino]benzoic acid
677290-42-5P, 5-(3-Methylbutyl)-2-[(phenylsulfonyl)amino]benzoic acid
677290-43-6P, 5-(2-Methylbutyl)-2-[(phenylsulfonyl)amino]benzoic acid
677290-44-7P, 5-Pentyl-2-[(phenylsulfonyl)amino]benzoic acid
677290-45-8P, 5-(2-Ethylbutyl)-2-[(phenylsulfonyl)amino]benzoic acid
677290-46-9P, 5-Hexyl-2-[(phenylsulfonyl)amino]benzoic acid
677290-47-0P, 2-[[(2-Chloro-4-fluorophenyl)sulfonyl]amino]-5-ethylbenzoic
acid 677290-48-1P, 5-Ethyl-2-[[(3-methylphenyl)sulfonyl]amino]benzoic
acid 677290-49-2P, 5-Ethyl-2-[[(2-fluorophenyl)sulfonyl]amino]benzoic
acid 677290-50-5P, 5-Ethyl-2-[[(3-fluorophenyl)sulfonyl]amino]benzoic
acid 677290-51-6P, 5-Ethyl-2-[[(4-fluorophenyl)sulfonyl]amino]benzoic
acid 677290-52-7P, 2-[[(2-Chlorophenyl)sulfonyl]amino]-5-ethylbenzoic
acid 677290-53-8P, 2-[[(3-Chlorophenyl)sulfonyl]amino]-5-ethylbenzoic
acid 677290-54-9P, 2-[[(3,4-Difluorophenyl)sulfonyl]amino]-5-
ethylbenzoic acid 677290-55-0P, 5-Ethyl-2-[(1-
naphthylsulfonyl)amino]benzoic acid 677290-56-1P, 5-Ethyl-2-([[3-
(trifluoromethyl)phenyl]sulfonyl]amino)benzoic acid 677290-57-2P,
2-[[(2,3-Dichlorophenyl)sulfonyl]amino]-5-ethylbenzoic acid
677290-58-3P, 2-[[(2,5-Dichlorophenyl)sulfonyl]amino]-5-ethylbenzoic acid
677290-59-4P, 2-[[(3,5-Dichlorophenyl)sulfonyl]amino]-5-ethylbenzoic acid
677290-60-7P, 2-[[(2-Bromophenyl)sulfonyl]amino]-5-ethylbenzoic acid
677290-61-8P, 2-[[(3-Bromophenyl)sulfonyl]amino]-5-ethylbenzoic acid
677290-62-9P, 5-Ethyl-2-[[(4-methylphenyl)sulfonyl]amino]benzoic acid
677290-63-0P, 2-[[(3-Cyanophenyl)sulfonyl]amino]-5-ethylbenzoic acid
677290-64-1P, 2-[[(4-Cyanophenyl)sulfonyl]amino]-5-ethylbenzoic acid
677290-65-2P, 2-[[(2,5-Dimethylphenyl)sulfonyl]amino]-5-ethylbenzoic acid

677290-66-3P, 5-Ethyl-2-[[(3-methoxyphenyl)sulfonyl]amino]benzoic acid
677290-67-4P, 2-[[(3-Chloro-4-fluorophenyl)sulfonyl]amino]-5-ethylbenzoic acid 677290-68-5P, 2-[[(2,5-Dimethoxyphenyl)sulfonyl]amino]-5-ethylbenzoic acid 677290-69-6P, 5-Ethyl-2-[[(5-fluoro-2-methylphenyl)sulfonyl]amino]benzoic acid 677290-70-9P, 5-Ethyl-2-[(8-quinolinylsulfonyl)amino]benzoic acid 677290-71-0P, 5-Ethyl-2-([[2-(methylsulfonyl)phenyl]sulfonyl]amino)benzoic acid
677290-72-1P, 5-Ethyl-2-([[2-(trifluoromethoxy)phenyl]sulfonyl]amino)benzoic acid 677290-73-2P, 2-([[5-(Dimethylamino)-1-naphthyl]sulfonyl]amino)-5-ethylbenzoic acid 677290-74-3P, 2-([[3,5-Bis(trifluoromethyl)phenyl]sulfonyl]amino)-5-ethylbenzoic acid 677290-75-4P, 2-[(Butylsulfonyl)amino]-5-ethylbenzoic acid 677290-76-5P, 5-Ethyl-2-[(2-thienylsulfonyl)amino]benzoic acid 677290-77-6P, 2-[[(5-Chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]amino]-5-ethylbenzoic acid
677290-78-7P, 5-Ethyl-2-([[2-(methoxycarbonyl)-3-thienyl]sulfonyl]amino)benzoic acid 677290-79-8P, 6-[(Phenylsulfonyl)amino]-5-indanecarboxylic acid 677290-80-1P, 2-[(Phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
677290-82-3P, 2-[(1-Naphthylsulfonyl)amino]-1-naphthoic acid
677290-83-4P, 7-Fluoro-2-[(phenylsulfonyl)amino]-1-naphthoic acid
677290-84-5P, 2-[[(4-Chlorophenyl)sulfonyl]amino]-1-naphthoic acid
677290-85-6P, 2-[[(4-Iodophenyl)sulfonyl]amino]-1-naphthoic acid
677290-86-7P, 2-[[(3-Fluorophenyl)sulfonyl]amino]-1-naphthoic acid
677290-87-8P, 2-[[(4-Fluorophenyl)sulfonyl]amino]-1-naphthoic acid
677290-88-9P, 2-[[(2-Methylphenyl)sulfonyl]amino]-1-naphthoic acid
677290-89-0P, 2-[[(3-Methylphenyl)sulfonyl]amino]-1-naphthoic acid
677290-90-3P, 2-[[(2-Fluorophenyl)sulfonyl]amino]-1-naphthoic acid
677290-91-4P, 2-([[2-(Trifluoromethoxy)phenyl]sulfonyl]amino)-1-naphthoic acid 677290-92-5P, 2-[([2-[(3-Aminopropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid 677290-93-6P, 2-[[(4-Methoxyphenyl)sulfonyl]amino]-1-naphthoic acid 677290-94-7P, 7-Fluoro-2-[[(4-fluorophenyl)sulfonyl]amino]-1-naphthoic acid 677290-95-8P, 7-Fluoro-2-[[(3-fluorophenyl)sulfonyl]amino]-1-naphthoic acid
677290-96-9P, 6-Bromo-2-[[(4-fluorophenyl)sulfonyl]amino]-1-naphthoic acid
677290-97-0P, 2-[[(3,4-Difluorophenyl)sulfonyl]amino]-1-naphthoic acid
677290-98-1P, 2-[[(2-Chloro-4-fluorophenyl)sulfonyl]amino]-1-naphthoic acid 677290-99-2P, 2-[[(5-Fluoro-2-methylphenyl)sulfonyl]amino]-1-naphthoic acid 677291-00-8P, 2-[[(2-Methoxy-5-methylphenyl)sulfonyl]amino]-1-naphthoic acid 677291-01-9P, 2-[[(2-Chloro-6-methylphenyl)sulfonyl]amino]-1-naphthoic acid
677291-03-1P, 2-([[4-Chloro-3-(trifluoromethyl)phenyl]sulfonyl]amino)-1-naphthoic acid 677291-04-2P, 2-[[(2,4-Dimethoxyphenyl)sulfonyl]amino]-1-naphthoic acid 677291-06-4P, 2-[(8-Quinolinylsulfonyl)amino]-1-naphthoic acid 677291-07-5P, 2-[(2,1,3-Benzothiadiazol-4-ylsulfonyl)amino]-1-naphthoic acid 677291-08-6P, 2-[(2-Thienylsulfonyl)amino]-1-naphthoic acid 677291-09-7P, 2-[[(3,5-Dimethyl-4-isoxazolyl)sulfonyl]amino]-1-naphthoic acid 677291-10-0P, 2-[[(5-Chloro-2-thienyl)sulfonyl]amino]-1-naphthoic acid 677291-11-1P, 2-[[(5-Chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]amino]-1-naphthoic acid 677291-12-2P, 2-([[2-(Methoxycarbonyl)-3-thienyl]sulfonyl]amino)-1-naphthoic acid
677291-13-3P, 2-([[5-(3-Isoxazolyl)-2-thienyl]sulfonyl]amino)-1-naphthoic acid 677291-14-4P, 2-([[2,5-Dichloro-3-thienyl]sulfonyl]amino)-1-naphthoic acid 677291-15-5P, 2-([[4,5-Dichloro-2-thienyl]sulfonyl]amino)-1-naphthoic acid 677291-17-7P, 2-[(Butylsulfonyl)amino]-1-naphthoic acid
677291-18-8P, 2-[(Benzylsulfonyl)amino]-1-naphthoic acid 677291-19-9P
677291-20-2P, 2-[[(3-Chloropropyl)sulfonyl]amino]-1-naphthoic acid
677291-21-3P, 2-[(Methylsulfonyl)amino]-1-naphthoic acid 677291-22-4P, 2-[(Ethylsulfonyl)amino]-1-naphthoic acid 677291-23-5P, 2-[(Propylsulfonyl)amino]-1-naphthoic acid 677297-03-9P, 2-[[(3,4-Difluorophenyl)sulfonyl]amino]-7-fluoro-1-naphthoic acid
681241-15-6P, 2-[[(3,5-Dichloro-2-hydroxyphenyl)sulfonyl]amino]-1-naphthoic acid 681241-17-8P, 2-[[(5-Bromo-6-chloro-3-pyridinyl)sulfonyl]amino]-1-naphthoic acid 681241-18-9P, 2-[[(2,4-Difluorophenyl)sulfonyl]amino]-7-fluoro-1-naphthoic acid
681241-19-0P, 2-[(Phenylsulfonyl)amino]-4-(trifluoromethyl)benzoic acid
681241-20-3P, 2-[(Phenylsulfonyl)amino]-4-(trifluoromethoxy)benzoic acid

681241-21-4P, 5-Nitro-2-[(phenylsulfonyl)amino]benzoic acid
681241-22-5P, 6-[(Phenylsulfonyl)amino]-5-quinolinecarboxylic acid
681241-23-6P, 6-[[(4-Methoxyphenyl)sulfonyl]amino]-5-quinolinecarboxylic acid 681241-24-7P, 2-[Ethyl[(4-fluorophenyl)sulfonyl]amino]-1-naphthoic acid 681241-25-8P, 2-[[(4-Fluorophenyl)sulfonyl](propyl)amino]-1-naphthoic acid 681241-26-9P, 2-[[(4-Fluorophenyl)sulfonyl][2-(methylsulfanyl)ethyl]amino]-1-naphthoicaci 681241-28-1P, 3-Bromo-2-methyl-6-[(phenylsulfonyl)amino]benzoic acid 681241-29-2P, 2-[[(4-Fluorophenyl)sulfonyl]amino]-8-hydroxy-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681241-30-5P, 8-Amino-2-[[(4-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681241-31-6P, 2-[[(4-Fluorophenyl)sulfonyl]amino]-8-hydroxy-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681241-32-7P, 3-Cyano-2-methyl-6-[(phenylsulfonyl)amino]benzoic acid 681241-33-8P, 3-Cyano-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoic acid
681241-34-9P, 3-Bromo-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoic acid
681241-35-0P, 2-[(2-Pyridinylsulfonyl)amino]-1-naphthoic acid
681241-36-1P, 3-Bromo-2-methyl-6-[(3-pyridinylsulfonyl)amino]benzoic acid
681241-37-2P, 3-Cyano-2-methyl-6-[(3-pyridinylsulfonyl)amino]benzoic acid
681241-38-3P, 3-Butyl-2-methyl-6-[(3-pyridinylsulfonyl)amino]benzoic acid
681241-39-4P, 6-[(1-Naphthylsulfonyl)amino]-1H-indole-7-carboxylic acid
681241-40-7P, 6-[[(3-Fluorophenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid 681241-41-8P, 6-[[(4-Fluorophenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid 681241-42-9P, 6-[[(2-Chloro-4-methoxyphenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid 681241-43-0P, 6-[[(4-Methylphenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid
681241-44-1P, 6-[[(2-Fluorophenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid 681241-45-2P, 6-[[(4-Chlorophenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid 681241-46-3P, 6-[(Phenylsulfonyl)amino]-1H-indole-7-carboxylic acid 681241-47-4P, 6-[[(3-Methylphenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid 681241-48-5P, 6-[[(4-Methoxyphenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid 681241-50-9P, 3-Bromo-6-[[(3-fluorophenyl)sulfonyl]amino]-2-methylbenzoic acid
681241-51-0P, 3-Bromo-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methylbenzoic acid 681241-52-1P, 2-[[(4-Fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681241-53-2P, 3-Oxo-5-[(phenylsulfonyl)amino]-4-indanecarboxylic acid 681241-54-3P, 3-Ethyl-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoic acid
681241-55-4P, 2-[[(4-Fluorophenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid 681241-56-5P, 2-[[(4-Fluorophenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid 681241-57-6P, 2-([[2-(Butylamino)phenyl]sulfonyl]amino)-1-naphthoic acid 681241-58-7P, 2-([[2-(sec-Butylamino)phenyl]sulfonyl]amino)-1-naphthoic acid 681241-59-8P, 2-([[2-(Isobutylamino)phenyl]sulfonyl]amino)-1-naphthoic acid 681241-60-1P, 2-([[2-(Pentylamino)phenyl]sulfonyl]amino)-1-naphthoic acid 681241-61-2P, 2-([[2-[(1-Methylbutyl)amino]phenyl]sulfonyl]amino)-1-naphthoic acid 681241-62-3P, 2-([[2-[(2-Methylbutyl)amino]phenyl]sulfonyl]amino)-1-naphthoic acid
681241-63-4P, 2-([[2-[(3-Methylbutyl)amino]phenyl]sulfonyl]amino)-1-naphthoic acid 681241-64-5P, 2-([[2-[(1,2-Dimethylpropyl)amino]phenyl]sulfonyl]amino)-1-naphthoic acid 681241-65-6P, 2-([[2-(Neopentylamino)phenyl]sulfonyl]amino)-1-naphthoic acid 681241-66-7P, 2-([[2-[(1-Ethylpropyl)amino]phenyl]sulfonyl]amino)-1-naphthoic acid
681241-67-8P, 2-([[2-(Hexylamino)phenyl]sulfonyl]amino)-1-naphthoic acid
681241-68-9P, 2-([[2-[(3,3-Dimethylbutyl)amino]phenyl]sulfonyl]amino)-1-naphthoic acid 681241-69-0P, 3-Ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methylbenzoic acid 681241-70-3P, 3-Chloro-2-[[(4-fluorophenyl)sulfonyl]amino]-1-naphthoic acid 681241-71-4P, 2-[(Phenylsulfonyl)amino]-4-vinylbenzoic acid 681241-72-5P, 2-Methyl-3-propyl-6-[(2-pyridinylsulfonyl)amino]benzoic acid
681241-73-6P, 2-[[(2-[[(3-Methoxypropyl)amino]carbonyl]phenyl)sulfonyl]amino]-1-naphthoic acid 681241-74-7P, 6-[[(4-Fluorophenyl)sulfonyl]amino]-2-methyl-3-propylbenzoic acid 681241-75-8P, 3-Bromo-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methoxybenzoic acid 681241-76-9P, 2-[([2-[(2-Ethoxyethyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid
681241-78-1P, 2-[([2-[(2-Isopropoxyethyl)amino]phenyl]sulfonyl)amino]-1-

naphthoic acid 681241-79-2P, 2-[([2-[(3-Propoxypropyl)amino]phenyl]sulfo
nyl)amino]-1-naphthoic acid 681241-80-5P, 2-[([2-[(3-
Methoxypropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid
681241-81-6P, 2-[([2-[(Cyclopropylmethyl)amino]phenyl]sulfonyl)amino]-1-
naphthoic acid 681241-82-7P, 2-[([2-(Cyclopentylamino)phenyl]sulfonyl)am
ino]-1-naphthoic acid 681241-83-8P, 2-[([2-[(Cyclopentylmethyl)amino]phe
nyl]sulfonyl)amino]-1-naphthoic acid 681241-84-9P, 2-[([2-
(Cyclohexylamino)phenyl]sulfonyl)amino]-1-naphthoic acid 681241-85-0P,
2-[([2-[(2-Ethylhexyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid
681241-86-1P, 2-[([2-[(3-Hydroxypropyl)amino]phenyl]sulfonyl)amino]-1-
naphthoic acid 681241-87-2P, 2-[([2-[(4-Hydroxybutyl)amino]phenyl]sulfon
yl)amino]-1-naphthoic acid 681241-88-3P, 2-[([2-[(2-
Propoxyethyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid 681241-89-4P,
2-[([2-[(3-Ethoxypropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid
681241-90-7P, 2-[([2-[(3-Butoxypropyl)amino]phenyl]sulfonyl)amino]-1-
naphthoic acid 681241-91-8P, 2-[([2-[(3-Isopropoxypropyl)amino]phenyl]su
lfonyl)amino]-1-naphthoic acid 681241-92-9P, 2-[([2-[(3-
Isobutoxypropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid
681241-93-0P, 2-[([2-[[3-(Methylsulfanyl)propyl]amino]phenyl]sulfonyl)amin
o]-1-naphthoic acid 681241-94-1P, 2-[([2-[[3-
(Diethylamino)propyl]amino]phenyl]sulfonyl)amino]-1-naphthoicaci
681241-95-2P, 2-[([2-[(2-Methoxyethyl)amino]phenyl]sulfonyl)amino]-1-
naphthoic acid 681241-96-3P, 2-[([2-(1-Pyrrolidinylcarbonyl)phenyl]sulfo
nyl)amino]-1-naphthoic acid 681241-97-4P, 2-Methyl-6-[(2-
pyridinylsulfonyl)amino]-3-vinylbenzoic acid 681241-98-5P,
6-[[(4-Fluorophenyl)sulfonyl]amino]-2-methyl-3-vinylbenzoic acid
681241-99-6P, 2-[([2-[(4-Methyl-1-piperazinyl)carbonyl]phenyl]sulfonyl)ami
no]-1-naphthoic acid 681242-00-2P, 2-[[(2-Chloro-4-
fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic
acid 681242-01-3P, 2-[(2-Thienylsulfonyl)amino]-5,6,7,8-tetrahydro-1-
naphthalenecarboxylic acid 681242-02-4P, 2-[(Benzylsulfonyl)amino]-
5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-03-5P,
2-[[(2-Methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-
naphthalenecarboxylic acid 681242-04-6P, 2-[[(3-
Methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic
acid 681242-05-7P, 2-[[(4-Methylphenyl)sulfonyl]amino]-5,6,7,8-
tetrahydro-1-naphthalenecarboxylic acid 681242-06-8P,
2-[[(2-Fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-
naphthalenecarboxylic acid 681242-07-9P, 2-[[(3-
Fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic
acid 681242-08-0P, 2-[[(3-Cyanophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-
1-naphthalenecarboxylic acid 681242-09-1P, 2-[[(4-
Cyanophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic
acid 681242-10-4P, 2-[[(2,5-Dimethylphenyl)sulfonyl]amino]-5,6,7,8-
tetrahydro-1-naphthalenecarboxylic acid 681242-11-5P,
2-[[(3-Methoxyphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-
naphthalenecarboxylic acid 681242-12-6P, 2-[[(4-
Methoxyphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic
acid 681242-13-7P, 2-[[(2-Chlorophenyl)sulfonyl]amino]-5,6,7,8-
tetrahydro-1-naphthalenecarboxylic acid 681242-14-8P,
2-[[(3-Chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-
naphthalenecarboxylic acid 681242-15-9P, 2-[[(4-
Chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic
acid 681242-16-0P, 2-[[(2,4-Difluorophenyl)sulfonyl]amino]-5,6,7,8-
tetrahydro-1-naphthalenecarboxylic acid 681242-17-1P,
2-[[(3,4-Difluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-
naphthalenecarboxylic acid 681242-18-2P, 2-[[(4-
Propylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic
acid 681242-19-3P, 2-[[(4-Isopropylphenyl)sulfonyl]amino]-5,6,7,8-
tetrahydro-1-naphthalenecarboxylic acid 681242-20-6P,
2-[(2-Naphthylsulfonyl)amino]-5,6,7,8-tetrahydro-1-
naphthalenecarboxylicaci 681242-21-7P, 2-[(1-Naphthylsulfonyl)amino]-
5,6,7,8-tetrahydro-1-naphthalenecarboxylicaci 681242-22-8P,
2-[[(4-tert-Butylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-
naphthalenecarboxylic acid 681242-23-9P, 2-[[(3-Chloro-4-
fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic

acid 681242-24-0P, 2-([[4-(Acetylamino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-25-1P, 2-[[(2,5-Dimethoxyphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-26-2P, 2-[[(3,4-Dimethoxyphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-27-3P, 2-[[(3-(Trifluoromethyl)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-28-4P, 2-[[(4-(Trifluoromethyl)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-29-5P, 2-[[(2,3-Dichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-30-8P, 2-[[(2,4-Dichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-31-9P, 2-[[(2,6-Dichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-32-0P, 2-[[(3,4-Dichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-33-1P, 2-[[(3,5-Dichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-34-2P, 2-[((1,1'-Biphenyl-4-yl)sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-35-3P, 2-[[(2-Bromophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-36-4P, 2-[[(3-Bromophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-37-5P, 2-[[(4-Bromophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-38-6P, 2-[[(4-(Trifluoromethoxy)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-40-0P, 2-[[(4-Fluorophenyl)sulfonyl]amino]-5-(methylsulfanyl)benzoic acid 681242-41-1P, 2-[[(4-Fluorophenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-42-2P, 3-(2-Carboxyethyl)-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoic acid 681242-43-3P, 5-(Methylsulfanyl)-2-[(phenylsulfonyl)amino]benzoic acid 681242-44-4P, 2-[[(2-[[2-(Dimethylamino)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-45-5P, 2-[[(2-[[2-(Diethylamino)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-46-6P, 2-[[(2-[[2-(1-Pyrrolidinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-47-7P, 2-[[(2-[[3-(Dimethylamino)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-48-8P, 2-[[(2-[[3-(4-Methyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-49-9P, 2-[[(2-[[3-(1-Piperidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-50-2P, 3-Butyl-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methylbenzoic acid 681242-52-4P, 2-Chloro-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid 681242-53-5P, 3-Bromo-2-chloro-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid 681242-54-6P, 2-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-55-7P, 3-Ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methylbenzoic acid 681242-56-8P, 6-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-methylbenzoic acid 681242-57-9P, 6-[[(2-[[4-(N,N-Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-methylbenzoic acid 681242-58-0P, 3-[1,2-Dihydroxyethyl]-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methylbenzoic acid 681242-59-1P, 6-[[(4-Fluorophenyl)sulfonyl]amino]-3-(hydroxymethyl)-2-methylbenzoic acid 681242-60-4P, 6-[[(2-[[2-(Diethylamino)ethyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-methylbenzoic acid 681242-61-5P, 3-Ethyl-6-[[(2-[[3-(1H-imidazol-1-yl)propyl]amino]phenyl)sulfonyl]amino]-2-methylbenzoic acid 681242-62-6P, 6-[[(2-[[3-(Dimethylamino)propyl](methyl)amino]phenyl)sulfonyl]amino]-3-ethyl-2-methylbenzoic acid 681242-63-7P, 3-Ethyl-2-methyl-6-([[2-(4-methyl-1-piperazinyl)phenyl]sulfonyl]amino)benzoic acid 681242-64-8P, 2-[[(3,5-Dimethyl-4-isoxazolyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT 681242-65-9P, 2-[[(5-Chloro-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-66-0P, 2-[[(5-Fluoro-2-methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-67-1P, 2-[[(2-Methoxy-5-methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-68-2P, 2-[[(3-Nitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-69-3P, 2-[[(2-Chloro-6-methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-70-6P, 2-[[(5-Chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-71-7P, 2-[(Mesitylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-72-8P, 2-[[(4-Nitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-73-9P, 2-[[(3-Chloro-4-methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-74-0P, 2-[(2,1,3-Benzothiadiazol-4-ylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-75-1P, 2-[[(2-Methyl-5-nitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-76-2P, 2-[[(5-(3-Isoxazolyl)-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-77-3P, 2-[[(2,5-Dichloro-3-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-78-4P, 2-[[(4,5-Dichloro-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-81-9P, 2-[[(7-Chloro-2,1,3-benzoxadiazol-4-yl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-82-0P, 2-[[(4-Chloro-3-nitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-83-1P, 2-[[(2-(Trifluoromethoxy)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-84-2P, 2-[[(5-Chloro-4-nitro-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-85-3P, 2-[[(2,4-Dinitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-86-4P, 2-[[(5-(Dimethylamino)-1-naphthyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-87-5P, 2-[[(4-Chloro-3-(trifluoromethyl)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-88-6P, 2-[[(2,4,5-Trichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-89-7P, 2-[[(2,3,4-Trichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-90-0P 681242-91-1P, 2-[[(5-Bromo-2-methoxyphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-92-2P, 2-[[(3,5-Bis(trifluoromethyl)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-93-3P, 2-[[(2-Butoxy-5-(1,1-dimethylpropyl)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-94-4P, 2-[[(5-(Phenylsulfonyl)-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-95-5P, 2-[[(5-[[(4-Chlorobenzoyl)amino]methyl]-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-96-6P, 2-[[(5-Bromo-6-chloro-3-pyridinyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-98-8P, 2-[[(5-[(Benzoylamino)methyl]-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681242-99-9P, 6-[[(4-Fluorophenyl)sulfonyl]amino]-3-[1-hydroxyethyl]-2-methylbenzoic acid 681243-00-5P, 2-[[(2-[[2-(Dimethylamino)ethyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid 681243-01-6P, 8-Methyl-2-[[(2-[[2-(1-pyrrolidinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid 681243-02-7P, 8-Methyl-2-[[(2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid 681243-03-8P, 2-[[(2-[[3-(Dimethylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid 681243-04-9P, 2-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid 681243-05-0P, 2-[[(2-[[2-(Diethylamino)ethyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid 681243-06-1P, 8-Methyl-2-[[(2-[[2-(4-morpholinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid 681243-07-2P, 8-Methyl-2-[[(2-[[3-[3-

(methylamino)phenyl]propyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid 681243-08-3P, 2-[[(2-(4-Benzyl-1-piperazinyl)phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid 681243-09-4P, 2-[[(2-[[4-(N,N-Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid 681243-10-7P, 2-[[(2-[[3-(Dibutylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid 681243-11-8P, 2-[[(4-Fluorophenyl)sulfonyl]amino]-8-methyl-7-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-12-9P, 2-[[(2-[[3-(1H-Imidazol-1-yl)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid 681243-13-0P, 8-Methyl-2-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid 681243-14-1P, 8-Methyl-2-[[(2-[[3-(1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid 681243-15-2P, 8-Methyl-2-[[(2-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid 681243-16-3P, 8-Methyl-2-[[(2-[[3-(2-methyl-1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid 681243-17-4P, 2-[[(2-[[3-(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid 681243-19-6P, 8-Methyl-2-[[(2-[[2-(1-piperidinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid 681243-20-9P 681243-21-0P 681243-22-1P, 2-([[2-([[2-(Diethylamino)ethyl]amino]carbonyl)phenyl]sulfonyl]amino)-1-naphthoic acid 681243-23-2P, 2-[[(2-[[2-(1-Piperazinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-24-3P, 2-[[(2-[[3-(2-Oxo-1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-26-5P, 2-[[(2-[[3-(4-Morpholinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-28-7P, 2-[[(2-[[2-(1-Methyl-2-pyrrolidinyl]ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-29-8P, 2-[[(2-[[3-(2-Methyl-1-piperidinyl]propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-30-1P, 2-[[(2-[[1-(Ethoxycarbonyl)-4-piperidinyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-32-3P, 2-[[(2-[[2-(4-Morpholinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-33-4P, 2-[[(2-[[2-[Bis-(2-hydroxyethyl)amino]ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-34-5P, 2-[[(2-[[2-(1-Piperidinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-35-6P, 2-[[(2-[[4-(Diethylamino)-1-methylbutyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-36-7P, 2-[[(2-[[3-(Dibutylamino)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-37-8P, 2-[[(2-[[3-(1H-Imidazol-1-yl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-38-9P, 2-[[(2-[[3-(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-39-0P, 2-[[(2-[[4-(N,N-Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-40-3P, 2-[[(2-[[2-(Dipropylamino)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-41-4P, 2-[[(2-[[3-(1-Pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-42-5P, 2-[[(2-[[2-(Diisopropylamino)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-43-6P, 2-[[(2-[[4-(Diethylamino)butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-45-8P 681243-46-9P, 6-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-hydroxybenzoic acid 681243-48-1P, 3-Ethyl-2-methoxy-6-[[(2-[[3-(1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid 681243-49-2P, 3-Ethyl-2-hydroxy-6-[[(2-[[3-(1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid

681243-50-5P, 3-Ethyl-2-hydroxy-6-[[(2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid 681243-51-6P, 6-[[(2-[[4-(N,N-Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-methoxybenzoic acid 681243-52-7P, 3-Ethyl-2-methoxy-6-[[(2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid 681243-53-8P, 2-([[2-([[2-(1-Piperidinyl)ethyl]amino]carbonyl)phenyl]sulfonyl]amino)-1-naphthoic acid 681243-54-9P, 2-[[(2-[[3-(Ethylamino)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-55-0P, 2-([[2-([3-[Bis(2-hydroxyethyl)amino]propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-58-3P, 2-[([2-[(3-Aminopropyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-59-4P, 2-[[(2-[[3-(Methylamino)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-60-7P, 6-[[(4-Fluorophenyl)sulfonyl]amino]-2-methoxy-3-vinylbenzoic acid 681243-61-8P, 2-[([2-[([[2-(Diethylamino)ethyl]amino]carbonyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-62-9P, 2-([[2-([[2-(Diethylamino)ethoxy]carbonyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-63-0P, 8-Methyl-2-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-64-1P, 8-Methyl-2-[[(2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-65-2P, 2-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-66-3P, 8-Methyl-2-[[(2-[[3-(2-methyl-1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-67-4P 681243-68-5P, 2-[[(2-[[3-(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-69-6P, 2-[[(2-[[4-(1-Pyrrolidinyl)butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-70-9P, 2-[[(2-[[4-[2-Methyl-1-pyrrolidinyl]butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-71-0P, 2-[[(2-[[4-[2,5-Dimethyl-1-pyrrolidinyl]butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-72-1P, 2-[[(2-[[4-(1-Piperidinyl)butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-73-2P, 2-[[(2-[[4-[2-Methyl-1-piperidinyl]butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-74-3P, 2-[[(2-[[4-[3-Methyl-1-piperidinyl]butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-75-4P, 2-[[(2-[[4-[4-Methyl-1-piperidinyl]butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-76-5P 681243-77-6P, 2-[[(2-[[4-(1-Azepanyl)butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-78-7P 681243-79-8P 681243-80-1P, 2-[([2-[(1-Benzyl-4-piperidinyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-81-2P, 2-[([2-[(1,2,2,6,6-Pentamethyl-4-piperidinyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-82-3P, 3-Ethyl-2-methoxy-6-[(2-pyridinylsulfonyl)amino]benzoic acid 681243-83-4P, 3-Ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methoxybenzoic acid 681243-84-5P, 2-[[(2-[[3-(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-7,7-dimethyl-8-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-85-6P, 7,7-Dimethyl-2-[[(2-[[2-[1-methyl-2-pyrrolidinyl]ethyl]amino]phenyl)sulfonyl]amino]-8-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-86-7P, 7,7-Dimethyl-2-[[(2-[[3-[2-methyl-1-piperidinyl]propyl]amino]phenyl)sulfonyl]amino]-8-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-87-8P, 7,7-Dimethyl-8-oxo-2-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-88-9P 681243-89-0P, 8-Methylene-2-[[(2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-90-3P, 8-Methylene-2-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-

naphthalenecarboxylic acid 681243-91-4P, 2-[[(2-[[4-(Aminocarbonyl)-1-piperidinyl]carbonyl]phenyl)sulfonyl]amino]-1-naphthoic acid 681243-92-5P, 3-Bromo-6-[[(2-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-2-methoxybenzoic acid 681243-93-6P, 3-Bromo-2-methoxy-6-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid 681243-94-7P, 3-Bromo-2-hydroxy-6-[[(2-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]phenyl)sulfonyl]amino]benzoic acid 681243-95-8P, 3-Bromo-2-methoxy-6-[[(2-[[3-(1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid 681243-96-9P, 2-([[2-([[2-(Diethylamino)ethyl]amino]carbonyl)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-97-0P, 2-[[(2-[[[3-(Dimethylamino)propyl](methyl)amino]carbonyl]phenyl)sulfonyl]amino]-1-naphthoic acid 681243-98-1P, 2-[[(2-[[3-(Isopropylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681243-99-2P, 3-Bromo-2-chloro-6-[[(2-fluorophenyl)sulfonyl]amino]benzoic acid 681244-02-0P, 2-Ethoxy-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid 681244-03-1P, 3-Bromo-2-ethoxy-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid 681244-04-2P, 2-Ethoxy-3-ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid 681244-05-3P, 2-Chloro-6-[[(2-[4-(N,N-dimethylamino)butyl]phenyl)sulfonyl]amino]-3-ethylbenzoic acid 681244-06-4P, 2-Chloro-6-[[(2-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-3-ethylbenzoic acid 681244-07-5P, 2-Chloro-3-ethyl-6-([[2-([2-[1-methyl-2-pyrrolidinyl]ethyl]amino)phenyl]sulfonyl]amino)benzoic acid 681244-08-6P 681244-09-7P, 2-[[(2-[[2,2-Dimethyl-3-(1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681244-13-3P 681244-14-4P 681244-15-5P, 2-[([2-[(4-Piperidinylmethyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681244-16-6P, 2-[([2-[(2-[1-Cyclobutyl-2-piperidinyl]ethyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681244-17-7P 681244-18-8P, 7,7-Dimethyl-2-([[2-([2-[1-methyl-2-pyrrolidinyl]ethyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681244-19-9P, 2-[[(2-Fluorophenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681244-20-2P, 2-[[(2-[[2,2-Dimethyl-3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681244-21-3P, 2-[[(2-[[2-Ethyl-2-(1-piperidinylmethyl)butyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681244-22-4P, 2-Ethoxy-3-ethyl-6-([[2-([2-[1-methyl-2-pyrrolidinyl]ethyl]amino)phenyl]sulfonyl]amino)benzoic acid 681244-23-5P, 6-[[(2-[[3-(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-2-ethoxy-3-ethylbenzoic acid 681244-24-6P 681244-25-7P, 6-[[(2-[[4-(Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-2-ethoxy-3-ethylbenzoic acid 681244-27-9P, 3-Bromo-6-([[2-([3-(dimethylamino)-2,2-dimethylpropyl]amino)phenyl]sulfonyl]amino)-2-propoxybenzoic acid 681244-28-0P, 3-Bromo-6-([[2-([4-(N,N-dimethylamino)butyl]amino)phenyl]sulfonyl]amino)-2-propoxybenzoic acid 681244-29-1P, 3-Bromo-6-[[(2-[[3-(4-morpholinyl)propyl]amino]phenyl)sulfonyl]amino]-2-propoxybenzoic acid 681244-30-4P 681244-31-5P, 2-[[(2-[[([2-[1-Methyl-2-pyrrolidinyl]ethyl]amino)carbonyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681244-32-6P, 2-[[[2-[([2-[1-Methyl-2-pyrrolidinyl]ethyl]amino)carbonyl]phenyl]sulfonyl)amino]-1-naphthoic acid 681244-33-7P, 2-[([2-[([3-[1-Pyrrolidinyl]propyl]amino)carbonyl]phenyl]sulfonyl)amino]-1-naphthoic acid 681244-34-8P, 2-[([2-[([3-(Isopropylamino)propyl]amino)carbonyl]phenyl]sulfonyl)amino]-1-naphthoic acid 681244-36-0P, 2-[([2-[([[2-(1-Piperidinyl)ethyl]amino)carbonyl]amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681244-38-2P, 2-[([2-[([[2-(1-Piperazinyl)ethyl]amino)carbonyl]amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681244-40-6P, 2-[([2-[([[3-(2-Methyl-1-Piperidinyl)propyl]amino)carbonyl]amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681244-42-8P, 2-[([2-[([[2-(4-Morpholinyl)ethyl]amino)carbonyl]amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid

681244-44-0P, 2-[([2-[([[3-(4-Morpholinyl)propyl]amino)carbonyl]amino]phen
yl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681244-46-2P, 2-[([2-[([[4-(Diethylamino)-1-methylbutyl]amino]carbonyl)ami
no]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681244-48-4P, 2-[([2-[([[3-(Dimethylamino)-2,2-
dimethylpropyl]amino]carbonyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-
tetrahydro-1-naphthalenecarboxylic acid 681244-50-8P,
2-[([2-[([[3-(1-Piperidinyl)propyl]amino]carbonyl)amino]phenyl]sulfonyl)am
ino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681244-52-0P,
2-[([2-[([[3-(1-Piperazinyl)propyl]amino]carbonyl)amino]phenyl]sulfonyl)am
ino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681244-53-1P,
3-Ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]-2-propoxybenzoic acid
681244-54-2P 681244-55-3P, 3-Ethyl-6-([[2-([3-[2-methyl-1-
piperidinyl]propyl]amino)phenyl]sulfonyl]amino)-2-propoxybenzoic acid
681244-56-4P, 3-Ethyl-6-([[2-([3-[4-morpholinyl]propyl]amino)phenyl]sulfon
yl]amino)-2-propoxybenzoic acid 681244-57-5P, 3-Bromo-6-[[(2-[[4-(N,N-
dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-2-methoxybenzoic acid
681244-58-6P, 3-Bromo-6-[[(2-[[4-(N,N-dimethylamino)butyl]amino]phenyl)sul
fonyl]amino]-2-hydroxybenzoic acid 681244-59-7P, 3-Bromo-2-hydroxy-6-
[[(2-[[3-(1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid
681244-60-0P, 3-Bromo-2-hydroxy-6-[[(2-[[3-(4-methyl-1-
piperazinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid
681244-61-1P, 3-Bromo-2-hydroxy-6-[[(2-[[3-(1-
pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid
681244-62-2P, 3-Bromo-6-[[(2-[[3-(diethylamino)propyl]amino]phenyl)sulfony
l]amino]-2-methoxybenzoic acid 681244-63-3P, 3-Bromo-6-[[(2-[[3-
(diethylamino)propyl]amino]phenyl)sulfonyl]amino]-2-hydroxybenzoic acid
681244-64-4P, 6-[[(2-[[4-(N,N-Dimethylamino)butyl]amino]phenyl)sulfonyl]am
ino]-3-ethyl-2-hydroxybenzoic acid 681244-65-5P, 6-[[(2-[[3-
(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-
methoxybenzoic acid 681244-66-6P, 3-Ethyl-2-hydroxy-6-[[(2-[[2-(1-methyl-
2-pyrrolidinyl)ethyl]amino]phenyl)sulfonyl]amino]benzoic acid
681244-67-7P, 6-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-
3-ethyl-2-methoxybenzoic acid 681244-68-8P, 3-Ethyl-2-methoxy-6-[[(2-[[3-
(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid
681244-69-9P, 3-Ethyl-2-hydroxy-6-[[(2-[[3-(1-
pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid
681244-70-2P, 3-Ethyl-2-methoxy-6-[[(2-[[3-(4-
morpholinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid
681244-71-3P, 3-Ethyl-2-methoxy-6-[[(2-[[4-(1-
pyrrolidinyl)butyl]amino]phenyl)sulfonyl]amino]benzoic acid 681244-72-4P
, 3-Bromo-2-methoxy-6-[[(2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl)sulf
onyl]amino]benzoic acid 681244-73-5P, 3-Bromo-2-methoxy-6-[[(2-[[3-[2-
methyl-1-piperidinyl]propyl]amino]phenyl)sulfonyl]amino]benzoic acid
681244-74-6P, 3-Ethyl-2-methoxy-6-[[(2-[[2-[1-methyl-2-
pyrrolidinyl]ethyl]amino]phenyl)sulfonyl]amino]benzoic acid
681244-75-7P, 3-Ethyl-6-[[(2-[[3-(1H-imidazol-1-
yl)propyl]amino]phenyl)sulfonyl]amino]-2-methoxybenzoic acid
681244-76-8P, 3-Ethyl-2-hydroxy-6-[[(2-[[3-(1H-imidazol-1-
yl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid 681244-77-9P,
3-Ethyl-2-hydroxy-6-[[(2-[[3-(4-morpholinyl)propyl]amino]phenyl)sulfonyl]a
mino]benzoic acid 681244-78-0P, 3-Bromo-5-ethyl-6-methyl-2-[(2-
pyridinylsulfonyl)amino]benzoic acid 681244-79-1P, 2-[[(2-[[2-[1-Methyl-
2-pyrrolidinyl]ethyl]amino]phenyl)sulfonyl]amino]-8-methoxy-5,6,7,8-
tetrahydro-1-naphthalenecarboxylic acid 681244-80-4P,
2-[[(2-[[3-(Isopropylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methoxy-
5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681244-81-5P,
2-[([2-[([2-[1-Methyl-2-pyrrolidinyl]ethyl]amino)carbonyl]phenyl]sulfonyl)
amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681244-82-6P,
2-[([4-[([2-[1-Methyl-2-pyrrolidinyl]ethyl]amino)carbonyl]-3-
thienyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681244-83-7P, 2-[([2-[([2-(1-Piperidinyl)ethyl]amino)carbonyl]phenyl]sulfo
nyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681244-84-8P,
2-[([4-[([2-(Diethylamino)ethyl]amino)carbonyl]-3-thienyl]sulfonyl)amino]-
5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681244-85-9P,
2-[([4-[([2-(1-Piperidinyl)ethyl]amino)carbonyl]-3-thienyl]sulfonyl)amino]-

5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681244-86-0P, 6-[([2-[(3-Aminopropyl)amino]phenyl]sulfonyl)amino]-3-ethyl-2-methoxybenzoic acid 681244-87-1P, 6-[([2-[(3-Aminopropyl)amino]phenyl]sulfonyl)amino]-3-ethyl-2-hydroxybenzoic acid 681244-88-2P, 2-(Carboxymethoxy)-3-ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid 681244-89-3P, 6-([[2-(Dimethylamino)phenyl]sulfonyl]amino)-3-ethyl-2-methoxybenzoic acid 681244-90-6P, 6-[[(2-[[3-(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-hydroxybenzoic acid 681244-91-7P, 3-Bromo-5-ethyl-2-[[(2-fluorophenyl)sulfonyl]amino]-6-methoxybenzoic acid 681244-92-8P, 5-Ethyl-2-[[(2-fluorophenyl)sulfonyl]amino]-4-methoxy-1,1'-biphenyl-3-carboxylic acid 681244-93-9P 681244-94-0P 681244-95-1P 681244-96-2P 681244-97-3P, 3-[(1E)-3-([2-[1-Methyl-2-pyrrolidinyl]ethyl]amino)-3-oxo-1-propenyl]-2-[(phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681244-98-4P, 3-((1E)-3-Oxo-3-[[2-(1-piperidinyl)ethyl]amino]-1-propenyl]-2-[(phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681244-99-5P, 3-((1E)-3-Oxo-3-[[3-(1-piperidinyl)propyl]amino]-1-propenyl]-2-[(phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-00-1P, 3-[(1E)-3-([[1-Ethyl-2-pyrrolidinyl]methyl]amino)-3-oxo-1-propenyl]-2-[(phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-01-2P, 3-((1E)-3-[[2-(Dimethylamino)ethyl]amino]-3-oxo-1-propenyl]-2-[(phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-02-3P 681245-03-4P 681245-04-5P 681245-05-6P 681245-06-7P 681245-07-8P 681245-08-9P, 2-[N-Methyl-N-([2-[(4-piperidinylmethyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-09-0P 681245-10-3P 681245-11-4P 681245-12-5P 681245-13-6P 681245-14-7P 681245-15-8P 681245-16-9P 681245-17-0P 681245-18-1P 681245-19-2P 681245-20-5P 681245-21-6P, 3-Bromo-2-methoxy-6-([[2-([2-[1-methyl-2-pyrrolidinyl]ethyl]amino)phenyl]sulfonyl]amino)benzoic acid 681245-22-7P, 3-Bromo-2-hydroxy-6-([[2-([3-[2-methyl-1-piperidinyl]propyl]amino)phenyl]sulfonyl]amino)benzoic acid 681245-23-8P, 2-[[(2-[[2-(Diethylamino)ethyl]sulfanyl]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-24-9P, 2-[[(2-([[3-(Diethylamino)propyl]amino]carbonyl)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT 681245-25-0P, 2-([[2-([[3-(Dimethylamino)-2,2-dimethylpropyl]amino]carbonyl)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-26-1P, 2-([[2-([[3-(Diethylamino)propyl]amino]carbonyl)-3-thienyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-27-2P, 2-([[2-([[3-(Dimethylamino)-2,2-dimethylpropyl]amino]carbonyl)-3-thienyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-28-3P, 2-([[2-([[4-(Diethylamino)-1-methylbutyl]amino]carbonyl)-3-thienyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-29-4P, 2-[[(2-[[[3-(Dimethylamino)propyl](methyl)amino]carbonyl]-3-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-30-7P 681245-31-8P, 2-[[(2-[[3-(4-Cyclopentyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-32-9P, 2-[[(2-[[3-(4-Isopropyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-33-0P 681245-34-1P 681245-35-2P, 2-([[2-([[4-(Diethylamino)butyl]amino]carbonyl)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-36-3P, 2-([[2-([[4-(Diethylamino)butyl]amino]carbonyl)-3-thienyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-37-4P, 2-([[2-([[4-(Diethylamino)butyl]amino]carbonyl)-4-fluorophenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-38-5P, 2-([[2-([[4-(Diethylamino)-1-methylbutyl]amino]carbonyl)-4-fluorophenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-39-6P,

2-([[2-([[4-(Diethylamino)-1-methylbutyl]amino]carbonyl)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-40-9P, 8-Methyl-2-[[(2-[[3-(4-morpholinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-41-0P, (8R)-2-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-42-1P, (8S)-2-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-43-2P, 2-(2-Aminoethoxy)-3-ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid 681245-44-3P, 2-(2-Aminoethoxy)-6-[[(2-bromophenyl)sulfonyl]amino]-3-ethylbenzoic acid 681245-45-4P, 2-(2-Aminoethoxy)-6-[[(2-[(1E)-3,3-dimethyl-1-butenyl]phenyl)sulfonyl]amino]-3-ethylbenzoic acid 681245-46-5P, 2-(2-Aminoethoxy)-6-[[(2-(3,3-dimethylbutyl)phenyl)sulfonyl]amino]-3-ethylbenzoic acid 681245-47-6P, 2-(2-Aminoethoxy)-6-[[(2-propylphenyl)sulfonyl]amino]-3-ethylbenzoic acid 681245-48-7P, 2-[([2-[(4-Pyridinylmethyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-49-8P 681245-50-1P, 2-[[(2-[[3-(Diethylamino)propyl]sulfanyl]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-51-2P, 2-[[(2-[[2-(Diethylamino)ethyl]sulfinyl]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-52-3P, 2-[[(2-[3-(Diethylamino)propoxy]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-53-4P 681245-54-5P 681245-55-6P 681245-56-7P 681245-57-8P 681245-58-9P 681245-59-0P 681245-60-3P 681245-61-4P 681245-62-5P 681245-63-6P 681245-64-7P 681245-65-8P 681245-66-9P 681245-67-0P 681245-68-1P 681245-69-2P 681245-70-5P 681245-71-6P, 2-([[2-([2,2-Dimethyl-3-(4-morpholinyl)propyl]amino)phenyl]sulfonyl]amino)-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-72-7P, 2-([[2-([3-Hydroxy-2,2-dimethylpropyl]amino)phenyl]sulfonyl]amino)-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-73-8P, 2-([[2-([3-[4-[4-(Trifluoromethyl)-2-pyrimidinyl]-1-piperazinyl]propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-74-9P, 2-([[2-([3-(1-Azepanyl)propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-75-0P, 2-([[2-([[1-(2-Ethylbutyl)-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-76-1P, 2-([[2-([[1-Cyclopentyl-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-77-2P, 2-([[2-([[1-[1-Methylpropyl]-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-79-4P, 2-([[2-([[1-Isobutyl-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-80-7P, 2-([[2-([[1-Methyl-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-81-8P, 2-([[2-([[1'-Methyl-1,4'-bipiperidin-4-yl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-82-9P, 2-([[2-([[1-Isopropyl-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-83-0P, 2-([[2-[(1E)-3-(Diethylamino)-1-propenyl]phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-84-1P, 2-([[2-[4-(Diethylamino)butyl]phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-85-2P, 2-([[2-[(1Z)-3-(Diethylamino)-1-propenyl]phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-86-3P, 2-([[2-[(1Z)-4-(Diethylamino)-1-butenyl]phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-87-4P, 2-([[2-([3-[3-Methyl-1-piperidinyl]propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-88-5P, 2-([[2-([3-[Cyclohexyl(methyl)amino]propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-89-6P, 2-([[2-([3-(3,4-Dihydro-2(1H)-isoquinolinyl)propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-91-0P, 2-([[2-([2-Methyl-3-(4-methyl-1-piperidinyl)propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-92-1P, 2-([[2-([3-[2,6-Dimethyl-1-piperidinyl]propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681245-93-2P

Search done by Noble Jarrell

681245-94-3P, 3-Ethyl-2-methoxy-6-([[2-(2-phenylethyl)phenyl]sulfonyl]amino)benzoic acid 681245-95-4P, 6-[([2-[2-(4-Chlorophenyl)ethyl]phenyl]sulfonyl)amino]-3-ethyl-2-methoxybenzoic acid 681245-96-5P, 3-Ethyl-2-methoxy-6-[[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]benzoicaci 681245-97-6P, 6-[[(1,2-Dimethyl-1H-imidazol-4-yl)sulfonyl]amino]-3-ethyl-2-methoxybenzoic acid 681245-98-7P, 2-(2-Aminoethoxy)-6-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-3-ethylbenzoic acid 681245-99-8P, 2-(3-Aminopropoxy)-6-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-3-ethylbenzoic acid 681246-00-4P, 3,5-Diethyl-2-methoxy-6-[[(2-[[3-(4-morpholinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid 681246-01-5P, 3,5-Diethyl-2-methoxy-6-[[(2-[[3-[2-methyl-1-piperidinyl]propyl]amino]phenyl)sulfonyl]amino]benzoic acid 681246-02-6P, 3,5-Diethyl-2-methoxy-6-[[(2-[[2-[1-methyl-2-pyrrolidinyl]ethyl]amino]phenyl)sulfonyl]amino]benzoic acid 681246-03-7P, 2-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-3,5-diethyl-6-methoxybenzoic acid 681246-04-8P, 2-[[(2-[[4-(N,N-Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-3,5-diethyl-6-methoxybenzoic acid 681246-05-9P, 3,5-Diethyl-2-methoxy-6-[[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]benzoic acid 681246-06-0P, 2-[[(1,2-Dimethyl-1H-imidazol-4-yl)sulfonyl]amino]-3,5-diethyl-6-methoxybenzoic acid 681246-07-1P, 3,5-Diethyl-2-methoxy-6-[(phenylsulfonyl)amino]benzoic acid 681246-08-2P, 3,5-Diethyl-2-[[(4-fluorophenyl)sulfonyl]amino]-6-methoxybenzoic acid 681246-09-3P, 3,5-Diethyl-2-methoxy-6-[[2-pyridinylsulfonyl]amino]benzoic acid 681246-10-6P, 2-[([2-[3-(Diethylamino)propyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681246-11-7P, 2-[([2-[(1Z)-5-(Diethylamino)-1-pentenyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681246-12-8P, 2-[([2-[(1E)-5-(Diethylamino)-1-pentenyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681246-13-9P, 2-[([2-[5-(Diethylamino)pentyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681246-14-0P 681246-15-1P, 2-(2-Aminoethoxy)-3-ethyl-6-[[(2-ethyl-4-fluorophenyl)sulfonyl]amino]benzoic acid 681246-17-3P, 2-(2-Aminoethoxy)-3-ethyl-6-[[(4-fluoro-2-propylphenyl)sulfonyl]amino]benzoic acid 681246-18-4P, 2-(2-Aminoethoxy)-3-ethyl-6-[[(4-fluoro-2-(2-phenylethyl)phenyl)sulfonyl]amino]benzoic acid 681246-21-9P, 8-Methyl-2-([[2-([3-(4-morpholinyl)-3-oxopropyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681246-22-0P, 8-Methyl-2-([[2-([3-oxo-3-(1-piperazinyl)propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681246-23-1P, 2-([[2-([2,2-Dimethyl-3-oxo-3-(1-piperazinyl)propyl]amino)phenyl]sulfonyl]amino)-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681246-24-2P, 3-Ethyl-6-[([4-fluoro-2-[4-(2-methyl-1-pyrrolidinyl)butyl]phenyl]sulfonyl)amino]-2-methoxybenzoic acid 681246-25-3P, 6-[([2-[4-(Diethylamino)butyl]-4-fluorophenyl]sulfonyl)amino]-3-ethyl-2-methoxybenzoic acid 681246-26-4P, 2-[[(2-[[2-(4-Pyridinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681246-27-5P, 2-[[(4-Bromo-2-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid 681255-09-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT 67-64-1, Acetone, reactions 75-26-3, 2-Bromopropane 78-81-9, Isobutylamine 78-84-2, 2-Methylpropanal 78-93-3, 2-Butanone, reactions 83-33-0, 1-Indanone 85-46-1, 1-Naphthalenesulfonyl chloride 91-59-8, 2-Naphthylamine 93-11-8, 2-Naphthalenesulfonyl chloride 96-15-1, 2-Methylbutylamine 96-17-3, 2-Methylbutanal 96-32-2, Methyl bromoacetate 96-33-3, Methyl acrylate 97-08-5, 4-Chloro-3-nitrobenzenesulfonyl chloride 97-96-1, 2-Ethylbutanal 98-09-9, Benzenesulfonyl chloride 98-31-7, 3,4-Dichlorobenzenesulfonyl chloride 98-58-8, 4-Bromobenzenesulfonyl chloride 98-59-9, 4-Methylbenzenesulfonyl chloride 98-60-2, 4-Chlorobenzenesulfonyl chloride 98-61-3, 4-Iodobenzenesulfonyl chloride 98-68-0, 4-

Methoxybenzenesulfonyl chloride 98-74-8, 4-Nitrobenzenesulfonyl chloride 98-80-6, Phenylboronic acid 100-36-7, N,N-Diethyl-1,2-ethanediamine 100-37-8, 2-(Diethylamino)ethanol 102-83-0, N,N-Dibutyl-1,3-propanediamine 104-75-6, 2-Ethylhexylamine 104-78-9, 3-(Diethylamino)propylamine 105-56-6, Ethyl cyanoacetate 107-85-7, 3-Methylbutylamine 108-00-9, N,N-Dimethyl-1,2-ethanediamine 108-91-8, Cyclohexylamine, reactions 108-94-1, Cyclohexanone, reactions 109-01-3, 1-Methylpiperazine 109-05-7, 2-Methylpiperidine 109-55-7, N,N-Dimethyl-1,3-propanediamine 109-73-9, Butylamine, reactions 109-76-2, 1,3-Diaminopropane 109-85-3, 2-Methoxyethylamine 110-58-7, 1-Aminopentane 110-76-9, 2-Ethoxyethylamine 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 111-26-2, 1-Aminohexane 111-49-9, Azepane 120-92-3, Cyclopentanone 121-02-8, 2-Methyl-5-nitrobenzenesulfonyl chloride 121-05-1, 2-(Diisopropylamino)ethylamine 121-51-7, 3-Nitrobenzenesulfonyl chloride 121-60-8, 4-(Acetylamino)benzenesulfonyl chloride 123-75-1, Pyrrolidine, reactions 133-59-5, 2-Methylbenzenesulfonyl chloride 140-31-8, 1-(2-Aminoethyl)piperazine 140-80-7, 4-(Diethylamino)-1-methylbutylamine 156-87-6, 3-Amino-1-propanol 313-12-2, 3-(Trifluoromethyl)anthranilic acid 349-88-2, 4-Fluorobenzenesulfonyl chloride 350-03-8, 3-Acetylpyridine 445-05-6, 2-Methyl-5-fluorobenzenesulfonyl chloride 574-98-1, N-(2-Bromoethyl)phthalimide 589-16-2, 4-Ethylaniline 590-50-1, 4,4-Dimethyl-2-pentanone 598-74-3, 2-Amino-3-methylbutane 605-65-2, 5-(Dimethylamino)-1-naphthalenesulfonyl chloride 609-09-6, Diethyl ketomalonate 616-79-5, 2-Amino-5-nitrobenzoic acid 622-93-5, 3-(Diethylamino)-1-propanol 625-36-5, 3-Chloropropanoyl chloride 626-56-2, 3-Methylpiperidine 626-58-4, 4-Methylpiperidine 701-27-9, 3-Fluorobenzenesulfonyl chloride 705-21-5, 3,5-Dichlorobenzenesulfonyl chloride 765-38-8, 2-Methylpyrrolidine 765-43-5, Acetylcyclopropane 773-64-8, 2,4,6-Trimethylbenzenesulfonyl chloride 777-44-6, 3-(Trifluoromethyl)benzenesulfonyl chloride 872-53-7, Cyclopentanecarboxaldehyde 927-74-2, 4-Hydroxy-1-butyne 1003-03-8, Cyclopentylamine 1003-04-9, Dihydro-3(2H)-thiophenone 1072-72-6, Tetrahydro-4H-thiopyran-4-one 1121-60-4, 2-Pyridinecarboxaldehyde 1191-95-3, Cyclobutanone 1445-73-4, 1-Methyl-4-piperidone 1483-28-9, 2,5-Dimethoxybenzenesulfonyl chloride 1489-69-6, Cyclopropanecarboxaldehyde 1623-93-4, 4-Phenylbenzenesulfonyl chloride 1633-82-5, 3-Chloro-1-propanesulfonyl chloride 1656-44-6, 2,4-Dinitrobenzenesulfonyl chloride 1663-39-4, tert-Butyl acrylate 1694-92-4, 2-Nitrobenzenesulfonyl chloride 1899-93-0, 3-Methylbenzenesulfonyl chloride 1939-99-7, Phenylmethanesulfonyl chloride 1942-52-5, 2-(Diethylamino)ethanethiol hydrochloride 2038-03-1, N-2-Aminoethylmorpholine 2043-61-0, Cyclohexanecarboxaldehyde 2148-56-3, 2-Amino-6-chlorobenzoic acid 2386-60-9, 1-Butanesulfonyl chloride 2516-47-4, Cyclopropylmethylamine 2706-56-1, 2-(2-Aminoethyl)pyridine 2759-28-6, 1-Benzylpiperazine 2766-74-7, 5-Chloro-2-thiophenesulfonyl chloride 2888-06-4, 3-Chlorobenzenesulfonyl chloride 2905-21-7, 2-Fluorobenzenesulfonyl chloride 2905-23-9, 2-Chlorobenzenesulfonyl chloride 2905-24-0, 3-Bromobenzenesulfonyl chloride 2905-25-1, 2-Bromobenzenesulfonyl chloride 2906-12-9, 3-Isopropoxypropylamine 2991-42-6, 4-(Trifluoromethyl)benzenesulfonyl chloride 3230-36-2 3360-16-5, 3-(Isopropylamino)propylamine 3378-71-0, 2,5-Dimethylpyrrolidine 3437-33-0, 3-(1-Azepanyl)-1-propanamine 3529-08-6, 1-Piperidinepropanamine 3529-10-0, N,N-Dimethyl-1,4-butanediamine 3731-53-1, 4-(Aminomethyl)pyridine 4079-68-9 4104-45-4 4318-42-7, 1-Isopropylpiperazine 4389-50-8, 2-Amino-6-methylbenzoic acid 4426-47-5, n-Butylboronic acid 4461-39-6, 2-[(3-Aminopropyl)amino]ethanol 4543-96-8, N,N,N'-Trimethyl-1,3-propanediamine 4572-03-6, 3-(4-Methyl-1-piperazinyl)-1-propanamine 4635-59-0, 4-Chlorobutanoyl chloride 4985-85-7, 2-[(3-Aminopropyl)(2-hydroxyethyl)amino]ethanol 5036-48-6, 3-(1H-Imidazol-1-yl)-1-propanamine 5271-38-5, 2-(Methylsulfanyl)ethanol 5332-73-0, 1-Methoxy-3-aminopropane 5390-04-5, 4-Pentyn-1-ol 5402-73-3, 2,5-Dichlorobenzenesulfonyl chloride 5460-29-7, N-(3-Bromopropyl)phthalimide 5596-87-2 5794-88-7 5813-64-9, 1-Amino-2,2-dimethylpropane 6053-81-2, (Cyclopentylmethyl)amine 6089-09-4, 4-Pentynoic acid 6291-85-6,

3-Ethoxypropylamine 6336-45-4, Dibutyl vinylboronate 6783-05-7, trans-2-Phenylvinylboronic acid 7154-73-6, 2-(1-Pyrrolidinyl)ethanamine 7486-35-3, Tributyl(vinyl)tin 7547-97-9, trans-Propenylboronic acid 7565-57-3, Cyclohexylzinc bromide 7663-77-6, 1-(3-Aminopropyl)-2-pyrrolidinone 10130-74-2, 3-Methoxybenzenesulfonyl chloride 10147-36-1, 1-Propanesulfonyl chloride 10563-23-2, 3-(Ethylamino)propylamine 13139-17-8 13258-63-4, 4-(2-Aminoethyl)pyridine 13325-10-5, 4-Amino-1-butanol 13918-92-8, 2,4-Difluorobenzenesulfonyl chloride 13952-84-6, 2-Aminobutane 14156-91-3, 3-(3-Methyl-1-piperidinyl)-1-propanamine 14165-22-1, 2-(Dipropylamino)ethylamine 15029-30-8, 1-Cyanoacetylpiperidine 15084-51-2, 4-tert-Butylbenzenesulfonyl chloride 15673-00-4, 1-Amino-3,3-dimethylbutane 15761-39-4, tert-Butoxycarbonyl-L-proline 15932-66-8, 2-(2-Aminoethyl)piperidine 15945-07-0, 2,4,5-Trichlorobenzenesulfonyl chloride 16133-25-8, 3-Pyridinesulfonyl chloride 16271-33-3, 2,4-Dichlorobenzenesulfonyl chloride 16499-88-0, 3-Butoxypropylamine 16629-19-9, 2-Thiophenesulfonyl chloride 16728-59-9, 3-Propoxypropylamine 18704-37-5, 8-Chlorosulfonylquinoline 19040-62-1, 2,5-Dimethylbenzenesulfonyl chloride 21043-40-3, 1-Cyclopentylpiperazine 22160-08-3, (2R)-2-Ethylpiperidine 23094-94-2, 2-Chloro-4-methoxybenzenesulfonyl chloride 23095-05-8, 5-Bromo-2-methoxybenzenesulfonyl chloride 23095-31-0, 3,4-Dimethoxybenzenesulfonyl chloride 23099-21-0, (3-Piperidinylmethyl)amine 23159-07-1, 3-(1-Pyrrolidinyl)propylamine 23378-88-3, 3,5-Dichloro-2-hydroxybenzenesulfonyl chloride 23418-85-1, 3-Butynyl 4-methylbenzenesulfonate 24425-40-9, 5-Indanamine 24715-90-0, 4-(1-Pyrrolidinyl)butylamine 25300-37-2, 2-Chloro-6-methylbenzenesulfonyl chloride 25560-00-3, 3-(2-Methyl-1-piperidinyl)propylamine 26116-12-1, 2-(Aminomethyl)-1-ethylpyrrolidine 26638-43-7, Methyl 2-(chlorosulfonyl)benzoate 26735-20-6, N-(3-Aminopropyl)-N-cyclohexyl-N-methylamine 27431-62-5, 4-(Diethylamino)butylamine 27578-60-5, 2-(1-Piperidinyl)ethylamine 29943-42-8, Tetrahydro-4H-pyran-4-one 32333-53-2, 4-Chloro-3-(trifluoromethyl)benzenesulfonyl chloride 32923-88-9, 3-Isobutoxypropylamine 34732-09-7, 2,3,4-Trichlorobenzenesulfonyl chloride 34885-02-4, 3-(1-Piperazinyl)propylamine 37784-17-1, N-tert-Butoxycarbonyl-D-proline 39234-86-1, 3,5-Di(trifluoromethyl)benzenesulfonyl chloride 39546-32-2, Isonipecotamide 40218-49-3, 2-Propyl-1,3,2-benzodioxaborole 40327-96-6, 4-Amino-1,2,2,6,6-pentamethylpiperidine 40353-34-2, 7-Nitro-3,4-dihydro-1(2H)-naphthalenone 42185-03-5, 2-Propoxyethylamine 42413-03-6, 3-Chloro-4-methylbenzenesulfonyl chloride 49584-26-1, 4-Cyanobenzenesulfonyl chloride 50541-93-0, 4-Amino-1-benzylpiperidine 51387-90-7, 2-[(1-Methyl-2-pyrrolidinyl]ethylamine 51605-97-1, 2-Bromo-4-isopropylaniline 52147-97-4, (E)-2-Phenylethylenesulfonyl chloride 52727-57-8, Methyl 2-amino-5-bromobenzoate 53369-71-4 53485-07-7, N-(3-Aminopropyl)-N-methylaniline 53600-33-2, 2-Amino-6-methoxybenzoic acid 54398-51-5, 6-Amino-5-quinolinecarbonitrile 54997-90-9 .55790-39-1, 3-(Diethylamino)propanethiol 56542-67-7, 3-Cyanobenzenesulfonyl chloride 56946-83-9, 2,5-Dichloro-3-thiophenesulfonyl chloride 57260-71-6, 1-tert-Butoxycarbonylpiperazine 58457-24-2, 5-Chloro-4-nitro-2-thiophenesulfonyl chloride 58859-46-4, Ethyl 4-amino-1-piperidinecarboxylate 59337-92-7, Methyl 3-(chlorosulfonyl)-2-thiophenecarboxylate 60956-26-5, 4-Bromo-2-nitrotoluene 63493-28-7, 2-Aminopentane 63624-28-2, 2,4-Dimethoxybenzenesulfonyl chloride 66715-65-9, 2-Pyridinesulfonyl chloride 73713-79-8, 2,1,3-Benzothiadiazole-4-sulfonyl chloride 75178-96-0, tert-Butyl [3-aminopropyl]carbamate 76745-74-9 80466-79-1, 3,5-Dimethyl-4-isoxazolesulfonyl chloride 81731-43-3, 2-Isopropoxyethylamine 82417-45-6, 2,3-Dichlorobenzenesulfonyl chloride 85723-72-4, 3-[2,6-Dimethyl-1-piperidinyl]-1-propanamine 85958-57-2, 2-Chloro-4-fluorobenzenesulfonyl chloride 86595-37-1 88040-86-2, 2-Methoxy-5-methylbenzenesulfonyl chloride 88398-93-0, 5-Chloro-1,3-dimethyl-1H-pyrazole-4-sulfonyl chloride 89265-35-0, 2-(Methylsulfonyl)benzenesulfonyl chloride 91170-93-3,

3-Chloro-4-fluorobenzenesulfonyl chloride 92273-73-9, Butylzinc bromide 92274-43-6 94108-56-2, 4-(Trifluoromethoxy)benzenesulfonyl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT 101555-60-6 103008-51-1, 2-(Trifluoromethoxy)benzenesulfonyl chloride 124397-96-2, Hexylzinc bromide 126403-67-6, Isobutylzinc bromide 126714-85-0, 4,5-Dichloro-2-thiophenesulfonyl chloride 127720-93-8, 7-Chloro-2,1,3-benzothiadiazole-4-sulfonyl chloride 137049-00-4, 1-Methyl-1H-imidazole-4-sulfonyl chloride 137049-02-6, 1,2-Dimethyl-1H-imidazole-4-sulfonyl chloride 138872-44-3, 5-[(Benzoylamino)methyl]-2-thiophenesulfonyl chloride 143193-41-3, 2-Butoxy-5-(1,1-dimethylpropyl)benzenesulfonyl chloride 144222-22-0, 1-tert-Butoxycarbonyl-4-(aminomethyl)piperidine 145758-05-0, 3,4-Difluorobenzenesulfonyl chloride 146949-07-7, 4-Propylbenzenesulfonyl chloride 154230-29-2 156567-57-6, Propylzinc bromide 160233-27-2, 5-(3-Isoxazolyl)-2-thiophenesulfonyl chloride 162167-97-7, 1-tert-Butoxycarbonyl-3-(aminomethyl)piperidine 166964-33-6 166964-34-7, 5-[[(4-Chlorobenzoyl)amino]methyl]-2-thiophenesulfonyl chloride 166964-37-0, 5-(Phenylsulfonyl)-2-thiophenesulfonyl chloride 171860-68-7, Cyclopentylzinc bromide 174311-79-6, Ethyl 6-amino-1H-indole-7-carboxylate 175278-17-8, 2-Bromo-4-(trifluoromethoxy)aniline 216159-03-4, 4-Bromo-2-fluorobenzenesulfonyl chloride 216394-05-7, 5-Bromo-6-chloro-3-pyridinesulfonyl chloride 270912-72-6, 1-tert-Butoxycarbonyl-3-(aminomethyl)pyrrolidine 308796-10-3, Pentylzinc bromide 312693-02-0, 2-Ethylbutylzinc bromide 351003-45-7, 2-Bromo-4-fluorobenzenesulfonyl chloride 496808-04-9, 1-[(1-Methyl-4-piperidinyl)methyl]-4-piperazine 681248-31-7 681248-32-8 681248-33-9 681248-34-0, Methyl 2-[([2-bromophenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681248-35-1, 3-[4-(4-Trifluoromethylpyrimidin-2-yl)piperazin-1-yl]propylamine 681248-36-2, 2-Methyl-3-(4-methyl-1-piperidinyl)-1-propanamine 681847-93-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT 123-00-2P, 3-(4-Morpholinyl)-1-propanamine 610-36-6P, 4-Amino-2-nitrobenzoic acid 2475-82-3P, 2-Amino-5-ethylbenzoic acid 4553-26-8P, 3-(4-Isopropyl-1-piperazinyl)-1-propanamine 5588-87-4P, 1H-Benzo[e]indole-1,2(3H)-dione 13991-22-5P 14227-95-3P, 3-Oxo-3-(1-pyrrolidinyl)propanenitrile 14227-98-6P 15029-32-0P, 3-(4-Morpholinyl)-3-oxopropanenitrile 17122-70-2P, N-(4-Ethylphenyl)-2-(hydroxyimino)acetamide 20776-50-5P, 2-Amino-4-bromobenzoic acid 22009-40-1P, 7-Amino-3,4-dihydro-1(2H)-naphthalenone 24623-24-3P, 6-Nitro-1-indanone 29777-09-1P, N,N-Diethyl-3-butyn-1-amine 62078-76-6P, (7-Fluoronaphth-2-yl)amine 64241-01-6P, Methyl 2-amino-6-hydroxybenzoate 67765-42-8P, 5-Methoxy-2H-3,1-benzoxazine-2,4(1H)-dione 68701-22-4P, 2-Amino-5-isopropylbenzoic acid 68748-07-2P, N-(2-Bromo-4-isopropylphenyl)acetamide 69610-40-8P 69975-65-1P, 6-Amino-1-indanone 77758-50-0P 79069-38-8P, 2-(Acetylamino)-5-isopropylbenzoic acid 79979-69-4P, 2-Amino-1-naphthoic acid 86661-32-7P, tert-Butyl (2S)-2-([[(4-methylphenyl)sulfonyl]oxy]methyl)-1-pyrrolidinecarboxylate 90321-34-9P 90796-54-6P, 2,2-Dimethyl-3-(4-morpholinyl)-1-propanamine 91569-18-5P 96202-56-1P, 5-Ethyl-1H-indole-2,3-dione 115186-37-3P 116487-43-5P, 7-Bromo-1H-benzo[e]indole-1,2(3H)-dione 124341-06-6P, 6-Amino-3-bromo-2-methylbenzoic acid 126378-10-7P, Benzyl (4E)-5-(tributylstannyl)-4-pentenoate 126378-11-8P, Benzyl 4-pentynoate 132482-06-5P, tert-Butyl (2R)-2-(2-hydroxyethyl)-1-pyrrolidinecarboxylate 132734-41-9P, 2-Amino-5,6,7,8-tetrahydro-naphthalene-1-carboxylic acid methyl ester 135484-65-0P, Methyl 5-bromo-2-[(phenylsulfonyl)amino]benzoate 136247-94-4P, 2-[(tert-Butoxycarbonyl)amino]-6-methoxybenzoic acid 159539-65-8P, 2,2-Dimethyl-7-nitro-3,4-dihydro-1(2H)-naphthalenone 159873-21-9P, tert-Butyl 4-(2-cyanoacetyl)-1-piperazinecarboxylate 214697-98-0P, 7-Amino-8-bromo-3,4-dihydro-1(2H)-naphthalenone 239483-09-1P, tert-Butyl (2S)-2-(2-aminoethyl)-1-pyrrolidinecarboxylate 269391-47-1P, 2-[(tert-Butoxycarbonyl)amino]-6-methylbenzoic acid 373608-47-0P,

3-(4-Cyclopentyl-1-piperazinyl)-1-propanamine 550378-07-9P, tert-Butyl (2R)-2-(2-aminoethyl)-1-pyrrolidinecarboxylate 616224-61-4P, 2-[(tert-Butoxycarbonyl)amino]-6-chlorobenzoic acid 677291-24-6P, 2-[[(2-Bromophenyl)sulfonyl]amino]-1-naphthoic acid 677291-25-7P, 2-Amino-7-fluoro-1-naphthoic acid 677291-27-9P, 2-Amino-6-bromo-1-naphthoic acid 681244-26-8P, 3-Bromo-6-[[(2-fluorophenyl)sulfonyl]amino]-2-propoxybenzoic acid 681246-29-7P 681246-31-1P, Methyl 5-nitro-2-[(phenylsulfonyl)amino]benzoate 681246-32-2P, 6-Amino-5-quinolinecarboxylic acid 681246-33-3P, Methyl 6-amino-5-quinolinecarboxylate 681246-34-4P, Methyl 6-[(phenylsulfonyl)amino]-5-quinolinecarboxylate 681246-35-5P, Methyl 2-[[(4-fluorophenyl)sulfonyl]amino]-1-naphthoate 681246-36-6P, N-(1-Bromo-8-oxo-5,6,7,8-tetrahydro-2-naphthalenyl)-4-fluorobenzenesulfonamide 681246-37-7P, 3-Bromo-6-[(tert-butoxycarbonyl)amino]-2-methylbenzoic acid 681246-39-9P, Benzyl 3-bromo-6-[(tert-butoxycarbonyl)amino]-2-methylbenzoate 681246-40-2P, Benzyl 6-amino-3-cyano-2-methylbenzoate 681246-41-3P, Benzyl 3-cyano-2-methyl-6-[(phenylsulfonyl)amino]benzoate 681246-42-4P, Benzyl 3-bromo-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoate 681246-43-5P, Methyl 2-[(2-pyridinylsulfonyl)amino]-1-naphthoate 681246-44-6P, Benzyl 3-butyl-2-methyl-6-[(3-pyridinylsulfonyl)amino]benzoate 681246-45-7P, Benzyl 6-amino-3-bromo-2-methylbenzoate 681246-46-8P, Benzyl 3-bromo-6-[[(3-fluorophenyl)sulfonyl]amino]-2-methylbenzoate 681246-47-9P, tert-Butyl 1,2-dioxo-1,2-dihydro-3H-benzo[e]indole-3-carboxylate 681246-48-0P, 2-[(tert-Butoxycarbonyl)amino]-1-naphthoic acid 681246-49-1P, 6-Amino-7-bromo-1-indanone 681246-50-4P, N-(4-Bromo-3-oxo-2,3-dihydro-1H-inden-5-yl)benzenesulfonamide 681246-51-5P, Benzyl 2-methyl-6-[(2-pyridinylsulfonyl)amino]-3-vinylbenzoate 681246-52-6P, N-(1-Bromo-5,6-dihydro-2-naphthalenyl)-4-fluorobenzenesulfonamide 681246-53-7P, N-(1-Bromo-8-methyl-5,6-dihydro-2-naphthalenyl)-4-fluorobenzenesulfonamide 681246-54-8P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-1-naphthoate 681246-55-9P, Benzyl 6-[(tert-butoxycarbonyl)amino]-2-methyl-3-vinylbenzoate 681246-56-0P, 6-[(tert-Butoxycarbonyl)amino]-3-ethyl-2-methylbenzoic acid 681246-57-1P, Methyl 2-amino-3-chloro-1-naphthoate 681246-58-2P, Methyl 3-chloro-2-[[(4-fluorophenyl)sulfonyl]amino]-1-naphthoate 681246-59-3P, Benzyl 6-[(tert-butoxycarbonyl)amino]-2-methyl-3-propylbenzoate 681246-60-6P, Benzyl 6-amino-2-methyl-3-propylbenzoate 681246-61-7P, Benzyl 2-methyl-3-propyl-6-[(2-pyridinylsulfonyl)amino]benzoate 681246-62-8P, Methyl 2-([[2-(methoxycarbonyl)phenyl]sulfonyl]amino)-1-naphthoate 681246-63-9P, 2-([[1-(Methoxycarbonyl)-2-naphthyl]amino]sulfonyl)benzoic acid 681246-64-0P, Methyl 2-[[(2-[[(3-methoxypropyl)amino]carbonyl]phenyl)sulfonyl]amino]-1-naphthoate 681246-65-1P, Benzyl 6-[[(4-fluorophenyl)sulfonyl]amino]-2-methyl-3-propylbenzoate 681246-66-2P, 3-Bromo-6-[(tert-butoxycarbonyl)amino]-2-methoxybenzoic acid 681246-67-3P, Methyl 2-([[2-(1-pyrrolidinylcarbonyl)phenyl]sulfonyl]amino)-1-naphthoate 681246-68-4P, Benzyl 3-bromo-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methylbenzoate 681246-69-5P, Benzyl 6-[[(2-fluorophenyl)sulfonyl]amino]-2-methyl-3-vinylbenzoate 681246-70-8P, Methyl 2-[([2-[(4-methyl-1-piperazinyl)carbonyl]phenyl]sulfonyl)amino]-1-naphthoate 681246-71-9P, Benzyl 3-[(1E)-3-methoxy-3-oxo-1-propenyl]-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoate 681246-72-0P, N-(1-Bromo-8-methyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4-fluorobenzenesulfonamide 681246-73-1P, 3-Bromo-6-[(tert-butoxycarbonyl)amino]-2-chlorobenzoic acid 681246-74-2P, Benzyl 3-bromo-6-[(tert-butoxycarbonyl)amino]-2-chlorobenzoate 681246-75-3P, Benzyl 6-amino-3-bromo-2-chlorobenzoate 681246-76-4P, Benzyl 3-bromo-2-chloro-6-[[(4-fluorophenyl)sulfonyl]amino]benzoate 681246-77-5P, Benzyl 2-chloro-6-[[(4-fluorophenyl)sulfonyl]amino]-3-vinylbenzoate 681246-78-6P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681246-79-7P, Benzyl 3-bromo-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methylbenzoate 681246-80-0P, Benzyl 6-[[(4-fluorophenyl)sulfonyl]amino]-3-(hydroxymethyl)-2-methylbenzoate 681246-82-2P, Benzyl 6-[[(4-fluorophenyl)sulfonyl]amino]-3-(1-hydroxyethyl)-2-methylbenzoate 681246-83-3P, N-(1-Bromo-8-oxo-5,6,7,8-

tetrahydro-2-naphthalenyl)-2-fluorobenzenesulfonamide 681246-84-4P, N-(1-Bromo-8-methyl-5,6-dihydro-2-naphthalenyl)-2-fluorobenzenesulfonamide 681246-85-5P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylate 681246-86-6P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681246-87-7P, N-(1-Bromo-8-methyl-7-oxo-5,6,7,8-tetrahydro-2-naphthalenyl)-4-fluorobenzenesulfonamide 681246-88-8P, Methyl 2-([[2-([[2-(diethylamino)ethyl]amino]carbonyl)phenyl]sulfonyl]amino)-1-naphthoate 681246-89-9P, Benzyl 3-bromo-6-[(tert-butoxycarbonyl)amino]-2-methoxybenzoate 681246-90-2P, Benzyl 6-amino-3-bromo-2-methoxybenzoate 681246-91-3P, Benzyl 3-bromo-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxybenzoate 681246-92-4P, Benzyl 6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxy-3-vinylbenzoate 681246-93-5P, Benzyl 3-bromo-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methoxybenzoate 681246-94-6P, N-(1-Bromo-7,8-dimethyl-5,8-dihydro-2-naphthalenyl)-2-fluorobenzenesulfonamide 681246-95-7P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-7,8-dimethyl-5,8-dihydro-1-naphthalenecarboxylate 681246-96-8P, Benzyl 3-bromo-2-methoxy-6-[(2-pyridinylsulfonyl)amino]benzoate 681246-97-9P, Benzyl 2-methoxy-6-[(2-pyridinylsulfonyl)amino]-3-vinylbenzoate 681246-98-0P, Benzyl 6-[[(4-fluorophenyl)sulfonyl]amino]-2-methoxy-3-vinylbenzoate 681246-99-1P, 7-Amino-8-bromo-2,2-dimethyl-3,4-dihydro-1(2H)-naphthalenone 681247-00-7P, N-(1-Bromo-7,7-dimethyl-8-oxo-5,6,7,8-tetrahydro-2-naphthalenyl)-2-fluorobenzenesulfonamide 681247-01-8P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-7,7-dimethyl-8-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-02-9P, N-(1-Bromo-8-methylene-5,6,7,8-tetrahydro-2-naphthalenyl)-2-fluorobenzenesulfonamide 681247-03-0P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-8-methylene-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-04-1P, 3-Bromo-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxybenzoic acid 681247-05-2P, Methyl 2-([[2-(methoxycarbonyl)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-06-3P, 2-([[1-(Methoxycarbonyl)-5,6,7,8-tetrahydro-2-naphthalenyl]amino]sulfonyl)benzoic acid 681247-07-4P, Methyl 2-([[2-([[2-(diethylamino)ethyl]amino]carbonyl)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-08-5P, Methyl 2-[[(2-[[[3-(dimethylamino)propyl](methyl)amino]carbonyl]phenyl)sulfonyl]amino]-1-naphthoate 681247-09-6P, 6-Bromo-5-methoxy-2H-3,1-benzoxazine-2,4(1H)-dione 681247-10-9P, 6-Bromo-5-hydroxy-2H-3,1-benzoxazine-2,4(1H)-dione 681247-11-0P, Methyl 6-amino-3-bromo-2-hydroxybenzoate 681247-12-1P, Methyl 6-amino-3-bromo-2-ethoxybenzoate 681247-13-2P, Methyl 3-bromo-2-ethoxy-6-[[(2-fluorophenyl)sulfonyl]amino]benzoate 681247-14-3P, Methyl 2-ethoxy-6-[[(2-fluorophenyl)sulfonyl]amino]-3-vinylbenzoate 681247-15-4P, Methyl 2-ethoxy-3-ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]benzoate 681247-16-5P, 5-Hydroxy-2H-3,1-benzoxazine-2,4(1H)-dione 681247-17-6P, Methyl 2-amino-6-ethoxybenzoate 681247-18-7P, Methyl 2-ethoxy-6-[[(4-fluorophenyl)sulfonyl]amino]benzoate 681247-19-8P, Methyl 3-bromo-2-ethoxy-6-[[(4-fluorophenyl)sulfonyl]amino]benzoate 681247-20-1P, Methyl 2-ethoxy-6-[[(4-fluorophenyl)sulfonyl]amino]-3-vinylbenzoate 681247-21-2P, Methyl 2-ethoxy-3-ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]benzoate 681247-22-3P, 2,2-Dimethyl-3-oxo-3-(1-piperidinyl)propanenitrile 681247-23-4P, 2,2-Dimethyl-3-(1-piperidinyl)-1-propanamine 681247-24-5P 681247-25-6P 681247-26-7P, 2,2-Dimethyl-3-oxo-3-(1-pyrrolidinyl)propanenitrile 681247-27-8P, 2,2-Dimethyl-3-(1-pyrrolidinyl)-1-propanamine 681247-28-9P, 2-Ethyl-2-(1-piperidinylmethyl)-1-butanamine 681247-29-0P, Methyl 6-amino-3-bromo-2-propoxybenzoate 681247-30-3P, Methyl 3-bromo-6-[[(2-fluorophenyl)sulfonyl]amino]-2-propoxybenzoate 681247-31-4P 681247-32-5P 681247-33-6P 681247-34-7P, Methyl 2-[[(2-nitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-35-8P, Methyl 2-[[(2-aminophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-36-9P, Methyl 6-[[(2-fluorophenyl)sulfonyl]amino]-2-propoxy-3-vinylbenzoate 681247-37-0P, Methyl 3-ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]-2-propoxybenzoate 681247-38-1P, Methyl

2-[[(2-fluorophenyl)sulfonyl]amino]-8-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-39-2P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-8-methoxy-5,6-dihydro-1-naphthalenecarboxylate 681247-40-5P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-8-methoxy-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-41-6P, Methyl 3-([[1-(methoxycarbonyl)-5,6,7,8-tetrahydro-2-naphthalenyl]amino]sulfonyl)-2-thiophenecarboxylate 681247-42-7P, 3-([[1-(Methoxycarbonyl)-5,6,7,8-tetrahydro-2-naphthalenyl]amino]sulfonyl)-2-thiophenecarboxylic acid 681247-43-8P, Methyl 2-([[2-([[2-(diethylamino)ethyl]amino]carbonyl)-3-thienyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-44-9P, Methyl 6-amino-3-bromo-2-(2-methoxy-2-oxoethoxy)benzoate 681247-45-0P, Methyl 3-bromo-6-[[(4-fluorophenyl)sulfonyl]amino]-2-(2-methoxy-2-oxoethoxy)benzoate 681247-46-1P, Methyl 6-[[(4-fluorophenyl)sulfonyl]amino]-2-(2-methoxy-2-oxoethoxy)-3-vinylbenzoate 681247-47-2P, Methyl 3-ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]-2-(2-methoxy-2-oxoethoxy)benzoate 681247-48-3P, Methyl 6-amino-3-bromo-2-methoxybenzoate 681247-49-4P, Methyl 3-bromo-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxybenzoate 681247-50-7P, Methyl 6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxy-3-vinylbenzoate 681247-51-8P, Methyl 3-ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxybenzoate 681247-52-9P, Methyl 3-bromo-5-ethyl-2-[[(2-fluorophenyl)sulfonyl]amino]-6-methoxybenzoate 681247-53-0P, Methyl 5-ethyl-2-[[(2-fluorophenyl)sulfonyl]amino]-4-methoxy-1,1'-biphenyl-3-carboxylate 681247-54-1P, Methyl 2-amino-3-bromo-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-55-2P, Methyl 2-amino-3-[(1E)-3-tert-butoxy-3-oxo-1-propenyl]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-56-3P, Methyl 3-[(1E)-3-tert-butoxy-3-oxo-1-propenyl]-2-[(phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-57-4P 681247-58-5P, Methyl 2-[methyl-([2-[(4-piperidinylmethyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-59-6P, Methyl 2-chloro-6-[[(2-fluorophenyl)sulfonyl]amino]benzoate 681247-60-9P, Methyl 2-[(1E)-5-(benzyloxy)-5-oxo-1-pentenyl]-6-[[(2-fluorophenyl)sulfonyl]amino]benzoate 681247-61-0P, 5-[3-[[(2-Fluorophenyl)sulfonyl]amino]-2-(methoxycarbonyl)phenyl]pentanoic acid 681247-62-1P 681247-63-2P 681247-64-3P 681247-65-4P, Methyl 2-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-66-5P, Methyl 2-[[(2-([[4-(diethylamino)-1-methylbutyl]amino]carbonyl)-4-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-67-6P, Methyl 6-amino-3-bromo-2-[2-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]benzoate 681247-68-7P, Methyl 6-amino-2-[2-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-vinylbenzoate 681247-69-8P, Methyl 6-amino-3-ethyl-2-[2-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]benzoate 681247-70-1P, Methyl 2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]benzoate 681247-71-2P, Methyl 6-[[(2-bromophenyl)sulfonyl]amino]-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethylbenzoate 681247-72-3P, Methyl 6-[[(2-[(1E)-3,3-dimethyl-1-butenyl]phenyl)sulfonyl]amino]-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethylbenzoate 681247-73-4P, Methyl 6-[[(2-(3,3-dimethylbutyl)phenyl)sulfonyl]amino]-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethylbenzoate 681247-74-5P, Methyl 2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethyl-6-[([2-[(1E)-1-propenyl]phenyl]sulfonyl)amino]benzoate 681247-75-6P, Methyl 2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethyl-6-[([2-propylphenyl]sulfonyl)amino]benzoate 681247-76-7P, N,N-Diethyl-N-[(3Z)-4-(tributylstannyl)-3-butenyl]amine 681247-77-8P, N,N-Diethyl-N-[(3E)-4-(tributylstannyl)-3-butenyl]amine 681247-78-9P, Methyl 2-[([2-[(1E)-4-(diethylamino)-1-butenyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-79-0P, tert-Butyl (2S)-2-(2-[[(benzyloxy)carbonyl]amino]ethyl)-1-pyrrolidinecarboxylate 681247-80-3P 681247-81-4P 681247-82-5P 681247-83-6P 681247-84-7P, 2,2-Dimethyl-3-(4-morpholinyl)-3-oxopropanenitrile 681247-85-8P 681247-86-9P 681247-87-0P, N,N-Diethyl-N-[(2E)-3-(tributylstannyl)-2-propenyl]amine 681247-88-1P, N,N-Diethyl-N-[(2Z)-3-(tributylstannyl)-2-

propenyl]amine 681247-89-2P, Methyl 2-[([2-[(1E)-3-(diethylamino)-1-propenyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-90-5P, Methyl 2-[([2-[4-(diethylamino)butyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-91-6P, Methyl 2-[([2-[(1Z)-3-(diethylamino)-1-propenyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-92-7P, Methyl 2-[([2-[(1Z)-4-(diethylamino)-1-butenyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-93-8P, Methyl 2-amino-3,5-dibromo-6-methoxybenzoate 681247-94-9P, Methyl 2-amino-6-methoxy-3,5-divinylbenzoate 681247-95-0P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-6-methoxy-3,5-divinylbenzoate 681247-96-1P, Methyl 3,5-diethyl-2-[[(2-fluorophenyl)sulfonyl]amino]-6-methoxybenzoate 681247-97-2P, Methyl 6-amino-2-methoxy-3-vinylbenzoate 681247-98-3P, Methyl 6-amino-3-ethyl-2-methoxybenzoate 681247-99-4P, Methyl 6-[[(2-bromophenyl)sulfonyl]amino]-3-ethyl-2-methoxybenzoate 681248-00-0P, Methyl 6-[[(2-[(1E)-2-(4-chlorophenyl)ethenyl]phenyl)sulfonyl]amino]-3-ethyl-2-methoxybenzoate 681248-01-1P, Methyl 3-ethyl-2-methoxy-6-([[2-(2-phenylethyl)phenyl]sulfonyl]amino)benzoate 681248-02-2P, Methyl 6-[([2-[2-(4-chlorophenyl)ethyl]phenyl]sulfonyl)amino]-3-ethyl-2-methoxybenzoate 681248-03-3P, Methyl 3-ethyl-2-methoxy-6-[[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]benzoate 681248-04-4P, Methyl 6-[[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]amino]-3-ethyl-2-methoxybenzoate 681248-05-5P, Methyl 6-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethylbenzoate 681248-06-6P, Methyl 6-amino-3-bromo-2-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propoxy]benzoate 681248-07-7P, Methyl 6-amino-2-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propoxy]-3-vinylbenzoate 681248-08-8P, Methyl 6-amino-2-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propoxy]-3-ethylbenzoate 681248-09-9P, Methyl 6-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-2-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propoxy]-3-ethylbenzoate 681248-10-2P, Methyl 2-amino-3,5-diethyl-6-methoxybenzoate 681248-11-3P, Methyl 2-[([2-[3-(diethylamino)propyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681248-12-4P, N,N-Diethyl-N-[(4E)-5-(tributylstannyl)-4-pentenyl]amine 681248-13-5P, N,N-Diethyl-N-[(4Z)-5-(tributylstannyl)-4-pentenyl]amine 681248-14-6P 681248-15-7P 681248-16-8P, Methyl 2-[([2-[5-(diethylamino)pentyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681248-17-9P, Methyl 2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethyl-6-[[(4-fluoro-2-vinylphenyl)sulfonyl]amino]benzoate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT 681248-18-0P, Methyl 2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethyl-6-[[(2-ethyl-4-fluorophenyl)sulfonyl]amino]benzoate 681248-19-1P 681248-20-4P 681248-21-5P 681248-22-6P 681248-23-7P 681248-24-8P, tert-Butyl 4-(3-amino-2,2-dimethylpropanoyl)-1-piperazinecarboxylate 681248-25-9P, Methyl 6-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-3-ethyl-2-methoxybenzoate 681248-26-0P, Methyl 3-ethyl-6-[[(4-fluoro-2-(4-hydroxy-1-butynyl)phenyl)sulfonyl]amino]-2-methoxybenzoate 681248-27-1P, Methyl 3-ethyl-6-[[(4-fluoro-2-(4-hydroxybutyl)phenyl)sulfonyl]amino]-2-methoxybenzoate 681248-28-2P, Methyl 3-ethyl-6-[[(4-fluoro-2-(4-[(methylsulfonyl)oxy]butyl)phenyl)sulfonyl]amino]-2-methoxybenzoate 681248-29-3P, Methyl 3-ethyl-6-[[(4-fluoro-2-(4-[2-methyl-1-pyrrolidinyl]butyl)phenyl)sulfonyl]amino]-2-methoxybenzoate 681248-30-6P, Methyl 6-[[(2-[4-(diethylamino)butyl]-4-fluorophenyl)sulfonyl]amino]-3-ethyl-2-methoxybenzoate 681255-11-8P, Benzyl 6-[[(4-fluorophenyl)sulfonyl]amino]-2-methyl-3-vinylbenzoate 681255-13-0P, Benzyl 2-chloro-6-[[(2-fluorophenyl)sulfonyl]amino]-3-vinylbenzoate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

```
=> b wpix;d all l4 tot

FILE 'WPIX' ENTERED AT 08:28:56 ON 01 SEP 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED:          26 AUG 2005      <20050826/UP>
MOST RECENT DERWENT UPDATE:     200555        <200555/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
    PLEASE VISIT:
 http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
    http://thomsonderwent.com/coverage/latestupdates/           <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
    GUIDES, PLEASE VISIT:
    http://thomsonderwent.com/support/userguides/               <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
    DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
    FIRST VIEW - FILE WPIFV.
    FOR FURTHER DETAILS: http://www.thomsonderwent.com/dwpifv  <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.
    PLEASE CHECK:
http://thomsonderwent.com/support/dwpiref/reftools/classification/code-revision/
    FOR DETAILS. <<<
'BIX BI,ABEX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE



L4   ANSWER 1 OF 1  WPIX  COPYRIGHT 2005 THE THOMSON CORP on STN
AN   2004-634414 [61]   WPIX
DNC  C2004-227825
TI   New sulfonamide compounds are methionine aminopeptidase-2 inhibitors used
     for treating e.g. cancer and abnormal neovascularization conditions of
     eye.
DC   B05
IN   BAMAUNG, N Y; BARNES, D M; COMESS, K M; ERICKSON, S A; FIDANZE, S D;
     HENKIN, J; KALVIN, D M; KAWAI, M; KIM, K H; KOLACZKOWSKI, L; MANTEI, R A;
     PARK, C H; PARK, D C; SANDERS, W J; SHEPPARD, G S; TEDROW, J S; VASUDEVAN,
     A; WANG, G T; WANG, J
PA   (BAMA-I) BAMAUNG N Y; (BARN-I) BARNES D M; (COME-I) COMESS K M; (ERIC-I)
     ERICKSON S A; (FIDA-I) FIDANZE S D; (HENK-I) HENKIN J; (KALV-I) KALVIN D
     M; (KAWA-I) KAWAI M; (KIMK-I) KIM K H; (KOLA-I) KOLACZKOWSKI L; (MANT-I)
     MANTEI R A; (PARK-I) PARK C H; (PARK-I) PARK D C; (SAND-I) SANDERS W J;
     (SHEP-I) SHEPPARD G S; (TEDR-I) TEDROW J S; (VASU-I) VASUDEVAN A; (WANG-I)
     WANG G T; (WANG-I) WANG J
CYC  1
PI   US 2004167128   A1 20040826 (200461)*     127    C07D279-12      <--
ADT  US 2004167128 A1 Provisional US 2002-416793P 20021008, US
     2003-681784 20031008
PRAI US 2002-416793P      20021008; US 2003-681784
     20031008
IC   ICM  C07D279-12
     ICS  A61K031-495; A61K031-537; A61K031-54; C07D277-04
AB   US2004167128 A UPAB: 20040923
     NOVELTY - Sulfonamide compounds (I), are new.
          DETAILED DESCRIPTION - Sulfonamide compounds of formula (I) and their
     salts are new.
          A = 5- or 6-membered aromatic or non-aromatic ring optionally
     containing 1-3 N, O or S heteroatoms and optionally fused to a second 5-7
     membered aromatic or non-aromatic ring optionally containing 1-3 N, O or S
     heteroatoms;
```

R1-R3 = H, alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyloxy, alkylidene, alkylsulfanyl, alkylsulfanylalkyl, alkylsulfonyl, alkylsulfonylalkyl, amino, aminoalkyl, aminoalkenyl, aminoalkoxy, aminocarbonylalkenyl, aryl, carboxyalkenyl, carboxyalkyl, CN, cycloalkyl, cycloalkylalkyl, halo, haloalkoxy, haloalkyl, heterocyclylalkyl, OH, hydroxyalkyl or NO2;

R4 = H, alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfonyl, aklylsulfanyl, alkylsulfanylalkyl, carboxy, CN, cyanoalkyl, cycloalkyl, cycloalkylalkyl, halo, haloalkoxy, haloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, heterocyclealkenyl, OH, hydroxyalkyl, NO2, phenyl, phenylsulfonyl, Rc4Rd4N, Rc4Rd4Nalkyl, Rc4Rd4Nalkenyl, Rc4Rd4Nalkynyl, Rc4Rd4Nalkoxy, Rc4Rd4Nalkoxycarbonyl, Rc4Rd4Ncarbonyl, Rc4Rd4Ncycloalkyl, Rc4Rd4Nalkylcycloalkyl, Rc4Rd4N(cycloalkyl)alkyl, Rc4Rd4Nsulfinyl, Re4Rf4Nalkyl(Rc4)N, Rc4Rf4Nalkyl(Rc4)N-carbonyl, Rc4Rf4Nalkyl(Rc4)N-carbonylalkenyl, Re4Rf4Nalkylcarbonyl(Rc4)N, Re4Rf4Nalkoxycarbonyl(Rc4)N, Rc4Rd4Nalkylsulfanyl, Rc4Rd4Nalkylsulfinyl, Rc4Rd4Nalkylsulfonyl or Rg4Rj4Nalkyl(Re4)N-carbonyl(Rc4)N (where phenyl, heteroaryl and heterocyclyl are all optionally substituted by 1-3 alkoxy, alkyl, CN, halo, haloalkoxy, haloalkyl or NO2);

Rc4, Rd4, Re4, Rf4, Rg4, Rj4 = T, or

NRc4Rd4, NRe4Rf4 or NRg4Rj4 = heterocyclyl;

T = H, alkyl, alkoxyalkyl, alkylcarbonyl, aminoalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl or phenyl;

R5 = alkyl, amino, aminoalkyl, aryl, arylalkenyl, arylalkyl, haloalkyl, heteroaryl, heteroarylalkenyl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl or heterocyclealkenyl (where aryl, heteroaryl and heterocyclyl are all optionally substituted by 1-3 alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfonyl, aminoalkyl, phenyl, phenylsulfonyl, carboxy, CN, cyanoalkyl, halo, haloalkoxy, haloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, OH, NO2, Rc5Rd5, Rc5Rd5Nalkyl, Rc5Rd5Nalkenyl, Rc5Rd5Nalkynyl, Rc5Rd5Nalkoxy, Rc5Rd5Nalkoxycarbonyl, Rc5Rd5Ncarbonyl, Rc5Rd5Ncycloalkyl, Rc5Rd5Nalkylcycloalkyl, Rc5Rd5Ncycloalkyl, Rc5Rd5Ncycloalkylalkyl, Rc5Rd5Nsulfinyl, Re5Rf5Nalkyl(Rc5)N, Re4Rf5Nalkyl(Rc5)Ncarbonyl, Re5Rf5Nalkyl(Rc5)Ncarbonylalkenyl, Re4Rf5Nalkylcarbonyl(Rc5)N, Re5Rf5Nalkoxycarbonyl(Rc5)N, Rc5Rd5Nalkylsulfanyl, Rc5Rd5Nalkylsulfinyl, Rc5Rd5Nalkylsulfonyl or Rg5Rj5Nalkyl(Re5)Ncarbonyl(Rc5)N (where phenyl, phenylsulfonyl, heteroaryl, heterocyclyl, heterocyclylalkyl or heterocyclylalkenyl are all optionally substituted by 1-3 alkoxy, alkyl, CN, halo, haloalkoxy, haloalkyl or NO2));

Rc5, Rd5, Re5, Rf5, Rg5, Rj5 = T, and

R6 = H, alkyl, alkylsulfanylalkyl, aryl or arylalkyl,

provided that when A is phenyl, then at least one of R1-R4 is not H, 1C alkyl or halo.

ACTIVITY - Cytostatic; Ophthalmological; Antibacterial; Antimalarial; Antiangiogenic; Immunosuppressive; Antirheumatic; Antiarthritic; Antipsoriatic; Antidiabetic; Dermatological; Vasotropic; Gynecological; Anorectic; Cerebroprotective; Vulnerary; Antiarteriosclerotic; Antiulcer; Antipyretic; Hemostatic.

MECHANISM OF ACTION - Methionine aminopeptidase-2 (MetAP2) inhibitor; Endothelial cell proliferation inhibitor.

In an assay for determining inhibition of MetAP2, results showed that (I) exhibited IC50 values of 0.005-10 (preferably 0.005-0.1 micro M.

USE - Used for treating cancer and abnormal neovascularization conditions of the eye (claimed). (I) Are also used for treating primary and metastatic solid tumors, autoimmune diseases such as rheumatoid, immune and degenerative arthritis, psoriatic arthritis, ocular diseases such as diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, retrolental fibroplasia, neovascular glaucoma, rubeosis, retinal neovascularization due to macular degeneration, hypoxia, angiogenesis in the eye associated with infection or surgical intervention, skin diseases such as psoriasis, blood vessel diseases such as hemangiomas, and capillary proliferation within atherosclerotic plaques, endometriosis, obesity, systemic sclerosis, juvenile angiofibroma, septic shock, cerebral edema (from head trauma),

Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma, wound granulation, diseases characterized by excessive or abnormal stimulation of endothelial cells, including intestinal adhesions, Crohn's disease, atherosclerosis, scleroderma and hypertrophic scars (keloids), as birth control agents by inhibiting ovulation and establishment of the placenta, in the treatment of diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (Rochele minutesalia quintosa) and ulcers (Helicobacter pylori) and to reduce bleeding by administration prior to surgery, especially for the treatment of resectable tumors. (I) is also useful as antibacterial, antimalarial and antileishmaniasis agents.

Dwg.0/0

FS CPI

FA AB; GI; DCN

MC CPI: B06-H; B07-H; B10-A08; B14-A01; B14-A03B; B14-A03E; B14-C03; B14-C09B; B14-D07C; B14-E08; B14-E10C; B14-E12; B14-F02D1; B14-F02F2; B14-F07; B14-F08; B14-G02D; B14-H01; B14-K01; B14-N03; B14-N14; B14-N17; B14-P01B; B14-S06

=> b home

FILE 'HOME' ENTERED AT 08:29:00 ON 01 SEP 2005

=>

```
=> d his full

     (FILE 'HOME' ENTERED AT 08:26:20 ON 01 SEP 2005)

     FILE 'HCAPLUS' ENTERED AT 08:26:28 ON 01 SEP 2005
L1             1 SEA ABB=ON  PLU=ON  US2004167128/PN OR (US2003-681784# OR
                 US2002-416793#)/AP,PRN

     FILE 'REGISTRY' ENTERED AT 08:27:16 ON 01 SEP 2005

     FILE 'HCAPLUS' ENTERED AT 08:27:16 ON 01 SEP 2005
L2             TRA L1 1- RN :     1111 TERMS

     FILE 'REGISTRY' ENTERED AT 08:27:17 ON 01 SEP 2005
L3          1111 SEA ABB=ON  PLU=ON  L2

     FILE 'WPIX' ENTERED AT 08:27:25 ON 01 SEP 2005
L4             1 SEA ABB=ON  PLU=ON  US2004167128/PN OR (US2003-681784# OR
                 US2002-416793#)/AP,PRN

     FILE 'REGISTRY' ENTERED AT 08:29:50 ON 01 SEP 2005
L5             STR

     FILE 'HCAPLUS' ENTERED AT 08:37:07 ON 01 SEP 2005
                 E COMESS K/AU
L6            19 SEA ABB=ON  PLU=ON  "COMESS KENNETH M"/AU
                 E ERICKOSN S/AU
                 E ERICKSON S/AU
L7             7 SEA ABB=ON  PLU=ON  ("ERICKSON S"/AU OR "ERICKSON S A"/AU)
                 E ERICKSON SCOTT/AU
L8            18 SEA ABB=ON  PLU=ON  ("ERICKSON SCOTT"/AU OR "ERICKSON SCOTT
                 A"/AU)
                 E HENKIN J/AU
L9           127 SEA ABB=ON  PLU=ON  ("HENKIN J"/AU OR "HENKIN JACK"/AU)
                 E KALVIN D/AU
L10           47 SEA ABB=ON  PLU=ON  ("KALVIN D"/AU OR "KALVIN DOUG"/AU OR
                 "KALVIN DOUGLAS"/AU OR "KALVIN DOUGLAS M"/AU OR "KALVIN
                 DOUGLAS MARK"/AU)
                 E KAWAI M/AU
L11          436 SEA ABB=ON  PLU=ON  "KAWAI M"/AU
                 E KAWAI MEGUMI/AU
L12           71 SEA ABB=ON  PLU=ON  "KAWAI MEGUMI"/AU
                 E KIM K/AU
L13         1185 SEA ABB=ON  PLU=ON  ("KIM K"/AU OR "KIM K H"/AU OR "KIM K H
                 P"/AU OR "KIM K HO"/AU OR "KIM K HWAN"/AU)
                 E KIM KI/AU
L14            9 SEA ABB=ON  PLU=ON  "KIM KI"/AU
                 E KIM KI H/AU
L15          871 SEA ABB=ON  PLU=ON  ("KIM KI H"/AU OR "KIM KI HAE"/AU OR "KIM
                 KI HAK"/AU OR "KIM KI HAN"/AU OR "KIM KI HANG"/AU OR "KIM KI
                 HEAN"/AU OR "KIM KI HEOK"/AU OR "KIM KI HEON"/AU OR "KIM KI
                 HEUN"/AU OR "KIM KI HO"/AU OR "KIM KI HONG"/AU OR "KIM KI
                 HOON"/AU OR "KIM KI HUN"/AU OR "KIM KI HWA"/AU OR "KIM KI
                 HWAI"/AU OR "KIM KI HWAN"/AU OR "KIM KI HYEON"/AU OR "KIM KI
                 HYON"/AU OR "KIM KI HYOUNG"/AU OR "KIM KI HYUK"/AU OR "KIM KI
                 HYUM"/AU OR "KIM KI HYUN"/AU OR "KIM KI HYUNE"/AU OR "KIM KI
                 HYUNG"/AU OR "KIM KI HYUP"/AU)
                 E BAMAUNG N/AU
L16           23 SEA ABB=ON  PLU=ON  ("BAMAUNG NWE"/AU OR "BAMAUNG NWE Y"/AU)
                 E PARK C/AU
L17          454 SEA ABB=ON  PLU=ON  ("PARK C"/AU OR "PARK C H"/AU OR "PARK C
                 HYUNG"/AU)
                 E PARK CHANG/AU
L18           18 SEA ABB=ON  PLU=ON  "PARK CHANG"/AU
                 E PARK CHANGH/AU
                 E PARK CHANG H/AU
```

```
L19          19 SEA ABB=ON  PLU=ON  "PARK CHANG H"/AU
                E PARK CHANG HOON/AU
L20           8 SEA ABB=ON  PLU=ON  "PARK CHANG HOON"/AU
                E PARK H/AU
L21        1002 SEA ABB=ON  PLU=ON  ("PARK H"/AU OR "PARK H C"/AU)
                E PARK HOON/AU
L22          95 SEA ABB=ON  PLU=ON  ("PARK HOON"/AU OR "PARK HOON C"/AU)
                E SHEPPARD G/AU
L23          95 SEA ABB=ON  PLU=ON  ("SHEPPARD G"/AU OR "SHEPPARD G S"/AU OR
                "SHEPPARD GEORGE"/AU OR "SHEPPARD GEORGE S"/AU OR "SHEPPARD
                GEORGE SHERMAN"/AU)
                E VASUDEVAN/AU
L24         175 SEA ABB=ON  PLU=ON  ("VASUDEVAN A"/AU OR "VASUDEVAN A K"/AU OR
                "VASUDEVAN ANIL"/AU)
                E WANG J/AU
L25        6151 SEA ABB=ON  PLU=ON  ("WANG J"/AU OR "WANG J A"/AU OR "WANG J
                B"/AU OR "WANG J BEI"/AU OR "WANG J C"/AU OR "WANG J C C"/AU
                OR "WANG J C F"/AU OR "WANG J C L"/AU OR "WANG J C T"/AU OR
                "WANG J C Y"/AU OR "WANG J C Z"/AU OR "WANG J CHIH"/AU OR
                "WANG J D"/AU OR "WANG J DON"/AU OR "WANG J E"/AU OR "WANG J
                F"/AU OR "WANG J F T"/AU OR "WANG J G"/AU OR "WANG J H"/AU OR
                "WANG J H C"/AU OR "WANG J H S"/AU OR "WANG J HUIPO"/AU OR
                "WANG J I"/AU OR "WANG J J"/AU OR "WANG J J H"/AU OR "WANG J J
                J J"/AU OR "WANG J J JUNZ"/AU OR "WANG J J L"/AU OR "WANG J
                JAMES"/AU OR "WANG J JOHN"/AU OR "WANG J K"/AU OR "WANG J K
                T"/AU OR "WANG J L"/AU OR "WANG J L F"/AU OR "WANG J L H"/AU
                OR "WANG J L S"/AU OR "WANG J LING FAI"/AU OR "WANG J M"/AU OR
                "WANG J MING"/AU OR "WANG J N"/AU OR "WANG J O"/AU OR "WANG J
                P"/AU OR "WANG J Q"/AU OR "WANG J R"/AU OR "WANG J S"/AU OR
                "WANG J S Y"/AU OR "WANG J SHY YIH"/AU OR "WANG J T"/AU OR
                "WANG J U"/AU OR "WANG J W"/AU OR "WANG J W P"/AU OR "WANG J
                WEN CHUAN"/AU OR "WANG J X"/AU OR "WANG J Y"/AU OR "WANG J Y
                C"/AU OR "WANG J Y J"/AU OR "WANG J Y N"/AU OR "WANG J Y
                PHILLIP"/AU OR "WANG J Y Y"/AU OR "WANG J YING"/AU OR "WANG J
                Z"/AU OR "WANG J Z H"/AU)
                E WANG JIEYI/AU
L26          49 SEA ABB=ON  PLU=ON  ("WANG JIEYI"/AU OR "WANG JIEYING"/AU)
                E BARNES D/AU
L27         401 SEA ABB=ON  PLU=ON  ("BARNES D"/AU OR "BARNES D A"/AU OR
                "BARNES D C"/AU OR "BARNES D E"/AU OR "BARNES D F"/AU OR
                "BARNES D G"/AU OR "BARNES D I"/AU OR "BARNES D IAN"/AU OR
                "BARNES D J"/AU OR "BARNES D JANE"/AU OR "BARNES D K"/AU OR
                "BARNES D K A"/AU OR "BARNES D L"/AU OR "BARNES D M"/AU OR
                "BARNES D P"/AU OR "BARNES D R"/AU OR "BARNES D S"/AU OR
                "BARNES D W"/AU OR "BARNES D W H"/AU)
                E BARNES DAV/AU
L28         126 SEA ABB=ON  PLU=ON  ("BARNES DAVID"/AU OR "BARNES DAVID M"/AU
                OR "BARNES DAVID MICHAEL"/AU)
                E FIDANZE S/AU
L29          16 SEA ABB=ON  PLU=ON  ("FIDANZE STEVE"/AU OR "FIDANZE STEVE
                D"/AU OR "FIDANZE STEVEN"/AU)
                E KOLACZKOWSKI/AU
                E KOLACZKOWSKI L/AU
L30          14 SEA ABB=ON  PLU=ON  ("KOLACZKOWSKI L"/AU OR "KOLACZKOWSKI
                LAWRENCE"/AU)
                E MANTEI R/AU
L31          31 SEA ABB=ON  PLU=ON  ("MANTEI R"/AU OR "MANTEI R A"/AU OR
                "MANTEI ROBERT"/AU OR "MANTEI ROBERT A"/AU)
                E MANTEI B/AU
                E PARK D/AU
L32         144 SEA ABB=ON  PLU=ON  ("PARK D"/AU OR "PARK D C"/AU)
                E PARK DAV/AU
L33           6 SEA ABB=ON  PLU=ON  ("PARK DAVE"/AU OR "PARK DAVID C"/AU)
                E TEDROW J/AU
L34          43 SEA ABB=ON  PLU=ON  ("TEDROW J C F"/AU OR "TEDROW JASON S"/AU
                OR "TEDROW JASON SCOT"/AU)
```

```
                E WANG G/AU
L35          691 SEA ABB=ON  PLU=ON  ("WANG G"/AU OR "WANG G T"/AU)
                E WANG GAR/AU
L36           65 SEA ABB=ON  PLU=ON  ("WANG GARY"/AU OR "WANG GARY T"/AU)
L37         8624 SEA ABB=ON  PLU=ON  (ABBOTT (W)LAB?)/CS,PA
L38              QUE ABB=ON  PLU=ON  PY<=2002 OR AY<=2002 OR PRY<=2002 OR
                 PD<20021008 OR AD<20021008 OR PRD<20021008

     FILE 'REGISTRY' ENTERED AT 08:54:52 ON 01 SEP 2005
L39              STR L5
L40           50 SEA SSS SAM L39
L41         2663 SEA SSS FUL L39
                 SAV TEM L41 SAC784F1/A
L42         1005 SEA ABB=ON  PLU=ON  L41 AND 2 46.150.18/RID
L43          494 SEA ABB=ON  PLU=ON  L42 AND NR=2
L44           33 SEA ABB=ON  PLU=ON  L43 AND 5(1A)ETHYL
L45            1 SEA ABB=ON  PLU=ON  677290-35-6/BI AND L44
L46           13 SEA ABB=ON  PLU=ON  C15H15NO4S AND L41

     FILE 'HCAPLUS' ENTERED AT 09:03:36 ON 01 SEP 2005
L47          683 SEA ABB=ON  PLU=ON  L41
L48            4 SEA ABB=ON  PLU=ON  L45
L49            4 SEA ABB=ON  PLU=ON  (L6 OR L7 OR L8 OR L9 OR L10 OR L11 OR L12
                 OR L13 OR L14 OR L15 OR L16 OR L17 OR L18 OR L19 OR L20 OR L21
                 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30
                 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR L37) AND L48
L50            7 SEA ABB=ON  PLU=ON  (L6 OR L7 OR L8 OR L9 OR L10 OR L11 OR L12
                 OR L13 OR L14 OR L15 OR L16 OR L17 OR L18 OR L19 OR L20 OR L21
                 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30
                 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR L37) AND L47
L51          679 SEA ABB=ON  PLU=ON  L47 NOT L49
L52          625 SEA ABB=ON  PLU=ON  L51 AND L38

     FILE 'REGISTRY' ENTERED AT 09:06:05 ON 01 SEP 2005
L53              STR L39
L54           50 SEA SUB=L41 SSS SAM L53
L55            0 SEA SUB=L41 CSS SAM L53
L56         2663 SEA SUB=L41 SSS FUL L53

     FILE 'HCAPLUS' ENTERED AT 09:10:13 ON 01 SEP 2005
L57          625 SEA ABB=ON  PLU=ON  L56 AND L52
L58          353 SEA ABB=ON  PLU=ON  L57 AND P/DT
                 SEL HIT RN 1-20

     FILE 'REGISTRY' ENTERED AT 09:10:58 ON 01 SEP 2005
L59           22 SEA ABB=ON  PLU=ON  (675124-12-6/BI OR 723305-84-8/BI OR
                 699016-88-1/BI OR 699016-98-3/BI OR 699017-82-8/BI OR 107143-69
                 -1/BI OR 159518-97-5/BI OR 162787-61-3/BI OR 300695-50-5/BI OR
                 321578-75-0/BI OR 496051-32-2/BI OR 501444-05-9/BI OR 6311-23-5
                 /BI OR 633340-08-6/BI OR 652995-96-5/BI OR 672300-08-2/BI OR
                 672300-15-1/BI OR 675124-13-7/BI OR 675124-15-9/BI OR 676161-28
                 -7/BI OR 679792-95-1/BI OR 681284-30-0/BI)
L60           15 SEA ABB=ON  PLU=ON  (107143-69-1/BI OR 159518-97-5/BI OR
                 162787-61-3/BI OR 300695-50-5/BI OR 321578-75-0/BI OR 496051-32
                 -2/BI OR 501444-05-9/BI OR 6311-23-5/BI OR 633340-08-6/BI OR
                 652995-96-5/BI OR 672300-08-2/BI OR 672300-15-1/BI OR 679792-95
                 -1/BI OR 681284-30-0/BI OR 723305-84-8/BI) AND L59

     FILE 'HCAPLUS' ENTERED AT 09:17:55 ON 01 SEP 2005
L61           58 SEA ABB=ON  PLU=ON  L60 AND L58

     FILE 'HCAOLD' ENTERED AT 09:18:04 ON 01 SEP 2005
L62           71 SEA ABB=ON  PLU=ON  L56
                 SEL HIT RN L62

     FILE 'REGISTRY' ENTERED AT 09:19:08 ON 01 SEP 2005
```

```
L63          91 SEA ABB=ON  PLU=ON  (10060-70-5/RN OR 34837-67-7/RN OR
                91-35-0/RN OR 103504-17-2/RN OR 108245-35-8/RN OR 122493-37-2/R
                N OR 530-73-4/RN OR 6311-23-5/RN OR 92872-33-8/RN OR 100724-52-
                5/RN OR 102546-20-3/RN OR 102595-18-6/RN OR 102595-41-5/RN OR
                103504-18-3/RN OR 103641-39-0/RN OR 106684-35-9/RN OR 112045-39
                -3/RN OR 112046-35-2/RN OR 135-10-4/RN OR 89979-12-4/RN OR
                95705-31-0/RN OR 95745-27-0/RN OR 95957-37-2/RN OR 96366-38-0/R
                N OR 96458-72-9/RN OR 96466-92-1/RN OR 96765-42-3/RN OR
                98483-77-3/RN OR 98483-78-4/RN OR 100719-04-8/RN OR 100766-94-7
                /RN OR 100970-32-9/RN OR 101176-38-9/RN OR 101504-19-2/RN OR
                101730-78-3/RN OR 101896-14-4/RN OR 101982-95-0/RN OR 102590-35
                -2/RN OR 102665-84-9/RN OR 102665-85-0/RN OR 102833-46-5/RN OR
                103007-04-1/RN OR 103071-11-0/RN OR 103640-93-3/RN OR 103640-94
                -4/RN OR 104098-08-0/RN OR 104397-04-8/RN OR 106272-56-4/RN OR
                106275-28-9/RN OR 106800-66-2/RN OR 106800-67-3/RN OR 111849-71
                -9/RN OR 112046-34-1/RN OR 114352-52-2/RN OR 115100-78-2/RN OR
                115213-11-1/RN OR 116602-74-5/RN OR 120175-88-4/RN OR 1247-56-9
                /RN OR 14054-65-0/RN OR 31100-24-0/RN OR 38957-45-8/RN OR
                38957-47-0/RN OR 51012-31-8/RN OR 6440-12-6/RN OR 84045-68-1/RN
                 OR 88613-48-3/RN OR 89694-26-8/RN OR 897-82-5/RN OR 89793-15-7
                /RN OR 90248-26-3/RN OR 92851-55-3/RN OR 93724-88-0/RN OR
                94211-65-1/RN OR 94333-03-6/RN OR 94862-89-2/RN OR 94866-21-4/R
                N OR 95006-56-7/RN OR 95034-78-9/RN OR 95489-17-1/RN OR
                95823-11-3/RN OR 96366-37-9/RN OR 96414-34-5/RN OR 96458-71-8/R
                N OR 96460-18-3/RN OR 96462-06-5/RN OR 96708-00-8/RN OR
                96709-47-6/RN OR 96868-79-0/RN OR 96868-80-3/RN OR 96968-45-5/R
                N OR 97074-83-4/RN)
L64           5 SEA ABB=ON  PLU=ON  L63 AND (C14H12N2O6S OR C15H15NO4S OR
                C14H15NO4S OR C14H17NO4S OR C13H9CL2NO4S)

     FILE 'HCAOLD' ENTERED AT 09:24:05 ON 01 SEP 2005
L65           5 SEA ABB=ON  PLU=ON  L64 AND L62
                SEL AN L62
                EDIT E131-E201 /AN /OREF

     FILE 'HCAPLUS' ENTERED AT 09:26:20 ON 01 SEP 2005
L66         133 SEA ABB=ON  PLU=ON  ("CA51:10069F"/OREF OR "CA51:10443I"/OREF
                OR "CA51:1146A"/OREF OR "CA51:12066E"/OREF OR "CA51:13408E"/ORE
                F OR "CA51:13934H"/OREF OR "CA51:14754G"/OREF OR "CA51:16561I"/
                OREF OR "CA51:16562A"/OREF OR "CA51:17190E"/OREF OR "CA51:2293F
                "/OREF OR "CA51:4720I"/OREF OR "CA51:5431E"/OREF OR "CA52:15079
                D"/OREF OR "CA52:17718F"/OREF OR "CA52:4363B"/OREF OR "CA52:440
                G"/OREF OR "CA52:5837F"/OREF OR "CA52:5838A"/OREF OR "CA52:9609
                G"/OREF OR "CA53:17035D"/OREF OR "CA53:3718I"/OREF OR "CA53:475
                1G"/OREF OR "CA54:1869D"/OREF OR "CA54:1869G"/OREF OR "CA54:206
                3I"/OREF OR "CA54:24449D"/OREF OR "CA54:3022E"/OREF OR
                "CA54:3980A"/OREF OR "CA54:3980F"/OREF OR "CA55:12537F"/OREF
                OR "CA55:2326B"/OREF OR "CA55:25147H"/OREF OR "CA55:27905G"/ORE
                F OR "CA55:5393H"/OREF OR "CA56:11755D"/OREF OR "CA56:15431D"/O
                REF OR "CA56:15450H"/OREF OR "CA56:3597F"/OREF OR "CA56:7471I"/
                OREF OR "CA56:8222A"/OREF OR "CA57:11791E"/OREF OR "CA57:12669I
                "/OREF OR "CA57:12670A"/OREF OR "CA57:3365E"/OREF OR "CA57:4002
                E"/OREF OR "CA57:6073D"/OREF OR "CA57:7274C"/OREF OR "CA58:1571
                A"/OREF OR "CA58:3346C"/OREF OR "CA58:3543H"/OREF OR "CA58:4419
                H"/OREF OR "CA59:11932C"/OREF OR "CA59:1441C"/OREF OR "CA59:158
                6D"/OREF OR "CA59:5289A"/OREF OR "CA59:7687D"/OREF OR "CA60:788
                7F"/OREF OR "CA61:13456D"/OREF OR "CA61:5574A"/OREF OR
                "CA61:7048D"/OREF OR "CA61:8229D"/OREF OR "CA61:8831C"/OREF OR
                "CA62:10562E"/OREF OR "CA62:11628A"/OREF OR "CA62:5255G"/OREF
                OR "CA62:6443C"/OREF OR "CA64:1192C"/OREF OR "CA65:2249E"/OREF
                OR "CA65:7983F"/OREF OR "CA65:8670H"/OREF)
L67           7 SEA ABB=ON  PLU=ON  (L49 OR L50)

     FILE 'HCAOLD' ENTERED AT 09:33:52 ON 01 SEP 2005
L68           0 L45
```

Search done by Noble Jarrell

```
=> b reg

FILE 'REGISTRY' ENTERED AT 09:28:19 ON 01 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   31 AUG 2005  HIGHEST RN 862246-83-1
DICTIONARY FILE UPDATES:  31 AUG 2005  HIGHEST RN 862246-83-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d que sta l41

L39                 STR
```




```
VAR G1=N/AK/CY
NODE ATTRIBUTES:
CONNECT IS E1  RC AT   4
CONNECT IS E1  RC AT   9
CONNECT IS E1  RC AT  10
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  10

STEREO ATTRIBUTES: NONE
L41        2663 SEA FILE=REGISTRY SSS FUL L39

100.0% PROCESSED   19093 ITERATIONS                    2663 ANSWERS
SEARCH TIME: 00.00.01
```

=> d ide can 145 tot

L45 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **677290-35-6** REGISTRY
ED Entered STN: 28 Apr 2004
CN **Benzoic acid, 5-ethyl-2-[(phenylsulfonyl)amino]- (9CI)** (CA INDEX NAME)
FS 3D CONCORD
MF C15 H15 N O4 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:173972

REFERENCE 2: 141:173970

REFERENCE 3: 140:357061

REFERENCE 4: 140:315047

```
=> b hcap
FILE 'HCAPLUS' ENTERED AT 09:28:39 ON 01 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 1 Sep 2005  VOL 143 ISS 10
FILE LAST UPDATED: 31 Aug 2005  (20050831/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d all fhitstr l67 tot

L67  ANSWER 1 OF 7  HCAPLUS  COPYRIGHT 2005 ACS on STN
AN   2004:701804  HCAPLUS
DN   141:173972
ED   Entered STN:  27 Aug 2004
TI   Preparation of sulfonamides having antiangiogenic and anticancer activity
IN   Comess, Kenneth M.; Erickson, Scott A.; Henkin,
     Jack; Kalvin, Douglas M.; Kawai, Megumi;
     Kim, Ki H.; Bamaung, Nwe Y.; Park, Chang Hoon;
     Sheppard, George S.; Vasudevan, Anil; Wang,
     Jieyi; Barnes, David M.; Fidanze, Steve D.;
     Kolaczkowski, Lawrence; Mantei, Robert A.; Park,
     David C.; Sanders, William J.; Tedrow, Jason S.; Wang,
     Gary T.
PA   USA
SO   U.S. Pat. Appl. Publ., 127 pp.
     CODEN: USXXCO
DT   Patent
LA   English
IC   ICM  C07D279-12
     ICS  C07D277-04; A61K031-54; A61K031-537; A61K031-495
INCL 514227800; 514237500; 514255010; 514352000; 514370000; 514374000;
     514398000; 514423000; 544059000; 544162000
CC   25-17 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
     Section cross-reference(s): 1, 63
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   US 2004167128        A1    20040826    US 2003-681784         20031008
PRAI US 2002-416793P      P     20021008
CLASS
 PATENT NO.       CLASS  PATENT FAMILY CLASSIFICATION CODES
 --------------   -----  ----------------------------------------------
 US 2004167128    ICM    C07D279-12
                  ICS    C07D277-04; A61K031-54; A61K031-537; A61K031-495
                  INCL   514227800; 514237500; 514255010; 514352000; 514370000;
                         514374000; 514398000; 514423000; 544059000; 544162000
 US 2004167128    NCL    514/227.800
                  ECLA   C07D213/70B; C07D213/70C; C07D231/18
OS   MARPAT 141:173972
```

GI



I

AB The title compds. [I; A = 5-6 membered (non)aromatic ring containing 0-3 atoms selected from N, O, and S (wherein the ring is optionally fused to a second 5-7 membered (non)aromatic ring containing 0-3 atoms selected from N, O, and S); R1-R3 = H, alkenyl, alkoxy, etc.; R4 = H, alkyl, alkoxy, etc.; R5 = alkyl, NH2, aminoalkyl, aryl, etc.; R6 = H, alkyl, aryl, etc.; provided that when A = Ph, at least one of R1-R4 is other than H, alkyl, halo] having methionine aminopeptidase-2 inhibitory (MetAP2) activity, were prepared E.g., a multi-step synthesis of 5-ethyl-2-[(phenylsulfonyl)amino]benzoic acid, starting from 4-ethylaniline, was given. Representative compds. I had IC50's between about 0.005 μM and >100 μM against MetAP2. Also described are pharmaceutical compns. comprising the compds. I, methods of treatment using the compds. I, methods of inhibiting angiogenesis, and methods of treating cancer.

ST sulfonamide prepn antitumor angiogenesis inhibitor methionine aminopeptidase2 MetAP2; benzoic acid sulfonylamino prepn methionine aminopeptidase2 MetAP2 inhibitor; naphthoic acid phenylsulfonylamino prepn methionine aminopeptidase2 MetAP2 inhibitor

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(eukaryotic initiation factor-2-associated, p67; preparation of sulfonamides having antiangiogenic and anticancer activity)

IT Angiogenesis
(neovascularization, treatment of abnormal neovascularization; preparation of sulfonamides having antiangiogenic and anticancer activity)

IT Angiogenesis
Angiogenesis inhibitors
Antitumor agents
Neoplasm
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT **677290-81-2P**, 2-[(Phenylsulfonyl)amino]-1-naphthoic acid **681241-27-0P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-8-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681241-49-6P**, 4-Bromo-2-[(phenylsulfonyl)amino]benzoic acid **681242-39-7P**, 3-(3-Methoxy-3-oxopropyl)-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoicac i **681242-51-3P 681242-97-7P**, 2-[[(2-Nitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-18-5P**, 2-[[(2-Aminophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-44-7P**, 3-Ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxybenzoic acid **681243-56-1P**, 2-([[2-([3-[(tert-Butoxycarbonyl)amino]propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-57-2P**, 2-([[2-([3-[(tert-Butoxycarbonyl)(methyl)amino]propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-00-8P**, 2-[[(2-[[2-(2-Pyridinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-01-9P**, 2-Ethoxy-3-ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]benzoic acid **681244-10-0P**, 2-([[2-([[1-(tert-Butoxycarbonyl)-3-piperidinyl]methyl]amino)phenyl]sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-11-1P**, 2-([[2-([[1-(tert-Butoxycarbonyl)-3-pyrrolidinyl]methyl]amino)phenyl]sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-12-2P**, 2-([[2-([[1-(tert-

Butoxycarbonyl)-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-90-9P**, 3,5-Diethyl-2-[[(2-fluorophenyl)sulfonyl]amino]-6-methoxybenzoic acid **681246-19-5P**, 2-([[2-([3-[4-(tert-Butoxycarbonyl)-1-piperazinyl]-3-oxopropyl]amino)phenyl]sulfonyl]amino)-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-20-8P**, 2-([[2-([3-[4-(tert-Butoxycarbonyl)-1-piperazinyl]-2,2-dimethyl-3-oxopropyl]amino)phenyl]sulfonyl]amino)-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT **107143-76-0P**, 5-Chloro-2-[[(3,4-dichlorophenyl)sulfonyl]amino]benzoic acid **134864-08-7P**, 2-[[(4-Methylphenyl)sulfonyl]amino]-1-naphthoic acid **254878-25-6P**, 2-[[(4-Chlorophenyl)sulfonyl]amino]-4,5-dimethoxybenzoic acid **562078-23-3P**, 5-Bromo-2-[(1-naphthylsulfonyl)amino]benzoic acid **677290-35-6P** **677290-36-7P**, 5-Isopropyl-2-[(phenylsulfonyl)amino]benzoic acid **677290-37-8P**, 5-Isobutyl-2-[(phenylsulfonyl)amino]benzoic acid **677290-38-9P**, 2-[(Phenylsulfonyl)amino]-5-propylbenzoic acid **677290-39-0P**, 5-Cyclopentyl-2-[(phenylsulfonyl)amino]benzoic acid **677290-40-3P**, 5-Cyclohexyl-2-[(phenylsulfonyl)amino]benzoic acid **677290-41-4P**, 5-Butyl-2-[(phenylsulfonyl)amino]benzoic acid **677290-42-5P**, 5-(3-Methylbutyl)-2-[(phenylsulfonyl)amino]benzoic acid **677290-43-6P**, 5-(2-Methylbutyl)-2-[(phenylsulfonyl)amino]benzoic acid **677290-44-7P**, 5-Pentyl-2-[(phenylsulfonyl)amino]benzoic acid **677290-45-8P**, 5-(2-Ethylbutyl)-2-[(phenylsulfonyl)amino]benzoic acid **677290-46-9P**, 5-Hexyl-2-[(phenylsulfonyl)amino]benzoic acid **677290-47-0P**, 2-[[(2-Chloro-4-fluorophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-48-1P**, 5-Ethyl-2-[[(3-methylphenyl)sulfonyl]amino]benzoic acid **677290-49-2P**, 5-Ethyl-2-[[(2-fluorophenyl)sulfonyl]amino]benzoic acid **677290-50-5P**, 5-Ethyl-2-[[(3-fluorophenyl)sulfonyl]amino]benzoic acid **677290-51-6P**, 5-Ethyl-2-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid **677290-52-7P**, 2-[[(2-Chlorophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-53-8P**, 2-[[(3-Chlorophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-54-9P**, 2-[[(3,4-Difluorophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-55-0P**, 5-Ethyl-2-[(1-naphthylsulfonyl)amino]benzoic acid **677290-56-1P**, 5-Ethyl-2-([[3-(trifluoromethyl)phenyl]sulfonyl]amino)benzoic acid **677290-57-2P**, 2-[[(2,3-Dichlorophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-58-3P**, 2-[[(2,5-Dichlorophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-59-4P**, 2-[[(3,5-Dichlorophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-60-7P**, 2-[[(2-Bromophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-61-8P**, 2-[[(3-Bromophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-62-9P**, 5-Ethyl-2-[[(4-methylphenyl)sulfonyl]amino]benzoic acid **677290-63-0P**, 2-[[(3-Cyanophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-64-1P**, 2-[[(4-Cyanophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-65-2P**, 2-[[(2,5-Dimethylphenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-66-3P**, 5-Ethyl-2-[[(3-methoxyphenyl)sulfonyl]amino]benzoic acid **677290-67-4P**, 2-[[(3-Chloro-4-fluorophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-68-5P**, 2-[[(2,5-Dimethoxyphenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-69-6P**, 5-Ethyl-2-[[(5-fluoro-2-methylphenyl)sulfonyl]amino]benzoic acid **677290-70-9P**, 5-Ethyl-2-[(8-quinolinylsulfonyl)amino]benzoic acid **677290-71-0P**, 5-Ethyl-2-([[2-(methylsulfonyl)phenyl]sulfonyl]amino)benzoic acid **677290-72-1P**, 5-Ethyl-2-([[2-(trifluoromethoxy)phenyl]sulfonyl]amino)benzoic acid **677290-73-2P**, 2-([[5-(Dimethylamino)-1-naphthyl]sulfonyl]amino)-5-ethylbenzoic acid **677290-74-3P**, 2-([[3,5-Bis(trifluoromethyl)phenyl]sulfonyl]amino)-5-ethylbenzoic acid **677290-75-4P**, 2-[(Butylsulfonyl)amino]-5-

ethylbenzoic acid **677290-76-5P**, 5-Ethyl-2-[(2-thienylsulfonyl)amino]benzoic acid **677290-77-6P**, 2-[[(5-Chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]amino]-5-ethylbenzoic acid **677290-78-7P**, 5-Ethyl-2-([[2-(methoxycarbonyl)-3-thienyl]sulfonyl]amino)benzoic acid **677290-79-8P**, 6-[(Phenylsulfonyl)amino]-5-indanecarboxylic acid **677290-80-1P**, 2-[(Phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **677290-82-3P**, 2-[(1-Naphthylsulfonyl)amino]-1-naphthoic acid **677290-83-4P**, 7-Fluoro-2-[(phenylsulfonyl)amino]-1-naphthoic acid **677290-84-5P**, 2-[[(4-Chlorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-85-6P**, 2-[[(4-Iodophenyl)sulfonyl]amino]-1-naphthoic acid **677290-86-7P**, 2-[[(3-Fluorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-87-8P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-88-9P**, 2-[[(2-Methylphenyl)sulfonyl]amino]-1-naphthoic acid **677290-89-0P**, 2-[[(3-Methylphenyl)sulfonyl]amino]-1-naphthoic acid **677290-90-3P**, 2-[[(2-Fluorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-91-4P**, 2-([[2-(Trifluoromethoxy)phenyl]sulfonyl]amino)-1-naphthoic acid **677290-92-5P**, 2-[([2-[(3-Aminopropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **677290-93-6P**, 2-[[(4-Methoxyphenyl)sulfonyl]amino]-1-naphthoic acid **677290-94-7P**, 7-Fluoro-2-[[(4-fluorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-95-8P**, 7-Fluoro-2-[[(3-fluorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-96-9P**, 6-Bromo-2-[[(4-fluorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-97-0P**, 2-[[(3,4-Difluorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-98-1P**, 2-[[(2-Chloro-4-fluorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-99-2P**, 2-[[(5-Fluoro-2-methylphenyl)sulfonyl]amino]-1-naphthoic acid **677291-00-8P**, 2-[[(2-Methoxy-5-methylphenyl)sulfonyl]amino]-1-naphthoic acid **677291-01-9P**, 2-[[(2-Chloro-6-methylphenyl)sulfonyl]amino]-1-naphthoic acid **677291-03-1P**, 2-([[4-Chloro-3-(trifluoromethyl)phenyl]sulfonyl]amino)-1-naphthoic acid **677291-04-2P**, 2-[[(2,4-Dimethoxyphenyl)sulfonyl]amino]-1-naphthoic acid **677291-06-4P**, 2-[(8-Quinolinylsulfonyl)amino]-1-naphthoic acid **677291-07-5P**, 2-[(2,1,3-Benzothiadiazol-4-ylsulfonyl)amino]-1-naphthoic acid **677291-08-6P**, 2-[(2-Thienylsulfonyl)amino]-1-naphthoic acid **677291-09-7P**, 2-[[(3,5-Dimethyl-4-isoxazolyl)sulfonyl]amino]-1-naphthoic acid **677291-10-0P**, 2-[[(5-Chloro-2-thienyl)sulfonyl]amino]-1-naphthoic acid **677291-11-1P**, 2-[[(5-Chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]amino]-1-naphthoic acid **677291-12-2P**, 2-([[2-(Methoxycarbonyl)-3-thienyl]sulfonyl]amino)-1-naphthoic acid **677291-13-3P**, 2-([[5-(3-Isoxazolyl)-2-thienyl]sulfonyl]amino)-1-naphthoic acid **677291-14-4P**, 2-([[2,5-Dichloro-3-thienyl]sulfonyl]amino)-1-naphthoic acid **677291-15-5P**, 2-([[4,5-Dichloro-2-thienyl]sulfonyl]amino)-1-naphthoic acid **677291-17-7P**, 2-[(Butylsulfonyl)amino]-1-naphthoic acid **677291-18-8P**, 2-[(Benzylsulfonyl)amino]-1-naphthoic acid **677291-19-9P** **677291-20-2P**, 2-[[(3-Chloropropyl)sulfonyl]amino]-1-naphthoic acid **677291-21-3P**, 2-[(Methylsulfonyl)amino]-1-naphthoic acid **677291-22-4P**, 2-[(Ethylsulfonyl)amino]-1-naphthoic acid **677291-23-5P**, 2-[(Propylsulfonyl)amino]-1-naphthoic acid **677297-03-9P**, 2-[[(3,4-Difluorophenyl)sulfonyl]amino]-7-fluoro-1-naphthoic acid **681241-15-6P**, 2-[[(3,5-Dichloro-2-hydroxyphenyl)sulfonyl]amino]-1-naphthoic acid **681241-17-8P**, 2-[[(5-Bromo-6-chloro-3-pyridinyl)sulfonyl]amino]-1-naphthoic acid **681241-18-9P**, 2-[[(2,4-Difluorophenyl)sulfonyl]amino]-7-fluoro-1-naphthoic acid **681241-19-0P**, 2-[(Phenylsulfonyl)amino]-4-(trifluoromethyl)benzoic acid **681241-20-3P**, 2-[(Phenylsulfonyl)amino]-4-(trifluoromethoxy)benzoic acid **681241-21-4P**, 5-Nitro-2-[(phenylsulfonyl)amino]benzoic acid **681241-22-5P**, 6-[(Phenylsulfonyl)amino]-5-quinolinecarboxylic acid **681241-23-6P**, 6-[[(4-Methoxyphenyl)sulfonyl]amino]-5-quinolinecarboxylic acid **681241-24-7P**, 2-[Ethyl[(4-fluorophenyl)sulfonyl]amino]-1-naphthoic acid **681241-25-8P**, 2-[[(4-Fluorophenyl)sulfonyl](propyl)amino]-1-

naphthoic acid **681241-26-9P**, 2-[[(4-Fluorophenyl)sulfonyl][2-(methylsulfanyl)ethyl]amino]-1-naphthoicaci **681241-28-1P**, 3-Bromo-2-methyl-6-[(phenylsulfonyl)amino]benzoic acid **681241-29-2P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-8-hydroxy-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681241-30-5P**, 8-Amino-2-[[(4-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681241-31-6P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-8-hydroxy-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681241-32-7P**, 3-Cyano-2-methyl-6-[(phenylsulfonyl)amino]benzoic acid **681241-33-8P**, 3-Cyano-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoic acid **681241-34-9P**, 3-Bromo-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoic acid **681241-35-0P**, 2-[(2-Pyridinylsulfonyl)amino]-1-naphthoic acid **681241-36-1P**, 3-Bromo-2-methyl-6-[(3-pyridinylsulfonyl)amino]benzoic acid **681241-37-2P**, 3-Cyano-2-methyl-6-[(3-pyridinylsulfonyl)amino]benzoic acid **681241-38-3P**, 3-Butyl-2-methyl-6-[(3-pyridinylsulfonyl)amino]benzoic acid **681241-39-4P**, 6-[(1-Naphthylsulfonyl)amino]-1H-indole-7-carboxylic acid **681241-40-7P**, 6-[[(3-Fluorophenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid **681241-41-8P**, 6-[[(4-Fluorophenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid **681241-42-9P**, 6-[[(2-Chloro-4-methoxyphenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid **681241-43-0P**, 6-[[(4-Methylphenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid **681241-44-1P**, 6-[[(2-Fluorophenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid **681241-45-2P**, 6-[[(4-Chlorophenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid **681241-46-3P**, 6-[(Phenylsulfonyl)amino]-1H-indole-7-carboxylic acid **681241-47-4P**, 6-[[(3-Methylphenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid **681241-48-5P**, 6-[[(4-Methoxyphenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid **681241-50-9P**, 3-Bromo-6-[[(3-fluorophenyl)sulfonyl]amino]-2-methylbenzoic acid **681241-51-0P**, 3-Bromo-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methylbenzoic acid **681241-52-1P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681241-53-2P**, 3-Oxo-5-[(phenylsulfonyl)amino]-4-indanecarboxylic acid **681241-54-3P**, 3-Ethyl-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoic acid **681241-55-4P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681241-56-5P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681241-57-6P**, 2-([[2-(Butylamino)phenyl]sulfonyl]amino)-1-naphthoic acid **681241-58-7P**, 2-([[2-(sec-Butylamino)phenyl]sulfonyl]amino)-1-naphthoic acid **681241-59-8P**, 2-([[2-(Isobutylamino)phenyl]sulfonyl]amino)-1-naphthoic acid **681241-60-1P**, 2-([[2-(Pentylamino)phenyl]sulfonyl]amino)-1-naphthoic acid **681241-61-2P**, 2-([[2-[(1-Methylbutyl)amino]phenyl]sulfonyl]amino)-1-naphthoic acid **681241-62-3P**, 2-([[2-[(2-Methylbutyl)amino]phenyl]sulfonyl]amino)-1-naphthoic acid **681241-63-4P**, 2-([[2-[(3-Methylbutyl)amino]phenyl]sulfonyl]amino)-1-naphthoic acid **681241-64-5P**, 2-([[2-[(1,2-Dimethylpropyl)amino]phenyl]sulfonyl]amino)-1-naphthoic acid **681241-65-6P**, 2-([[2-(Neopentylamino)phenyl]sulfonyl]amino)-1-naphthoic acid **681241-66-7P**, 2-([[2-[(1-Ethylpropyl)amino]phenyl]sulfonyl]amino)-1-naphthoic acid **681241-67-8P**, 2-([[2-(Hexylamino)phenyl]sulfonyl]amino)-1-naphthoic acid **681241-68-9P**, 2-([[2-[(3,3-Dimethylbutyl)amino]phenyl]sulfonyl]amino)-1-naphthoic acid **681241-69-0P**, 3-Ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methylbenzoic acid **681241-70-3P**, 3-Chloro-2-[[(4-fluorophenyl)sulfonyl]amino]-1-naphthoic acid **681241-71-4P**, 2-[(Phenylsulfonyl)amino]-4-vinylbenzoic acid **681241-72-5P**, 2-Methyl-3-propyl-6-[(2-pyridinylsulfonyl)amino]benzoic acid **681241-73-6P**, 2-[[(2-[[(3-Methoxypropyl)amino]carbonyl]phenyl)sulfonyl]amino]-1-naphthoic acid **681241-74-7P**, 6-[[(4-Fluorophenyl)sulfonyl]amino]-2-methyl-3-propylbenzoic acid

681241-75-8P, 3-Bromo-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methoxybenzoic acid **681241-76-9P**, 2-[([2-[(2-Ethoxyethyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-78-1P**, 2-[([2-[(2-Isopropoxyethyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-79-2P**, 2-[([2-[(3-Propoxypropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-80-5P**, 2-[([2-[(3-Methoxypropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-81-6P**, 2-[([2-[(Cyclopropylmethyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-82-7P**, 2-[([2-(Cyclopentylamino)phenyl]sulfonyl)amino]-1-naphthoic acid **681241-83-8P**, 2-[([2-[(Cyclopentylmethyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-84-9P**, 2-[([2-(Cyclohexylamino)phenyl]sulfonyl)amino]-1-naphthoic acid **681241-85-0P**, 2-[([2-[(2-Ethylhexyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-86-1P**, 2-[([2-[(3-Hydroxypropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-87-2P**, 2-[([2-[(4-Hydroxybutyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-88-3P**, 2-[([2-[(2-Propoxyethyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-89-4P**, 2-[([2-[(3-Ethoxypropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-90-7P**, 2-[([2-[(3-Butoxypropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-91-8P**, 2-[([2-[(3-Isopropoxypropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-92-9P**, 2-[([2-[(3-Isobutoxypropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-93-0P**, 2-[([2-[[3-(Methylsulfanyl)propyl]amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-94-1P**, 2-[([2-[[3-(Diethylamino)propyl]amino]phenyl]sulfonyl)amino]-1-naphthoicaci **681241-95-2P**, 2-[([2-[(2-Methoxyethyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-96-3P**, 2-[([2-(1-Pyrrolidinylcarbonyl)phenyl]sulfonyl)amino]-1-naphthoic acid **681241-97-4P**, 2-Methyl-6-[(2-pyridinylsulfonyl)amino]-3-vinylbenzoic acid **681241-98-5P**, 6-[[(4-Fluorophenyl)sulfonyl]amino]-2-methyl-3-vinylbenzoic acid **681241-99-6P**, 2-[([2-[(4-Methyl-1-piperazinyl)carbonyl]phenyl]sulfonyl)amino]-1-naphthoic acid **681242-00-2P**, 2-[[(2-Chloro-4-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-01-3P**, 2-[(2-Thienylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-02-4P**, 2-[(Benzylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-03-5P**, 2-[[(2-Methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-04-6P**, 2-[[(3-Methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-05-7P**, 2-[[(4-Methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-06-8P**, 2-[[(2-Fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-07-9P**, 2-[[(3-Fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-08-0P**, 2-[[(3-Cyanophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-09-1P**, 2-[[(4-Cyanophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-10-4P**, 2-[[(2,5-Dimethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-11-5P**, 2-[[(3-Methoxyphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-12-6P**, 2-[[(4-Methoxyphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-13-7P**, 2-[[(2-Chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-14-8P**, 2-[[(3-Chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-15-9P**, 2-[[(4-Chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-16-0P**, 2-[[(2,4-Difluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-17-1P**, 2-[[(3,4-Difluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-18-2P**, 2-[[(4-Propylphenyl)sulfonyl]amino]-5,6,7,8-

tetrahydro-1-naphthalenecarboxylic acid **681242-19-3P**, 2-[[(4-Isopropylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-20-6P**, 2-[(2-Naphthylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylicaci **681242-21-7P**, 2-[(1-Naphthylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylicaci **681242-22-8P**, 2-[[(4-tert-Butylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-23-9P**, 2-[[(3-Chloro-4-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-24-0P**, 2-([[4-(Acetylamino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-25-1P**, 2-[[(2,5-Dimethoxyphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-26-2P**, 2-[[(3,4-Dimethoxyphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-27-3P**, 2-[[(3-(Trifluoromethyl)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-28-4P**, 2-[[(4-(Trifluoromethyl)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-29-5P**, 2-[[(2,3-Dichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-30-8P**, 2-[[(2,4-Dichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-31-9P**, 2-[[(2,6-Dichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-32-0P**, 2-[[(3,4-Dichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-33-1P**, 2-[[(3,5-Dichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-34-2P**, 2-[((1,1'-Biphenyl-4-yl)sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-35-3P**, 2-[[(2-Bromophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-36-4P**, 2-[[(3-Bromophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-37-5P**, 2-[[(4-Bromophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-38-6P**, 2-[[(4-(Trifluoromethoxy)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-40-0P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-5-(methylsulfanyl)benzoic acid **681242-41-1P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-42-2P**, 3-(2-Carboxyethyl)-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoic acid **681242-43-3P**, 5-(Methylsulfanyl)-2-[(phenylsulfonyl)amino]benzoic acid **681242-44-4P**, 2-[[(2-[[2-(Dimethylamino)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-45-5P**, 2-[[(2-[[2-(Diethylamino)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-46-6P**, 2-[[(2-[[2-(1-Pyrrolidinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-47-7P**, 2-[[(2-[[3-(Dimethylamino)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-48-8P**, 2-[[(2-[[3-(4-Methyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-49-9P**, 2-[[(2-[[3-(1-Piperidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-50-2P**, 3-Butyl-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methylbenzoic acid **681242-52-4P**, 2-Chloro-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid **681242-53-5P**, 3-Bromo-2-chloro-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid **681242-54-6P**, 2-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-55-7P**
, 3-Ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methylbenzoic acid **681242-56-8P**, 6-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-methylbenzoic acid **681242-57-9P**, 6-[[(2-[[4-(N,N-Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-methylbenzoic acid **681242-58-0P**, 3-[1,2-Dihydroxyethyl]-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methylbenzoic acid **681242-59-1P**, 6-[[(4-Fluorophenyl)sulfonyl]amino]-3-(hydroxymethyl)-2-methylbenzoic acid

681242-60-4P, 6-[[(2-[[2-(Diethylamino)ethyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-methylbenzoic acid **681242-61-5P**, 3-Ethyl-6-[[(2-[[3-(1H-imidazol-1-yl)propyl]amino]phenyl)sulfonyl]amino]-2-methylbenzoic acid **681242-62-6P**, 6-[[(2-[[3-(Dimethylamino)propyl](methyl)amino]phenyl)sulfonyl]amino]-3-ethyl-2-methylbenzoic acid **681242-63-7P**, 3-Ethyl-2-methyl-6-([[2-(4-methyl-1-piperazinyl)phenyl]sulfonyl]amino)benzoic acid **681242-64-8P**, 2-[[(3,5-Dimethyl-4-isoxazolyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT **681242-65-9P**, 2-[[(5-Chloro-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-66-0P**, 2-[[(5-Fluoro-2-methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-67-1P**, 2-[[(2-Methoxy-5-methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-68-2P**, 2-[[(3-Nitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-69-3P**, 2-[[(2-Chloro-6-methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-70-6P**, 2-[[(5-Chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-71-7P**, 2-[(Mesitylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-72-8P**, 2-[[(4-Nitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-73-9P**, 2-[[(3-Chloro-4-methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-74-0P**, 2-[(2,1,3-Benzothiadiazol-4-ylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-75-1P**, 2-[[(2-Methyl-5-nitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-76-2P**, 2-[[(5-(3-Isoxazolyl)-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-77-3P**, 2-[[(2,5-Dichloro-3-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-78-4P**, 2-[[(4,5-Dichloro-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-81-9P**, 2-[[(7-Chloro-2,1,3-benzoxadiazol-4-yl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-82-0P**, 2-[[(4-Chloro-3-nitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-83-1P**, 2-[[(2-(Trifluoromethoxy)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-84-2P**, 2-[[(5-Chloro-4-nitro-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-85-3P**, 2-[[(2,4-Dinitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-86-4P**, 2-[[(5-(Dimethylamino)-1-naphthyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-87-5P**, 2-[[(4-Chloro-3-(trifluoromethyl)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-88-6P**, 2-[[(2,4,5-Trichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-89-7P**, 2-[[(2,3,4-Trichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-90-0P** **681242-91-1P**, 2-[[(5-Bromo-2-methoxyphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-92-2P**, 2-[[(3,5-Bis(trifluoromethyl)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-93-3P**, 2-[[(2-Butoxy-5-(1,1-dimethylpropyl)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-94-4P**, 2-[[(5-(Phenylsulfonyl)-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-95-5P**, 2-[[(5-[[(4-Chlorobenzoyl)amino]methyl]-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-96-6P**, 2-[[(5-Bromo-6-chloro-3-pyridinyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-98-8P**, 2-[[(5-[(Benzoylamino)methyl]-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-

naphthalenecarboxylic acid **681242-99-9P**, 6-[[(4-Fluorophenyl)sulfonyl]amino]-3-[1-hydroxyethyl]-2-methylbenzoic acid **681243-00-5P**, 2-[[(2-[[2-(Dimethylamino)ethyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-01-6P**, 8-Methyl-2-[[(2-[[2-(1-pyrrolidinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-02-7P**, 8-Methyl-2-[[(2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-03-8P**, 2-[[(2-[[3-(Dimethylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-04-9P**, 2-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-05-0P**, 2-[[(2-[[2-(Diethylamino)ethyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-06-1P**, 8-Methyl-2-[[(2-[[2-(4-morpholinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-07-2P**, 8-Methyl-2-[[(2-[[3-[3-(methylamino)phenyl]propyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-08-3P**, 2-[[(2-(4-Benzyl-1-piperazinyl)phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-09-4P**, 2-[[(2-[[4-(N,N-Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-10-7P**, 2-[[(2-[[3-(Dibutylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-11-8P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-8-methyl-7-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-12-9P**, 2-[[(2-[[3-(1H-Imidazol-1-yl)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-13-0P**, 8-Methyl-2-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-14-1P**, 8-Methyl-2-[[(2-[[3-(1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-15-2P**, 8-Methyl-2-[[(2-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-16-3P**, 8-Methyl-2-[[(2-[[3-(2-methyl-1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-17-4P**, 2-[[(2-[[3-(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-19-6P**, 8-Methyl-2-[[(2-[[2-(1-piperidinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-20-9P** **681243-21-0P** **681243-22-1P**, 2-([[2-([[2-(Diethylamino)ethyl]amino]carbonyl)phenyl]sulfonyl]amino)-1-naphthoic acid **681243-23-2P**, 2-[[(2-[[2-(1-Piperazinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-24-3P**, 2-[[(2-[[3-(2-Oxo-1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-26-5P**, 2-[[(2-[[3-(4-Morpholinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-28-7P**, 2-[[(2-[[2-(1-Methyl-2-pyrrolidinyl]ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-29-8P**, 2-[[(2-[[3-(2-Methyl-1-piperidinyl]propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-30-1P**, 2-[[(2-[[1-(Ethoxycarbonyl)-4-piperidinyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-32-3P**, 2-[[(2-[[2-(4-Morpholinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-33-4P**, 2-[[(2-[[2-[Bis-(2-hydroxyethyl)amino]ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-34-5P**, 2-[[(2-[[2-(1-Piperidinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-35-6P**, 2-[[(2-[[4-(Diethylamino)-1-methylbutyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-36-7P**, 2-[[(2-[[3-(Dibutylamino)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-37-8P**,

2-[[(2-[[3-(1H-Imidazol-1-yl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-38-9P**, 2-[[(2-[[3-(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-39-0P**, 2-[[(2-[[4-(N,N-Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-40-3P**, 2-[[(2-[[2-(Dipropylamino)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-41-4P**, 2-[[(2-[[3-(1-Pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-42-5P**, 2-[[(2-[[2-(Diisopropylamino)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-43-6P**, 2-[[(2-[[4-(Diethylamino)butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-45-8P** **681243-46-9P**, 6-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-hydroxybenzoic acid **681243-48-1P**, 3-Ethyl-2-methoxy-6-[[(2-[[3-(1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681243-49-2P**, 3-Ethyl-2-hydroxy-6-[[(2-[[3-(1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681243-50-5P**, 3-Ethyl-2-hydroxy-6-[[(2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681243-51-6P**, 6-[[(2-[[4-(N,N-Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-methoxybenzoic acid **681243-52-7P**, 3-Ethyl-2-methoxy-6-[[(2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681243-53-8P**, 2-([[2-([[2-(1-Piperidinyl)ethyl]amino]carbonyl)phenyl]sulfonyl]amino)-1-naphthoic acid **681243-54-9P**, 2-[[(2-[[3-(Ethylamino)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-55-0P**, 2-([[2-([3-[Bis(2-hydroxyethyl)amino]propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-58-3P**, 2-[([2-[(3-Aminopropyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-59-4P**, 2-[[(2-[[3-(Methylamino)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-60-7P**, 6-[[(4-Fluorophenyl)sulfonyl]amino]-2-methoxy-3-vinylbenzoic acid **681243-61-8P**, 2-[([2-[([[2-(Diethylamino)ethyl]amino]carbonyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-62-9P**, 2-([[2-([[2-(Diethylamino)ethoxy]carbonyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-63-0P**, 8-Methyl-2-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-64-1P**, 8-Methyl-2-[[(2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-65-2P**, 2-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-66-3P**, 8-Methyl-2-[[(2-[[3-(2-methyl-1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-67-4P** **681243-68-5P**, 2-[[(2-[[3-(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-69-6P**, 2-[[(2-[[4-(1-Pyrrolidinyl)butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-70-9P**, 2-[[(2-[[4-[2-Methyl-1-pyrrolidinyl]butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-71-0P**, 2-[[(2-[[4-[2,5-Dimethyl-1-pyrrolidinyl]butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-72-1P**, 2-[[(2-[[4-(1-Piperidinyl)butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-73-2P**, 2-[[(2-[[4-[2-Methyl-1-piperidinyl]butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-74-3P**, 2-[[(2-[[4-[3-Methyl-1-piperidinyl]butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-75-4P**, 2-[[(2-[[4-[4-Methyl-1-piperidinyl]butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-76-5P** **681243-77-6P**, 2-[[(2-[[4-(1-Azepanyl)butanoyl]amino]phenyl)sulfony

l]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-78-7P 681243-79-8P 681243-80-1P**, 2-[([2-[(1-Benzyl-4-piperidinyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-81-2P**, 2-[([2-[(1,2,2,6,6-Pentamethyl-4-piperidinyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-82-3P**, 3-Ethyl-2-methoxy-6-[(2-pyridinylsulfonyl)amino]benzoic acid **681243-83-4P**, 3-Ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methoxybenzoic acid **681243-84-5P**, 2-[[(2-[[3-(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-7,7-dimethyl-8-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-85-6P**, 7,7-Dimethyl-2-[[(2-[[2-[1-methyl-2-pyrrolidinyl]ethyl]amino]phenyl)sulfonyl]amino]-8-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-86-7P**, 7,7-Dimethyl-2-[[(2-[[3-[2-methyl-1-piperidinyl]propyl]amino]phenyl)sulfonyl]amino]-8-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-87-8P**, 7,7-Dimethyl-8-oxo-2-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-88-9P 681243-89-0P**, 8-Methylene-2-[[(2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-90-3P**, 8-Methylene-2-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-91-4P**, 2-[[(2-[[4-(Aminocarbonyl)-1-piperidinyl]carbonyl]phenyl)sulfonyl]amino]-1-naphthoic acid **681243-92-5P**, 3-Bromo-6-[[(2-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-2-methoxybenzoic acid **681243-93-6P**, 3-Bromo-2-methoxy-6-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681243-94-7P**, 3-Bromo-2-hydroxy-6-[[(2-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]phenyl)sulfonyl]amino]benzoic acid **681243-95-8P**, 3-Bromo-2-methoxy-6-[[(2-[[3-(1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681243-96-9P**, 2-([[2-([[2-(Diethylamino)ethyl]amino]carbonyl)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-97-0P**, 2-[[(2-[[[3-(Dimethylamino)propyl](methyl)amino]carbonyl]phenyl)sulfonyl]amino]-1-naphthoic acid **681243-98-1P**, 2-[[(2-[[3-(Isopropylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-99-2P**, 3-Bromo-2-chloro-6-[[(2-fluorophenyl)sulfonyl]amino]benzoic acid **681244-02-0P**, 2-Ethoxy-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid **681244-03-1P**, 3-Bromo-2-ethoxy-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid **681244-04-2P**, 2-Ethoxy-3-ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid **681244-05-3P**, 2-Chloro-6-[[(2-[4-(N,N-dimethylamino)butyl]phenyl)sulfonyl]amino]-3-ethylbenzoic acid **681244-06-4P**, 2-Chloro-6-[[(2-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-3-ethylbenzoic acid **681244-07-5P**, 2-Chloro-3-ethyl-6-([[2-([2-[1-methyl-2-pyrrolidinyl]ethyl]amino)phenyl]sulfonyl]amino)benzoic acid **681244-08-6P 681244-09-7P**, 2-[[(2-[[2,2-Dimethyl-3-(1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-13-3P 681244-14-4P 681244-15-5P**, 2-[([2-[(4-Piperidinylmethyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-16-6P**, 2-[([2-[(2-[1-Cyclobutyl-2-piperidinyl]ethyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-17-7P 681244-18-8P**, 7,7-Dimethyl-2-([[2-([2-[1-methyl-2-pyrrolidinyl]ethyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-19-9P**, 2-[[(2-Fluorophenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-20-2P**, 2-[[(2-[[2,2-Dimethyl-3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-21-3P**, 2-[[(2-[[2-Ethyl-2-(1-piperidinylmethyl)butyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid

681244-22-4P, 2-Ethoxy-3-ethyl-6-([[2-([2-[1-methyl-2-pyrrolidinyl]ethyl]amino)phenyl]sulfonyl]amino)benzoic acid **681244-23-5P**, 6-[[(2-[[3-(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-2-ethoxy-3-ethylbenzoic acid **681244-24-6P 681244-25-7P**, 6-[[(2-[[4-(Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-2-ethoxy-3-ethylbenzoic acid **681244-27-9P**, 3-Bromo-6-([[2-([3-(dimethylamino)-2,2-dimethylpropyl]amino)phenyl]sulfonyl]amino)-2-propoxybenzoic acid **681244-28-0P**, 3-Bromo-6-([[2-([4-(N,N-dimethylamino)butyl]amino)phenyl]sulfonyl]amino)-2-propoxybenzoic acid **681244-29-1P**, 3-Bromo-6-[[(2-[[3-(4-morpholinyl)propyl]amino]phenyl)sulfonyl]amino]-2-propoxybenzoic acid **681244-30-4P** **681244-31-5P**, 2-[[(2-[[([2-[1-Methyl-2-pyrrolidinyl]ethyl]amino)carbonyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-32-6P**, 2-[([2-[([2-[1-Methyl-2-pyrrolidinyl]ethyl]amino)carbonyl]phenyl]sulfonyl)amino]-1-naphthoic acid **681244-33-7P**, 2-[([2-[([3-[1-Pyrrolidinyl]propyl]amino)carbonyl]phenyl]sulfonyl)amino]-1-naphthoic acid **681244-34-8P**, 2-[([2-[([3-(Isopropylamino)propyl]amino)carbonyl]phenyl]sulfonyl)amino]-1-naphthoic acid **681244-36-0P**, 2-[([2-[([[2-(1-Piperidinyl)ethyl]amino)carbonyl]amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-38-2P**, 2-[([2-[([[2-(1-Piperazinyl)ethyl]amino)carbonyl]amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-40-6P**, 2-[([2-[([[3-(2-Methyl-1-Piperidinyl)propyl]amino)carbonyl]amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-42-8P**, 2-[([2-[([[2-(4-Morpholinyl)ethyl]amino)carbonyl]amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-44-0P**, 2-[([2-[([[3-(4-Morpholinyl)propyl]amino)carbonyl]amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-46-2P**, 2-[([2-[([[4-(Diethylamino)-1-methylbutyl]amino]carbonyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-48-4P**, 2-[([2-[([[3-(Dimethylamino)-2,2-dimethylpropyl]amino]carbonyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-50-8P**, 2-[([2-[([[3-(1-Piperidinyl)propyl]amino]carbonyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-52-0P**, 2-[([2-[([[3-(1-Piperazinyl)propyl]amino]carbonyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-53-1P**, 3-Ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]-2-propoxybenzoic acid **681244-54-2P 681244-55-3P**, 3-Ethyl-6-([[2-([3-[2-methyl-1-piperidinyl]propyl]amino)phenyl]sulfonyl]amino)-2-propoxybenzoic acid **681244-56-4P**, 3-Ethyl-6-([[2-([3-[4-morpholinyl]propyl]amino)phenyl]sulfonyl]amino)-2-propoxybenzoic acid **681244-57-5P**, 3-Bromo-6-[[(2-[[4-(N,N-dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-2-methoxybenzoic acid **681244-58-6P**, 3-Bromo-6-[[(2-[[4-(N,N-dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-2-hydroxybenzoic acid **681244-59-7P**, 3-Bromo-2-hydroxy-6-[[(2-[[3-(1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-60-0P**, 3-Bromo-2-hydroxy-6-[[(2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-61-1P**, 3-Bromo-2-hydroxy-6-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-62-2P**, 3-Bromo-6-[[(2-[[3-(diethylamino)propyl]amino]phenyl)sulfonyl]amino]-2-methoxybenzoic acid **681244-63-3P**, 3-Bromo-6-[[(2-[[3-(diethylamino)propyl]amino]phenyl)sulfonyl]amino]-2-hydroxybenzoic acid **681244-64-4P**, 6-[[(2-[[4-(N,N-Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-hydroxybenzoic acid **681244-65-5P**, 6-[[(2-[[3-(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-methoxybenzoic acid **681244-66-6P**, 3-Ethyl-2-hydroxy-6-[[(2-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-67-7P**, 6-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-methoxybenzoic acid **681244-68-8P**, 3-Ethyl-2-methoxy-6-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]

amino]benzoic acid **681244-69-9P**, 3-Ethyl-2-hydroxy-6-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-70-2P**, 3-Ethyl-2-methoxy-6-[[(2-[[3-(4-morpholinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-71-3P**, 3-Ethyl-2-methoxy-6-[[(2-[[4-(1-pyrrolidinyl)butyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-72-4P**, 3-Bromo-2-methoxy-6-[[(2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-73-5P**, 3-Bromo-2-methoxy-6-[[(2-[[3-[2-methyl-1-piperidinyl]propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-74-6P**, 3-Ethyl-2-methoxy-6-[[(2-[[2-[1-methyl-2-pyrrolidinyl]ethyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-75-7P**, 3-Ethyl-6-[[(2-[[3-(1H-imidazol-1-yl)propyl]amino]phenyl)sulfonyl]amino]-2-methoxybenzoic acid **681244-76-8P**, 3-Ethyl-2-hydroxy-6-[[(2-[[3-(1H-imidazol-1-yl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-77-9P**, 3-Ethyl-2-hydroxy-6-[[(2-[[3-(4-morpholinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-78-0P**, 3-Bromo-5-ethyl-6-methyl-2-[(2-pyridinylsulfonyl)amino]benzoic acid **681244-79-1P**, 2-[[(2-[[2-[1-Methyl-2-pyrrolidinyl]ethyl]amino]phenyl)sulfonyl]amino]-8-methoxy-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-80-4P**, 2-[[(2-[[3-(Isopropylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methoxy-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-81-5P**, 2-[([2-[([2-[1-Methyl-2-pyrrolidinyl]ethyl]amino)carbonyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-82-6P**, 2-[([4-[([2-[1-Methyl-2-pyrrolidinyl]ethyl]amino)carbonyl]-3-thienyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-83-7P**, 2-[([2-[([2-(1-Piperidinyl)ethyl]amino)carbonyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-84-8P**, 2-[([4-[([2-(Diethylamino)ethyl]amino)carbonyl]-3-thienyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-85-9P**, 2-[([4-[([2-(1-Piperidinyl)ethyl]amino)carbonyl]-3-thienyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-86-0P**, 6-[([2-[(3-Aminopropyl)amino]phenyl]sulfonyl)amino]-3-ethyl-2-methoxybenzoic acid **681244-87-1P**, 6-[([2-[(3-Aminopropyl)amino]phenyl]sulfonyl)amino]-3-ethyl-2-hydroxybenzoic acid **681244-88-2P**, 2-(Carboxymethoxy)-3-ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid **681244-89-3P**, 6-([[2-(Dimethylamino)phenyl]sulfonyl]amino)-3-ethyl-2-methoxybenzoic acid **681244-90-6P**, 6-[[(2-[[3-(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-hydroxybenzoic acid **681244-91-7P**, 3-Bromo-5-ethyl-2-[[(2-fluorophenyl)sulfonyl]amino]-6-methoxybenzoic acid **681244-92-8P**, 5-Ethyl-2-[[(2-fluorophenyl)sulfonyl]amino]-4-methoxy-1,1'-biphenyl-3-carboxylic acid **681244-93-9P** **681244-94-0P** **681244-95-1P** **681244-96-2P** **681244-97-3P**, 3-[(1E)-3-([2-[1-Methyl-2-pyrrolidinyl]ethyl]amino)-3-oxo-1-propenyl]-2-[(phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-98-4P**, 3-((1E)-3-Oxo-3-[[2-(1-piperidinyl)ethyl]amino]-1-propenyl]-2-[(phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-99-5P**, 3-((1E)-3-Oxo-3-[[3-(1-piperidinyl)propyl]amino]-1-propenyl]-2-[(phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-00-1P**, 3-[(1E)-3-([[1-Ethyl-2-pyrrolidinyl]methyl]amino)-3-oxo-1-propenyl]-2-[(phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-01-2P**, 3-((1E)-3-[[2-(Dimethylamino)ethyl]amino]-3-oxo-1-propenyl]-2-[(phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-02-3P** **681245-03-4P** **681245-04-5P** **681245-05-6P** **681245-06-7P** **681245-07-8P** **681245-08-9P**, 2-[N-Methyl-N-([2-[(4-piperidinylmethyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-09-0P** **681245-10-3P** **681245-11-4P** **681245-12-5P** **681245-13-6P** **681245-14-7P** **681245-15-8P** **681245-16-9P** **681245-17-0P** **681245-18-1P** **681245-19-2P** **681245-20-5P**

681245-21-6P, 3-Bromo-2-methoxy-6-([[2-([2-[1-methyl-2-pyrrolidinyl]ethyl]amino)phenyl]sulfonyl]amino)benzoic acid
681245-22-7P, 3-Bromo-2-hydroxy-6-([[2-([3-[2-methyl-1-piperidinyl]propyl]amino)phenyl]sulfonyl]amino)benzoic acid
681245-23-8P, 2-[[(2-[[2-(Diethylamino)ethyl]sulfanyl]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681245-24-9P, 2-[[(2-([[3-(Diethylamino)propyl]amino]carbonyl)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT **681245-25-0P**, 2-([[2-([[3-(Dimethylamino)-2,2-dimethylpropyl]amino]carbonyl)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-26-1P**, 2-([[2-([[3-(Diethylamino)propyl]amino]carbonyl)-3-thienyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-27-2P**, 2-([[2-([[3-(Dimethylamino)-2,2-dimethylpropyl]amino]carbonyl)-3-thienyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-28-3P**, 2-([[2-([[4-(Diethylamino)-1-methylbutyl]amino]carbonyl)-3-thienyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-29-4P**, 2-[[(2-[[[3-(Dimethylamino)propyl](methyl)amino]carbonyl]-3-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-30-7P** **681245-31-8P**, 2-[[(2-[[3-(4-Cyclopentyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-32-9P**, 2-[[(2-[[3-(4-Isopropyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-33-0P** **681245-34-1P** **681245-35-2P**, 2-([[2-([[4-(Diethylamino)butyl]amino]carbonyl)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-36-3P**, 2-([[2-([[4-(Diethylamino)butyl]amino]carbonyl)-3-thienyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-37-4P**, 2-([[2-([[4-(Diethylamino)butyl]amino]carbonyl)-4-fluorophenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-38-5P**, 2-([[2-([[4-(Diethylamino)-1-methylbutyl]amino]carbonyl)-4-fluorophenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-39-6P**, 2-([[2-([[4-(Diethylamino)-1-methylbutyl]amino]carbonyl)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-40-9P**, 8-Methyl-2-[[(2-[[3-(4-morpholinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-41-0P**, (8R)-2-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-42-1P**, (8S)-2-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-43-2P**, 2-(2-Aminoethoxy)-3-ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid **681245-44-3P**, 2-(2-Aminoethoxy)-6-[[(2-bromophenyl)sulfonyl]amino]-3-ethylbenzoic acid **681245-45-4P**, 2-(2-Aminoethoxy)-6-[[(2-[(1E)-3,3-dimethyl-1-butenyl]phenyl)sulfonyl]amino]-3-ethylbenzoic acid **681245-46-5P**, 2-(2-Aminoethoxy)-6-[[(2-(3,3-dimethylbutyl)phenyl)sulfonyl]amino]-3-ethylbenzoic acid **681245-47-6P**, 2-(2-Aminoethoxy)-6-[[(2-propylphenyl)sulfonyl]amino]-3-ethylbenzoic acid **681245-48-7P**, 2-[([2-[(4-Pyridinylmethyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-49-8P** **681245-50-1P**, 2-[[(2-[[3-(Diethylamino)propyl]sulfanyl]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-51-2P**, 2-[[(2-[[2-(Diethylamino)ethyl]sulfinyl]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-52-3P**, 2-[[(2-[3-(Diethylamino)propoxy]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-53-4P** **681245-54-5P** **681245-55-6P** **681245-56-7P** **681245-57-8P** **681245-58-9P** **681245-59-0P** **681245-60-3P** **681245-61-4P** **681245-62-5P** **681245-63-6P**

681245-64-7P 681245-65-8P 681245-66-9P
681245-67-0P 681245-68-1P 681245-69-2P
681245-70-5P 681245-71-6P, 2-([[2-([2,2-Dimethyl-3-(4-morpholinyl)propyl]amino)phenyl]sulfonyl]amino)-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-72-7P**, 2-([[2-([3-Hydroxy-2,2-dimethylpropyl]amino)phenyl]sulfonyl]amino)-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-73-8P**, 2-([[2-([3-[4-[4-(Trifluoromethyl)-2-pyrimidinyl]-1-piperazinyl]propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-74-9P**, 2-([[2-([3-(1-Azepanyl)propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-75-0P**, 2-([[2-([[1-(2-Ethylbutyl)-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-76-1P**, 2-([[2-([[1-Cyclopentyl-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-77-2P**, 2-([[2-([[1-[1-Methylpropyl]-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-79-4P**, 2-([[2-([[1-Isobutyl-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-80-7P**, 2-([[2-([[1-Methyl-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-81-8P**, 2-([[2-([[1'-Methyl-1,4'-bipiperidin-4-yl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-82-9P**, 2-([[2-([[1-Isopropyl-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-83-0P**, 2-([[2-[(1E)-3-(Diethylamino)-1-propenyl]phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-84-1P**, 2-([[2-[4-(Diethylamino)butyl]phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-85-2P**, 2-([[2-[(1Z)-3-(Diethylamino)-1-propenyl]phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-86-3P**, 2-([[2-[(1Z)-4-(Diethylamino)-1-butenyl]phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-87-4P**, 2-([[2-([3-[3-Methyl-1-piperidinyl]propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-88-5P**, 2-([[2-([3-[Cyclohexyl(methyl)amino]propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-89-6P**, 2-([[2-([3-(3,4-Dihydro-2(1H)-isoquinolinyl)propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-91-0P**, 2-([[2-([2-Methyl-3-(4-methyl-1-piperidinyl)propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-92-1P**, 2-([[2-([3-[2,6-Dimethyl-1-piperidinyl]propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-93-2P 681245-94-3P**, 3-Ethyl-2-methoxy-6-([[2-(2-phenylethyl)phenyl]sulfonyl]amino)benzoic acid **681245-95-4P**, 6-[([2-[2-(4-Chlorophenyl)ethyl]phenyl]sulfonyl)amino]-3-ethyl-2-methoxybenzoic acid **681245-96-5P**, 3-Ethyl-2-methoxy-6-[[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]benzoicaci **681245-97-6P**, 6-[[(1,2-Dimethyl-1H-imidazol-4-yl)sulfonyl]amino]-3-ethyl-2-methoxybenzoic acid **681245-98-7P**, 2-(2-Aminoethoxy)-6-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-3-ethylbenzoic acid **681245-99-8P**, 2-(3-Aminopropoxy)-6-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-3-ethylbenzoic acid **681246-00-4P**, 3,5-Diethyl-2-methoxy-6-[[(2-[[3-(4-morpholinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681246-01-5P**, 3,5-Diethyl-2-methoxy-6-[[(2-[[3-[2-methyl-1-piperidinyl]propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681246-02-6P**, 3,5-Diethyl-2-methoxy-6-[[(2-[[2-[1-methyl-2-pyrrolidinyl]ethyl]amino]phenyl)sulfonyl]amino]benzoic acid **681246-03-7P**, 2-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-3,5-diethyl-6-methoxybenzoic acid **681246-04-8P**, 2-[[(2-[[4-(N,N-Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-3,5-diethyl-6-methoxybenzoic acid **681246-05-9P**, 3,5-Diethyl-2-methoxy-6-[[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]benzoic acid **681246-06-0P**, 2-[[(1,2-Dimethyl-1H-imidazol-4-yl)sulfonyl]amino]-3,5-diethyl-6-methoxybenzoic acid **681246-07-1P**,

3,5-Diethyl-2-methoxy-6-[(phenylsulfonyl)amino]benzoic acid **681246-08-2P**, 3,5-Diethyl-2-[[(4-fluorophenyl)sulfonyl]amino]-6-methoxybenzoic acid **681246-09-3P**, 3,5-Diethyl-2-methoxy-6-[[2-pyridinylsulfonyl]amino]benzoic acid **681246-10-6P**, 2-[([2-[3-(Diethylamino)propyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-11-7P**, 2-[([2-[(1Z)-5-(Diethylamino)-1-pentenyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-12-8P**, 2-[([2-[(1E)-5-(Diethylamino)-1-pentenyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-13-9P**, 2-[([2-[5-(Diethylamino)pentyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-14-0P 681246-15-1P**, 2-(2-Aminoethoxy)-3-ethyl-6-[[(2-ethyl-4-fluorophenyl)sulfonyl]amino]benzoic acid **681246-17-3P**, 2-(2-Aminoethoxy)-3-ethyl-6-[[(4-fluoro-2-propylphenyl)sulfonyl]amino]benzoic acid **681246-18-4P**, 2-(2-Aminoethoxy)-3-ethyl-6-[[(4-fluoro-2-(2-phenylethyl)phenyl)sulfonyl]amino]benzoic acid **681246-21-9P**, 8-Methyl-2-([[2-([3-(4-morpholinyl)-3-oxopropyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-22-0P**, 8-Methyl-2-([[2-([3-oxo-3-(1-piperazinyl)propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-23-1P**, 2-([[2-([2,2-Dimethyl-3-oxo-3-(1-piperazinyl)propyl]amino)phenyl]sulfonyl]amino)-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-24-2P**, 3-Ethyl-6-[([4-fluoro-2-[4-(2-methyl-1-pyrrolidinyl)butyl]phenyl]sulfonyl)amino]-2-methoxybenzoic acid **681246-25-3P**, 6-[([2-[4-(Diethylamino)butyl]-4-fluorophenyl]sulfonyl)amino]-3-ethyl-2-methoxybenzoic acid **681246-26-4P**, 2-[[(2-[[2-(4-Pyridinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-27-5P**, 2-[[(4-Bromo-2-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681255-09-4P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT 67-64-1, Acetone, reactions 75-26-3, 2-Bromopropane 78-81-9, Isobutylamine 78-84-2, 2-Methylpropanal 78-93-3, 2-Butanone, reactions 83-33-0, 1-Indanone 85-46-1, 1-Naphthalenesulfonyl chloride 91-59-8, 2-Naphthylamine 93-11-8, 2-Naphthalenesulfonyl chloride 96-15-1, 2-Methylbutylamine 96-17-3, 2-Methylbutanal 96-32-2, Methyl bromoacetate 96-33-3, Methyl acrylate 97-08-5, 4-Chloro-3-nitrobenzenesulfonyl chloride 97-96-1, 2-Ethylbutanal 98-09-9, Benzenesulfonyl chloride 98-31-7, 3,4-Dichlorobenzenesulfonyl chloride 98-58-8, 4-Bromobenzenesulfonyl chloride 98-59-9, 4-Methylbenzenesulfonyl chloride 98-60-2, 4-Chlorobenzenesulfonyl chloride 98-61-3, 4-Iodobenzenesulfonyl chloride 98-68-0, 4-Methoxybenzenesulfonyl chloride 98-74-8, 4-Nitrobenzenesulfonyl chloride 98-80-6, Phenylboronic acid 100-36-7, N,N-Diethyl-1,2-ethanediamine 100-37-8, 2-(Diethylamino)ethanol 102-83-0, N,N-Dibutyl-1,3-propanediamine 104-75-6, 2-Ethylhexylamine 104-78-9, 3-(Diethylamino)propylamine 105-56-6, Ethyl cyanoacetate 107-85-7, 3-Methylbutylamine 108-00-9, N,N-Dimethyl-1,2-ethanediamine 108-91-8, Cyclohexylamine, reactions 108-94-1, Cyclohexanone, reactions 109-01-3, 1-Methylpiperazine 109-05-7, 2-Methylpiperidine 109-55-7, N,N-Dimethyl-1,3-propanediamine 109-73-9, Butylamine, reactions 109-76-2, 1,3-Diaminopropane 109-85-3, 2-Methoxyethylamine 110-58-7, 1-Aminopentane 110-76-9, 2-Ethoxyethylamine 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 111-26-2, 1-Aminohexane 111-49-9, Azepane 120-92-3, Cyclopentanone 121-02-8, 2-Methyl-5-nitrobenzenesulfonyl chloride 121-05-1, 2-(Diisopropylamino)ethylamine 121-51-7, 3-Nitrobenzenesulfonyl chloride 121-60-8, 4-(Acetylamino)benzenesulfonyl chloride 123-75-1, Pyrrolidine, reactions 133-59-5, 2-Methylbenzenesulfonyl chloride 140-31-8, 1-(2-Aminoethyl)piperazine 140-80-7, 4-(Diethylamino)-1-methylbutylamine 156-87-6, 3-Amino-1-propanol 313-12-2, 3-(Trifluoromethyl)anthranilic acid 349-88-2, 4-Fluorobenzenesulfonyl chloride 350-03-8,

3-Acetylpyridine 445-05-6, 2-Methyl-5-fluorobenzenesulfonyl chloride 574-98-1, N-(2-Bromoethyl)phthalimide 589-16-2, 4-Ethylaniline 590-50-1, 4,4-Dimethyl-2-pentanone 598-74-3, 2-Amino-3-methylbutane 605-65-2, 5-(Dimethylamino)-1-naphthalenesulfonyl chloride 609-09-6, Diethyl ketomalonate 616-79-5, 2-Amino-5-nitrobenzoic acid 622-93-5, 3-(Diethylamino)-1-propanol 625-36-5, 3-Chloropropanoyl chloride 626-56-2, 3-Methylpiperidine 626-58-4, 4-Methylpiperidine 701-27-9, 3-Fluorobenzenesulfonyl chloride 705-21-5, 3,5-Dichlorobenzenesulfonyl chloride 765-38-8, 2-Methylpyrrolidine 765-43-5, Acetylcyclopropane 773-64-8, 2,4,6-Trimethylbenzenesulfonyl chloride 777-44-6, 3-(Trifluoromethyl)benzenesulfonyl chloride 872-53-7, Cyclopentanecarboxaldehyde 927-74-2, 4-Hydroxy-1-butyne 1003-03-8, Cyclopentylamine 1003-04-9, Dihydro-3(2H)-thiophenone 1072-72-6, Tetrahydro-4H-thiopyran-4-one 1121-60-4, 2-Pyridinecarboxaldehyde 1191-95-3, Cyclobutanone 1445-73-4, 1-Methyl-4-piperidone 1483-28-9, 2,5-Dimethoxybenzenesulfonyl chloride 1489-69-6, Cyclopropanecarboxaldehyde 1623-93-4, 4-Phenylbenzenesulfonyl chloride 1633-82-5, 3-Chloro-1-propanesulfonyl chloride 1656-44-6, 2,4-Dinitrobenzenesulfonyl chloride 1663-39-4, tert-Butyl acrylate 1694-92-4, 2-Nitrobenzenesulfonyl chloride 1899-93-0, 3-Methylbenzenesulfonyl chloride 1939-99-7, Phenylmethanesulfonyl chloride 1942-52-5, 2-(Diethylamino)ethanethiol hydrochloride 2038-03-1, N-2-Aminoethylmorpholine 2043-61-0, Cyclohexanecarboxaldehyde 2148-56-3, 2-Amino-6-chlorobenzoic acid 2386-60-9, 1-Butanesulfonyl chloride 2516-47-4, Cyclopropylmethylamine 2706-56-1, 2-(2-Aminoethyl)pyridine 2759-28-6, 1-Benzylpiperazine 2766-74-7, 5-Chloro-2-thiophenesulfonyl chloride 2888-06-4, 3-Chlorobenzenesulfonyl chloride 2905-21-7, 2-Fluorobenzenesulfonyl chloride 2905-23-9, 2-Chlorobenzenesulfonyl chloride 2905-24-0, 3-Bromobenzenesulfonyl chloride 2905-25-1, 2-Bromobenzenesulfonyl chloride 2906-12-9, 3-Isopropoxypropylamine 2991-42-6, 4-(Trifluoromethyl)benzenesulfonyl chloride 3230-36-2 3360-16-5, 3-(Isopropylamino)propylamine 3378-71-0, 2,5-Dimethylpyrrolidine 3437-33-0, 3-(1-Azepanyl)-1-propanamine 3529-08-6, 1-Piperidinepropanamine 3529-10-0, N,N-Dimethyl-1,4-butanediamine 3731-53-1, 4-(Aminomethyl)pyridine 4079-68-9 4104-45-4 4318-42-7, 1-Isopropylpiperazine 4389-50-8, 2-Amino-6-methylbenzoic acid 4426-47-5, n-Butylboronic acid 4461-39-6, 2-[(3-Aminopropyl)amino]ethanol 4543-96-8, N,N,N'-Trimethyl-1,3-propanediamine 4572-03-6, 3-(4-Methyl-1-piperazinyl)-1-propanamine 4635-59-0, 4-Chlorobutanoyl chloride 4985-85-7, 2-[(3-Aminopropyl)(2-hydroxyethyl)amino]ethanol 5036-48-6, 3-(1H-Imidazol-1-yl)-1-propanamine 5271-38-5, 2-(Methylsulfanyl)ethanol 5332-73-0, 1-Methoxy-3-aminopropane 5390-04-5, 4-Pentyn-1-ol 5402-73-3, 2,5-Dichlorobenzenesulfonyl chloride 5460-29-7, N-(3-Bromopropyl)phthalimide 5596-87-2 5794-88-7 5813-64-9, 1-Amino-2,2-dimethylpropane 6053-81-2, (Cyclopentylmethyl)amine 6089-09-4, 4-Pentynoic acid 6291-85-6, 3-Ethoxypropylamine 6336-45-4, Dibutyl vinylboronate 6783-05-7, trans-2-Phenylvinylboronic acid 7154-73-6, 2-(1-Pyrrolidinyl)ethanamine 7486-35-3, Tributyl(vinyl)tin 7547-97-9, trans-Propenylboronic acid 7565-57-3, Cyclohexylzinc bromide 7663-77-6, 1-(3-Aminopropyl)-2-pyrrolidinone 10130-74-2, 3-Methoxybenzenesulfonyl chloride 10147-36-1, 1-Propanesulfonyl chloride 10563-23-2, 3-(Ethylamino)propylamine 13139-17-8 13258-63-4, 4-(2-Aminoethyl)pyridine 13325-10-5, 4-Amino-1-butanol 13918-92-8, 2,4-Difluorobenzenesulfonyl chloride 13952-84-6, 2-Aminobutane 14156-91-3, 3-(3-Methyl-1-piperidinyl)-1-propanamine 14165-22-1, 2-(Dipropylamino)ethylamine 15029-30-8, 1-Cyanoacetylpiperidine 15084-51-2, 4-tert-Butylbenzenesulfonyl chloride 15673-00-4, 1-Amino-3,3-dimethylbutane 15761-39-4, tert-Butoxycarbonyl-L-proline 15932-66-8, 2-(2-Aminoethyl)piperidine 15945-07-0, 2,4,5-Trichlorobenzenesulfonyl chloride 16133-25-8, 3-Pyridinesulfonyl chloride 16271-33-3, 2,4-Dichlorobenzenesulfonyl chloride 16499-88-0, 3-Butoxypropylamine 16629-19-9, 2-Thiophenesulfonyl chloride 16728-59-9, 3-Propoxypropylamine 18704-37-5, 8-Chlorosulfonylquinoline 19040-62-1, 2,5-Dimethylbenzenesulfonyl chloride 21043-40-3, 1-Cyclopentylpiperazine 22160-08-3, (2R)-2-Ethylpiperidine 23094-94-2,

2-Chloro-4-methoxybenzenesulfonyl chloride 23095-05-8,
5-Bromo-2-methoxybenzenesulfonyl chloride 23095-31-0,
3,4-Dimethoxybenzenesulfonyl chloride 23099-21-0, (3-
Piperidinylmethyl)amine 23159-07-1, 3-(1-Pyrrolidinyl)propylamine
23378-88-3, 3,5-Dichloro-2-hydroxybenzenesulfonyl chloride 23418-85-1,
3-Butynyl 4-methylbenzenesulfonate 24425-40-9, 5-Indanamine
24715-90-0, 4-(1-Pyrrolidinyl)butylamine 25300-37-2,
2-Chloro-6-methylbenzenesulfonyl chloride 25560-00-3,
3-(2-Methyl-1-piperidinyl)propylamine 26116-12-1, 2-(Aminomethyl)-1-
ethylpyrrolidine 26638-43-7, Methyl 2-(chlorosulfonyl)benzoate
26735-20-6, N-(3-Aminopropyl)-N-cyclohexyl-N-methylamine 27431-62-5,
4-(Diethylamino)butylamine 27578-60-5, 2-(1-Piperidinyl)ethylamine
29943-42-8, Tetrahydro-4H-pyran-4-one 32333-53-2, 4-Chloro-3-
(trifluoromethyl)benzenesulfonyl chloride 32923-88-9,
3-Isobutoxypropylamine 34732-09-7, 2,3,4-Trichlorobenzenesulfonyl
chloride 34885-02-4, 3-(1-Piperazinyl)propylamine 37784-17-1,
N-tert-Butoxycarbonyl-D-proline 39234-86-1, 3,5-
Di(trifluoromethyl)benzenesulfonyl chloride 39546-32-2, Isonipecotamide
40218-49-3, 2-Propyl-1,3,2-benzodioxaborole 40327-96-6,
4-Amino-1,2,2,6,6-pentamethylpiperidine 40353-34-2, 7-Nitro-3,4-dihydro-
1(2H)-naphthalenone 42185-03-5, 2-Propoxyethylamine 42413-03-6,
3-Chloro-4-methylbenzenesulfonyl chloride 49584-26-1,
4-Cyanobenzenesulfonyl chloride 50541-93-0, 4-Amino-1-benzylpiperidine
51387-90-7, 2-[(1-Methyl-2-pyrrolidinyl]ethylamine 51605-97-1,
2-Bromo-4-isopropylaniline 52147-97-4, (E)-2-Phenylethylenesulfonyl
chloride 52727-57-8, Methyl 2-amino-5-bromobenzoate 53369-71-4
53485-07-7, N-(3-Aminopropyl)-N-methylaniline 53600-33-2,
2-Amino-6-methoxybenzoic acid 54398-51-5, 6-Amino-5-
quinolinecarbonitrile 54997-90-9 55790-39-1, 3-
(Diethylamino)propanethiol 56542-67-7, 3-Cyanobenzenesulfonyl chloride
56946-83-9, 2,5-Dichloro-3-thiophenesulfonyl chloride 57260-71-6,
1-tert-Butoxycarbonylpiperazine 58457-24-2, 5-Chloro-4-nitro-2-
thiophenesulfonyl chloride 58859-46-4, Ethyl 4-amino-1-
piperidinecarboxylate 59337-92-7, Methyl 3-(chlorosulfonyl)-2-
thiophenecarboxylate 60956-26-5, 4-Bromo-2-nitrotoluene 63493-28-7,
2-Aminopentane 63624-28-2, 2,4-Dimethoxybenzenesulfonyl chloride
66715-65-9, 2-Pyridinesulfonyl chloride 73713-79-8, 2,1,3-
Benzothiadiazole-4-sulfonyl chloride 75178-96-0, tert-Butyl
[3-aminopropyl]carbamate 76745-74-9 80466-79-1, 3,5-Dimethyl-4-
isoxazolesulfonyl chloride 81731-43-3, 2-Isopropoxyethylamine
82417-45-6, 2,3-Dichlorobenzenesulfonyl chloride 85723-72-4,
3-[2,6-Dimethyl-1-piperidinyl]-1-propanamine 85958-57-2,
2-Chloro-4-fluorobenzenesulfonyl chloride 86595-37-1 88040-86-2,
2-Methoxy-5-methylbenzenesulfonyl chloride 88398-93-0,
5-Chloro-1,3-dimethyl-1H-pyrazole-4-sulfonyl chloride 89265-35-0,
2-(Methylsulfonyl)benzenesulfonyl chloride 91170-93-3,
3-Chloro-4-fluorobenzenesulfonyl chloride 92273-73-9, Butylzinc bromide
92274-43-6 94108-56-2, 4-(Trifluoromethoxy)benzenesulfonyl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT 101555-60-6 103008-51-1, 2-(Trifluoromethoxy)benzenesulfonyl chloride
124397-96-2, Hexylzinc bromide 126403-67-6, Isobutylzinc bromide
126714-85-0, 4,5-Dichloro-2-thiophenesulfonyl chloride 127720-93-8,
7-Chloro-2,1,3-benzothiadiazole-4-sulfonyl chloride 137049-00-4,
1-Methyl-1H-imidazole-4-sulfonyl chloride 137049-02-6,
1,2-Dimethyl-1H-imidazole-4-sulfonyl chloride 138872-44-3,
5-[(Benzoylamino)methyl]-2-thiophenesulfonyl chloride 143193-41-3,
2-Butoxy-5-(1,1-dimethylpropyl)benzenesulfonyl chloride 144222-22-0,
1-tert-Butoxycarbonyl-4-(aminomethyl)piperidine 145758-05-0,
3,4-Difluorobenzenesulfonyl chloride 146949-07-7, 4-
Propylbenzenesulfonyl chloride 154230-29-2 156567-57-6, Propylzinc
bromide 160233-27-2, 5-(3-Isoxazolyl)-2-thiophenesulfonyl chloride
162167-97-7, 1-tert-Butoxycarbonyl-3-(aminomethyl)piperidine 166964-33-6
166964-34-7, 5-[[(4-Chlorobenzoyl)amino]methyl]-2-thiophenesulfonyl
chloride 166964-37-0, 5-(Phenylsulfonyl)-2-thiophenesulfonyl chloride
171860-68-7, Cyclopentylzinc bromide 174311-79-6, Ethyl

6-amino-1H-indole-7-carboxylate 175278-17-8, 2-Bromo-4-(trifluoromethoxy)aniline 216159-03-4, 4-Bromo-2-fluorobenzenesulfonyl chloride 216394-05-7, 5-Bromo-6-chloro-3-pyridinesulfonyl chloride 270912-72-6, 1-tert-Butoxycarbonyl-3-(aminomethyl)pyrrolidine 308796-10-3, Pentylzinc bromide 312693-02-0, 2-Ethylbutylzinc bromide 351003-45-7, 2-Bromo-4-fluorobenzenesulfonyl chloride 496808-04-9, 1-[(1-Methyl-4-piperidinyl)methyl]-4-piperazine 681248-31-7 **681248-32-8 681248-33-9** 681248-34-0, Methyl 2-[([2-bromophenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681248-35-1, 3-[4-(4-Trifluoromethylpyrimidin-2-yl)piperazin-1-yl]propylamine 681248-36-2, 2-Methyl-3-(4-methyl-1-piperidinyl)-1-propanamine 681847-93-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT 123-00-2P, 3-(4-Morpholinyl)-1-propanamine 610-36-6P, 4-Amino-2-nitrobenzoic acid 2475-82-3P, 2-Amino-5-ethylbenzoic acid 4553-26-8P, 3-(4-Isopropyl-1-piperazinyl)-1-propanamine 5588-87-4P, 1H-Benzo[e]indole-1,2(3H)-dione 13991-22-5P 14227-95-3P, 3-Oxo-3-(1-pyrrolidinyl)propanenitrile 14227-98-6P 15029-32-0P, 3-(4-Morpholinyl)-3-oxopropanenitrile 17122-70-2P, N-(4-Ethylphenyl)-2-(hydroxyimino)acetamide 20776-50-5P, 2-Amino-4-bromobenzoic acid 22009-40-1P, 7-Amino-3,4-dihydro-1(2H)-naphthalenone 24623-24-3P, 6-Nitro-1-indanone 29777-09-1P, N,N-Diethyl-3-butyn-1-amine 62078-76-6P, (7-Fluoronaphth-2-yl)amine 64241-01-6P, Methyl 2-amino-6-hydroxybenzoate 67765-42-8P, 5-Methoxy-2H-3,1-benzoxazine-2,4(1H)-dione 68701-22-4P, 2-Amino-5-isopropylbenzoic acid 68748-07-2P, N-(2-Bromo-4-isopropylphenyl)acetamide 69610-40-8P 69975-65-1P, 6-Amino-1-indanone 77758-50-0P 79069-38-8P, 2-(Acetylamino)-5-isopropylbenzoic acid 79979-69-4P, 2-Amino-1-naphthoic acid 86661-32-7P, tert-Butyl (2S)-2-([[(4-methylphenyl)sulfonyl]oxy]methyl)-1-pyrrolidinecarboxylate 90321-34-9P 90796-54-6P, 2,2-Dimethyl-3-(4-morpholinyl)-1-propanamine 91569-18-5P 96202-56-1P, 5-Ethyl-1H-indole-2,3-dione 115186-37-3P 116487-43-5P, 7-Bromo-1H-benzo[e]indole-1,2(3H)-dione 124341-06-6P, 6-Amino-3-bromo-2-methylbenzoic acid 126378-10-7P, Benzyl (4E)-5-(tributylstannyl)-4-pentenoate 126378-11-8P, Benzyl 4-pentynoate 132482-06-5P, tert-Butyl (2R)-2-(2-hydroxyethyl)-1-pyrrolidinecarboxylate 132734-41-9P, 2-Amino-5,6,7,8-tetrahydro-naphthalene-1-carboxylic acid methyl ester 135484-65-0P, Methyl 5-bromo-2-[(phenylsulfonyl)amino]benzoate 136247-94-4P, 2-[(tert-Butoxycarbonyl)amino]-6-methoxybenzoic acid 159539-65-8P, 2,2-Dimethyl-7-nitro-3,4-dihydro-1(2H)-naphthalenone 159873-21-9P, tert-Butyl 4-(2-cyanoacetyl)-1-piperazinecarboxylate 214697-98-0P, 7-Amino-8-bromo-3,4-dihydro-1(2H)-naphthalenone 239483-09-1P, tert-Butyl (2S)-2-(2-aminoethyl)-1-pyrrolidinecarboxylate 269391-47-1P, 2-[(tert-Butoxycarbonyl)amino]-6-methylbenzoic acid 373608-47-0P, 3-(4-Cyclopentyl-1-piperazinyl)-1-propanamine 550378-07-9P, tert-Butyl (2R)-2-(2-aminoethyl)-1-pyrrolidinecarboxylate 616224-61-4P, 2-[(tert-Butoxycarbonyl)amino]-6-chlorobenzoic acid **677291-24-6P**, 2-[[(2-Bromophenyl)sulfonyl]amino]-1-naphthoic acid 677291-25-7P, 2-Amino-7-fluoro-1-naphthoic acid 677291-27-9P, 2-Amino-6-bromo-1-naphthoic acid **681244-26-8P**, 3-Bromo-6-[[(2-fluorophenyl)sulfonyl]amino]-2-propoxybenzoic acid 681246-29-7P 681246-31-1P, Methyl 5-nitro-2-[(phenylsulfonyl)amino]benzoate 681246-32-2P, 6-Amino-5-quinolinecarboxylic acid 681246-33-3P, Methyl 6-amino-5-quinolinecarboxylate 681246-34-4P, Methyl 6-[(phenylsulfonyl)amino]-5-quinolinecarboxylate 681246-35-5P, Methyl 2-[[(4-fluorophenyl)sulfonyl]amino]-1-naphthoate 681246-36-6P, N-(1-Bromo-8-oxo-5,6,7,8-tetrahydro-2-naphthalenyl)-4-fluorobenzenesulfonamide 681246-37-7P, 3-Bromo-6-[(tert-butoxycarbonyl)amino]-2-methylbenzoic acid 681246-39-9P, Benzyl 3-bromo-6-[(tert-butoxycarbonyl)amino]-2-methylbenzoate 681246-40-2P, Benzyl 6-amino-3-cyano-2-methylbenzoate 681246-41-3P, Benzyl 3-cyano-2-methyl-6-[(phenylsulfonyl)amino]benzoate 681246-42-4P, Benzyl 3-bromo-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoate 681246-43-5P, Methyl 2-[(2-pyridinylsulfonyl)amino]-1-naphthoate 681246-44-6P, Benzyl

3-butyl-2-methyl-6-[(3-pyridinylsulfonyl)amino]benzoate 681246-45-7P, Benzyl 6-amino-3-bromo-2-methylbenzoate 681246-46-8P, Benzyl 3-bromo-6-[[(3-fluorophenyl)sulfonyl]amino]-2-methylbenzoate 681246-47-9P, tert-Butyl 1,2-dioxo-1,2-dihydro-3H-benzo[e]indole-3-carboxylate 681246-48-0P, 2-[(tert-Butoxycarbonyl)amino]-1-naphthoic acid 681246-49-1P, 6-Amino-7-bromo-1-indanone 681246-50-4P, N-(4-Bromo-3-oxo-2,3-dihydro-1H-inden-5-yl)benzenesulfonamide 681246-51-5P, Benzyl 2-methyl-6-[(2-pyridinylsulfonyl)amino]-3-vinylbenzoate 681246-52-6P, N-(1-Bromo-5,6-dihydro-2-naphthalenyl)-4-fluorobenzenesulfonamide 681246-53-7P, N-(1-Bromo-8-methyl-5,6-dihydro-2-naphthalenyl)-4-fluorobenzenesulfonamide 681246-54-8P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-1-naphthoate 681246-55-9P, Benzyl 6-[(tert-butoxycarbonyl)amino]-2-methyl-3-vinylbenzoate 681246-56-0P, 6-[(tert-Butoxycarbonyl)amino]-3-ethyl-2-methylbenzoic acid 681246-57-1P, Methyl 2-amino-3-chloro-1-naphthoate 681246-58-2P, Methyl 3-chloro-2-[[(4-fluorophenyl)sulfonyl]amino]-1-naphthoate 681246-59-3P, Benzyl 6-[(tert-butoxycarbonyl)amino]-2-methyl-3-propylbenzoate 681246-60-6P, Benzyl 6-amino-2-methyl-3-propylbenzoate 681246-61-7P, Benzyl 2-methyl-3-propyl-6-[(2-pyridinylsulfonyl)amino]benzoate 681246-62-8P, Methyl 2-([[2-(methoxycarbonyl)phenyl]sulfonyl]amino)-1-naphthoate 681246-63-9P, 2-([[1-(Methoxycarbonyl)-2-naphthyl]amino]sulfonyl)benzoic acid 681246-64-0P, Methyl 2-[[(2-[[(3-methoxypropyl)amino]carbonyl]phenyl)sulfonyl]amino]-1-naphthoate 681246-65-1P, Benzyl 6-[[(4-fluorophenyl)sulfonyl]amino]-2-methyl-3-propylbenzoate 681246-66-2P, 3-Bromo-6-[(tert-butoxycarbonyl)amino]-2-methoxybenzoic acid 681246-67-3P, Methyl 2-([[2-(1-pyrrolidinylcarbonyl)phenyl]sulfonyl]amino)-1-naphthoate 681246-68-4P, Benzyl 3-bromo-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methylbenzoate 681246-69-5P, Benzyl 6-[[(2-fluorophenyl)sulfonyl]amino]-2-methyl-3-vinylbenzoate 681246-70-8P, Methyl 2-[([2-[(4-methyl-1-piperazinyl)carbonyl]phenyl]sulfonyl)amino]-1-naphthoate 681246-71-9P, Benzyl 3-[(1E)-3-methoxy-3-oxo-1-propenyl]-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoate 681246-72-0P, N-(1-Bromo-8-methyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4-fluorobenzenesulfonamide 681246-73-1P, 3-Bromo-6-[(tert-butoxycarbonyl)amino]-2-chlorobenzoic acid 681246-74-2P, Benzyl 3-bromo-6-[(tert-butoxycarbonyl)amino]-2-chlorobenzoate 681246-75-3P, Benzyl 6-amino-3-bromo-2-chlorobenzoate 681246-76-4P, Benzyl 3-bromo-2-chloro-6-[[(4-fluorophenyl)sulfonyl]amino]benzoate 681246-77-5P, Benzyl 2-chloro-6-[[(4-fluorophenyl)sulfonyl]amino]-3-vinylbenzoate 681246-78-6P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681246-79-7P, Benzyl 3-bromo-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methylbenzoate 681246-80-0P, Benzyl 6-[[(4-fluorophenyl)sulfonyl]amino]-3-(hydroxymethyl)-2-methylbenzoate 681246-82-2P, Benzyl 6-[[(4-fluorophenyl)sulfonyl]amino]-3-(1-hydroxyethyl)-2-methylbenzoate 681246-83-3P, N-(1-Bromo-8-oxo-5,6,7,8-tetrahydro-2-naphthalenyl)-2-fluorobenzenesulfonamide 681246-84-4P, N-(1-Bromo-8-methyl-5,6-dihydro-2-naphthalenyl)-2-fluorobenzenesulfonamide 681246-85-5P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylate 681246-86-6P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681246-87-7P, N-(1-Bromo-8-methyl-7-oxo-5,6,7,8-tetrahydro-2-naphthalenyl)-4-fluorobenzenesulfonamide 681246-88-8P, Methyl 2-([[2-([[2-(diethylamino)ethyl]amino]carbonyl)phenyl]sulfonyl]amino)-1-naphthoate 681246-89-9P, Benzyl 3-bromo-6-[(tert-butoxycarbonyl)amino]-2-methoxybenzoate 681246-90-2P, Benzyl 6-amino-3-bromo-2-methoxybenzoate 681246-91-3P, Benzyl 3-bromo-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxybenzoate 681246-92-4P, Benzyl 6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxy-3-vinylbenzoate 681246-93-5P, Benzyl 3-bromo-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methoxybenzoate 681246-94-6P, N-(1-Bromo-7,8-dimethyl-5,8-dihydro-2-naphthalenyl)-2-fluorobenzenesulfonamide 681246-95-7P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-7,8-dimethyl-5,8-dihydro-1-naphthalenecarboxylate 681246-96-8P, Benzyl 3-bromo-2-methoxy-6-[(2-pyridinylsulfonyl)amino]benzoate 681246-97-9P, Benzyl

2-methoxy-6-[(2-pyridinylsulfonyl)amino]-3-vinylbenzoate 681246-98-0P, Benzyl 6-[[(4-fluorophenyl)sulfonyl]amino]-2-methoxy-3-vinylbenzoate 681246-99-1P, 7-Amino-8-bromo-2,2-dimethyl-3,4-dihydro-1(2H)-naphthalenone 681247-00-7P, N-(1-Bromo-7,7-dimethyl-8-oxo-5,6,7,8-tetrahydro-2-naphthalenyl)-2-fluorobenzenesulfonamide 681247-01-8P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-7,7-dimethyl-8-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-02-9P, N-(1-Bromo-8-methylene-5,6,7,8-tetrahydro-2-naphthalenyl)-2-fluorobenzenesulfonamide 681247-03-0P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-8-methylene-5,6,7,8-tetrahydro-1-naphthalenecarboxylate **681247-04-1P**, 3-Bromo-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxybenzoic acid 681247-05-2P, Methyl 2-([[2-(methoxycarbonyl)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-06-3P, 2-([[1-(Methoxycarbonyl)-5,6,7,8-tetrahydro-2-naphthalenyl]amino]sulfonyl)benzoic acid 681247-07-4P, Methyl 2-([[2-([[2-(diethylamino)ethyl]amino]carbonyl)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-08-5P, Methyl 2-[[(2-[[[3-(dimethylamino)propyl](methyl)amino]carbonyl]phenyl)sulfonyl]amino]-1-naphthoate 681247-09-6P, 6-Bromo-5-methoxy-2H-3,1-benzoxazine-2,4(1H)-dione 681247-10-9P, 6-Bromo-5-hydroxy-2H-3,1-benzoxazine-2,4(1H)-dione 681247-11-0P, Methyl 6-amino-3-bromo-2-hydroxybenzoate 681247-12-1P, Methyl 6-amino-3-bromo-2-ethoxybenzoate 681247-13-2P, Methyl 3-bromo-2-ethoxy-6-[[(2-fluorophenyl)sulfonyl]amino]benzoate 681247-14-3P, Methyl 2-ethoxy-6-[[(2-fluorophenyl)sulfonyl]amino]-3-vinylbenzoate 681247-15-4P, Methyl 2-ethoxy-3-ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]benzoate 681247-16-5P, 5-Hydroxy-2H-3,1-benzoxazine-2,4(1H)-dione 681247-17-6P, Methyl 2-amino-6-ethoxybenzoate 681247-18-7P, Methyl 2-ethoxy-6-[[(4-fluorophenyl)sulfonyl]amino]benzoate 681247-19-8P, Methyl 3-bromo-2-ethoxy-6-[[(4-fluorophenyl)sulfonyl]amino]benzoate 681247-20-1P, Methyl 2-ethoxy-6-[[(4-fluorophenyl)sulfonyl]amino]-3-vinylbenzoate 681247-21-2P, Methyl 2-ethoxy-3-ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]benzoate 681247-22-3P, 2,2-Dimethyl-3-oxo-3-(1-piperidinyl)propanenitrile 681247-23-4P, 2,2-Dimethyl-3-(1-piperidinyl)-1-propanamine **681247-24-5P** 681247-25-6P 681247-26-7P, 2,2-Dimethyl-3-oxo-3-(1-pyrrolidinyl)propanenitrile 681247-27-8P, 2,2-Dimethyl-3-(1-pyrrolidinyl)-1-propanamine 681247-28-9P, 2-Ethyl-2-(1-piperidinylmethyl)-1-butanamine 681247-29-0P, Methyl 6-amino-3-bromo-2-propoxybenzoate 681247-30-3P, Methyl 3-bromo-6-[[(2-fluorophenyl)sulfonyl]amino]-2-propoxybenzoate 681247-31-4P 681247-32-5P 681247-33-6P 681247-34-7P, Methyl 2-[[(2-nitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-35-8P, Methyl 2-[[(2-aminophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-36-9P, Methyl 6-[[(2-fluorophenyl)sulfonyl]amino]-2-propoxy-3-vinylbenzoate 681247-37-0P, Methyl 3-ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]-2-propoxybenzoate 681247-38-1P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-8-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-39-2P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-8-methoxy-5,6-dihydro-1-naphthalenecarboxylate 681247-40-5P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-8-methoxy-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-41-6P, Methyl 3-([[1-(methoxycarbonyl)-5,6,7,8-tetrahydro-2-naphthalenyl]amino]sulfonyl)-2-thiophenecarboxylate 681247-42-7P, 3-([[1-(Methoxycarbonyl)-5,6,7,8-tetrahydro-2-naphthalenyl]amino]sulfonyl)-2-thiophenecarboxylic acid 681247-43-8P, Methyl 2-([[2-([[2-(diethylamino)ethyl]amino]carbonyl)-3-thienyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-44-9P, Methyl 6-amino-3-bromo-2-(2-methoxy-2-oxoethoxy)benzoate 681247-45-0P, Methyl 3-bromo-6-[[(4-fluorophenyl)sulfonyl]amino]-2-(2-methoxy-2-oxoethoxy)benzoate 681247-46-1P, Methyl 6-[[(4-fluorophenyl)sulfonyl]amino]-2-(2-methoxy-2-oxoethoxy)-3-vinylbenzoate 681247-47-2P, Methyl 3-ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]-2-(2-methoxy-2-oxoethoxy)benzoate 681247-48-3P, Methyl 6-amino-3-bromo-2-methoxybenzoate 681247-49-4P, Methyl 3-bromo-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxybenzoate 681247-50-7P, Methyl 6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxy-3-vinylbenzoate

681247-51-8P, Methyl 3-ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxybenzoate 681247-52-9P, Methyl 3-bromo-5-ethyl-2-[[(2-fluorophenyl)sulfonyl]amino]-6-methoxybenzoate 681247-53-0P, Methyl 5-ethyl-2-[[(2-fluorophenyl)sulfonyl]amino]-4-methoxy-1,1'-biphenyl-3-carboxylate 681247-54-1P, Methyl 2-amino-3-bromo-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-55-2P, Methyl 2-amino-3-[(1E)-3-tert-butoxy-3-oxo-1-propenyl]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-56-3P, Methyl 3-[(1E)-3-tert-butoxy-3-oxo-1-propenyl]-2-[(phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-57-4P 681247-58-5P, Methyl 2-[methyl-([2-[(4-piperidinylmethyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-59-6P, Methyl 2-chloro-6-[[(2-fluorophenyl)sulfonyl]amino]benzoate 681247-60-9P, Methyl 2-[(1E)-5-(benzyloxy)-5-oxo-1-pentenyl]-6-[[(2-fluorophenyl)sulfonyl]amino]benzoate 681247-61-0P, 5-[3-[[(2-Fluorophenyl)sulfonyl]amino]-2-(methoxycarbonyl)phenyl]pentanoic acid 681247-62-1P 681247-63-2P 681247-64-3P 681247-65-4P, Methyl 2-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-66-5P, Methyl 2-[[(2-([[4-(diethylamino)-1-methylbutyl]amino]carbonyl)-4-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-67-6P, Methyl 6-amino-3-bromo-2-[2-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]benzoate 681247-68-7P, Methyl 6-amino-2-[2-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-vinylbenzoate 681247-69-8P, Methyl 6-amino-3-ethyl-2-[2-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]benzoate 681247-70-1P, Methyl 2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]benzoate 681247-71-2P, Methyl 6-[[(2-bromophenyl)sulfonyl]amino]-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethylbenzoate 681247-72-3P, Methyl 6-[[(2-[(1E)-3,3-dimethyl-1-butenyl]phenyl)sulfonyl]amino]-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethylbenzoate 681247-73-4P, Methyl 6-[[(2-(3,3-dimethylbutyl)phenyl)sulfonyl]amino]-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethylbenzoate 681247-74-5P, Methyl 2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethyl-6-[([2-[(1E)-1-propenyl]phenyl]sulfonyl)amino]benzoate 681247-75-6P, Methyl 2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethyl-6-[([2-propylphenyl]sulfonyl)amino]benzoate 681247-76-7P, N,N-Diethyl-N-[(3Z)-4-(tributylstannyl)-3-butenyl]amine 681247-77-8P, N,N-Diethyl-N-[(3E)-4-(tributylstannyl)-3-butenyl]amine 681247-78-9P, Methyl 2-[([2-[(1E)-4-(diethylamino)-1-butenyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-79-0P, tert-Butyl (2S)-2-(2-[[(benzyloxy)carbonyl]amino]ethyl)-1-pyrrolidinecarboxylate 681247-80-3P 681247-81-4P 681247-82-5P 681247-83-6P 681247-84-7P, 2,2-Dimethyl-3-(4-morpholinyl)-3-oxopropanenitrile 681247-85-8P 681247-86-9P 681247-87-0P, N,N-Diethyl-N-[(2E)-3-(tributylstannyl)-2-propenyl]amine 681247-88-1P, N,N-Diethyl-N-[(2Z)-3-(tributylstannyl)-2-propenyl]amine 681247-89-2P, Methyl 2-[([2-[(1E)-3-(diethylamino)-1-propenyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-90-5P, Methyl 2-[([2-[4-(diethylamino)butyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-91-6P, Methyl 2-[([2-[(1Z)-3-(diethylamino)-1-propenyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-92-7P, Methyl 2-[([2-[(1Z)-4-(diethylamino)-1-butenyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-93-8P, Methyl 2-amino-3,5-dibromo-6-methoxybenzoate 681247-94-9P, Methyl 2-amino-6-methoxy-3,5-divinylbenzoate 681247-95-0P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-6-methoxy-3,5-divinylbenzoate 681247-96-1P, Methyl 3,5-diethyl-2-[[(2-fluorophenyl)sulfonyl]amino]-6-methoxybenzoate 681247-97-2P, Methyl 6-amino-2-methoxy-3-vinylbenzoate 681247-98-3P, Methyl 6-amino-3-ethyl-2-methoxybenzoate 681247-99-4P, Methyl 6-[[(2-bromophenyl)sulfonyl]amino]-3-ethyl-2-methoxybenzoate 681248-00-0P, Methyl 6-[[(2-[(1E)-2-(4-chlorophenyl)ethenyl]phenyl)sulfonyl]amino]-3-ethyl-2-methoxybenzoate 681248-01-1P, Methyl 3-ethyl-2-methoxy-6-([[2-(2-phenylethyl)phenyl]sulfonyl]amino)benzoate 681248-02-2P, Methyl 6-[([2-[2-(4-chlorophenyl)ethyl]phenyl]sulfonyl)amino

]-3-ethyl-2-methoxybenzoate 681248-03-3P, Methyl 3-ethyl-2-methoxy-6-[[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]benzoate 681248-04-4P, Methyl 6-[[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]amino]-3-ethyl-2-methoxybenzoate 681248-05-5P, Methyl 6-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethylbenzoate 681248-06-6P, Methyl 6-amino-3-bromo-2-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propoxy]benzoate 681248-07-7P, Methyl 6-amino-2-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propoxy]-3-vinylbenzoate 681248-08-8P, Methyl 6-amino-2-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propoxy]-3-ethylbenzoate 681248-09-9P, Methyl 6-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-2-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propoxy]-3-ethylbenzoate 681248-10-2P, Methyl 2-amino-3,5-diethyl-6-methoxybenzoate 681248-11-3P, Methyl 2-[([2-[3-(diethylamino)propyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681248-12-4P, N,N-Diethyl-N-[(4E)-5-(tributylstannyl)-4-pentenyl]amine 681248-13-5P, N,N-Diethyl-N-[(4Z)-5-(tributylstannyl)-4-pentenyl]amine 681248-14-6P 681248-15-7P 681248-16-8P, Methyl 2-[([2-[5-(diethylamino)pentyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681248-17-9P, Methyl 2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethyl-6-[[(4-fluoro-2-vinylphenyl)sulfonyl]amino]benzoate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT 681248-18-0P, Methyl 2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethyl-6-[[(2-ethyl-4-fluorophenyl)sulfonyl]amino]benzoate 681248-19-1P 681248-20-4P 681248-21-5P 681248-22-6P 681248-23-7P 681248-24-8P, tert-Butyl 4-(3-amino-2,2-dimethylpropanoyl)-1-piperazinecarboxylate 681248-25-9P, Methyl 6-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-3-ethyl-2-methoxybenzoate 681248-26-0P, Methyl 3-ethyl-6-[[(4-fluoro-2-(4-hydroxy-1-butynyl)phenyl)sulfonyl]amino]-2-methoxybenzoate 681248-27-1P, Methyl 3-ethyl-6-[[(4-fluoro-2-(4-hydroxybutyl)phenyl)sulfonyl]amino]-2-methoxybenzoate 681248-28-2P, Methyl 3-ethyl-6-[[(4-fluoro-2-(4-[(methylsulfonyl)oxy]butyl)phenyl)sulfonyl]amino]-2-methoxybenzoate 681248-29-3P, Methyl 3-ethyl-6-[[(4-fluoro-2-(4-[2-methyl-1-pyrrolidinyl]butyl)phenyl)sulfonyl]amino]-2-methoxybenzoate 681248-30-6P, Methyl 6-[[(2-[4-(diethylamino)butyl]-4-fluorophenyl)sulfonyl]amino]-3-ethyl-2-methoxybenzoate 681255-11-8P, Benzyl 6-[[(4-fluorophenyl)sulfonyl]amino]-2-methyl-3-vinylbenzoate 681255-13-0P, Benzyl 2-chloro-6-[[(2-fluorophenyl)sulfonyl]amino]-3-vinylbenzoate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT **677290-81-2P**, 2-[(Phenylsulfonyl)amino]-1-naphthoic acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

RN 677290-81-2 HCAPLUS
CN 1-Naphthalenecarboxylic acid, 2-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



L67 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:652631 HCAPLUS
DN 141:173970

ED Entered STN: 13 Aug 2004
TI Preparation of sulfonamides having antiangiogenic and anticancer activity
IN **Comess, Kenneth M.; Erickson, Scott A.; Henkin, Jack; Kalvin, Douglas M.; Kawai, Megumi; Kim, Ki H.; Bamaung, Nwe Y.; Park, Chang Hoon; Sheppard, George S.; Vasudevan, Anil; Wang, Jieyi; Barnes, David M.; Fidanze, Steve D.; Kolaczkowski, Lawrence; Mantei, Robert A.; Park, David C.**; Sanders, William J.; **Tedrow, Jason S.; Wang, Gary T.**
PA USA
SO U.S. Pat. Appl. Publ., 129 pp., Cont.-in-part of U.S. Ser. No. 267,081.
CODEN: USXXCO
DT Patent
LA English
IC ICM C07D279-12
ICS C07D277-04; C07D211-92
INCL 514227200; 514237500; 514255010; 514317000; 514370000; 514377000; 514423000; 514562000; 544059000; 544159000
CC 25-17 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 63
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004157836	A1	20040812	US 2003-667358	20030923
	US 2004068012	A1	20040408	US 2002-267081	20021008
	CA 2501520	AA	20040422	CA 2003-2501520	20031006
	WO 2004033419	A1	20040422	WO 2003-US31671	20031006
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1549613	A1	20050706	EP 2003-773182	20031006
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-267081	A2	20021008		
	US 2003-667358	A	20030923		
	WO 2003-US31671	W	20031006		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004157836	ICM	C07D279-12
	ICS	C07D277-04; C07D211-92
	INCL	514227200; 514237500; 514255010; 514317000; 514370000; 514377000; 514423000; 514562000; 544059000; 544159000
US 2004157836	NCL	514/227.200
	ECLA	C07C311/08; C07C311/13; C07C311/29; C07C311/37; C07C311/44; C07C311/46; C07C317/28; C07C323/25D2; C07C323/49; C07C323/63; C07C323/67; C07D209/08; C07D209/42; C07D213/70C; C07D213/71; C07D215/36; C07D215/48; C07D231/18; C07D233/54C; C07D233/84; C07D261/10B; C07D285/06; C07D285/14D; C07D333/34; C07D333/38; C07D413/04; C07D413/04+333B+261
US 2004068012	NCL	514/562.000
	ECLA	C07C311/08; C07C311/13; C07C311/29; C07C311/37; C07C311/44; C07C311/46; C07C317/28; C07C323/25D2; C07C323/49; C07C323/63; C07C323/67; C07D209/08; C07D209/42; C07D213/70C; C07D213/71; C07D215/36; C07D215/48; C07D231/18; C07D233/54C; C07D233/84; C07D261/10B; C07D285/06; C07D285/14D; C07D333/34;

		C07D333/38; C07D413/04; C07D413/04+333B+261
CA 2501520	ECLA	C07C311/08; C07C311/13; C07C311/21; C07C311/29; C07C311/37; C07C311/44; C07C311/46; C07C317/28; C07C323/25D2; C07C323/49; C07C323/63; C07C323/67; C07D209/08; C07D213/71; C07D215/36; C07D215/48; C07D231/18; C07D233/54C; C07D233/84; C07D261/10B; C07D285/14D; C07D333/34; C07D333/38; C07D413/04+333B+261
WO 2004033419	ECLA	C07C311/08; C07C311/13; C07C311/21; C07C311/29; C07C311/37; C07C311/44; C07C311/46; C07C317/28; C07C323/25D2; C07C323/49; C07C323/63; C07C323/67; C07D209/08; C07D213/71; C07D215/36; C07D215/48; C07D231/18; C07D233/54C; C07D233/84; C07D261/10B; C07D285/14D; C07D333/34; C07D333/38; C07D413/04+333B+261
EP 1549613	ECLA	C07C311/08; C07C311/13; C07C311/21; C07C311/29; C07C311/37; C07C311/44; C07C311/46; C07C317/28; C07C323/25D2; C07C323/49; C07C323/63; C07C323/67; C07D209/08; C07D213/71; C07D215/36; C07D215/48; C07D231/18; C07D233/54C; C07D233/84; C07D261/10B; C07D285/14D; C07D333/34; C07D333/38; C07D413/04+333B+261

OS MARPAT 141:173970

GI



I

AB The title compds. [I; A = 5-6 membered (non)aromatic ring containing 0-3 atoms selected from N, O, and S (wherein the ring is optionally fused to a second 5-7 membered (non)aromatic ring containing 0-3 atoms selected from N, O, and S); R1-R3 = H, alkenyl, alkoxy, etc.; R4 = H, alkyl, alkoxy, etc.; R5 = alkyl, NH2, aminoalkyl, aryl, etc.; R6 = H, alkyl, aryl, etc.; provided that when A = Ph, at least one of R1-R4 is other than H, alkyl, halo] having methionine aminopeptidase-2 inhibitory (MetAP2) activity, were prepared E.g., a multi-step synthesis of 5-ethyl-2-[(phenylsulfonyl)amino]benzoic acid, starting from 4-ethylaniline, was given. Representative compds. I had IC50's between about 0.005 μM and >100 μM against MetAP2. Also described are pharmaceutical compns. comprising the compds. I, methods of treatment using the compds. I, methods of inhibiting angiogenesis, and methods of treating cancer.

ST sulfonamide prepn antitumor angiogenesis inhibitor methionine aminopeptidase2 MetAP2; benzoic acid sulfonylamino prepn methionine aminopeptidase2 MetAP2 inhibitor; naphthoic acid phenylsulfonylamino prepn methionine aminopeptidase2 MetAP2 inhibitor

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(eukaryotic initiation factor-2-associated, p67; preparation of sulfonamides having antiangiogenic and anticancer activity)

IT Angiogenesis
(neovascularization, treatment of abnormal neovascularization; preparation of sulfonamides having antiangiogenic and anticancer activity)

IT Angiogenesis
Angiogenesis inhibitors
Antitumor agents
Neoplasm
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT **677290-81-2P**, 2-[(Phenylsulfonyl)amino]-1-naphthoic acid
681241-27-0P, 2-[[(4-Fluorophenyl)sulfonyl]amino]-8-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681241-49-6P**, 4-Bromo-2-[(phenylsulfonyl)amino]benzoic acid **681242-39-7P**, 3-(3-Methoxy-3-oxopropyl)-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoicac i **681242-51-3P 681242-97-7P**, 2-[[(2-Nitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-18-5P**, 2-[[(2-Aminophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-44-7P**, 3-Ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxybenzoic acid **681243-56-1P**, 2-([[2-([3-[(tert-Butoxycarbonyl)amino]propyl]amino) phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-57-2P**, 2-([[2-([3-[(tert-Butoxycarbonyl)(methyl)amino]propy l]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-00-8P**, 2-[[(2-[[2-(2-Pyridinyl)ethyl]amino]phenyl)su lfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-01-9P**, 2-Ethoxy-3-ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]benzoic acid **681244-10-0P**, 2-([[2-([[1-(tert-Butoxycarbonyl)-3-piperidinyl]methyl]amino)phenyl]sulfon yl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-11-1P**, 2-([[2-([[1-(tert-Butoxycarbonyl)-3-pyrrolidinyl]methyl]amino)phenyl]sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-12-2P**, 2-([[2-([[1-(tert-Butoxycarbonyl)-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-90-9P**, 3,5-Diethyl-2-[[(2-fluorophenyl)sulfonyl]amino]-6-methoxybenzoic acid **681246-19-5P**, 2-([[2-([3-[4-(tert-Butoxycarbonyl)-1-piperazinyl]-3-oxopropyl]amino)phenyl]sulfonyl]amino)-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-20-8P**, 2-([[2-([3-[4-(tert-Butoxycarbonyl)-1-piperazinyl]-2,2-dimethyl-3-oxopropyl]amino)phenyl]sulfonyl]amino)-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT **107143-76-0P**, 5-Chloro-2-[[(3,4-dichlorophenyl)sulfonyl]amino]benzoic acid **134864-08-7P**, 2-[[(4-Methylphenyl)sulfonyl]amino]-1-naphthoic acid **254878-25-6P**, 2-[[(4-Chlorophenyl)sulfonyl]amino]-4,5-dimethoxybenzoic acid **562078-23-3P**, 5-Bromo-2-[(1-naphthylsulfonyl)amino]benzoic acid **677290-35-6P**
677290-36-7P, 5-Isopropyl-2-[(phenylsulfonyl)amino]benzoic acid
677290-37-8P, 5-Isobutyl-2-[(phenylsulfonyl)amino]benzoic acid
677290-38-9P, 2-[(Phenylsulfonyl)amino]-5-propylbenzoic acid
677290-39-0P, 5-Cyclopentyl-2-[(phenylsulfonyl)amino]benzoic acid
677290-40-3P, 5-Cyclohexyl-2-[(phenylsulfonyl)amino]benzoic acid
677290-41-4P, 5-Butyl-2-[(phenylsulfonyl)amino]benzoic acid
677290-42-5P, 5-(3-Methylbutyl)-2-[(phenylsulfonyl)amino]benzoic acid **677290-43-6P**, 5-(2-Methylbutyl)-2-[(phenylsulfonyl)amino]benzoic acid **677290-44-7P**, 5-Pentyl-2-[(phenylsulfonyl)amino]benzoic acid **677290-45-8P**, 5-(2-Ethylbutyl)-2-[(phenylsulfonyl)amino]benzoic acid
677290-46-9P, 5-Hexyl-2-[(phenylsulfonyl)amino]benzoic acid
677290-47-0P, 2-[[(2-Chloro-4-fluorophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-48-1P**, 5-Ethyl-2-[[(3-methylphenyl)sulfonyl]amino]benzoic acid **677290-49-2P**, 5-Ethyl-2-[[(2-fluorophenyl)sulfonyl]amino]benzoic acid
677290-50-5P, 5-Ethyl-2-[[(3-fluorophenyl)sulfonyl]amino]benzoic acid **677290-51-6P**, 5-Ethyl-2-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid **677290-52-7P**, 2-[[(2-Chlorophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-53-8P**, 2-[[(3-Chlorophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-54-9P**, 2-[[(3,4-Difluorophenyl)sulfonyl]amino]-5-ethylbenzoic acid
677290-55-0P, 5-Ethyl-2-[(1-naphthylsulfonyl)amino]benzoic acid
677290-56-1P, 5-Ethyl-2-([[3-(trifluoromethyl)phenyl]sulfonyl]amino)benzoic acid **677290-57-2P**, 2-[[(2,3-

Dichlorophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-58-3P**, 2-[[(2,5-Dichlorophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-59-4P**, 2-[[(3,5-Dichlorophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-60-7P**, 2-[[(2-Bromophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-61-8P**, 2-[[(3-Bromophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-62-9P**, 5-Ethyl-2-[[(4-methylphenyl)sulfonyl]amino]benzoic acid **677290-63-0P**, 2-[[(3-Cyanophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-64-1P**, 2-[[(4-Cyanophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-65-2P**, 2-[[(2,5-Dimethylphenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-66-3P**, 5-Ethyl-2-[[(3-methoxyphenyl)sulfonyl]amino]benzoic acid **677290-67-4P**, 2-[[(3-Chloro-4-fluorophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-68-5P**, 2-[[(2,5-Dimethoxyphenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-69-6P**, 5-Ethyl-2-[[(5-fluoro-2-methylphenyl)sulfonyl]amino]benzoic acid **677290-70-9P**, 5-Ethyl-2-[(8-quinolinylsulfonyl)amino]benzoic acid **677290-71-0P**, 5-Ethyl-2-([[2-(methylsulfonyl)phenyl]sulfonyl]amino)benzoic acid **677290-72-1P**, 5-Ethyl-2-([[2-(trifluoromethoxy)phenyl]sulfonyl]amino)benzoic acid **677290-73-2P**, 2-([[5-(Dimethylamino)-1-naphthyl]sulfonyl]amino)-5-ethylbenzoic acid **677290-74-3P**, 2-([[3,5-Bis(trifluoromethyl)phenyl]sulfonyl]amino)-5-ethylbenzoic acid **677290-75-4P**, 2-[(Butylsulfonyl)amino]-5-ethylbenzoic acid **677290-76-5P**, 5-Ethyl-2-[(2-thienylsulfonyl)amino]benzoic acid **677290-77-6P**, 2-[[(5-Chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]amino]-5-ethylbenzoic acid **677290-78-7P**, 5-Ethyl-2-([[2-(methoxycarbonyl)-3-thienyl]sulfonyl]amino)benzoic acid **677290-79-8P**, 6-[(Phenylsulfonyl)amino]-5-indanecarboxylic acid **677290-80-1P**, 2-[(Phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **677290-82-3P**, 2-[(1-Naphthylsulfonyl)amino]-1-naphthoic acid **677290-83-4P**, 7-Fluoro-2-[(phenylsulfonyl)amino]-1-naphthoic acid **677290-84-5P**, 2-[[(4-Chlorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-85-6P**, 2-[[(4-Iodophenyl)sulfonyl]amino]-1-naphthoic acid **677290-86-7P**, 2-[[(3-Fluorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-87-8P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-88-9P**, 2-[[(2-Methylphenyl)sulfonyl]amino]-1-naphthoic acid **677290-89-0P**, 2-[[(3-Methylphenyl)sulfonyl]amino]-1-naphthoic acid **677290-90-3P**, 2-[[(2-Fluorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-91-4P**, 2-([[2-(Trifluoromethoxy)phenyl]sulfonyl]amino)-1-naphthoic acid **677290-92-5P**, 2-[([2-[(3-Aminopropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **677290-93-6P**, 2-[[(4-Methoxyphenyl)sulfonyl]amino]-1-naphthoic acid **677290-94-7P**, 7-Fluoro-2-[[(4-fluorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-95-8P**, 7-Fluoro-2-[[(3-fluorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-96-9P**, 6-Bromo-2-[[(4-fluorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-97-0P**, 2-[[(3,4-Difluorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-98-1P**, 2-[[(2-Chloro-4-fluorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-99-2P**, 2-[[(5-Fluoro-2-methylphenyl)sulfonyl]amino]-1-naphthoic acid **677291-00-8P**, 2-[[(2-Methoxy-5-methylphenyl)sulfonyl]amino]-1-naphthoic acid **677291-01-9P**, 2-[[(2-Chloro-6-methylphenyl)sulfonyl]amino]-1-naphthoic acid **677291-03-1P**, 2-([[4-Chloro-3-(trifluoromethyl)phenyl]sulfonyl]amino)-1-naphthoic acid **677291-04-2P**, 2-[[(2,4-Dimethoxyphenyl)sulfonyl]amino]-1-naphthoic acid **677291-06-4P**, 2-[(8-Quinolinylsulfonyl)amino]-1-naphthoic acid **677291-07-5P**, 2-[(2,1,3-Benzothiadiazol-4-ylsulfonyl)amino]-1-naphthoic acid **677291-08-6P**, 2-[(2-Thienylsulfonyl)amino]-1-naphthoic acid **677291-09-7P**, 2-[[(3,5-Dimethyl-4-isoxazolyl)sulfonyl]amino]-1-naphthoic acid **677291-10-0P**, 2-[[(5-Chloro-2-thienyl)sulfonyl]amino]-1-naphthoic acid **677291-11-1P**, 2-[[(5-Chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]amino]-1-naphthoic acid **677291-12-2P**, 2-([[2-(Methoxycarbonyl)-3-thienyl]sulfonyl]amino)-1-naphthoic acid **677291-13-3P**, 2-([[5-(3-Isoxazolyl)-2-thienyl]sulfonyl]amino)-1-

naphthoic acid **677291-14-4P**, 2-([[2,5-Dichloro-3-thienyl]sulfonyl]amino)-1-naphthoic acid **677291-15-5P**, 2-([[4,5-Dichloro-2-thienyl]sulfonyl]amino)-1-naphthoic acid **677291-17-7P**, 2-[(Butylsulfonyl)amino]-1-naphthoic acid **677291-18-8P**, 2-[(Benzylsulfonyl)amino]-1-naphthoic acid **677291-19-9P 677291-20-2P**, 2-[[(3-Chloropropyl)sulfonyl]amino]-1-naphthoic acid **677291-21-3P**, 2-[(Methylsulfonyl)amino]-1-naphthoic acid **677291-22-4P**, 2-[(Ethylsulfonyl)amino]-1-naphthoic acid **677291-23-5P**, 2-[(Propylsulfonyl)amino]-1-naphthoic acid **677297-03-9P**, 2-[[(3,4-Difluorophenyl)sulfonyl]amino]-7-fluoro-1-naphthoic acid **681241-15-6P**, 2-[[(3,5-Dichloro-2-hydroxyphenyl)sulfonyl]amino]-1-naphthoic acid **681241-17-8P**, 2-[[(5-Bromo-6-chloro-3-pyridinyl)sulfonyl]amino]-1-naphthoic acid **681241-18-9P**, 2-[[(2,4-Difluorophenyl)sulfonyl]amino]-7-fluoro-1-naphthoic acid **681241-19-0P**, 2-[(Phenylsulfonyl)amino]-4-(trifluoromethyl)benzoic acid **681241-20-3P**, 2-[(Phenylsulfonyl)amino]-4-(trifluoromethoxy)benzoic acid **681241-21-4P**, 5-Nitro-2-[(phenylsulfonyl)amino]benzoic acid **681241-22-5P**, 6-[(Phenylsulfonyl)amino]-5-quinolinecarboxylic acid **681241-23-6P**, 6-[[(4-Methoxyphenyl)sulfonyl]amino]-5-quinolinecarboxylic acid **681241-24-7P**, 2-[Ethyl[(4-fluorophenyl)sulfonyl]amino]-1-naphthoic acid **681241-25-8P**, 2-[[(4-Fluorophenyl)sulfonyl](propyl)amino]-1-naphthoic acid **681241-26-9P**, 2-[[(4-Fluorophenyl)sulfonyl][2-(methylsulfanyl)ethyl]amino]-1-naphthoicaci **681241-28-1P**, 3-Bromo-2-methyl-6-[(phenylsulfonyl)amino]benzoic acid **681241-29-2P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-8-hydroxy-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681241-30-5P**, 8-Amino-2-[[(4-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681241-31-6P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-8-hydroxy-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681241-32-7P**, 3-Cyano-2-methyl-6-[(phenylsulfonyl)amino]benzoic acid **681241-33-8P**, 3-Cyano-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoic acid **681241-34-9P**, 3-Bromo-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoic acid **681241-35-0P**, 2-[(2-Pyridinylsulfonyl)amino]-1-naphthoic acid **681241-36-1P**, 3-Bromo-2-methyl-6-[(3-pyridinylsulfonyl)amino]benzoic acid **681241-37-2P**, 3-Cyano-2-methyl-6-[(3-pyridinylsulfonyl)amino]benzoic acid **681241-38-3P**, 3-Butyl-2-methyl-6-[(3-pyridinylsulfonyl)amino]benzoic acid **681241-39-4P**, 6-[(1-Naphthylsulfonyl)amino]-1H-indole-7-carboxylic acid **681241-40-7P**, 6-[[(3-Fluorophenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid **681241-41-8P**, 6-[[(4-Fluorophenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid **681241-42-9P**, 6-[[(2-Chloro-4-methoxyphenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid **681241-43-0P**, 6-[[(4-Methylphenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid **681241-44-1P**, 6-[[(2-Fluorophenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid **681241-45-2P**, 6-[[(4-Chlorophenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid **681241-46-3P**, 6-[(Phenylsulfonyl)amino]-1H-indole-7-carboxylic acid **681241-47-4P**, 6-[[(3-Methylphenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid **681241-48-5P**, 6-[[(4-Methoxyphenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid **681241-50-9P**, 3-Bromo-6-[[(3-fluorophenyl)sulfonyl]amino]-2-methylbenzoic acid **681241-51-0P**, 3-Bromo-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methylbenzoic acid **681241-52-1P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681241-53-2P**, 3-Oxo-5-[(phenylsulfonyl)amino]-4-indanecarboxylic acid **681241-54-3P**, 3-Ethyl-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoic acid **681241-55-4P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681241-56-5P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681241-57-6P**, 2-([[2-(Butylamino)phenyl]sulfonyl]amino)-1-naphthoic acid **681241-58-7P**

Search done by Noble Jarrell

, 2-([[2-(sec-Butylamino)phenyl]sulfonyl]amino)-1-naphthoic acid **681241-59-8P**, 2-([[2-(Isobutylamino)phenyl]sulfonyl]amino)-1-naphthoic acid **681241-60-1P**, 2-([[2-(Pentylamino)phenyl]sulfonyl]amino)-1-naphthoic acid **681241-61-2P**, 2-([[2-[(1-Methylbutyl)amino]phenyl]sulfonyl]amino)-1-naphthoic acid **681241-62-3P**, 2-([[2-[(2-Methylbutyl)amino]phenyl]sulfonyl]amino)-1-naphthoic acid **681241-63-4P**, 2-([[2-[(3-Methylbutyl)amino]phenyl]sulfonyl]amino)-1-naphthoic acid **681241-64-5P**, 2-([[2-[(1,2-Dimethylpropyl)amino]phenyl]sulfonyl]amino)-1-naphthoic acid **681241-65-6P**, 2-([[2-(Neopentylamino)phenyl]sulfonyl]amino)-1-naphthoic acid **681241-66-7P**, 2-([[2-[(1-Ethylpropyl)amino]phenyl]sulfonyl]amino)-1-naphthoic acid **681241-67-8P**, 2-([[2-(Hexylamino)phenyl]sulfonyl]amino)-1-naphthoic acid **681241-68-9P**, 2-([[2-[(3,3-Dimethylbutyl)amino]phenyl]sulfonyl]amino)-1-naphthoic acid **681241-69-0P**, 3-Ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methylbenzoic acid **681241-70-3P**, 3-Chloro-2-[[(4-fluorophenyl)sulfonyl]amino]-1-naphthoic acid **681241-71-4P**, 2-[(Phenylsulfonyl)amino]-4-vinylbenzoic acid **681241-72-5P**, 2-Methyl-3-propyl-6-[(2-pyridinylsulfonyl)amino]benzoic acid **681241-73-6P**, 2-[[(2-[[(3-Methoxypropyl)amino]carbonyl]phenyl)sulfonyl]amino]-1-naphthoic acid **681241-74-7P**, 6-[[(4-Fluorophenyl)sulfonyl]amino]-2-methyl-3-propylbenzoic acid **681241-75-8P**, 3-Bromo-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methoxybenzoic acid **681241-76-9P**, 2-[([2-[(2-Ethoxyethyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-78-1P**, 2-[([2-[(2-Isopropoxyethyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-79-2P**, 2-[([2-[(3-Propoxypropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-80-5P**, 2-[([2-[(3-Methoxypropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-81-6P**, 2-[([2-[(Cyclopropylmethyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-82-7P**, 2-[([2-(Cyclopentylamino)phenyl]sulfonyl)amino]-1-naphthoic acid **681241-83-8P**, 2-[([2-[(Cyclopentylmethyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-84-9P**, 2-[([2-(Cyclohexylamino)phenyl]sulfonyl)amino]-1-naphthoic acid **681241-85-0P**, 2-[([2-[(2-Ethylhexyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-86-1P**, 2-[([2-[(3-Hydroxypropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-87-2P**, 2-[([2-[(4-Hydroxybutyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-88-3P**, 2-[([2-[(2-Propoxyethyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-89-4P**, 2-[([2-[(3-Ethoxypropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-90-7P**, 2-[([2-[(3-Butoxypropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-91-8P**, 2-[([2-[(3-Isopropoxypropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-92-9P**, 2-[([2-[(3-Isobutoxypropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-93-0P**, 2-[([2-[[3-(Methylsulfanyl)propyl]amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-94-1P**, 2-[([2-[[3-(Diethylamino)propyl]amino]phenyl]sulfonyl)amino]-1-naphthoicaci **681241-95-2P**, 2-[([2-[(2-Methoxyethyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-96-3P**, 2-[([2-(1-Pyrrolidinylcarbonyl)phenyl]sulfonyl)amino]-1-naphthoic acid **681241-97-4P**, 2-Methyl-6-[(2-pyridinylsulfonyl)amino]-3-vinylbenzoic acid **681241-98-5P**, 6-[[(4-Fluorophenyl)sulfonyl]amino]-2-methyl-3-vinylbenzoic acid **681241-99-6P**, 2-[([2-[(4-Methyl-1-piperazinyl)carbonyl]phenyl]sulfonyl)amino]-1-naphthoic acid **681242-00-2P**, 2-[[(2-Chloro-4-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-01-3P**, 2-[(2-Thienylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-02-4P**, 2-[(Benzylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-03-5P**, 2-[[(2-Methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-04-6P**, 2-[[(3-Methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-

naphthalenecarboxylic acid **681242-05-7P**, 2-[[(4-Methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-06-8P**, 2-[[(2-Fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-07-9P**, 2-[[(3-Fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-08-0P**, 2-[[(3-Cyanophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-09-1P**, 2-[[(4-Cyanophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-10-4P**, 2-[[(2,5-Dimethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-11-5P**, 2-[[(3-Methoxyphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-12-6P**, 2-[[(4-Methoxyphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-13-7P**, 2-[[(2-Chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-14-8P**, 2-[[(3-Chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-15-9P**, 2-[[(4-Chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-16-0P**, 2-[[(2,4-Difluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-17-1P**, 2-[[(3,4-Difluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-18-2P**, 2-[[(4-Propylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-19-3P**, 2-[[(4-Isopropylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-20-6P**, 2-[(2-Naphthylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylicaci **681242-21-7P**, 2-[(1-Naphthylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylicaci **681242-22-8P**, 2-[[(4-tert-Butylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-23-9P**, 2-[[(3-Chloro-4-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-24-0P**, 2-([[4-(Acetylamino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-25-1P**, 2-[[(2,5-Dimethoxyphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-26-2P**, 2-[[(3,4-Dimethoxyphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-27-3P**, 2-[[(3-(Trifluoromethyl)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-28-4P**, 2-[[(4-(Trifluoromethyl)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-29-5P**, 2-[[(2,3-Dichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-30-8P**, 2-[[(2,4-Dichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-31-9P**, 2-[[(2,6-Dichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-32-0P**, 2-[[(3,4-Dichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-33-1P**, 2-[[(3,5-Dichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-34-2P**, 2-[((1,1'-Biphenyl-4-yl)sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-35-3P**, 2-[[(2-Bromophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-36-4P**, 2-[[(3-Bromophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-37-5P**, 2-[[(4-Bromophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-38-6P**, 2-[[(4-(Trifluoromethoxy)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-40-0P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-5-(methylsulfanyl)benzoic acid **681242-41-1P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-42-2P**, 3-(2-Carboxyethyl)-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoic acid **681242-43-3P**, 5-(Methylsulfanyl)-2-[(phenylsulfonyl)amino]benzoic acid **681242-44-4P**, 2-[[(2-[[2-(Dimethylamino)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-45-5P**, 2-[[(2-[[2-(Diethylamino)ethyl]amino]phenyl)sulfonyl

]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-46-6P**, 2-[[(2-[[2-(1-Pyrrolidinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-47-7P**, 2-[[(2-[[3-(Dimethylamino)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-48-8P**, 2-[[(2-[[3-(4-Methyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-49-9P**, 2-[[(2-[[3-(1-Piperidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-50-2P**, 3-Butyl-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methylbenzoic acid **681242-52-4P**, 2-Chloro-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid **681242-53-5P**, 3-Bromo-2-chloro-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid **681242-54-6P**, 2-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-55-7P**

, 3-Ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methylbenzoic acid **681242-56-8P**, 6-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-methylbenzoic acid **681242-57-9P**, 6-[[(2-[[4-(N,N-Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-methylbenzoic acid **681242-58-0P**, 3-[1,2-Dihydroxyethyl]-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methylbenzoic acid **681242-59-1P**, 6-[[(4-Fluorophenyl)sulfonyl]amino]-3-(hydroxymethyl)-2-methylbenzoic acid **681242-60-4P**, 6-[[(2-[[2-(Diethylamino)ethyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-methylbenzoic acid **681242-61-5P**, 3-Ethyl-6-[[(2-[[3-(1H-imidazol-1-yl)propyl]amino]phenyl)sulfonyl]amino]-2-methylbenzoic acid **681242-62-6P**, 6-[[(2-[[3-(Dimethylamino)propyl](methyl)amino]phenyl)sulfonyl]amino]-3-ethyl-2-methylbenzoic acid **681242-63-7P**, 3-Ethyl-2-methyl-6-([[2-(4-methyl-1-piperazinyl)phenyl]sulfonyl]amino)benzoic acid **681242-64-8P**, 2-[[(3,5-Dimethyl-4-isoxazolyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT **681242-65-9P**, 2-[[(5-Chloro-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-66-0P**, 2-[[(5-Fluoro-2-methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-67-1P**, 2-[[(2-Methoxy-5-methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-68-2P**, 2-[[(3-Nitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-69-3P**, 2-[[(2-Chloro-6-methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-70-6P**, 2-[[(5-Chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-71-7P**, 2-[(Mesitylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-72-8P**, 2-[[(4-Nitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-73-9P**, 2-[[(3-Chloro-4-methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-74-0P**, 2-[(2,1,3-Benzothiadiazol-4-ylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-75-1P**, 2-[[(2-Methyl-5-nitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-76-2P**, 2-[[(5-(3-Isoxazolyl)-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-77-3P**, 2-[[(2,5-Dichloro-3-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-78-4P**, 2-[[(4,5-Dichloro-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-81-9P**, 2-[[(7-Chloro-2,1,3-benzoxadiazol-4-yl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-82-0P**, 2-[[(4-Chloro-3-nitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-83-1P**, 2-[[(2-(Trifluoromethoxy)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-84-2P**,

2-[[(5-Chloro-4-nitro-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-85-3P**, 2-[[(2,4-Dinitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-86-4P**, 2-[[(5-(Dimethylamino)-1-naphthyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-87-5P**, 2-[[(4-Chloro-3-(trifluoromethyl)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-88-6P**, 2-[[(2,4,5-Trichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-89-7P**, 2-[[(2,3,4-Trichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-90-0P** **681242-91-1P**, 2-[[(5-Bromo-2-methoxyphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-92-2P**, 2-[[(3,5-Bis(trifluoromethyl)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-93-3P**, 2-[[(2-Butoxy-5-(1,1-dimethylpropyl)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-94-4P**, 2-[[(5-(Phenylsulfonyl)-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-95-5P**, 2-[[(5-[[(4-Chlorobenzoyl)amino]methyl]-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-96-6P**, 2-[[(5-Bromo-6-chloro-3-pyridinyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-98-8P**, 2-[[(5-[(Benzoylamino)methyl]-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-99-9P**, 6-[[(4-Fluorophenyl)sulfonyl]amino]-3-[1-hydroxyethyl]-2-methylbenzoic acid **681243-00-5P**, 2-[[(2-[[2-(Dimethylamino)ethyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-01-6P**, 8-Methyl-2-[[(2-[[2-(1-pyrrolidinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-02-7P**, 8-Methyl-2-[[(2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-03-8P**, 2-[[(2-[[3-(Dimethylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-04-9P**, 2-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-05-0P**, 2-[[(2-[[2-(Diethylamino)ethyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-06-1P**, 8-Methyl-2-[[(2-[[2-(4-morpholinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-07-2P**, 8-Methyl-2-[[(2-[[3-[3-(methylamino)phenyl]propyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-08-3P**, 2-[[(2-(4-Benzyl-1-piperazinyl)phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-09-4P**, 2-[[(2-[[4-(N,N-Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-10-7P**, 2-[[(2-[[3-(Dibutylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-11-8P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-8-methyl-7-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-12-9P**, 2-[[(2-[[3-(1H-Imidazol-1-yl)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-13-0P**, 8-Methyl-2-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-14-1P**, 8-Methyl-2-[[(2-[[3-(1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-15-2P**, 8-Methyl-2-[[(2-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-16-3P**, 8-Methyl-2-[[(2-[[3-(2-methyl-1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-17-4P**, 2-[[(2-[[3-(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-19-6P**, 8-Methyl-2-[[(2-[[2-(1-piperidinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-20-9P** **681243-21-0P** **681243-22-1P**, 2-([[2-([[2-(Diethylamino)ethyl]amino]carbonyl)phenyl]sulfonyl]amino)-1-naphthoic acid

681243-23-2P, 2-[[(2-[[2-(1-Piperazinyl)ethyl]amino]phenyl)sulfony
l]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681243-24-3P, 2-[[(2-[[3-(2-Oxo-1-pyrrolidinyl)propyl]amino]phenyl
)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681243-26-5P, 2-[[(2-[[3-(4-Morpholinyl)propyl]amino]phenyl)sulfon
yl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681243-28-7P, 2-[[(2-[[2-(1-Methyl-2-pyrrolidinyl]ethyl]amino]phen
yl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681243-29-8P, 2-[[(2-[[3-(2-Methyl-1-piperidinyl]propyl]amino]phen
yl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681243-30-1P, 2-[[(2-[[1-(Ethoxycarbonyl)-4-
piperidinyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-
naphthalenecarboxylic acid **681243-32-3P**, 2-[[(2-[[2-(4-
Morpholinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-
naphthalenecarboxylic acid **681243-33-4P**, 2-[[(2-[[2-[Bis-(2-
hydroxyethyl)amino]ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-
naphthalenecarboxylic acid **681243-34-5P**, 2-[[(2-[[2-(1-
Piperidinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-
naphthalenecarboxylic acid **681243-35-6P**, 2-[[(2-[[4-
(Diethylamino)-1-methylbutyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-
tetrahydro-1-naphthalenecarboxylic acid **681243-36-7P**,
2-[[(2-[[3-(Dibutylamino)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-
tetrahydro-1-naphthalenecarboxylic acid **681243-37-8P**,
2-[[(2-[[3-(1H-Imidazol-1-yl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-
tetrahydro-1-naphthalenecarboxylic acid **681243-38-9P**,
2-[[(2-[[3-(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-
5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-39-0P**,
2-[[(2-[[4-(N,N-Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-
tetrahydro-1-naphthalenecarboxylic acid **681243-40-3P**,
2-[[(2-[[2-(Dipropylamino)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-
tetrahydro-1-naphthalenecarboxylic acid **681243-41-4P**,
2-[[(2-[[3-(1-Pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-
tetrahydro-1-naphthalenecarboxylic acid **681243-42-5P**,
2-[[(2-[[2-(Diisopropylamino)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-
tetrahydro-1-naphthalenecarboxylic acid **681243-43-6P**,
2-[[(2-[[4-(Diethylamino)butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-
tetrahydro-1-naphthalenecarboxylic acid **681243-45-8P**
681243-46-9P, 6-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfony
l]amino]-3-ethyl-2-hydroxybenzoic acid **681243-48-1P**,
3-Ethyl-2-methoxy-6-[[(2-[[3-(1-piperidinyl)propyl]amino]phenyl)sulfonyl]a
mino]benzoic acid **681243-49-2P**, 3-Ethyl-2-hydroxy-6-[[(2-[[3-(1-
piperidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid
681243-50-5P, 3-Ethyl-2-hydroxy-6-[[(2-[[3-(4-methyl-1-
piperazinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid
681243-51-6P, 6-[[(2-[[4-(N,N-Dimethylamino)butyl]amino]phenyl)sul
fonyl]amino]-3-ethyl-2-methoxybenzoic acid **681243-52-7P**,
3-Ethyl-2-methoxy-6-[[(2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl)s
ulfonyl]amino]benzoic acid **681243-53-8P**, 2-([[2-([[2-(1-
Piperidinyl)ethyl]amino]carbonyl)phenyl]sulfonyl]amino)-1-naphthoic acid
681243-54-9P, 2-[[(2-[[3-(Ethylamino)propyl]amino]phenyl)sulfonyl]
amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681243-55-0P, 2-([[2-([3-[Bis(2-hydroxyethyl)amino]propyl]amino)ph
enyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681243-58-3P, 2-[([2-[(3-Aminopropyl)amino]phenyl]sulfonyl)amino]-
5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-59-4P**,
2-[[(2-[[3-(Methylamino)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-
tetrahydro-1-naphthalenecarboxylic acid **681243-60-7P**,
6-[[(4-Fluorophenyl)sulfonyl]amino]-2-methoxy-3-vinylbenzoic acid
681243-61-8P, 2-([[2-[([[2-(Diethylamino)ethyl]amino]carbonyl)amin
o]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681243-62-9P, 2-([[2-([[2-(Diethylamino)ethoxy]carbonyl]amino)phen
yl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681243-63-0P, 8-Methyl-2-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phe
nyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681243-64-1P, 8-Methyl-2-[[(2-[[3-(4-methyl-1-
piperazinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-

naphthalenecarboxylic acid **681243-65-2P**, 2-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-66-3P**, 8-Methyl-2-[[(2-[[3-(2-methyl-1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-67-4P** **681243-68-5P**, 2-[[(2-[[3-(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-69-6P**, 2-[[(2-[[4-(1-Pyrrolidinyl)butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-70-9P**, 2-[[(2-[[4-[2-Methyl-1-pyrrolidinyl]butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-71-0P**, 2-[[(2-[[4-[2,5-Dimethyl-1-pyrrolidinyl]butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-72-1P**, 2-[[(2-[[4-(1-Piperidinyl)butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-73-2P**, 2-[[(2-[[4-[2-Methyl-1-piperidinyl]butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-74-3P**, 2-[[(2-[[4-[3-Methyl-1-piperidinyl]butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-75-4P**, 2-[[(2-[[4-[4-Methyl-1-piperidinyl]butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-76-5P** **681243-77-6P**, 2-[[(2-[[4-(1-Azepanyl)butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-78-7P** **681243-79-8P** **681243-80-1P**, 2-[([2-[(1-Benzyl-4-piperidinyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-81-2P**, 2-[([2-[(1,2,2,6,6-Pentamethyl-4-piperidinyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-82-3P**, 3-Ethyl-2-methoxy-6-[(2-pyridinylsulfonyl)amino]benzoic acid **681243-83-4P**, 3-Ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methoxybenzoic acid **681243-84-5P**, 2-[[(2-[[3-(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-7,7-dimethyl-8-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-85-6P**, 7,7-Dimethyl-2-[[(2-[[2-[1-methyl-2-pyrrolidinyl]ethyl]amino]phenyl)sulfonyl]amino]-8-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-86-7P**, 7,7-Dimethyl-2-[[(2-[[3-[2-methyl-1-piperidinyl]propyl]amino]phenyl)sulfonyl]amino]-8-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-87-8P**, 7,7-Dimethyl-8-oxo-2-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-88-9P** **681243-89-0P**, 8-Methylene-2-[[(2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-90-3P**, 8-Methylene-2-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-91-4P**, 2-[[(2-[[4-(Aminocarbonyl)-1-piperidinyl]carbonyl]phenyl)sulfonyl]amino]-1-naphthoic acid **681243-92-5P**, 3-Bromo-6-[[(2-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-2-methoxybenzoic acid **681243-93-6P**, 3-Bromo-2-methoxy-6-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681243-94-7P**, 3-Bromo-2-hydroxy-6-[[(2-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]phenyl)sulfonyl]amino]benzoic acid **681243-95-8P**, 3-Bromo-2-methoxy-6-[[(2-[[3-(1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681243-96-9P**, 2-([[2-([[2-(Diethylamino)ethyl]amino]carbonyl)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-97-0P**, 2-[[(2-[[[3-(Dimethylamino)propyl](methyl)amino]carbonyl]phenyl)sulfonyl]amino]-1-naphthoic acid **681243-98-1P**, 2-[[(2-[[3-(Isopropylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-99-2P**, 3-Bromo-2-chloro-6-[[(2-fluorophenyl)sulfonyl]amino]benzoic acid **681244-02-0P**, 2-Ethoxy-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid **681244-03-1P**, 3-Bromo-2-ethoxy-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid **681244-04-2P**, 2-Ethoxy-3-ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid

681244-05-3P, 2-Chloro-6-[[(2-[4-(N,N-dimethylamino)butyl]phenyl)sulfonyl]amino]-3-ethylbenzoic acid **681244-06-4P**, 2-Chloro-6-[[(2-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-3-ethylbenzoic acid **681244-07-5P**, 2-Chloro-3-ethyl-6-([[2-([2-[1-methyl-2-pyrrolidinyl]ethyl]amino)phenyl]sulfonyl]amino)benzoic acid **681244-08-6P 681244-09-7P**, 2-[[(2-[[2,2-Dimethyl-3-(1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-13-3P 681244-14-4P 681244-15-5P**, 2-[([2-[(4-Piperidinylmethyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-16-6P**, 2-[([2-[(2-[1-Cyclobutyl-2-piperidinyl]ethyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-17-7P 681244-18-8P**, 7,7-Dimethyl-2-([[2-([2-[1-methyl-2-pyrrolidinyl]ethyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-19-9P**, 2-[[(2-Fluorophenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-20-2P**, 2-[[(2-[[2,2-Dimethyl-3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-21-3P**, 2-[[(2-[[2-Ethyl-2-(1-piperidinylmethyl)butyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-22-4P**, 2-Ethoxy-3-ethyl-6-([[2-([2-[1-methyl-2-pyrrolidinyl]ethyl]amino)phenyl]sulfonyl]amino)benzoic acid **681244-23-5P**, 6-[[(2-[[3-(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-2-ethoxy-3-ethylbenzoic acid **681244-24-6P 681244-25-7P**, 6-[[(2-[[4-(Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-2-ethoxy-3-ethylbenzoic acid **681244-27-9P**, 3-Bromo-6-([[2-([3-(dimethylamino)-2,2-dimethylpropyl]amino)phenyl]sulfonyl]amino)-2-propoxybenzoic acid **681244-28-0P**, 3-Bromo-6-([[2-([4-(N,N-dimethylamino)butyl]amino)phenyl]sulfonyl]amino)-2-propoxybenzoic acid **681244-29-1P**, 3-Bromo-6-[[(2-[[3-(4-morpholinyl)propyl]amino]phenyl)sulfonyl]amino]-2-propoxybenzoic acid **681244-30-4P 681244-31-5P**, 2-[[(2-[[([2-[1-Methyl-2-pyrrolidinyl]ethyl]amino)carbonyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-32-6P**, 2-[([2-[([2-[1-Methyl-2-pyrrolidinyl]ethyl]amino)carbonyl]phenyl]sulfonyl)amino]-1-naphthoic acid **681244-33-7P**, 2-[([2-[([3-[1-Pyrrolidinyl]propyl]amino)carbonyl]phenyl]sulfonyl)amino]-1-naphthoic acid **681244-34-8P**, 2-[([2-[([3-(Isopropylamino)propyl]amino)carbonyl]phenyl]sulfonyl)amino]-1-naphthoic acid **681244-36-0P**, 2-[([2-[([[2-(1-Piperidinyl)ethyl]amino)carbonyl]amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-38-2P**, 2-[([2-[([[2-(1-Piperazinyl)ethyl]amino)carbonyl]amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-40-6P**, 2-[([2-[([[3-(2-Methyl-1-Piperidinyl)propyl]amino)carbonyl]amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-42-8P**, 2-[([2-[([[2-(4-Morpholinyl)ethyl]amino)carbonyl]amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-44-0P**, 2-[([2-[([[3-(4-Morpholinyl)propyl]amino)carbonyl]amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-46-2P**, 2-[([2-[([[4-(Diethylamino)-1-methylbutyl]amino]carbonyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-48-4P**, 2-[([2-[([[3-(Dimethylamino)-2,2-dimethylpropyl]amino]carbonyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-50-8P**, 2-[([2-[([[3-(1-Piperidinyl)propyl]amino]carbonyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-52-0P**, 2-[([2-[([[3-(1-Piperazinyl)propyl]amino]carbonyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-53-1P**, 3-Ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]-2-propoxybenzoic acid **681244-54-2P 681244-55-3P**, 3-Ethyl-6-([[2-([3-[2-methyl-1-piperidinyl]propyl]amino)phenyl]sulfonyl]amino)-2-propoxybenzoic acid **681244-56-4P**, 3-Ethyl-6-([[2-([3-[4-

morpholinyl]propyl]amino)phenyl]sulfonyl]amino)-2-propoxybenzoic acid **681244-57-5P**, 3-Bromo-6-[[(2-[[4-(N,N-dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-2-methoxybenzoic acid **681244-58-6P**, 3-Bromo-6-[[(2-[[4-(N,N-dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-2-hydroxybenzoic acid **681244-59-7P**, 3-Bromo-2-hydroxy-6-[[(2-[[3-(1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-60-0P**, 3-Bromo-2-hydroxy-6-[[(2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-61-1P**, 3-Bromo-2-hydroxy-6-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-62-2P**, 3-Bromo-6-[[(2-[[3-(diethylamino)propyl]amino]phenyl)sulfonyl]amino]-2-methoxybenzoic acid **681244-63-3P**, 3-Bromo-6-[[(2-[[3-(diethylamino)propyl]amino]phenyl)sulfonyl]amino]-2-hydroxybenzoic acid **681244-64-4P**, 6-[[(2-[[4-(N,N-Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-hydroxybenzoic acid **681244-65-5P**, 6-[[(2-[[3-(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-methoxybenzoic acid **681244-66-6P**, 3-Ethyl-2-hydroxy-6-[[(2-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-67-7P**, 6-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-methoxybenzoic acid **681244-68-8P**, 3-Ethyl-2-methoxy-6-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-69-9P**, 3-Ethyl-2-hydroxy-6-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-70-2P**, 3-Ethyl-2-methoxy-6-[[(2-[[3-(4-morpholinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-71-3P**, 3-Ethyl-2-methoxy-6-[[(2-[[4-(1-pyrrolidinyl)butyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-72-4P**, 3-Bromo-2-methoxy-6-[[(2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-73-5P**, 3-Bromo-2-methoxy-6-[[(2-[[3-[2-methyl-1-piperidinyl]propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-74-6P**, 3-Ethyl-2-methoxy-6-[[(2-[[2-[1-methyl-2-pyrrolidinyl]ethyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-75-7P**, 3-Ethyl-6-[[(2-[[3-(1H-imidazol-1-yl)propyl]amino]phenyl)sulfonyl]amino]-2-methoxybenzoic acid **681244-76-8P**, 3-Ethyl-2-hydroxy-6-[[(2-[[3-(1H-imidazol-1-yl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-77-9P**, 3-Ethyl-2-hydroxy-6-[[(2-[[3-(4-morpholinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-78-0P**, 3-Bromo-5-ethyl-6-methyl-2-[(2-pyridinylsulfonyl)amino]benzoic acid **681244-79-1P**, 2-[[(2-[[2-[1-Methyl-2-pyrrolidinyl]ethyl]amino]phenyl)sulfonyl]amino]-8-methoxy-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-80-4P**, 2-[[(2-[[3-(Isopropylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methoxy-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-81-5P**, 2-[([2-[([2-[1-Methyl-2-pyrrolidinyl]ethyl]amino)carbonyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-82-6P**, 2-[([4-[([2-[1-Methyl-2-pyrrolidinyl]ethyl]amino)carbonyl]-3-thienyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-83-7P**, 2-[([2-[([2-(1-Piperidinyl)ethyl]amino)carbonyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-84-8P**, 2-[([4-[([2-(Diethylamino)ethyl]amino)carbonyl]-3-thienyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-85-9P**, 2-[([4-[([2-(1-Piperidinyl)ethyl]amino)carbonyl]-3-thienyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-86-0P**, 6-[([2-[(3-Aminopropyl)amino]phenyl]sulfonyl)amino]-3-ethyl-2-methoxybenzoic acid **681244-87-1P**, 6-[([2-[(3-Aminopropyl)amino]phenyl]sulfonyl)amino]-3-ethyl-2-hydroxybenzoic acid **681244-88-2P**, 2-(Carboxymethoxy)-3-ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid **681244-89-3P**, 6-([[2-(Dimethylamino)phenyl]sulfonyl]amino)-3-ethyl-2-methoxybenzoic acid **681244-90-6P**, 6-[[(2-[[3-(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-hydroxybenzoic acid **681244-91-7P**, 3-Bromo-5-ethyl-2-[[(2-fluorophenyl)sulfonyl]amino]-

6-methoxybenzoic acid **681244-92-8P**, 5-Ethyl-2-[[(2-fluorophenyl)sulfonyl]amino]-4-methoxy-1,1'-biphenyl-3-carboxylic acid **681244-93-9P 681244-94-0P 681244-95-1P 681244-96-2P 681244-97-3P**, 3-[(1E)-3-([2-[1-Methyl-2-pyrrolidinyl]ethyl]amino)-3-oxo-1-propenyl]-2-[(phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-98-4P**, 3-((1E)-3-Oxo-3-[[2-(1-piperidinyl)ethyl]amino]-1-propenyl]-2-[(phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-99-5P**, 3-((1E)-3-Oxo-3-[[3-(1-piperidinyl)propyl]amino]-1-propenyl]-2-[(phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-00-1P**, 3-[(1E)-3-([[1-Ethyl-2-pyrrolidinyl]methyl]amino)-3-oxo-1-propenyl]-2-[(phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-01-2P**, 3-((1E)-3-[[2-(Dimethylamino)ethyl]amino]-3-oxo-1-propenyl]-2-[(phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-02-3P 681245-03-4P 681245-04-5P 681245-05-6P 681245-06-7P 681245-07-8P 681245-08-9P**, 2-[N-Methyl-N-([2-[(4-piperidinylmethyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-09-0P 681245-10-3P 681245-11-4P 681245-12-5P 681245-13-6P 681245-14-7P 681245-15-8P 681245-16-9P 681245-17-0P 681245-18-1P 681245-19-2P 681245-20-5P 681245-21-6P**, 3-Bromo-2-methoxy-6-([[2-([2-[1-methyl-2-pyrrolidinyl]ethyl]amino)phenyl]sulfonyl]amino)benzoic acid **681245-22-7P**, 3-Bromo-2-hydroxy-6-([[2-([3-[2-methyl-1-piperidinyl]propyl]amino)phenyl]sulfonyl]amino)benzoic acid **681245-23-8P**, 2-[[(2-[[2-(Diethylamino)ethyl]sulfanyl]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-24-9P**, 2-[[(2-([[3-(Diethylamino)propyl]amino]carbonyl)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT **681245-25-0P**, 2-([[2-([[3-(Dimethylamino)-2,2-dimethylpropyl]amino]carbonyl)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-26-1P**, 2-([[2-([[3-(Diethylamino)propyl]amino]carbonyl)-3-thienyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-27-2P**, 2-([[2-([[3-(Dimethylamino)-2,2-dimethylpropyl]amino]carbonyl)-3-thienyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-28-3P**, 2-([[2-([[4-(Diethylamino)-1-methylbutyl]amino]carbonyl)-3-thienyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-29-4P**, 2-[[(2-[[[3-(Dimethylamino)propyl](methyl)amino]carbonyl]-3-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-30-7P 681245-31-8P**, 2-[[(2-[[3-(4-Cyclopentyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-32-9P**, 2-[[(2-[[3-(4-Isopropyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-33-0P 681245-34-1P 681245-35-2P**, 2-([[2-([[4-(Diethylamino)butyl]amino]carbonyl)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-36-3P**, 2-([[2-([[4-(Diethylamino)butyl]amino]carbonyl)-3-thienyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-37-4P**, 2-([[2-([[4-(Diethylamino)butyl]amino]carbonyl)-4-fluorophenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-38-5P**, 2-([[2-([[4-(Diethylamino)-1-methylbutyl]amino]carbonyl)-4-fluorophenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-39-6P**, 2-([[2-([[4-(Diethylamino)-1-methylbutyl]amino]carbonyl)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-40-9P**, 8-Methyl-2-[[(2-[[3-(4-morpholinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-41-0P**,

(8R)-2-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-42-1P**, (8S)-2-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-43-2P**, 2-(2-Aminoethoxy)-3-ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid **681245-44-3P**, 2-(2-Aminoethoxy)-6-[[(2-bromophenyl)sulfonyl]amino]-3-ethylbenzoic acid **681245-45-4P**, 2-(2-Aminoethoxy)-6-[[(2-[(1E)-3,3-dimethyl-1-butenyl]phenyl)sulfonyl]amino]-3-ethylbenzoic acid **681245-46-5P**, 2-(2-Aminoethoxy)-6-[[(2-(3,3-dimethylbutyl)phenyl)sulfonyl]amino]-3-ethylbenzoic acid **681245-47-6P**, 2-(2-Aminoethoxy)-6-[[(2-propylphenyl)sulfonyl]amino]-3-ethylbenzoic acid **681245-48-7P**, 2-[([2-[(4-Pyridinylmethyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-49-8P** **681245-50-1P**, 2-[[(2-[[3-(Diethylamino)propyl]sulfanyl]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-51-2P**, 2-[[(2-[[2-(Diethylamino)ethyl]sulfinyl]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-52-3P**, 2-[[(2-[3-(Diethylamino)propoxy]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-53-4P** **681245-54-5P** **681245-55-6P** **681245-56-7P** **681245-57-8P** **681245-58-9P** **681245-59-0P** **681245-60-3P** **681245-61-4P** **681245-62-5P** **681245-63-6P** **681245-64-7P** **681245-65-8P** **681245-66-9P** **681245-67-0P** **681245-68-1P** **681245-69-2P** **681245-70-5P** **681245-71-6P**, 2-([[2-([2,2-Dimethyl-3-(4-morpholinyl)propyl]amino)phenyl]sulfonyl]amino)-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-72-7P**, 2-([[2-([3-Hydroxy-2,2-dimethylpropyl]amino)phenyl]sulfonyl]amino)-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-73-8P**, 2-([[2-([3-[4-[4-(Trifluoromethyl)-2-pyrimidinyl]-1-piperazinyl]propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-74-9P**, 2-([[2-([3-(1-Azepanyl)propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-75-0P**, 2-([[2-([[1-(2-Ethylbutyl)-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-76-1P**, 2-([[2-([[1-Cyclopentyl-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-77-2P**, 2-([[2-([[1-[1-Methylpropyl]-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-79-4P**, 2-([[2-([[1-Isobutyl-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-80-7P**, 2-([[2-([[1-Methyl-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-81-8P**, 2-([[2-([[1'-Methyl-1,4'-bipiperidin-4-yl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-82-9P**, 2-([[2-([[1-Isopropyl-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-83-0P**, 2-([[2-[(1E)-3-(Diethylamino)-1-propenyl]phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-84-1P**, 2-([[2-[4-(Diethylamino)butyl]phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-85-2P**, 2-([[2-[(1Z)-3-(Diethylamino)-1-propenyl]phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-86-3P**, 2-([[2-[(1Z)-4-(Diethylamino)-1-butenyl]phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-87-4P**, 2-([[2-([3-[3-Methyl-1-piperidinyl]propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-88-5P**, 2-([[2-([3-[Cyclohexyl(methyl)amino]propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-89-6P**, 2-([[2-([3-(3,4-Dihydro-2(1H)-isoquinolinyl)propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-91-0P**, 2-([[2-([2-Methyl-3-(4-methyl-1-piperidinyl)propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-92-1P**, 2-([[2-([3-[2,6-Dimethyl-1-

piperidinyl]propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-93-2P** **681245-94-3P**, 3-Ethyl-2-methoxy-6-([[2-(2-phenylethyl)phenyl]sulfonyl]amino)benzoic acid **681245-95-4P**, 6-[([2-[2-(4-Chlorophenyl)ethyl]phenyl]sulfonyl)amino]-3-ethyl-2-methoxybenzoic acid **681245-96-5P**, 3-Ethyl-2-methoxy-6-[[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]benzoicaci **681245-97-6P**, 6-[[(1,2-Dimethyl-1H-imidazol-4-yl)sulfonyl]amino]-3-ethyl-2-methoxybenzoic acid **681245-98-7P**, 2-(2-Aminoethoxy)-6-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-3-ethylbenzoic acid **681245-99-8P**, 2-(3-Aminopropoxy)-6-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-3-ethylbenzoic acid **681246-00-4P**, 3,5-Diethyl-2-methoxy-6-[[(2-[[3-(4-morpholinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681246-01-5P**, 3,5-Diethyl-2-methoxy-6-[[(2-[[3-[2-methyl-1-piperidinyl]propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681246-02-6P**, 3,5-Diethyl-2-methoxy-6-[[(2-[[2-[1-methyl-2-pyrrolidinyl]ethyl]amino]phenyl)sulfonyl]amino]benzoic acid **681246-03-7P**, 2-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-3,5-diethyl-6-methoxybenzoic acid **681246-04-8P**, 2-[[(2-[[4-(N,N-Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-3,5-diethyl-6-methoxybenzoic acid **681246-05-9P**, 3,5-Diethyl-2-methoxy-6-[[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]benzoic acid **681246-06-0P**, 2-[[(1,2-Dimethyl-1H-imidazol-4-yl)sulfonyl]amino]-3,5-diethyl-6-methoxybenzoic acid **681246-07-1P**, 3,5-Diethyl-2-methoxy-6-[(phenylsulfonyl)amino]benzoic acid **681246-08-2P**, 3,5-Diethyl-2-[[(4-fluorophenyl)sulfonyl]amino]-6-methoxybenzoic acid **681246-09-3P**, 3,5-Diethyl-2-methoxy-6-[[2-pyridinylsulfonyl]amino]benzoic acid **681246-10-6P**, 2-[([2-[3-(Diethylamino)propyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-11-7P**, 2-[([2-[(1Z)-5-(Diethylamino)-1-pentenyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-12-8P**, 2-[([2-[(1E)-5-(Diethylamino)-1-pentenyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-13-9P**, 2-[([2-[5-(Diethylamino)pentyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-14-0P** **681246-15-1P**, 2-(2-Aminoethoxy)-3-ethyl-6-[[(2-ethyl-4-fluorophenyl)sulfonyl]amino]benzoic acid **681246-17-3P**, 2-(2-Aminoethoxy)-3-ethyl-6-[[(4-fluoro-2-propylphenyl)sulfonyl]amino]benzoic acid **681246-18-4P**, 2-(2-Aminoethoxy)-3-ethyl-6-[[(4-fluoro-2-(2-phenylethyl)phenyl)sulfonyl]amino]benzoic acid **681246-21-9P**, 8-Methyl-2-([[2-([3-(4-morpholinyl)-3-oxopropyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-22-0P**, 8-Methyl-2-([[2-([3-oxo-3-(1-piperazinyl)propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-23-1P**, 2-([[2-([2,2-Dimethyl-3-oxo-3-(1-piperazinyl)propyl]amino)phenyl]sulfonyl]amino)-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-24-2P**, 3-Ethyl-6-[([4-fluoro-2-[4-(2-methyl-1-pyrrolidinyl)butyl]phenyl]sulfonyl)amino]-2-methoxybenzoic acid **681246-25-3P**, 6-[([2-[4-(Diethylamino)butyl]-4-fluorophenyl]sulfonyl)amino]-3-ethyl-2-methoxybenzoic acid **681246-26-4P**, 2-[[(2-[[2-(4-Pyridinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-27-5P**, 2-[[(4-Bromo-2-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681255-09-4P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT 67-64-1, Acetone, reactions 75-26-3, 2-Bromopropane 78-81-9, Isobutylamine 78-84-2, 2-Methylpropanal 78-93-3, 2-Butanone, reactions 83-33-0, 1-Indanone 85-46-1, 1-Naphthalenesulfonyl chloride 91-59-8, 2-Naphthylamine 93-11-8, 2-Naphthalenesulfonyl chloride 96-15-1, 2-Methylbutylamine 96-17-3, 2-Methylbutanal 96-32-2, Methyl bromoacetate 96-33-3, Methyl acrylate 97-08-5, 4-Chloro-3-nitrobenzenesulfonyl chloride 97-96-1, 2-Ethylbutanal 98-09-9, Benzenesulfonyl chloride 98-31-7, 3,4-Dichlorobenzenesulfonyl chloride

98-58-8, 4-Bromobenzenesulfonyl chloride 98-59-9, 4-Methylbenzenesulfonyl chloride 98-60-2, 4-Chlorobenzenesulfonyl chloride 98-61-3, 4-Iodobenzenesulfonyl chloride 98-68-0, 4-Methoxybenzenesulfonyl chloride 98-74-8, 4-Nitrobenzenesulfonyl chloride 98-80-6, Phenylboronic acid 100-36-7, N,N-Diethyl-1,2-ethanediamine 100-37-8, 2-(Diethylamino)ethanol 102-83-0, N,N-Dibutyl-1,3-propanediamine 104-75-6, 2-Ethylhexylamine 104-78-9, 3-(Diethylamino)propylamine 105-56-6, Ethyl cyanoacetate 107-85-7, 3-Methylbutylamine 108-00-9, N,N-Dimethyl-1,2-ethanediamine 108-91-8, Cyclohexylamine, reactions 108-94-1, Cyclohexanone, reactions 109-01-3, 1-Methylpiperazine 109-05-7, 2-Methylpiperidine 109-55-7, N,N-Dimethyl-1,3-propanediamine 109-73-9, Butylamine, reactions 109-76-2, 1,3-Diaminopropane 109-85-3, 2-Methoxyethylamine 110-58-7, 1-Aminopentane 110-76-9, 2-Ethoxyethylamine 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 111-26-2, 1-Aminohexane 111-49-9, Azepane 120-92-3, Cyclopentanone 121-02-8, 2-Methyl-5-nitrobenzenesulfonyl chloride 121-05-1, 2-(Diisopropylamino)ethylamine 121-51-7, 3-Nitrobenzenesulfonyl chloride 121-60-8, 4-(Acetylamino)benzenesulfonyl chloride 123-75-1, Pyrrolidine, reactions 133-59-5, 2-Methylbenzenesulfonyl chloride 140-31-8, 1-(2-Aminoethyl)piperazine 140-80-7, 4-(Diethylamino)-1-methylbutylamine 156-87-6, 3-Amino-1-propanol 313-12-2, 3-(Trifluoromethyl)anthranilic acid 349-88-2, 4-Fluorobenzenesulfonyl chloride 350-03-8, 3-Acetylpyridine 445-05-6, 2-Methyl-5-fluorobenzenesulfonyl chloride 574-98-1, N-(2-Bromoethyl)phthalimide 589-16-2, 4-Ethylaniline 590-50-1, 4,4-Dimethyl-2-pentanone 598-74-3, 2-Amino-3-methylbutane 605-65-2, 5-(Dimethylamino)-1-naphthalenesulfonyl chloride 609-09-6, Diethyl ketomalonate 616-79-5, 2-Amino-5-nitrobenzoic acid 622-93-5, 3-(Diethylamino)-1-propanol 625-36-5, 3-Chloropropanoyl chloride 626-56-2, 3-Methylpiperidine 626-58-4, 4-Methylpiperidine 701-27-9, 3-Fluorobenzenesulfonyl chloride 705-21-5, 3,5-Dichlorobenzenesulfonyl chloride 765-38-8, 2-Methylpyrrolidine 765-43-5, Acetylcyclopropane 773-64-8, 2,4,6-Trimethylbenzenesulfonyl chloride 777-44-6, 3-(Trifluoromethyl)benzenesulfonyl chloride 872-53-7, Cyclopentanecarboxaldehyde 927-74-2, 4-Hydroxy-1-butyne 1003-03-8, Cyclopentylamine 1003-04-9, Dihydro-3(2H)-thiophenone 1072-72-6, Tetrahydro-4H-thiopyran-4-one 1121-60-4, 2-Pyridinecarboxaldehyde 1191-95-3, Cyclobutanone 1445-73-4, 1-Methyl-4-piperidone 1483-28-9, 2,5-Dimethoxybenzenesulfonyl chloride 1489-69-6, Cyclopropanecarboxaldehyde 1623-93-4, 4-Phenylbenzenesulfonyl chloride 1633-82-5, 3-Chloro-1-propanesulfonyl chloride 1656-44-6, 2,4-Dinitrobenzenesulfonyl chloride 1663-39-4, tert-Butyl acrylate 1694-92-4, 2-Nitrobenzenesulfonyl chloride 1899-93-0, 3-Methylbenzenesulfonyl chloride 1939-99-7, Phenylmethanesulfonyl chloride 1942-52-5, 2-(Diethylamino)ethanethiol hydrochloride 2038-03-1, N-2-Aminoethylmorpholine 2043-61-0, Cyclohexanecarboxaldehyde 2148-56-3, 2-Amino-6-chlorobenzoic acid 2386-60-9, 1-Butanesulfonyl chloride 2516-47-4, Cyclopropylmethylamine 2706-56-1, 2-(2-Aminoethyl)pyridine 2759-28-6, 1-Benzylpiperazine 2766-74-7, 5-Chloro-2-thiophenesulfonyl chloride 2888-06-4, 3-Chlorobenzenesulfonyl chloride 2905-21-7, 2-Fluorobenzenesulfonyl chloride 2905-23-9, 2-Chlorobenzenesulfonyl chloride 2905-24-0, 3-Bromobenzenesulfonyl chloride 2905-25-1, 2-Bromobenzenesulfonyl chloride 2906-12-9, 3-Isopropoxypropylamine 2991-42-6, 4-(Trifluoromethyl)benzenesulfonyl chloride 3230-36-2 3360-16-5, 3-(Isopropylamino)propylamine 3378-71-0, 2,5-Dimethylpyrrolidine 3437-33-0, 3-(1-Azepanyl)-1-propanamine 3529-08-6, 1-Piperidinepropanamine 3529-10-0, N,N-Dimethyl-1,4-butanediamine 3731-53-1, 4-(Aminomethyl)pyridine 4079-68-9 4104-45-4 4318-42-7, 1-Isopropylpiperazine 4389-50-8, 2-Amino-6-methylbenzoic acid 4426-47-5, n-Butylboronic acid 4461-39-6, 2-[(3-Aminopropyl)amino]ethanol 4543-96-8, N,N,N'-Trimethyl-1,3-propanediamine 4572-03-6, 3-(4-Methyl-1-piperazinyl)-1-propanamine 4635-59-0, 4-Chlorobutanoyl chloride 4985-85-7, 2-[(3-Aminopropyl)(2-hydroxyethyl)amino]ethanol 5036-48-6, 3-(1H-Imidazol-1-yl)-1-propanamine 5271-38-5, 2-(Methylsulfanyl)ethanol 5332-73-0, 1-Methoxy-3-aminopropane 5390-04-5, 4-Pentyn-1-ol 5402-73-3, 2,5-Dichlorobenzenesulfonyl chloride

5460-29-7, N-(3-Bromopropyl)phthalimide 5596-87-2 5794-88-7
5813-64-9, 1-Amino-2,2-dimethylpropane 6053-81-2,
(Cyclopentylmethyl)amine 6089-09-4, 4-Pentynoic acid 6291-85-6,
3-Ethoxypropylamine 6336-45-4, Dibutyl vinylboronate 6783-05-7,
trans-2-Phenylvinylboronic acid 7154-73-6, 2-(1-Pyrrolidinyl)ethanamine
7486-35-3, Tributyl(vinyl)tin 7547-97-9, trans-Propenylboronic acid
7565-57-3, Cyclohexylzinc bromide 7663-77-6, 1-(3-Aminopropyl)-2-
pyrrolidinone 10130-74-2, 3-Methoxybenzenesulfonyl chloride
10147-36-1, 1-Propanesulfonyl chloride 10563-23-2, 3-
(Ethylamino)propylamine 13139-17-8 13258-63-4, 4-(2-
Aminoethyl)pyridine 13325-10-5, 4-Amino-1-butanol 13918-92-8,
2,4-Difluorobenzenesulfonyl chloride 13952-84-6, 2-Aminobutane
14156-91-3, 3-(3-Methyl-1-piperidinyl)-1-propanamine 14165-22-1,
2-(Dipropylamino)ethylamine 15029-30-8, 1-Cyanoacetylpiperidine
15084-51-2, 4-tert-Butylbenzenesulfonyl chloride 15673-00-4,
1-Amino-3,3-dimethylbutane 15761-39-4, tert-Butoxycarbonyl-L-proline
15932-66-8, 2-(2-Aminoethyl)piperidine 15945-07-0, 2,4,5-
Trichlorobenzenesulfonyl chloride 16133-25-8, 3-Pyridinesulfonyl
chloride 16271-33-3, 2,4-Dichlorobenzenesulfonyl chloride 16499-88-0,
3-Butoxypropylamine 16629-19-9, 2-Thiophenesulfonyl chloride
16728-59-9, 3-Propoxypropylamine 18704-37-5, 8-Chlorosulfonylquinoline
19040-62-1, 2,5-Dimethylbenzenesulfonyl chloride 21043-40-3,
1-Cyclopentylpiperazine 22160-08-3, (2R)-2-Ethylpiperidine 23094-94-2,
2-Chloro-4-methoxybenzenesulfonyl chloride 23095-05-8,
5-Bromo-2-methoxybenzenesulfonyl chloride 23095-31-0,
3,4-Dimethoxybenzenesulfonyl chloride 23099-21-0, (3-
Piperidinylmethyl)amine 23159-07-1, 3-(1-Pyrrolidinyl)propylamine
23378-88-3, 3,5-Dichloro-2-hydroxybenzenesulfonyl chloride 23418-85-1,
3-Butynyl 4-methylbenzenesulfonate 24425-40-9, 5-Indanamine
24715-90-0, 4-(1-Pyrrolidinyl)butylamine 25300-37-2,
2-Chloro-6-methylbenzenesulfonyl chloride 25560-00-3,
3-(2-Methyl-1-piperidinyl)propylamine 26116-12-1, 2-(Aminomethyl)-1-
ethylpyrrolidine 26638-43-7, Methyl 2-(chlorosulfonyl)benzoate
26735-20-6, N-(3-Aminopropyl)-N-cyclohexyl-N-methylamine 27431-62-5,
4-(Diethylamino)butylamine 27578-60-5, 2-(1-Piperidinyl)ethylamine
29943-42-8, Tetrahydro-4H-pyran-4-one 32333-53-2, 4-Chloro-3-
(trifluoromethyl)benzenesulfonyl chloride 32923-88-9,
3-Isobutoxypropylamine 34732-09-7, 2,3,4-Trichlorobenzenesulfonyl
chloride 34885-02-4, 3-(1-Piperazinyl)propylamine 37784-17-1,
N-tert-Butoxycarbonyl-D-proline 39234-86-1, 3,5-
Di(trifluoromethyl)benzenesulfonyl chloride 39546-32-2, Isonipecotamide
40218-49-3, 2-Propyl-1,3,2-benzodioxaborole 40327-96-6,
4-Amino-1,2,2,6,6-pentamethylpiperidine 40353-34-2, 7-Nitro-3,4-dihydro-
1(2H)-naphthalenone 42185-03-5, 2-Propoxyethylamine 42413-03-6,
3-Chloro-4-methylbenzenesulfonyl chloride 49584-26-1,
4-Cyanobenzenesulfonyl chloride 50541-93-0, 4-Amino-1-benzylpiperidine
51387-90-7, 2-[(1-Methyl-2-pyrrolidinyl]ethylamine 51605-97-1,
2-Bromo-4-isopropylaniline 52147-97-4, (E)-2-Phenylethylenesulfonyl
chloride 52727-57-8, Methyl 2-amino-5-bromobenzoate 53369-71-4
53485-07-7, N-(3-Aminopropyl)-N-methylaniline 53600-33-2,
2-Amino-6-methoxybenzoic acid 54398-51-5, 6-Amino-5-
quinolinecarbonitrile 54997-90-9 55790-39-1, 3-
(Diethylamino)propanethiol 56542-67-7, 3-Cyanobenzenesulfonyl chloride
56946-83-9, 2,5-Dichloro-3-thiophenesulfonyl chloride 57260-71-6,
1-tert-Butoxycarbonylpiperazine 58457-24-2, 5-Chloro-4-nitro-2-
thiophenesulfonyl chloride 58859-46-4, Ethyl 4-amino-1-
piperidinecarboxylate 59337-92-7, Methyl 3-(chlorosulfonyl)-2-
thiophenecarboxylate 60956-26-5, 4-Bromo-2-nitrotoluene 63493-28-7,
2-Aminopentane 63624-28-2, 2,4-Dimethoxybenzenesulfonyl chloride
66715-65-9, 2-Pyridinesulfonyl chloride 73713-79-8, 2,1,3-
Benzothiadiazole-4-sulfonyl chloride 75178-96-0, tert-Butyl
[3-aminopropyl]carbamate 76745-74-9 80466-79-1, 3,5-Dimethyl-4-
isoxazolesulfonyl chloride 81731-43-3, 2-Isopropoxyethylamine
82417-45-6, 2,3-Dichlorobenzenesulfonyl chloride 85723-72-4,
3-[2,6-Dimethyl-1-piperidinyl]-1-propanamine 85958-57-2,
2-Chloro-4-fluorobenzenesulfonyl chloride 86595-37-1 88040-86-2,

2-Methoxy-5-methylbenzenesulfonyl chloride 88398-93-0,
5-Chloro-1,3-dimethyl-1H-pyrazole-4-sulfonyl chloride 89265-35-0,
2-(Methylsulfonyl)benzenesulfonyl chloride 91170-93-3,
3-Chloro-4-fluorobenzenesulfonyl chloride 92273-73-9, Butylzinc bromide
92274-43-6 94108-56-2, 4-(Trifluoromethoxy)benzenesulfonyl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT 101555-60-6 103008-51-1, 2-(Trifluoromethoxy)benzenesulfonyl chloride
124397-96-2, Hexylzinc bromide 126403-67-6, Isobutylzinc bromide
126714-85-0, 4,5-Dichloro-2-thiophenesulfonyl chloride 127720-93-8,
7-Chloro-2,1,3-benzothiadiazole-4-sulfonyl chloride 137049-00-4,
1-Methyl-1H-imidazole-4-sulfonyl chloride 137049-02-6,
1,2-Dimethyl-1H-imidazole-4-sulfonyl chloride 138872-44-3,
5-[(Benzoylamino)methyl]-2-thiophenesulfonyl chloride 143193-41-3,
2-Butoxy-5-(1,1-dimethylpropyl)benzenesulfonyl chloride 144222-22-0,
1-tert-Butoxycarbonyl-4-(aminomethyl)piperidine 145758-05-0,
3,4-Difluorobenzenesulfonyl chloride 146949-07-7, 4-
Propylbenzenesulfonyl chloride 154230-29-2 156567-57-6, Propylzinc
bromide 160233-27-2, 5-(3-Isoxazolyl)-2-thiophenesulfonyl chloride
162167-97-7, 1-tert-Butoxycarbonyl-3-(aminomethyl)piperidine 166964-33-6
166964-34-7, 5-[[(4-Chlorobenzoyl)amino]methyl]-2-thiophenesulfonyl
chloride 166964-37-0, 5-(Phenylsulfonyl)-2-thiophenesulfonyl chloride
171860-68-7, Cyclopentylzinc bromide 174311-79-6, Ethyl
6-amino-1H-indole-7-carboxylate 175278-17-8, 2-Bromo-4-
(trifluoromethoxy)aniline 216159-03-4, 4-Bromo-2-fluorobenzenesulfonyl
chloride 216394-05-7, 5-Bromo-6-chloro-3-pyridinesulfonyl chloride
270912-72-6, 1-tert-Butoxycarbonyl-3-(aminomethyl)pyrrolidine
308796-10-3, Pentylzinc bromide 312693-02-0, 2-Ethylbutylzinc bromide
351003-45-7, 2-Bromo-4-fluorobenzenesulfonyl chloride 496808-04-9,
1-[(1-Methyl-4-piperidinyl)methyl]-4-piperazine 681248-31-7
681248-32-8 681248-33-9 681248-34-0, Methyl
2-[([2-bromophenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-
naphthalenecarboxylate 681248-35-1, 3-[4-(4-Trifluoromethylpyrimidin-2-
yl)piperazin-1-yl]propylamine 681248-36-2, 2-Methyl-3-(4-methyl-1-
piperidinyl)-1-propanamine 681847-93-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT 123-00-2P, 3-(4-Morpholinyl)-1-propanamine 610-36-6P,
4-Amino-2-nitrobenzoic acid 2475-82-3P, 2-Amino-5-ethylbenzoic acid
4553-26-8P, 3-(4-Isopropyl-1-piperazinyl)-1-propanamine 5588-87-4P,
1H-Benzo[e]indole-1,2(3H)-dione 13991-22-5P 14227-95-3P,
3-Oxo-3-(1-pyrrolidinyl)propanenitrile 14227-98-6P 15029-32-0P,
3-(4-Morpholinyl)-3-oxopropanenitrile 17122-70-2P, N-(4-Ethylphenyl)-2-
(hydroxyimino)acetamide 20776-50-5P, 2-Amino-4-bromobenzoic acid
22009-40-1P, 7-Amino-3,4-dihydro-1(2H)-naphthalenone 24623-24-3P,
6-Nitro-1-indanone 29777-09-1P, N,N-Diethyl-3-butyn-1-amine
62078-76-6P, (7-Fluoronaphth-2-yl)amine 64241-01-6P, Methyl
2-amino-6-hydroxybenzoate 67765-42-8P, 5-Methoxy-2H-3,1-benzoxazine-
2,4(1H)-dione 68701-22-4P, 2-Amino-5-isopropylbenzoic acid
68748-07-2P, N-(2-Bromo-4-isopropylphenyl)acetamide 69610-40-8P
69975-65-1P, 6-Amino-1-indanone 77758-50-0P 79069-38-8P,
2-(Acetylamino)-5-isopropylbenzoic acid 79979-69-4P, 2-Amino-1-naphthoic
acid 86661-32-7P, tert-Butyl (2S)-2-([[(4-methylphenyl)sulfonyl]oxy]meth
yl)-1-pyrrolidinecarboxylate 90321-34-9P 90796-54-6P,
2,2-Dimethyl-3-(4-morpholinyl)-1-propanamine 91569-18-5P 96202-56-1P,
5-Ethyl-1H-indole-2,3-dione 115186-37-3P 116487-43-5P,
7-Bromo-1H-benzo[e]indole-1,2(3H)-dione 124341-06-6P,
6-Amino-3-bromo-2-methylbenzoic acid 126378-10-7P, Benzyl
(4E)-5-(tributylstannyl)-4-pentenoate 126378-11-8P, Benzyl 4-pentynoate
132482-06-5P, tert-Butyl (2R)-2-(2-hydroxyethyl)-1-pyrrolidinecarboxylate
132734-41-9P, 2-Amino-5,6,7,8-tetrahydro-naphthalene-1-carboxylic acid
methyl ester 135484-65-0P, Methyl 5-bromo-2-
[(phenylsulfonyl)amino]benzoate 136247-94-4P, 2-[(tert-
Butoxycarbonyl)amino]-6-methoxybenzoic acid 159539-65-8P,
2,2-Dimethyl-7-nitro-3,4-dihydro-1(2H)-naphthalenone 159873-21-9P,
tert-Butyl 4-(2-cyanoacetyl)-1-piperazinecarboxylate 214697-98-0P,

7-Amino-8-bromo-3,4-dihydro-1(2H)-naphthalenone 239483-09-1P, tert-Butyl (2S)-2-(2-aminoethyl)-1-pyrrolidinecarboxylate 269391-47-1P, 2-[(tert-Butoxycarbonyl)amino]-6-methylbenzoic acid 373608-47-0P, 3-(4-Cyclopentyl-1-piperazinyl)-1-propanamine 550378-07-9P, tert-Butyl (2R)-2-(2-aminoethyl)-1-pyrrolidinecarboxylate 616224-61-4P, 2-[(tert-Butoxycarbonyl)amino]-6-chlorobenzoic acid **677291-24-6P**, 2-[[(2-Bromophenyl)sulfonyl]amino]-1-naphthoic acid 677291-25-7P, 2-Amino-7-fluoro-1-naphthoic acid 677291-27-9P, 2-Amino-6-bromo-1-naphthoic acid **681244-26-8P**, 3-Bromo-6-[[(2-fluorophenyl)sulfonyl]amino]-2-propoxybenzoic acid 681246-29-7P 681246-31-1P, Methyl 5-nitro-2-[(phenylsulfonyl)amino]benzoate 681246-32-2P, 6-Amino-5-quinolinecarboxylic acid 681246-33-3P, Methyl 6-amino-5-quinolinecarboxylate 681246-34-4P, Methyl 6-[(phenylsulfonyl)amino]-5-quinolinecarboxylate 681246-35-5P, Methyl 2-[[(4-fluorophenyl)sulfonyl]amino]-1-naphthoate 681246-36-6P, N-(1-Bromo-8-oxo-5,6,7,8-tetrahydro-2-naphthalenyl)-4-fluorobenzenesulfonamide 681246-37-7P, 3-Bromo-6-[(tert-butoxycarbonyl)amino]-2-methylbenzoic acid 681246-39-9P, Benzyl 3-bromo-6-[(tert-butoxycarbonyl)amino]-2-methylbenzoate 681246-40-2P, Benzyl 6-amino-3-cyano-2-methylbenzoate 681246-41-3P, Benzyl 3-cyano-2-methyl-6-[(phenylsulfonyl)amino]benzoate 681246-42-4P, Benzyl 3-bromo-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoate 681246-43-5P, Methyl 2-[(2-pyridinylsulfonyl)amino]-1-naphthoate 681246-44-6P, Benzyl 3-butyl-2-methyl-6-[(3-pyridinylsulfonyl)amino]benzoate 681246-45-7P, Benzyl 6-amino-3-bromo-2-methylbenzoate 681246-46-8P, Benzyl 3-bromo-6-[[(3-fluorophenyl)sulfonyl]amino]-2-methylbenzoate 681246-47-9P, tert-Butyl 1,2-dioxo-1,2-dihydro-3H-benzo[e]indole-3-carboxylate 681246-48-0P, 2-[(tert-Butoxycarbonyl)amino]-1-naphthoic acid 681246-49-1P, 6-Amino-7-bromo-1-indanone 681246-50-4P, N-(4-Bromo-3-oxo-2,3-dihydro-1H-inden-5-yl)benzenesulfonamide 681246-51-5P, Benzyl 2-methyl-6-[(2-pyridinylsulfonyl)amino]-3-vinylbenzoate 681246-52-6P, N-(1-Bromo-5,6-dihydro-2-naphthalenyl)-4-fluorobenzenesulfonamide 681246-53-7P, N-(1-Bromo-8-methyl-5,6-dihydro-2-naphthalenyl)-4-fluorobenzenesulfonamide 681246-54-8P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-1-naphthoate 681246-55-9P, Benzyl 6-[(tert-butoxycarbonyl)amino]-2-methyl-3-vinylbenzoate 681246-56-0P, 6-[(tert-Butoxycarbonyl)amino]-3-ethyl-2-methylbenzoic acid 681246-57-1P, Methyl 2-amino-3-chloro-1-naphthoate 681246-58-2P, Methyl 3-chloro-2-[[(4-fluorophenyl)sulfonyl]amino]-1-naphthoate 681246-59-3P, Benzyl 6-[(tert-butoxycarbonyl)amino]-2-methyl-3-propylbenzoate 681246-60-6P, Benzyl 6-amino-2-methyl-3-propylbenzoate 681246-61-7P, Benzyl 2-methyl-3-propyl-6-[(2-pyridinylsulfonyl)amino]benzoate 681246-62-8P, Methyl 2-([[2-(methoxycarbonyl)phenyl]sulfonyl]amino)-1-naphthoate 681246-63-9P, 2-([[1-(Methoxycarbonyl)-2-naphthyl]amino]sulfonyl)benzoic acid 681246-64-0P, Methyl 2-[[(2-[[(3-methoxypropyl)amino]carbonyl]phenyl)sulfonyl]amino]-1-naphthoate 681246-65-1P, Benzyl 6-[[(4-fluorophenyl)sulfonyl]amino]-2-methyl-3-propylbenzoate 681246-66-2P, 3-Bromo-6-[(tert-butoxycarbonyl)amino]-2-methoxybenzoic acid 681246-67-3P, Methyl 2-([[2-(1-pyrrolidinylcarbonyl)phenyl]sulfonyl]amino)-1-naphthoate 681246-68-4P, Benzyl 3-bromo-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methylbenzoate 681246-69-5P, Benzyl 6-[[(2-fluorophenyl)sulfonyl]amino]-2-methyl-3-vinylbenzoate 681246-70-8P, Methyl 2-[([2-[(4-methyl-1-piperazinyl)carbonyl]phenyl]sulfonyl)amino]-1-naphthoate 681246-71-9P, Benzyl 3-[(1E)-3-methoxy-3-oxo-1-propenyl]-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoate 681246-72-0P, N-(1-Bromo-8-methyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4-fluorobenzenesulfonamide 681246-73-1P, 3-Bromo-6-[(tert-butoxycarbonyl)amino]-2-chlorobenzoic acid 681246-74-2P, Benzyl 3-bromo-6-[(tert-butoxycarbonyl)amino]-2-chlorobenzoate 681246-75-3P, Benzyl 6-amino-3-bromo-2-chlorobenzoate 681246-76-4P, Benzyl 3-bromo-2-chloro-6-[[(4-fluorophenyl)sulfonyl]amino]benzoate 681246-77-5P, Benzyl 2-chloro-6-[[(4-fluorophenyl)sulfonyl]amino]-3-vinylbenzoate 681246-78-6P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681246-79-7P, Benzyl 3-bromo-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methylbenzoate 681246-80-0P, Benzyl

6-[[(4-fluorophenyl)sulfonyl]amino]-3-(hydroxymethyl)-2-methylbenzoate 681246-82-2P, Benzyl 6-[[(4-fluorophenyl)sulfonyl]amino]-3-(1-hydroxyethyl)-2-methylbenzoate 681246-83-3P, N-(1-Bromo-8-oxo-5,6,7,8-tetrahydro-2-naphthalenyl)-2-fluorobenzenesulfonamide 681246-84-4P, N-(1-Bromo-8-methyl-5,6-dihydro-2-naphthalenyl)-2-fluorobenzenesulfonamide 681246-85-5P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylate 681246-86-6P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681246-87-7P, N-(1-Bromo-8-methyl-7-oxo-5,6,7,8-tetrahydro-2-naphthalenyl)-4-fluorobenzenesulfonamide 681246-88-8P, Methyl 2-([[2-([[2-(diethylamino)ethyl]amino]carbonyl)phenyl]sulfonyl]amino)-1-naphthoate 681246-89-9P, Benzyl 3-bromo-6-[(tert-butoxycarbonyl)amino]-2-methoxybenzoate 681246-90-2P, Benzyl 6-amino-3-bromo-2-methoxybenzoate 681246-91-3P, Benzyl 3-bromo-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxybenzoate 681246-92-4P, Benzyl 6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxy-3-vinylbenzoate 681246-93-5P, Benzyl 3-bromo-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methoxybenzoate 681246-94-6P, N-(1-Bromo-7,8-dimethyl-5,8-dihydro-2-naphthalenyl)-2-fluorobenzenesulfonamide 681246-95-7P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-7,8-dimethyl-5,8-dihydro-1-naphthalenecarboxylate 681246-96-8P, Benzyl 3-bromo-2-methoxy-6-[(2-pyridinylsulfonyl)amino]benzoate 681246-97-9P, Benzyl 2-methoxy-6-[(2-pyridinylsulfonyl)amino]-3-vinylbenzoate 681246-98-0P, Benzyl 6-[[(4-fluorophenyl)sulfonyl]amino]-2-methoxy-3-vinylbenzoate 681246-99-1P, 7-Amino-8-bromo-2,2-dimethyl-3,4-dihydro-1(2H)-naphthalenone 681247-00-7P, N-(1-Bromo-7,7-dimethyl-8-oxo-5,6,7,8-tetrahydro-2-naphthalenyl)-2-fluorobenzenesulfonamide 681247-01-8P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-7,7-dimethyl-8-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-02-9P, N-(1-Bromo-8-methylene-5,6,7,8-tetrahydro-2-naphthalenyl)-2-fluorobenzenesulfonamide 681247-03-0P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-8-methylene-5,6,7,8-tetrahydro-1-naphthalenecarboxylate **681247-04-1P**, 3-Bromo-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxybenzoic acid 681247-05-2P, Methyl 2-([[2-(methoxycarbonyl)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-06-3P, 2-([[1-(Methoxycarbonyl)-5,6,7,8-tetrahydro-2-naphthalenyl]amino]sulfonyl)benzoic acid 681247-07-4P, Methyl 2-([[2-([[2-(diethylamino)ethyl]amino]carbonyl)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-08-5P, Methyl 2-[[(2-[[[3-(dimethylamino)propyl](methyl)amino]carbonyl]phenyl)sulfonyl]amino]-1-naphthoate 681247-09-6P, 6-Bromo-5-methoxy-2H-3,1-benzoxazine-2,4(1H)-dione 681247-10-9P, 6-Bromo-5-hydroxy-2H-3,1-benzoxazine-2,4(1H)-dione 681247-11-0P, Methyl 6-amino-3-bromo-2-hydroxybenzoate 681247-12-1P, Methyl 6-amino-3-bromo-2-ethoxybenzoate 681247-13-2P, Methyl 3-bromo-2-ethoxy-6-[[(2-fluorophenyl)sulfonyl]amino]benzoate 681247-14-3P, Methyl 2-ethoxy-6-[[(2-fluorophenyl)sulfonyl]amino]-3-vinylbenzoate 681247-15-4P, Methyl 2-ethoxy-3-ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]benzoate 681247-16-5P, 5-Hydroxy-2H-3,1-benzoxazine-2,4(1H)-dione 681247-17-6P, Methyl 2-amino-6-ethoxybenzoate 681247-18-7P, Methyl 2-ethoxy-6-[[(4-fluorophenyl)sulfonyl]amino]benzoate 681247-19-8P, Methyl 3-bromo-2-ethoxy-6-[[(4-fluorophenyl)sulfonyl]amino]benzoate 681247-20-1P, Methyl 2-ethoxy-6-[[(4-fluorophenyl)sulfonyl]amino]-3-vinylbenzoate 681247-21-2P, Methyl 2-ethoxy-3-ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]benzoate 681247-22-3P, 2,2-Dimethyl-3-oxo-3-(1-piperidinyl)propanenitrile 681247-23-4P, 2,2-Dimethyl-3-(1-piperidinyl)-1-propanamine **681247-24-5P** 681247-25-6P 681247-26-7P, 2,2-Dimethyl-3-oxo-3-(1-pyrrolidinyl)propanenitrile 681247-27-8P, 2,2-Dimethyl-3-(1-pyrrolidinyl)-1-propanamine 681247-28-9P, 2-Ethyl-2-(1-piperidinylmethyl)-1-butanamine 681247-29-0P, Methyl 6-amino-3-bromo-2-propoxybenzoate 681247-30-3P, Methyl 3-bromo-6-[[(2-fluorophenyl)sulfonyl]amino]-2-propoxybenzoate 681247-31-4P 681247-32-5P 681247-33-6P 681247-34-7P, Methyl 2-[[(2-nitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-35-8P, Methyl 2-[[(2-aminophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate

681247-36-9P, Methyl 6-[[(2-fluorophenyl)sulfonyl]amino]-2-propoxy-3-vinylbenzoate 681247-37-0P, Methyl 3-ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]-2-propoxybenzoate 681247-38-1P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-8-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-39-2P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-8-methoxy-5,6-dihydro-1-naphthalenecarboxylate 681247-40-5P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-8-methoxy-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-41-6P, Methyl 3-([[1-(methoxycarbonyl)-5,6,7,8-tetrahydro-2-naphthalenyl]amino]sulfonyl)-2-thiophenecarboxylate 681247-42-7P, 3-([[1-(Methoxycarbonyl)-5,6,7,8-tetrahydro-2-naphthalenyl]amino]sulfonyl)-2-thiophenecarboxylic acid 681247-43-8P, Methyl 2-([[2-([[2-(diethylamino)ethyl]amino]carbonyl)-3-thienyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-44-9P, Methyl 6-amino-3-bromo-2-(2-methoxy-2-oxoethoxy)benzoate 681247-45-0P, Methyl 3-bromo-6-[[(4-fluorophenyl)sulfonyl]amino]-2-(2-methoxy-2-oxoethoxy)benzoate 681247-46-1P, Methyl 6-[[(4-fluorophenyl)sulfonyl]amino]-2-(2-methoxy-2-oxoethoxy)-3-vinylbenzoate 681247-47-2P, Methyl 3-ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]-2-(2-methoxy-2-oxoethoxy)benzoate 681247-48-3P, Methyl 6-amino-3-bromo-2-methoxybenzoate 681247-49-4P, Methyl 3-bromo-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxybenzoate 681247-50-7P, Methyl 6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxy-3-vinylbenzoate 681247-51-8P, Methyl 3-ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxybenzoate 681247-52-9P, Methyl 3-bromo-5-ethyl-2-[[(2-fluorophenyl)sulfonyl]amino]-6-methoxybenzoate 681247-53-0P, Methyl 5-ethyl-2-[[(2-fluorophenyl)sulfonyl]amino]-4-methoxy-1,1'-biphenyl-3-carboxylate 681247-54-1P, Methyl 2-amino-3-bromo-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-55-2P, Methyl 2-amino-3-[(1E)-3-tert-butoxy-3-oxo-1-propenyl]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-56-3P, Methyl 3-[(1E)-3-tert-butoxy-3-oxo-1-propenyl]-2-[(phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-57-4P 681247-58-5P, Methyl 2-[methyl-([2-[(4-piperidinylmethyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-59-6P, Methyl 2-chloro-6-[[(2-fluorophenyl)sulfonyl]amino]benzoate 681247-60-9P, Methyl 2-[(1E)-5-(benzyloxy)-5-oxo-1-pentenyl]-6-[[(2-fluorophenyl)sulfonyl]amino]benzoate 681247-61-0P, 5-[3-[[(2-Fluorophenyl)sulfonyl]amino]-2-(methoxycarbonyl)phenyl]pentanoic acid 681247-62-1P 681247-63-2P 681247-64-3P 681247-65-4P, Methyl 2-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-66-5P, Methyl 2-[[(2-([[4-(diethylamino)-1-methylbutyl]amino]carbonyl)-4-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-67-6P, Methyl 6-amino-3-bromo-2-[2-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]benzoate 681247-68-7P, Methyl 6-amino-2-[2-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-vinylbenzoate 681247-69-8P, Methyl 6-amino-3-ethyl-2-[2-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]benzoate 681247-70-1P, Methyl 2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]benzoate 681247-71-2P, Methyl 6-[[(2-bromophenyl)sulfonyl]amino]-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethylbenzoate 681247-72-3P, Methyl 6-[[(2-[(1E)-3,3-dimethyl-1-butenyl]phenyl)sulfonyl]amino]-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethylbenzoate 681247-73-4P, Methyl 6-[[(2-(3,3-dimethylbutyl)phenyl)sulfonyl]amino]-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethylbenzoate 681247-74-5P, Methyl 2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethyl-6-[([2-[(1E)-1-propenyl]phenyl]sulfonyl)amino]benzoate 681247-75-6P, Methyl 2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethyl-6-[([2-propylphenyl]sulfonyl)amino]benzoate 681247-76-7P, N,N-Diethyl-N-[(3Z)-4-(tributylstannyl)-3-butenyl]amine 681247-77-8P, N,N-Diethyl-N-[(3E)-4-(tributylstannyl)-3-butenyl]amine 681247-78-9P, Methyl 2-[([2-[(1E)-4-(diethylamino)-1-butenyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-79-0P, tert-Butyl (2S)-2-(2-[[(benzyloxy)carbonyl]amino]ethyl)-1-pyrrolidinecarboxylate 681247-80-3P 681247-81-4P 681247-82-5P 681247-83-6P 681247-84-7P,

2,2-Dimethyl-3-(4-morpholinyl)-3-oxopropanenitrile 681247-85-8P
681247-86-9P 681247-87-0P, N,N-Diethyl-N-[(2E)-3-(tributylstannyl)-2-propenyl]amine 681247-88-1P, N,N-Diethyl-N-[(2Z)-3-(tributylstannyl)-2-propenyl]amine 681247-89-2P, Methyl 2-[([2-[(1E)-3-(diethylamino)-1-propenyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-90-5P, Methyl 2-[([2-[4-(diethylamino)butyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-91-6P, Methyl 2-[([2-[(1Z)-3-(diethylamino)-1-propenyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-92-7P, Methyl 2-[([2-[(1Z)-4-(diethylamino)-1-butenyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-93-8P, Methyl 2-amino-3,5-dibromo-6-methoxybenzoate 681247-94-9P, Methyl 2-amino-6-methoxy-3,5-divinylbenzoate 681247-95-0P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-6-methoxy-3,5-divinylbenzoate 681247-96-1P, Methyl 3,5-diethyl-2-[[(2-fluorophenyl)sulfonyl]amino]-6-methoxybenzoate 681247-97-2P, Methyl 6-amino-2-methoxy-3-vinylbenzoate 681247-98-3P, Methyl 6-amino-3-ethyl-2-methoxybenzoate 681247-99-4P, Methyl 6-[[(2-bromophenyl)sulfonyl]amino]-3-ethyl-2-methoxybenzoate 681248-00-0P, Methyl 6-[[(2-[(1E)-2-(4-chlorophenyl)ethenyl]phenyl)sulfonyl]amino]-3-ethyl-2-methoxybenzoate 681248-01-1P, Methyl 3-ethyl-2-methoxy-6-([[2-(2-phenylethyl)phenyl]sulfonyl]amino)benzoate 681248-02-2P, Methyl 6-[([2-[2-(4-chlorophenyl)ethyl]phenyl]sulfonyl)amino]-3-ethyl-2-methoxybenzoate 681248-03-3P, Methyl 3-ethyl-2-methoxy-6-[[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]benzoate 681248-04-4P, Methyl 6-[[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]amino]-3-ethyl-2-methoxybenzoate 681248-05-5P, Methyl 6-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethylbenzoate 681248-06-6P, Methyl 6-amino-3-bromo-2-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propoxy]benzoate 681248-07-7P, Methyl 6-amino-2-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propoxy]-3-vinylbenzoate 681248-08-8P, Methyl 6-amino-2-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propoxy]-3-ethylbenzoate 681248-09-9P, Methyl 6-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-2-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propoxy]-3-ethylbenzoate 681248-10-2P, Methyl 2-amino-3,5-diethyl-6-methoxybenzoate 681248-11-3P, Methyl 2-[([2-[3-(diethylamino)propyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681248-12-4P, N,N-Diethyl-N-[(4E)-5-(tributylstannyl)-4-pentenyl]amine 681248-13-5P, N,N-Diethyl-N-[(4Z)-5-(tributylstannyl)-4-pentenyl]amine 681248-14-6P 681248-15-7P 681248-16-8P, Methyl 2-[([2-[5-(diethylamino)pentyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681248-17-9P, Methyl 2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethyl-6-[[(4-fluoro-2-vinylphenyl)sulfonyl]amino]benzoate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT 681248-18-0P, Methyl 2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethyl-6-[[(2-ethyl-4-fluorophenyl)sulfonyl]amino]benzoate 681248-19-1P 681248-20-4P 681248-21-5P 681248-22-6P 681248-23-7P 681248-24-8P, tert-Butyl 4-(3-amino-2,2-dimethylpropanoyl)-1-piperazinecarboxylate 681248-25-9P, Methyl 6-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-3-ethyl-2-methoxybenzoate 681248-26-0P, Methyl 3-ethyl-6-[[(4-fluoro-2-(4-hydroxy-1-butynyl)phenyl)sulfonyl]amino]-2-methoxybenzoate 681248-27-1P, Methyl 3-ethyl-6-[[(4-fluoro-2-(4-hydroxybutyl)phenyl)sulfonyl]amino]-2-methoxybenzoate 681248-28-2P, Methyl 3-ethyl-6-[[(4-fluoro-2-(4-[(methylsulfonyl)oxy]butyl)phenyl)sulfonyl]amino]-2-methoxybenzoate 681248-29-3P, Methyl 3-ethyl-6-[[(4-fluoro-2-(4-[2-methyl-1-pyrrolidinyl]butyl)phenyl)sulfonyl]amino]-2-methoxybenzoate 681248-30-6P, Methyl 6-[[(2-[4-(diethylamino)butyl]-4-fluorophenyl)sulfonyl]amino]-3-ethyl-2-methoxybenzoate 681255-11-8P, Benzyl 6-[[(4-fluorophenyl)sulfonyl]amino]-2-methyl-3-vinylbenzoate 681255-13-0P, Benzyl 2-chloro-6-[[(2-fluorophenyl)sulfonyl]amino]-3-vinylbenzoate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of sulfonamides having antiangiogenic and anticancer activity)
IT **677290-81-2P**, 2-[(Phenylsulfonyl)amino]-1-naphthoic acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of sulfonamides having antiangiogenic and anticancer activity)
RN 677290-81-2 HCAPLUS
CN 1-Naphthalenecarboxylic acid, 2-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



L67 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:333690 HCAPLUS
DN 140:357061
ED Entered STN: 23 Apr 2004
TI Preparation of sulfonamides having antiangiogenic and anticancer activity
IN **Comess, Kenneth M.**; **Erickson, Scott A.**; **Henkin, Jack**; **Kalvin, Douglas M.**; **Kawai, Megumi**; **Kim, Ki H.**; **Bamaung, Nwe Y.**; Park, Chan Hoon; **Sheppard, George S.**; **Vasudevan, Anil**; **Wang, Jieyi**; **Barnes, David M.**; **Fidanze, Steve D.**; Kolaczkowsi, Lawrence; **Mantei, Robert A.**; **Park, David C.**; Sanders, William J.; **Tedrow, Jason S.**; **Wang, Gary T.**
PA **Abbott Laboratories**, USA
SO PCT Int. Appl., 309 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07C311-08
ICS C07C311-13; C07C311-21; C07C311-29; C07C311-44; C07D209-08; C07D213-70; C07D215-36; C07D231-18; C07D261-10; C07D285-06; C07D285-14; C07D333-34; C07D333-38; C07D413-04; A61K031-196; A61K031-277; A61K031-381; A61K031-404; A61K031-415
CC 25-17 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 63
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004033419	A1	20040422	WO 2003-US31671	20031006
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004068012	A1	20040408	US 2002-267081	20021008
US 2004157836	A1	20040812	US 2003-667358	20030923
CA 2501520	AA	20040422	CA 2003-2501520	20031006
EP 1549613	A1	20050706	EP 2003-773182	20031006
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI US 2002-267081	A	20021008		
US 2003-667358	A	20030923		

WO 2003-US31671 W 20031006

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004033419	ICM	C07C311-08
	ICS	C07C311-13; C07C311-21; C07C311-29; C07C311-44; C07D209-08; C07D213-70; C07D215-36; C07D231-18; C07D261-10; C07D285-06; C07D285-14; C07D333-34; C07D333-38; C07D413-04; A61K031-196; A61K031-277; A61K031-381; A61K031-404; A61K031-415
WO 2004033419	ECLA	C07C311/08; C07C311/13; C07C311/21; C07C311/29; C07C311/37; C07C311/44; C07C311/46; C07C317/28; C07C323/25D2; C07C323/49; C07C323/63; C07C323/67; C07D209/08; C07D213/71; C07D215/36; C07D215/48; C07D231/18; C07D233/54C; C07D233/84; C07D261/10B; C07D285/14D; C07D333/34; C07D333/38; C07D413/04+333B+261
US 2004068012	NCL	514/562.000
	ECLA	C07C311/08; C07C311/13; C07C311/29; C07C311/37; C07C311/44; C07C311/46; C07C317/28; C07C323/25D2; C07C323/49; C07C323/63; C07C323/67; C07D209/08; C07D209/42; C07D213/70C; C07D213/71; C07D215/36; C07D215/48; C07D231/18; C07D233/54C; C07D233/84; C07D261/10B; C07D285/06; C07D285/14D; C07D333/34; C07D333/38; C07D413/04; C07D413/04+333B+261
US 2004157836	NCL	514/227.200
	ECLA	C07C311/08; C07C311/13; C07C311/29; C07C311/37; C07C311/44; C07C311/46; C07C317/28; C07C323/25D2; C07C323/49; C07C323/63; C07C323/67; C07D209/08; C07D209/42; C07D213/70C; C07D213/71; C07D215/36; C07D215/48; C07D231/18; C07D233/54C; C07D233/84; C07D261/10B; C07D285/06; C07D285/14D; C07D333/34; C07D333/38; C07D413/04; C07D413/04+333B+261
CA 2501520	ECLA	C07C311/08; C07C311/13; C07C311/21; C07C311/29; C07C311/37; C07C311/44; C07C311/46; C07C317/28; C07C323/25D2; C07C323/49; C07C323/63; C07C323/67; C07D209/08; C07D213/71; C07D215/36; C07D215/48; C07D231/18; C07D233/54C; C07D233/84; C07D261/10B; C07D285/14D; C07D333/34; C07D333/38; C07D413/04+333B+261
EP 1549613	ECLA	C07C311/08; C07C311/13; C07C311/21; C07C311/29; C07C311/37; C07C311/44; C07C311/46; C07C317/28; C07C323/25D2; C07C323/49; C07C323/63; C07C323/67; C07D209/08; C07D213/71; C07D215/36; C07D215/48; C07D231/18; C07D233/54C; C07D233/84; C07D261/10B; C07D285/14D; C07D333/34; C07D333/38; C07D413/04+333B+261

OS MARPAT 140:357061

GI



I

AB The title compds. [I; A = 5-6 membered (non)aromatic ring containing 0-3 atoms selected from N, O, and S (wherein the ring is optionally fused to a second 5-7 membered (non)aromatic ring containing 0-3 atoms selected from N, O, and S); R1-R3 = H, alkenyl, alkoxy, etc.; R4 = H, alkyl, alkoxy, etc.; R5

= alkyl, NH2, aminoalkyl, aryl, etc.; R6 = H, alkyl, aryl, etc.; provided that when A = Ph, at least one of R1-R4 is other than H, alkyl, halo] having methionine aminopeptidase-2 inhibitory (MetAP2) activity, were prepared E.g., a multi-step synthesis of 5-ethyl-2-[(phenylsulfonyl)amino]benzoic acid, starting from 4-ethylaniline, was given. Representative compds. I had IC50's between about 0.005 μM and >100 μM against MetAP2. Also described are pharmaceutical compns. comprising the compds. I, methods of treatment using the compds. I, methods of inhibiting angiogenesis, and methods of treating cancer.

ST sulfonamide prepn antitumor angiogenesis inhibitor methionine aminopeptidase2 MetAP2; benzoic acid sulfonylamino prepn methionine aminopeptidase2 MetAP2 inhibitor; naphthoic acid phenylsulfonylamino prepn methionine aminopeptidase2 MetAP2 inhibitor

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(eukaryotic initiation factor-2-associated, p67; preparation of sulfonamides having antiangiogenic and anticancer activity)

IT Angiogenesis
(neovascularization, treatment of abnormal neovascularization; preparation of sulfonamides having antiangiogenic and anticancer activity)

IT Angiogenesis
Angiogenesis inhibitors
Antitumor agents
Neoplasm
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT **677290-81-2P**, 2-[(Phenylsulfonyl)amino]-1-naphthoic acid **681241-27-0P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-8-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681241-49-6P**, 4-Bromo-2-[(phenylsulfonyl)amino]benzoic acid **681242-39-7P**, 3-(3-Methoxy-3-oxopropyl)-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoic acid **681242-51-3P 681242-97-7P**, 2-[[(2-Nitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-18-5P**, 2-[[(2-Aminophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-44-7P**, 3-Ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxybenzoic acid **681243-56-1P**, 2-([[2-([3-[(tert-Butoxycarbonyl)amino]propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-57-2P**, 2-([[2-([3-[(tert-Butoxycarbonyl)(methyl)amino]propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-00-8P**, 2-[[(2-[[2-(2-Pyridinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-01-9P**, 2-Ethoxy-3-ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]benzoic acid **681244-10-0P**, 2-([[2-([[1-(tert-Butoxycarbonyl)-3-piperidinyl]methyl]amino)phenyl]sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-11-1P**, 2-([[2-([[1-(tert-Butoxycarbonyl)-3-pyrrolidinyl]methyl]amino)phenyl]sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-12-2P**, 2-([[2-([[1-(tert-Butoxycarbonyl)-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-90-9P**, 3,5-Diethyl-2-[[(2-fluorophenyl)sulfonyl]amino]-6-methoxybenzoic acid **681246-19-5P**, 2-([[2-([3-[4-(tert-Butoxycarbonyl)-1-piperazinyl]-3-oxopropyl]amino)phenyl]sulfonyl]amino)-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-20-8P**, 2-([[2-([3-[4-(tert-Butoxycarbonyl)-1-piperazinyl]-2,2-dimethyl-3-oxopropyl]amino)phenyl]sulfonyl]amino)-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT **107143-76-0P**, 5-Chloro-2-[[(3,4-dichlorophenyl)sulfonyl]amino]benzoic acid **134864-08-7P**, 2-[[(4-Methylphenyl)sulfonyl]amino]-1-naphthoic acid **254878-25-6P**, 2-[[(4-Chlorophenyl)sulfonyl]amino]-4,5-dimethoxybenzoic acid **562078-23-3P**, 5-Bromo-2-[(1-naphthylsulfonyl)amino]benzoic acid **677290-35-6P**

677290-36-7P, 5-Isopropyl-2-[(phenylsulfonyl)amino]benzoic acid
677290-37-8P, 5-Isobutyl-2-[(phenylsulfonyl)amino]benzoic acid
677290-38-9P, 2-[(Phenylsulfonyl)amino]-5-propylbenzoic acid
677290-39-0P, 5-Cyclopentyl-2-[(phenylsulfonyl)amino]benzoic acid
677290-40-3P, 5-Cyclohexyl-2-[(phenylsulfonyl)amino]benzoic acid
677290-41-4P, 5-Butyl-2-[(phenylsulfonyl)amino]benzoic acid
677290-42-5P, 5-(3-Methylbutyl)-2-[(phenylsulfonyl)amino]benzoic acid **677290-43-6P**, 5-(2-Methylbutyl)-2-[(phenylsulfonyl)amino]benzoic acid **677290-44-7P**, 5-Pentyl-2-[(phenylsulfonyl)amino]benzoic acid **677290-45-8P**, 5-(2-Ethylbutyl)-2-[(phenylsulfonyl)amino]benzoic acid **677290-46-9P**, 5-Hexyl-2-[(phenylsulfonyl)amino]benzoic acid **677290-47-0P**, 2-[[(2-Chloro-4-fluorophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-48-1P**, 5-Ethyl-2-[[(3-methylphenyl)sulfonyl]amino]benzoic acid **677290-49-2P**, 5-Ethyl-2-[[(2-fluorophenyl)sulfonyl]amino]benzoic acid **677290-50-5P**, 5-Ethyl-2-[[(3-fluorophenyl)sulfonyl]amino]benzoic acid **677290-51-6P**, 5-Ethyl-2-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid **677290-52-7P**, 2-[[(2-Chlorophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-53-8P**, 2-[[(3-Chlorophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-54-9P**, 2-[[(3,4-Difluorophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-55-0P**, 5-Ethyl-2-[(1-naphthylsulfonyl)amino]benzoic acid **677290-56-1P**, 5-Ethyl-2-([[3-(trifluoromethyl)phenyl]sulfonyl]amino)benzoic acid **677290-57-2P**, 2-[[(2,3-Dichlorophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-58-3P**, 2-[[(2,5-Dichlorophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-59-4P**, 2-[[(3,5-Dichlorophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-60-7P**, 2-[[(2-Bromophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-61-8P**, 2-[[(3-Bromophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-62-9P**, 5-Ethyl-2-[[(4-methylphenyl)sulfonyl]amino]benzoic acid **677290-63-0P**, 2-[[(3-Cyanophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-64-1P**, 2-[[(4-Cyanophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-65-2P**, 2-[[(2,5-Dimethylphenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-66-3P**, 5-Ethyl-2-[[(3-methoxyphenyl)sulfonyl]amino]benzoic acid **677290-67-4P**, 2-[[(3-Chloro-4-fluorophenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-68-5P**, 2-[[(2,5-Dimethoxyphenyl)sulfonyl]amino]-5-ethylbenzoic acid **677290-69-6P**, 5-Ethyl-2-[[(5-fluoro-2-methylphenyl)sulfonyl]amino]benzoic acid **677290-70-9P**, 5-Ethyl-2-[(8-quinolinylsulfonyl)amino]benzoic acid **677290-71-0P**, 5-Ethyl-2-([[2-(methylsulfonyl)phenyl]sulfonyl]amino)benzoic acid **677290-72-1P**, 5-Ethyl-2-([[2-(trifluoromethoxy)phenyl]sulfonyl]amino)benzoic acid **677290-73-2P**, 2-([[5-(Dimethylamino)-1-naphthyl]sulfonyl]amino)-5-ethylbenzoic acid **677290-74-3P**, 2-([[3,5-Bis(trifluoromethyl)phenyl]sulfonyl]amino)-5-ethylbenzoic acid **677290-75-4P**, 2-[(Butylsulfonyl)amino]-5-ethylbenzoic acid **677290-76-5P**, 5-Ethyl-2-[(2-thienylsulfonyl)amino]benzoic acid **677290-77-6P**, 2-[[(5-Chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]amino]-5-ethylbenzoic acid **677290-78-7P**, 5-Ethyl-2-([[2-(methoxycarbonyl)-3-thienyl]sulfonyl]amino)benzoic acid **677290-79-8P**, 6-[(Phenylsulfonyl)amino]-5-indanecarboxylic acid **677290-80-1P**, 2-[(Phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **677290-82-3P**, 2-[(1-Naphthylsulfonyl)amino]-1-naphthoic acid **677290-83-4P**, 7-Fluoro-2-[(phenylsulfonyl)amino]-1-naphthoic acid **677290-84-5P**, 2-[[(4-Chlorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-85-6P**, 2-[[(4-Iodophenyl)sulfonyl]amino]-1-naphthoic acid **677290-86-7P**, 2-[[(3-Fluorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-87-8P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-88-9P**, 2-[[(2-Methylphenyl)sulfonyl]amino]-1-naphthoic acid **677290-89-0P**, 2-[[(3-Methylphenyl)sulfonyl]amino]-1-naphthoic acid **677290-90-3P**, 2-[[(2-Fluorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-91-4P**, 2-([[2-(Trifluoromethoxy)phenyl]sulfonyl]amino)-1-naphthoic acid **677290-92-5P**, 2-[([2-[(3-

Aminopropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **677290-93-6P**, 2-[[(4-Methoxyphenyl)sulfonyl]amino]-1-naphthoic acid **677290-94-7P**, 7-Fluoro-2-[[(4-fluorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-95-8P**, 7-Fluoro-2-[[(3-fluorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-96-9P**, 6-Bromo-2-[[(4-fluorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-97-0P**, 2-[[(3,4-Difluorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-98-1P**, 2-[[(2-Chloro-4-fluorophenyl)sulfonyl]amino]-1-naphthoic acid **677290-99-2P**, 2-[[(5-Fluoro-2-methylphenyl)sulfonyl]amino]-1-naphthoic acid **677291-00-8P**, 2-[[(2-Methoxy-5-methylphenyl)sulfonyl]amino]-1-naphthoic acid **677291-01-9P**, 2-[[(2-Chloro-6-methylphenyl)sulfonyl]amino]-1-naphthoic acid **677291-03-1P**, 2-([[4-Chloro-3-(trifluoromethyl)phenyl]sulfonyl]amino)-1-naphthoic acid **677291-04-2P**, 2-[[(2,4-Dimethoxyphenyl)sulfonyl]amino]-1-naphthoic acid **677291-06-4P**, 2-[(8-Quinolinylsulfonyl)amino]-1-naphthoic acid **677291-07-5P**, 2-[(2,1,3-Benzothiadiazol-4-ylsulfonyl)amino]-1-naphthoic acid **677291-08-6P**, 2-[(2-Thienylsulfonyl)amino]-1-naphthoic acid **677291-09-7P**, 2-[[(3,5-Dimethyl-4-isoxazolyl)sulfonyl]amino]-1-naphthoic acid **677291-10-0P**, 2-[[(5-Chloro-2-thienyl)sulfonyl]amino]-1-naphthoic acid **677291-11-1P**, 2-[[(5-Chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]amino]-1-naphthoic acid **677291-12-2P**, 2-([[2-(Methoxycarbonyl)-3-thienyl]sulfonyl]amino)-1-naphthoic acid **677291-13-3P**, 2-([[5-(3-Isoxazolyl)-2-thienyl]sulfonyl]amino)-1-naphthoic acid **677291-14-4P**, 2-([[2,5-Dichloro-3-thienyl]sulfonyl]amino)-1-naphthoic acid **677291-15-5P**, 2-([[4,5-Dichloro-2-thienyl]sulfonyl]amino)-1-naphthoic acid **677291-17-7P**, 2-[(Butylsulfonyl)amino]-1-naphthoic acid **677291-18-8P**, 2-[(Benzylsulfonyl)amino]-1-naphthoic acid **677291-19-9P 677291-20-2P**, 2-[[(3-Chloropropyl)sulfonyl]amino]-1-naphthoic acid **677291-21-3P**, 2-[(Methylsulfonyl)amino]-1-naphthoic acid **677291-22-4P**, 2-[(Ethylsulfonyl)amino]-1-naphthoic acid **677291-23-5P**, 2-[(Propylsulfonyl)amino]-1-naphthoic acid **677297-03-9P**, 2-[[(3,4-Difluorophenyl)sulfonyl]amino]-7-fluoro-1-naphthoic acid **681241-15-6P**, 2-[[(3,5-Dichloro-2-hydroxyphenyl)sulfonyl]amino]-1-naphthoic acid **681241-17-8P**, 2-[[(5-Bromo-6-chloro-3-pyridinyl)sulfonyl]amino]-1-naphthoic acid **681241-18-9P**, 2-[[(2,4-Difluorophenyl)sulfonyl]amino]-7-fluoro-1-naphthoic acid **681241-19-0P**, 2-[(Phenylsulfonyl)amino]-4-(trifluoromethyl)benzoic acid **681241-20-3P**, 2-[(Phenylsulfonyl)amino]-4-(trifluoromethoxy)benzoic acid **681241-21-4P**, 5-Nitro-2-[(phenylsulfonyl)amino]benzoic acid **681241-22-5P**, 6-[(Phenylsulfonyl)amino]-5-quinolinecarboxylic acid **681241-23-6P**, 6-[[(4-Methoxyphenyl)sulfonyl]amino]-5-quinolinecarboxylic acid **681241-24-7P**, 2-[Ethyl[(4-fluorophenyl)sulfonyl]amino]-1-naphthoic acid **681241-25-8P**, 2-[[(4-Fluorophenyl)sulfonyl](propyl)amino]-1-naphthoic acid **681241-26-9P**, 2-[[(4-Fluorophenyl)sulfonyl][2-(methylsulfanyl)ethyl]amino]-1-naphthoic acid **681241-28-1P**, 3-Bromo-2-methyl-6-[(phenylsulfonyl)amino]benzoic acid **681241-29-2P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-8-hydroxy-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681241-30-5P**, 8-Amino-2-[[(4-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681241-31-6P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-8-hydroxy-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681241-32-7P**, 3-Cyano-2-methyl-6-[(phenylsulfonyl)amino]benzoic acid **681241-33-8P**, 3-Cyano-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoic acid **681241-34-9P**, 3-Bromo-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoic acid **681241-35-0P**, 2-[(2-Pyridinylsulfonyl)amino]-1-naphthoic acid **681241-36-1P**, 3-Bromo-2-methyl-6-[(3-pyridinylsulfonyl)amino]benzoic acid **681241-37-2P**, 3-Cyano-2-methyl-6-[(3-pyridinylsulfonyl)amino]benzoic acid **681241-38-3P**, 3-Butyl-2-methyl-6-[(3-pyridinylsulfonyl)amino]benzoic acid **681241-39-4P**, 6-[(1-Naphthylsulfonyl)amino]-1H-indole-7-

carboxylic acid **681241-40-7P**, 6-[[(3-Fluorophenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid **681241-41-8P**, 6-[[(4-Fluorophenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid **681241-42-9P**, 6-[[(2-Chloro-4-methoxyphenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid **681241-43-0P**, 6-[[(4-Methylphenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid **681241-44-1P**, 6-[[(2-Fluorophenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid **681241-45-2P**, 6-[[(4-Chlorophenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid **681241-46-3P**, 6-[(Phenylsulfonyl)amino]-1H-indole-7-carboxylic acid **681241-47-4P**, 6-[[(3-Methylphenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid **681241-48-5P**, 6-[[(4-Methoxyphenyl)sulfonyl]amino]-1H-indole-7-carboxylic acid **681241-50-9P**, 3-Bromo-6-[[(3-fluorophenyl)sulfonyl]amino]-2-methylbenzoic acid **681241-51-0P**, 3-Bromo-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methylbenzoic acid **681241-52-1P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681241-53-2P**, 3-Oxo-5-[(phenylsulfonyl)amino]-4-indanecarboxylic acid **681241-54-3P**, 3-Ethyl-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoic acid **681241-55-4P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681241-56-5P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681241-57-6P**, 2-([[2-(Butylamino)phenyl]sulfonyl]amino)-1-naphthoic acid **681241-58-7P**, 2-([[2-(sec-Butylamino)phenyl]sulfonyl]amino)-1-naphthoic acid **681241-59-8P**, 2-([[2-(Isobutylamino)phenyl]sulfonyl]amino)-1-naphthoic acid **681241-60-1P**, 2-([[2-(Pentylamino)phenyl]sulfonyl]amino)-1-naphthoic acid **681241-61-2P**, 2-([[2-[(1-Methylbutyl)amino]phenyl]sulfonyl]amino)-1-naphthoic acid **681241-62-3P**, 2-([[2-[(2-Methylbutyl)amino]phenyl]sulfonyl]amino)-1-naphthoic acid **681241-63-4P**, 2-([[2-[(3-Methylbutyl)amino]phenyl]sulfonyl]amino)-1-naphthoic acid **681241-64-5P**, 2-([[2-[(1,2-Dimethylpropyl)amino]phenyl]sulfonyl]amino)-1-naphthoic acid **681241-65-6P**, 2-([[2-(Neopentylamino)phenyl]sulfonyl]amino)-1-naphthoic acid **681241-66-7P**, 2-([[2-[(1-Ethylpropyl)amino]phenyl]sulfonyl]amino)-1-naphthoic acid **681241-67-8P**, 2-([[2-(Hexylamino)phenyl]sulfonyl]amino)-1-naphthoic acid **681241-68-9P**, 2-([[2-[(3,3-Dimethylbutyl)amino]phenyl]sulfonyl]amino)-1-naphthoic acid **681241-69-0P**, 3-Ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methylbenzoic acid **681241-70-3P**, 3-Chloro-2-[[(4-fluorophenyl)sulfonyl]amino]-1-naphthoic acid **681241-71-4P**, 2-[(Phenylsulfonyl)amino]-4-vinylbenzoic acid **681241-72-5P**, 2-Methyl-3-propyl-6-[(2-pyridinylsulfonyl)amino]benzoic acid **681241-73-6P**, 2-[[(2-[[(3-Methoxypropyl)amino]carbonyl]phenyl)sulfonyl]amino]-1-naphthoic acid **681241-74-7P**, 6-[[(4-Fluorophenyl)sulfonyl]amino]-2-methyl-3-propylbenzoic acid **681241-75-8P**, 3-Bromo-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methoxybenzoic acid **681241-76-9P**, 2-[([2-[(2-Ethoxyethyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-78-1P**, 2-[([2-[(2-Isopropoxyethyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-79-2P**, 2-[([2-[(3-Propoxypropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-80-5P**, 2-[([2-[(3-Methoxypropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-81-6P**, 2-[([2-[(Cyclopropylmethyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-82-7P**, 2-[([2-(Cyclopentylamino)phenyl]sulfonyl)amino]-1-naphthoic acid **681241-83-8P**, 2-[([2-[(Cyclopentylmethyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-84-9P**, 2-[([2-(Cyclohexylamino)phenyl]sulfonyl)amino]-1-naphthoic acid **681241-85-0P**, 2-[([2-[(2-Ethylhexyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-86-1P**, 2-[([2-[(3-Hydroxypropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-87-2P**, 2-[([2-[(4-Hydroxybutyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid

681241-88-3P, 2-[([2-[(2-Propoxyethyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-89-4P**, 2-[([2-[(3-Ethoxypropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-90-7P**, 2-[([2-[(3-Butoxypropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-91-8P**, 2-[([2-[(3-Isopropoxypropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-92-9P**, 2-[([2-[(3-Isobutoxypropyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-93-0P**, 2-[([2-[[3-(Methylsulfanyl)propyl]amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-94-1P**, 2-[([2-[[3-(Diethylamino)propyl]amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-95-2P**, 2-[([2-[(2-Methoxyethyl)amino]phenyl]sulfonyl)amino]-1-naphthoic acid **681241-96-3P**, 2-[([2-(1-Pyrrolidinylcarbonyl)phenyl]sulfonyl)amino]-1-naphthoic acid **681241-97-4P**, 2-Methyl-6-[(2-pyridinylsulfonyl)amino]-3-vinylbenzoic acid **681241-98-5P**, 6-[[(4-Fluorophenyl)sulfonyl]amino]-2-methyl-3-vinylbenzoic acid **681241-99-6P**, 2-[([2-[(4-Methyl-1-piperazinyl)carbonyl]phenyl]sulfonyl)amino]-1-naphthoic acid **681242-00-2P**, 2-[[(2-Chloro-4-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-01-3P**, 2-[(2-Thienylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-02-4P**, 2-[(Benzylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-03-5P**, 2-[[(2-Methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-04-6P**, 2-[[(3-Methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-05-7P**, 2-[[(4-Methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-06-8P**, 2-[[(2-Fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-07-9P**, 2-[[(3-Fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-08-0P**, 2-[[(3-Cyanophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-09-1P**, 2-[[(4-Cyanophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-10-4P**, 2-[[(2,5-Dimethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-11-5P**, 2-[[(3-Methoxyphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-12-6P**, 2-[[(4-Methoxyphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-13-7P**, 2-[[(2-Chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-14-8P**, 2-[[(3-Chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-15-9P**, 2-[[(4-Chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-16-0P**, 2-[[(2,4-Difluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-17-1P**, 2-[[(3,4-Difluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-18-2P**, 2-[[(4-Propylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-19-3P**, 2-[[(4-Isopropylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-20-6P**, 2-[(2-Naphthylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-21-7P**, 2-[(1-Naphthylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-22-8P**, 2-[[(4-tert-Butylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-23-9P**, 2-[[(3-Chloro-4-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-24-0P**, 2-([[4-(Acetylamino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-25-1P**, 2-[[(2,5-Dimethoxyphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-26-2P**, 2-[[(3,4-Dimethoxyphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-27-3P**, 2-[[(3-(Trifluoromethyl)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-28-4P**, 2-[[(4-(Trifluoromethyl)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-29-5P**, 2-[[(2,3-

Dichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-30-8P**, 2-[[(2,4-Dichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-31-9P**, 2-[[(2,6-Dichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-32-0P**, 2-[[(3,4-Dichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-33-1P**, 2-[[(3,5-Dichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-34-2P**, 2-[[(1,1'-Biphenyl-4-yl)sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-35-3P**, 2-[[(2-Bromophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-36-4P**, 2-[[(3-Bromophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-37-5P**, 2-[[(4-Bromophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-38-6P**, 2-[[(4-(Trifluoromethoxy)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-40-0P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-5-(methylsulfanyl)benzoic acid **681242-41-1P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-42-2P**, 3-(2-Carboxyethyl)-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoic acid **681242-43-3P**, 5-(Methylsulfanyl)-2-[(phenylsulfonyl)amino]benzoic acid **681242-44-4P**, 2-[[(2-[[2-(Dimethylamino)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-45-5P**, 2-[[(2-[[2-(Diethylamino)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-46-6P**, 2-[[(2-[[2-(1-Pyrrolidinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-47-7P**, 2-[[(2-[[3-(Dimethylamino)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-48-8P**, 2-[[(2-[[3-(4-Methyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-49-9P**, 2-[[(2-[[3-(1-Piperidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-50-2P**, 3-Butyl-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methylbenzoic acid **681242-52-4P**, 2-Chloro-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid **681242-53-5P**, 3-Bromo-2-chloro-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid **681242-54-6P**, 2-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-55-7P**
, 3-Ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methylbenzoic acid **681242-56-8P**, 6-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-methylbenzoic acid **681242-57-9P**, 6-[[(2-[[4-(N,N-Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-methylbenzoic acid **681242-58-0P**, 3-[1,2-Dihydroxyethyl]-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methylbenzoic acid **681242-59-1P**, 6-[[(4-Fluorophenyl)sulfonyl]amino]-3-(hydroxymethyl)-2-methylbenzoic acid **681242-60-4P**, 6-[[(2-[[2-(Diethylamino)ethyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-methylbenzoic acid **681242-61-5P**, 3-Ethyl-6-[[(2-[[3-(1H-imidazol-1-yl)propyl]amino]phenyl)sulfonyl]amino]-2-methylbenzoic acid **681242-62-6P**, 6-[[(2-[[3-(Dimethylamino)propyl](methyl)amino]phenyl)sulfonyl]amino]-3-ethyl-2-methylbenzoic acid **681242-63-7P**, 3-Ethyl-2-methyl-6-([[2-(4-methyl-1-piperazinyl)phenyl]sulfonyl]amino)benzoic acid **681242-64-8P**, 2-[[(3,5-Dimethyl-4-isoxazolyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT **681242-65-9P**, 2-[[(5-Chloro-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-66-0P**, 2-[[(5-Fluoro-2-methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-67-1P**, 2-[[(2-Methoxy-5-methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic

acid **681242-68-2P**, 2-[[(3-Nitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-69-3P**, 2-[[(2-Chloro-6-methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-70-6P**, 2-[[(5-Chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-71-7P**, 2-[(Mesitylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-72-8P**, 2-[[(4-Nitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-73-9P**, 2-[[(3-Chloro-4-methylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-74-0P**, 2-[(2,1,3-Benzothiadiazol-4-ylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-75-1P**, 2-[[(2-Methyl-5-nitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-76-2P**, 2-[[(5-(3-Isoxazolyl)-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-77-3P**, 2-[[(2,5-Dichloro-3-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-78-4P**, 2-[[(4,5-Dichloro-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-81-9P**, 2-[[(7-Chloro-2,1,3-benzoxadiazol-4-yl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-82-0P**, 2-[[(4-Chloro-3-nitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-83-1P**, 2-[[(2-(Trifluoromethoxy)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-84-2P**, 2-[[(5-Chloro-4-nitro-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-85-3P**, 2-[[(2,4-Dinitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-86-4P**, 2-[[(5-(Dimethylamino)-1-naphthyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-87-5P**, 2-[[(4-Chloro-3-(trifluoromethyl)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-88-6P**, 2-[[(2,4,5-Trichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-89-7P**, 2-[[(2,3,4-Trichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-90-0P** **681242-91-1P**, 2-[[(5-Bromo-2-methoxyphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-92-2P**, 2-[[(3,5-Bis(trifluoromethyl)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-93-3P**, 2-[[(2-Butoxy-5-(1,1-dimethylpropyl)phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-94-4P**, 2-[[(5-(Phenylsulfonyl)-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-95-5P**, 2-[[(5-[[(4-Chlorobenzoyl)amino]methyl]-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-96-6P**, 2-[[(5-Bromo-6-chloro-3-pyridinyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-98-8P**, 2-[[(5-[(Benzoylamino)methyl]-2-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681242-99-9P**, 6-[[(4-Fluorophenyl)sulfonyl]amino]-3-[1-hydroxyethyl]-2-methylbenzoic acid **681243-00-5P**, 2-[[(2-[[2-(Dimethylamino)ethyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-01-6P**, 8-Methyl-2-[[(2-[[2-(1-pyrrolidinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-02-7P**, 8-Methyl-2-[[(2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-03-8P**, 2-[[(2-[[3-(Dimethylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-04-9P**, 2-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-05-0P**, 2-[[(2-[[2-(Diethylamino)ethyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-06-1P**, 8-Methyl-2-[[(2-[[2-(4-morpholinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-07-2P**, 8-Methyl-2-[[(2-[[3-[3-(methylamino)phenyl]propyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-

naphthalenecarboxylic acid **681243-08-3P**, 2-[[(2-(4-Benzyl-1-piperazinyl)phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-09-4P**, 2-[[(2-[[4-(N,N-Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-10-7P**, 2-[[(2-[[3-(Dibutylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-11-8P**, 2-[[(4-Fluorophenyl)sulfonyl]amino]-8-methyl-7-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-12-9P**, 2-[[(2-[[3-(1H-Imidazol-1-yl)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-13-0P**, 8-Methyl-2-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-14-1P**, 8-Methyl-2-[[(2-[[3-(1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-15-2P**, 8-Methyl-2-[[(2-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-16-3P**, 8-Methyl-2-[[(2-[[3-(2-methyl-1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-17-4P**, 2-[[(2-[[3-(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylic acid **681243-19-6P**, 8-Methyl-2-[[(2-[[2-(1-piperidinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6-dihydro-1-naphthalenecarboxylic acid **681243-20-9P** **681243-21-0P** **681243-22-1P**, 2-([[2-([[2-(Diethylamino)ethyl]amino]carbonyl)phenyl]sulfonyl]amino)-1-naphthoic acid **681243-23-2P**, 2-[[(2-[[2-(1-Piperazinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-24-3P**, 2-[[(2-[[3-(2-Oxo-1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-26-5P**, 2-[[(2-[[3-(4-Morpholinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-28-7P**, 2-[[(2-[[2-(1-Methyl-2-pyrrolidinyl]ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-29-8P**, 2-[[(2-[[3-(2-Methyl-1-piperidinyl]propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-30-1P**, 2-[[(2-[[1-(Ethoxycarbonyl)-4-piperidinyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-32-3P**, 2-[[(2-[[2-(4-Morpholinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-33-4P**, 2-[[(2-[[2-[Bis-(2-hydroxyethyl)amino]ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-34-5P**, 2-[[(2-[[2-(1-Piperidinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-35-6P**, 2-[[(2-[[4-(Diethylamino)-1-methylbutyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-36-7P**, 2-[[(2-[[3-(Dibutylamino)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-37-8P**, 2-[[(2-[[3-(1H-Imidazol-1-yl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-38-9P**, 2-[[(2-[[3-(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-39-0P**, 2-[[(2-[[4-(N,N-Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-40-3P**, 2-[[(2-[[2-(Dipropylamino)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-41-4P**, 2-[[(2-[[3-(1-Pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-42-5P**, 2-[[(2-[[2-(Diisopropylamino)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-43-6P**, 2-[[(2-[[4-(Diethylamino)butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-45-8P** **681243-46-9P**, 6-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-hydroxybenzoic acid **681243-48-1P**, 3-Ethyl-2-methoxy-6-[[(2-[[3-(1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681243-49-2P**, 3-Ethyl-2-hydroxy-6-[[(2-[[3-(1-

piperidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681243-50-5P**, 3-Ethyl-2-hydroxy-6-[[(2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681243-51-6P**, 6-[[(2-[[4-(N,N-Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-methoxybenzoic acid **681243-52-7P**, 3-Ethyl-2-methoxy-6-[[(2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681243-53-8P**, 2-([[2-([[2-(1-Piperidinyl)ethyl]amino]carbonyl)phenyl]sulfonyl]amino)-1-naphthoic acid **681243-54-9P**, 2-[[(2-[[3-(Ethylamino)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-55-0P**, 2-([[2-([3-[Bis(2-hydroxyethyl)amino]propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-58-3P**, 2-[([2-[(3-Aminopropyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-59-4P**, 2-[[(2-[[3-(Methylamino)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-60-7P**, 6-[[(4-Fluorophenyl)sulfonyl]amino]-2-methoxy-3-vinylbenzoic acid **681243-61-8P**, 2-([[2-[([[2-(Diethylamino)ethyl]amino]carbonyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-62-9P**, 2-([[2-([[2-(Diethylamino)ethoxy]carbonyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-63-0P**, 8-Methyl-2-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-64-1P**, 8-Methyl-2-[[(2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-65-2P**, 2-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-66-3P**, 8-Methyl-2-[[(2-[[3-(2-methyl-1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-67-4P** **681243-68-5P**, 2-[[(2-[[3-(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-69-6P**, 2-[[(2-[[4-(1-Pyrrolidinyl)butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-70-9P**, 2-[[(2-[[4-[2-Methyl-1-pyrrolidinyl]butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-71-0P**, 2-[[(2-[[4-[2,5-Dimethyl-1-pyrrolidinyl]butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-72-1P**, 2-[[(2-[[4-(1-Piperidinyl)butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-73-2P**, 2-[[(2-[[4-[2-Methyl-1-piperidinyl]butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-74-3P**, 2-[[(2-[[4-[3-Methyl-1-piperidinyl]butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-75-4P**, 2-[[(2-[[4-[4-Methyl-1-piperidinyl]butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-76-5P** **681243-77-6P**, 2-[[(2-[[4-(1-Azepanyl)butanoyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-78-7P** **681243-79-8P** **681243-80-1P**, 2-[([2-[(1-Benzyl-4-piperidinyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-81-2P**, 2-[([2-[(1,2,2,6,6-Pentamethyl-4-piperidinyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-82-3P**, 3-Ethyl-2-methoxy-6-[(2-pyridinylsulfonyl)amino]benzoic acid **681243-83-4P**, 3-Ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methoxybenzoic acid **681243-84-5P**, 2-[[(2-[[3-(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-7,7-dimethyl-8-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-85-6P**, 7,7-Dimethyl-2-[[(2-[[2-[1-methyl-2-pyrrolidinyl]ethyl]amino]phenyl)sulfonyl]amino]-8-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-86-7P**, 7,7-Dimethyl-2-[[(2-[[3-[2-methyl-1-piperidinyl]propyl]amino]phenyl)sulfonyl]amino]-8-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-87-8P**, 7,7-Dimethyl-8-oxo-2-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-88-9P**

Search done by Noble Jarrell

681243-89-0P, 8-Methylene-2-[[(2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-90-3P**, 8-Methylene-2-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-91-4P**, 2-[[(2-[[4-(Aminocarbonyl)-1-piperidinyl]carbonyl]phenyl)sulfonyl]amino]-1-naphthoic acid **681243-92-5P**, 3-Bromo-6-[[(2-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-2-methoxybenzoic acid **681243-93-6P**, 3-Bromo-2-methoxy-6-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681243-94-7P**, 3-Bromo-2-hydroxy-6-[[(2-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]phenyl)sulfonyl]amino]benzoic acid **681243-95-8P**, 3-Bromo-2-methoxy-6-[[(2-[[3-(1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681243-96-9P**, 2-([[2-([[2-(Diethylamino)ethyl]amino]carbonyl)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-97-0P**, 2-[[(2-[[[3-(Dimethylamino)propyl](methyl)amino]carbonyl]phenyl)sulfonyl]amino]-1-naphthoic acid **681243-98-1P**, 2-[[(2-[[3-(Isopropylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681243-99-2P**, 3-Bromo-2-chloro-6-[[(2-fluorophenyl)sulfonyl]amino]benzoic acid **681244-02-0P**, 2-Ethoxy-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid **681244-03-1P**, 3-Bromo-2-ethoxy-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid **681244-04-2P**, 2-Ethoxy-3-ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid **681244-05-3P**, 2-Chloro-6-[[(2-[4-(N,N-dimethylamino)butyl]phenyl)sulfonyl]amino]-3-ethylbenzoic acid **681244-06-4P**, 2-Chloro-6-[[(2-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-3-ethylbenzoic acid **681244-07-5P**, 2-Chloro-3-ethyl-6-([[2-([2-[1-methyl-2-pyrrolidinyl]ethyl]amino)phenyl]sulfonyl]amino)benzoic acid **681244-08-6P 681244-09-7P**, 2-[[(2-[[2,2-Dimethyl-3-(1-piperidinyl)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-13-3P 681244-14-4P 681244-15-5P**, 2-[([2-[(4-Piperidinylmethyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-16-6P**, 2-[([2-[(2-[1-Cyclobutyl-2-piperidinyl]ethyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-17-7P 681244-18-8P**, 7,7-Dimethyl-2-([[2-([2-[1-methyl-2-pyrrolidinyl]ethyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-19-9P**, 2-[[(2-Fluorophenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-20-2P**, 2-[[(2-[[2,2-Dimethyl-3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-21-3P**, 2-[[(2-[[2-Ethyl-2-(1-piperidinylmethyl)butyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-22-4P**, 2-Ethoxy-3-ethyl-6-([[2-([2-[1-methyl-2-pyrrolidinyl]ethyl]amino)phenyl]sulfonyl]amino)benzoic acid **681244-23-5P**, 6-[[(2-[[3-(Dimethylamino)-2,2-dimethylpropyl]amino]phenyl)sulfonyl]amino]-2-ethoxy-3-ethylbenzoic acid **681244-24-6P 681244-25-7P**, 6-[[(2-[[4-(Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-2-ethoxy-3-ethylbenzoic acid **681244-27-9P**, 3-Bromo-6-([[2-([3-(dimethylamino)-2,2-dimethylpropyl]amino)phenyl]sulfonyl]amino)-2-propoxybenzoic acid **681244-28-0P**, 3-Bromo-6-([[2-([4-(N,N-dimethylamino)butyl]amino)phenyl]sulfonyl]amino)-2-propoxybenzoic acid **681244-29-1P**, 3-Bromo-6-[[(2-[[3-(4-morpholinyl)propyl]amino]phenyl)sulfonyl]amino]-2-propoxybenzoic acid **681244-30-4P 681244-31-5P**, 2-[[(2-[[([2-[1-Methyl-2-pyrrolidinyl]ethyl]amino)carbonyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-32-6P**, 2-[([2-[([2-[1-Methyl-2-pyrrolidinyl]ethyl]amino)carbonyl]phenyl]sulfonyl)amino]-1-naphthoic acid **681244-33-7P**, 2-[([2-[([3-[1-Pyrrolidinyl]propyl]amino)carbonyl]phenyl]sulfonyl)amino]-1-naphthoic acid

681244-34-8P, 2-[([2-[([3-(Isopropylamino)propyl]amino)carbonyl]ph
enyl]sulfonyl)amino]-1-naphthoic acid **681244-36-0P**,
2-[([2-[([[2-(1-Piperidinyl)ethyl]amino)carbonyl]amino]phenyl]sulfonyl)ami
no]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-38-2P**
, 2-[([2-[([[2-(1-Piperazinyl)ethyl]amino)carbonyl]amino]phenyl]sulfonyl)amino]-
5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-40-6P**,
2-[([2-[([[3-(2-Methyl-1-Piperidinyl)propyl]amino)carbonyl]amino]phenyl]su
lfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681244-42-8P, 2-[([2-[([[2-(4-Morpholinyl)ethyl]amino)carbonyl]ami
no]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681244-44-0P, 2-[([2-[([[3-(4-Morpholinyl)propyl]amino)carbonyl]am
ino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681244-46-2P, 2-[([2-[([[4-(Diethylamino)-1-
methylbutyl]amino]carbonyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-
1-naphthalenecarboxylic acid **681244-48-4P**, 2-[([2-[([[3-
(Dimethylamino)-2,2-dimethylpropyl]amino]carbonyl)amino]phenyl]sulfonyl)am
ino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-50-8P**
, 2-[([2-[([[3-(1-Piperidinyl)propyl]amino]carbonyl)amino]phenyl]sulfonyl)
amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681244-52-0P, 2-[([2-[([[3-(1-Piperazinyl)propyl]amino]carbonyl)am
ino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681244-53-1P, 3-Ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]-2-
propoxybenzoic acid **681244-54-2P** **681244-55-3P**,
3-Ethyl-6-([[2-([3-[2-methyl-1-piperidinyl]propyl]amino)phenyl]sulfonyl]am
ino)-2-propoxybenzoic acid **681244-56-4P**, 3-Ethyl-6-([[2-([3-[4-
morpholinyl]propyl]amino)phenyl]sulfonyl]amino)-2-propoxybenzoic acid
681244-57-5P, 3-Bromo-6-[[(2-[[4-(N,N-
dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-2-methoxybenzoic acid
681244-58-6P, 3-Bromo-6-[[(2-[[4-(N,N-
dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-2-hydroxybenzoic acid
681244-59-7P, 3-Bromo-2-hydroxy-6-[[(2-[[3-(1-
piperidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid
681244-60-0P, 3-Bromo-2-hydroxy-6-[[(2-[[3-(4-methyl-1-
piperazinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid
681244-61-1P, 3-Bromo-2-hydroxy-6-[[(2-[[3-(1-
pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid
681244-62-2P, 3-Bromo-6-[[(2-[[3-(diethylamino)propyl]amino]phenyl
)sulfonyl]amino]-2-methoxybenzoic acid **681244-63-3P**,
3-Bromo-6-[[(2-[[3-(diethylamino)propyl]amino]phenyl)sulfonyl]amino]-2-
hydroxybenzoic acid **681244-64-4P**, 6-[[(2-[[4-(N,N-
Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-hydroxybenzoic
acid **681244-65-5P**, 6-[[(2-[[3-(Dimethylamino)-2,2-
dimethylpropyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-methoxybenzoic acid
681244-66-6P, 3-Ethyl-2-hydroxy-6-[[(2-[[2-(1-methyl-2-
pyrrolidinyl)ethyl]amino]phenyl)sulfonyl]amino]benzoic acid
681244-67-7P, 6-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfony
l]amino]-3-ethyl-2-methoxybenzoic acid **681244-68-8P**,
3-Ethyl-2-methoxy-6-[[(2-[[3-(1-pyrrolidinyl)propyl]amino]phenyl)sulfonyl]
amino]benzoic acid **681244-69-9P**, 3-Ethyl-2-hydroxy-6-[[(2-[[3-(1-
pyrrolidinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid
681244-70-2P, 3-Ethyl-2-methoxy-6-[[(2-[[3-(4-
morpholinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid
681244-71-3P, 3-Ethyl-2-methoxy-6-[[(2-[[4-(1-
pyrrolidinyl)butyl]amino]phenyl)sulfonyl]amino]benzoic acid
681244-72-4P, 3-Bromo-2-methoxy-6-[[(2-[[3-(4-methyl-1-
piperazinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid
681244-73-5P, 3-Bromo-2-methoxy-6-[[(2-[[3-[2-methyl-1-
piperidinyl]propyl]amino]phenyl)sulfonyl]amino]benzoic acid
681244-74-6P, 3-Ethyl-2-methoxy-6-[[(2-[[2-[1-methyl-2-
pyrrolidinyl]ethyl]amino]phenyl)sulfonyl]amino]benzoic acid
681244-75-7P, 3-Ethyl-6-[[(2-[[3-(1H-imidazol-1-
yl)propyl]amino]phenyl)sulfonyl]amino]-2-methoxybenzoic acid
681244-76-8P, 3-Ethyl-2-hydroxy-6-[[(2-[[3-(1H-imidazol-1-
yl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681244-77-9P**,
3-Ethyl-2-hydroxy-6-[[(2-[[3-(4-morpholinyl)propyl]amino]phenyl)sulfonyl]a
mino]benzoic acid **681244-78-0P**, 3-Bromo-5-ethyl-6-methyl-2-[(2-

pyridinylsulfonyl)amino]benzoic acid **681244-79-1P**,
2-[[(2-[[2-[1-Methyl-2-pyrrolidinyl]ethyl]amino]phenyl)sulfonyl]amino]-8-
methoxy-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681244-80-4P, 2-[[(2-[[3-(Isopropylamino)propyl]amino]phenyl)sulfo
nyl]amino]-8-methoxy-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681244-81-5P, 2-[([2-[([2-[1-Methyl-2-
pyrrolidinyl]ethyl]amino)carbonyl]phenyl]sulfonyl)amino]-5,6,7,8-
tetrahydro-1-naphthalenecarboxylic acid **681244-82-6P**,
2-[([4-[([2-[1-Methyl-2-pyrrolidinyl]ethyl]amino)carbonyl]-3-
thienyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681244-83-7P, 2-[([2-[([2-(1-Piperidinyl)ethyl]amino)carbonyl]phen
yl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681244-84-8P, 2-[([4-[([2-(Diethylamino)ethyl]amino)carbonyl]-3-
thienyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681244-85-9P, 2-[([4-[([2-(1-Piperidinyl)ethyl]amino)carbonyl]-3-
thienyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681244-86-0P, 6-[([2-[(3-Aminopropyl)amino]phenyl]sulfonyl)amino]-
3-ethyl-2-methoxybenzoic acid **681244-87-1P**, 6-[([2-[(3-
Aminopropyl)amino]phenyl]sulfonyl)amino]-3-ethyl-2-hydroxybenzoic acid
681244-88-2P, 2-(Carboxymethoxy)-3-ethyl-6-[[(4-
fluorophenyl)sulfonyl]amino]benzoic acid **681244-89-3P**,
6-([[2-(Dimethylamino)phenyl]sulfonyl]amino)-3-ethyl-2-methoxybenzoic acid
681244-90-6P, 6-[[(2-[[3-(Dimethylamino)-2,2-
dimethylpropyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-hydroxybenzoic acid
681244-91-7P, 3-Bromo-5-ethyl-2-[[(2-fluorophenyl)sulfonyl]amino]-
6-methoxybenzoic acid **681244-92-8P**, 5-Ethyl-2-[[(2-
fluorophenyl)sulfonyl]amino]-4-methoxy-1,1'-biphenyl-3-carboxylic acid
681244-93-9P 681244-94-0P 681244-95-1P
681244-96-2P 681244-97-3P, 3-[(1E)-3-([2-[1-Methyl-2-
pyrrolidinyl]ethyl]amino)-3-oxo-1-propenyl]-2-[(phenylsulfonyl)amino]-
5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681244-98-4P**,
3-((1E)-3-Oxo-3-[[2-(1-piperidinyl)ethyl]amino]-1-propenyl]-2-
[(phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681244-99-5P, 3-((1E)-3-Oxo-3-[[3-(1-piperidinyl)propyl]amino]-1-
propenyl]-2-[(phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-
naphthalenecarboxylic acid **681245-00-1P**, 3-[(1E)-3-([[1-Ethyl-2-
pyrrolidinyl]methyl]amino)-3-oxo-1-propenyl]-2-[(phenylsulfonyl)amino]-
5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-01-2P**,
3-((1E)-3-[[2-(Dimethylamino)ethyl]amino]-3-oxo-1-propenyl]-2-
[(phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681245-02-3P 681245-03-4P 681245-04-5P
681245-05-6P 681245-06-7P 681245-07-8P
681245-08-9P, 2-[N-Methyl-N-([2-[(4-piperidinylmethyl)amino]phenyl
]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681245-09-0P 681245-10-3P 681245-11-4P
681245-12-5P 681245-13-6P 681245-14-7P
681245-15-8P 681245-16-9P 681245-17-0P
681245-18-1P 681245-19-2P 681245-20-5P
681245-21-6P, 3-Bromo-2-methoxy-6-([[2-([2-[1-methyl-2-
pyrrolidinyl]ethyl]amino)phenyl]sulfonyl]amino)benzoic acid
681245-22-7P, 3-Bromo-2-hydroxy-6-([[2-([3-[2-methyl-1-
piperidinyl]propyl]amino)phenyl]sulfonyl]amino)benzoic acid
681245-23-8P, 2-[[(2-[[2-(Diethylamino)ethyl]sulfanyl]phenyl)sulfo
nyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
681245-24-9P, 2-[[(2-([[3-(Diethylamino)propyl]amino]carbonyl)phen
yl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT **681245-25-0P**, 2-([[2-([[3-(Dimethylamino)-2,2-
dimethylpropyl]amino]carbonyl)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-
naphthalenecarboxylic acid **681245-26-1P**, 2-([[2-([[3-
(Diethylamino)propyl]amino]carbonyl)-3-thienyl]sulfonyl]amino)-5,6,7,8-
tetrahydro-1-naphthalenecarboxylic acid **681245-27-2P**,
2-([[2-([[3-(Dimethylamino)-2,2-dimethylpropyl]amino]carbonyl)-3-

thienyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-28-3P**, 2-([[2-([[4-(Diethylamino)-1-methylbutyl]amino]carbonyl)-3-thienyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-29-4P**, 2-[[(2-[[[3-(Dimethylamino)propyl](methyl)amino]carbonyl]-3-thienyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-30-7P** **681245-31-8P**, 2-[[(2-[[3-(4-Cyclopentyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-32-9P**, 2-[[(2-[[3-(4-Isopropyl-1-piperazinyl)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-33-0P** **681245-34-1P** **681245-35-2P**, 2-([[2-([[4-(Diethylamino)butyl]amino]carbonyl)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-36-3P**, 2-([[2-([[4-(Diethylamino)butyl]amino]carbonyl)-3-thienyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-37-4P**, 2-([[2-([[4-(Diethylamino)butyl]amino]carbonyl)-4-fluorophenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-38-5P**, 2-([[2-([[4-(Diethylamino)-1-methylbutyl]amino]carbonyl)-4-fluorophenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-39-6P**, 2-([[2-([[4-(Diethylamino)-1-methylbutyl]amino]carbonyl)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-40-9P**, 8-Methyl-2-[[(2-[[3-(4-morpholinyl)propyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-41-0P**, (8R)-2-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-42-1P**, (8S)-2-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-43-2P**, 2-(2-Aminoethoxy)-3-ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid **681245-44-3P**, 2-(2-Aminoethoxy)-6-[[(2-bromophenyl)sulfonyl]amino]-3-ethylbenzoic acid **681245-45-4P**, 2-(2-Aminoethoxy)-6-[[(2-[(1E)-3,3-dimethyl-1-butenyl]phenyl)sulfonyl]amino]-3-ethylbenzoic acid **681245-46-5P**, 2-(2-Aminoethoxy)-6-[[(2-(3,3-dimethylbutyl)phenyl)sulfonyl]amino]-3-ethylbenzoic acid **681245-47-6P**, 2-(2-Aminoethoxy)-6-[[(2-propylphenyl)sulfonyl]amino]-3-ethylbenzoic acid **681245-48-7P**, 2-[([2-[(4-Pyridinylmethyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-49-8P** **681245-50-1P**, 2-[[(2-[[3-(Diethylamino)propyl]sulfanyl]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-51-2P**, 2-[[(2-[[2-(Diethylamino)ethyl]sulfinyl]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-52-3P**, 2-[[(2-[3-(Diethylamino)propoxy]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-53-4P** **681245-54-5P** **681245-55-6P** **681245-56-7P** **681245-57-8P** **681245-58-9P** **681245-59-0P** **681245-60-3P** **681245-61-4P** **681245-62-5P** **681245-63-6P** **681245-64-7P** **681245-65-8P** **681245-66-9P** **681245-67-0P** **681245-68-1P** **681245-69-2P** **681245-70-5P** **681245-71-6P**, 2-([[2-([2,2-Dimethyl-3-(4-morpholinyl)propyl]amino)phenyl]sulfonyl]amino)-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-72-7P**, 2-([[2-([3-Hydroxy-2,2-dimethylpropyl]amino)phenyl]sulfonyl]amino)-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-73-8P**, 2-([[2-([3-[4-[4-(Trifluoromethyl)-2-pyrimidinyl]-1-piperazinyl]propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-74-9P**, 2-([[2-([3-(1-Azepanyl)propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-75-0P**, 2-([[2-([[1-(2-Ethylbutyl)-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-76-1P**, 2-([[2-([[1-Cyclopentyl-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-77-2P**, 2-([[2-([[1-[1-Methylpropyl]-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-79-4P**

, 2-([[2-([[1-Isobutyl-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-80-7P**, 2-([[2-([[1-Methyl-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-81-8P**, 2-([[2-([[1'-Methyl-1,4'-bipiperidin-4-yl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-82-9P** , 2-([[2-([[1-Isopropyl-4-piperidinyl]methyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-83-0P**, 2-([[2-[(1E)-3-(Diethylamino)-1-propenyl]phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-84-1P**, 2-([[2-[4-(Diethylamino)butyl]phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-85-2P**, 2-([[2-[(1Z)-3-(Diethylamino)-1-propenyl]phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-86-3P**, 2-([[2-[(1Z)-4-(Diethylamino)-1-butenyl]phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-87-4P**, 2-([[2-([3-[3-Methyl-1-piperidinyl]propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-88-5P**, 2-([[2-([3-[Cyclohexyl(methyl)amino]propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-89-6P**, 2-([[2-([3-(3,4-Dihydro-2(1H)-isoquinolinyl)propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-91-0P** , 2-([[2-([2-Methyl-3-(4-methyl-1-piperidinyl)propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-92-1P**, 2-([[2-([3-[2,6-Dimethyl-1-piperidinyl]propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681245-93-2P** **681245-94-3P**, 3-Ethyl-2-methoxy-6-([[2-(2-phenylethyl)phenyl]sulfonyl]amino)benzoic acid **681245-95-4P**, 6-[([2-[2-(4-Chlorophenyl)ethyl]phenyl]sulfonyl)amino]-3-ethyl-2-methoxybenzoic acid **681245-96-5P**, 3-Ethyl-2-methoxy-6-[[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]benzoic acid **681245-97-6P**, 6-[[(1,2-Dimethyl-1H-imidazol-4-yl)sulfonyl]amino]-3-ethyl-2-methoxybenzoic acid **681245-98-7P**, 2-(2-Aminoethoxy)-6-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-3-ethylbenzoic acid **681245-99-8P**, 2-(3-Aminopropoxy)-6-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-3-ethylbenzoic acid **681246-00-4P**, 3,5-Diethyl-2-methoxy-6-[[(2-[[3-(4-morpholinyl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681246-01-5P**, 3,5-Diethyl-2-methoxy-6-[[(2-[[3-[2-methyl-1-piperidinyl]propyl]amino]phenyl)sulfonyl]amino]benzoic acid **681246-02-6P**, 3,5-Diethyl-2-methoxy-6-[[(2-[[2-[1-methyl-2-pyrrolidinyl]ethyl]amino]phenyl)sulfonyl]amino]benzoic acid **681246-03-7P**, 2-[[(2-[[3-(Diethylamino)propyl]amino]phenyl)sulfonyl]amino]-3,5-diethyl-6-methoxybenzoic acid **681246-04-8P**, 2-[[(2-[[4-(N,N-Dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-3,5-diethyl-6-methoxybenzoic acid **681246-05-9P**, 3,5-Diethyl-2-methoxy-6-[[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]benzoic acid **681246-06-0P**, 2-[[(1,2-Dimethyl-1H-imidazol-4-yl)sulfonyl]amino]-3,5-diethyl-6-methoxybenzoic acid **681246-07-1P**, 3,5-Diethyl-2-methoxy-6-[(phenylsulfonyl)amino]benzoic acid **681246-08-2P**, 3,5-Diethyl-2-[[(4-fluorophenyl)sulfonyl]amino]-6-methoxybenzoic acid **681246-09-3P**, 3,5-Diethyl-2-methoxy-6-[[2-pyridinylsulfonyl]amino]benzoic acid **681246-10-6P**, 2-[([2-[3-(Diethylamino)propyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-11-7P**, 2-[([2-[(1Z)-5-(Diethylamino)-1-pentenyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-12-8P**, 2-[([2-[(1E)-5-(Diethylamino)-1-pentenyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-13-9P**, 2-[([2-[5-(Diethylamino)pentyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-14-0P** **681246-15-1P**, 2-(2-Aminoethoxy)-3-ethyl-6-[[(2-ethyl-4-fluorophenyl)sulfonyl]amino]benzoic acid **681246-17-3P**, 2-(2-Aminoethoxy)-3-ethyl-6-[[(4-fluoro-2-propylphenyl)sulfonyl]amino]benzoic acid **681246-18-4P**, 2-(2-Aminoethoxy)-3-ethyl-6-[[(4-fluoro-2-(2-phenylethyl)phenyl)sulfonyl]amino]benzoic acid **681246-21-9P**, 8-Methyl-2-([[2-([3-(4-morpholinyl)-3-oxopropyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-

naphthalenecarboxylic acid **681246-22-0P**, 8-Methyl-2-([[2-([3-oxo-3-(1-piperazinyl)propyl]amino)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-23-1P**, 2-([[2-([2,2-Dimethyl-3-oxo-3-(1-piperazinyl)propyl]amino)phenyl]sulfonyl]amino)-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-24-2P**, 3-Ethyl-6-[([4-fluoro-2-[4-(2-methyl-1-pyrrolidinyl)butyl]phenyl]sulfonyl)amino]-2-methoxybenzoic acid **681246-25-3P**, 6-[([2-[4-(Diethylamino)butyl]-4-fluorophenyl]sulfonyl)amino]-3-ethyl-2-methoxybenzoic acid **681246-26-4P**, 2-[[(2-[[2-(4-Pyridinyl)ethyl]amino]phenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681246-27-5P**, 2-[[(4-Bromo-2-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid **681255-09-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT 67-64-1, Acetone, reactions 75-26-3, 2-Bromopropane 78-81-9, Isobutylamine 78-84-2, 2-Methylpropanal 78-93-3, 2-Butanone, reactions 83-33-0, 1-Indanone 85-46-1, 1-Naphthalenesulfonyl chloride 91-59-8, 2-Naphthylamine 93-11-8, 2-Naphthalenesulfonyl chloride 96-15-1, 2-Methylbutylamine 96-17-3, 2-Methylbutanal 96-32-2, Methyl bromoacetate 96-33-3, Methyl acrylate 97-08-5, 4-Chloro-3-nitrobenzenesulfonyl chloride 97-96-1, 2-Ethylbutanal 98-09-9, Benzenesulfonyl chloride 98-31-7, 3,4-Dichlorobenzenesulfonyl chloride 98-58-8, 4-Bromobenzenesulfonyl chloride 98-59-9, 4-Methylbenzenesulfonyl chloride 98-60-2, 4-Chlorobenzenesulfonyl chloride 98-61-3, 4-Iodobenzenesulfonyl chloride 98-68-0, 4-Methoxybenzenesulfonyl chloride 98-74-8, 4-Nitrobenzenesulfonyl chloride 98-80-6, Phenylboronic acid 100-36-7, N,N-Diethyl-1,2-ethanediamine 100-37-8, 2-(Diethylamino)ethanol 102-83-0, N,N-Dibutyl-1,3-propanediamine 104-75-6, 2-Ethylhexylamine 104-78-9, 3-(Diethylamino)propylamine 105-56-6, Ethyl cyanoacetate 107-85-7, 3-Methylbutylamine 108-00-9, N,N-Dimethyl-1,2-ethanediamine 108-91-8, Cyclohexylamine, reactions 108-94-1, Cyclohexanone, reactions 109-01-3, 1-Methylpiperazine 109-05-7, 2-Methylpiperidine 109-55-7, N,N-Dimethyl-1,3-propanediamine 109-73-9, Butylamine, reactions 109-76-2, 1,3-Diaminopropane 109-85-3, 2-Methoxyethylamine 110-58-7, 1-Aminopentane 110-76-9, 2-Ethoxyethylamine 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 111-26-2, 1-Aminohexane 111-49-9, Azepane 120-92-3, Cyclopentanone 121-02-8, 2-Methyl-5-nitrobenzenesulfonyl chloride 121-05-1, 2-(Diisopropylamino)ethylamine 121-51-7, 3-Nitrobenzenesulfonyl chloride 121-60-8, 4-(Acetylamino)benzenesulfonyl chloride 123-75-1, Pyrrolidine, reactions 133-59-5, 2-Methylbenzenesulfonyl chloride 140-31-8, 1-(2-Aminoethyl)piperazine 140-80-7, 4-(Diethylamino)-1-methylbutylamine 156-87-6, 3-Amino-1-propanol 313-12-2, 3-(Trifluoromethyl)anthranilic acid 349-88-2, 4-Fluorobenzenesulfonyl chloride 350-03-8, 3-Acetylpyridine 445-05-6, 2-Methyl-5-fluorobenzenesulfonyl chloride 574-98-1, N-(2-Bromoethyl)phthalimide 589-16-2, 4-Ethylaniline 590-50-1, 4,4-Dimethyl-2-pentanone 598-74-3, 2-Amino-3-methylbutane 605-65-2, 5-(Dimethylamino)-1-naphthalenesulfonyl chloride 609-09-6, Diethyl ketomalonate 616-79-5, 2-Amino-5-nitrobenzoic acid 622-93-5, 3-(Diethylamino)-1-propanol 625-36-5, 3-Chloropropanoyl chloride 626-56-2, 3-Methylpiperidine 626-58-4, 4-Methylpiperidine 701-27-9, 3-Fluorobenzenesulfonyl chloride 705-21-5, 3,5-Dichlorobenzenesulfonyl chloride 765-38-8, 2-Methylpyrrolidine 765-43-5, Acetylcyclopropane 773-64-8, 2,4,6-Trimethylbenzenesulfonyl chloride 777-44-6, 3-(Trifluoromethyl)benzenesulfonyl chloride 872-53-7, Cyclopentanecarboxaldehyde 927-74-2, 4-Hydroxy-1-butyne 1003-03-8, Cyclopentylamine 1003-04-9, Dihydro-3(2H)-thiophenone 1072-72-6, Tetrahydro-4H-thiopyran-4-one 1121-60-4, 2-Pyridinecarboxaldehyde 1191-95-3, Cyclobutanone 1445-73-4, 1-Methyl-4-piperidone 1483-28-9, 2,5-Dimethoxybenzenesulfonyl chloride 1489-69-6, Cyclopropanecarboxaldehyde 1623-93-4, 4-Phenylbenzenesulfonyl chloride 1633-82-5, 3-Chloro-1-propanesulfonyl chloride 1656-44-6,

2,4-Dinitrobenzenesulfonyl chloride 1663-39-4, tert-Butyl acrylate 1694-92-4, 2-Nitrobenzenesulfonyl chloride 1899-93-0, 3-Methylbenzenesulfonyl chloride 1939-99-7, Phenylmethanesulfonyl chloride 1942-52-5, 2-(Diethylamino)ethanethiol hydrochloride 2038-03-1, N-2-Aminoethylmorpholine 2043-61-0, Cyclohexanecarboxaldehyde 2148-56-3, 2-Amino-6-chlorobenzoic acid 2386-60-9, 1-Butanesulfonyl chloride 2516-47-4, Cyclopropylmethylamine 2706-56-1, 2-(2-Aminoethyl)pyridine 2759-28-6, 1-Benzylpiperazine 2766-74-7, 5-Chloro-2-thiophenesulfonyl chloride 2888-06-4, 3-Chlorobenzenesulfonyl chloride 2905-21-7, 2-Fluorobenzenesulfonyl chloride 2905-23-9, 2-Chlorobenzenesulfonyl chloride 2905-24-0, 3-Bromobenzenesulfonyl chloride 2905-25-1, 2-Bromobenzenesulfonyl chloride 2906-12-9, 3-Isopropoxypropylamine 2991-42-6, 4-(Trifluoromethyl)benzenesulfonyl chloride 3230-36-2 3360-16-5, 3-(Isopropylamino)propylamine 3378-71-0, 2,5-Dimethylpyrrolidine 3437-33-0, 3-(1-Azepanyl)-1-propanamine 3529-08-6, 1-Piperidinepropanamine 3529-10-0, N,N-Dimethyl-1,4-butanediamine 3731-53-1, 4-(Aminomethyl)pyridine 4079-68-9 4104-45-4 4318-42-7, 1-Isopropylpiperazine 4389-50-8, 2-Amino-6-methylbenzoic acid 4426-47-5, n-Butylboronic acid 4461-39-6, 2-[(3-Aminopropyl)amino]ethanol 4543-96-8, N,N,N'-Trimethyl-1,3-propanediamine 4572-03-6, 3-(4-Methyl-1-piperazinyl)-1-propanamine 4635-59-0, 4-Chlorobutanoyl chloride 4985-85-7, 2-[(3-Aminopropyl)(2-hydroxyethyl)amino]ethanol 5036-48-6, 3-(1H-Imidazol-1-yl)-1-propanamine 5271-38-5, 2-(Methylsulfanyl)ethanol 5332-73-0, 1-Methoxy-3-aminopropane 5390-04-5, 4-Pentyn-1-ol 5402-73-3, 2,5-Dichlorobenzenesulfonyl chloride 5460-29-7, N-(3-Bromopropyl)phthalimide 5596-87-2 5794-88-7 5813-64-9, 1-Amino-2,2-dimethylpropane 6053-81-2, (Cyclopentylmethyl)amine 6089-09-4, 4-Pentynoic acid 6291-85-6, 3-Ethoxypropylamine 6336-45-4, Dibutyl vinylboronate 6783-05-7, trans-2-Phenylvinylboronic acid 7154-73-6, 2-(1-Pyrrolidinyl)ethanamine 7486-35-3, Tributyl(vinyl)tin 7547-97-9, trans-Propenylboronic acid 7565-57-3, Cyclohexylzinc bromide 7663-77-6, 1-(3-Aminopropyl)-2-pyrrolidinone 10130-74-2, 3-Methoxybenzenesulfonyl chloride 10147-36-1, 1-Propanesulfonyl chloride 10563-23-2, 3-(Ethylamino)propylamine 13139-17-8 13258-63-4, 4-(2-Aminoethyl)pyridine 13325-10-5, 4-Amino-1-butanol 13918-92-8, 2,4-Difluorobenzenesulfonyl chloride 13952-84-6, 2-Aminobutane 14156-91-3, 3-(3-Methyl-1-piperidinyl)-1-propanamine 14165-22-1, 2-(Dipropylamino)ethylamine 15029-30-8, 1-Cyanoacetylpiperidine 15084-51-2, 4-tert-Butylbenzenesulfonyl chloride 15673-00-4, 1-Amino-3,3-dimethylbutane 15761-39-4, tert-Butoxycarbonyl-L-proline 15932-66-8, 2-(2-Aminoethyl)piperidine 15945-07-0, 2,4,5-Trichlorobenzenesulfonyl chloride 16133-25-8, 3-Pyridinesulfonyl chloride 16271-33-3, 2,4-Dichlorobenzenesulfonyl chloride 16499-88-0, 3-Butoxypropylamine 16629-19-9, 2-Thiophenesulfonyl chloride 16728-59-9, 3-Propoxypropylamine 18704-37-5, 8-Chlorosulfonylquinoline 19040-62-1, 2,5-Dimethylbenzenesulfonyl chloride 21043-40-3, 1-Cyclopentylpiperazine 22160-08-3, (2R)-2-Ethylpiperidine 23094-94-2, 2-Chloro-4-methoxybenzenesulfonyl chloride 23095-05-8, 5-Bromo-2-methoxybenzenesulfonyl chloride 23095-31-0, 3,4-Dimethoxybenzenesulfonyl chloride 23099-21-0, (3-Piperidinylmethyl)amine 23159-07-1, 3-(1-Pyrrolidinyl)propylamine 23378-88-3, 3,5-Dichloro-2-hydroxybenzenesulfonyl chloride 23418-85-1, 3-Butynyl 4-methylbenzenesulfonate 24425-40-9, 5-Indanamine 24715-90-0, 4-(1-Pyrrolidinyl)butylamine 25300-37-2, 2-Chloro-6-methylbenzenesulfonyl chloride 25560-00-3, 3-(2-Methyl-1-piperidinyl)propylamine 26116-12-1, 2-(Aminomethyl)-1-ethylpyrrolidine 26638-43-7, Methyl 2-(chlorosulfonyl)benzoate 26735-20-6, N-(3-Aminopropyl)-N-cyclohexyl-N-methylamine 27431-62-5, 4-(Diethylamino)butylamine 27578-60-5, 2-(1-Piperidinyl)ethylamine 29943-42-8, Tetrahydro-4H-pyran-4-one 32333-53-2, 4-Chloro-3-(trifluoromethyl)benzenesulfonyl chloride 32923-88-9, 3-Isobutoxypropylamine 34732-09-7, 2,3,4-Trichlorobenzenesulfonyl chloride 34885-02-4, 3-(1-Piperazinyl)propylamine 37784-17-1, N-tert-Butoxycarbonyl-D-proline 39234-86-1, 3,5-Di(trifluoromethyl)benzenesulfonyl chloride 39546-32-2, Isonipecotamide

40218-49-3, 2-Propyl-1,3,2-benzodioxaborole 40327-96-6,
4-Amino-1,2,2,6,6-pentamethylpiperidine 40353-34-2, 7-Nitro-3,4-dihydro-
1(2H)-naphthalenone 42185-03-5, 2-Propoxyethylamine 42413-03-6,
3-Chloro-4-methylbenzenesulfonyl chloride 49584-26-1,
4-Cyanobenzenesulfonyl chloride 50541-93-0, 4-Amino-1-benzylpiperidine
51387-90-7, 2-[(1-Methyl-2-pyrrolidinyl]ethylamine 51605-97-1,
2-Bromo-4-isopropylaniline 52147-97-4, (E)-2-Phenylethylenesulfonyl
chloride 52727-57-8, Methyl 2-amino-5-bromobenzoate 53369-71-4
53485-07-7, N-(3-Aminopropyl)-N-methylaniline 53600-33-2,
2-Amino-6-methoxybenzoic acid 54398-51-5, 6-Amino-5-
quinolinecarbonitrile 54997-90-9 55790-39-1, 3-
(Diethylamino)propanethiol 56542-67-7, 3-Cyanobenzenesulfonyl chloride
56946-83-9, 2,5-Dichloro-3-thiophenesulfonyl chloride 57260-71-6,
1-tert-Butoxycarbonylpiperazine 58457-24-2, 5-Chloro-4-nitro-2-
thiophenesulfonyl chloride 58859-46-4, Ethyl 4-amino-1-
piperidinecarboxylate 59337-92-7, Methyl 3-(chlorosulfonyl)-2-
thiophenecarboxylate 60956-26-5, 4-Bromo-2-nitrotoluene 63493-28-7,
2-Aminopentane 63624-28-2, 2,4-Dimethoxybenzenesulfonyl chloride
66715-65-9, 2-Pyridinesulfonyl chloride 73713-79-8, 2,1,3-
Benzothiadiazole-4-sulfonyl chloride 75178-96-0, tert-Butyl
[3-aminopropyl]carbamate 76745-74-9 80466-79-1, 3,5-Dimethyl-4-
isoxazolesulfonyl chloride 81731-43-3, 2-Isopropoxyethylamine
82417-45-6, 2,3-Dichlorobenzenesulfonyl chloride 85723-72-4,
3-[2,6-Dimethyl-1-piperidinyl]-1-propanamine 85958-57-2,
2-Chloro-4-fluorobenzenesulfonyl chloride 86595-37-1 88040-86-2,
2-Methoxy-5-methylbenzenesulfonyl chloride 88398-93-0,
5-Chloro-1,3-dimethyl-1H-pyrazole-4-sulfonyl chloride 89265-35-0,
2-(Methylsulfonyl)benzenesulfonyl chloride 91170-93-3,
3-Chloro-4-fluorobenzenesulfonyl chloride 92273-73-9, Butylzinc bromide
92274-43-6 94108-56-2, 4-(Trifluoromethoxy)benzenesulfonyl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT 101555-60-6 103008-51-1, 2-(Trifluoromethoxy)benzenesulfonyl chloride
124397-96-2, Hexylzinc bromide 126403-67-6, Isobutylzinc bromide
126714-85-0, 4,5-Dichloro-2-thiophenesulfonyl chloride 127720-93-8,
7-Chloro-2,1,3-benzothiadiazole-4-sulfonyl chloride 137049-00-4,
1-Methyl-1H-imidazole-4-sulfonyl chloride 137049-02-6,
1,2-Dimethyl-1H-imidazole-4-sulfonyl chloride 138872-44-3,
5-[(Benzoylamino)methyl]-2-thiophenesulfonyl chloride 143193-41-3,
2-Butoxy-5-(1,1-dimethylpropyl)benzenesulfonyl chloride 144222-22-0,
1-tert-Butoxycarbonyl-4-(aminomethyl)piperidine 145758-05-0,
3,4-Difluorobenzenesulfonyl chloride 146949-07-7, 4-
Propylbenzenesulfonyl chloride 154230-29-2 156567-57-6, Propylzinc
bromide 160233-27-2, 5-(3-Isoxazolyl)-2-thiophenesulfonyl chloride
162167-97-7, 1-tert-Butoxycarbonyl-3-(aminomethyl)piperidine 166964-33-6
166964-34-7, 5-[[(4-Chlorobenzoyl)amino]methyl]-2-thiophenesulfonyl
chloride 166964-37-0, 5-(Phenylsulfonyl)-2-thiophenesulfonyl chloride
171860-68-7, Cyclopentylzinc bromide 174311-79-6, Ethyl
6-amino-1H-indole-7-carboxylate 175278-17-8, 2-Bromo-4-
(trifluoromethoxy)aniline 216159-03-4, 4-Bromo-2-fluorobenzenesulfonyl
chloride 216394-05-7, 5-Bromo-6-chloro-3-pyridinesulfonyl chloride
270912-72-6, 1-tert-Butoxycarbonyl-3-(aminomethyl)pyrrolidine
308796-10-3, Pentylzinc bromide 312693-02-0, 2-Ethylbutylzinc bromide
351003-45-7, 2-Bromo-4-fluorobenzenesulfonyl chloride 496808-04-9,
1-[(1-Methyl-4-piperidinyl)methyl]-4-piperazine 681248-31-7
681248-32-8 681248-33-9 681248-34-0, Methyl
2-[([2-bromophenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-
naphthalenecarboxylate 681248-35-1, 3-[4-(4-Trifluoromethylpyrimidin-2-
yl)piperazin-1-yl]propylamine 681248-36-2, 2-Methyl-3-(4-methyl-1-
piperidinyl)-1-propanamine 681847-93-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT 123-00-2P, 3-(4-Morpholinyl)-1-propanamine 610-36-6P,
4-Amino-2-nitrobenzoic acid 2475-82-3P, 2-Amino-5-ethylbenzoic acid
4553-26-8P, 3-(4-Isopropyl-1-piperazinyl)-1-propanamine 5588-87-4P,
1H-Benzo[e]indole-1,2(3H)-dione 13991-22-5P 14227-95-3P,

3-Oxo-3-(1-pyrrolidinyl)propanenitrile 14227-98-6P 15029-32-0P, 3-(4-Morpholinyl)-3-oxopropanenitrile 17122-70-2P, N-(4-Ethylphenyl)-2-(hydroxyimino)acetamide 20776-50-5P, 2-Amino-4-bromobenzoic acid 22009-40-1P, 7-Amino-3,4-dihydro-1(2H)-naphthalenone 24623-24-3P, 6-Nitro-1-indanone 29777-09-1P, N,N-Diethyl-3-butyn-1-amine 62078-76-6P, (7-Fluoronaphth-2-yl)amine 64241-01-6P, Methyl 2-amino-6-hydroxybenzoate 67765-42-8P, 5-Methoxy-2H-3,1-benzoxazine-2,4(1H)-dione 68701-22-4P, 2-Amino-5-isopropylbenzoic acid 68748-07-2P, N-(2-Bromo-4-isopropylphenyl)acetamide 69610-40-8P 69975-65-1P, 6-Amino-1-indanone 77758-50-0P 79069-38-8P, 2-(Acetylamino)-5-isopropylbenzoic acid 79979-69-4P, 2-Amino-1-naphthoic acid 86661-32-7P, tert-Butyl (2S)-2-([[(4-methylphenyl)sulfonyl]oxy]methyl)-1-pyrrolidinecarboxylate 90321-34-9P 90796-54-6P, 2,2-Dimethyl-3-(4-morpholinyl)-1-propanamine 91569-18-5P 96202-56-1P, 5-Ethyl-1H-indole-2,3-dione 115186-37-3P 116487-43-5P, 7-Bromo-1H-benzo[e]indole-1,2(3H)-dione 124341-06-6P, 6-Amino-3-bromo-2-methylbenzoic acid 126378-10-7P, Benzyl (4E)-5-(tributylstannyl)-4-pentenoate 126378-11-8P, Benzyl 4-pentynoate 132482-06-5P, tert-Butyl (2R)-2-(2-hydroxyethyl)-1-pyrrolidinecarboxylate 132734-41-9P, 2-Amino-5,6,7,8-tetrahydro-naphthalene-1-carboxylic acid methyl ester 135484-65-0P, Methyl 5-bromo-2-[(phenylsulfonyl)amino]benzoate 136247-94-4P, 2-[(tert-Butoxycarbonyl)amino]-6-methoxybenzoic acid 159539-65-8P, 2,2-Dimethyl-7-nitro-3,4-dihydro-1(2H)-naphthalenone 159873-21-9P, tert-Butyl 4-(2-cyanoacetyl)-1-piperazinecarboxylate 214697-98-0P, 7-Amino-8-bromo-3,4-dihydro-1(2H)-naphthalenone 239483-09-1P, tert-Butyl (2S)-2-(2-aminoethyl)-1-pyrrolidinecarboxylate 269391-47-1P, 2-[(tert-Butoxycarbonyl)amino]-6-methylbenzoic acid 373608-47-0P, 3-(4-Cyclopentyl-1-piperazinyl)-1-propanamine 550378-07-9P, tert-Butyl (2R)-2-(2-aminoethyl)-1-pyrrolidinecarboxylate 616224-61-4P, 2-[(tert-Butoxycarbonyl)amino]-6-chlorobenzoic acid **677291-24-6P**, 2-[[(2-Bromophenyl)sulfonyl]amino]-1-naphthoic acid 677291-25-7P, 2-Amino-7-fluoro-1-naphthoic acid 677291-27-9P, 2-Amino-6-bromo-1-naphthoic acid **681244-26-8P**, 3-Bromo-6-[[(2-fluorophenyl)sulfonyl]amino]-2-propoxybenzoic acid 681246-29-7P 681246-31-1P, Methyl 5-nitro-2-[(phenylsulfonyl)amino]benzoate 681246-32-2P, 6-Amino-5-quinolinecarboxylic acid 681246-33-3P, Methyl 6-amino-5-quinolinecarboxylate 681246-34-4P, Methyl 6-[(phenylsulfonyl)amino]-5-quinolinecarboxylate 681246-35-5P, Methyl 2-[[(4-fluorophenyl)sulfonyl]amino]-1-naphthoate 681246-36-6P, N-(1-Bromo-8-oxo-5,6,7,8-tetrahydro-2-naphthalenyl)-4-fluorobenzenesulfonamide 681246-37-7P, 3-Bromo-6-[(tert-butoxycarbonyl)amino]-2-methylbenzoic acid 681246-39-9P, Benzyl 3-bromo-6-[(tert-butoxycarbonyl)amino]-2-methylbenzoate 681246-40-2P, Benzyl 6-amino-3-cyano-2-methylbenzoate 681246-41-3P, Benzyl 3-cyano-2-methyl-6-[(phenylsulfonyl)amino]benzoate 681246-42-4P, Benzyl 3-bromo-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoate 681246-43-5P, Methyl 2-[(2-pyridinylsulfonyl)amino]-1-naphthoate 681246-44-6P, Benzyl 3-butyl-2-methyl-6-[(3-pyridinylsulfonyl)amino]benzoate 681246-45-7P, Benzyl 6-amino-3-bromo-2-methylbenzoate 681246-46-8P, Benzyl 3-bromo-6-[[(3-fluorophenyl)sulfonyl]amino]-2-methylbenzoate 681246-47-9P, tert-Butyl 1,2-dioxo-1,2-dihydro-3H-benzo[e]indole-3-carboxylate 681246-48-0P, 2-[(tert-Butoxycarbonyl)amino]-1-naphthoic acid 681246-49-1P, 6-Amino-7-bromo-1-indanone 681246-50-4P, N-(4-Bromo-3-oxo-2,3-dihydro-1H-inden-5-yl)benzenesulfonamide 681246-51-5P, Benzyl 2-methyl-6-[(2-pyridinylsulfonyl)amino]-3-vinylbenzoate 681246-52-6P, N-(1-Bromo-5,6-dihydro-2-naphthalenyl)-4-fluorobenzenesulfonamide 681246-53-7P, N-(1-Bromo-8-methyl-5,6-dihydro-2-naphthalenyl)-4-fluorobenzenesulfonamide 681246-54-8P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-1-naphthoate 681246-55-9P, Benzyl 6-[(tert-butoxycarbonyl)amino]-2-methyl-3-vinylbenzoate 681246-56-0P, 6-[(tert-Butoxycarbonyl)amino]-3-ethyl-2-methylbenzoic acid 681246-57-1P, Methyl 2-amino-3-chloro-1-naphthoate 681246-58-2P, Methyl 3-chloro-2-[[(4-fluorophenyl)sulfonyl]amino]-1-naphthoate 681246-59-3P, Benzyl 6-[(tert-butoxycarbonyl)amino]-2-methyl-3-propylbenzoate 681246-60-6P, Benzyl 6-amino-2-methyl-3-propylbenzoate 681246-61-7P,

Benzyl 2-methyl-3-propyl-6-[(2-pyridinylsulfonyl)amino]benzoate 681246-62-8P, Methyl 2-([[2-(methoxycarbonyl)phenyl]sulfonyl]amino)-1-naphthoate 681246-63-9P, 2-([[1-(Methoxycarbonyl)-2-naphthyl]amino]sulfonyl)benzoic acid 681246-64-0P, Methyl 2-[[(2-[[(3-methoxypropyl)amino]carbonyl]phenyl)sulfonyl]amino]-1-naphthoate 681246-65-1P, Benzyl 6-[[(4-fluorophenyl)sulfonyl]amino]-2-methyl-3-propylbenzoate 681246-66-2P, 3-Bromo-6-[(tert-butoxycarbonyl)amino]-2-methoxybenzoic acid 681246-67-3P, Methyl 2-([[2-(1-pyrrolidinylcarbonyl)phenyl]sulfonyl]amino)-1-naphthoate 681246-68-4P, Benzyl 3-bromo-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methylbenzoate 681246-69-5P, Benzyl 6-[[(2-fluorophenyl)sulfonyl]amino]-2-methyl-3-vinylbenzoate 681246-70-8P, Methyl 2-[([2-[(4-methyl-1-piperazinyl)carbonyl]phenyl]sulfonyl)amino]-1-naphthoate 681246-71-9P, Benzyl 3-[(1E)-3-methoxy-3-oxo-1-propenyl]-2-methyl-6-[(2-pyridinylsulfonyl)amino]benzoate 681246-72-0P, N-(1-Bromo-8-methyl-5,6,7,8-tetrahydro-2-naphthalenyl)-4-fluorobenzenesulfonamide 681246-73-1P, 3-Bromo-6-[(tert-butoxycarbonyl)amino]-2-chlorobenzoic acid 681246-74-2P, Benzyl 3-bromo-6-[(tert-butoxycarbonyl)amino]-2-chlorobenzoate 681246-75-3P, Benzyl 6-amino-3-bromo-2-chlorobenzoate 681246-76-4P, Benzyl 3-bromo-2-chloro-6-[[(4-fluorophenyl)sulfonyl]amino]benzoate 681246-77-5P, Benzyl 2-chloro-6-[[(4-fluorophenyl)sulfonyl]amino]-3-vinylbenzoate 681246-78-6P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681246-79-7P, Benzyl 3-bromo-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methylbenzoate 681246-80-0P, Benzyl 6-[[(4-fluorophenyl)sulfonyl]amino]-3-(hydroxymethyl)-2-methylbenzoate 681246-82-2P, Benzyl 6-[[(4-fluorophenyl)sulfonyl]amino]-3-(1-hydroxyethyl)-2-methylbenzoate 681246-83-3P, N-(1-Bromo-8-oxo-5,6,7,8-tetrahydro-2-naphthalenyl)-2-fluorobenzenesulfonamide 681246-84-4P, N-(1-Bromo-8-methyl-5,6-dihydro-2-naphthalenyl)-2-fluorobenzenesulfonamide 681246-85-5P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-8-methyl-5,6-dihydro-1-naphthalenecarboxylate 681246-86-6P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681246-87-7P, N-(1-Bromo-8-methyl-7-oxo-5,6,7,8-tetrahydro-2-naphthalenyl)-4-fluorobenzenesulfonamide 681246-88-8P, Methyl 2-([[2-([[2-(diethylamino)ethyl]amino]carbonyl)phenyl]sulfonyl]amino)-1-naphthoate 681246-89-9P, Benzyl 3-bromo-6-[(tert-butoxycarbonyl)amino]-2-methoxybenzoate 681246-90-2P, Benzyl 6-amino-3-bromo-2-methoxybenzoate 681246-91-3P, Benzyl 3-bromo-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxybenzoate 681246-92-4P, Benzyl 6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxy-3-vinylbenzoate 681246-93-5P, Benzyl 3-bromo-6-[[(4-fluorophenyl)sulfonyl]amino]-2-methoxybenzoate 681246-94-6P, N-(1-Bromo-7,8-dimethyl-5,8-dihydro-2-naphthalenyl)-2-fluorobenzenesulfonamide 681246-95-7P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-7,8-dimethyl-5,8-dihydro-1-naphthalenecarboxylate 681246-96-8P, Benzyl 3-bromo-2-methoxy-6-[(2-pyridinylsulfonyl)amino]benzoate 681246-97-9P, Benzyl 2-methoxy-6-[(2-pyridinylsulfonyl)amino]-3-vinylbenzoate 681246-98-0P, Benzyl 6-[[(4-fluorophenyl)sulfonyl]amino]-2-methoxy-3-vinylbenzoate 681246-99-1P, 7-Amino-8-bromo-2,2-dimethyl-3,4-dihydro-1(2H)-naphthalenone 681247-00-7P, N-(1-Bromo-7,7-dimethyl-8-oxo-5,6,7,8-tetrahydro-2-naphthalenyl)-2-fluorobenzenesulfonamide 681247-01-8P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-7,7-dimethyl-8-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-02-9P, N-(1-Bromo-8-methylene-5,6,7,8-tetrahydro-2-naphthalenyl)-2-fluorobenzenesulfonamide 681247-03-0P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-8-methylene-5,6,7,8-tetrahydro-1-naphthalenecarboxylate **681247-04-1P**, 3-Bromo-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxybenzoic acid 681247-05-2P, Methyl 2-([[2-(methoxycarbonyl)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-06-3P, 2-([[1-(Methoxycarbonyl)-5,6,7,8-tetrahydro-2-naphthalenyl]amino]sulfonyl)benzoic acid 681247-07-4P, Methyl 2-([[2-([[2-(diethylamino)ethyl]amino]carbonyl)phenyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-08-5P, Methyl 2-[[(2-[[[3-(dimethylamino)propyl](methyl)amino]carbonyl]phenyl)sulfonyl]amino]-1-naphthoate 681247-09-6P, 6-Bromo-5-methoxy-2H-3,1-benzoxazine-

2,4(1H)-dione 681247-10-9P, 6-Bromo-5-hydroxy-2H-3,1-benzoxazine-2,4(1H)-dione 681247-11-0P, Methyl 6-amino-3-bromo-2-hydroxybenzoate 681247-12-1P, Methyl 6-amino-3-bromo-2-ethoxybenzoate 681247-13-2P, Methyl 3-bromo-2-ethoxy-6-[[(2-fluorophenyl)sulfonyl]amino]benzoate 681247-14-3P, Methyl 2-ethoxy-6-[[(2-fluorophenyl)sulfonyl]amino]-3-vinylbenzoate 681247-15-4P, Methyl 2-ethoxy-3-ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]benzoate 681247-16-5P, 5-Hydroxy-2H-3,1-benzoxazine-2,4(1H)-dione 681247-17-6P, Methyl 2-amino-6-ethoxybenzoate 681247-18-7P, Methyl 2-ethoxy-6-[[(4-fluorophenyl)sulfonyl]amino]benzoate 681247-19-8P, Methyl 3-bromo-2-ethoxy-6-[[(4-fluorophenyl)sulfonyl]amino]benzoate 681247-20-1P, Methyl 2-ethoxy-6-[[(4-fluorophenyl)sulfonyl]amino]-3-vinylbenzoate 681247-21-2P, Methyl 2-ethoxy-3-ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]benzoate 681247-22-3P, 2,2-Dimethyl-3-oxo-3-(1-piperidinyl)propanenitrile 681247-23-4P, 2,2-Dimethyl-3-(1-piperidinyl)-1-propanamine **681247-24-5P** 681247-25-6P 681247-26-7P, 2,2-Dimethyl-3-oxo-3-(1-pyrrolidinyl)propanenitrile 681247-27-8P, 2,2-Dimethyl-3-(1-pyrrolidinyl)-1-propanamine 681247-28-9P, 2-Ethyl-2-(1-piperidinylmethyl)-1-butanamine 681247-29-0P, Methyl 6-amino-3-bromo-2-propoxybenzoate 681247-30-3P, Methyl 3-bromo-6-[[(2-fluorophenyl)sulfonyl]amino]-2-propoxybenzoate 681247-31-4P 681247-32-5P 681247-33-6P 681247-34-7P, Methyl 2-[[(2-nitrophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-35-8P, Methyl 2-[[(2-aminophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-36-9P, Methyl 6-[[(2-fluorophenyl)sulfonyl]amino]-2-propoxy-3-vinylbenzoate 681247-37-0P, Methyl 3-ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]-2-propoxybenzoate 681247-38-1P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-8-oxo-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-39-2P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-8-methoxy-5,6-dihydro-1-naphthalenecarboxylate 681247-40-5P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-8-methoxy-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-41-6P, Methyl 3-([[1-(methoxycarbonyl)-5,6,7,8-tetrahydro-2-naphthalenyl]amino]sulfonyl)-2-thiophenecarboxylate 681247-42-7P, 3-([[1-(Methoxycarbonyl)-5,6,7,8-tetrahydro-2-naphthalenyl]amino]sulfonyl)-2-thiophenecarboxylic acid 681247-43-8P, Methyl 2-([[2-([[2-(diethylamino)ethyl]amino]carbonyl)-3-thienyl]sulfonyl]amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-44-9P, Methyl 6-amino-3-bromo-2-(2-methoxy-2-oxoethoxy)benzoate 681247-45-0P, Methyl 3-bromo-6-[[(4-fluorophenyl)sulfonyl]amino]-2-(2-methoxy-2-oxoethoxy)benzoate 681247-46-1P, Methyl 6-[[(4-fluorophenyl)sulfonyl]amino]-2-(2-methoxy-2-oxoethoxy)-3-vinylbenzoate 681247-47-2P, Methyl 3-ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]-2-(2-methoxy-2-oxoethoxy)benzoate 681247-48-3P, Methyl 6-amino-3-bromo-2-methoxybenzoate 681247-49-4P, Methyl 3-bromo-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxybenzoate 681247-50-7P, Methyl 6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxy-3-vinylbenzoate 681247-51-8P, Methyl 3-ethyl-6-[[(2-fluorophenyl)sulfonyl]amino]-2-methoxybenzoate 681247-52-9P, Methyl 3-bromo-5-ethyl-2-[[(2-fluorophenyl)sulfonyl]amino]-6-methoxybenzoate 681247-53-0P, Methyl 5-ethyl-2-[[(2-fluorophenyl)sulfonyl]amino]-4-methoxy-1,1'-biphenyl-3-carboxylate 681247-54-1P, Methyl 2-amino-3-bromo-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-55-2P, Methyl 2-amino-3-[(1E)-3-tert-butoxy-3-oxo-1-propenyl]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-56-3P, Methyl 3-[(1E)-3-tert-butoxy-3-oxo-1-propenyl]-2-[(phenylsulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-57-4P 681247-58-5P, Methyl 2-[methyl-([2-[(4-piperidinylmethyl)amino]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-59-6P, Methyl 2-chloro-6-[[(2-fluorophenyl)sulfonyl]amino]benzoate 681247-60-9P, Methyl 2-[(1E)-5-(benzyloxy)-5-oxo-1-pentenyl]-6-[[(2-fluorophenyl)sulfonyl]amino]benzoate 681247-61-0P, 5-[3-[[(2-Fluorophenyl)sulfonyl]amino]-2-(methoxycarbonyl)phenyl]pentanoic acid 681247-62-1P 681247-63-2P 681247-64-3P 681247-65-4P, Methyl 2-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-

naphthalenecarboxylate 681247-66-5P, Methyl 2-[[(2-([[4-(diethylamino)-1-methylbutyl]amino]carbonyl)-4-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-67-6P, Methyl 6-amino-3-bromo-2-[2-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]benzoate 681247-68-7P, Methyl 6-amino-2-[2-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-vinylbenzoate 681247-69-8P, Methyl 6-amino-3-ethyl-2-[2-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]benzoate 681247-70-1P, Methyl 2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]benzoate 681247-71-2P, Methyl 6-[[(2-bromophenyl)sulfonyl]amino]-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethylbenzoate 681247-72-3P, Methyl 6-[[(2-[(1E)-3,3-dimethyl-1-butenyl]phenyl)sulfonyl]amino]-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethylbenzoate 681247-73-4P, Methyl 6-[[(2-(3,3-dimethylbutyl)phenyl)sulfonyl]amino]-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethylbenzoate 681247-74-5P, Methyl 2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethyl-6-[([2-[(1E)-1-propenyl]phenyl]sulfonyl)amino]benzoate 681247-75-6P, Methyl 2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethyl-6-[([2-propylphenyl]sulfonyl)amino]benzoate 681247-76-7P, N,N-Diethyl-N-[(3Z)-4-(tributylstannyl)-3-butenyl]amine 681247-77-8P, N,N-Diethyl-N-[(3E)-4-(tributylstannyl)-3-butenyl]amine 681247-78-9P, Methyl 2-[([2-[(1E)-4-(diethylamino)-1-butenyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-79-0P, tert-Butyl (2S)-2-(2-[[(benzyloxy)carbonyl]amino]ethyl)-1-pyrrolidinecarboxylate 681247-80-3P 681247-81-4P 681247-82-5P 681247-83-6P 681247-84-7P, 2,2-Dimethyl-3-(4-morpholinyl)-3-oxopropanenitrile 681247-85-8P 681247-86-9P 681247-87-0P, N,N-Diethyl-N-[(2E)-3-(tributylstannyl)-2-propenyl]amine 681247-88-1P, N,N-Diethyl-N-[(2Z)-3-(tributylstannyl)-2-propenyl]amine 681247-89-2P, Methyl 2-[([2-[(1E)-3-(diethylamino)-1-propenyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-90-5P, Methyl 2-[([2-[4-(diethylamino)butyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-91-6P, Methyl 2-[([2-[(1Z)-3-(diethylamino)-1-propenyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-92-7P, Methyl 2-[([2-[(1Z)-4-(diethylamino)-1-butenyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681247-93-8P, Methyl 2-amino-3,5-dibromo-6-methoxybenzoate 681247-94-9P, Methyl 2-amino-6-methoxy-3,5-divinylbenzoate 681247-95-0P, Methyl 2-[[(2-fluorophenyl)sulfonyl]amino]-6-methoxy-3,5-divinylbenzoate 681247-96-1P, Methyl 3,5-diethyl-2-[[(2-fluorophenyl)sulfonyl]amino]-6-methoxybenzoate 681247-97-2P, Methyl 6-amino-2-methoxy-3-vinylbenzoate 681247-98-3P, Methyl 6-amino-3-ethyl-2-methoxybenzoate 681247-99-4P, Methyl 6-[[(2-bromophenyl)sulfonyl]amino]-3-ethyl-2-methoxybenzoate 681248-00-0P, Methyl 6-[[(2-[(1E)-2-(4-chlorophenyl)ethenyl]phenyl)sulfonyl]amino]-3-ethyl-2-methoxybenzoate 681248-01-1P, Methyl 3-ethyl-2-methoxy-6-([[2-(2-phenylethyl)phenyl]sulfonyl]amino)benzoate 681248-02-2P, Methyl 6-[([2-[2-(4-chlorophenyl)ethyl]phenyl]sulfonyl)amino]-3-ethyl-2-methoxybenzoate 681248-03-3P, Methyl 3-ethyl-2-methoxy-6-[[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]benzoate 681248-04-4P, Methyl 6-[[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]amino]-3-ethyl-2-methoxybenzoate 681248-05-5P, Methyl 6-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethylbenzoate 681248-06-6P, Methyl 6-amino-3-bromo-2-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propoxy]benzoate 681248-07-7P, Methyl 6-amino-2-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propoxy]-3-vinylbenzoate 681248-08-8P, Methyl 6-amino-2-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propoxy]-3-ethylbenzoate 681248-09-9P, Methyl 6-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-2-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propoxy]-3-ethylbenzoate 681248-10-2P, Methyl 2-amino-3,5-diethyl-6-methoxybenzoate 681248-11-3P, Methyl 2-[([2-[3-(diethylamino)propyl]phenyl]sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681248-12-4P, N,N-Diethyl-N-[(4E)-5-(tributylstannyl)-4-pentenyl]amine 681248-13-5P, N,N-Diethyl-N-[(4Z)-5-(tributylstannyl)-4-pentenyl]amine 681248-14-6P 681248-15-7P 681248-16-8P, Methyl 2-[([2-[5-(diethylamino)pentyl]phenyl]sulfonyl)amino]-

5,6,7,8-tetrahydro-1-naphthalenecarboxylate 681248-17-9P, Methyl 2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethyl-6-[[(4-fluoro-2-vinylphenyl)sulfonyl]amino]benzoate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

IT 681248-18-0P, Methyl 2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-3-ethyl-6-[[(2-ethyl-4-fluorophenyl)sulfonyl]amino]benzoate 681248-19-1P 681248-20-4P 681248-21-5P 681248-22-6P 681248-23-7P 681248-24-8P, tert-Butyl 4-(3-amino-2,2-dimethylpropanoyl)-1-piperazinecarboxylate 681248-25-9P, Methyl 6-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-3-ethyl-2-methoxybenzoate 681248-26-0P, Methyl 3-ethyl-6-[[(4-fluoro-2-(4-hydroxy-1-butynyl)phenyl)sulfonyl]amino]-2-methoxybenzoate 681248-27-1P, Methyl 3-ethyl-6-[[(4-fluoro-2-(4-hydroxybutyl)phenyl)sulfonyl]amino]-2-methoxybenzoate 681248-28-2P, Methyl 3-ethyl-6-[[(4-fluoro-2-(4-[(methylsulfonyl)oxy]butyl)phenyl)sulfonyl]amino]-2-methoxybenzoate 681248-29-3P, Methyl 3-ethyl-6-[[(4-fluoro-2-(4-[2-methyl-1-pyrrolidinyl]butyl)phenyl)sulfonyl]amino]-2-methoxybenzoate 681248-30-6P, Methyl 6-[[(2-[4-(diethylamino)butyl]-4-fluorophenyl)sulfonyl]amino]-3-ethyl-2-methoxybenzoate 681255-11-8P, Benzyl 6-[[(4-fluorophenyl)sulfonyl]amino]-2-methyl-3-vinylbenzoate 681255-13-0P, Benzyl 2-chloro-6-[[(2-fluorophenyl)sulfonyl]amino]-3-vinylbenzoate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) American Cyanamid Company; WO 9816503 A 1998 HCAPLUS
(2) American Cyanamid Company; WO 9816506 A 1998 HCAPLUS
(3) American Cyanamid Company; WO 9816514 A 1998 HCAPLUS
(4) American Cyanamid Company; WO 9816520 A 1998 HCAPLUS
(5) Anon; BULL CHEM SOC JPN 1967, V40, P2844
(6) Anon; CHEM BER 1943, V76, P128
(7) Anon; CHEM HETEROCYCL COMPD 1971, V7, P964
(8) Anon; CHEM HETEROCYCL COMPD 1972, V8, P1212
(9) Anon; CHEM HETEROCYCL COMPD 1972, V8, P557
(10) Anon; CHEM PHARM BULL 1993, V41(5), P894
(11) Anon; HETEROCYCLES 1993, V36(9), P2109
(12) Anon; J AM CHEM SOC 1945, V67, P1711
(13) Anon; J AM CHEM SOC 1987, V109(21), P6493
(14) Anon; J CHEM SOC 1950, P961
(15) Anon; J CHEM SOC PERKIN TRANS I 1973, P1602
(16) Anon; J CHEM SOC PERKIN TRANS I 1973, P2313
(17) Anon; J HETEROCYCL CHEM 1993, V30(6), P1613
(18) Anon; J MED CHEM 1981, V24(9), P1097
(19) Anon; J MED CHEM 1990, V33(5), P1312
(20) Anon; J ORG CHEM 1973, V38, P1512
(21) Anon; J ORG CHEM 1988, V53(7), P1380
(22) Anon; NIPPON KAGAKU KAISHI 1978, P723
(23) Anon; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2002, V99(15), P10066
(24) Anon; SYNTHESIS 1981, V6, P487
(25) Anon; SYNTHESIS 1989, V4, P280
(26) Anon; TETRAHEDRON 1988, V44(5), P1465
(27) Ewins, A; US 2335221 A 1943 HCAPLUS
(28) I G Farbenindustrie Akt Ges; DE 686644 C 1940
(29) Liu, J; US 6207704 B1 2001 HCAPLUS
(30) Senju Seiyaku Kk; JP 2001240581 A 2001 HCAPLUS
(31) Wien, O; AT 272351 B 1969 HCAPLUS

IT **677290-81-2P**, 2-[(Phenylsulfonyl)amino]-1-naphthoic acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of sulfonamides having antiangiogenic and anticancer activity)

RN 677290-81-2 HCAPLUS

CN 1-Naphthalenecarboxylic acid, 2-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



L67 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN ✓
AN 2004:293400 HCAPLUS
DN 140:315047
ED Entered STN: 09 Apr 2004
TI Sulfonamides having antiangiogenic and anticancer activity
IN **Comess, Kenneth M.; Erickson, Scott A.; Henkin, Jack; Kalvin, Douglas M.; Kawai, Megumi; Kim, Ki Hwan; Bamaung, Nwe Y.; Park, Chang Hoon ; Sheppard, George S.; Vasudevan, Anil; Wang, Jieyi**
PA USA
SO U.S. Pat. Appl. Publ., 26 pp.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K031-195
INCL 514562000; 562430000
CC 1-6 (Pharmacology)
Section cross-reference(s): 27, 28, 63
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004068012	A1	20040408	US 2002-267081	20021008
	US 2004157836	A1	20040812	US 2003-667358	20030923
	CA 2501520	AA	20040422	CA 2003-2501520	20031006
	WO 2004033419	A1	20040422	WO 2003-US31671	20031006
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1549613	A1	20050706	EP 2003-773182	20031006
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-267081	A2	20021008		
	US 2003-667358	A	20030923		
	WO 2003-US31671	W	20031006		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004068012	ICM	A61K031-195
	INCL	514562000; 562430000
US 2004068012	NCL	514/562.000
	ECLA	C07C311/08; C07C311/13; C07C311/29; C07C311/37; C07C311/44; C07C311/46; C07C317/28; C07C323/25D2; C07C323/49; C07C323/63; C07C323/67; C07D209/08; C07D209/42; C07D213/70C; C07D213/71; C07D215/36; C07D215/48; C07D231/18; C07D233/54C; C07D233/84;

C07D261/10B; C07D285/06; C07D285/14D; C07D333/34;
C07D333/38; C07D413/04; C07D413/04+333B+261
US 2004157836 NCL 514/227.200
ECLA C07C311/08; C07C311/13; C07C311/29; C07C311/37;
C07C311/44; C07C311/46; C07C317/28; C07C323/25D2;
C07C323/49; C07C323/63; C07C323/67; C07D209/08;
C07D209/42; C07D213/70C; C07D213/71; C07D215/36;
C07D215/48; C07D231/18; C07D233/54C; C07D233/84;
C07D261/10B; C07D285/06; C07D285/14D; C07D333/34;
C07D333/38; C07D413/04; C07D413/04+333B+261
CA 2501520 ECLA C07C311/08; C07C311/13; C07C311/21; C07C311/29;
C07C311/37; C07C311/44; C07C311/46; C07C317/28;
C07C323/25D2; C07C323/49; C07C323/63; C07C323/67;
C07D209/08; C07D213/71; C07D215/36; C07D215/48;
C07D231/18; C07D233/54C; C07D233/84; C07D261/10B;
C07D285/14D; C07D333/34; C07D333/38;
C07D413/04+333B+261
WO 2004033419 ECLA C07C311/08; C07C311/13; C07C311/21; C07C311/29;
C07C311/37; C07C311/44; C07C311/46; C07C317/28;
C07C323/25D2; C07C323/49; C07C323/63; C07C323/67;
C07D209/08; C07D213/71; C07D215/36; C07D215/48;
C07D231/18; C07D233/54C; C07D233/84; C07D261/10B;
C07D285/14D; C07D333/34; C07D333/38;
C07D413/04+333B+261
EP 1549613 ECLA C07C311/08; C07C311/13; C07C311/21; C07C311/29;
C07C311/37; C07C311/44; C07C311/46; C07C317/28;
C07C323/25D2; C07C323/49; C07C323/63; C07C323/67;
C07D209/08; C07D213/71; C07D215/36; C07D215/48;
C07D231/18; C07D233/54C; C07D233/84; C07D261/10B;
C07D285/14D; C07D333/34; C07D333/38;
C07D413/04+333B+261

AB Compds. having methionine aminopeptidase-2 inhibitory (MetAP2) are described. Also described are pharmaceutical compns. comprising the compds., methods of treatment using the compds., methods of inhibiting angiogenesis, and methods of treating cancer.

ST sulfonamide antiangiogenic anticancer methionine aminopeptidase 2 inhibitor

IT Proteins
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(eukaryotic initiation factor-2-associated, p67, inhibitors; sulfonamides having antiangiogenic and anticancer activity)

IT Angiogenesis inhibitors
Antitumor agents
Drug delivery systems
Human
(sulfonamides having antiangiogenic and anticancer activity)

IT Sulfonamides
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(sulfonamides having antiangiogenic and anticancer activity)

IT **134864-08-7P 677290-35-6P 677290-36-7P**
677290-37-8P 677290-38-9P 677290-39-0P
677290-40-3P 677290-41-4P 677290-42-5P
677290-43-6P 677290-44-7P 677290-45-8P
677290-46-9P 677290-47-0P 677290-48-1P
677290-49-2P 677290-50-5P 677290-51-6P
677290-52-7P 677290-53-8P 677290-54-9P
677290-55-0P 677290-56-1P 677290-57-2P
677290-58-3P 677290-59-4P 677290-60-7P
677290-61-8P 677290-62-9P 677290-63-0P
677290-64-1P 677290-65-2P 677290-66-3P
677290-67-4P 677290-68-5P 677290-69-6P
677290-70-9P 677290-71-0P 677290-72-1P

677290-73-2P 677290-74-3P 677290-75-4P
677290-76-5P 677290-77-6P 677290-78-7P
677290-79-8P 677290-80-1P 677290-81-2P
677290-82-3P 677290-83-4P 677290-84-5P
677290-85-6P 677290-86-7P 677290-87-8P
677290-88-9P 677290-89-0P 677290-90-3P
677290-91-4P 677290-92-5P 677290-93-6P
677290-94-7P 677290-95-8P 677290-96-9P
677290-97-0P 677290-98-1P 677290-99-2P
677291-00-8P 677291-01-9P 677291-02-0P
677291-03-1P 677291-04-2P 677291-05-3P
677291-06-4P 677291-07-5P 677291-08-6P
677291-09-7P 677291-10-0P 677291-11-1P
677291-12-2P 677291-13-3P 677291-14-4P
677291-15-5P 677291-16-6P 677291-17-7P
677291-18-8P 677291-19-9P 677291-20-2P
677291-21-3P 677291-22-4P 677291-23-5P
677297-03-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(sulfonamides having antiangiogenic and anticancer activity)

IT 91-59-8, 2-Naphthalenamine 98-09-9, Benzenesulfonyl chloride 108-24-7 109-76-2, 1,3-Propanediamine 302-17-0 349-88-2 589-16-2 2905-25-1 3230-36-2 5470-11-1 51605-97-1 126403-67-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(sulfonamides having antiangiogenic and anticancer activity)

IT 2475-82-3P 5588-87-4P, 1H-Benz[e]indole-1,2(3H)-dione 17122-70-2P 62078-76-6P 68701-22-4P 68748-07-2P 79069-38-8P 79979-69-4P 96202-56-1P 135484-65-0P **677291-24-6P** 677291-25-7P 677291-26-8P 677291-27-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(sulfonamides having antiangiogenic and anticancer activity)

IT **134864-08-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(sulfonamides having antiangiogenic and anticancer activity)

RN 134864-08-7 HCAPLUS
CN 1-Naphthalenecarboxylic acid, 2-[[(4-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



L67 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:502539 HCAPLUS
DN 129:135923
ED Entered STN: 13 Aug 1998
TI Cyclobutane derivatives as inhibitors of squalene synthetase and protein farnesyltransferase
IN Baker, William R.; Rosenberg, Saul H.; Fung, Anthony K. L.; Rockway, Todd W.; Fakhoury, Stephen A.; Garvey, David S.; Donner, B. Gregory; O'Connor, Stephen J.; Prasad, Rajnandan N.; Shen, Wang; Stout, David M.; Sullivan, Gerard M.
PA **Abbott Laboratories**, USA
SO U.S., 103 pp., Cont.-in-part of U.S. Ser. No. 429,095, abandoned.
CODEN: USXXAM

DT Patent
LA English
IC ICM A61K031-16
ICS A61K031-19; A61K031-215; A61K031-41
INCL 514381000
CC 24-3 (Alicyclic Compounds)
Section cross-reference(s): 1, 63
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5783593	A	19980721	US 1996-633262	19960429
	WO 9634851	A1	19961107	WO 1996-US6193	19960502
	W: AU, CA, JP, KR, MX				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9656731	A1	19961121	AU 1996-56731	19960502
PRAI	US 1993-147708	B2'	19931104		
	US 1994-289711	B2	19940909		
	US 1994-322783	B2	19941018		
	US 1995-429095	B2	19950503		
	US 1996-633262	A	19960429		
	WO 1996-US6193	W	19960502		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 5783593	ICM	A61K031-16
	ICS	A61K031-19; A61K031-215; A61K031-41
	INCL	514381000
US 5783593	NCL	514/381.000; 514/018.000; 514/019.000; 514/533.000; 514/542.000; 514/557.000; 514/559.000; 514/561.000; 514/562.000; 514/563.000; 514/572.000; 514/613.000; 514/616.000; 514/617.000; 514/619.000; 514/621.000; 514/729.000; 530/330.000; 530/331.000; 548/251.000; 548/253.000; 548/254.000; 560/019.000; 560/037.000; 560/045.000; 560/048.000; 560/049.000; 560/076.000; 560/123.000; 562/405.000; 562/426.000; 562/433.000; 562/442.000; 562/443.000; 562/452.000; 562/465.000; 562/480.000; 562/488.000; 562/489.000; 562/505.000; 562/553.000; 562/607.000; 564/057.000; 564/152.000; 564/153.000; 564/155.000; 564/161.000; 564/163.000; 564/164.000; 564/169.000; 564/180.000
	ECLA	C07C311/51; C07D271/10D3; C07D309/32; C07D319/06

OS MARPAT 129:135923
GI



AB The invention provides compds. I [A1, A2 = -XC(O)G, -XC(S)G, -(CH2)qNR1R2; X = bond, CH2, O, S, (un)substituted NH; G = R2, NR1R2, OR2, SR2; R1 = H,

alkyl, alkenyl, (un)substituted aryl, heterocyclyl, etc.; R2 = alkenyl, (un)substituted aryl, heterocyclyl, etc.; q = 0-2; B1, B2 = CH2OH, CH:NOH, WR3, etc.; W = bond, alkylene, alkenylene, CONH, NHCONH; R3 = various (un)substituted heterocyclic groups or squaric acid residue]. Also disclosed are preparation processes, intermediates, pharmaceutical compns., and treatment of hypercholesterolemic disorders (hyperlipidemia, atherosclerosis) , cancer, or fungal infections using the compds. I inhibit biosynthesis of cholesterol (and also fungal growth) by inhibiting squalene synthetase. I also inhibit farnesylation of the oncogene protein Ras by inhibiting protein farnesyltransferase (no data). For example, aminolysis of 1,2,3,4-cyclobutanetetracarboxylic dianhydride with 2 equiv 4-(PhO)C6H4CH2NHPr, followed by monoesterification of the resultant diacid with (R)-(-)-sec-phenethyl alc., separation of one diastereomer, hydrogenolytic deesterification to a single diacid enantiomer, diesterification of this with diazomethane, and partial hydrolysis with LiOH, gave claimed title compound (-)-II. A large group of tested compds. I gave 50-99% inhibition of rat liver microsomal squalene synthetase at 10 μM in vitro. Approx. 380 synthetic examples (over 185 compds. with data) are given.

ST cyclobutane inhibitor squalene synthetase protein farnesyltransferase; cholesterol biosynthesis inhibitor cyclobutane prepn; antitumor cyclobutane prepn; antifungal cyclobutane prepn

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of cyclobutane derivs. as inhibitors of squalene synthetase and protein farnesyltransferase)

IT G proteins (guanine nucleotide-binding proteins)
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(gene RAS, inhibitors of farnesylation of; preparation of cyclobutane derivs. as inhibitors of squalene synthetase and protein farnesyltransferase)

IT Ras proteins
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(inhibitors of farnesylation of; preparation of cyclobutane derivs. as inhibitors of squalene synthetase and protein farnesyltransferase)

IT Farnesylation
(inhibitors; preparation of cyclobutane derivs. as inhibitors of squalene synthetase and protein farnesyltransferase)

IT Anticholesteremic agents
Antitumor agents
Fungicides
Hypolipemic agents
(preparation of cyclobutane derivs. as inhibitors of squalene synthetase and protein farnesyltransferase)

IT 57-88-5, Cholesterol, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
(biosynthesis inhibitors; preparation of cyclobutane derivs. as inhibitors of squalene synthetase and protein farnesyltransferase)

IT 169943-31-1P 169943-32-2P 169943-33-3P 169943-34-4P 169943-35-5P 169943-36-6P 169943-37-7P 169943-38-8P 169943-39-9P
RL: BYP (Byproduct); PREP (Preparation)
(byproduct; preparation of cyclobutane derivs. as inhibitors of squalene synthetase and protein farnesyltransferase)

IT 169943-15-1P
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of cyclobutane derivs. as inhibitors of squalene synthetase and protein farnesyltransferase)

IT 2215-78-3P 2303-25-5P 4973-29-9P, 4-Phenoxystyrene 6053-81-2P, Cyclopentanemethanamine 10194-09-9P 16282-41-0P 22325-80-0P 24789-49-9P, 4-(3-Methylphenoxy)benzonitrile 31719-76-3P, 4-(Phenoxymethyl)benzoic acid 36881-42-2P 52446-51-2P 56355-19-2P, Ethyl 4-(thiazol-2-yloxy)benzoate 56705-84-1P, 4-(3-Methylphenoxy)aniline 60698-30-8P, 5-Phenoxy-2-furaldehyde

61343-83-7P, 4-(4-Methylphenoxy)benzaldehyde 61343-84-8P,
4-(3-Methylphenoxy)benzaldehyde 63343-66-8P 70278-64-7P 73420-63-0P
73461-23-1P 79124-75-7P, 3-Methyl-4-phenoxybenzaldehyde 100005-68-3P,
Ethyl 4-(furan-2-yloxy)benzoate 101480-26-6P, N-(4-
Phenoxyphenyl)propionamide 107622-80-0P 111480-00-3P,
5-Phenoxythiophene-2-carboxaldehyde 112430-87-2P 115510-54-8P
118468-18-1P 120375-17-9P, 4-(Cyclohex-2-enyloxy)benzaldehyde
122594-72-3P 124397-37-1P, Methyl 4-(phenoxymethyl)benzoate
129535-80-4P 132747-89-8P 142800-65-5P 143426-60-2P 158771-13-2P,
4-(2-Naphthyloxy)benzaldehyde 169942-83-0P 169942-84-1P 169942-85-2P
169942-86-3P 169942-87-4P 169942-88-5P 169942-89-6P 169942-90-9P
169942-91-0P 169942-92-1P 169942-93-2P 169942-94-3P 169942-95-4P
169942-96-5P 169942-97-6P 169942-98-7P 169942-99-8P 169943-00-4P
169943-01-5P 169943-02-6P 169943-03-7P 169943-04-8P 169943-05-9P
169943-06-0P 169943-07-1P 169943-08-2P 169943-09-3P 169943-10-6P
169943-11-7P 169943-12-8P 169943-13-9P 169943-14-0P 169943-16-2P
169943-17-3P 169943-18-4P 169943-19-5P 169943-20-8P 169943-21-9P
169943-22-0P 169943-23-1P 169943-24-2P 169943-25-3P 169943-26-4P
169943-27-5P 169943-28-6P 169943-29-7P 169943-30-0P 169943-40-2P
169943-41-3P 169943-42-4P 169943-43-5P 169943-44-6P,
N-[2-(4-Phenoxyphenyl)ethyl]propionamide 169943-45-7P 169943-46-8P,
N-Propyl-4-phenoxyaniline 169943-47-9P 169943-48-0P 169943-49-1P
169943-50-4P 169943-51-5P 169943-52-6P 169943-53-7P 169943-54-8P
169943-55-9P 169943-56-0P 169943-57-1P, N-(4-
Phenoxybenzyl)cyclobutanecarboxamide 169943-58-2P 169943-59-3P
169943-60-6P 169943-61-7P 169943-62-8P 169943-63-9P 169943-64-0P
169943-65-1P 169943-66-2P, 4-(Phenylamino)-N-propylbenzamide
169943-67-3P 169943-68-4P 169943-69-5P 169943-70-8P 169943-71-9P
169943-72-0P 169943-73-1P 169943-74-2P, 4-(Furan-2-yloxy)benzaldehyde
169943-75-3P 169943-76-4P 169943-77-5P, 4-(Thiazol-2-
yloxy)benzaldehyde 169943-78-6P 169943-79-7P 169943-80-0P
169943-81-1P 169943-82-2P 169943-83-3P 169943-84-4P 169943-85-5P
169943-86-6P, 4-(1-Naphthyloxy)benzaldehyde 169943-87-7P 169943-88-8P
169943-89-9P 169943-90-2P 169943-91-3P 170207-72-4P 171349-83-0P
184488-11-7P 185209-93-2P 185209-94-3P 185209-95-4P 185209-96-5P
185209-97-6P 185209-98-7P 185209-99-8P 185210-00-8P 185210-02-0P
185210-03-1P 185210-05-3P 185210-06-4P 185210-07-5P 185210-08-6P
185210-09-7P 185210-10-0P 185210-11-1P 185210-12-2P 185210-13-3P
185210-14-4P 185210-15-5P 185210-16-6P 185210-17-7P 185210-18-8P
185210-19-9P 185210-21-3P 185210-22-4P 185210-23-5P 185210-24-6P
185210-25-7P 185210-26-8P 185210-27-9P 185210-28-0P 185210-29-1P
185210-30-4P 185210-31-5P 185210-32-6P 185210-33-7P 185210-34-8P
185210-35-9P 185210-36-0P 185210-37-1P 185254-81-3P 185254-82-4P
185254-83-5P 210643-45-1P 210643-46-2P 210643-47-3P 210643-48-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(intermediate; preparation of cyclobutane derivs. as inhibitors of squalene
synthetase and protein farnesyltransferase)

IT 169942-32-9P 169942-55-6P 169942-56-7P 169942-61-4P 185209-71-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT
(Reactant or reagent); USES (Uses)
(preparation of cyclobutane derivs. as inhibitors of squalene synthetase and
protein farnesyltransferase)

IT 169941-79-1P 169941-80-4P 169941-81-5P 169941-82-6P 169941-83-7P
169941-84-8P 169941-85-9P 169941-86-0P 169941-87-1P 169941-88-2P
169941-89-3P 169941-90-6P 169941-91-7P 169941-92-8P 169941-93-9P
169941-94-0P 169941-95-1P 169941-96-2P 169941-97-3P 169941-98-4P
169941-99-5P 169942-00-1P 169942-01-2P 169942-02-3P 169942-03-4P
169942-04-5P 169942-05-6P 169942-06-7P 169942-07-8P 169942-08-9P
169942-09-0P 169942-10-3P 169942-11-4P 169942-12-5P 169942-13-6P
169942-14-7P 169942-15-8P 169942-16-9P 169942-17-0P 169942-18-1P
169942-19-2P 169942-20-5P 169942-21-6P 169942-22-7P 169942-23-8P
169942-24-9P 169942-25-0P 169942-26-1P 169942-27-2P 169942-28-3P
169942-29-4P 169942-30-7P 169942-31-8P 169942-33-0P 169942-34-1P

169942-35-2P 169942-36-3P 169942-37-4P 169942-38-5P 169942-39-6P
169942-40-9P 169942-41-0P 169942-42-1P 169942-43-2P 169942-44-3P
169942-45-4P 169942-46-5P 169942-47-6P 169942-48-7P 169942-49-8P
169942-50-1P 169942-51-2P 169942-52-3P 169942-53-4P 169942-54-5P
169942-57-8P 169942-58-9P **169942-59-0P** 169942-60-3P
169942-62-5P 169942-63-6P 169942-64-7P 169942-65-8P 169942-66-9P
169942-67-0P 169942-68-1P 169942-69-2P 169942-70-5P 169942-71-6P
169942-72-7P 169942-73-8P 169942-74-9P 169942-75-0P 169942-76-1P
169942-77-2P 169942-78-3P 169942-79-4P 169942-80-7P 169942-81-8P
169942-82-9P 169944-08-5P 169944-09-6P 170207-64-4P 170207-65-5P
170207-66-6P 170207-67-7P 170207-68-8P 170207-69-9P 170207-70-2P
170207-71-3P 170207-73-5P 170207-74-6P 185209-36-3P 185209-37-4P
185209-38-5P 185209-39-6P 185209-40-9P 185209-41-0P 185209-42-1P
185209-43-2P 185209-44-3P 185209-45-4P 185209-46-5P 185209-47-6P
185209-48-7P 185209-49-8P 185209-50-1P 185209-51-2P 185209-52-3P
185209-53-4P 185209-54-5P 185209-55-6P 185209-57-8P 185209-58-9P
185209-59-0P 185209-61-4P 185209-62-5P 185209-63-6P 185209-64-7P
185209-65-8P 185209-66-9P 185209-67-0P 185209-68-1P 185209-69-2P
185209-70-5P 185209-72-7P 185209-73-8P 185209-74-9P 185209-75-0P
185209-76-1P 185209-77-2P 185209-78-3P 185209-79-4P 185209-80-7P
185209-81-8P 185209-82-9P 185209-83-0P 185209-84-1P 185209-85-2P
185254-41-5P 185254-51-7P 185254-60-8P 185254-68-6P 185254-69-7P
185254-70-0P 185254-77-7P 185254-78-8P 185254-79-9P 185254-80-2P
210643-32-6P 210643-34-8P 210643-35-9P 210643-36-0P 210643-37-1P
210643-38-2P 210643-39-3P 210643-40-6P 210643-41-7P 210643-42-8P
210643-43-9P 210643-44-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclobutane derivs. as inhibitors of squalene synthetase and protein farnesyltransferase)

IT 9077-14-9, Squalene synthetase 131384-38-8, Protein farnesyltransferase
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(preparation of cyclobutane derivs. as inhibitors of squalene synthetase and protein farnesyltransferase)

IT 185210-20-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of cyclobutane derivs. as inhibitors of squalene synthetase and protein farnesyltransferase)

IT 64-04-0, Phenethylamine 67-36-7, 4-Phenoxybenzaldehyde 74-89-5, Methylamine, reactions 78-81-9, Isobutylamine 79-03-8, Propionyl chloride 90-15-3, 1-Naphthalenol 100-46-9, Benzylamine, reactions 100-51-6, Benzenemethanol, reactions 101-54-2, N-Phenyl-1,4-phenylenediamine 103-49-1, N,N-Dibenzylamine 104-88-1, 4-Chlorobenzaldehyde, reactions 106-44-5, Reactions, reactions 107-10-8, n-Propylamine, reactions 108-30-5, reactions 108-39-4, Reactions, reactions 108-91-8, Cyclohexanamine, reactions 108-95-2, Phenol, reactions 109-85-3, 2-Methoxyethylamine 109-97-7, Pyrrole 110-00-9, Furan 120-20-7, 3,4-Dimethoxyphenethylamine 120-47-8, Ethyl 4-hydroxybenzoate 124-63-0, Methanesulfonyl chloride 135-19-3, 2-Naphthalenol, reactions 139-59-3, 4-Phenoxyaniline 140-75-0, 4-Fluorobenzylamine 334-88-3, Diazomethane 455-88-9, 2-Fluoro-5-nitrotoluene 459-57-4, p-Fluorobenzaldehyde 460-08-2, 2-Fluoroethylamine hydrochloride 513-49-5, (S)-sec-Butylamine 533-31-3, 3,4-Methylenedioxyphenol 539-47-9, Furan-2-acrylic acid 698-63-5, 5-Nitro-2-furaldehyde, reactions 1003-03-8, Cyclopentylamine 1074-82-4, Potassium phthalimide 1208-88-4, 4-(Phenylthio)benzaldehyde 1470-94-6, 5-Hydroxyindane 1517-69-7 1779-49-3, Methyltriphenylphosphonium bromide 2038-57-5, Benzenepropanamine 2039-67-0, 3-Methoxyphenethylamine 2417-72-3, Methyl 4-(bromomethyl)benzoate 2450-71-7, Propargylamine 2516-34-9, Cyclobutylamine 2516-47-4, (Cyclopropylmethyl)amine 2605-67-6, Methyl (triphenylphosphoranylidene)acetate 2687-43-6, O-Benzylhydroxylamine hydrochloride 2892-51-5 3034-53-5, 2-Bromothiazole 3721-95-7,

Cyclobutanecarboxylic acid 4254-02-8, Cyclopentanecarbonitrile 4411-19-2 4415-87-6, 1,2,3,4-Cyclobutanetetracarboxylic anhydride 4418-61-5, 5-Aminotetrazole 4521-33-9, 5-Nitrothiophene-2-carboxaldehyde 4755-77-5, Ethyl oxalyl chloride 5335-05-7, Chloromethyl benzoate 5394-63-8, 2,2,6-Trimethyl-4H-1,3-dioxin-4-one 5402-53-9, Chloromethyl propionate 6246-48-6 6328-74-1, 4-Phenoxyphenylacetic acid 7355-51-3, 4-(Cyclohex-2-enyloxy)benzoic acid 13214-66-9, Benzenebutanamine 13250-12-9, (R)-sec-Butylamine 16251-45-9 17040-20-9, 4-(Phenylamino)benzoic acid 17066-34-1 17201-43-3, 4-(Bromomethyl)benzonitrile 18542-42-2, 2-(Methylthio)ethylamine 18997-19-8, Chloromethyl pivalate 27757-85-3, (2-Thienylmethyl)amine 29916-48-1 32752-54-8, α-Bromo-p-benzoyltoluene 33657-49-7, Chloromethyl butyrate 36489-03-9, 2-(Ethylthio)ethylamine 39096-01-0 39515-51-0, 3-Phenoxybenzaldehyde 40258-80-8, 1-Chloroethyl pivalate 40510-81-4, Chloromethyl methyl carbonate 58304-44-2, 1-Chloroethyl propionate 61644-18-6, Chloromethyl isobutyrate 77300-48-2 91109-83-0 100108-45-0 110931-72-1 129535-78-0 129535-94-0 141320-84-5 169943-92-4 169943-93-5 169943-94-6 169943-95-7 169943-96-8 169943-97-9 169943-98-0 169943-99-1 169944-00-7 169944-01-8 169944-02-9 169944-03-0 169944-04-1 169944-05-2 169944-06-3 169944-07-4 174075-91-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of cyclobutane derivs. as inhibitors of squalene synthetase and protein farnesyltransferase)

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Anon; EP 0448393 1991 HCAPLUS
(2) Anon; EP 0503520 1992 HCAPLUS
(3) Anon; WO 9212158 1992 HCAPLUS
(4) Anon; EP 526936 1993 HCAPLUS
(5) Anon; EP 0611749 1994 HCAPLUS
(6) Anon; WO 9418167 1994 HCAPLUS
(7) Anon; WO 9422870 1994 HCAPLUS
(8) Anon; WO 9504025 1995 HCAPLUS
(9) Anon; WO 9521815 1995 HCAPLUS
(10) Bergstrom; US 5102907 1992 HCAPLUS
(11) Biller; US 5025003 1991 HCAPLUS
(12) Biller; US 5095136 1992 HCAPLUS
(13) Bisacchi; US 5064961 1991 HCAPLUS
(14) Buhler; US 4349564 1982 HCAPLUS
(15) Carr; US 4202902 1980 HCAPLUS
(16) de Vries; US 4387106 1983 HCAPLUS
(17) Gounder; US 4340715 1982 HCAPLUS
(18) Kluender; US 4220795 1980 HCAPLUS
(19) Kuneida; J Am Chem Soc 1967, V89(16), P4232
(20) Kunieda; 1967, P9417 HCAPLUS
(21) Largman; US 3720712 1973 HCAPLUS
(22) Moore, J; Chemistry of Materials 1989, V1, P163 HCAPLUS
(23) Nakanishi; Polymer 1973, V14, P440 HCAPLUS
(24) Rhum; US 3236801 1966 HCAPLUS
(25) Richter; Angew Chem Int Edit 1969, V8(3), P208 HCAPLUS
(26) Rynbrandt; US 3786156 1974 HCAPLUS
(27) Singh; US 5245061 1993 HCAPLUS
(28) Singh; US 5260465 1993 HCAPLUS
(29) Singh; US 5260479 1993 HCAPLUS
(30) Slusarchyk; US 5130462 1992 HCAPLUS
(31) Stein; US 5631401 1997 HCAPLUS
(32) Witkop; 1971, P461 HCAPLUS

IT **169942-59-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclobutane derivs. as inhibitors of squalene synthetase and protein farnesyltransferase)

RN 169942-59-0 HCAPLUS

CN Cyclobutanecarboxylic acid, 2,3-bis[[[(4-phenoxyphenyl)methyl]propylamino]

carbonyl]-4-[[(trifluoromethyl)sulfonyl]amino]-, (1R,2R,3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L67 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:48721 HCAPLUS
DN 126:59736
ED Entered STN: 23 Jan 1997
TI Preparation of (4-phenoxybenzyl)aminocarbonyl-substituted cyclobutane derivatives as inhibitors of protein farnesyltransferase
IN Arendsen, David L.; Rosenberg, Saul H.; Rockway, Todd W.; Stein, Herman H.; Fung, Anthony K. L.
PA **Abbott Laboratories**, USA
SO PCT Int. Appl., 309 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07C233-60
ICS C07C323-40; C07D257-04; C07C237-24; C07C235-40; C07D257-06; C07D271-10; A61K031-16; A61K031-41
CC 25-10 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9634850	A1	19961107	WO 1996-US6156	19960502
	W: AU, CA, JP, KR, MX				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9657227	A1	19961121	AU 1996-57227	19960502
PRAI	US 1995-433718	A	19950503		
	US 1995-564836	A	19951129		
	US 1996-633205	A	19960426		
	WO 1996-US6156	W	19960502		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9634850	ICM	C07C233-60
	ICS	C07C323-40; C07D257-04; C07C237-24; C07C235-40; C07D257-06; C07D271-10; A61K031-16; A61K031-41

OS MARPAT 126:59736
GI



I



II

AB The title compds. [I; A1, A2 = XC(O)G, XC(S)G (wherein X = a bond, CH2, O, etc.; G = mono- or disubstituted NH2, substituted OH, SH); B1, B2 = CH2OH, CH2CH2OH, CHO, etc.], useful for inhibiting squalene synthetase and cholesterol biosynthesis, and treating hyperlipidemia, atherosclerosis and a fungal infection, were prepared Thus, reaction of 1,2,3,4-cyclobutanecarboxylic dianhydride with N-methyl-N-(4-phenoxybenzyl)amine in the presence of Et3N in DMF afforded 28% (1α,2β,3β,4.alpha.)-II which showed 54% inhibition of squalene synthetase in vitro at 10 μM.

ST cyclobutane phenoxybenzylaminocarbonyl prepn protein farnesyltransferase inhibitor; squalene synthetase inhibitor cyclobutane phenoxybenzylaminocarbonyl prepn; antihyperlipidemic cyclobutane phenoxybenzylaminocarbonyl prepn; anticholesteremic agent cyclobutane phenoxybenzylaminocarbonyl prepn; antiatherosclerotic cyclobutane phenoxybenzylaminocarbonyl prepn; fungicide cyclobutane phenoxybenzylaminocarbonyl prepn

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of N-(4-phenoxybenzyl)aminocarbonyl-substituted cyclobutane derivs. as inhibitors of protein farnesyltransferase)

IT Anticholesteremic agents
Fungicides
(preparation of N-(4-phenoxybenzyl)aminocarbonyl-substituted cyclobutane derivs. as inhibitors of protein farnesyltransferase)

IT 169941-79-1P 169941-80-4P 169941-81-5P 169941-82-6P 169941-83-7P
169941-84-8P 169941-85-9P 169941-86-0P 169941-87-1P 169941-89-3P
169941-90-6P 169941-91-7P 169941-92-8P 169941-93-9P 169941-94-0P
169941-95-1P 169941-96-2P 169941-97-3P 169941-98-4P 169942-01-2P
169942-02-3P 169942-03-4P 169942-04-5P 169942-05-6P 169942-06-7P
169942-07-8P 169942-08-9P 169942-09-0P 169942-10-3P 169942-11-4P
169942-12-5P 169942-13-6P 169942-14-7P 169942-15-8P 169942-16-9P
169942-17-0P 169942-18-1P 169942-19-2P 169942-20-5P 169942-21-6P
169942-22-7P 169942-23-8P 169942-24-9P 169942-25-0P 169942-26-1P
169942-27-2P 169942-28-3P 169942-29-4P 169942-30-7P 169942-31-8P
169942-32-9P 169942-33-0P 169942-34-1P 169942-35-2P 169942-36-3P
169942-37-4P 169942-38-5P 169942-41-0P 169942-42-1P 169942-43-2P
169942-44-3P 169942-45-4P 169942-46-5P 169942-47-6P 169942-49-8P
169942-50-1P 169942-51-2P 169942-52-3P 169942-53-4P 169942-54-5P
169942-55-6P 169942-56-7P 169942-57-8P 169942-58-9P
169942-59-0P 169942-60-3P 169942-61-4P 169942-62-5P
169942-64-7P 169942-65-8P 169942-67-0P 169942-70-5P 169942-71-6P
169942-72-7P 169942-73-8P 169942-74-9P 169942-75-0P 169942-76-1P
169942-77-2P 169942-78-3P 169942-79-4P 169942-80-7P 169942-81-8P
169942-82-9P 170207-65-5P 170207-66-6P 170207-67-7P 170207-68-8P
170207-69-9P 170207-70-2P 170207-71-3P 185209-29-4P 185209-30-7P
185209-31-8P 185209-32-9P 185209-33-0P 185209-34-1P 185209-36-3P

185209-37-4P 185209-38-5P 185209-39-6P 185209-40-9P 185209-41-0P
185209-42-1P 185209-43-2P 185209-44-3P 185209-45-4P 185209-46-5P
185209-47-6P 185209-48-7P 185209-49-8P 185209-50-1P 185209-51-2P
185209-52-3P 185209-53-4P 185209-54-5P 185209-55-6P 185209-56-7P
185209-57-8P 185209-58-9P 185209-59-0P 185209-60-3P 185209-61-4P
185209-62-5P 185209-63-6P 185209-64-7P 185209-65-8P 185209-66-9P
185209-67-0P 185209-68-1P 185209-69-2P 185209-70-5P 185209-71-6P
185209-72-7P 185209-73-8P 185209-74-9P 185209-75-0P 185209-76-1P
185209-77-2P 185209-78-3P 185209-79-4P 185209-80-7P 185209-81-8P
185209-82-9P 185209-83-0P 185209-84-1P 185209-85-2P 185209-86-3P
185253-88-7P 185253-90-1P 185253-91-2P 185253-92-3P 185254-05-1P
185254-41-5P 185254-51-7P 185254-60-8P 185254-68-6P 185254-69-7P
185254-70-0P 185254-77-7P 185254-78-8P 185254-79-9P 185254-80-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(4-phenoxybenzyl)aminocarbonyl-substituted cyclobutane derivs. as inhibitors of protein farnesyltransferase)

IT 9077-14-9, Squalene synthetase 131384-38-8, Protein farnesyltransferase 169942-48-7
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(preparation of N-(4-phenoxybenzyl)aminocarbonyl-substituted cyclobutane derivs. as inhibitors of protein farnesyltransferase)

IT 64-04-0, Phenethylamine 67-36-7, 4-Phenoxybenzaldehyde 75-65-0, tert-Butanol, reactions 79-03-8, Propionyl chloride 90-15-3, 1-Naphthol 100-46-9, Benzylamine, reactions 100-51-6, Benzyl alcohol, reactions 101-54-2, N-Phenyl-1,4-phenylenediamine 103-49-1, N,N-Dibenzylamine 104-88-1, 4-Chlorobenzaldehyde, reactions 107-10-8, Propylamine, reactions 107-18-6, Allyl alcohol, reactions 108-91-8, Cyclohexylamine, reactions 108-95-2, Phenol, reactions 109-85-3, 2-Methoxyethylamine 109-97-7, Pyrrole 110-00-9, Furan 120-20-7, 3,4-Dimethoxyphenethylamine 120-47-8, Ethyl 4-hydroxybenzoate 135-19-3, 2-Naphthol, reactions 139-59-3, 4-Phenoxyaniline 140-75-0, 4-Fluorobenzylamine 455-88-9, 2-Fluoro-5-nitrotoluene 459-57-4, p-Fluorobenzaldehyde 460-08-2, 2-Fluoroethylamine hydrochloride 513-49-5, (S)-sec-Butylamine 533-31-3, 3,4-Methylenedioxyphenol 539-47-9, Furan-2-acrylic acid 556-56-9, Allyl iodide 590-97-6, Bromomethyl acetate 617-89-0, Furfurylamine 698-63-5, 5-Nitro-2-furaldehyde, reactions 1003-03-8, Cyclopentylamine 1074-82-4, Potassium phthalimide 1208-88-4, 4-Phenylthiobenzaldehyde 1470-94-6, 5-Hydroxyindane 1517-69-7 2038-57-5, Benzenepropanamine 2039-67-0, 3-Methoxyphenethylamine 2417-72-3, Methyl 4-(bromomethyl)benzoate 2450-71-7, Propargylamine 2516-34-9, Cyclobutylamine 2516-47-4, Cyclopropylmethylamine 2605-67-6 2687-43-6, O-Benzylhydroxylamine hydrochloride 3034-53-5, 2-Bromothiazole 4254-02-8, Cyclopentanecarbonitrile 4415-87-6 4418-61-5, 5-Aminotetrazole 4426-11-3, Cyclobutanecarbonitrile 4521-33-9, 5-Nitrothiophene-2-carboxaldehyde 5335-05-7, Chloromethyl benzoate 5394-63-8, 2,2,6-Trimethyl-4H-1,3-dioxin-4-one 5402-53-9, Chloromethyl propionate 6246-48-6 6328-74-1, 4-Phenoxyphenylacetic acid 7355-51-3 13214-66-9, Benzenebutanamine 13250-12-9 16251-45-9 17040-20-9, 4-Phenylaminobenzoic acid 17066-34-1 17201-43-3, 4-(Bromomethyl)benzonitrile 18542-42-2, 2-(Methylthio)ethylamine 18997-19-8, Chloromethyl pivalate 27757-85-3, 2-Thienylmethylamine 29916-48-1 32752-54-8, α-Bromo-p-benzoyltoluene 33657-49-7, Chloromethyl butyrate 39096-01-0 39515-51-0, 3-Phenoxybenzaldehyde 40258-80-8, 1-Chloroethyl pivalate 40510-81-4, Chloromethyl methyl carbonate 54303-30-9, 2-(Ethylthio)ethylamine hydrochloride 58304-44-2, 1-Chloroethyl propionate 77300-48-2 91109-83-0 100108-45-0 141320-84-5 150864-99-6 150865-02-4 169943-94-6 169943-97-9 169943-99-1 169944-00-7 169944-01-8 169944-02-9 169944-03-0 169944-04-1 169944-06-3 169944-07-4 174075-91-3 185210-37-1 185210-38-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-(4-phenoxybenzyl)aminocarbonyl-substituted cyclobutane

derivs. as inhibitors of protein farnesyltransferase)

IT 2215-78-3P, 4-Phenoxybenzyl alcohol 2303-25-5P 4973-29-9P, 4-Phenoxystyrene 6053-81-2P, Cyclopentanemethanamine 10194-09-9P 16282-41-0P 22325-80-0P 24789-49-9P 31719-76-3P, 4-Phenoxymethylbenzoic acid 52446-51-2P 56355-19-2P 56705-84-1P 60698-30-8P, 5-Phenoxy-2-furaldehyde 61343-83-7P 61343-84-8P 63343-66-8P 70278-64-7P 73420-63-0P 73461-23-1P 79124-75-7P, 3-Methyl-4-phenoxybenzaldehyde 100005-68-3P 101480-26-6P 107622-80-0P 111480-00-3P, 5-Phenoxythiophene-2-carboxaldehyde 112430-87-2P 115510-54-8P 118468-18-1P 120375-17-9P 122594-72-3P 124397-37-1P, Methyl 4-phenoxymethylbenzoate 129535-80-4P 132747-89-8P 142800-65-5P 143426-60-2P 158771-13-2P 169942-84-1P 169942-85-2P 169942-86-3P 169942-87-4P 169942-88-5P 169942-90-9P 169942-91-0P 169942-93-2P 169942-94-3P 169942-95-4P 169942-96-5P 169942-97-6P 169942-98-7P 169942-99-8P 169943-03-7P 169943-04-8P 169943-05-9P 169943-06-0P 169943-07-1P 169943-08-2P 169943-09-3P 169943-10-6P 169943-11-7P 169943-12-8P 169943-13-9P 169943-14-0P 169943-15-1P 169943-16-2P 169943-17-3P 169943-18-4P 169943-19-5P 169943-20-8P 169943-21-9P 169943-22-0P 169943-23-1P 169943-24-2P 169943-25-3P 169943-26-4P 169943-27-5P 169943-28-6P 169943-29-7P 169943-30-0P 169943-39-9P 169943-40-2P 169943-41-3P 169943-42-4P 169943-43-5P 169943-44-6P 169943-45-7P 169943-46-8P 169943-47-9P 169943-48-0P 169943-49-1P 169943-50-4P 169943-51-5P 169943-52-6P 169943-53-7P 169943-54-8P 169943-55-9P 169943-56-0P 169943-57-1P 169943-58-2P 169943-59-3P 169943-60-6P 169943-61-7P 169943-62-8P 169943-63-9P 169943-64-0P 169943-65-1P 169943-66-2P 169943-67-3P 169943-68-4P 169943-69-5P 169943-70-8P 169943-71-9P 169943-72-0P 169943-73-1P 169943-74-2P 169943-75-3P 169943-76-4P 169943-77-5P 169943-78-6P 169943-79-7P 169943-80-0P 169943-81-1P 169943-82-2P 169943-83-3P 169943-84-4P 169943-85-5P 169943-86-6P 169943-87-7P 169943-88-8P 169943-89-9P 169943-90-2P 169943-91-3P 170207-72-4P 171349-83-0P 184488-11-7P 185209-87-4P 185209-88-5P 185209-89-6P 185209-90-9P 185209-92-1P 185209-93-2P 185209-94-3P 185209-95-4P 185209-96-5P 185209-97-6P 185209-98-7P 185209-99-8P 185210-00-8P 185210-01-9P 185210-02-0P 185210-03-1P 185210-04-2P 185210-05-3P 185210-06-4P 185210-07-5P 185210-08-6P 185210-09-7P 185210-10-0P 185210-11-1P 185210-12-2P 185210-13-3P 185210-14-4P 185210-15-5P 185210-16-6P 185210-17-7P 185210-18-8P 185210-19-9P 185210-20-2P 185210-21-3P 185210-22-4P 185210-23-5P 185210-24-6P 185210-25-7P 185210-26-8P 185210-27-9P 185210-28-0P 185210-29-1P 185210-30-4P 185210-31-5P 185210-32-6P 185210-33-7P 185210-34-8P 185210-35-9P 185210-36-0P 185254-81-3P 185254-82-4P 185254-83-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-(4-phenoxybenzyl)aminocarbonyl-substituted cyclobutane derivs. as inhibitors of protein farnesyltransferase)

IT 2114-11-6P, Allyl carbamate 169943-31-1P 169943-32-2P 185210-39-3P 185210-40-6P 185210-41-7P 185210-42-8P 185210-43-9P 185210-44-0P 185210-45-1P 185210-46-2P 185210-47-3P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of N-(4-phenoxybenzyl)aminocarbonyl-substituted cyclobutane derivs. as inhibitors of protein farnesyltransferase)

IT **169942-59-0P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-(4-phenoxybenzyl)aminocarbonyl-substituted cyclobutane derivs. as inhibitors of protein farnesyltransferase)

RN 169942-59-0 HCAPLUS

CN Cyclobutanecarboxylic acid, 2,3-bis[[[(4-phenoxyphenyl)methyl]propylamino]carbonyl]-4-[[(trifluoromethyl)sulfonyl]amino]-, (1R,2R,3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L67 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:902590 HCAPLUS
DN 123:313433
ED Entered STN: 08 Nov 1995
TI Cyclobutane derivatives as inhibitors of squalene synthetase and protein farnesyltransferase
IN Baker, William R.; Rockway, Todd W.; Donner, B. Gregory; Shen, Wang; Rosenberg, Saul H.; Fakhoury, Stephen A.; O'Connor, Stephen J.; Stout, David M.; Fung, Anthony K. L.; et al.
PA **Abbott Laboratories**, USA
SO PCT Int. Appl., 223 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07C233-60
ICS C07C323-40; C07D257-04; A61K031-16; A61K031-41
CC 24-3 (Alicyclic Compounds)
Section cross-reference(s): 1
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9512572	A1	19950511	WO 1994-US12132	19941020
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2152822	AA	19950511	CA 1994-2152822	19941020
	EP 677039	A1	19951018	EP 1994-931987	19941020
	EP 677039	B1	19990310		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 08505646	T2	19960618	JP 1994-513255	19941020
	AT 177420	E	19990315	AT 1994-931987	19941020
	ES 2130452	T3	19990701	ES 1994-931987	19941020
PRAI	US 1993-147708	A	19931104		
	US 1994-289711	A	19940909		
	WO 1994-US12132	W	19941020		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9512572	ICM	C07C233-60
	ICS	C07C323-40; C07D257-04; A61K031-16; A61K031-41
WO 9512572	ECLA	C07C069/74; C07C233/19; C07C233/58; C07C233/59; C07C233/60; C07C233/61; C07C233/62; C07C233/63; C07C235/36; C07C235/40; C07C237/24; C07C245/14; C07C251/42; C07C259/08; C07C311/51; C07C323/40; C07C323/46; C07D309/32; C07D319/06; C07D333/58

OS MARPAT 123:313433
GI



AB The invention provides compds. I [A1, A2 = -XC(O)G, -XC(S)G, -(CH2)qNR1R2; X = bond, CH2, O, S, (un)substituted NH; G = R2, NR1R2, OR2, SR2; R1 = H, alkyl, alkenyl, (un)substituted aryl, heterocyclyl, etc.; R2 = alkenyl, (un)substituted aryl, heterocyclyl, etc.; q = 0-2; B1, B2 = CH2OH, CH:NOH, WR3, addnl. carbonyl-containing groups; W = bond, alkylene, alkenylene, CONH, NHCONH; R3 = various (un)substituted heterocyclic groups or squaric acid residue]. Also disclosed are preparation processes, intermediates, pharmaceutical compns., and treatment of hypercholesterolemic disorders, cancer, or fungal infections using the compds. I inhibit biosynthesis of cholesterol (and also fungal growth) by inhibiting squalene synthetase. I also inhibit farnesylation of the oncogene protein Ras by inhibiting protein farnesyltransferase (no data). For example, reaction of anti-1,2,3,4-cyclobutanetetracarboxylic dianhydride with 2 equiv 4-PhOC6H4CH2NHCH2Ph in THF at 25°, followed by workup and chromatog. of the isomeric products, gave 6% title compound II. In an in vitro test, II at 10 μM gave 99% inhibition of rat liver microsomal squalene synthetase. Over 160 synthetic examples (approx. 115 compds. I with data) are given, with similar test data for most compds.

ST cyclobutane inhibitor squalene synthetase protein farnesyltransferase; cholesterol biosynthesis inhibitor cyclobutane prepn; antitumor cyclobutane prepn; antifungal cyclobutane prepn

IT Anticholesteremics and Hypolipemics
Fungicides and Fungistats
Neoplasm inhibitors
(preparation of cyclobutane derivs. as inhibitors of squalene synthetase and protein farnesyltransferase)

IT Antiarteriosclerotics
(antiatherosclerotics, preparation of cyclobutane derivs. as inhibitors of squalene synthetase and protein farnesyltransferase)

IT G proteins (guanine nucleotide-binding proteins)
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(gene RAS, inhibitors of farnesylation of; preparation of cyclobutane derivs. as inhibitors of squalene synthetase and protein farnesyltransferase)

IT 57-88-5, Cholesterol, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
(biosynthesis inhibitors; preparation of cyclobutane derivs. as inhibitors of squalene synthetase and protein farnesyltransferase)

IT 169943-31-1P 169943-32-2P 169943-33-3P 169943-34-4P 169943-35-5P 169943-36-6P 169943-37-7P 169943-38-8P 169943-39-9P
RL: BYP (Byproduct); PREP (Preparation)
(byproduct; preparation of cyclobutane derivs. as inhibitors of squalene synthetase and protein farnesyltransferase)

IT 169943-15-1P
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of cyclobutane derivs. as inhibitors of squalene

synthetase and protein farnesyltransferase)

IT 2215-78-3P 2303-25-5P 4973-29-9P, 4-Phenoxystyrene 6053-81-2P, Cyclopentanemethanamine 10194-09-9P 16282-41-0P 22325-80-0P 24789-49-9P, 4-(3-Methylphenoxy)benzonitrile 31719-76-3P, 4-(Phenoxymethyl)benzoic acid 36881-42-2P 52446-51-2P 56355-19-2P, Ethyl 4-(thiazol-2-yloxy)benzoate 56705-84-1P, 4-(3-Methylphenoxy)aniline 60698-30-8P, 5-Phenoxy-2-furaldehyde 61343-83-7P, 4-(4-Methylphenoxy)benzaldehyde 61343-84-8P, 4-(3-Methylphenoxy)benzaldehyde 73420-63-0P 73461-23-1P 79124-75-7P, 3-Methyl-4-phenoxybenzaldehyde 100005-68-3P, Ethyl 4-(furan-2-yloxy)benzoate 101480-26-6P, N-(4-Phenoxyphenyl)propionamide 107622-80-0P 111480-00-3P, 5-Phenoxythiophene-2-carboxaldehyde 112430-87-2P 118468-18-1P 120375-17-9P, 4-(Cyclohex-2-enyloxy)benzaldehyde 122594-72-3P 124397-37-1P, Methyl 4-(phenoxymethyl)benzoate 129535-80-4P 132747-89-8P 142800-65-5P 143426-60-2P 158771-13-2P, 4-(2-Naphthyloxy)benzaldehyde 169942-83-0P 169942-84-1P 169942-85-2P 169942-86-3P 169942-87-4P 169942-88-5P 169942-89-6P 169942-90-9P 169942-91-0P 169942-92-1P 169942-93-2P 169942-94-3P 169942-95-4P 169942-96-5P 169942-97-6P 169942-98-7P 169942-99-8P 169943-00-4P 169943-01-5P 169943-02-6P 169943-03-7P 169943-04-8P 169943-05-9P 169943-06-0P 169943-07-1P 169943-08-2P 169943-09-3P 169943-10-6P 169943-11-7P 169943-12-8P 169943-13-9P 169943-14-0P 169943-16-2P 169943-17-3P 169943-18-4P 169943-19-5P 169943-20-8P 169943-21-9P 169943-22-0P 169943-23-1P 169943-24-2P 169943-25-3P 169943-26-4P 169943-27-5P 169943-28-6P 169943-29-7P 169943-30-0P 169943-40-2P 169943-41-3P 169943-42-4P 169943-43-5P 169943-44-6P, N-[2-(4-Phenoxyphenyl)ethyl]propionamide 169943-45-7P 169943-46-8P, N-Propyl-4-phenoxyaniline 169943-47-9P 169943-48-0P 169943-49-1P 169943-50-4P 169943-51-5P 169943-52-6P 169943-53-7P 169943-54-8P 169943-55-9P 169943-56-0P 169943-57-1P, N-(4-Phenoxybenzyl)cyclobutanecarboxamide 169943-58-2P 169943-59-3P 169943-60-6P 169943-61-7P 169943-62-8P 169943-63-9P 169943-64-0P 169943-65-1P 169943-66-2P, 4-(Phenylamino)-N-propylbenzamide 169943-67-3P 169943-68-4P 169943-69-5P 169943-70-8P 169943-71-9P 169943-72-0P 169943-73-1P 169943-74-2P, 4-(Furan-2-yloxy)benzaldehyde 169943-75-3P 169943-76-4P 169943-77-5P, 4-(Thiazol-2-yloxy)benzaldehyde 169943-78-6P 169943-79-7P 169943-80-0P 169943-81-1P 169943-82-2P 169943-83-3P 169943-84-4P 169943-85-5P 169943-86-6P, 4-(1-Naphthyloxy)benzaldehyde 169943-87-7P 169943-88-8P 169943-89-9P 169943-90-2P 169943-91-3P 170207-72-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of cyclobutane derivs. as inhibitors of squalene synthetase and protein farnesyltransferase)

IT 169942-32-9P 169942-55-6P 169942-56-7P 169942-61-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of cyclobutane derivs. as inhibitors of squalene synthetase and protein farnesyltransferase)

IT 169941-79-1P 169941-80-4P 169941-81-5P 169941-82-6P 169941-83-7P 169941-84-8P 169941-85-9P 169941-86-0P 169941-87-1P 169941-88-2P 169941-89-3P 169941-90-6P 169941-91-7P 169941-92-8P 169941-93-9P 169941-94-0P 169941-95-1P 169941-96-2P 169941-97-3P 169941-98-4P 169941-99-5P 169942-00-1P 169942-01-2P 169942-02-3P 169942-03-4P 169942-04-5P 169942-05-6P 169942-06-7P 169942-07-8P 169942-08-9P 169942-09-0P 169942-10-3P 169942-11-4P 169942-12-5P 169942-13-6P 169942-14-7P 169942-15-8P 169942-16-9P 169942-17-0P 169942-18-1P 169942-19-2P 169942-20-5P 169942-21-6P 169942-22-7P 169942-23-8P 169942-24-9P 169942-25-0P 169942-26-1P 169942-27-2P 169942-28-3P 169942-29-4P 169942-30-7P 169942-31-8P 169942-33-0P 169942-34-1P 169942-35-2P 169942-36-3P 169942-37-4P 169942-38-5P 169942-39-6P 169942-40-9P 169942-41-0P 169942-42-1P 169942-43-2P 169942-44-3P 169942-45-4P 169942-46-5P 169942-47-6P 169942-48-7P 169942-49-8P 169942-50-1P 169942-51-2P 169942-52-3P 169942-53-4P 169942-54-5P

169942-57-8P 169942-58-9P **169942-59-0P** 169942-60-3P
169942-62-5P 169942-63-6P 169942-64-7P 169942-65-8P 169942-66-9P
169942-67-0P 169942-68-1P 169942-69-2P 169942-70-5P 169942-71-6P
169942-72-7P 169942-73-8P 169942-74-9P 169942-75-0P 169942-76-1P
169942-77-2P 169942-78-3P 169942-79-4P 169942-80-7P 169942-81-8P
169942-82-9P 169944-08-5P 169944-09-6P 170207-64-4P 170207-65-5P
170207-66-6P 170207-67-7P 170207-68-8P 170207-69-9P 170207-70-2P
170207-71-3P 170207-73-5P 170207-74-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclobutane derivs. as inhibitors of squalene synthetase and protein farnesyltransferase)

IT 9077-14-9, Squalene synthetase 131384-38-8, Protein farnesyltransferase
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(preparation of cyclobutane derivs. as inhibitors of squalene synthetase and protein farnesyltransferase)

IT 64-04-0, Phenethylamine 67-36-7, 4-Phenoxybenzaldehyde 74-89-5, Methylamine, reactions 78-81-9, Isobutylamine 79-03-8, Propionyl chloride 90-15-3, 1-Naphthalenol 100-46-9, Benzylamine, reactions 100-51-6, Benzenemethanol, reactions 101-54-2, N-Phenyl-1,4-phenylenediamine 103-49-1, N,N-Dibenzylamine 104-88-1, 4-Chlorobenzaldehyde, reactions 106-44-5, reactions 107-10-8, n-Propylamine, reactions 108-30-5, Succinic anhydride, reactions 108-39-4, reactions 108-91-8, Cyclohexanamine, reactions 108-95-2, Phenol, reactions 109-85-3, 2-Methoxyethylamine 109-97-7, Pyrrole 110-00-9, Furan 120-20-7, 3,4-Dimethoxyphenethylamine 120-47-8, Ethyl 4-hydroxybenzoate 124-63-0, Methanesulfonyl chloride 135-19-3, 2-Naphthalenol, reactions 139-59-3, 4-Phenoxyaniline 140-75-0, 4-Fluorobenzylamine 334-88-3, Diazomethane 455-88-9, 2-Fluoro-5-nitrotoluene 459-57-4, p-Fluorobenzaldehyde 460-08-2, 2-Fluoroethylamine hydrochloride 533-31-3, 3,4-Methylenedioxyphenol 539-47-9, Furan-2-acrylic acid 698-63-5, 5-Nitro-2-furaldehyde, reactions 1003-03-8, Cyclopentylamine 1074-82-4, Potassium phthalimide 1208-88-4, 4-(Phenylthio)benzaldehyde 1517-69-7 1779-49-3, Methyltriphenylphosphonium bromide 2038-57-5, Benzenepropanamine 2039-67-0, 3-Methoxyphenethylamine 2417-72-3, Methyl 4-(bromomethyl)benzoate 2450-71-7, Propargylamine 2516-34-9, Cyclobutylamine 2516-47-4, (Cyclopropylmethyl)amine 2605-67-6, Methyl (triphenylphosphoranylidene)acetate 2687-43-6, O-Benzylhydroxylamine hydrochloride 3034-53-5, 2-Bromothiazole 3721-95-7, Cyclobutanecarboxylic acid 4254-02-8, Cyclopentanecarbonitrile 4411-19-2 4418-61-5, 5-Aminotetrazole 4521-33-9, 5-Nitrothiophene-2-carboxaldehyde 4755-77-5, Ethyl oxalyl chloride 6328-74-1, 4-Phenoxyphenylacetic acid 7355-51-3, 4-(Cyclohex-2-enyloxy)benzoic acid 13214-66-9, Benzenebutanamine 17040-20-9, 4-(Phenylamino)benzoic acid 17201-43-3, 4-(Bromomethyl)benzonitrile 18542-42-2, 2-(Methylthio)ethylamine 27757-85-3, (2-Thienylmethyl)amine 32752-54-8, α-Bromo-p-benzoyltoluene 36489-03-9, 2-(Ethylthio)ethylamine 39515-51-0, 3-Phenoxybenzaldehyde 77300-48-2 91109-83-0 110931-72-1 129535-78-0 129535-94-0 141320-84-5 169943-92-4 169943-93-5 169943-94-6 169943-95-7 169943-96-8 169943-97-9 169943-98-0 169943-99-1 169944-00-7 169944-01-8 169944-02-9 169944-03-0 169944-04-1 169944-05-2 169944-06-3 169944-07-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of cyclobutane derivs. as inhibitors of squalene synthetase and protein farnesyltransferase)

IT **169942-59-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclobutane derivs. as inhibitors of squalene synthetase and protein farnesyltransferase)

RN 169942-59-0 HCAPLUS
CN Cyclobutanecarboxylic acid, 2,3-bis[[[(4-phenoxyphenyl)methyl]propylamino]

carbonyl]-4-[[(trifluoromethyl)sulfonyl]amino]-, (1R,2R,3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



=> d all hitstr l61 1-20

L61 ANSWER 1 OF 58 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:497502 HCAPLUS
DN 143:53440
ED Entered STN: 10 Jun 2005
TI Substituted benzoimidazole compounds as transcription factor-modulating compounds useful as anti-infectives
IN Levy, Stuart B.; Alekshun, Michael N.; Podlogar, Brent L.; Ohemeng, Kwasi; Verma, Atul K.; Warchol, Tadeusz; Bhatia, Beena; Bowser, Todd; Grier, Mark
PA Paratek Pharmaceuticals, Inc., USA
SO U.S. Pat. Appl. Publ., 463 pp., Cont.-in-part of U.S. Ser. No. 139,591.
CODEN: USXXCO
DT **Patent**
LA English
IC ICM A61K031-4184
INCL 514394000
CC 1-5 (Pharmacology)
Section cross-reference(s): 10, 28, 63
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005124678	A1	20050609	US 2003-700661	20031103 <--
	CA 2445515	AA	20021104	CA 2002-2445515	20020506 <--
	EP 1524974	A2	20050427	EP 2002-807554	20020506 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2005519998	T2	20050707	JP 2004-515557	20020506 <--
	US 2003229065	A1	20031211	US 2002-139591	20020814 <--
	US 2004106553	A1	20040603	US 2003-602562	20030624 <--
PRAI	US 2001-288660P	P	20010504	<--	
	US 2002-139591	A2	20020814	<--	
	US 2002-423319P	P	20021101	<--	
	US 2002-425916P	P	20021113	<--	
	WO 2002-US14255	W	20020506	<--	
	US 2002-391345P	P	20020624	<--	
	US 2002-421218P	P	20021025	<--	
	US 2002-429142P	P	20021126	<--	
	US 2003-458935P	P	20030331		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES

US 2005124678	ICM	A61K031-4184
	INCL	514394000
US 2005124678	NCL	514/394.000 <--
JP 2005519998	FTERM	2G045/AA40; 2G045/BB20; 2G045/CB21; 4B024/AA01; 4B024/AA11; 4B024/BA80; 4B024/CA04; 4B024/DA06; 4B024/EA04; 4B024/GA11; 4B024/GA19; 4B063/QA01; 4B063/QA18; 4B063/QQ06; 4B063/QQ13; 4B063/QS38; 4C037/KA09; 4C050/AA01; 4C050/BB04; 4C050/BB05; 4C050/CC04; 4C050/CC05; 4C050/DD02; 4C050/EE02; 4C050/EE05; 4C050/FF02; 4C050/FF05; 4C050/FF10; 4C050/GG01; 4C050/GG03; 4C050/HH01; 4C050/HH04; 4C056/AA01; 4C056/AB01; 4C056/AC01; 4C056/AD08; 4C056/AE03; 4C056/FA01; 4C056/FB01; 4C056/FC01; 4C062/EE50; 4C063/AA01; 4C063/BB01; 4C063/CC41; 4C063/CC47; 4C063/CC75; 4C063/DD14; 4C063/DD29; 4C063/DD41; 4C063/EE01; 4C065/AA03; 4C065/AA04; 4C065/AA18; 4C065/BB05; 4C065/CC01; 4C065/CC09; 4C065/DD02; 4C065/DD03; 4C065/EE02; 4C065/HH01; 4C065/HH05; 4C065/HH08; 4C065/JJ01; 4C065/KK01; 4C065/KK02; 4C065/KK09; 4C065/LL01; 4C065/LL03; 4C065/PP03; 4C065/PP07; 4C072/AA01; 4C072/AA06; 4C072/BB02; 4C072/BB03; 4C072/BB06; 4C072/CC02; 4C072/CC04; 4C072/CC11; 4C072/CC16; 4C072/DD06; 4C072/DD10; 4C072/EE03; 4C072/EE09; 4C072/EE13; 4C072/FF05; 4C072/FF06; 4C072/FF09; 4C072/GG01; 4C072/GG07; 4C072/HH02; 4C072/HH07; 4C072/UU01; 4C076/CC10; 4C076/CC11; 4C076/CC17; 4C076/CC34; 4C076/DD48F; 4C076/DD55F; 4C076/DD60F; 4C076/EE23F; 4C076/FF43; 4C084/AA02; 4C084/AA13; 4C084/AA17; 4C084/AA27; 4C084/BA35; 4C084/NA14; 4C084/ZA342; 4C084/ZA362; 4C084/ZA672; 4C084/ZA812; 4C084/ZA892; 4C084/ZA962; 4C084/ZB112; 4C084/ZB352; 4C086/AA01; 4C086/AA02; 4C086/EA16; 4C086/MA01; 4C086/MA04; 4C086/NA14; 4C086/ZA34; 4C086/ZA36; 4C086/ZA67; 4C086/ZA81; 4C086/ZA89; 4C086/ZA96; 4C086/ZB11; 4C086/ZB35 <--
US 2003229065	NCL	514/185.000
	ECLA	A61K031/40; A61K031/407; A61K031/415; A61K031/47; A61K031/4745; A61K031/505; A61K031/555 <--
US 2004106553	NCL	514/012.000 <--

AB Substituted benzoimidazole compds. useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. Methods of making and using substituted benzoimidazole compds., as well as pharmaceutical prepns. thereof, in, e.g., reducing antibiotic resistance and inhibiting biofilms. The present invention identifies microbial transcription factors, especially transcription factors of the AraC-XylS family, as virulence factors in microbes and shows that inhibition of these factors reduces the virulence of microbial cells. Because these transcription factors control virulence, rather than essential cellular processes, the development of resistance is much less likely.

ST transcription factor modulator antimicrobial drug resistance

IT Bacteroides
(3452A homol. group; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MarA; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Rob; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(SOX; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)

IT Pyridinium compounds
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkyl, iodides, co-treatment with; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)
IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(araC (arabinose operon regulatory protein C); substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)
IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(bHLH (basic helix-loop-helix); substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)
IT Infection
(bacterial; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)
IT Surfactants
(biosurfactants, co-treatment with; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)
IT Tooth, disease
(caries, treatment of biofilms in; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)
IT Drug delivery systems
(carriers; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)
IT Medical goods
(catheters, cleaning and disinfecting of; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)
IT Contact lenses
Medical goods
(cleaning and disinfecting of; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)
IT Antibiotics
Surfactants
(co-treatment with; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)
IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-treatment with; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)
IT Heart, disease
Inflammation
(endocarditis, treatment of biofilms in; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)
IT Dental materials and appliances
Prosthetic materials and Prosthetics
(implants, cleaning and disinfecting of; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)
IT Ear
(middle, disease, infection, treatment of biofilms in; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)
IT Prosthetic materials and Prosthetics
(orthopedic, cleaning and disinfecting of; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)
IT Inflammation
Prostate gland, disease
(prostatitis, treatment of biofilms in; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)
IT Drug resistance
(reduction of; substituted benzoimidazole compds. as transcription

factor-modulating compds. useful as anti-infectives)
IT Glycolipids
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rhamnose-containing, co-treatment with; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)
IT Sulfonic acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(salts, co-treatment with; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)
IT Acinetobacter calcoaceticus
Acinetobacter haemolyticus
Aeromonas hydrophila
Anti-infective agents
Antibacterial agents
Antimicrobial agents
Bacteroides distasonis
Bacteroides eggerthii
Bacteroides fragilis
Bacteroides ovatus
Bacteroides splanchnicus
Bacteroides thetaiotaomicron
Bacteroides uniformis
Bacteroides vulgatus
Biofilms (microbial)
Bordetella bronchiseptica
Bordetella parapertussis
Bordetella pertussis
Borrelia burgdorferi
Burkholderia cepacia
Campylobacter coli
Campylobacter fetus
Campylobacter jejuni
Citrobacter freundii
Clostridium difficile
Comamonas acidovorans
Combination chemotherapy
Corynebacterium diphtheriae
Disinfectants
Drug resistance modulators
Drug targets
Enterobacter aerogenes
Enterobacter cloacae
Enterococcus faecalis
Enterococcus faecium
Escherichia coli
Francisella tularensis
Gardnerella vaginalis
Haemophilus ducreyi
Haemophilus haemolyticus
Haemophilus influenzae
Haemophilus parahaemolyticus
Haemophilus parainfluenzae
Helicobacter pylori
Human
Klebsiella oxytoca
Klebsiella pneumoniae
Legionella pneumophila
Listeria monocytogenes
Mammalia
Mannheimia haemolytica
Moraxella catarrhalis
Morganella morganii
Mycobacterium avium
Mycobacterium intracellulare
Mycobacterium leprae
Mycobacterium tuberculosis

Neisseria gonorrhoeae
Neisseria meningitidis
Pasteurella multocida
Prokaryota
Proteus mirabilis
Proteus vulgaris
Providencia alcalifaciens
Providencia rettgeri
Providencia stuartii
Pseudomonas aeruginosa
Pseudomonas alcaligenes
Pseudomonas fluorescens
Pseudomonas putida
Salmonella enteritidis
Salmonella paratyphi
Salmonella typhi
Salmonella typhimurium
Serratia marcescens
Shigella dysenteriae
Shigella flexneri
Shigella sonnei
Staphylococcus aureus
Staphylococcus epidermidis
Staphylococcus hemolyticus
Staphylococcus hominis
Staphylococcus hyicus hyicus
Staphylococcus intermedius
Staphylococcus saccharolyticus
Staphylococcus saprophyticus
Stenotrophomonas maltophilia
Streptococcus agalactiae
Streptococcus pneumoniae
Streptococcus pyogenes
Vibrio cholerae
Vibrio parahaemolyticus
Virulence (microbial)
Yersinia intermedia
(substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)

IT Immunodeficiency
(treatment in; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)

IT Acne
Cystic fibrosis
Osteomyelitis
(treatment of biofilms in; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)

IT 151-21-3, Sodium dodecyl sulfate, biological studies 9002-93-1, Triton X 100 9004-95-9, Brij 56 9005-65-6, Tween 80 9005-70-3, Tween 85 252023-70-4, Surfactin 496064-69-8, Visconsin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-treatment with; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)

IT 70-34-8, 1-Fluoro-2,4-dinitrobenzene 91-56-5, Isatin 105-36-2, Ethyl bromoacetate 5680-79-5 35371-03-0, 4-Iodothioanisole
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)

IT 164623-85-2, GenBank U21191 170896-13-6, GenBank U34257
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(substituted benzoimidazole compds. as transcription factor-modulating

compds. useful as anti-infectives)

IT 634190-87-7P 634190-88-8P 691354-52-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)

IT 117-39-5 480-23-9 520-36-5 891-43-0 1218-82-2 1571-90-0
1645-21-2 1772-39-0 2513-33-9 2555-29-5 3164-28-1 3283-93-0
4143-63-9 4143-74-2 5211-78-9 5346-13-4 5452-31-3 5460-84-4
10066-15-6 10420-73-2 14172-90-8 14172-91-9 14172-92-0
14244-55-4 14514-68-2 14518-23-1 16796-31-9 18384-19-5
18706-63-3 22198-48-7 22395-22-8 22697-40-1 22894-67-3
25437-73-4 31283-09-7 32396-64-8 33289-14-4 36387-84-5
39679-60-2 39776-53-9 41383-95-3 41383-96-4 49619-82-1
50287-25-7 50878-11-0 55736-01-1 57645-95-1 58996-65-9
62536-78-1 63046-14-0 63576-07-8 65047-30-5 67574-58-7
70188-31-7 70591-05-8 71348-79-3 71720-87-1 76648-60-7
79049-98-2 84437-40-1 88379-74-2 89002-85-7 89813-65-0
91352-96-4 91486-87-2 92301-83-2 92831-11-3 92897-45-5
95356-81-3 95594-15-3 95716-70-4 96754-58-4 103855-21-6
104676-23-5 106726-42-5 107607-43-2 107792-87-0 109211-66-7
109723-54-8 110442-19-8 116718-53-7 126145-51-5 129415-03-8
129718-80-5 129886-25-5 129886-26-6 138884-21-6 138915-42-1
140410-61-3 146618-32-8 154269-13-3 154546-75-5 154678-99-6
154867-12-6 155276-97-4 156172-93-9 157428-39-2 157428-40-5
158584-21-5 159325-85-6 161466-04-2 164355-99-1 164356-03-0
167493-42-7 168209-86-7 175136-52-4 177082-78-9 177082-79-0
177082-84-7 182171-05-7 210639-69-3 210639-84-2 214140-91-7
216880-62-5 221179-01-7 222715-96-0 222716-13-4 222716-32-7
232927-14-9 248595-25-7 252331-98-9 253178-59-5 254980-04-6
254980-06-8 254980-08-0 255395-82-5 255714-31-9 255725-40-7
256347-92-9 256417-22-8 256488-11-6 256488-13-8 256521-48-9
257861-94-2 257869-87-7 261946-03-6 261946-04-7 261946-06-9
262856-10-0 262856-11-1 262856-14-4 262856-15-5 263016-22-4
263016-25-7 263744-91-8 263766-87-6 263766-88-7 263766-94-5
263766-96-7 264232-74-8 264626-20-2 264626-22-4 265130-20-9
266362-06-5 266362-07-6 266362-08-7 266362-72-5 271775-19-0
279691-70-2 282523-56-2 282523-61-9 285980-79-2 285985-78-6
285985-96-8 285987-31-7 286439-77-8 289651-63-4 289651-74-7
289651-75-8 292170-06-0 292640-33-6 292641-43-1 292641-59-9
292641-66-8 292641-77-1 292641-89-5 292641-94-2 292641-96-4
292870-96-3 292871-13-7 292871-19-3 292871-23-9 292871-24-0
292871-26-2 292871-48-8 292871-52-4 292871-54-6 292871-55-7
292871-65-9 292871-69-3 292871-78-4 292871-81-9 292871-86-4
292871-94-4 292871-99-9 292872-04-9 292872-05-0 292872-11-8
292872-14-1 292875-92-4 292876-62-1 292877-08-8 292877-14-6
292877-44-2 293760-39-1 293760-44-8 294873-89-5 295787-47-2
296772-03-7 296790-72-2 296790-73-3 296790-75-5 296790-77-7
296791-26-9 296791-46-3 296791-48-5 296791-57-6 296793-15-2
296885-59-1 299198-34-8 299921-77-0 299964-86-6 300360-28-5
300377-27-9 300377-30-4 300377-54-2 300377-60-0 300590-03-8
300690-35-1 **300695-50-5** 300700-73-6 300701-30-8
300716-40-9 300723-23-3 300805-10-1 301354-45-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)

IT 302575-31-1 302935-50-8 302950-94-3 303100-86-9 303100-87-0
303121-28-0 303122-04-5 303140-78-5 303148-61-0 303148-63-2
303148-99-4 303149-18-0 303226-67-7 304878-27-1 304896-73-9
305331-86-6 305332-46-1 305332-58-5 305333-17-9 305337-60-4
305362-03-2 305859-05-6 305865-87-6 305865-91-2 305866-04-0
305866-28-8 305866-71-1 305867-31-6 306288-57-3 306308-80-5
306308-92-9 306308-94-1 306309-07-9 306309-33-1 306309-35-3
306309-36-4 306309-44-4 306309-52-4 306309-74-0 306310-02-1

306310-03-2 306310-21-4 306310-22-5 306310-23-6 306310-24-7
306310-26-9 306310-35-0 306319-47-1 306764-57-8 306956-43-4
309271-93-0 309274-37-1 309289-92-7 309293-80-9 309294-15-3
309294-32-4 309735-50-0 309735-52-2 309736-48-9 309736-49-0
309736-53-6 309737-21-1 309920-59-0 309921-09-3 309928-00-5
310447-13-3 311774-09-1 311798-45-5 312264-89-4 312269-59-3
312278-72-1 312287-95-9 312317-18-3 312495-33-3 312497-06-6
312502-43-5 312505-29-6 312506-77-7 312521-88-3 312522-33-1
312529-33-2 312531-21-8 312536-81-5 312603-44-4 312621-22-0
312621-26-4 312635-81-7 312703-25-6 312703-26-7 312703-27-8
312703-28-9 312703-30-3 312703-32-5 312703-35-8 312704-86-2
312758-70-6 312935-38-9 312935-46-9 313068-17-6 313068-18-7
313068-39-2 313068-55-2 313068-60-9 313068-87-0 313272-50-3
313361-39-6 313377-25-2 313381-33-8 313389-91-2 313391-70-7
313397-97-6 313400-70-3 313400-73-6 313400-84-9 313400-88-3
313400-90-7 313400-92-9 313518-30-8 313518-33-1 313518-34-2
313518-35-3 313647-42-6 313705-02-1 313955-78-1 313955-79-2
313955-80-5 313955-82-7 313955-84-9 313955-88-3 313955-91-8
313955-95-2 313957-07-2 313957-10-7 313957-11-8 313965-69-4
313965-70-7 313965-71-8 313965-79-6 313966-29-9 313966-34-6
313976-26-0 313982-23-9 313982-24-0 313982-31-9 313982-32-0
313982-33-1 313982-38-6 313982-40-0 314027-98-0 314035-11-5
314035-14-8 314035-22-8 314035-24-0 314045-76-6 314046-18-9
314054-59-6 314054-60-9 314054-61-0 314054-63-2 314054-66-5
315183-66-5 315184-13-5 315184-21-5 316360-75-5 317374-73-5
320784-76-7 321392-06-7 321392-09-0 321975-78-4 324030-86-6
324071-14-9 324071-58-1 324071-63-8 324071-66-1 324072-02-8
324072-03-9 324072-06-2 324072-21-1 324072-23-3 324073-95-2
324542-36-1 324542-97-4 324543-00-2 324543-03-5 324543-49-9
324566-54-3 324567-44-4 326612-29-7 327031-34-5 327031-45-8
327031-83-4 327032-26-8 327032-30-4 327032-47-3 327032-59-7
327032-83-7 327032-85-9 327055-09-4 327055-16-3 327055-27-6
327055-29-8 327055-30-1 327055-48-1 327055-51-6 327055-58-3
327055-59-4 327055-62-9 327055-63-0 327055-65-2 327055-66-3
327055-68-5 327055-72-1 327055-96-9 327055-97-0 327056-03-1
327056-05-3 327100-35-6 328012-23-3 328118-26-9 328264-08-0
328264-17-1 328264-18-2 328264-19-3 328264-25-1 328264-26-2
328264-27-3 328264-31-9 328264-33-1 328264-35-3 328264-60-4
328264-66-0 328264-67-1 328264-76-2 328264-77-3 328264-80-8
328264-82-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)

IT 328264-83-1 328264-85-3 328264-87-5 328271-66-5 328271-67-6
328271-69-8 328271-70-1 328271-71-2 328271-76-7 328271-77-8
328271-79-0 328271-80-3 328271-84-7 328271-85-8 328271-88-1
328271-92-7 328272-06-6 328272-07-7 328272-08-8 328272-11-3
328272-13-5 328285-97-8 328391-94-2 329689-08-9 329693-08-5
329740-08-1 330560-95-7 330571-22-7 330852-05-6 330852-85-2
330854-50-7 331002-28-9 331002-56-3 331253-46-4 331253-51-1
331260-25-4 331260-26-5 331260-28-7 331261-77-9 331261-78-0
331261-92-8 331262-03-4 331262-07-8 331262-11-4 331263-52-6
331263-58-2 331710-55-5 331711-61-6 331749-70-3 331749-72-5
331760-77-1 331852-08-5 331856-24-7 331859-20-2 331944-58-2
331976-76-2 331978-51-9 332022-52-3 332022-53-4 332030-63-4
332075-02-2 332102-86-0 332102-89-3 332102-91-7 332102-93-9
332159-11-2 332401-95-3 332412-67-6 332867-75-1 333769-72-5
333770-99-3 333793-27-4 337918-76-0 337919-26-3 337921-53-6
337921-56-9 338791-19-8 338791-34-7 338791-35-8 338791-36-9
338987-62-5 339009-79-9 339009-92-6 339009-95-9 339009-96-0
339009-98-2 339010-04-7 339026-82-3 339026-84-5 339026-96-9
339104-28-8 339314-09-9 340204-12-8 340207-27-4 341538-13-4
341538-41-8 341538-50-9 341538-59-8 343591-38-8 347363-05-7
347866-94-8 348163-00-8 350503-73-0 350503-74-1 350503-75-2
350503-77-4 350503-78-5 350612-07-6 350612-82-7 350612-83-8

350612-84-9 350680-42-1 351166-54-6 351210-57-6 351210-59-8
351210-65-6 351210-67-8 351213-06-4 351213-09-7 351213-11-1
351213-13-3 351213-15-5 351213-32-6 351213-33-7 351213-48-4
351213-55-3 351213-61-1 351213-64-4 351213-71-3 351213-73-5
351213-74-6 351213-75-7 351222-84-9 351504-60-4 351509-71-2
351510-77-5 351514-75-5 351514-86-8 351514-87-9 351515-00-9
351515-09-8 351516-01-3 351516-08-0 351516-12-6 351516-31-9
351516-76-2 351517-40-3 351517-44-7 351517-48-1 351517-73-2
351517-92-5 351518-64-4 351518-77-9 351518-85-9 351518-93-9
351518-95-1 351895-44-8 351895-47-1 351895-49-3 352023-44-0
352204-86-5 352204-90-1 352226-44-9 352226-46-1 352304-59-7
352304-63-3 352455-56-2 352455-70-0 352455-85-7 352455-89-1
352455-95-9 352455-98-2 352456-00-9 352456-02-1 352456-21-4
352456-23-6 352456-31-6 352531-64-7 352554-28-0 352639-80-6
352647-29-1 352647-46-2 352657-21-7 352663-86-6 353254-75-8
353264-13-8 353467-61-5 353467-63-7 353467-65-9 353470-55-0
353470-72-1 353470-81-2 353504-56-0 353514-57-5 353774-04-6
353776-27-9 353776-40-6 353777-01-2 353781-12-1 353781-19-8
354143-43-4 354543-27-4 354557-15-6 357162-68-6 357227-12-4
357430-14-9 357432-12-3 357432-15-6 357432-69-0 357432-74-7
357432-77-0 357433-19-3 357434-16-3 357434-22-1 357440-09-6
357441-42-0 357441-45-3 358731-11-0 360764-84-7 360764-99-4
361178-70-3 361371-95-1 362482-78-8 363590-74-3 370074-53-6
371127-11-6 371917-60-1 372155-97-0 372157-62-5 372503-90-7
373618-99-6 374707-65-0 374708-40-4 374758-72-2 374759-01-0
375839-59-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)

IT 381223-51-4 383375-26-6 383376-13-4 383391-54-6 384822-05-3
392325-80-3 398472-83-8 400754-38-3 400821-72-9 401466-92-0
413619-86-0 414873-85-1 414886-56-9 414906-10-8 415691-91-7
415699-86-4 415928-40-4 416878-53-0 416884-40-7 416885-05-7
416885-29-5 416894-20-7 418774-87-5 418792-63-9 418801-37-3
418803-13-1 418805-97-7 418809-85-5 418810-07-8 419537-97-6
419538-24-2 419538-42-4 419538-58-2 419539-53-0 419539-99-4
419540-52-6 419540-66-2 419540-81-1 419540-97-9 419541-01-8
419541-49-4 419541-76-7 419541-79-0 419544-90-4 419544-97-1
419546-31-9 419546-75-1 419547-14-1 419550-77-9 419550-80-4
419551-35-2 419551-60-3 419551-61-4 419577-67-6 420099-12-3
420103-39-5 420104-82-1 420105-40-4 423151-53-5 445025-50-3
464155-99-5 468093-19-8 470471-35-3 470471-80-8 470687-12-8
478048-43-0 487021-77-2 500118-46-7 500864-49-3 551921-20-1
634189-25-6 634189-26-7 634189-27-8 634189-28-9 634189-29-0
634189-30-3 634189-31-4 634189-32-5 634189-33-6 634189-34-7
634189-35-8 634189-36-9 634189-37-0 634189-38-1 634189-39-2
634189-40-5 634189-41-6 634189-42-7 634189-43-8 634189-44-9
634189-45-0 634189-47-2 634189-48-3 634189-49-4 634189-50-7
634189-51-8 634189-52-9 634189-53-0 634189-54-1 634189-55-2
634189-56-3 634189-58-5 634189-61-0 634189-62-1 634189-63-2
634189-64-3 634189-65-4 634189-66-5 634189-67-6 634189-68-7
634189-69-8 634189-70-1 634189-71-2 634189-72-3 634189-74-5
634189-76-7 634189-77-8 634189-78-9 634189-79-0 634189-80-3
634189-82-5 634189-84-7 634189-85-8 634189-86-9 634189-87-0
634189-88-1 634189-89-2 634189-90-5 634189-91-6 634189-92-7
634189-94-9 634189-95-0 634189-96-1 634189-97-2 634189-99-4
634190-00-4 634190-01-5 634190-02-6 634190-03-7 634190-04-8
634190-05-9 634190-06-0 634190-07-1 634190-08-2 634190-09-3
634190-10-6 634190-11-7 634190-12-8 634190-13-9 634190-14-0
634190-15-1 634190-16-2 634190-17-3 634190-18-4 634190-19-5
634190-20-8 634190-21-9 634190-22-0 634190-23-1 634190-24-2
634190-25-3 634190-26-4 634190-27-5 634190-28-6 634190-29-7
634190-32-2 634190-34-4 634190-36-6 634190-39-9 634190-40-2
634190-44-6 634190-46-8 634190-51-5 634190-52-6 634190-69-5
634190-71-9 634190-72-0 634190-73-1 634190-74-2 634190-75-3

634190-76-4 634190-77-5 634190-78-6 634190-79-7 634190-80-0
634197-52-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)

IT 107-13-1, Acrylonitrile, reactions 1571-85-3, 5-Nitro-2-phenylbenzimidazole
RL: RCT (Reactant); RACT (Reactant or reagent)
(substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)

IT 634190-86-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)

IT 51-17-2D, Benzoimidazole, compds.
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)

IT 5310-51-0P 27161-64-4P 41383-89-5P 634190-81-1P 634190-82-2P
634190-85-5P 691352-92-8P 691352-93-9P 691354-51-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthetic intermediate; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)

IT 853826-51-4 853826-53-6
RL: PRP (Properties)
(unclaimed nucleotide sequence; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)

IT 853826-52-5 853826-54-7
RL: PRP (Properties)
(unclaimed protein sequence; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)

IT 853826-55-8 853826-56-9 853826-57-0 853826-58-1 853826-59-2
853826-60-5 853826-61-6 853826-62-7 853826-63-8 853826-64-9
853826-65-0 853826-66-1 853826-67-2 853826-68-3 853826-69-4
853826-70-7 853826-71-8 853826-72-9 853826-73-0 853826-74-1
853826-75-2 853826-76-3 853826-77-4 853826-78-5 853826-79-6
853826-80-9 853826-81-0 853826-82-1 853826-83-2 853826-84-3
853826-85-4 853826-86-5 853826-87-6 853826-88-7 853826-89-8
853826-90-1 853826-91-2 853826-92-3 853826-93-4 853826-94-5
853826-95-6 853826-96-7 853826-97-8 853826-98-9 853826-99-0
853827-00-6 853827-01-7 853827-02-8 853827-03-9 853827-04-0
853827-05-1 853827-06-2 853827-07-3 853827-08-4 853827-09-5
853827-10-8 853827-11-9 853827-12-0 853827-13-1 853827-14-2
853827-15-3 853827-16-4 853827-17-5 853827-18-6 853827-19-7
853827-20-0 853827-21-1 853827-22-2 853827-23-3 853827-24-4
853827-25-5 853827-26-6 853827-27-7 853827-28-8 853827-29-9
853827-30-2 853827-31-3 853827-32-4 853827-33-5 853827-34-6
853827-35-7 853827-36-8 853827-37-9 853827-38-0 853827-39-1
853827-40-4 853827-41-5 853827-42-6 853827-43-7 853827-44-8
853827-45-9 853827-46-0 853827-47-1 853827-48-2 853827-49-3
853827-50-6 853827-51-7 853827-52-8 853827-53-9 853827-54-0
853827-55-1 853827-56-2 853827-57-3 853827-58-4 853827-59-5
853827-60-8 853827-61-9 853827-62-0 853827-63-1 853827-64-2
853827-65-3 853827-66-4 853827-67-5 853827-68-6 853827-69-7
853827-70-0 853827-71-1 853827-72-2 853827-73-3 853827-74-4
853827-75-5 853827-76-6 853827-77-7 853827-78-8 853827-79-9
853827-80-2 853827-81-3 853827-82-4 853827-83-5 853827-84-6
853827-85-7 853827-86-8 853827-87-9 853827-88-0 853827-89-1
853827-90-4 853827-91-5 853827-92-6 853827-93-7 853827-94-8
853827-95-9 853827-96-0 853827-97-1 853827-98-2 853827-99-3
853828-00-9 853828-01-0 853828-02-1 853828-03-2 853828-04-3
853828-05-4 853828-06-5 853828-07-6 853828-08-7 853828-09-8
853828-10-1 853828-11-2 853828-12-3 853828-13-4 853828-14-5

853828-15-6 853828-16-7 853828-17-8 853828-18-9 853828-19-0
853828-20-3 853828-21-4 853828-22-5 853828-23-6 853828-24-7
853828-25-8 853828-26-9 853828-27-0 853828-28-1 853828-29-2
853828-30-5 853828-31-6 853828-32-7 853828-33-8 853828-34-9
853828-35-0 853828-36-1 853828-37-2 853828-38-3 853828-39-4
853828-40-7 853828-41-8 853828-42-9 853828-43-0 853828-44-1
853828-45-2 853828-46-3 853828-47-4 853828-48-5 853828-49-6
853828-50-9 853828-51-0 853828-52-1 853828-53-2 853828-54-3
853828-55-4 853828-56-5 853828-57-6 853828-58-7 853828-59-8
853828-60-1 853828-61-2 853828-62-3 853828-63-4 853828-64-5
853828-65-6 853828-66-7 853828-67-8 853828-68-9 853828-69-0
853828-70-3 853828-71-4 853828-72-5 853828-73-6 853828-74-7
853828-75-8 853828-76-9 853828-77-0 853828-78-1 853828-79-2
853828-80-5 853828-81-6 853828-82-7 853828-83-8 853828-84-9
RL: PRP (Properties)
(unclaimed sequence; substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)

IT **300695-50-5**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)

RN 300695-50-5 HCAPLUS
CN Benzoic acid, 5-[[(2-carboxyphenyl)amino]sulfonyl]-2-hydroxy- (9CI) (CA INDEX NAME)



L61 ANSWER 2 OF 58 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:349010 HCAPLUS
DN 142:411094
ED Entered STN: 22 Apr 2005
TI Preparation of aryl sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of Th2- and eosinophil-mediated diseases
IN Dai, Mingshi; Guan, Bing; Bennett, Robert A.; Burdi, Douglas F.; Ghosh, Shomir; Li, Gang; Minor, Charles; Jenkins, Tracy J.
PA Millennium Pharmaceuticals, Inc., USA
SO U.S. Pat. Appl. Publ., 215 pp., Cont.-in-part of U.S. Ser. No. 744,236.
CODEN: USXXCO
DT **Patent**
LA English
IC ICM A61K031-44
ICS A61K031-40; A61K031-325; A61K031-165
INCL 514357000; 514408000; 514485000; 546335000; 548571000; 560024000; 564152000; 514616000
CC 25-22 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 27, 63
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005085518	A1	20050421	US 2004-891362	20040714 <--
	US 2004209948	A1	20041021	US 2003-744585	20031223 <--
	US 2004224978	A1	20041111	US 2003-744236	20031223 <--
PRAI	US 2002-436508P	P	20021223 <--		
	US 2002-436537P	P	20021223 <--		
	US 2003-744236	A2	20031223		
	US 2003-744585	A2	20031223		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2005085518	ICM	A61K031-44
	ICS	A61K031-40; A61K031-325; A61K031-165
	INCL	514357000; 514408000; 514485000; 546335000; 548571000; 560024000; 564152000; 514616000
US 2005085518	NCL	514/357.000 <--
US 2004209948	NCL	514/484.000
	ECLA	C07C311/46; C07C311/47; C07C335/16; C07D207/14; C07D211/28; C07D211/58; C07D401/12+211+209; C07D401/12+213+211; C07D401/12+233+211; C07D405/12+307B+211; C07D405/12+309+211; C07D413/12+261+211 <--
US 2004224978	NCL	514/310.000 <--

OS MARPAT 142:411094

GI



II

AB The title compds. R1(CH2)mXC(:Z)N(R2)X1ArS(:O)nNR3R4 (I) [Ar = (un)substituted bivalent six-membered aryl group fused to either a six-membered aromatic moiety or to a five- or six-membered nonarom. moiety; R1 = (un)substituted aromatic or nonarom. group; R2 = H, alkyl; R3 = H; R4 = (un)substituted aromatic, nonarom. ring or a bridged bicyclic ring; or NR3R4 = (un)substituted non-aromatic heterocyclyl; X = bond, O, NR5 (R5 = H, alkyl); X1 = bond, carbonyl, (un)substituted methylene; Z = O, NH, S; m = 0-3; n = 1-2] such as II are prepared as inhibitors of the chemokine receptor CCR8 for the treatment of diseases such as asthma, atopic or allergic contact dermatitis, allergic rhinitis, systemic anaphylaxis, rheumatoid arthritis, inflammatory bowel disease, or graft rejection which are mediated by either Th2 cells or eosinophils. Acylation of 4-amino-1-naphthalenesulfonic acid with benzoyl chloride, chlorination of the derived 4-(benzoylamino)-1-naphthalenesulfonic acid pyridine salt with thionyl chloride, and addition of m-anisidine yields II. Ki values for the binding of I to CCR8 are disclosed; for example, II binds to CCCR8 with a Ki value of < 0.5 μM.

ST sulfonamide prepn inhibitor CCR8 treatment Th2 eosinophil mediated disease; aryl sulfonamide prepn inhibitor CCR8 asthma allergy; antiasthmatic aryl sulfonamide prepn; allergy inhibitor aryl sulfonamide prepn

IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CCR8; preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT Allergy
Inflammation
Nose, disease
(allergic rhinitis; preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT Dermatitis

(atopic; preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT Autoimmune disease
Inflammation
Thyroid gland, disease
(autoimmune thyroiditis; preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT Dermatitis
(contact, allergic; preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT Inflammation
Kidney, disease
(glomerulonephritis; preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT T cell (lymphocyte)
(helper cell/inducer, TH2; preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT Allergy
(hypersensitivity; preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT Intestine, disease
(inflammatory; preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT Allergy
(insect sting; preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT Autoimmune disease
(insulin-dependent diabetes mellitus; preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT Diabetes mellitus
(insulin-dependent; preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT Allergy inhibitors
Anaphylaxis
Antiarthritics
Antiasthmatics
Antidiabetic agents
Antirheumatic agents
Asthma
Behcet's syndrome
Dermatitis
Drug allergy
Eczema
Eosinophil
Human
Immunosuppressants
Multiple sclerosis
Myasthenia gravis
Osteoarthritis

Rheumatoid arthritis
Transplant rejection
Urticaria
(preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT Lupus erythematosus
(systemic; preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 723306-51-2P 723306-54-5P 723307-06-0P
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(drug candidate; preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 723306-52-3P 723306-53-4P 723306-55-6P 723306-56-7P 723307-21-9P
723307-22-0P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 419539-65-4P 723304-75-4P 723305-14-4P 723305-56-4P 723305-79-1P
723305-83-7P 723306-07-8P 723306-15-8P 723306-16-9P 723306-20-5P
723306-24-9P 723306-39-6P 723306-41-0P 723306-42-1P 723306-44-3P
723306-49-8P 723306-50-1P 723306-64-7P 723306-65-8P 723306-74-9P
723306-75-0P 723306-76-1P 723306-77-2P 723306-94-3P 723307-14-0P
723307-15-1P 723307-23-1P 723307-24-2P 723307-26-4P 723307-27-5P
723307-28-6P 723307-29-7P 723307-30-0P 723307-31-1P 723307-32-2P
723307-33-3P 723307-34-4P 723307-35-5P 723307-36-6P 723307-37-7P
723307-38-8P 723307-39-9P 723307-58-2P 723307-60-6P 723307-61-7P
723307-62-8P 723308-44-9P 723308-45-0P 723308-46-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 723304-37-8P 723304-38-9P 723304-39-0P 723304-40-3P 723304-41-4P
723304-42-5P 723304-43-6P 723304-44-7P 723304-46-9P 723304-47-0P
723304-48-1P 723304-49-2P 723304-50-5P 723304-51-6P 723304-52-7P
723304-53-8P 723304-54-9P 723304-55-0P 723304-56-1P 723304-57-2P
723304-58-3P 723304-59-4P 723304-60-7P 723304-61-8P 723304-62-9P
723304-63-0P 723304-64-1P 723304-65-2P 723304-66-3P 723304-67-4P
723304-68-5P 723304-69-6P 723304-70-9P 723304-71-0P 723304-72-1P
723304-73-2P 723304-74-3P 723304-76-5P 723304-77-6P 723304-78-7P
723304-79-8P 723304-80-1P 723304-81-2P 723304-82-3P 723304-83-4P
723304-85-6P 723304-87-8P 723304-88-9P 723304-89-0P 723304-90-3P
723304-91-4P 723304-92-5P 723304-93-6P 723304-94-7P 723304-95-8P
723304-96-9P 723304-97-0P 723304-98-1P 723304-99-2P 723305-00-8P
723305-01-9P 723305-02-0P 723305-03-1P 723305-04-2P 723305-05-3P
723305-06-4P 723305-07-5P 723305-08-6P 723305-09-7P 723305-10-0P
723305-11-1P 723305-12-2P 723305-13-3P 723305-15-5P 723305-16-6P
723305-17-7P 723305-18-8P 723305-19-9P 723305-20-2P 723305-21-3P
723305-22-4P 723305-25-7P 723305-26-8P 723305-27-9P 723305-28-0P
723305-29-1P 723305-30-4P 723305-31-5P 723305-32-6P 723305-33-7P
723305-34-8P 723305-35-9P 723305-37-1P 723305-38-2P 723305-39-3P
723305-40-6P 723305-41-7P 723305-42-8P 723305-43-9P 723305-45-1P
723305-46-2P 723305-47-3P 723305-48-4P 723305-49-5P 723305-50-8P
723305-51-9P 723305-52-0P 723305-53-1P 723305-54-2P 723305-55-3P
723305-57-5P 723305-58-6P 723305-59-7P 723305-60-0P 723305-61-1P
723305-62-2P 723305-63-3P 723305-64-4P 723305-65-5P 723305-66-6P

723305-67-7P 723305-68-8P 723305-69-9P 723305-70-2P 723305-71-3P
723305-73-5P 723305-74-6P 723305-75-7P 723305-76-8P 723305-77-9P
723305-80-4P 723305-81-5P **723305-84-8P** 723305-85-9P
723305-86-0P 723305-87-1P 723305-88-2P 723305-89-3P 723305-90-6P
723305-91-7P 723305-92-8P 723305-93-9P 723305-94-0P 723305-95-1P
723305-97-3P 723305-99-5P 723306-00-1P 723306-01-2P 723306-04-5P
723306-05-6P 723306-06-7P 723306-08-9P 723306-09-0P 723306-10-3P
723306-11-4P 723306-12-5P 723306-13-6P 723306-14-7P 723306-17-0P
723306-18-1P 723306-19-2P 723306-21-6P 723306-22-7P 723306-23-8P
723306-25-0P 723306-26-1P 723306-27-2P 723306-28-3P 723306-29-4P
723306-31-8P 723306-32-9P 723306-34-1P 723306-35-2P 723306-36-3P
723306-37-4P 723306-46-5P 723306-48-7P 723306-57-8P 723306-58-9P
723306-59-0P 723306-60-3P 723306-61-4P 723306-62-5P 723306-63-6P
723306-66-9P 723306-67-0P 723306-68-1P 723306-69-2P 723306-70-5P
723306-71-6P 723306-72-7P 723306-73-8P 723306-78-3P 723306-79-4P
723306-80-7P 723306-81-8P 723306-82-9P 723306-83-0P 723306-84-1P
723306-85-2P 723306-86-3P 723306-87-4P 723306-88-5P 723306-89-6P
723306-90-9P 723306-91-0P 723306-92-1P 723306-93-2P 723306-95-4P
723306-96-5P 723306-97-6P 723306-98-7P 723306-99-8P 723307-00-4P
723307-01-5P 723307-02-6P 723307-03-7P 723307-04-8P 723307-05-9P
723307-07-1P 723307-08-2P 723307-09-3P 723307-10-6P 723307-11-7P
723307-12-8P 723307-13-9P 723307-16-2P 723307-17-3P 723307-18-4P
723307-19-5P 723307-20-8P 723307-25-3P 723307-40-2P 723307-41-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 723307-42-4P 723307-43-5P 723307-44-6P 723307-45-7P 723307-46-8P
723307-47-9P 723307-48-0P 723307-49-1P 723307-50-4P 723307-51-5P
723307-52-6P 723307-53-7P 723307-54-8P 723307-55-9P 723307-56-0P
723307-57-1P 723307-63-9P 723307-64-0P 723307-65-1P 723307-67-3P
723307-69-5P 723307-71-9P 723307-73-1P 723307-75-3P 723307-77-5P
723307-79-7P 723307-81-1P 723307-83-3P 723307-85-5P 723307-87-7P
723307-89-9P 723307-91-3P 723307-93-5P 723307-95-7P 723307-97-9P
723307-98-0P 723307-99-1P 723308-00-7P 723308-01-8P 723308-02-9P
723308-03-0P 723308-04-1P 723308-05-2P 723308-06-3P 723308-07-4P
723308-08-5P 723308-09-6P 723308-10-9P 723308-11-0P 723308-12-1P
723308-13-2P 723308-14-3P 723308-15-4P 723308-16-5P 723308-18-7P
723308-19-8P 723308-20-1P 723308-21-2P 723308-22-3P 723308-23-4P
723308-24-5P 723308-25-6P 723308-26-7P 723308-27-8P 723308-28-9P
723308-29-0P 723308-30-3P 723308-31-4P 723308-33-6P 723308-34-7P
723308-35-8P 723308-36-9P 723308-37-0P 723308-38-1P 723308-39-2P
723308-40-5P 723308-41-6P 723308-42-7P 723308-43-8P 723308-47-2P
723308-48-3P 723308-49-4P 723308-50-7P 723308-51-8P 723308-52-9P
723309-01-1P 723311-86-2P 724762-72-5P 724762-74-7P 724762-75-8P
724762-76-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 316-69-8P, 4-Fluoro-1-naphthalenesulfonyl chloride 700-45-8P 836-21-5P
6968-09-8P 31861-08-2P 82378-86-7P 92309-57-4P 124868-89-9P
181269-69-2P 294840-12-3P 460985-74-4P 473838-36-7P 723308-53-0P
723308-54-1P 723308-55-2P 723308-56-3P 723308-57-4P 723308-58-5P
723308-59-6P 723308-60-9P 723308-61-0P 723308-62-1P 723308-63-2P
723308-64-3P 723308-65-4P 723308-66-5P 723308-67-6P 723308-68-7P
723308-69-8P 723308-70-1P 723308-71-2P 723308-72-3P 723308-73-4P
723308-75-6P 723308-76-7P 723308-77-8P 723308-78-9P 723308-79-0P
723308-80-3P 723308-81-4P 723308-82-5P 723308-83-6P 723308-84-7P
723309-00-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 723305-23-5P 723305-24-6P 723305-36-0P 723305-44-0P 723305-72-4P
723306-02-3P 723306-03-4P 724762-73-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 850330-16-4P 850330-17-5P 850330-18-6P 850330-19-7P 850330-20-0P
850330-21-1P 850330-22-2P 850330-23-3P 850330-24-4P 850330-25-5P
850330-26-6P 850330-27-7P 850330-28-8P 850330-29-9P 850330-30-2P
850330-31-3P 850330-32-4P 850330-33-5P 850330-34-6P 850330-35-7P
850330-36-8P 850330-37-9P 850330-38-0P 850330-39-1P 850330-40-4P
850330-42-6P 850330-44-8P 850330-46-0P 850330-48-2P 850330-51-7P
850330-54-0P 850330-57-3P 850330-59-5P 850330-61-9P 850330-63-1P
850330-65-3P 850330-67-5P 850330-68-6P 850330-69-7P 850330-70-0P
850330-71-1P 850330-72-2P 850330-73-3P 850330-76-6P 850330-78-8P
850330-80-2P 850330-82-4P 850330-84-6P 850330-86-8P 850330-88-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 723304-35-6 723304-36-7 723305-82-6 723306-38-5 723306-40-9
850330-74-4 850330-75-5 850330-91-5 850330-92-6 850330-93-7
850330-94-8 850330-95-9 850330-96-0 850330-97-1 850330-98-2
850330-99-3 850331-00-9 850331-01-0 850331-02-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 141-75-3, Butyryl chloride 541-41-3, Ethyl chloroformate 850330-89-1
850330-90-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 62-53-3, Aniline, reactions 75-07-0, Acetaldehyde, reactions 75-31-0, Isopropylamine, reactions 79-14-1, Hydroxyacetic acid, reactions 79-44-7, Dimethylcarbamyl chloride 84-86-6, 4-Amino-1-naphthalenesulfonic acid 84-89-9, 1-Naphthylamine-5-sulfonic acid 85-44-9, Phthalic anhydride 86-52-2, 1-Chloromethylnaphthalene 86-55-5, 1-Naphthalenecarboxylic acid 87-59-2, 2,3-Dimethylaniline 88-10-8, Diethylcarbamyl chloride 89-98-5, 2-Chlorobenzaldehyde 92-54-6, 1-Phenylpiperazine 92-67-1, 4-Biphenylamine 95-51-2, 2-Chloroaniline 98-01-1, 2-Furancarboxaldehyde, reactions 98-09-9, Benzenesulfonyl chloride 99-88-7, 4-Isopropylaniline 100-07-2, p-Methoxybenzoyl chloride 100-46-9, Benzylamine, reactions 100-60-7, N-Methylcyclohexylamine 103-71-9, Phenyl isocyanate, reactions 103-72-0, Phenyl isothiocyanate 103-80-0, Phenylacetyl chloride 104-53-0, 3-Phenylpropionaldehyde 104-88-1, 4-Chlorobenzaldehyde, reactions 108-00-9, 2-(Dimethylamino)ethylamine 108-91-8, Cyclohexylamine, reactions 108-94-1, Cyclohexanone, reactions 109-01-3, 1-Methylpiperazine 109-89-7, Diethylamine, reactions 110-78-1, 1-Isocyanatopropane 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 119-28-8, 8-Amino-2-naphthalenesulfonic acid 122-04-3, p-Nitrobenzoyl chloride 122-78-1, Phenylacetaldehyde 123-11-5, 4-Methoxybenzaldehyde, reactions 123-75-1, Pyrrolidine, reactions 321-38-0, 1-Fluoronaphthalene 371-40-4, 4-Fluoroaniline 393-52-2, 2-Fluorobenzoyl chloride 455-14-1, 4-Trifluoromethylaniline 459-57-4, 4-Fluorobenzaldehyde 462-08-8, 3-Aminopyridine 475-11-6,

N-Methylproline 498-60-2, 3-Furancarboxaldehyde 500-22-1, 3-Pyridinecarboxaldehyde 504-24-5, 4-Aminopyridine 504-29-0, 2-Aminopyridine 527-69-5, 2-Furancarbonyl chloride 529-20-4, 2-Methylbenzaldehyde 587-04-2, 3-Chlorobenzaldehyde 589-16-2, 4-Ethylaniline 615-18-9, 2-Chlorobenzoxazole 872-85-5, 4-Pyridinecarboxaldehyde 933-88-0, 2-Methylbenzoyl chloride 1003-03-8, Cyclopentylamine 1074-82-4, Potassium phthalimide 1121-60-4, 2-Pyridinecarboxaldehyde 1192-63-8, 1-Pyrrolidinecarbonyl chloride 1445-73-4, 1-Methyl-4-piperidinone 1530-88-7, 1-Pyrrolidinecarbonitrile 1711-05-3, 3-Methoxybenzoyl chloride 1711-06-4, 3-Methylbenzoyl chloride 1795-48-8, 2-Isocyanatopropane 2043-61-0, Cyclohexanecarboxaldehyde 2217-41-6, 5,6,7,8-Tetrahydro-1-naphthalenamine 2627-86-3, (S)-α-Methylbenzylamine 2719-27-9, Cyclohexylcarbonyl chloride 3612-20-2, 1-Benzyl-4-piperidone 3731-53-1, 4-(Aminomethyl)pyridine 3839-22-3, 2-Cyanobenzoic acid 3886-69-9, (R)-α-Methylbenzylamine 3939-01-3 4023-34-1, Cyclopropanecarbonyl chloride 4530-20-5, Boc-glycine 4595-60-2, 2-Bromopyrimidine 5006-22-4, Cyclobutanecarbonyl chloride 5337-03-1, Tetrahydropyran-4-carboxylic acid 5657-70-5, 1-Methyl-3-piperidinecarboxylic acid 10111-08-7, 1H-Imidazole-2-carboxaldehyde 13939-69-0, 1-Piperidinecarbonyl chloride 14254-57-0, Isonicotinoyl chloride 15761-38-3 15761-39-4 16948-16-6 20260-53-1, Nicotinoyl chloride hydrochloride 21615-34-9, 2-Methoxybenzoyl chloride 21900-46-9, 2,3-Dimethylbenzoyl chloride 22328-43-4, 2,5-Dimethylbenzoyl chloride 31301-45-8 32202-61-2, 4-Aminoindan 34306-42-8 34737-89-8, 1-Benzyl-3-methyl-4-piperidinone 38870-89-2, Methoxyacetyl chloride 39178-35-3, Isonicotinoyl chloride hydrochloride 41716-12-5 50541-93-0, 1-Benzyl-4-piperidinamine 51552-16-0, Dimethylaminoacetyl chloride 53035-92-0, 4-Tetrahydropyranyl isocyanate 58859-46-4, Ethyl 4-amino-1-piperidinecarboxylate 60853-81-8, N,N-Dimethylaminoacetyl chloride hydrochloride 64588-88-1 68947-43-3, 1-Methyl-4-piperidinecarboxylic acid 71985-80-3, 1-Methyl-4-piperidinecarboxylic acid hydrochloride 169229-06-5, 2-Methylnicotinoyl chloride 186550-13-0, tert-Butyl 3-amino-1-pyrrolidinecarboxylate 723308-85-8 723308-86-9 723308-88-1 723308-92-7 723308-93-8 723308-94-9 723308-95-0 723308-96-1 723308-97-2 723308-98-3 723308-99-4 723309-02-2 723309-03-3 724762-77-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 850520-67-1 850520-68-2
RL: PRP (Properties)
(unclaimed nucleotide sequence; preparation of aryl sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of Th2- and eosinophil-mediated diseases)

IT 724479-29-2 724479-30-5
RL: PRP (Properties)
(unclaimed nucleotide sequence; preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT **723305-84-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of sulfonamides as inhibitors of the chemokine receptor CCR8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

RN 723305-84-8 HCAPLUS
CN 3-Piperidinecarboxylic acid, 4-[[[4-[(2-methylbenzoyl)amino]-1-naphthalenyl]sulfonyl]amino]-1-(1-oxobutyl)-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L61 ANSWER 3 OF 58 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:58101 HCAPLUS
DN 142:129794
ED Entered STN: 21 Jan 2005
TI Nuclease inhibitor cocktail
IN Latham, Gary J.; Winkler, Matthew M.; Pasloske, Brittan L.; Kudlicki, W. Antoni
PA Ambion, Inc., USA
SO U.S. Pat. Appl. Publ., 66 pp., Cont.-in-part of U.S. Ser. No. 675,860.
CODEN: USXXCO
DT **Patent**
LA English
IC ICM C12Q001-68
ICS C12N009-99
INCL 435006000; 435184000
CC 7-3 (Enzymes)
Section cross-reference(s): 3
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 2005014169	A1	20050120	US 2004-786875	20040225	<--
	US 6664379	B1	20031216	US 2000-669301	20000925	<--
	US 2005026284	A1	20050203	US 2003-675860	20030930	<--
PRAI	US 1999-155874P	P	19990924	<--		
	US 2000-669301	A1	20000925	<--		
	US 2003-675860	A2	20030930			

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
US 2005014169	ICM	C12Q001-68	
	ICS	C12N009-99	
	INCL	435006000; 435184000	
US 2005014169	NCL	435/006.000	
	ECLA	C07K016/40; C12N015/10A; C12N015/10D; C12Q001/34; G01N033/573	<--
US 6664379	NCL	530/387.900; 435/006.000; 530/388.100; 530/388.200; 530/389.100	
	ECLA	C07K016/40; C12N015/10A; C12N015/10D; C12Q001/34; G01N033/573	<--
US 2005026284	NCL	435/455.000	

ECLA C07K016/40; C12N015/10A; C12N015/10D; C12Q001/34; G01N033/573 <--

AB Methods and compns. for inhibiting and/or inactivating nucleases by using nuclease inhibitors are provided. The nuclease inhibitors comprise anti-nuclease antibodies and non-antibody nuclease inhibitors.

ST nuclease inhibitor cocktail

IT Cation exchangers
(SP sulfopropyl; nuclease inhibitor cocktail)

IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(anti-nuclease; nuclease inhibitor cocktail)

IT Nucleosides, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(bromoacetamido-; nuclease inhibitor cocktail)

IT Denaturants
(chaotropic; nuclease inhibitor cocktail)

IT Reverse transcription
Transcription, genetic
Translation, genetic
(in vitro; nuclease inhibitor cocktail)

IT Chelating agents
Detergents
Reducing agents
(nuclease inhibitor cocktail)

IT Aflatoxins
Deoxyribonucleoside triphosphates
Nucleoside triphosphates
Nucleotides, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(nuclease inhibitor cocktail)

IT 992-59-6, Benzopurpurin 4B
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Benzopurpurin B; nuclease inhibitor cocktail)

IT 7782-44-7, Oxygen, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hydroxylamine, cupric ion and; nuclease inhibitor cocktail)

IT 15158-11-9, Cupric ion, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hydroxylamine, oxygen and; nuclease inhibitor cocktail)

IT 52-90-4, Cysteine, biological studies 56-65-5, ATP, biological studies 58-64-0, 5'-ADP, biological studies 60-00-4, EDTA, biological studies 60-24-2, 2-Mercaptoethanol 61-19-8, 5'-AMP, biological studies 64-17-5, Ethanol, biological studies 64-19-7D, Acetic acid, halo derivs. 64-69-7, Iodoacetic acid 67-42-5, EGTA 70-34-8, Dinitrofluorobenzene 75-12-7, Formamide, biological studies 77-92-9, Citric acid, biological studies 83-44-3 84-53-7, 3'-UMP 85-75-6, NCI 7557 85-94-9, 2'-CMP 87-03-6, NCI 1698 91-45-2, NCI 1741 97-78-9, N-Laurylsarcosine 110-60-1, Putrescine 117-46-4, NCI 16169 118-50-3, NCI 1743 120-73-0, Purine 128-08-5, N-Bromosuccinimide 131-83-9, 2'-UMP 132-34-3, NCI 16224 138-85-2, p-Chloromercuribenzoate 145-63-1, Suramin 289-95-2, Pyrimidine 302-04-5, Thiocyanate, biological studies 593-84-0, Guanidinium thiocyanate 611-08-5, 5-Nitrouracil 701-64-4, Phenyl phosphate 915-67-3, Amaranth 994-36-5, Sodium citrate 1053-73-2 1074-12-0, Phenylglyoxal 1113-59-3, Bromopyruvic acid 1184-84-5D, Vinylsulfonic acid, oligomers 1609-47-8, Diethyl pyrocarbonate 1716-22-9, NCI 9360 1738-02-9, NCI 174066 1787-61-7, Eriochrome black T 1936-15-8, Orange G 1937-35-5, Direct red 13 2429-84-7, Direct red 1 2610-05-1, NCI 9617 2611-82-7, New coccine 2783-94-0, Sunset yellow 2863-04-9, PTp 3483-12-3, DTT 3761-53-3, Xylidene ponceau 2R 4321-69-1, Acid violet 7 4431-00-9, Aurintricarboxylic acid 4682-47-7, NCI 45542 5542-28-9, Ap4A 5859-04-1, NCI 45538 5859-05-2, NCI 45540 5859-07-4, NCI 7814 5959-90-0, Ap3A 5961-85-3, TCEP 6252-76-2, Violamine R 6268-29-7, NCI 37176 6360-07-2, Acid red 37 6373-39-3, NCI 16163 6635-00-3, NCI 42067 6814-92-2, 4-Thiouridine 3'-phosphate 7250-00-2, NCI 17061 7330-46-3, CB 37136 7439-89-6, Iron, biological studies 7439-93-2,

Lithium, biological studies 7439-95-4, Magnesium, biological studies 7439-96-5, Manganese, biological studies 7440-50-8, Copper, biological studies 7440-62-2D, Vanadium, complexes 7440-66-6, Zinc, biological studies 7440-70-2, Calcium, biological studies 7447-40-7, Potassium chloride, biological studies 7647-14-5, Sodium chloride, biological studies 7783-20-2, Ammonium sulfate, biological studies 9001-72-3, Pancreatic proteinase 9001-92-7, Protease 9001-99-4, Ribonuclease 9002-93-1, Triton X100 9003-98-9, DNase 9005-64-5, Tween 20 9013-53-0, Micrococcal nuclease 9014-01-1, Subtilisin 9016-45-9, NP40 9026-12-4, Ribonuclease T1 9026-81-7, Nuclease 10261-17-3, NCI 12455 13400-10-7 14269-87-5, NCI 45557 14797-73-0, Perchlorate 17851-32-0, CB 152591 19192-40-6 25180-30-7, NCI 47755 25188-31-2, NCI 7815 25188-44-7, NCI 75778 25215-10-5, Guanidinium 25305-76-4, NCI 8674 25317-07-1, S321443 25747-19-7, NCI 65820 26101-52-0, Polyvinylsulfonic acid 30211-77-9 31325-39-0, Tyrosine-glutamate copolymer 32266-60-7, NCI 88947 35290-55-2 37288-25-8, S1 Nuclease 39450-01-6, Proteinase K 41708-91-2, Ap5A 47793-13-5, CB 186847 51321-79-0, NCI 224131 51550-25-5, Beryllon II 53524-14-4, NCI 45550 62587-73-9, Cefsulodin 71494-74-1, NCI 45541 71799-74-1, NCI 47740 85233-19-8, BAPTA 96748-60-6 98727-78-7, NCI 45571 109352-11-6, NCI 227726 114752-67-9 125091-26-1, NCI 75916 151780-52-8, NCI 34933 151780-56-2, NCI 79741 152795-86-3, CB 180553 157872-23-6, NCI 12857 209794-02-5, DUppAp 209794-04-7, DUppA2'p 209794-06-9, PdUppAp 209794-08-1, PTppAp 209794-11-6, TppdA 221170-25-8 257641-01-3 318263-94-4, CB 181429 330448-66-3, CB 181145 330466-77-8, CB 039263 331675-78-6, CB 473872 333396-35-3, CB 534510 339230-14-7, CB 181431 351891-58-2, CB 467929 351891-59-3, CB 477474 351893-66-8, CB 224197 413582-16-8, CB 205125 **501444-05-9**, CB 180582 501444-06-0, NCI 65828 556795-91-6, NCI 65841 556795-92-7, NCI 79596 556795-93-8, NCI 45618 556795-94-9, NCI 65568 556795-95-0, NCI 65553 556795-96-1, NCI 58047 556795-97-2, NCI 65847 556795-98-3, NCI 45608 556795-99-4, NCI 75661 556796-01-1, NCI 724225 556796-02-2, NCI 47735 556796-03-3, NCI 65844 556796-04-4, NCI 45601 556796-05-5, NCI 65546 556796-06-6, NCI 65855 556796-07-7, NCI 75963 556796-08-8, NCI 45612 556796-12-4, NCI 37169 557796-41-5, NCI 65845 755040-79-0, PrBZBP 755040-80-3, NCI 73416 755040-81-4, JLJ-1 755040-82-5, JLJ-2 755040-83-6, JLJ-3 755040-84-7, NCI 77521 755040-85-8, NCI 79744 755040-86-9, NCI D726712 755040-94-9, CB 540408 755040-95-0, CB 202516 784984-43-6 824944-55-0 824944-63-0
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(nuclease inhibitor cocktail)

IT 7803-49-8, Hydroxylamine, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(oxygen, cupric ion and; nuclease inhibitor cocktail)

IT **501444-05-9**, CB 180582
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(nuclease inhibitor cocktail)

RN 501444-05-9 HCAPLUS

CN Benzoic acid, 3,3'-methylenebis[6-[[(4-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



L61 ANSWER 4 OF 58 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:565230 HCAPLUS

DN 141:140197

ED Entered STN: 15 Jul 2004

TI Sulfonamides prepared as inhibitors of the cytokine receptor Ccr8 for the

treatment of Th2- and eosinophil-mediated diseases
IN Dai, Mingshi; Jenkins, Tracy J.; Guan, Bing; Ghosh, Shomir; Minor, Charles
PA Millennium Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 251 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM C07D295-26
ICS C07D213-42; C07D211-58; C07D207-14; C07C311-46; A61K031-18; A61K031-4402; A61K031-4406; A61K031-4409; A61K031-4468; A61K031-40; A61P011-06; A61P029-00; A61P037-08
CC 25-22 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 63
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004058736	A1	20040715	WO 2003-US41199	20031223 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-436508P P 20021223 <--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004058736	ICM	C07D295-26
	ICS	C07D213-42; C07D211-58; C07D207-14; C07C311-46; A61K031-18; A61K031-4402; A61K031-4406; A61K031-4409; A61K031-4468; A61K031-40; A61P011-06; A61P029-00; A61P037-08
WO 2004058736	ECLA	C07C311/37; C07C311/46; C07D207/14; C07D211/58; C07D213/42C; C07D295/22C2 <--

OS MARPAT 141:140197
GI



II

AB Compds. R1(CH2)mXYN(R2)X1ArS(:O)nNHR3 (I) [Ar = (un)substituted bivalent six-membered aryl group fused to either a six-membered aromatic moiety or to a five- or six-membered nonarom. moiety; R1 = (un)substituted aromatic or nonarom. group; R2, R4 = H, alkyl, (un)substituted aromatic or nonarom. group; R3 = (un)substituted Ph, benzyl, phenethyl, or a non-aromatic ring; X = bond, O, R4N; X1 = bond, carbonyl, (un)substituted methylene; Y = bond, CH2, C(:Z); Z = O, NH, S (if Y = bond then X = bond); m = 0-3; n = 1-2; if X = NR4, R4N(CH2)mR1 may comprise an (un)substituted nonarom. heterocyclic group] such as II are prepared as inhibitors of the chemokine receptor Ccr8 for the treatment of diseases such as asthma, atopic or allergic contact dermatitis, allergic rhinitis, systemic anaphylaxis, rheumatoid arthritis,

inflammatory bowel disease, or graft rejection which are mediated by either Th2 cells or eosinophils. Acylation of 4-amino-1-naphthalenesulfonic acid with benzoyl chloride, chlorination of the derived 4-(benzoylamino)-1-naphthalenesulfonic acid pyridine salt with thionyl chloride, and addition of m-anisidine yields II. Ki values for the binding of I to Ccr8 are disclosed; for example, II binds to Ccr8 with a Ki value of < 0.5 μM.

ST sulfonamide prepn inhibitor Ccr8 treatment Th2 eosinophil mediated disease

IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CCR8; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT Allergy
Inflammation
Nose, disease
(allergic rhinitis; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases)

IT Dermatitis
(atopic; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases)

IT Autoimmune disease
Inflammation
Thyroid gland, disease
(autoimmune thyroiditis; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases)

IT Dermatitis
(contact, allergic; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT Inflammation
Kidney, disease
(glomerulonephritis; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases)

IT T cell (lymphocyte)
(helper cell/inducer, TH2; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT Allergy
(hypersensitivity; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases)

IT Intestine, disease
(inflammatory; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases)

IT Allergy
(insect sting; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases)

IT Autoimmune disease
(insulin-dependent diabetes mellitus; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases)

IT Diabetes mellitus
(insulin-dependent; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases)

IT Allergy inhibitors
Anaphylaxis
Antiarthritics

Antiasthmatics
Antidiabetic agents
Behcet's syndrome
Drug allergy
Eczema
Immunosuppressants
Multiple sclerosis
Myasthenia gravis
Osteoarthritis
Transplant rejection
Urticaria
(preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases)

IT Asthma
Dermatitis
Eosinophil
Rheumatoid arthritis
(preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT Lupus erythematosus
(systemic; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases)

IT 723306-51-2P 723306-54-5P 723307-06-0P
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(drug candidate; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 723306-52-3P 723306-53-4P 723306-55-6P 723306-56-7P 723307-21-9P
723307-22-0P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 419539-65-4P 723304-75-4P 723305-14-4P 723305-23-5P 723305-24-6P
723305-36-0P 723305-44-0P 723305-56-4P 723305-72-4P 723305-79-1P
723305-83-7P 723306-02-3P 723306-03-4P 723306-07-8P 723306-15-8P
723306-16-9P 723306-20-5P 723306-24-9P 723306-39-6P 723306-41-0P
723306-42-1P 723306-44-3P 723306-49-8P 723306-50-1P 723306-64-7P
723306-65-8P 723306-74-9P 723306-75-0P 723306-76-1P 723306-77-2P
723307-14-0P 723307-15-1P 723307-23-1P 723307-24-2P 723307-26-4P
723307-27-5P 723307-28-6P 723307-29-7P 723307-30-0P 723307-31-1P
723307-32-2P 723307-33-3P 723307-34-4P 723307-35-5P 723307-36-6P
723307-37-7P 723307-38-8P 723307-39-9P 723307-58-2P 723307-60-6P
723307-61-7P 723307-62-8P 724762-73-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 723304-47-0P 723304-48-1P 723304-49-2P 723304-50-5P 723304-51-6P
723304-52-7P 723304-53-8P 723304-54-9P 723304-55-0P 723304-56-1P
723304-57-2P 723304-58-3P 723304-59-4P 723304-60-7P 723304-61-8P
723304-62-9P 723304-63-0P 723304-64-1P 723304-65-2P 723304-66-3P
723304-67-4P 723304-68-5P 723304-69-6P 723304-70-9P 723304-71-0P
723304-72-1P 723304-73-2P 723304-74-3P 723304-76-5P 723304-77-6P
723304-78-7P 723304-79-8P 723304-80-1P 723304-81-2P 723304-82-3P
723304-83-4P 723304-85-6P 723304-87-8P 723304-88-9P 723304-89-0P
723304-90-3P 723304-91-4P 723304-92-5P 723304-93-6P 723304-94-7P

723304-95-8P 723304-96-9P 723304-97-0P 723304-98-1P 723304-99-2P
723305-00-8P 723305-01-9P 723305-02-0P 723305-03-1P 723305-04-2P
723305-05-3P 723305-06-4P 723305-07-5P 723305-08-6P 723305-09-7P
723305-10-0P 723305-11-1P 723305-12-2P 723305-13-3P 723305-15-5P
723305-16-6P 723305-17-7P 723305-18-8P 723305-19-9P 723305-20-2P
723305-21-3P 723305-22-4P 723305-25-7P 723305-26-8P 723305-27-9P
723305-28-0P 723305-29-1P 723305-30-4P 723305-31-5P 723305-32-6P
723305-33-7P 723305-34-8P 723305-35-9P 723305-37-1P 723305-38-2P
723305-39-3P 723305-40-6P 723305-41-7P 723305-42-8P 723305-43-9P
723305-45-1P 723305-46-2P 723305-47-3P 723305-48-4P 723305-49-5P
723305-50-8P 723305-51-9P 723305-52-0P 723305-53-1P 723305-54-2P
723305-55-3P 723305-57-5P 723305-58-6P 723305-59-7P 723305-60-0P
723305-61-1P 723305-62-2P 723305-63-3P 723305-64-4P 723305-65-5P
723305-66-6P 723305-67-7P 723305-68-8P 723305-69-9P 723305-70-2P
723305-71-3P 723305-73-5P 723305-74-6P 723305-75-7P 723305-76-8P
723305-77-9P 723305-80-4P 723305-81-5P **723305-84-8P**
723305-85-9P 723305-86-0P 723305-87-1P 723305-88-2P 723305-89-3P
723305-90-6P 723305-91-7P 723305-92-8P 723305-93-9P 723305-94-0P
723305-95-1P 723305-97-3P 723305-99-5P 723306-00-1P 723306-01-2P
723306-04-5P 723306-05-6P 723306-06-7P 723306-08-9P 723306-09-0P
723306-10-3P 723306-11-4P 723306-12-5P 723306-13-6P 723306-14-7P
723306-17-0P 723306-18-1P 723306-19-2P 723306-21-6P 723306-22-7P
723306-23-8P 723306-25-0P 723306-26-1P 723306-27-2P 723306-28-3P
723306-29-4P 723306-31-8P 723306-32-9P 723306-34-1P 723306-35-2P
723306-36-3P 723306-37-4P 723306-46-5P 723306-48-7P 723306-57-8P
723306-58-9P 723306-59-0P 723306-60-3P 723306-61-4P 723306-62-5P
723306-63-6P 723306-66-9P 723306-67-0P 723306-68-1P 723306-69-2P
723306-70-5P 723306-71-6P 723306-72-7P 723306-73-8P 723306-78-3P
723306-79-4P 723306-80-7P 723306-81-8P 723306-82-9P 723306-83-0P
723306-84-1P 723306-85-2P 723306-86-3P 723306-87-4P 723306-88-5P
723306-89-6P 723306-90-9P 723306-91-0P 723306-92-1P 723306-93-2P
723306-94-3P 723306-95-4P 723306-96-5P 723306-97-6P 723306-98-7P
723306-99-8P 723307-00-4P 723307-01-5P 723307-02-6P 723307-03-7P
723307-04-8P 723307-05-9P 723307-07-1P 723307-08-2P 723307-09-3P
723307-10-6P 723307-11-7P 723307-12-8P 723307-13-9P 723307-16-2P
723307-17-3P 723307-18-4P 723307-19-5P 723307-20-8P 723307-25-3P
723307-40-2P 723307-41-3P 723307-42-4P 723307-43-5P 723307-44-6P
723307-45-7P 723307-46-8P 723307-47-9P 723307-48-0P 723307-49-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 723307-50-4P 723307-51-5P 723307-52-6P 723307-53-7P 723307-54-8P
723307-55-9P 723307-56-0P 723307-57-1P 723307-63-9P 723307-64-0P
723307-65-1P 723307-67-3P 723307-69-5P 723307-71-9P 723307-73-1P
723307-75-3P 723307-77-5P 723307-79-7P 723307-81-1P 723307-83-3P
723307-85-5P 723307-87-7P 723307-89-9P 723307-91-3P 723307-93-5P
723307-95-7P 723307-97-9P 723307-98-0P 723307-99-1P 723308-00-7P
723308-01-8P 723308-02-9P 723308-03-0P 723311-86-2P 724438-28-2P
724438-31-7P 724762-72-5P 724762-74-7P 724762-75-8P 724762-76-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 316-69-8P, 4-Fluoro-1-naphthalenesulfonyl chloride 700-45-8P 836-21-5P
31861-08-2P 82378-86-7P 92309-57-4P 124868-89-9P 181269-69-2P
460985-74-4P 473838-36-7P 723308-53-0P 723308-54-1P 723308-55-2P
723308-56-3P 723308-57-4P 723308-58-5P 723308-59-6P 723308-60-9P
723308-61-0P 723308-62-1P 723308-63-2P 723308-64-3P 723308-65-4P
723308-66-5P 723308-67-6P 723308-68-7P 723308-69-8P 723308-70-1P
723308-71-2P 723308-72-3P 723308-73-4P 723308-75-6P 723308-76-7P
723308-77-8P 723308-78-9P 723308-79-0P 723308-80-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 723309-00-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; sulfonamides prepared as inhibitors of the cytokine receptor Ccr8 for the treatment of Th2- and eosinophil-mediated diseases)

IT 62-53-3, Aniline, reactions 75-07-0, Acetaldehyde, reactions 75-31-0, Isopropylamine, reactions 79-14-1, Hydroxyacetic acid, reactions 79-44-7, Dimethylcarbamyl chloride 84-86-6, 4-Amino-1-naphthalenesulfonic acid 85-44-9, Phthalic anhydride 88-10-8, Diethylcarbamyl chloride 89-98-5, 2-Chlorobenzaldehyde 92-54-6, 1-Phenylpiperazine 92-67-1, 4-Biphenylamine 98-01-1, 2-Furancarboxaldehyde, reactions 98-09-9, Benzenesulfonyl chloride 99-88-7, 4-Isopropylaniline 100-07-2, p-Methoxybenzoyl chloride 100-46-9, Benzylamine, reactions 100-60-7, N-Methylcyclohexylamine 103-71-9, Phenyl isocyanate, reactions 103-72-0, Phenyl isothiocyanate 103-80-0, Phenylacetyl chloride 104-53-0, 3-Phenylpropionaldehyde 104-88-1, 4-Chlorobenzaldehyde, reactions 108-00-9, 2-(Dimethylamino)ethylamine 108-91-8, Cyclohexylamine, reactions 108-94-1, Cyclohexanone, reactions 109-01-3, 1-Methylpiperazine 109-89-7, Diethylamine, reactions 110-78-1, 1-Isocyanatopropane 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 122-04-3, p-Nitrobenzoyl chloride 122-78-1, Phenylacetaldehyde 123-11-5, 4-Methoxybenzaldehyde, reactions 123-75-1, Pyrrolidine, reactions 321-38-0, 1-Fluoronaphthalene 371-40-4, 4-Fluoroaniline 393-52-2, 2-Fluorobenzoyl chloride 455-14-1, 4-Trifluoromethylaniline 459-57-4, 4-Fluorobenzaldehyde 462-08-8, 3-Aminopyridine 475-11-6, N-Methylproline 498-60-2, 3-Furancarboxaldehyde 500-22-1, 3-Pyridinecarboxaldehyde 504-24-5, 4-Aminopyridine 504-29-0, 2-Aminopyridine 527-69-5, 2-Furancarbonyl chloride 529-20-4, 2-Methylbenzaldehyde 587-04-2, 3-Chlorobenzaldehyde 589-16-2, 4-Ethylaniline 615-18-9, 2-Chlorobenzoxazole 872-85-5, 4-Pyridinecarboxaldehyde 933-88-0, 2-Methylbenzoyl chloride 1003-03-8, Cyclopentylamine 1074-82-4, Potassium phthalimide 1121-60-4, 2-Pyridinecarboxaldehyde 1192-63-8, 1-Pyrrolidinecarbonyl chloride 1445-73-4, 1-Methyl-4-piperidinone 1530-88-7, 1-Pyrrolidinecarbonitrile 1711-05-3, 3-Methoxybenzoyl chloride 1711-06-4, 3-Methylbenzoyl chloride 1795-48-8, 2-Isocyanatopropane 2043-61-0, Cyclohexanecarboxaldehyde 2217-41-6, 5,6,7,8-Tetrahydro-1-naphthalenamine 2627-86-3, (S)-α-Methylbenzylamine 2719-27-9, Cyclohexylcarbonyl chloride 3612-20-2, 1-Benzyl-4-piperidone 3731-53-1, 4-(Aminomethyl)pyridine 3839-22-3, 2-Cyanobenzoic acid 3886-69-9, (R)-α-Methylbenzylamine 3939-01-3 4023-34-1, Cyclopropanecarbonyl chloride 4530-20-5, Boc-glycine 4595-60-2, 2-Bromopyrimidine 5006-22-4, Cyclobutanecarbonyl chloride 5337-03-1, Tetrahydropyran-4-carboxylic acid 5657-70-5, 1-Methyl-3-piperidinecarboxylic acid 10111-08-7, 1H-Imidazole-2-carboxaldehyde 13939-69-0, 1-Piperidinecarbonyl chloride 14254-57-0, Isonicotinoyl chloride 15761-38-3 15761-39-4 16948-16-6 20260-53-1, Nicotinoyl chloride hydrochloride 21615-34-9, 2-Methoxybenzoyl chloride 21900-46-9, 2,3-Dimethylbenzoyl chloride 22328-43-4, 2,5-Dimethylbenzoyl chloride 31301-45-8 34306-42-8 34737-89-8, 1-Benzyl-3-methyl-4-piperidinone 38870-89-2, Methoxyacetyl chloride 39178-35-3, Isonicotinoyl chloride hydrochloride 41716-12-5 50541-93-0, 1-Benzyl-4-piperidinamine 51552-16-0, Dimethylaminoacetyl chloride 53035-92-0, 4-Tetrahydropyranyl isocyanate 58859-46-4, Ethyl 4-amino-1-piperidinecarboxylate 60853-81-8, N,N-Dimethylaminoacetyl chloride hydrochloride 64588-88-1 68947-43-3, 1-Methyl-4-piperidinecarboxylic acid 71985-80-3, 1-Methyl-4-piperidinecarboxylic acid hydrochloride 169229-06-5, 2-Methylnicotinoyl chloride 186550-13-0, tert-Butyl 3-amino-1-pyrrolidinecarboxylate 723308-85-8 723308-86-9 723308-88-1 723308-92-7 723308-93-8 723308-94-9

723308-95-0 723308-96-1 723308-97-2 723308-98-3 723308-99-4
724762-77-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 725372-11-2 725372-12-3
RL: PRP (Properties)
(unclaimed sequence; sulfonamides prepared as inhibitors of the cytokine receptor Ccr8 for the treatment of Th2- and eosinophil-mediated diseases)

IT **723305-84-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

RN 723305-84-8 HCAPLUS
CN 3-Piperidinecarboxylic acid, 4-[[[4-[(2-methylbenzoyl)amino]-1-naphthalenyl]sulfonyl]amino]-1-(1-oxobutyl)-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L61 ANSWER 5 OF 58 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:565207 HCAPLUS
DN 141:123482
ED Entered STN: 15 Jul 2004
TI Sulfonamides prepared as inhibitors of the cytokine receptor Ccr8 for the treatment of Th2- and eosinophil-mediated diseases
IN Guan, Bing; Minor, Charles; Dai, Mingshi; Ghosh, Shomir; Jenkins, Tracy J.; Li, Gang; Burdi, Douglas F.; Bennett, Robert A.
PA Millennium Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 301 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM C07D211-58
ICS C07D207-14; C07D213-81; C07C311-46; A61K031-18; A61K031-4402;

A61K031-4406; A61K031-4409; A61K031-4468; A61K031-40; A61P011-06; A61P029-00; A61P037-08; C07D213-76; C07D211-28

CC 25-22 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 63

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004058709	A1	20040715	WO 2003-US41360	20031223 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-436537P P 20021223 <--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004058709	ICM	C07D211-58
	ICS	C07D207-14; C07D213-81; C07C311-46; A61K031-18; A61K031-4402; A61K031-4406; A61K031-4409; A61K031-4468; A61K031-40; A61P011-06; A61P029-00; A61P037-08; C07D213-76; C07D211-28
WO 2004058709	ECLA	C07C311/46; C07C311/47; C07C335/16; C07D207/14; C07D211/28; C07D211/58; C07D401/12+211+209; C07D401/12+213+211; C07D401/12+233+211; C07D405/12+307B+211; C07D405/12+309+211; C07D413/12+261+211 <--

OS MARPAT 141:123482

GI



II

AB Compds. R1(CH2)mXYN(R2)X1ArS(:O)nNHR3 (I) [Ar = (un)substituted bivalent six-membered aryl group fused to either a six-membered aromatic moiety or to a five- or six-membered nonarom. moiety; R1 = (un)substituted aromatic or nonarom. group; R2, R4 = H, alkyl, (un)substituted aromatic or nonarom. group; R3 = (un)substituted Ph, benzyl, phenethyl, or a non-aromatic ring; X = bond, O, R4N; X1 = bond, carbonyl, (un)substituted methylene; Y = bond, CH2, C(:Z); Z = O, NH, S (if Y = bond then X = bond); m = 0-3; n = 1-2; if X = NR4, R4N(CH2)mR1 may comprise an (un)substituted nonarom. heterocyclic group] such as II are prepared as inhibitors of the chemokine receptor Ccr8 for the treatment of diseases such as asthma, atopic or allergic contact dermatitis, allergic rhinitis, systemic anaphylaxis, rheumatoid arthritis, inflammatory bowel disease, or graft rejection which are mediated by either Th2 cells or eosinophils. Acylation of 4-amino-1-naphthalenesulfonic acid with benzoyl chloride, chlorination of the derived 4-(benzoylamino)-1-naphthalenesulfonic acid pyridine salt with thionyl chloride, and addition of m-anisidine yields II. Ki values for the binding of I to Ccr8 are disclosed; for example, II binds to Ccr8 with a Ki value of < 0.5 μM.

ST sulfonamide prepn inhibitor Ccr8 treatment Th2 eosinophil mediated disease

IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CCR8; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)
IT Allergy
Inflammation
Nose, disease
(allergic rhinitis; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases)
IT Dermatitis
(atopic; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases)
IT Autoimmune disease
Inflammation
Thyroid gland, disease
(autoimmune thyroiditis; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases)
IT Dermatitis
(contact, allergic; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)
IT Inflammation
Kidney, disease
(glomerulonephritis; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases)
IT T cell (lymphocyte)
(helper cell/inducer, TH2; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)
IT Allergy
(hypersensitivity; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases)
IT Intestine, disease
(inflammatory; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases)
IT Allergy
(insect sting; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases)
IT Autoimmune disease
(insulin-dependent diabetes mellitus; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases)
IT Diabetes mellitus
(insulin-dependent; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases)
IT Allergy inhibitors
Anaphylaxis
Antiarthritics
Antiasthmatics
Antidiabetic agents
Behcet's syndrome
Drug allergy
Eczema
Immunosuppressants
Multiple sclerosis
Myasthenia gravis

Osteoarthritis
Transplant rejection
Urticaria
(preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases)

IT Asthma
Dermatitis
Eosinophil
Rheumatoid arthritis
(preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT Lupus erythematosus
(systemic; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases)

IT 723306-51-2P 723306-54-5P 723307-06-0P
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(drug candidate; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 723306-52-3P 723306-53-4P 723306-55-6P 723306-56-7P 723307-21-9P
723307-22-0P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 419539-65-4P 723304-75-4P 723305-14-4P 723305-23-5P 723305-24-6P
723305-36-0P 723305-44-0P 723305-56-4P 723305-72-4P 723305-79-1P
723305-83-7P 723306-02-3P 723306-03-4P 723306-07-8P 723306-15-8P
723306-16-9P 723306-20-5P 723306-24-9P 723306-39-6P 723306-41-0P
723306-42-1P 723306-44-3P 723306-49-8P 723306-50-1P 723306-64-7P
723306-65-8P 723306-74-9P 723306-75-0P 723306-76-1P 723306-77-2P
723307-14-0P 723307-15-1P 723307-23-1P 723307-24-2P 723307-26-4P
723307-27-5P 723307-28-6P 723307-29-7P 723307-30-0P 723307-31-1P
723307-32-2P 723307-33-3P 723307-34-4P 723307-35-5P 723307-36-6P
723307-37-7P 723307-38-8P 723307-39-9P 723307-58-2P 723307-60-6P
723307-61-7P 723307-62-8P 723308-44-9P 723308-45-0P 723308-46-1P
724762-73-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 723304-35-6P 723304-36-7P 723304-37-8P 723304-38-9P 723304-39-0P
723304-40-3P 723304-41-4P 723304-42-5P 723304-43-6P 723304-44-7P
723304-45-8P 723304-46-9P 723304-47-0P 723304-48-1P 723304-49-2P
723304-50-5P 723304-51-6P 723304-52-7P 723304-53-8P 723304-54-9P
723304-55-0P 723304-56-1P 723304-57-2P 723304-58-3P 723304-59-4P
723304-60-7P 723304-61-8P 723304-62-9P 723304-63-0P 723304-64-1P
723304-65-2P 723304-66-3P 723304-67-4P 723304-68-5P 723304-69-6P
723304-70-9P 723304-71-0P 723304-72-1P 723304-73-2P 723304-74-3P
723304-76-5P 723304-77-6P 723304-78-7P 723304-79-8P 723304-80-1P
723304-81-2P 723304-82-3P 723304-83-4P 723304-85-6P 723304-87-8P
723304-88-9P 723304-89-0P 723304-90-3P 723304-91-4P 723304-92-5P
723304-93-6P 723304-94-7P 723304-95-8P 723304-96-9P 723304-97-0P
723304-98-1P 723304-99-2P 723305-00-8P 723305-01-9P 723305-02-0P
723305-03-1P 723305-04-2P 723305-05-3P 723305-06-4P 723305-07-5P
723305-08-6P 723305-09-7P 723305-10-0P 723305-11-1P 723305-12-2P
723305-13-3P 723305-15-5P 723305-16-6P 723305-17-7P 723305-18-8P

723305-19-9P 723305-20-2P 723305-21-3P 723305-22-4P 723305-25-7P
723305-26-8P 723305-27-9P 723305-28-0P 723305-29-1P 723305-30-4P
723305-31-5P 723305-32-6P 723305-33-7P 723305-34-8P 723305-35-9P
723305-37-1P 723305-38-2P 723305-39-3P 723305-40-6P 723305-41-7P
723305-42-8P 723305-43-9P 723305-45-1P 723305-46-2P 723305-47-3P
723305-48-4P 723305-49-5P 723305-50-8P 723305-51-9P 723305-52-0P
723305-53-1P 723305-54-2P 723305-55-3P 723305-57-5P 723305-58-6P
723305-59-7P 723305-60-0P 723305-61-1P 723305-62-2P 723305-63-3P
723305-64-4P 723305-65-5P 723305-66-6P 723305-67-7P 723305-68-8P
723305-69-9P 723305-70-2P 723305-71-3P 723305-73-5P 723305-74-6P
723305-75-7P 723305-76-8P 723305-77-9P 723305-80-4P 723305-81-5P
723305-84-8P 723305-85-9P 723305-86-0P 723305-87-1P
723305-88-2P 723305-89-3P 723305-90-6P 723305-91-7P 723305-92-8P
723305-93-9P 723305-94-0P 723305-95-1P 723305-97-3P 723305-99-5P
723306-00-1P 723306-01-2P 723306-04-5P 723306-05-6P 723306-06-7P
723306-08-9P 723306-09-0P 723306-10-3P 723306-11-4P 723306-12-5P
723306-13-6P 723306-14-7P 723306-17-0P 723306-18-1P 723306-19-2P
723306-21-6P 723306-22-7P 723306-23-8P 723306-25-0P 723306-26-1P
723306-27-2P 723306-28-3P 723306-29-4P 723306-31-8P 723306-32-9P
723306-34-1P 723306-35-2P 723306-36-3P 723306-37-4P 723306-46-5P
723306-48-7P 723306-57-8P 723306-58-9P 723306-59-0P 723306-60-3P
723306-61-4P 723306-62-5P 723306-63-6P 723306-66-9P 723306-67-0P
723306-68-1P 723306-69-2P 723306-70-5P 723306-71-6P 723306-72-7P
723306-73-8P 723306-78-3P 723306-79-4P 723306-80-7P 723306-81-8P
723306-82-9P 723306-83-0P 723306-84-1P 723306-85-2P 723306-86-3P
723306-87-4P 723306-88-5P 723306-89-6P 723306-90-9P 723306-91-0P
723306-92-1P 723306-93-2P 723306-94-3P 723306-95-4P 723306-96-5P
723306-97-6P 723306-98-7P 723306-99-8P 723307-00-4P 723307-01-5P
723307-02-6P 723307-03-7P 723307-04-8P 723307-05-9P 723307-07-1P
723307-08-2P 723307-09-3P 723307-10-6P 723307-11-7P 723307-12-8P
723307-13-9P 723307-16-2P 723307-17-3P 723307-18-4P 723307-19-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 723307-20-8P 723307-25-3P 723307-40-2P 723307-41-3P 723307-42-4P
723307-43-5P 723307-44-6P 723307-45-7P 723307-46-8P 723307-47-9P
723307-48-0P 723307-49-1P 723307-50-4P 723307-51-5P 723307-52-6P
723307-53-7P 723307-54-8P 723307-55-9P 723307-56-0P 723307-57-1P
723307-63-9P 723307-64-0P 723307-65-1P 723307-67-3P 723307-69-5P
723307-71-9P 723307-73-1P 723307-75-3P 723307-77-5P 723307-79-7P
723307-81-1P 723307-83-3P 723307-85-5P 723307-87-7P 723307-89-9P
723307-91-3P 723307-93-5P 723307-95-7P 723307-97-9P 723307-98-0P
723307-99-1P 723308-00-7P 723308-01-8P 723308-02-9P 723308-03-0P
723308-04-1P 723308-05-2P 723308-06-3P 723308-07-4P 723308-08-5P
723308-09-6P 723308-10-9P 723308-11-0P 723308-12-1P 723308-13-2P
723308-14-3P 723308-15-4P 723308-16-5P 723308-18-7P 723308-19-8P
723308-20-1P 723308-21-2P 723308-22-3P 723308-23-4P 723308-24-5P
723308-25-6P 723308-26-7P 723308-27-8P 723308-28-9P 723308-29-0P
723308-30-3P 723308-31-4P 723308-33-6P 723308-34-7P 723308-35-8P
723308-36-9P 723308-37-0P 723308-38-1P 723308-39-2P 723308-40-5P
723308-41-6P 723308-42-7P 723308-43-8P 723308-47-2P 723308-48-3P
723308-49-4P 723308-50-7P 723308-51-8P 723308-52-9P 723309-01-1P
723311-86-2P 724762-72-5P 724762-74-7P 724762-75-8P 724762-76-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 316-69-8P, 4-Fluoro-1-naphthalenesulfonyl chloride 700-45-8P 836-21-5P
6968-09-8P 31861-08-2P 82378-86-7P 92309-57-4P 124868-89-9P
181269-69-2P 294840-12-3P 460985-74-4P 473838-36-7P 723308-53-0P
723308-54-1P 723308-55-2P 723308-56-3P 723308-57-4P 723308-58-5P

723308-59-6P 723308-60-9P 723308-61-0P 723308-62-1P 723308-63-2P
723308-64-3P 723308-65-4P 723308-66-5P 723308-67-6P 723308-68-7P
723308-69-8P 723308-70-1P 723308-71-2P 723308-72-3P 723308-73-4P
723308-75-6P 723308-76-7P 723308-77-8P 723308-78-9P 723308-79-0P
723308-80-3P 723308-81-4P 723308-82-5P 723308-83-6P 723308-84-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 723309-00-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; sulfonamides prepared as inhibitors of the cytokine receptor Ccr8 for the treatment of Th2- and eosinophil-mediated diseases)

IT 62-53-3, Aniline, reactions 75-07-0, Acetaldehyde, reactions 75-31-0, Isopropylamine, reactions 79-14-1, Hydroxyacetic acid, reactions 79-44-7, Dimethylcarbamyl chloride 84-86-6, 4-Amino-1-naphthalenesulfonic acid 84-89-9, 1-Naphthylamine-5-sulfonic acid 85-44-9, Phthalic anhydride 86-52-2, 1-Chloromethylnaphthalene 86-55-5, 1-Naphthalenecarboxylic acid 87-59-2, 2,3-Dimethylaniline 88-10-8, Diethylcarbamyl chloride 89-98-5, 2-Chlorobenzaldehyde 92-54-6, 1-Phenylpiperazine 92-67-1, 4-Biphenylamine 95-51-2, 2-Chloroaniline 98-01-1, 2-Furancarboxaldehyde, reactions 98-09-9, Benzenesulfonyl chloride 99-88-7, 4-Isopropylaniline 100-07-2, p-Methoxybenzoyl chloride 100-46-9, Benzylamine, reactions 100-60-7, N-Methylcyclohexylamine 103-71-9, Phenyl isocyanate, reactions 103-72-0, Phenyl isothiocyanate 103-80-0, Phenylacetyl chloride 104-53-0, 3-Phenylpropionaldehyde 104-88-1, 4-Chlorobenzaldehyde, reactions 108-00-9, 2-(Dimethylamino)ethylamine 108-91-8, Cyclohexylamine, reactions 108-94-1, Cyclohexanone, reactions 109-01-3, 1-Methylpiperazine 109-89-7, Diethylamine, reactions 110-78-1, 1-Isocyanatopropane 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 119-28-8, 8-Amino-2-naphthalenesulfonic acid 122-04-3, p-Nitrobenzoyl chloride 122-78-1, Phenylacetaldehyde 123-11-5, 4-Methoxybenzaldehyde, reactions 123-75-1, Pyrrolidine, reactions 321-38-0, 1-Fluoronaphthalene 371-40-4, 4-Fluoroaniline 393-52-2, 2-Fluorobenzoyl chloride 455-14-1, 4-Trifluoromethylaniline 459-57-4, 4-Fluorobenzaldehyde 462-08-8, 3-Aminopyridine 475-11-6, N-Methylproline 498-60-2, 3-Furancarboxaldehyde 500-22-1, 3-Pyridinecarboxaldehyde 504-24-5, 4-Aminopyridine 504-29-0, 2-Aminopyridine 527-69-5, 2-Furancarbonyl chloride 529-20-4, 2-Methylbenzaldehyde 587-04-2, 3-Chlorobenzaldehyde 589-16-2, 4-Ethylaniline 615-18-9, 2-Chlorobenzoxazole 872-85-5, 4-Pyridinecarboxaldehyde 933-88-0, 2-Methylbenzoyl chloride 1003-03-8, Cyclopentylamine 1074-82-4, Potassium phthalimide 1121-60-4, 2-Pyridinecarboxaldehyde 1192-63-8, 1-Pyrrolidinecarbonyl chloride 1445-73-4, 1-Methyl-4-piperidinone 1530-88-7, 1-Pyrrolidinecarbonitrile 1711-05-3, 3-Methoxybenzoyl chloride 1711-06-4, 3-Methylbenzoyl chloride 1795-48-8, 2-Isocyanatopropane 2043-61-0, Cyclohexanecarboxaldehyde 2217-41-6, 5,6,7,8-Tetrahydro-1-naphthalenamine 2627-86-3, (S)-α-Methylbenzylamine 2719-27-9, Cyclohexylcarbonyl chloride 3612-20-2, 1-Benzyl-4-piperidone 3731-53-1, 4-(Aminomethyl)pyridine 3839-22-3, 2-Cyanobenzoic acid 3886-69-9, (R)-α-Methylbenzylamine 3939-01-3 4023-34-1, Cyclopropanecarbonyl chloride 4530-20-5, Boc-glycine 4595-60-2, 2-Bromopyrimidine 5006-22-4, Cyclobutanecarbonyl chloride 5337-03-1, Tetrahydropyran-4-carboxylic acid 5657-70-5, 1-Methyl-3-piperidinecarboxylic acid 10111-08-7, 1H-Imidazole-2-carboxaldehyde 13939-69-0, 1-Piperidinecarbonyl chloride 14254-57-0, Isonicotinoyl chloride 15761-38-3 15761-39-4 16948-16-6 20260-53-1, Nicotinoyl chloride hydrochloride 21615-34-9, 2-Methoxybenzoyl chloride 21900-46-9, 2,3-Dimethylbenzoyl chloride 22328-43-4, 2,5-Dimethylbenzoyl chloride 31301-45-8 32202-61-2, 4-Aminoindan 34306-42-8 34737-89-8, 1-Benzyl-3-methyl-4-piperidinone 38870-89-2, Methoxyacetyl chloride 39178-35-3, Isonicotinoyl chloride

hydrochloride 41716-12-5 50541-93-0, 1-Benzyl-4-piperidinamine 51552-16-0, Dimethylaminoacetyl chloride 53035-92-0, 4-Tetrahydropyranyl isocyanate 58859-46-4, Ethyl 4-amino-1-piperidinecarboxylate 60853-81-8, N,N-Dimethylaminoacetyl chloride hydrochloride 64588-88-1 68947-43-3, 1-Methyl-4-piperidinecarboxylic acid 71985-80-3, 1-Methyl-4-piperidinecarboxylic acid hydrochloride 169229-06-5, 2-Methylnicotinoyl chloride 186550-13-0, tert-Butyl 3-amino-1-pyrrolidinecarboxylate 723308-85-8 723308-86-9 723308-88-1 723308-92-7 723308-93-8 723308-94-9 723308-95-0 723308-96-1 723308-97-2 723308-98-3 723308-99-4 723309-02-2 723309-03-3 724762-77-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

IT 724479-29-2 724479-30-5
RL: PRP (Properties)
(unclaimed nucleotide sequence; sulfonamides prepared as inhibitors of the cytokine receptor Ccr8 for the treatment of Th2- and eosinophil-mediated diseases)

IT **723305-84-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of sulfonamides as inhibitors of the chemokine receptor Ccr8 for the treatment of eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis)

RN 723305-84-8 HCAPLUS
CN 3-Piperidinecarboxylic acid, 4-[[[4-[(2-methylbenzoyl)amino]-1-naphthalenyl]sulfonyl]amino]-1-(1-oxobutyl)-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L61 ANSWER 6 OF 58 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:534173 HCAPLUS
DN 141:89016
ED Entered STN: 02 Jul 2004
TI Preparation of benzimidazolylazabicyclooctylethylpiperidines as Ccr5 antagonists for the treatment of HIV infection

IN Kazmierski, Wieslaw Mieczyslaw; Aquino, Christopher Joseph; Bifulco, Neil; Boros, Eric Eugene; Chauder, Brian Andrew; Chong, Pek Yoke; Duan, Maosheng; Deanda, Felix, Jr.; Koble, Cecilia Suarez; Mclean, Ed Williams; Peckham, Jennifer Poole; Perkins, Angilique C.; Thompson, James Benjamin; Vanderwall, Dana

PA Smithkline Beecham Corporation, USA; et al.

SO PCT Int. Appl., 859 pp.
CODEN: PIXXD2

DT **Patent**

LA English

IC ICM C07D211-00

CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 10, 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004054974	A2	20040701	WO 2003-US39644	20031212 <--
WO 2004054974	A3	20040902		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-433634P P 20021213 <--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004054974	ICM	C07D211-00
WO 2004054974	ECLA	C07D451/04B <--

OS MARPAT 141:89016

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds. I [R1 = (optionally substituted) alkyl, aryl, heteroaryl, carbocyclyl; R2 = H, (optionally substituted) alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroarylalkyl, heteroarylcycloalkyl, aralkylcarbonyl, heteroarylsulfinyl; R3 = H, halo, cyano, trifluoromethyl, (optionally substituted) amino, acylamino, alkyl; X = C1-5 alkylene, optionally substituted with oxo or thioxo groups or halogen atoms, and optionally containing 1-3 oxygen, nitrogen, sulfur, or phosphorus atoms; Y = carbonyl, thiocarbonyl, 1,2-dioxoethylene, oxyalkylcarbonyl, sulfinyl, sulfonyl, oxycyanoimino, (optionally substituted) aminocarbonyl, carbonylamino, aminothiocarbonyl, oxyiminomethyl, thioiminomethyl, amino(cyanoimino)methyl, (cyanoimino)methyl, amino(acylimino)methyl, amino(sulfonylimino)methyl, amino(sulfinylimino)methyl, amino(alkoxyimino)methyl, amino(imino)methyl, (cyanoimino)methoxy, iminomethoxy, (cyanoimino)methanethiyl, alkylcarbonyloxy; A = saturated, partially saturated, or aromatic monocyclic ring with 5-6 atoms or a bicyclic ring with 8-10 members containing 0-5 nitrogen, oxygen, and/or sulfur atoms] such as II are prepared I are prepared as Ccr5 antagonists for the treatment of viral infections, (particularly HIV infection), related syndromes such as AIDS-related complex (ARC), progressive generalized lymphadenopathy, Kaposi's sarcoma, and neurol. conditions, and other diseases such as multiple sclerosis, rheumatoid arthritis, Crohn's disease, and immune-mediated disorders. The invention compds. have pIC50 values of ≥5 in assays for Ccr5 antagonism. Piperidineacetaldehyde III is prepared in four steps from

4-phenyl-4-piperidinecarbonitrile by protection of the piperidine with Boc anhydride, reduction of the nitrile with diisobutylaluminum hydride, Wittig olefination with methoxymethylphosphonium chloride, and hydrolysis of the enol ether with catalytic p-toluenesulfonic acid monohydrate. The hydrochloride of endo-(benzimidazolyl)azabicyclooctane IV is prepared in five steps from tert-Bu endo-3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate; reductive amination with benzylamine, reductive cleavage of the benzyl group by palladium-mediated hydrogenation, a nucleophilic aryl substitution reaction with 1-fluoro-2-nitrobenzene, reduction of the nitro group by hydrogenation over palladium on carbon, and treatment with tri-Et orthoacetate followed by treatment with hydrochloric acid in ethanol. Coupling of III and IV by reductive amination with sodium triacetoxyborohydride, cleavage of the Boc group with hydrochloric acid in dioxane, and acylation with pivaloyl chloride and triethylamine yields II.

ST benzimidazolylazabicyclooctylethylpiperidine prepn Ccr5 antagonist HIV treatment

IT AIDS (disease)
(-related complex; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly HIV infections)

IT Multiple sclerosis
(AIDS-related; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as multiple sclerosis)

IT Nervous system, disease
(AIDS-related; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly HIV infections)

IT Inflammation
(Crohn's disease; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as Crohn's disease)

IT Intestine, disease
(Crohn's; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as Crohn's disease)

IT Sarcoma
(Kaposi's; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly HIV infections)

IT Allergy
Inflammation
Nose, disease
(allergic rhinitis; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as allergic rhinitis)

IT Nervous system, disease
(amyotrophic lateral sclerosis; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as amyotrophic lateral sclerosis)

IT Cytokines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antagonists; therapeutic agents used in conjunction with benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly HIV infection)

IT Thrombosis
(arterial; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as arterial thrombosis)

IT Infection
(bacterial; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases)

IT Drug delivery systems
(capsules; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5

antagonists in the treatment of bacterial and viral infections and other diseases)

IT Mental disorder
(dementia, AIDS-related; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly HIV infections)

IT Immunity
(disorder; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as immune disorders)

IT Kidney
(excretion inhibitors; therapeutic agents used in conjunction with benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly HIV infection)

IT Autoimmune disease
(exptl. autoimmune encephalomyelitis; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as autoimmune encephalomyelitis)

IT Encephalomyelitis
(exptl. autoimmune; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as autoimmune encephalomyelitis)

IT Kidney, disease
(glomerulus; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as glomerular disease)

IT Envelope proteins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gp120env, antagonists; therapeutic agents used in conjunction with benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly HIV infection)

IT Intestine, disease
(inflammatory; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as inflammatory bowel disease)

IT Fusion, biological
(inhibitors; therapeutic agents used in conjunction with benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly HIV infection)

IT Autoimmune disease
(insulin-dependent diabetes mellitus; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as autoimmune diabetes)

IT Diabetes mellitus
(insulin-dependent; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as autoimmune diabetes)

IT Drug delivery systems
(liqs.; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases)

IT Lymph node, disease
(lymphadenopathy; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly HIV infections)

IT Inflammation
Kidney, disease
(nephrotoxic nephritis; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as nephrotoxic serum nephritis)

IT Anti-inflammatory agents
(nonsteroidal; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly HIV infections)

IT Transport proteins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleoside transporter, inhibitors; therapeutic agents used in conjunction with benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly HIV infection)
IT Wound healing
(preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and in the promotion of wound healing)
IT Antibacterial agents
Drug interactions
Human
(preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases)
IT Alzheimer's disease
Anti-Alzheimer's agents
(preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as Alzheimer's disease)
IT Sjogren's syndrome
(preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as Sjogren's syndrome)
IT Antiarteriosclerotics
Arteriosclerosis
(preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as arteriosclerosis)
IT Antiasthmatics
Asthma
(preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as asthma)
IT Leukocyte
Neoplasm
(preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as cancers with leukocyte infilitration)
IT Transplant rejection
(preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as chronic transplant rejection)
IT Human papillomavirus
(preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as human papilloma virus infection)
IT Inflammation
(preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as inflammatory disease)
IT Kidney, disease
(preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as kidney disease)
IT Antitumor agents
Prostate gland, neoplasm
(preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as prostate cancer)
IT Antirheumatic agents
Rheumatoid arthritis
(preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as rheumatoid arthritis)

IT AIDS (disease)
Anti-AIDS agents
(preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly HIV infections)
IT CD4 (antigen)
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soluble; therapeutic agents used in conjunction with benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections, particularly HIV infection, and other diseases)
IT Lupus erythematosus
(systemic; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases such as systemic lupus erythematosus)
IT Drug delivery systems
(tablets; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases)
IT Interleukin 2
Trichosanthin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic agents used in conjunction with benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections, particularly HIV infection, and other diseases)
IT Immunomodulators
(therapeutic agents used in conjunction with benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly HIV infection)
IT Acyclonucleosides
Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic agents used in conjunction with benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly HIV infection)
IT Purpura (disease)
(thrombocytopenic; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly HIV infections)
IT Infection
(viral; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly HIV infections)
IT Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α; therapeutic agents used in conjunction with benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections, particularly HIV infection, and other diseases)
IT 52350-85-3, Integrase
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antagonists; therapeutic agents used in conjunction with benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly HIV infection)
IT 244606-37-9P 701272-36-8P 716361-94-3P 716362-75-3P
RL: BYP (Byproduct); PREP (Preparation)
(byproduct; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases)
IT 280768-46-9P 716344-72-8P 716344-76-2P 716344-78-4P 716344-80-8P
716344-82-0P 716344-84-2P 716348-30-0P 716349-45-0P 716349-49-4P
716349-53-0P 716349-70-1P 716350-01-5P 716350-02-6P 716351-83-6P
716352-17-9P 716352-85-1P 716352-86-2P 716353-09-2P 716353-12-7P
716353-16-1P 716353-24-1P 716353-25-2P 716354-04-0P 716355-01-0P
716355-06-5P 716355-10-1P 716355-12-3P 716355-15-6P 716355-18-9P

716355-24-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases)

IT 716344-73-9P 716344-74-0P 716344-75-1P 716344-77-3P 716344-79-5P
716344-81-9P 716344-83-1P 716344-85-3P 716344-86-4P 716344-87-5P
716344-88-6P 716344-89-7P 716344-90-0P 716344-92-2P 716344-93-3P
716344-94-4P 716344-95-5P 716344-96-6P 716344-98-8P 716344-99-9P
716345-00-5P 716345-01-6P 716345-02-7P 716345-03-8P 716345-04-9P
716345-05-0P 716345-06-1P 716345-07-2P 716345-08-3P 716345-09-4P
716345-10-7P 716345-11-8P 716345-12-9P 716345-13-0P 716345-14-1P
716345-15-2P 716345-16-3P 716345-17-4P 716345-18-5P 716345-19-6P
716345-20-9P 716345-21-0P 716345-22-1P 716345-23-2P 716345-24-3P
716345-25-4P 716345-26-5P 716345-27-6P 716345-28-7P 716345-29-8P
716345-30-1P 716345-31-2P 716345-32-3P 716345-33-4P 716345-34-5P
716345-35-6P 716345-36-7P 716345-37-8P 716345-38-9P 716345-39-0P
716345-40-3P 716345-41-4P 716345-42-5P 716345-43-6P 716345-44-7P
716345-45-8P 716345-46-9P 716345-47-0P 716345-48-1P 716345-49-2P
716345-50-5P 716345-51-6P 716345-52-7P 716345-53-8P 716345-54-9P
716345-55-0P 716345-56-1P 716345-57-2P 716345-58-3P 716345-59-4P
716345-60-7P 716345-61-8P 716345-62-9P 716345-63-0P 716345-64-1P
716345-65-2P 716345-66-3P 716345-67-4P 716345-68-5P 716345-69-6P
716345-70-9P 716345-71-0P 716345-72-1P 716345-73-2P 716345-74-3P
716345-75-4P 716345-78-7P 716345-80-1P 716345-82-3P 716345-84-5P
716345-86-7P 716345-88-9P 716345-90-3P 716345-91-4P 716345-92-5P
716345-94-7P 716345-96-9P 716345-98-1P 716346-00-8P 716346-02-0P
716346-04-2P 716346-06-4P 716346-08-6P 716346-10-0P 716346-12-2P
716346-14-4P 716346-15-5P 716346-16-6P 716346-18-8P 716346-20-2P
716346-22-4P 716346-24-6P 716346-26-8P 716346-28-0P 716346-30-4P
716346-32-6P 716346-34-8P 716346-36-0P 716346-38-2P 716346-40-6P
716346-42-8P 716346-43-9P 716346-44-0P 716346-45-1P 716346-46-2P
716346-47-3P 716346-48-4P 716346-49-5P 716346-50-8P 716346-51-9P
716346-52-0P 716346-53-1P 716346-54-2P 716346-55-3P 716346-56-4P
716346-57-5P 716346-58-6P 716346-59-7P 716346-60-0P 716346-61-1P
716346-62-2P 716346-63-3P 716346-64-4P 716346-65-5P 716346-66-6P
716346-67-7P 716346-68-8P 716346-69-9P 716346-70-2P 716346-71-3P
716346-72-4P 716346-73-5P 716346-74-6P 716346-75-7P 716346-76-8P
716346-77-9P 716346-78-0P 716346-79-1P 716346-80-4P 716346-81-5P
716346-82-6P 716346-83-7P 716346-84-8P 716346-85-9P 716346-86-0P
716346-87-1P 716346-88-2P 716346-89-3P 716346-90-6P 716346-91-7P
716346-92-8P 716346-93-9P 716346-95-1P 716346-96-2P 716346-97-3P
716346-98-4P 716346-99-5P 716347-00-1P 716347-01-2P 716347-04-5P
716347-06-7P 716347-07-8P 716347-08-9P 716347-09-0P 716347-10-3P
716347-11-4P 716347-12-5P 716347-13-6P 716347-14-7P 716347-15-8P
716347-16-9P 716347-17-0P 716347-18-1P 716347-19-2P 716347-20-5P
716347-21-6P 716347-23-8P 716347-24-9P 716347-25-0P 716347-26-1P
716347-27-2P 716347-28-3P 716347-29-4P 716347-30-7P 716347-31-8P
716347-32-9P 716347-33-0P 716347-34-1P 716347-35-2P 716347-36-3P
716347-37-4P 716347-38-5P 716347-39-6P 716347-40-9P 716347-41-0P
716347-42-1P 716347-43-2P 716347-44-3P 716347-45-4P 716347-46-5P
716347-47-6P 716347-48-7P 716347-49-8P 716347-50-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases)

IT 716347-51-2P 716347-52-3P 716347-53-4P 716347-55-6P 716347-56-7P
716347-57-8P 716347-58-9P 716347-59-0P 716347-60-3P 716347-61-4P
716347-62-5P 716347-64-7P 716347-65-8P 716347-66-9P 716347-67-0P
716347-68-1P 716347-69-2P 716347-70-5P 716347-71-6P 716347-72-7P
716347-74-9P 716347-75-0P 716347-76-1P 716347-77-2P 716347-78-3P
716347-79-4P 716347-80-7P 716347-81-8P 716347-82-9P 716347-83-0P

716347-84-1P 716347-85-2P 716347-86-3P 716347-87-4P 716347-88-5P
716347-89-6P 716347-90-9P 716347-91-0P 716347-92-1P 716347-93-2P
716347-94-3P 716347-95-4P 716347-96-5P 716347-97-6P 716347-98-7P
716347-99-8P 716348-00-4P 716348-01-5P 716348-02-6P 716348-03-7P
716348-04-8P 716348-05-9P 716348-06-0P 716348-07-1P 716348-08-2P
716348-09-3P 716348-10-6P 716348-11-7P 716348-12-8P 716348-13-9P
716348-14-0P 716348-15-1P 716348-16-2P 716348-17-3P 716348-18-4P
716348-19-5P 716348-20-8P 716348-21-9P 716348-22-0P 716348-23-1P
716348-24-2P 716348-25-3P 716348-26-4P 716348-27-5P 716348-28-6P
716348-29-7P 716348-31-1P 716348-32-2P 716348-33-3P 716348-34-4P
716348-35-5P 716348-36-6P 716348-37-7P 716348-38-8P 716348-39-9P
716348-40-2P 716348-45-7P 716348-47-9P 716348-50-4P 716348-52-6P
716348-54-8P 716348-56-0P 716348-58-2P 716348-60-6P 716348-62-8P
716348-64-0P 716348-66-2P 716348-68-4P 716348-70-8P 716348-72-0P
716348-75-3P 716348-77-5P 716348-79-7P 716348-81-1P 716348-83-3P
716348-85-5P 716348-88-8P 716348-90-2P 716348-92-4P 716348-94-6P
716348-96-8P 716348-98-0P 716349-00-7P 716349-02-9P 716349-04-1P
716349-06-3P 716349-08-5P 716349-10-9P 716349-12-1P 716349-14-3P
716349-15-4P 716349-17-6P 716349-18-7P 716349-19-8P 716349-21-2P
716349-23-4P 716349-24-5P 716349-26-7P 716349-28-9P 716349-29-0P
716349-30-3P 716349-31-4P 716349-32-5P 716349-33-6P 716349-34-7P
716349-35-8P 716349-36-9P 716349-37-0P 716349-38-1P 716349-39-2P
716349-40-5P 716349-41-6P 716349-42-7P 716349-43-8P 716349-44-9P
716349-46-1P 716349-47-2P 716349-48-3P 716349-50-7P 716349-51-8P
716349-52-9P 716349-54-1P 716349-55-2P 716349-56-3P 716349-57-4P
716349-58-5P 716349-59-6P 716349-61-0P 716349-64-3P 716349-67-6P
716349-68-7P 716349-72-3P 716349-74-5P 716349-76-7P 716349-78-9P
716349-80-3P 716349-82-5P 716349-84-7P 716349-85-8P 716349-87-0P
716349-88-1P 716349-89-2P 716349-90-5P 716349-91-6P 716349-92-7P
716349-93-8P 716349-94-9P 716349-95-0P 716349-96-1P 716349-97-2P
716349-98-3P 716349-99-4P 716350-00-4P 716350-03-7P 716350-04-8P
716350-05-9P 716350-06-0P 716350-07-1P 716350-08-2P 716350-09-3P
716350-10-6P 716350-11-7P 716350-12-8P 716350-13-9P 716350-14-0P
716350-15-1P 716350-16-2P 716350-17-3P 716350-18-4P 716350-19-5P
716350-20-8P 716350-21-9P 716350-22-0P 716350-23-1P 716350-24-2P
716350-25-3P 716350-26-4P 716350-27-5P 716350-28-6P 716350-29-7P
716350-30-0P 716350-31-1P 716350-32-2P 716350-33-3P 716350-34-4P
716350-35-5P 716350-36-6P 716350-37-7P 716350-38-8P 716350-39-9P
716350-40-2P 716350-41-3P 716350-42-4P 716350-44-6P 716350-45-7P
716350-46-8P 716350-47-9P 716350-48-0P 716350-49-1P 716350-50-4P
716350-51-5P 716350-52-6P 716350-53-7P 716350-54-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases)

IT 716350-55-9P 716350-56-0P 716350-57-1P 716350-58-2P 716350-59-3P
716350-60-6P 716350-61-7P 716350-62-8P 716350-63-9P 716350-64-0P
716350-65-1P 716350-66-2P 716350-67-3P 716350-68-4P 716350-69-5P
716350-70-8P 716350-71-9P 716350-72-0P 716350-73-1P 716350-75-3P
716350-76-4P 716350-77-5P 716350-78-6P 716350-79-7P 716350-80-0P
716350-81-1P 716350-82-2P 716350-83-3P 716350-84-4P 716350-86-6P
716350-87-7P 716350-88-8P 716350-89-9P 716350-90-2P 716350-92-4P
716350-93-5P 716350-94-6P 716350-95-7P 716350-96-8P 716350-97-9P
716350-98-0P 716350-99-1P 716351-00-7P 716351-01-8P 716351-02-9P
716351-04-1P 716351-05-2P 716351-06-3P 716351-07-4P 716351-08-5P
716351-09-6P 716351-10-9P 716351-12-1P 716351-13-2P 716351-14-3P
716351-15-4P 716351-16-5P 716351-17-6P 716351-18-7P 716351-19-8P
716351-20-1P 716351-21-2P 716351-22-3P 716351-23-4P 716351-24-5P
716351-25-6P 716351-26-7P 716351-27-8P 716351-28-9P 716351-29-0P
716351-30-3P 716351-31-4P 716351-32-5P 716351-33-6P 716351-34-7P
716351-35-8P 716351-36-9P 716351-37-0P 716351-38-1P 716351-39-2P
716351-40-5P 716351-41-6P 716351-42-7P 716351-43-8P 716351-44-9P
716351-45-0P 716351-46-1P 716351-47-2P 716351-48-3P 716351-49-4P
716351-50-7P 716351-52-9P 716351-53-0P 716351-54-1P 716351-55-2P

716351-56-3P 716351-57-4P 716351-58-5P 716351-59-6P 716351-60-9P
716351-61-0P 716351-62-1P 716351-63-2P 716351-64-3P 716351-66-5P
716351-68-7P 716351-70-1P 716351-71-2P 716351-72-3P 716351-74-5P
716351-75-6P 716351-76-7P 716351-77-8P 716351-78-9P 716351-79-0P
716351-80-3P 716351-81-4P 716351-82-5P 716351-84-7P 716351-85-8P
716351-86-9P 716351-87-0P 716351-88-1P 716351-89-2P 716351-90-5P
716351-91-6P 716351-92-7P 716351-93-8P 716351-94-9P 716351-95-0P
716351-96-1P 716351-97-2P 716351-98-3P 716352-00-0P 716352-01-1P
716352-02-2P 716352-03-3P 716352-04-4P 716352-06-6P 716352-07-7P
716352-08-8P 716352-10-2P 716352-11-3P 716352-13-5P 716352-15-7P
716352-20-4P 716352-22-6P 716352-25-9P 716352-27-1P 716352-29-3P
716352-31-7P 716352-33-9P 716352-36-2P 716352-38-4P 716352-40-8P
716352-43-1P 716352-47-5P 716352-51-1P 716352-54-4P 716352-57-7P
716352-60-2P 716352-63-5P 716352-65-7P 716352-66-8P 716352-68-0P
716352-71-5P 716352-73-7P 716352-74-8P 716352-75-9P 716352-76-0P
716352-77-1P 716352-78-2P 716352-79-3P 716352-80-6P 716352-81-7P
716352-82-8P 716352-84-0P 716352-88-4P 716352-90-8P 716352-91-9P
716352-92-0P 716352-93-1P 716352-94-2P 716352-95-3P 716352-96-4P
716352-97-5P 716352-98-6P 716352-99-7P 716353-00-3P 716353-01-4P
716353-02-5P 716353-03-6P 716353-04-7P 716353-05-8P 716353-07-0P
716353-10-5P 716353-11-6P 716353-13-8P 716353-14-9P 716353-15-0P
716353-17-2P 716353-18-3P 716353-19-4P 716353-21-8P 716353-23-0P
716353-26-3P 716353-27-4P 716353-28-5P 716353-29-6P 716353-30-9P
716353-31-0P 716353-32-1P 716353-33-2P 716353-34-3P 716353-35-4P
716353-36-5P 716353-37-6P 716353-38-7P 716353-39-8P 716353-40-1P
716353-41-2P 716353-42-3P 716353-43-4P 716353-44-5P 716353-45-6P
716353-46-7P 716353-47-8P 716353-48-9P 716353-49-0P 716353-50-3P
716353-52-5P 716353-54-7P 716353-55-8P 716353-57-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases)

IT 716353-58-1P 716353-60-5P 716353-61-6P 716353-62-7P 716353-63-8P
716353-64-9P 716353-65-0P 716353-66-1P 716353-67-2P 716353-68-3P
716353-69-4P 716353-70-7P 716353-71-8P 716353-72-9P 716353-73-0P
716353-74-1P 716353-75-2P 716353-76-3P 716353-78-5P 716353-80-9P
716353-82-1P 716353-84-3P 716353-86-5P 716353-88-7P 716353-89-8P
716353-90-1P 716353-92-3P 716353-93-4P 716353-95-6P 716353-97-8P
716353-98-9P 716353-99-0P 716354-01-7P 716354-03-9P 716354-05-1P
716354-06-2P 716354-07-3P 716354-08-4P 716354-09-5P 716354-10-8P
716354-11-9P 716354-12-0P 716354-13-1P 716354-14-2P 716354-15-3P
716354-16-4P 716354-17-5P 716354-18-6P 716354-19-7P 716354-20-0P
716354-21-1P 716354-22-2P 716354-23-3P 716354-24-4P 716354-25-5P
716354-26-6P 716354-27-7P 716354-28-8P 716354-29-9P 716354-30-2P
716354-31-3P 716354-32-4P 716354-33-5P 716354-34-6P 716354-35-7P
716354-36-8P 716354-37-9P 716354-38-0P 716354-39-1P 716354-40-4P
716354-41-5P 716354-42-6P 716354-43-7P 716354-44-8P 716354-45-9P
716354-46-0P 716354-47-1P 716354-48-2P 716354-49-3P 716354-50-6P
716354-51-7P 716354-52-8P 716354-53-9P 716354-54-0P 716354-55-1P
716354-56-2P 716354-57-3P 716354-58-4P 716354-59-5P 716354-60-8P
716354-61-9P 716354-62-0P 716354-63-1P 716354-64-2P 716354-65-3P
716354-66-4P 716354-67-5P 716354-68-6P 716354-69-7P 716354-71-1P
716354-72-2P 716354-74-4P 716354-75-5P 716354-76-6P 716354-77-7P
716354-78-8P 716354-79-9P 716354-80-2P 716354-81-3P 716354-82-4P
716354-83-5P 716354-85-7P 716354-86-8P 716354-87-9P 716354-88-0P
716354-89-1P 716354-90-4P 716354-91-5P 716354-92-6P 716354-93-7P
716354-94-8P 716354-95-9P 716354-96-0P 716354-97-1P 716354-98-2P
716354-99-3P 716355-00-9P 716355-02-1P 716355-03-2P 716355-04-3P
716355-05-4P 716355-07-6P 716355-08-7P 716355-09-8P 716355-11-2P
716355-13-4P 716355-14-5P 716355-16-7P 716355-17-8P 716355-19-0P
716355-20-3P 716355-21-4P 716355-22-5P 716355-23-6P 716355-25-8P
716355-26-9P 716355-27-0P 716355-28-1P 716355-29-2P 716355-30-5P
716355-31-6P 716355-32-7P 716355-33-8P 716355-34-9P 716355-35-0P
716355-36-1P 716355-37-2P 716355-38-3P 716355-39-4P 716355-40-7P

716355-41-8P 716355-42-9P 716355-43-0P 716355-44-1P 716355-45-2P
716355-46-3P 716355-47-4P 716355-48-5P 716355-49-6P 716355-50-9P
716355-51-0P 716355-52-1P 716355-53-2P 716355-55-4P 716355-56-5P
716355-57-6P 716355-58-7P 716355-59-8P 716355-60-1P 716355-61-2P
716355-62-3P 716355-63-4P 716355-64-5P 716355-65-6P 716355-66-7P
716355-67-8P 716355-68-9P 716355-69-0P 716355-70-3P 716355-71-4P
716355-72-5P 716355-73-6P 716355-74-7P 716355-75-8P 716355-76-9P
716355-77-0P 716355-78-1P 716355-79-2P 716355-80-5P 716355-81-6P
716355-82-7P 716355-83-8P 716355-84-9P 716355-85-0P 716355-86-1P
716355-87-2P 716355-88-3P 716355-89-4P 716355-90-7P 716355-91-8P
716355-92-9P 716355-93-0P 716355-94-1P 716355-95-2P 716355-96-3P
716355-97-4P 716355-98-5P 716355-99-6P 716356-00-2P 716356-01-3P
716356-02-4P 716356-03-5P 716356-04-6P 716356-05-7P 716356-06-8P
716356-07-9P 716356-08-0P 716356-09-1P 716356-10-4P 716356-11-5P
716356-12-6P 716356-13-7P 716356-14-8P 716356-15-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases)

IT 716356-16-0P 716356-17-1P 716356-18-2P 716356-19-3P 716356-20-6P
716356-21-7P 716356-22-8P 716356-23-9P 716356-24-0P 716356-25-1P
716356-26-2P 716356-27-3P 716356-28-4P 716356-29-5P 716356-30-8P
716356-31-9P 716356-32-0P 716356-33-1P 716356-34-2P 716356-35-3P
716356-36-4P 716356-37-5P 716356-38-6P 716356-39-7P 716356-40-0P
716356-41-1P 716356-42-2P 716356-43-3P 716356-44-4P 716356-45-5P
716356-46-6P 716356-47-7P 716356-48-8P 716356-49-9P 716356-50-2P
716356-51-3P 716356-52-4P 716356-53-5P 716356-54-6P 716356-55-7P
716356-56-8P 716356-57-9P 716356-58-0P 716356-59-1P 716356-60-4P
716356-61-5P 716356-62-6P 716356-63-7P 716356-64-8P 716356-65-9P
716356-66-0P 716356-67-1P 716356-68-2P 716356-69-3P 716356-70-6P
716356-71-7P 716356-72-8P 716356-73-9P 716356-74-0P 716356-75-1P
716356-76-2P 716356-77-3P 716356-78-4P 716356-79-5P 716356-80-8P
716356-81-9P 716356-82-0P 716356-83-1P 716356-84-2P 716356-85-3P
716356-86-4P 716356-87-5P 716356-88-6P 716356-89-7P 716356-90-0P
716356-91-1P 716356-92-2P 716356-93-3P 716356-94-4P 716356-95-5P
716356-96-6P 716356-97-7P 716356-98-8P 716356-99-9P 716357-00-5P
716357-01-6P 716357-02-7P 716357-03-8P 716357-04-9P 716357-06-1P
716357-08-3P 716357-10-7P 716357-12-9P 716357-14-1P 716357-16-3P
716357-17-4P 716357-18-5P 716357-19-6P 716357-20-9P 716357-21-0P
716357-22-1P 716357-23-2P 716357-24-3P 716357-25-4P 716357-26-5P
716357-27-6P 716357-28-7P 716357-29-8P 716357-30-1P 716357-31-2P
716357-32-3P 716357-33-4P 716357-34-5P 716357-35-6P 716357-36-7P
716357-37-8P 716357-38-9P 716357-39-0P 716357-40-3P 716357-41-4P
716357-42-5P 716357-43-6P 716357-44-7P 716357-45-8P 716357-46-9P
716357-47-0P 716357-48-1P 716357-49-2P 716357-50-5P 716357-51-6P
716357-52-7P 716357-53-8P 716357-54-9P 716357-55-0P 716357-56-1P
716357-57-2P 716357-58-3P 716357-59-4P 716357-60-7P 716357-61-8P
716357-62-9P 716357-63-0P 716357-64-1P 716357-65-2P 716357-66-3P
716357-67-4P 716357-68-5P 716357-69-6P 716357-70-9P 716357-71-0P
716357-72-1P 716357-73-2P 716357-74-3P 716357-75-4P 716357-76-5P
716357-77-6P 716357-78-7P 716357-79-8P 716357-80-1P 716357-81-2P
716357-82-3P 716357-83-4P 716357-84-5P 716357-85-6P 716357-86-7P
716357-87-8P 716357-88-9P 716357-89-0P 716357-90-3P 716357-91-4P
716357-92-5P 716357-93-6P 716357-94-7P 716357-95-8P 716357-96-9P
716357-97-0P 716357-98-1P 716358-03-1P 716358-04-2P 716358-04-2P
716358-08-6P 716358-09-7P 716358-10-0P 716358-11-1P 716358-12-2P
716358-14-4P 716358-15-5P 716358-16-6P 716358-17-7P 716358-19-9P
716358-20-2P 716358-21-3P 716358-22-4P 716358-23-5P 716358-24-6P
716358-25-7P 716358-26-8P 716358-27-9P 716358-28-0P 716358-29-1P
716358-30-4P 716358-31-5P 716358-32-6P 716358-33-7P 717100-00-0P
717100-01-1P 717100-03-3P 717101-41-2P 717101-43-4P 717101-44-5P
717101-54-7P 717101-57-0P 717101-59-2P 717101-61-6P 717101-63-8P
717101-65-0P 717101-68-3P 717101-71-8P 717101-73-0P 717101-75-2P
717101-76-3P 717101-77-4P 717101-78-5P 717101-79-6P 717101-90-1P

717101-99-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases)

IT 9047-64-7, Ribonucleotide reductase 9068-38-6, Reverse transcriptase 144114-21-6, HIV-1 Protease
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; therapeutic agents used in conjunction with benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of viral infections, particularly HIV infection)

IT 55-51-6P 97-04-1P 619-45-4P 1429-44-3P 1463-52-1P 1535-45-1P
2494-79-3P 4793-22-0P 4847-36-3P 5471-77-2P 7151-76-0P
7286-84-2P 10252-66-1P 18469-52-8P 18729-17-4P 20532-06-3P
28547-13-9P 28957-72-4P 29872-68-2P 30170-04-8P 42122-75-8P
46004-37-9P 51887-56-0P 53553-05-2P 53553-16-5P 53916-70-4P
54450-84-9P 59210-61-6P 59815-19-9P 68901-09-7P 73792-08-2P
74138-28-6P 74138-29-7P 76272-34-9P 76272-36-1P 93504-83-7P
99329-67-6P 102507-13-1P 109029-85-8P 112887-25-9P 140617-83-0P
142576-91-8P 149476-35-7P 152122-32-2P 157335-93-8P 158144-79-7P
158144-80-0P 158579-73-8P 158580-82-6P 160376-88-5P 185629-32-7P
193537-11-0P 207405-67-2P 207405-68-3P 244606-33-5P 264927-50-6P
280762-05-2P 280762-06-3P 280762-12-1P 280762-13-2P 280762-20-1P
329909-29-7P 348624-10-2P 450368-37-3P 476156-65-7P 509094-14-8P
543739-84-0P 546115-64-4P 576169-99-8P 632300-30-2P 644982-76-3P
669068-10-4P 701253-01-2P 701258-80-2P 714968-42-0P 714968-43-1P
714968-45-3P 714968-46-4P 714968-47-5P 716324-50-4P 716358-34-8P
716358-35-9P 716358-36-0P 716358-37-1P 716358-38-2P 716358-39-3P
716358-40-6P 716358-41-7P 716358-42-8P 716358-43-9P 716358-44-0P
716358-45-1P 716358-46-2P 716358-47-3P 716358-48-4P 716358-49-5P
716358-50-8P 716358-51-9P 716358-52-0P 716358-53-1P 716358-54-2P
716358-55-3P 716358-56-4P 716358-57-5P 716358-58-6P 716358-59-7P
716358-60-0P 716358-61-1P 716358-62-2P 716358-63-3P 716358-64-4P
716358-65-5P 716358-66-6P 716358-67-7P 716358-68-8P 716358-69-9P
716358-70-2P 716358-71-3P 716358-72-4P 716358-73-5P 716358-74-6P
716358-75-7P 716358-76-8P 716358-77-9P 716358-78-0P 716358-79-1P
716358-81-5P 716358-82-6P 716358-83-7P 716358-84-8P 716358-85-9P
716358-86-0P 716358-87-1P 716358-88-2P 716358-89-3P 716358-90-6P
716358-91-7P 716358-94-0P 716358-96-2P 716358-98-4P 716358-99-5P
716359-00-1P 716359-01-2P 716359-02-3P 716359-03-4P 716359-04-5P
716359-05-6P 716359-06-7P 716359-07-8P 716359-08-9P 716359-09-0P
716359-10-3P 716359-11-4P 716359-12-5P 716359-14-7P 716359-17-0P
716359-23-8P 716359-24-9P 716359-25-0P 716359-26-1P 716359-27-2P
716359-28-3P 716359-29-4P 716359-30-7P 716359-31-8P 716359-32-9P
716359-33-0P 716359-34-1P 716359-35-2P 716359-36-3P 716359-37-4P
716359-38-5P 716359-39-6P 716359-40-9P 716359-41-0P 716359-42-1P
716359-43-2P 716359-44-3P 716359-45-4P 716359-46-5P 716359-47-6P
716359-48-7P 716359-49-8P 716359-50-1P 716359-51-2P 716359-52-3P
716359-53-4P 716359-54-5P 716359-55-6P 716359-56-7P 716359-57-8P
716359-58-9P 716359-59-0P 716359-61-4P 716359-62-5P 716359-63-6P
716359-64-7P 716359-65-8P 716359-66-9P 716359-67-0P 716359-69-2P
716359-71-6P 716359-73-8P 716359-75-0P 716359-77-2P 716359-79-4P
716359-81-8P 716359-83-0P 716359-86-3P 716359-88-5P 716359-90-9P
716359-92-1P 716359-94-3P 716359-95-4P 716359-96-5P 716359-97-6P
716359-98-7P 716359-99-8P 716360-00-8P 716360-01-9P 716360-02-0P
716360-03-1P 716360-04-2P 716360-05-3P 716360-06-4P 716360-07-5P
716360-08-6P 716360-09-7P 716360-10-0P 716360-11-1P 716360-12-2P
716360-13-3P 716360-14-4P 716360-15-5P 716360-16-6P 716360-17-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases)

IT 716360-18-8P 716360-19-9P 716360-20-2P 716360-21-3P 716360-22-4P

716360-23-5P 716360-26-8P 716360-27-9P 716360-28-0P 716360-29-1P
716360-30-4P 716360-31-5P 716360-32-6P 716360-33-7P 716360-34-8P
716360-35-9P 716360-36-0P 716360-37-1P 716360-38-2P 716360-39-3P
716360-40-6P 716360-41-7P 716360-42-8P 716360-43-9P 716360-44-0P
716360-45-1P 716360-46-2P 716360-47-3P 716360-48-4P 716360-49-5P
716360-51-9P 716360-53-1P 716360-56-4P 716360-58-6P 716360-60-0P
716360-63-3P 716360-66-6P 716360-68-8P 716360-69-9P 716360-71-3P
716360-73-5P 716360-75-7P 716360-77-9P 716360-79-1P 716360-81-5P
716360-82-6P 716360-84-8P 716360-85-9P 716360-87-1P 716360-88-2P
716360-89-3P 716360-90-6P 716360-91-7P 716360-92-8P 716360-93-9P
716360-94-0P 716360-96-2P 716360-98-4P 716360-99-5P 716361-00-1P
716361-01-2P 716361-02-3P 716361-03-4P 716361-04-5P 716361-05-6P
716361-06-7P 716361-07-8P 716361-08-9P 716361-11-4P 716361-13-6P
716361-15-8P 716361-17-0P 716361-19-2P 716361-21-6P 716361-23-8P
716361-25-0P 716361-27-2P 716361-29-4P 716361-31-8P 716361-33-0P
716361-35-2P 716361-36-3P 716361-37-4P 716361-38-5P 716361-39-6P
716361-40-9P 716361-41-0P 716361-42-1P 716361-43-2P 716361-44-3P
716361-45-4P 716361-46-5P 716361-47-6P 716361-48-7P 716361-49-8P
716361-50-1P 716361-51-2P 716361-52-3P 716361-53-4P 716361-54-5P
716361-55-6P 716361-56-7P 716361-57-8P 716361-58-9P 716361-59-0P
716361-60-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases)

IT 50-30-6, 2,6-Dichlorobenzoic acid 50-45-3, 2,3-Dichlorobenzoic acid 50-78-2 50-84-0, 2,4-Dichlorobenzoic acid 51-36-5, 3,5-Dichlorobenzoic acid 54-31-9 56-91-7 62-23-7, 4-Nitrobenzoic acid 65-86-1 69-72-7, reactions 74-11-3, 4-Chlorobenzoic acid 75-98-9, Trimethylacetic acid 76-05-1, reactions 77-25-8, Diethyl 2,2-diethylmalonate 77-55-4, 1-Phenyl-1-cyclopentanecarboxylic acid 78-39-7, 1,1,1-Triethoxyethane 79-09-4, Propanoic acid, reactions 79-31-2, 2-Methylpropanoic acid 79-91-4 85-44-9, Phthalic anhydride 86-55-5, 1-Naphthoic acid 87-51-4, 3-Indoleacetic acid, reactions 88-13-1, 3-Thiophenecarboxylic acid 88-97-1 88-98-2, 4-Cyclohexene-1,2-dicarboxylic acid 89-01-0, 2,3-Pyrazinedicarboxylic acid 89-52-1, 2-(Acetylamino)benzoic acid 89-54-3 93-09-4, 2-Naphthoic acid 93-10-7, 2-Quinolinecarboxylic acid 94-53-1, 1,3-Benzodioxole-5-carboxylic acid 98-01-1, 2-Furancarboxaldehyde, reactions 98-73-7, 4-tert-Butylbenzoic acid 98-80-6 98-97-5, Pyrazinecarboxylic acid 99-04-7, 3-Methylbenzoic acid 99-05-8 99-06-9, reactions 99-96-7, reactions 100-46-9, Benzylamine, reactions 100-52-7, Benzaldehyde, reactions 103-82-2, Benzeneacetic acid, reactions 105-56-6, Ethyl cyanoacetate 107-92-6, Butanoic acid, reactions 108-18-9 109-89-7, reactions 110-15-6, Butanedioic acid, reactions 110-94-1, Pentanedioic acid 121-92-6, 3-Nitrobenzoic acid 124-02-7 133-90-4 134-11-2, 2-Ethoxybenzoic acid 137-64-4 137-65-5 138-41-0, p-Carboxybenzenesulfonamide 140-77-2, Cyclopentanepropanoic acid 321-12-0, 2-Fluoro-5-methylbenzoic acid 330-17-6 343-10-2 364-74-9 374-35-6 385-00-2 393-55-5 395-33-5 402-51-7 402-61-9 403-20-3, 3-Fluoro-4-methoxybenzoic acid 406-93-9, 4,4,4-Trifluorobutanoic acid 434-75-3, 2-Chloro-6-fluorobenzoic acid 434-76-4 445-29-4, 2-Fluorobenzoic acid 446-31-1 453-72-5 454-92-2, 3-(Trifluoromethyl)benzoic acid 455-24-3, 4-(Trifluoromethyl)benzoic acid 455-38-9, 3-Fluorobenzoic acid 455-40-3, 3,5-Difluorobenzoic acid 455-86-7, 3,4-Difluorobenzoic acid 455-87-8 471-88-5 480-63-7, 2,4,6-Trimethylbenzoic acid 480-65-9 496-41-3, 2-Benzofurancarboxylic acid 499-06-9, 3,5-Dimethylbenzoic acid 501-81-5, 3-Pyridineacetic acid 503-74-2, 3-Methylbutanoic acid 512-16-3 527-69-5, 2-Furoyl chloride 527-72-0, 2-Thiophenecarboxylic acid 531-81-7 535-80-8, 3-Chlorobenzoic acid 536-66-3, 4-Isopropylbenzoic acid 536-95-8 542-05-2, 3-Oxopentanedioic acid 552-16-9, 2-Nitrobenzoic acid 556-08-1, 4-(Acetylamino)benzoic acid 556-61-6 574-92-5 577-56-0, 2-Acetylbenzoic acid 583-08-4 585-70-6 586-42-5, 3-Acetylbenzoic acid 586-61-8 586-89-0, 4-Acetylbenzoic acid

587-48-4, 3-(Acetylamino)benzoic acid 591-17-3 594-61-6,
2-Hydroxy-2-methylpropanoic acid 595-37-9, 2,2-Dimethylbutanoic acid
597-43-3 609-71-2, 2-Hydroxy-3-pyridinecarboxylic acid 610-72-0,
2,5-Dimethylbenzoic acid 611-01-8, 2,4-Dimethylbenzoic acid 611-73-4
619-04-5, 3,4-Dimethylbenzoic acid 619-64-7, 4-Ethylbenzoic acid
619-65-8 619-86-3, 4-Ethoxybenzoic acid 621-36-3, 3-
Methylbenzeneacetic acid 624-78-2 625-08-1, 3-Hydroxy-3-methylbutanoic
acid 625-38-7, 3-Butenoic acid 625-99-0, 1-Chloro-3-iodobenzene
632-46-2 634-97-9, 1H-Pyrrole-2-carboxylic acid 636-44-2 636-76-0,
3-(Sulfamoyl)benzoic acid 636-78-2, 4-Sulfobenzoic acid 638-32-4
644-36-0, 2-Methylbenzeneacetic acid 662-22-6 675-67-2 699-98-9,
Furo[3,4-b]pyridine-5,7-dione 705-21-5 712-57-2 765-30-0,
Cyclopropanamine 771-50-6, 3-Indolecarboxylic acid 777-44-6 821-48-7
879-65-2, 2-Quinoxalinecarboxylic acid 934-60-1 940-31-8,
2-Phenoxypropanoic acid 947-84-2, 2-Phenylbenzoic acid 1009-67-2
1021-25-6 1072-84-0, 4-Imidazolecarboxylic acid 1075-49-6,
4-Vinylbenzoic acid 1118-68-9, N,N-Dimethylglycine 1122-82-3
1123-00-8, Cyclopentaneacetic acid 1123-28-0, 1-Hydroxy-1-
cyclohexanecarboxylic acid 1127-08-8, 1,1-Cyclohexanedicarboxylic acid
1136-45-4 1204-75-7 1206-37-7, 4-(Dimethylaminosulfonyl)benzoic acid
1213-06-5, 4-(Diethylsulfamoyl)benzoic acid 1438-96-6 1457-59-6
1460-38-4 1466-76-8 1493-27-2, 1-Fluoro-2-nitrobenzene 1505-50-6,
4-Methylbenzenepropanoic acid 1548-13-6 1559-02-0 1572-98-1
1578-63-8, α-Fluorobenzeneacetic acid 1596-84-5 1609-86-5
1619-62-1 1679-64-7 1687-30-5, 1,2-Cyclohexanedicarboxylic acid
1759-53-1, Cyclopropanecarboxylic acid 1765-93-1 1795-48-8
1877-71-0, Isophthalic acid monomethyl ester 1877-72-1 1878-65-5,
3-Chlorobenzeneacetic acid 1899-93-0 1914-58-5 1918-77-0,
2-Thiopheneacetic acid 1918-79-2 1929-29-9, 4-Methoxybenzenepropanoic
acid 2028-12-8 2028-13-9 2051-95-8, γ-Oxobenzenebutanoic acid
2051-96-9 2100-31-4, 2-Propoxybenzoic acid 2114-68-3 2124-55-2,
4-Indolecarboxylic acid 2131-55-7 2148-56-3 2237-36-7,
2-Hydroxy-4-methoxybenzoic acid 2253-73-8 2267-40-5 2280-27-5
2345-34-8 2398-81-4 2438-05-3, 4-Propylbenzoic acid 2439-38-5
2457-76-3 2497-02-1, N-Acetyl-L-histidine 2510-37-4 2566-29-2
2568-34-5, N-Benzoyl-N-methylglycine 2612-02-4, 2-Hydroxy-5-
methoxybenzoic acid 2625-49-2 2631-79-0 2635-13-4 2655-84-7
2736-23-4, 5-(Aminosulfonyl)-2,4-dichlorobenzoic acid 2740-88-7
2768-42-5 2815-95-4, 1,3-Benzodioxole-5-propanoic acid 2840-28-0
2861-28-1, 1,3-Benzodioxole-5-acetic acid 2888-06-4 2942-59-8,
2-Chloro-3-pyridinecarboxylic acid 2949-22-6 2991-28-8,
2,5-Difluorobenzoic acid 2991-42-6 3006-96-0, 4-(Hydroxymethyl)benzoic
acid 3167-49-5, 6-Amino-3-pyridinecarboxylic acid 3173-53-3
3222-47-7, 6-Methyl-3-pyridinecarboxylic acid 3222-56-8 3303-18-2
3612-20-2 3622-35-3, 6-Benzothiazolecarboxylic acid 3639-21-2,
2-Ethyl-2-hydroxybutanoic acid 3641-16-5 3663-80-7 3779-29-1,
Diethyl 1,1-cyclobutanedicarboxylate 3839-22-3 3966-30-1 4023-34-1,
Cyclopropanecarbonyl chloride 4042-36-8 4052-30-6,
4-(Methylsulfonyl)benzoic acid 4100-13-4, 1,2,3-Thiadiazole-4-carboxylic
acid 4166-51-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of benzimidazolylazabicyclooctylethylpiperid
ine Ccr5 antagonists in the treatment of bacterial and viral infections
and other diseases)

IT 4166-67-0 4320-91-6, 2H-1,2,3-Triazole-2-acetic acid 4337-53-5
4389-50-8 4408-60-0 4412-96-8 4414-37-3 4481-28-1 4519-39-5,
2,3-Difluorobenzoic acid 4524-93-0, Cyclopentanecarbonyl chloride
4670-10-4 4692-98-2 4693-00-9 4706-33-6 4743-17-3 4793-24-2,
5-(Aminosulfonyl)-2-chloro-4-fluorobenzoic acid 4835-90-9,
3-Hydroxy-2,2-dimethylpropanoic acid 4839-46-7 4928-87-4,
1H-1,2,4-Triazole-3-carboxylic acid 4940-39-0 5006-66-6,
6-Hydroxy-3-pyridinecarboxylic acid 5087-21-8 5106-98-9 5118-07-0
5326-23-8, 6-Chloro-3-pyridinecarboxylic acid 5345-27-7,
3-(Methylsulfonyl)benzoic acid 5345-47-1, 2-Amino-3-pyridinecarboxylic
acid 5378-41-6 5391-50-4 5438-19-7, 4-Propoxybenzoic acid
5464-11-9 5470-18-8 5521-55-1 5626-41-5 5657-19-2,

N-(2-Furoyl)glycine 5694-02-0 5720-07-0 5736-19-6 5744-59-2
5807-30-7, 3,4-Dichlorobenzeneacetic acid 5927-18-4 6120-95-2,
1-Phenylcyclopropanecarboxylic acid 6160-65-2 6168-83-8,
(S)-3-Hydroxybutanoic acid 6313-51-5 6324-10-3 6342-77-4
6443-85-2, 3-Pyridineacetonitrile 6622-04-4 6628-11-1 6914-74-5,
1-(Aminocarbonyl)-1-cyclopropanecarboxylic acid 6914-76-7,
1-Methylcyclopropanecarboxylic acid 6914-79-0, 1-Cyano-1-
cyclopropanecarboxylic acid 6945-55-7 6973-60-0 7046-76-6
7087-68-5 7311-63-9 7311-64-0 7326-73-0 7340-22-9,
3-(2-Pyridyl)acrylic acid 7366-56-5 7383-14-4 7499-18-5
10111-08-7, 1H-Imidazole-2-carboxaldehyde 10128-71-9 10167-50-7
10191-60-3 10200-59-6, 2-Thiazolecarboxaldehyde 10252-63-8
10315-03-4 10453-89-1, Chrysanthemic acid 10502-44-0 10516-71-9,
3-Methoxybenzenepropanoic acid 13113-71-8 13129-22-1 13205-46-4,
4-Isopropoxybenzoic acid 13306-99-5 13593-94-7 13602-12-5
13626-59-0 13734-41-3 13958-93-5 14714-24-0 15030-72-5
15761-39-4 15962-46-6, N-Acetylphenylglycine 15966-72-0 16386-93-9,
2,2-Dimethyl-4-pentenoic acid 16386-97-3 16498-81-0,
2-Methoxy-3-pyridinecarboxylic acid 16681-70-2, 1H-1,2,3-Triazole-4-
carboxylic acid 16681-71-3 16727-43-8, 2,6-Dimethoxy-3-
pyridinecarboxylic acid 16728-01-1, 1-(4-Methoxyphenyl)-1-
cyclopropanecarboxylic acid 16841-19-3, 1-Hydroxy-1-
cyclopentanecarboxylic acid 16874-33-2 16879-68-8 16880-12-9
16880-20-9 16880-29-8 16880-48-1 17093-74-2 17616-04-5,
4-(1-Imidazolyl)benzoic acid 17653-94-0 17874-79-2 17994-25-1,
1-Hydroxy-1-cyclopropanecarboxylic acid 18212-21-0 18282-59-2
18409-49-9, N-Carbamoyl-L-alanine 18620-04-7 19064-24-5 19094-56-5
19436-52-3, N-Acetyl-D-alanine 19621-92-2, 6-Hydroxy-2-
pyridinecarboxylic acid 20320-33-6 20532-05-2 20607-43-6
20621-95-8 20781-20-8 20920-03-0, 1-Hydroxy-1-cycloheptanecarboxylic
acid 21277-16-7 21451-29-6 21579-35-1 22117-85-7 22892-96-2
23012-13-7, 4-Oxazolecarboxylic acid 23754-43-0 23814-12-2,
1H-Benzotriazole-5-carboxylic acid 23945-44-0 23945-50-8 23985-59-3
24036-63-3 24065-33-6 24135-76-0 24195-02-6 24242-17-9
24667-09-2 24940-57-6, N,N-Dimethyl-L-histidine 25206-12-6
25277-91-2 25307-82-8 25335-74-4 25503-90-6, 1-Acetyl-4-
piperidinecarboxylic acid 27890-92-2 28252-74-6 29555-02-0
30270-19-0 30529-70-5 30709-69-4 30992-29-1 31457-07-5
32387-21-6, 1-Methyl-3-indolecarboxylic acid 32863-21-1,
2,1,3-Benzoxadiazole-4-carboxylic acid 33206-18-7 33733-73-2
33863-76-2 33996-33-7 34113-69-4, 4-Chloro-3-hydroxybenzoic acid
34263-53-1 34306-42-8 34785-11-0 35264-09-6 35623-11-1
36282-40-3 36567-72-3, (S)-3-Hydroxy-3-phenylpropanoic acid 36901-90-3
37028-84-5 37028-85-6 37718-11-9, 1H-Pyrazole-4-carboxylic acid
38076-80-1 38116-61-9 38496-18-3 38649-35-3 39079-62-4
39891-55-9 39894-60-5 40284-70-6, 2-Chloro-5-sulfobenzoic acid
41248-15-1 41680-34-6 41716-18-1 45654-48-6 46006-36-4,
1H-Benzimidazole-4-carboxylic acid 49606-98-6 49769-60-0 50602-38-5
50920-46-2 51304-58-6, 4-Phenyl-4-piperidinecarbonitrile hydrochloride
51373-14-9 51727-06-1 51991-94-7 52546-46-0 52565-56-7
53137-27-2 53940-10-6 54127-63-8 54221-95-3, 2-(Acetylamino)-4-
pyridinecarboxylic acid 54379-17-8 54955-42-9 55314-30-2
55512-98-6 56205-88-0 56269-39-7 56481-26-6 57479-70-6,
4-Chloro-2-methoxybenzoic acid 57658-36-3 57683-71-3 58138-55-9
58859-52-2 59481-43-5 60143-00-2 60421-25-2 60811-21-4
60875-16-3 62031-77-0 62291-37-6 62348-13-4, 5-Isoxazolecarbonyl
chloride 62965-35-9 62972-61-6, 1H-Benzotriazole-4-carboxylic acid
63480-10-4 64415-15-2 65560-35-2 66572-55-2 67367-33-3
67367-37-7 67531-86-6 68867-17-4, 5-Benzothiazolecarboxylic acid
69727-40-8 70585-53-4 72290-28-9 72934-37-3, 1-(4-
Chlorophenyl)cyclopropanecarboxylic acid 73096-39-6,
3-(5-Tetrazolyl)benzoic acid 73294-89-0 73889-61-9 74557-73-6
74840-47-4 75727-33-2 79099-07-3, tert-Butyl 4-oxo-1-
piperidinecarboxylate
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of benzimidazolylazabicyclooctylethylpiperid

ine Ccr5 antagonists in the treatment of bacterial and viral infections and other diseases)

IT 80194-69-0 80548-40-9 80859-00-3 83096-36-0 83734-48-9
84358-13-4 84832-02-0 85076-01-3 85471-45-0, N-Tosyl-D-alanine
85740-98-3, 4-Chloro-3-methoxybenzoic acid 85844-99-1 86427-02-3,
3-Chloro-2-thiophenecarbonyl chloride 87407-12-3 89364-31-8
89375-28-0 89531-67-9 89639-83-8 89942-59-6 90004-33-4
90260-13-2 90610-69-8 90770-91-5 90978-90-8 92116-87-5
92116-88-6 94084-75-0 94101-69-6 94839-07-3 95460-25-6
98027-63-5 98534-81-7 98594-72-0 99323-62-3 100379-00-8
100960-55-2 105184-38-1, 3,5-Difluorobenzeneacetic acid 105611-99-2
106058-86-0 109234-02-8 109844-67-9 111331-82-9 113375-21-6
114537-99-4 114776-15-7 115693-71-5 116293-90-4 118736-95-1
120100-15-4 121602-93-5, 3,4,5-Trifluorobenzoic acid 125072-73-3
125568-73-2 127413-03-0 130721-79-8 131738-73-3 131947-13-2
132741-30-1 132741-31-2 135449-68-2 135449-70-6 138499-08-8
139926-23-1, 3-Ethoxy-2-thiophenecarboxylic acid 139937-99-8
139938-00-4 141073-11-2 141772-31-8 142758-87-0 151858-64-9
153203-57-7 155377-19-8 156270-06-3 156270-08-5 157994-39-3
158063-66-2, 4-(Trifluoromethyl)-3-pyridinecarboxylic acid 161796-10-7
162607-18-3 **162787-61-3** 167626-64-4 171178-50-0
172975-69-8 175201-94-2 175276-99-0 175277-09-5 175277-11-9
175415-95-9 178316-77-3 179174-23-3 183158-34-1 185099-67-6
188106-94-7 192725-55-6 200403-27-6 245671-68-5 247128-20-7
261735-01-7 280762-26-7 280762-27-8 282727-75-7 288266-54-6
291289-41-3 303148-48-3 304674-35-9 306936-37-8 306936-39-0
306936-40-3 319490-74-9 343966-22-3 345292-73-1 353770-03-3
380463-01-4 398141-96-3 406951-04-0 409326-60-9 423769-07-7
445008-91-3 473895-86-2, 1H-Benzimidazole-5-acetic acid
496051-32-2 501081-61-4 540521-54-8 544463-00-5
544703-97-1 551915-35-6 558441-00-2 593287-44-6 618414-82-7
618414-88-3 644982-46-7 660416-36-4 714968-48-6 716327-42-3
716327-43-4 716361-62-5 716361-63-6 716361-66-9 716361-67-0
716361-68-1 716361-69-2 716361-70-5 716361-71-6 716361-72-7
716361-74-9 716361-75-0 716361-76-1 716361-77-2 716361-78-3
716361-79-4 716361-80-7 716361-81-8 716361-82-9 716361-83-0
716361-89-6 716361-90-9 716361-91-0 716361-92-1 716361-93-2
716361-96-5 716361-97-6 716361-98-7 716361-99-8 716362-00-4
716362-01-5 716362-02-6 716362-03-7 716362-04-8 716362-05-9
716362-06-0 716362-07-1 716362-08-2 716362-09-3 716362-10-6
716362-11-7 716362-12-8 716362-13-9 716362-14-0 716362-15-1
716362-16-2 716362-17-3 716362-18-4 716362-19-5 716362-20-8
716362-21-9 716362-22-0, 2,1-Benzisoxazole-4-carboxylic acid
716362-23-1 716362-24-2 716362-25-3 716362-26-4 716362-27-5
716362-28-6 716362-29-7 716362-30-0 716362-31-1 716362-32-2
716362-33-3 716362-34-4 716362-35-5 716362-36-6 716362-37-7
716362-38-8 716362-39-9 716362-40-2 716362-41-3 716362-42-4
716362-43-5 716362-44-6 716362-45-7 716362-46-8 716362-47-9
716362-48-0 716362-49-1 716362-50-4 716362-51-5 716362-52-6
716362-53-7 716362-54-8 716362-55-9 716362-56-0 716362-57-1
716362-58-2 716362-59-3 716362-60-6 716362-61-7 716362-62-8
716362-63-9 716362-64-0 716362-65-1 716362-66-2 716362-67-3
716362-68-4 716362-69-5 716362-70-8 716362-71-9 716362-72-0
716362-73-1 716362-74-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of benzimidazolylazabicyclooctylethylpiperid
ine Ccr5 antagonists in the treatment of bacterial and viral infections
and other diseases)

IT 54-42-2, Idoxuridine 57-66-9, Probenecid 58-32-2, Dipyridamole
123-77-3, 1,1'-Azobisformamide 127-07-1, Hydroxyurea 616-91-1,
N-Acetylcysteine 3056-17-5, Stavudine 4428-95-9, Phosphonoformic acid
6493-05-6, Pentoxifylline 7481-89-2, Zalcitabine 11096-26-7,
Erythropoietin 15477-76-6D, Phosphonate, nucleoside derivs.
19771-63-2, Procysteine 25526-93-6, 3'-Deoxy-3'-fluorothymidine
29321-75-3, PRO-2000 29706-85-2 30516-87-1, AZT 39809-25-1,
Penciclovir 59277-89-3, Acyclovir 61512-21-8, Thymosin 69655-05-6,

2',3'-Dideoxyinosine 82410-32-0, Ganciclovir 83869-56-1, GM-CSF
104227-87-4, Famciclovir 113269-46-8, Oxetanocin-G 113852-37-2, HPMPC
119644-22-3 124265-89-0, H2G 124832-26-4, Valaciclovir 127142-14-7
127759-89-1, SQ-34514 127779-20-8, Saquinavir 129618-40-2, Nevirapine
134678-17-4, Lamivudine 136470-78-5, Abacavir 136817-59-9, Delavirdine
142340-99-6, Bis-POM PMEA 142632-32-4, (+)-Calanolide A 143491-54-7,
FTC 145514-04-1, DAPD 147127-20-6, Tenofovir 147318-81-8, KNI-272
147362-57-0, Loviride 149950-60-7, MKC-442 150378-17-9, Indinavir
154598-52-4, Efavirenz 155148-31-5, AMD-3100 155213-67-5, Ritonavir
159989-64-7, Nelfinavir 161814-49-9, Amprenavir 170020-61-8, FP-21399
174391-92-5, Mozenavir 174484-41-4, Tipranavir 178979-85-6,
Capravirine 195156-77-5, ABT-606 198904-31-3, BMS-232632
201341-05-1, Bis-POC-PMPA 213252-22-3, Reticulose 214287-99-7, DPC-083
216863-66-0, MK-944A 226700-79-4, Fosamprenavir 352234-06-1, AG-1776
383198-58-1, PRO-542
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic agents used in conjunction with
benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists in the
treatment of bacterial and viral infections, particularly HIV
infection, and other diseases)

IT **162787-61-3 496051-32-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of benzimidazolylazabicyclooctylethylpiperid
ine Ccr5 antagonists in the treatment of bacterial and viral infections
and other diseases)

RN 162787-61-3 HCAPLUS
CN Benzoic acid, 2-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 496051-32-2 HCAPLUS
CN 3-Thiophenecarboxylic acid, 2-methyl-4-[[(4-methylphenyl)sulfonyl]amino]-
(9CI) (CA INDEX NAME)



L61 ANSWER 7 OF 58 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:513531 HCAPLUS
DN 141:67401
ED Entered STN: 25 Jun 2004
TI Labeled macrophage scavenger receptor antagonists for imaging
cardiovascular diseases
IN Wilson, Ian; Wynn, Duncan

Search done by Noble Jarrell

PA Amersham Plc, UK
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM A61K031-18
ICS A61K051-04; A61P009-10
CC 8-9 (Radiation Biochemistry)
Section cross-reference(s): 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004052357	A1	20040624	WO 2003-GB5319	20031205 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI GB 2002-28490 A 20021206 <--
CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004052357	ICM	A61K031-18
	ICS	A61K051-04; A61P009-10
WO 2004052357	ECLA	A61K031/18; A61K051/04; C07C311/21; C07F013/00B <--

OS MARPAT 141:67401
AB The present invention is in the field of diagnostic imaging. In one aspect, the invention relates to novel imaging agents comprising synthetic macrophage scavenger receptor A antagonists, said imaging agents being useful in the diagnostic imaging of cardiovascular disease. Also claimed in the present invention is a pharmaceutical composition comprising the novel imaging agents of the invention, said pharmaceutical composition being useful for the diagnostic imaging of cardiovascular disease in humans. Another aspect of the present invention is a kit useful in the preparation of the pharmaceutical composition of the invention. Furthermore, the use of the imaging agent of the invention for the diagnostic imaging of cardiovascular disease is also claimed.
ST macrophage scavenger receptor antagonist imaging cardiovascular diseases
IT Scavenger receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(class A; labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases)
IT Radionuclides, biological studies
RL: DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
(complexes, radionuclides; labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases)
IT Artery, disease
(coronary; labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases)
IT Atherosclerosis
Cardiovascular system, disease
Human
Imaging agents
Ischemia
Kidney, disease
Radiopharmaceuticals
Test kits
Thrombosis
(labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases)
IT 7439-89-6D, Iron, complexes 7439-96-5D, Manganese, complexes

7723-14-0D, Phosphorus 31, compds. 7782-41-4D, Fluorine 19, compds. 10043-66-0D, Iodine 131, compds., biological studies 13981-22-1D, Nitrogen 13, compds., biological studies 13981-25-4D, Copper 64, complexes, biological studies 13981-56-1D, Fluorine 18, compds., biological studies 13982-25-7D, Cobalt 55, complexes, biological studies 13982-43-9D, Oxygen 15, compds., biological studies 14093-04-0D, Iron 52, complexes, biological studies 14119-09-6D, Gallium 67, complexes, biological studies 14158-30-6D, Iodine 124, compds., biological studies 14304-87-1D, Silicon 29, compds., biological studies 14331-97-6D, Vanadium 48, complexes, biological studies 14333-33-6D, Carbon 11, compds., biological studies 14390-95-5D, Fluorine 17, compds., biological studies 14390-96-6D, Nitrogen 15, compds., biological studies 14762-74-4D, Carbon 13, compds., biological studies 14809-47-3D, Bromine 75, compds., biological studies 15715-08-9D, Iodine 123, compds., biological studies 15750-15-9D, Indium 111, complexes, biological studies 15757-14-9D, Gallium 68, complexes, biological studies 15757-86-5D, Copper 67, complexes, biological studies 15765-38-5D, Bromine 76, compds., biological studies 22541-19-1D, Gadolinium ion(3+), complexes, biological studies
RL: DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
(labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases)

IT 709658-26-4P 709658-30-0P 710287-66-4P
RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases)

IT 1830-54-2, Dimethyl 3-oxoglutarate 2605-67-6, Carbomethoxymethylenetriphenylphosphorane 26377-50-4 30708-26-0, N-(4-Bromophenyl)-2-amino-5-bromobenzamide 37557-67-8, 3-Chloro-3-methyl-2-nitrosobutane 64835-30-9, 3-Chloro-4-nitrobenzenesulfonyl chloride **107143-69-1** 209685-11-0 709658-21-9 709658-23-1 709658-28-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases)

IT 53378-75-9P, Tris(2-hydroxyethyl)methane 57056-37-8P 57056-38-9P 87986-82-1P 460078-00-6P 488706-14-5P 488706-16-7P 488706-22-5P 709658-20-8P 709658-22-0P 709658-24-2P 709658-25-3P 709658-27-5P 709658-29-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases)

IT 314018-71-8P 709658-31-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases)

IT 14133-76-7D, Technetium 99, complexes, biological studies 14809-55-3D, Technetium 94, complexes, biological studies 14885-78-0D, Indium 113, complexes, biological studies
RL: DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
(metastable; labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases)

IT **107143-69-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases)

RN 107143-69-1 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[(4-chlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



L61 ANSWER 8 OF 58 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:331915 HCAPLUS
DN 140:357353
ED Entered STN: 23 Apr 2004
TI Preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents
IN King, Bryan W.; Sheppeck, James; Gilmore, John L.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM A61K
CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004032846	A2	20040422	WO 2003-US31537	20031003 <--
WO 2004032846	A3	20040715		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004116491	A1	20040617	US 2003-678331	20031003 <--
EP 1558581	A2	20050803	EP 2003-776228	20031003 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI US 2002-416709P	P	20021007 <--		
WO 2003-US31537	W	20031003		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004032846	ICM	A61K
WO 2004032846	ECLA	C07D401/12+249B+215; C07D401/14+249B+215+207; C07D401/14+249B+215+211; C07D403/12+249B+235C; C07D405/14+249B+235C+215; C07D405/14+307+249B+235C; C07D405/14+309+249B+215; C07D417/14+279+249B+207 <--
US 2004116491	NCL	514/383.000
	ECLA	C07D401/12+249B+215; C07D401/14+249B+215+207; C07D401/14+249B+215+211; C07D403/12+249B+235C; C07D405/14+249B+235C+215; C07D405/14+307+249B+235C; C07D405/14+309+249B+215; C07D417/14+279+249B+207 <--
EP 1558581	ECLA	C07D401/12+249B+215; C07D401/14+249B+215+207; C07D401/14+249B+215+211; C07D403/12+249B+235C; C07D405/14+249B+235C+215; C07D405/14+307+249B+235C; C07D405/14+309+249B+215; C07D417/14+279+249B+207 <--

OS MARPAT 140:357353
GI



I II

AB The present application describes novel hydantoin derivs. (shown as I; A = O, S; L-R11 represents a very large variety of substituents and is defined in the claims; e.g. II) or pharmaceutically acceptable salt or prodrug forms thereof, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), aggrecanase, or a combination thereof. Some examples of I exhibit Ki's <10 μM but individual data are not presented. Although the methods of preparation are not claimed, 37 example prepns. are included. For example, II was prepared in 4 steps (100, 66, 73 and 82%, resp.) starting with condensation of Et 4-aminobutyrate hydrochloride with 4-(2-methylquinolin-4-ylmethoxy)benzoyl chloride hydrochloride followed by base hydrolysis to the acid, followed by hydrazide formation with thiosemicarbazide followed by cyclization.

ST triazolone triazolethione prepn inhibitor matrix metalloproteinase TACE antiinflammatory; TNF alpha converting enzyme inhibitor triazolone triazolethione prepn; aggrecanase inhibitor triazolone triazolethione prepn

IT Inflammation
(Crohn's disease; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Intestine, disease
(Crohn's; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Arthritis
(Felty's syndrome; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Arthritis
(Reiter's syndrome; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Granulomatous disease
(Wegener's granulomatosis; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Inflammation
Reproductive tract, disease
(adnexitis; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Liver, disease
(alc.; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT Allergy
Allergy inhibitors
(allergic asthma; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT Asthma
(allergic; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT Lung, disease
(alveolus, hyperoxic alveolar injury; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT Antiarteriosclerotics
(antiatherosclerotics; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT Aneurysm
(aortic; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT Disease, animal
(arthropathy, enteropathic; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT Disease, animal
(asthenia, post-radiation; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT Dermatitis
(atopic; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT Hepatitis
(autoimmune; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT Infection
(bacterial, mycobacterial; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT Fatigue, biological
(chronic fatigue syndrome; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT Lung, disease
(chronic obstructive; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT Eye, disease
(cornea, ulcer; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT Ulcer
(corneal; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT Joint, anatomical
(disease, enteropathic; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT Heart, disease

(failure; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Muscle, disease
(fibromyalgia; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Gingiva, disease
Inflammation
(gingivitis; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Transplant and Transplantation
(graft-vs.-host reaction; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Arthritis
(infectious; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Reperfusion
(injury, post-ischemic; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Arthritis
(intermittent hydrarthrosis; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Rheumatoid arthritis
(juvenile; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Eye, disease
(macula, senile degeneration; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Antitumor agents
Neoplasm
(metastasis; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Antibacterial agents
(mycobacterial; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Antiglaucoma agents
Glaucoma (disease)
(neovascular; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Inflammation
Periodontium, disease
(periodontitis; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Bone, disease
Inflammation
(polychondritis, relapsing; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Myositis
(polymyositis; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT AIDS (disease)
Acute-phase response

Allergy
Allergy inhibitors
Aneurysm
Anorexia
Anti-AIDS agents
Anti-infective agents
Anti-inflammatory agents
Antiarthritics
Antiasthmatics
Antipyretics
Antirheumatic agents
Antitumor agents
Asthma
Atherosclerosis
Autoimmune disease
Behcet's syndrome
Cachexia
Cardiovascular agents
Cardiovascular system, disease
Dermatitis
Dermatomyositis
Drug delivery systems
Emphysema
Fever and Hyperthermia
Fibrosis
Gout
Hemorrhage
Hemostatics
Human
Immunomodulators
Infection
Inflammation
Lyme disease
Meningitis
Multiple sclerosis
Myasthenia gravis
Osteoarthritis
Psoriasis
Rheumatic fever
Rheumatoid arthritis
Sarcoidosis
Shock (circulatory collapse)
Sjogren's syndrome
(preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Arthritis
(pseudogout; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Arthritis
(psoriatic arthritis; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Skin, disease
(pydoderma gangrenosum; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Injury
(reperfusion, post-ischemic; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Connective tissue, disease
(scleroderma; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT Sepsis
(sepsis syndrome; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT Neoplasm
(solid; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT Inflammation
Spinal column, disease
(spondylitis; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT Brain, disease
(stroke; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT Lupus erythematosus
(systemic; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT Inflammation
Intestine, disease
(ulcerative colitis; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT Eye, disease
Inflammation
(uveitis; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT Blood vessel, disease
Inflammation
(vasculitis; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT Glucocorticoids
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(withdrawal syndrome; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT 681283-79-4P 681283-84-1P 681283-88-5P 681283-91-0P 681283-94-3P
681283-95-4P 681283-98-7P 681283-99-8P 681284-03-7P 681284-04-8P
681284-06-0P 681284-07-1P 681284-10-6P 681284-14-0P 681284-18-4P
681284-23-1P 681284-27-5P 681284-28-6P 681284-32-2P 681284-35-5P
681284-36-6P 681284-41-3P 681284-46-8P 681284-50-4P 681284-52-6P
681284-58-2P 681284-62-8P 681284-63-9P 681284-67-3P 681284-68-4P
681284-70-8P 681284-71-9P 681284-80-0P 681284-81-1P 681284-91-3P
681284-99-1P 681285-00-7P 681285-02-9P 681285-03-0P 681285-05-2P
681285-06-3P 681285-16-5P 681285-17-6P 681285-21-2P 681285-22-3P
681285-29-0P 681285-35-8P 681285-36-9P 681285-39-2P 681285-40-5P
681285-43-8P 681285-44-9P 681285-46-1P 681285-47-2P 681285-49-4P
681285-50-7P 681285-51-8P 681285-52-9P 681285-53-0P 681285-54-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT 141907-41-7, Matrix metalloproteinase 147172-61-0, Aggrecanase
151769-16-3, TACE
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)
IT 123-38-6, Propionaldehyde, reactions 623-33-6, Glycine ethyl ester

hydrochloride 4138-35-6, β-Alanine methyl ester 6937-16-2, Ethyl 4-aminobutyrate hydrochloride 119993-55-4 142547-15-7 362488-44-6 362488-51-5, 4-(2-Methylquinolin-4-ylmethoxy)benzoic acid 362489-62-1 362489-71-2 362489-81-4 362490-25-3 362698-25-7 362703-22-8 362703-57-9 362703-58-0 362707-20-8, 4-(2-Methylquinolin-4-ylmethoxy)benzoyl chloride hydrochloride 441774-62-5 461665-32-7 461665-69-0 461665-78-1, 4-(2-Methylquinolin-4-ylmethyl)benzoic acid 607710-13-4 681284-00-4 681284-37-7 681284-42-4 681284-83-3 681284-93-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT 362488-46-8P 362489-83-6P 362489-93-8P 503168-49-8P 681283-80-7P
681283-81-8P 681283-83-0P 681283-85-2P 681283-86-3P 681283-87-4P
681283-89-6P 681283-90-9P 681283-93-2P 681283-96-5P 681283-97-6P
681284-01-5P 681284-02-6P 681284-05-9P 681284-08-2P 681284-09-3P
681284-11-7P 681284-12-8P 681284-13-9P 681284-15-1P 681284-16-2P
681284-17-3P 681284-19-5P 681284-20-8P 681284-21-9P 681284-24-2P
681284-25-3P 681284-26-4P 681284-29-7P **681284-30-0P**
681284-31-1P 681284-33-3P 681284-34-4P 681284-38-8P 681284-39-9P
681284-40-2P 681284-43-5P 681284-44-6P 681284-47-9P 681284-48-0P
681284-53-7P 681284-55-9P 681284-60-6P 681284-64-0P 681284-65-1P
681284-66-2P 681284-69-5P 681284-74-2P 681284-76-4P 681284-78-6P
681284-85-5P 681284-87-7P 681284-89-9P 681284-95-7P 681284-97-9P
681285-10-9P 681285-12-1P 681285-14-3P 681285-18-7P 681285-19-8P
681285-20-1P 681285-25-6P 681285-27-8P 681285-31-4P 681285-33-6P
681285-34-7P 681285-37-0P 681285-38-1P 681285-42-7P 681285-45-0P
681285-48-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

IT **681284-30-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents)

RN 681284-30-0 HCAPLUS
CN Cyclopentanecarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



L61 ANSWER 9 OF 58 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:331897 HCAPLUS
DN 140:350578
ED Entered STN: 23 Apr 2004
TI Small organic compounds for modulation of cholesterol transport via regulation of the scavenger receptor SR-BI for HDL
IN Nieland, Thomas J. F.; Krieger, Monty; Kirchhausen, Tomas
PA Massachusetts Institute of Technology, USA; Center for Blood Research, Inc.
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM A61B
CC 1-8 (Pharmacology)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004032716	A2	20040422	WO 2003-US31918	20031008 <--
	WO 2004032716	C2	20040819		
	WO 2004032716	A3	20040930		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2501685	AA	20040422	CA 2003-2501685	20031008 <--
	US 2004171073	A1	20040902	US 2003-681746	20031008 <--
	EP 1562605	A2	20050817	EP 2003-781314	20031008 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-417083P	P	20021008 <--		
	WO 2003-US31918	W	20031008		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES

WO 2004032716 ICM A61B
US 2004171073 NCL 435/007.100 <--

AB Methods for regulation of lipid and cholesterol uptake are described which are based on regulation of the expression or function of the SR-BI HDL receptor. The examples demonstrate that estrogen dramatically down-regulates SR-BI under conditions of tremendous upregulation of the LDL-receptor. The examples also demonstrate the upregulation of SR-BI in rat adrenal membranes and other non-placental steroidogenic tissues from animals treated with estrogen, but not in other non-placental non-steroidogenic tissues, including lung, liver, and skin. Examples further demonstrate the uptake of fluorescently labeled HDL into the liver cells of animal, which does not occur when the animals are treated with estrogen. Examples also demonstrate the in vivo effects of SR-BI expression on HDL metabolism, in mice transiently overexpressing hepatic SR-BI following recombinant adenovirus infection. Overexpression of the SR-BI in the hepatic tissue caused a dramatic decrease in cholesterol blood levels. These results demonstrate that modulation of SR-BI levels, either directly or indirectly, can be used to modulate levels of cholesterol in the blood. Over 200 small organic compds. are identified that alter the transfer of lipids between HDL and cells mediated by the HDL receptor SR-BI, cellular and selective lipid uptake of HDL cholesteryl ether, and efflux of cellular cholesterol to HDL; several compds. have IC50 values in the micromolar or lower range. They specifically alter SR-BI binding, as they required the expression of active SR-BI receptors and they did not interfere with several clathrin-dependent and independent endocytic pathways, the secretory pathway, nor the actin- or tubulin cytoskeletal networks. Strikingly, inhibition of lipid transfer was accompanied by enhanced HDL binding affinity (reduced dissociation rates).

ST cholesterol transport regulation HDL scavenger receptor SRBI

IT Scavenger receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(SR-BI; small organic compds. for modulation of cholesterol transport via regulation of the scavenger receptor SR-BI for HDL)

IT Lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(high-d.; small organic compds. for modulation of cholesterol transport via regulation of the scavenger receptor SR-BI for HDL)

IT Biological transport
Drug screening
(small organic compds. for modulation of cholesterol transport via regulation of the scavenger receptor SR-BI for HDL)

IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(small organic compds. for modulation of cholesterol transport via regulation of the scavenger receptor SR-BI for HDL)

IT 57-88-5, Cholesterol, biological studies 2469-23-0, Cholesteryl ether
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(small organic compds. for modulation of cholesterol transport via regulation of the scavenger receptor SR-BI for HDL)

IT 536-20-9, 2,4,6-Pyridinetricarboxylic acid 946-13-4 1151-31-1
1521-23-9 2697-61-2 3426-65-1 3440-28-6 4365-60-0 4381-88-8
5102-18-1 5118-80-9 5165-45-7 10102-94-0 10286-90-5 13721-16-9
18015-03-7 18265-72-0 19258-27-6 21762-74-3 24834-68-2
31436-27-8 33350-83-3 34326-53-9 34600-41-4 34812-69-6
35128-95-1 35458-31-2 36800-78-9 53305-35-4 53691-91-1
54258-41-2, 1,10-Phenanthrolin-5-amine 58039-06-8 58136-76-8
62941-10-0 63236-62-4 64741-15-7 66121-84-4 67727-65-5
75460-28-5 76492-71-2 77373-46-7 82859-76-5 88704-72-7
89143-27-1 89159-65-9 90429-57-5 92884-66-7 94678-96-3
95557-97-4 96749-32-5 99093-72-8 100615-32-5 101733-97-5
102355-48-6 109567-63-7 109940-24-1 112117-88-1 113697-57-7
119512-15-1 123044-10-0 132214-10-9 136402-19-2 136402-20-5
149225-69-4 164355-96-8 164355-99-1 169673-73-8 172986-02-6
173601-65-5 183486-59-1 194425-28-0 200279-30-7 202190-83-8
202202-36-6 203574-13-4 220194-89-8 251917-79-0 290829-51-5
293323-99-6 293765-11-4 293765-96-5 294654-81-2 294669-13-9

296265-02-6 298217-72-8 298219-68-8 300667-82-7 300670-54-6
300708-15-0 300814-84-0 300814-92-0 300835-44-3 300860-55-3
301208-20-8 301354-95-0 301357-29-9 301359-53-5 302605-23-8
302819-94-9 302902-82-5 302902-85-8 302928-33-2 302928-47-8
303018-57-7 303051-04-9 303775-26-0 303795-69-9 303796-91-0
303991-36-8 304444-21-1 304455-21-8 306315-63-9 306744-57-0
306744-62-7 306745-36-8 306763-98-4 307509-17-7 307525-79-7
311328-49-1 311777-84-1 312592-76-0 312742-68-0 312915-20-1
312929-58-1 313226-23-2 313258-92-3 313364-25-9 313372-07-5
313496-02-5 313509-24-9 313536-73-1 313647-25-5 313953-24-1
313958-90-6 314031-82-8 314250-43-6 316130-78-6 316133-27-4
316137-06-1 **321578-75-0** 321673-30-7 324055-11-0
324060-54-0 325990-08-7 327982-01-4 328265-49-2 329061-94-1
329180-46-3 329272-20-0 329782-40-3 330447-36-4 330448-31-2
330448-51-6 330448-63-0 330819-79-9 330834-48-5 331243-89-1
331245-08-0 331247-11-1 331417-48-2 331422-88-9 331424-77-2
331429-91-5 331435-62-2 331465-03-3 331648-90-9 331947-10-5
339208-29-6 339303-87-6 340737-11-3 344929-32-4 346719-00-4
346723-87-3 347366-97-6 351491-72-0 352446-44-7 352553-24-3
352564-51-3 356586-79-3 356586-96-4 363590-63-0 371951-42-7
374696-74-9 398131-57-2 400840-54-2 404377-92-0 404911-33-7
412945-77-8 412947-27-4 412962-93-7 413571-56-9 413572-53-9
413581-92-7 413584-09-5 413594-56-6 413605-68-2 413609-62-8
413612-56-3 413618-26-5 413619-39-3 413619-43-9 413620-13-0
462059-44-5 462060-09-9 462061-30-9 464154-35-6 464876-56-0
490017-20-4 551911-04-7 681281-65-2 681281-67-4 681281-68-5
681281-69-6 681281-70-9 681281-71-0 681281-72-1 681281-73-2
681281-74-3 681281-75-4 681281-76-5 681281-77-6 681281-78-7
681281-79-8 681281-80-1 681281-82-3 681281-83-4 681281-84-5
681281-85-6 681281-86-7 681281-88-9 681281-89-0 681281-90-3
681281-91-4 681281-92-5 681281-93-6 681281-94-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(small organic compds. for modulation of cholesterol transport via regulation of the scavenger receptor SR-BI for HDL)

IT 681281-95-8 681281-96-9 681281-97-0 681281-98-1 681281-99-2
681282-00-8 681282-02-0 681282-03-1 681282-04-2 681282-05-3
681282-06-4 681282-07-5 681282-08-6 681282-09-7 681282-10-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(small organic compds. for modulation of cholesterol transport via regulation of the scavenger receptor SR-BI for HDL)

IT **321578-75-0**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(small organic compds. for modulation of cholesterol transport via regulation of the scavenger receptor SR-BI for HDL)

RN 321578-75-0 HCAPLUS
CN Benzoic acid, 2-[[(2-phenylethenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



L61 ANSWER 10 OF 58 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:308396 HCAPLUS
DN 140:339072
ED Entered STN: 15 Apr 2004
TI Preparation of benzamide derivatives as LPA receptor antagonists
IN Terakado, Masahiko; Nakade, Shinji; Seko, Takuya; Takaoka, Yoshikazu

PA Ono Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 304 pp.
CODEN: PIXXD2
DT **Patent**
LA Japanese
IC ICM C07C065-40
ICS C07C235-52; A61K031-192; A61K031-216; A61K031-402; A61K031-4035; A61K031-404; A61K031-41; A61K031-4184; A61K031-4402; A61K031-445; A61K031-472; A61K031-517; A61K031-5415
CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004031118	A1	20040415	WO 2003-JP6680	20030528 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1553075	A1	20050713	EP 2003-733131	20030528 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI JP 2002-291137	A	20021003 <--		
WO 2003-JP6680	W	20030528		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004031118	ICM	C07C065-40
	ICS	C07C235-52; A61K031-192; A61K031-216; A61K031-402; A61K031-4035; A61K031-404; A61K031-41; A61K031-4184; A61K031-4402; A61K031-445; A61K031-472; A61K031-517; A61K031-5415

OS MARPAT 140:339072
GI



I



II

Search done by Noble Jarrell

AB The title compds. I [wherein R = (un)substituted aliphatic hydrocarbyl or cyclyl; G = a bond or a spacer; T = CH2 or a spacer; J = N or CH; B = (un)substituted aliphatic hydrocarbyl or cyclyl; K = a bond or a spacer; Q = a bond or a spacer; ring D = (un)substituted cyclic ring; L = a bond or a spacer; ring E = (un)substituted cyclic ring; n = 0 or 1; M = a bond or a spacer; Z = a acid group] or prodrugs, or salts thereof are prepared as lysophosphatidic acids (LPA) receptor antagonists. For example, the compound II was prepared in a multi-step synthesis. II showed inhibitory activity with IC50 of 0.095 μM against human EDG-2. I are useful for the treatment of urinary diseases, cancer-related diseases, proliferative diseases, inflammatory immune diseases, diseases caused by secretion failures, brain-related diseases, etc. (no data). Formulations containing I as an active ingredient were also described.

ST phenoxy phenyl benzamide lysophosphatidic acid receptor antagonist prepn formulation; human treatment urinary disease cancer inflammation prepn benzamide phenyl

IT Immunity
(disorder; preparation of benzamide derivs. as LPA receptor antagonists)

IT Secretion (process)
(disorders; preparation of benzamide derivs. as LPA receptor antagonists)

IT Anti-inflammatory agents
Antitumor agents
Brain, disease
Human
Immunomodulators
Inflammation
Neoplasm
Urinary tract, disease
(preparation of benzamide derivs. as LPA receptor antagonists)

IT Disease, animal
(proliferative; preparation of benzamide derivs. as LPA receptor antagonists)

IT Lysophosphatidic acids
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(receptor antagonists; preparation of benzamide derivs. as LPA receptor antagonists)

IT 638132-34-0P 638132-38-4P 679790-90-0P 679790-91-1P 679790-92-2P
679790-93-3P 679791-58-3P 679792-75-7P 679792-84-8P 679792-91-7P
679793-04-5P 679793-08-9P 679793-21-6P 679793-24-9P 679793-26-1P
679793-28-3P 679793-30-7P 679793-32-9P 679793-34-1P 679793-41-0P
679793-43-2P 679793-45-4P 679793-47-6P 679793-50-1P 679793-51-2P
679793-53-4P 679793-55-6P 679793-57-8P 679793-59-0P 679793-61-4P
679793-64-7P 679793-67-0P 679793-73-8P 679793-77-2P 679793-79-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of benzamide derivs. as LPA receptor antagonists)

IT 638132-25-9P 638132-26-0P 638132-27-1P 638132-28-2P 638132-29-3P
638132-35-1P 638132-36-2P 638132-37-3P 679789-49-2P 679789-50-5P
679789-51-6P 679789-52-7P 679789-53-8P 679789-54-9P 679789-55-0P
679789-56-1P 679789-57-2P 679789-58-3P 679789-59-4P 679789-60-7P
679789-61-8P 679789-62-9P 679789-63-0P 679789-64-1P 679789-65-2P
679789-66-3P 679789-67-4P 679789-68-5P 679789-69-6P 679789-70-9P
679789-71-0P 679789-72-1P 679789-73-2P 679789-74-3P 679789-75-4P
679789-76-5P 679789-77-6P 679789-78-7P 679789-79-8P 679789-80-1P
679789-81-2P 679789-82-3P 679789-83-4P 679789-84-5P 679789-85-6P
679789-86-7P 679789-87-8P 679789-88-9P 679789-89-0P 679789-90-3P
679789-91-4P 679789-92-5P 679789-93-6P 679789-94-7P 679789-95-8P
679789-96-9P 679789-97-0P 679789-98-1P 679789-99-2P 679790-00-2P
679790-01-3P 679790-02-4P 679790-03-5P 679790-04-6P 679790-05-7P
679790-06-8P 679790-07-9P 679790-08-0P 679790-09-1P 679790-10-4P
679790-11-5P 679790-12-6P 679790-13-7P 679790-14-8P 679790-15-9P
679790-16-0P 679790-17-1P 679790-18-2P 679790-19-3P 679790-20-6P
679790-21-7P 679790-22-8P 679790-23-9P 679790-24-0P 679790-25-1P

679790-26-2P 679790-27-3P 679790-28-4P 679790-29-5P 679790-30-8P
679790-31-9P 679790-32-0P 679790-33-1P 679790-34-2P 679790-35-3P
679790-36-4P 679790-37-5P 679790-38-6P 679790-39-7P 679790-40-0P
679790-41-1P 679790-42-2P 679790-43-3P 679790-44-4P 679790-45-5P
679790-46-6P 679790-47-7P 679790-48-8P 679790-49-9P 679790-50-2P
679790-51-3P 679790-52-4P 679790-53-5P 679790-54-6P 679790-55-7P
679790-56-8P 679790-57-9P 679790-58-0P 679790-59-1P 679790-60-4P
679790-61-5P 679790-62-6P 679790-63-7P 679790-64-8P 679790-65-9P
679790-66-0P 679790-67-1P 679790-68-2P 679790-69-3P 679790-70-6P
679790-71-7P 679790-72-8P 679790-73-9P 679790-74-0P 679790-75-1P
679790-76-2P 679790-77-3P 679790-78-4P 679790-79-5P 679790-80-8P
679790-81-9P 679790-82-0P 679790-83-1P 679790-84-2P 679790-85-3P
679790-86-4P 679790-87-5P 679790-88-6P 679790-89-7P 679790-94-4P
679790-95-5P 679790-97-7P 679790-99-9P 679791-01-6P 679791-03-8P
679791-05-0P 679791-06-1P 679791-07-2P 679791-08-3P 679791-09-4P
679791-10-7P 679791-11-8P 679791-12-9P 679791-13-0P 679791-14-1P
679791-15-2P 679791-16-3P 679791-17-4P 679791-18-5P 679791-19-6P
679791-20-9P 679791-21-0P 679791-22-1P 679791-23-2P 679791-24-3P
679791-25-4P 679791-26-5P 679791-27-6P 679791-28-7P 679791-29-8P
679791-30-1P 679791-32-3P 679791-34-5P 679791-35-6P 679791-36-7P
679791-37-8P 679791-38-9P 679791-39-0P 679791-40-3P 679791-41-4P
679791-42-5P 679791-43-6P 679791-44-7P 679791-45-8P 679791-46-9P
679791-47-0P 679791-48-1P 679791-49-2P 679791-50-5P 679791-51-6P
679791-52-7P 679791-53-8P 679791-54-9P 679791-55-0P 679791-56-1P
679791-57-2P 679791-59-4P 679791-60-7P 679791-61-8P 679791-62-9P
679791-63-0P 679791-64-1P 679791-65-2P 679791-66-3P 679791-67-4P
679791-68-5P 679791-69-6P 679791-70-9P 679791-71-0P 679791-72-1P
679791-73-2P 679791-74-3P 679791-75-4P 679791-76-5P 679791-77-6P
679791-78-7P 679791-79-8P 679791-80-1P 679791-81-2P 679791-82-3P
679791-83-4P 679791-84-5P 679791-85-6P 679791-86-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzamide derivs. as LPA receptor antagonists)

IT 679791-87-8P 679791-88-9P 679791-89-0P 679791-90-3P 679791-91-4P
679791-92-5P 679791-93-6P 679791-94-7P 679791-95-8P 679791-97-0P
679791-98-1P 679791-99-2P 679792-00-8P 679792-01-9P 679792-02-0P
679792-03-1P 679792-04-2P 679792-05-3P 679792-06-4P 679792-07-5P
679792-08-6P 679792-09-7P 679792-10-0P 679792-11-1P 679792-12-2P
679792-13-3P 679792-14-4P 679792-15-5P 679792-16-6P 679792-17-7P
679792-18-8P 679792-19-9P 679792-20-2P 679792-21-3P 679792-22-4P
679792-23-5P 679792-24-6P 679792-25-7P 679792-26-8P 679792-27-9P
679792-28-0P 679792-29-1P 679792-30-4P 679792-31-5P 679792-32-6P
679792-33-7P 679792-34-8P 679792-35-9P 679792-36-0P 679792-37-1P
679792-38-2P 679792-39-3P 679792-40-6P 679792-41-7P 679792-42-8P
679792-43-9P 679792-44-0P 679792-45-1P 679792-46-2P 679792-47-3P
679792-48-4P 679792-49-5P 679792-50-8P 679792-51-9P 679792-52-0P
679792-53-1P 679792-54-2P 679792-55-3P 679792-56-4P 679792-57-5P
679792-58-6P 679792-59-7P 679792-60-0P 679792-61-1P 679792-62-2P
679792-63-3P 679792-64-4P 679792-65-5P 679792-66-6P 679792-67-7P
679792-68-8P 679792-69-9P 679792-70-2P 679792-71-3P 679792-72-4P
679792-73-5P 679792-74-6P 679792-76-8P 679792-77-9P 679792-78-0P
679792-79-1P 679792-80-4P 679792-81-5P 679792-82-6P 679792-83-7P
679792-85-9P 679792-86-0P 679792-87-1P 679792-88-2P 679792-89-3P
679792-90-6P 679792-92-8P 679792-93-9P 679792-94-0P
679792-95-1P 679792-96-2P 679792-97-3P 679792-98-4P
679792-99-5P 679793-00-1P 679793-01-2P 679793-02-3P 679793-03-4P
679793-05-6P 679793-06-7P 679793-07-8P 679793-09-0P 679793-10-3P
679793-11-4P 679793-12-5P 679793-13-6P 679793-14-7P 679793-15-8P
679793-16-9P 679793-17-0P 679793-18-1P 679793-19-2P 679793-20-5P
679793-22-7P 679793-23-8P 679793-25-0P 679793-27-2P 679793-29-4P
679793-31-8P 679793-33-0P 679793-35-2P 679793-36-3P 679793-37-4P
679793-38-5P 679793-39-6P 679793-40-9P 679793-42-1P 679793-44-3P
679793-46-5P 679793-48-7P 679793-52-3P 679793-54-5P 679793-56-7P
679793-58-9P 679793-60-3P 679793-62-5P 679793-63-6P 679793-65-8P

679793-66-9P 679793-68-1P 679793-69-2P 679793-70-5P 679793-71-6P
679793-72-7P 679793-74-9P 679793-75-0P 679793-76-1P 679793-78-3P
679793-80-7P 679793-81-8P 679793-82-9P 679793-83-0P 679793-84-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzamide derivs. as LPA receptor antagonists)

IT 6515-21-5P 118779-14-9P 144291-47-4P 170147-24-7P 183158-78-3P
528812-95-5P 638132-41-9P 679793-85-2P 679793-86-3P 679793-87-4P
679793-88-5P 679793-89-6P 679793-90-9P 679793-91-0P 679793-92-1P
679793-93-2P 679793-94-3P 679793-95-4P 679793-96-5P 679793-97-6P
679793-98-7P 679793-99-8P 679794-00-4P 679794-01-5P 679794-02-6P
679794-03-7P 679794-04-8P 679794-05-9P 679794-06-0P 679794-07-1P
679794-08-2P 679794-09-3P 679794-10-6P 679794-11-7P 679794-12-8P
679794-13-9P 679794-14-0P 679794-15-1P 679794-17-3P 679794-18-4P
679794-19-5P 679794-20-8P 679794-21-9P 679794-22-0P 679794-23-1P
679794-24-2P 679794-25-3P 679794-52-6P 679794-53-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of benzamide derivs. as LPA receptor antagonists)

IT 64-04-0, 2-Phenylethylamine 65-85-0, Benzoic acid, reactions 86-81-7, 3,4,5-Trimethoxybenzaldehyde 96-32-2, Methyl bromoacetate 98-09-9, Benzenesulfonyl chloride 100-39-0, Benzyl bromide 103-63-9, Phenethyl bromide 105-36-2, Ethyl bromoacetate 109-73-9, Butylamine, reactions 118-41-2, 3,4,5-Trimethoxybenzoic acid, reactions 123-08-0, 4-Hydroxybenzaldehyde 147-93-3 364-73-8, 4-Bromo-1-fluoro-2-nitrobenzene 394-35-4, Methyl 2-fluorobenzoate 530-57-4, 4-Hydroxy-3,5-dimethoxybenzoic acid 610-94-6, 2-Bromobenzoic acid methyl ester 638-29-9, Pentanoyl chloride 867-13-0, Ethyl diethoxyphosphorylacetate 1016-19-9, 3,4,5-Trimethoxyphenyl isocyanate 1100-88-5, Benzyltriphenylphosphonium chloride 1215-59-4, 5-Benzyloxyindole 2038-57-5, 3-Phenylpropylamine 3173-56-6, Benzyl isocyanate 3940-75-8 4521-61-3, 3,4,5-Trimethoxybenzoyl chloride 6361-23-5, 2,5-Dichlorobenzaldehyde 7311-34-4, 3,5-Dimethoxybenzaldehyde 7795-95-1, Octylsulfonyl chloride 10075-50-0, 5-Bromoindole 15903-94-3, 6-Benzyloxyindole 19438-10-9, Methyl 3-hydroxybenzoate 24424-99-5, Di-tert-butyl dicarbonate 34523-76-7, Benzoyl chloride, 3,5-dimethoxy-4-methyl- 35186-98-2 40138-16-7, 2-Formylphenylboronic acid 40216-83-9 51828-69-4 52415-29-9, 6-Bromoindole 54812-94-1, 3-Phenylpropylmagnesium chloride 72640-99-4 87199-17-5, 4-Formylphenylboronic acid 155586-39-3 281232-92-6 374538-03-1
679794-26-4 679794-27-5 679794-28-6 679794-29-7 679794-30-0
679794-31-1 679794-32-2 679794-33-3 679794-34-4 679794-35-5
679794-37-7 679794-39-9 679794-41-3 679794-49-1 679794-51-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzamide derivs. as LPA receptor antagonists)

IT 334832-75-6, EDG-2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(receptor antagonists; preparation of benzamide derivs. as LPA receptor antagonists)

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Abbott Laboratories; JP 08-505646 A 1995
(2) Abbott Laboratories; EP 677039 A1 1995 HCAPLUS
(3) Abbott Laboratories; WO 9512572 A1 1995 HCAPLUS
(4) Daiichi Pharmaceutical Co Ltd; WO 01206 A1 2001
(5) Daiichi Pharmaceutical Co Ltd; EP 1189612 A1 2001 HCAPLUS
(6) Daiichi Pharmaceutical Co Ltd; JP 2003503350 A 2001
(7) Daiichi Pharmaceutical Co Ltd; US 200378249 A1 2001
(8) Dr Reddy's Research Foundation; EP 1073643 A1 1999 HCAPLUS
(9) Dr Reddy's Research Foundation; US 6369067 A 1999 HCAPLUS
(10) Dr Reddy's Research Foundation; WO 998501 A1 1999
(11) Dr Reddy's Research Foundation; WO 0262798 A1 2002
(12) Dr Reddy's Research Foundation; US 2002169175 A1 2002 HCAPLUS
(13) Eli Lilly And Co; JP 07-304752 A 1993 HCAPLUS

(14) Eli Lilly And Co; US 5401851 A 1993 HCAPLUS
(15) Eli Lilly And Co; US 5484780 A 1993 HCAPLUS
(16) Eli Lilly And Co; EP 573271 A1 1993 HCAPLUS
(17) Hokuriku Seiyaku Co Ltd; JP 56-90067 A 1981 HCAPLUS
(18) Ono Pharmaceutical Co Ltd; JP 02-209861 A 1989 HCAPLUS
(19) Ono Pharmaceutical Co Ltd; EP 341081 A1 1989 HCAPLUS
(20) Ono Pharmaceutical Co Ltd; US 5017589 A 1989 HCAPLUS
(21) Ono Pharmaceutical Co Ltd; US 5202340 A 1989 HCAPLUS
(22) Ono Pharmaceutical Co Ltd; US 5317021 A 1989 HCAPLUS
(23) Ono Pharmaceutical Co Ltd; WO 0262389 A1 2002
(24) Otsuka Pharmaceutical Co Ltd; JP 10-287634 A 1998 HCAPLUS
(25) Pfizer Inc; US 5482941 A 1993 HCAPLUS
(26) Pfizer Inc; EP 628032 A1 1993 HCAPLUS
(27) Pfizer Inc; WO 9312095 A1 1993 HCAPLUS
(28) Pfizer Inc; JP 07-502029 A 1995
(29) Smithkline Beecham Corp; WO 02646 A1 2002 HCAPLUS
(30) Ssp Co Ltd; JP 11-158144 A 1999 HCAPLUS
(31) University Of Virginian Patent Foundation; WO 0229001 A 2002 HCAPLUS
(32) University Of Virginian Patent Foundation; AU 200196536 A1 2002
(33) Wakunaga Seiyaku Kabushiki Kaisha; JP 02-258783 A 1990 HCAPLUS
(34) Wakunaga Seiyaku Kabushiki Kaisha; JP 03-7260 A 1990 HCAPLUS
(35) Wakunaga Seiyaku Kabushiki Kaisha; EP 390215 A1 1990 HCAPLUS
(36) Wakunaga Seiyaku Kabushiki Kaisha; US 5153203 A 1990 HCAPLUS

IT **679792-95-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzamide derivs. as LPA receptor antagonists)

RN 679792-95-1 HCAPLUS
CN Benzoic acid, 2-[[[4-[[(3,5-dimethoxy-4-methylbenzoyl)(3-phenylpropyl)amino]methyl]phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



L61 ANSWER 11 OF 58 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:253128 HCAPLUS
DN 140:270734
ED Entered STN: 28 Mar 2004
TI Preparation of sulfonyl-containing 2,3-diarylindoles as cyclooxygenase-2 inhibitors.
IN Guo, Zongru; Cheng, Guifang; Chu, Fengming
PA Peop. Rep. China
SO U.S. Pat. Appl. Publ., 28 pp.
CODEN: USXXCO
DT **Patent**
LA English
IC ICM A61K031-405
ICS C07D209-56
INCL 514415000; 548506000
CC 27-11 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI US 2004058977 A1 20040325 US 2002-243957 20020916 <--
PRAI US 2002-243957 20020916 <--
CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004058977	ICM	A61K031-405
	ICS	C07D209-56
	INCL	514415000; 548506000
US 2004058977	NCL	514/415.000
	ECLA	C07D209/08 <--

OS MARPAT 140:270734
GI



I

AB Title compds. (I; R1, R2 = 4-methylsulfonyl, 4-aminosulfonyl, H, halo, alkyl, alkoxy, OH, cyano, NO2, amino, CF3; R3 = H, halo, alkyl, alkoxy, OH, cyano, NO2, amino, CF3), were prepared Thus, 2-[N-(4-aminosulfonylbenzoyl)amino]-4'-methoxybenzophenone (preparation given) was refluxed with Zn and TiCl4 in THF to give 73.9% 2-(4-aminosulfonylphenyl)-3-(4-methoxyphenyl)indole. The latter inhibited cyclooxygenase-2 with IC50 = 6.70 + 10-12 M.

ST sulfonyl contg diarylindole prepn cyclooxygenase inhibitor; indole aryl aminosulfonyl methylsulfonyl prepn antiinflammatory

IT Anti-inflammatory agents
Inflammation
(preparation of sulfonyl-containing 2,3-diarylindoles as cyclooxygenase-2 inhibitors)

IT Lewis acids
RL: CAT (Catalyst use); USES (Uses)
(preparation of sulfonyl-containing 2,3-diarylindoles as cyclooxygenase-2 inhibitors)

IT 329900-75-6, COX-2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(COX-2; preparation of sulfonyl-containing 2,3-diarylindoles as cyclooxygenase-2 inhibitors)

IT 462120-56-5P, 2-(4-Methylsulfonylphenyl)-3-phenylindole 462120-57-6P, 2-(4-Aminosulfonylphenyl)-3-phenylindole 500870-87-1P, 2-(4-Methylsulfonylphenyl)-3-(4-chlorophenyl)indole 500870-88-2P, 2-(4-Aminosulfonylphenyl)-3-(4-chlorophenyl)indole 500870-90-6P, 2-(4-Aminosulfonylphenyl)-3-(4-bromophenyl)indole 500870-91-7P, 2-(4-Methylsulfonylphenyl)-3-(4-methylphenyl)indole 500870-92-8P, 2-(4-Aminosulfonylphenyl)-3-(4-methylphenyl)indole 500870-93-9P, 2-(4-Methylsulfonylphenyl)-3-(3,4-dimethylphenyl)indole 500870-94-0P, 2-(4-Aminosulfonylphenyl)-3-(3,4-dimethylphenyl)indole 500870-95-1P, 2-(4-Methylsulfonylphenyl)-3-(4-methoxyphenyl)indole 500870-96-2P, 2-(4-Aminosulfonylphenyl)-3-(4-methoxyphenyl)indole
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of sulfonyl-containing 2,3-diarylindoles as cyclooxygenase-2 inhibitors)

IT 178614-29-4P, 2-(4-Methylsulfonylphenyl)-3-(4-fluorophenyl)indole 462120-58-7P, 2-(4-Aminosulfonylphenyl)-3-phenyl-5-fluoroindole

462120-59-8P, 2-(4-Aminosulfonylphenyl)-3-phenyl-5-chloroindole
462120-60-1P, 2-(4-Methylsulfonylphenyl)-3-phenyl-5-chloroindole
500870-89-3P, 2-(4-Methylsulfonylphenyl)-3-(4-bromophenyl)indole
565452-81-5P, 2-(4-Aminosulfonylphenyl)-3-(4-fluorophenyl)indole
565452-82-6P, 2-(4-Aminosulfonylphenyl)-3-(4-hydroxyphenyl)indole
565452-83-7P 565452-86-0P, 2-(4-Aminosulfonylphenyl)-3-(3-chlorophenyl)-5-chloroindole 565452-87-1P, 2-(4-Methylsulfonylphenyl)-3-(3-chlorophenyl)-5-chloroindole 565452-88-2P, 2-(4-Aminosulfonylphenyl)-3-(2-chlorophenyl)-5-chloroindole 565452-89-3P, 2-(4-Methylsulfonylphenyl)-3-(2-chlorophenyl)-5-chloroindole 565452-90-6P, 2-(4-Methylsulfonylphenyl)-3-phenyl-5-fluoroindole 565452-91-7P, 2-(4-Aminosulfonylphenyl)-3-phenyl-5-bromoindole 565452-92-8P, 2-(4-Methylsulfonylphenyl)-3-phenyl-5-bromoindole 565452-93-9P, 2-(4-Aminosulfonylphenyl)-3-phenyl-5-methylindole 565452-94-0P, 2-(4-Methylsulfonylphenyl)-3-phenyl-5-methylindole 660441-65-6P, 2-Phenyl-3-(4-methylsulfonylphenyl)-5-chloroindole 660441-66-7P, 2-(2-Fluorophenyl)-3-(4-methylsulfonylphenyl)-5-chloroindole 660441-67-8P, 2-(4-Chlorophenyl)-3-(4-methylsulfonylphenyl)-5-chloroindole 660441-68-9P, 2-(4-Methylphenyl)-3-(4-methylsulfonylphenyl)-5-chloroindole 660441-69-0P, 2-(4-Methoxyphenyl)-3-(4-methylsulfonylphenyl)-5-chloroindole 660441-70-3P, 2-(2-Acetyloxyphenyl)-3-(4-methylsulfonylphenyl)-5-chloroindole 660441-71-4P, 2-(4-Acetyloxyphenyl)-3-(4-methylsulfonylphenyl)-5-chloroindole 660441-72-5P, 2-(4-Methylsulfonylphenyl)-3-(4-methylsulfonylphenyl)-5-chloroindole 660441-74-7P, 2-Phenyl-3-(4-methylsulfonylphenyl)indole 660441-75-8P, 2-Phenyl-3-(4-aminosulfonylphenyl)indole 674803-11-3P, 2-(4-Hydroxyphenyl)-3-(4-methylsulfonylphenyl)-5-chloroindole
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonyl-containing 2,3-diarylindoles as cyclooxygenase-2 inhibitors)

IT 59-88-1, Phenylhydrazine hydrochloride 65-85-0, Benzoic acid, reactions 71-43-2, Benzene, reactions 74-11-3, p-Chlorobenzoic acid 77-78-1, Dimethyl sulfate 95-47-6, 3,4-Dimethylbenzene, reactions 98-59-9, p-Toluenesulfonyl chloride 98-88-4, Benzoyl chloride 100-07-2, 4-Methoxybenzoyl chloride 100-66-3, Anisole, reactions 106-40-1, 4-Bromoaniline 106-45-6, p-Methylthiophenol 106-47-8, 4-Chloroaniline, reactions 106-49-0, p-Toluidine, reactions 108-86-1, Bromobenzene, reactions 108-88-3, Toluene, reactions 108-90-7, Chlorobenzene, reactions 118-91-2, o-Chlorobenzoic acid 118-92-3, Anthranilic acid 122-01-0, 4-Chlorobenzoyl chloride 371-40-4, 4-Fluoroaniline 393-52-2, 2-Fluorobenzoyl chloride 462-06-6, Fluorobenzene 535-80-8, m-Chlorobenzoic acid 874-60-2, 4-Methylbenzoyl chloride 5538-51-2, 2-Acetoxybenzoyl chloride 22958-64-1, 4-Aminosulfonylphenylacetic acid 27914-73-4, 4-Acetoxybenzoyl chloride 40913-92-6, 4-Methylsulfonylbenzoyl chloride 51594-97-9, 4-Aminosulfonylbenzoyl chloride 90536-66-6, 4-Methylsulfonylphenylacetic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of sulfonyl-containing 2,3-diarylindoles as cyclooxygenase-2 inhibitors)

IT 70-55-3P, p-Toluenesulfonamide 100-68-5P, Thioanisole 138-41-0P, p-Aminosulfonylbenzoic acid 362-46-9P, 2-Amino-5-fluorobenzophenone 719-59-5P, 2-Amino-5-chlorobenzophenone 837-58-1P, 2-Amino-5-chloro-4'-chlorobenzophenone 1140-17-6P, 2-Amino-4'-bromobenzophenone 2835-77-0P, 2-Aminobenzophenone 2894-51-1P, 2-Amino-4'-chlorobenzophenone 2958-36-3P, 2-Amino-5-chloro-2'-chlorobenzophenone 3800-06-4P, 2-Amino-4'-fluorobenzophenone 4052-30-6P, p-Methylsulfonylbenzoic acid 5625-08-1P, 2-Amino-5-chloro-3'-chlorobenzophenone **6311-23-5P**, N-(p-Toluenesulfonyl)anthranilic acid 17852-28-7P, 2-Amino-5-methylbenzophenone 36192-61-7P, 2-Amino-4'-methoxybenzophenone 36192-63-9P, 2-Amino-4'-methylbenzophenone 39859-36-4P, 2-Amino-5-bromobenzophenone 181697-05-2P 198126-70-4P 462120-51-0P 462120-52-1P 462120-53-2P 462120-55-4P 500870-77-9P 500870-78-0P 500870-79-1P 500870-81-5P 500870-82-6P 500870-83-7P 500870-84-8P 500870-85-9P 500870-86-0P

615564-18-6P 660441-76-9P, 2-Amino-5-chloro-4'-methylsulfonylbenzophenone 660441-77-0P 674802-89-2P, 2-Amino-3,4'-dimethylbenzophenone 674802-90-5P 674802-91-6P 674802-92-7P 674802-93-8P 674802-95-0P 674802-96-1P 674802-97-2P 674802-98-3P 674802-99-4P 674803-00-0P 674803-01-1P 674803-02-2P 674803-03-3P 674803-04-4P 674803-05-5P 674803-06-6P 674803-07-7P 674803-08-8P 674803-09-9P 674803-10-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of sulfonyl-containing 2,3-diarylindoles as cyclooxygenase-2 inhibitors)

IT 7440-66-6, Zinc, reactions 7550-45-0, Titanium tetrachloride, reactions 7719-09-7, Thionyl chloride 7722-64-7, Potassium permanganate
RL: RGT (Reagent); RACT (Reactant or reagent)
(preparation of sulfonyl-containing 2,3-diarylindoles as cyclooxygenase-2 inhibitors)

IT **6311-23-5P**, N-(p-Toluenesulfonyl)anthranilic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of sulfonyl-containing 2,3-diarylindoles as cyclooxygenase-2 inhibitors)

RN 6311-23-5 HCAPLUS
CN Benzoic acid, 2-[[(4-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



L61 ANSWER 12 OF 58 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:220303 HCAPLUS
DN 140:270631
ED Entered STN: 19 Mar 2004
TI Preparation of (hetero)arylamides as chloride channel blockers
IN Dahl, Bjarne H.; Christophersen, Palle; Engsig, Michael Thyrring; Karsdal, Morten Asser; Foged, Niels Taekker; Jensen, Flemming Reissig
PA Neurosearch A/s, Den.
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM C07C233-00
ICS C07C235-00; C07C311-15; C07D257-04; C07D207-00; C07D209-00; C07D333-02; A61K031-165; A61K031-395; A61K031-381; A61P019-00; A61P043-00
CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 27
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004022525	A1	20040318	WO 2003-DK576	20030904 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI DK 2002-1307 A 20020905 <--
DK 2002-1309 A 20020905 <--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004022525	ICM	C07C233-00
	ICS	C07C235-00; C07C311-15; C07D257-04; C07D207-00; C07D209-00; C07D333-02; A61K031-165; A61K031-395; A61K031-381; A61P019-00; A61P043-00

OS MARPAT 140:270631

AB ALB [1 of A, B = Ph, pyridyl, naphthyl, pyrolidinyl, cyclohexanyl substituted with 2 neighboring F or with tetrazolyl, CO2H; and which ring system is optionally further substituted with ≥1 halo, alkyl, Ph optionally substituted with CONRbRc; Rb, Rc = alkyl; or CH(CO2H)Rd; Rd = Ph optionally substituted by halo, CF3; the other of A, B = Ph, thienyl, indolyl, naphthyl, optionally substituted with ≥1 halo, trifluoromethyl, nitro, amino, alkoxy; L = NHCO, NHSO2, NHCOCH2, NCOCH2O, CO], were prepared for treatment of osteoporosis, cancer, glaucoma, etc. (no data). Thus, 3-chlorobenzoyl chloride and 2-amino-4-chlorobenzoic acid were heated at 90° for 4 h to give 4-chloro-2-(3-chlorobenzoylamino)benzoic acid.

ST arylamide prepn chloride channel blocker; benzoylaminobenzoate prepn cancer glaucoma osteoporosis hypertension treatment; fluorophenylbenzamide prepn ulcer diarrhea arthritis treatment; phenylacetylaminobenzoate prepn edema psoriasis sickle cell anemia treatment; thienoylaminobenzoate prepn corneal neovascularization retinopathy macular degeneration treatment

IT Inflammation
(Crohn's disease, treatment; preparation of (hetero)arylamides as chloride channel blockers)

IT Intestine, disease
(Crohn's, treatment; preparation of (hetero)arylamides as chloride channel blockers)

IT Bone, disease
(Paget's, treatment; preparation of (hetero)arylamides as chloride channel blockers)

IT Allergy
(allergic dermatitis, treatment; preparation of (hetero)arylamides as chloride channel blockers)

IT Allergy
Inflammation
Nose, disease
(allergic rhinitis, treatment; preparation of (hetero)arylamides as chloride channel blockers)

IT Dermatitis
(allergic, treatment; preparation of (hetero)arylamides as chloride channel blockers)

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of (hetero)arylamides as chloride channel blockers)

IT Mycosis
(aspergillosis, allergic bronchopulmonary, treatment; preparation of (hetero)arylamides as chloride channel blockers)

IT Dermatitis
(atopic, treatment; preparation of (hetero)arylamides as chloride channel blockers)

IT Chloride channel
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(blockers; preparation of (hetero)arylamides as chloride channel blockers)

IT Ischemia
(cardiac, treatment; preparation of (hetero)arylamides as chloride channel blockers)

IT Edema
(cerebral, treatment; preparation of (hetero)arylamides as chloride channel blockers)

IT Lung, disease
(chronic obstructive, treatment; preparation of (hetero)arylamides as

chloride channel blockers)
IT Intestine, neoplasm
(colon, treatment; preparation of (hetero)arylamides as chloride channel blockers)
IT Dermatitis
(contact, treatment; preparation of (hetero)arylamides as chloride channel blockers)
IT Eye, disease
(corneal neovascularization treatment; preparation of (hetero)arylamides as chloride channel blockers)
IT Eye, disease
Eye, disease
(diabetic retinopathy, treatment; preparation of (hetero)arylamides as chloride channel blockers)
IT Heart, disease
(dilated cardiomyopathy, treatment; preparation of (hetero)arylamides as chloride channel blockers)
IT Allergy
(drug-induced, treatment; preparation of (hetero)arylamides as chloride channel blockers)
IT Brain, disease
(edema, treatment; preparation of (hetero)arylamides as chloride channel blockers)
IT Lung, disease
(fibrosis, treatment; preparation of (hetero)arylamides as chloride channel blockers)
IT Carcinoma
(hepatocellular, treatment; preparation of (hetero)arylamides as chloride channel blockers)
IT Liver, neoplasm
(hepatoma, treatment; preparation of (hetero)arylamides as chloride channel blockers)
IT Allergy
Inflammation
Lung, disease
(hypersensitivity pneumonitis, treatment; preparation of (hetero)arylamides as chloride channel blockers)
IT Heart, disease
(ischemia, treatment; preparation of (hetero)arylamides as chloride channel blockers)
IT Eye, disease
(macula, degeneration, treatment; preparation of (hetero)arylamides as chloride channel blockers)
IT Eye, disease
(macula, senile degeneration, treatment; preparation of (hetero)arylamides as chloride channel blockers)
IT Osteoclast
(osteoclast related bone disease treatment; preparation of (hetero)arylamides as chloride channel blockers)
IT Neoplasm
(osteolytic, treatment; preparation of (hetero)arylamides as chloride channel blockers)
IT Osteoporosis
(postmenopausal, treatment; preparation of (hetero)arylamides as chloride channel blockers)
IT Angiogenesis inhibitors
Antiarthritics
Antiasthmatics
Antidiarrheals
Antiglaucoma agents
Antihypertensives
Antitumor agents
Antiulcer agents
Basophil
Cardiovascular agents
Human

Ion channel blockers
Mast cell
(preparation of (hetero)arylamides as chloride channel blockers)

IT Amides, preparation
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (hetero)arylamides as chloride channel blockers)

IT Fibrosis
(pulmonary, treatment; preparation of (hetero)arylamides as chloride channel blockers)

IT Eye, disease
(retinopathy, ischemic, treatment; preparation of (hetero)arylamides as chloride channel blockers)

IT Eye, disease
(retinopathy, treatment; preparation of (hetero)arylamides as chloride channel blockers)

IT Eye, disease
(retrolental fibroplasia, treatment; preparation of (hetero)arylamides as chloride channel blockers)

IT Connective tissue, disease
(scleroderma, treatment; preparation of (hetero)arylamides as chloride channel blockers)

IT Osteoporosis
(secondary, treatment; preparation of (hetero)arylamides as chloride channel blockers)

IT Allergy
(skin reaction treatment; preparation of (hetero)arylamides as chloride channel blockers)

IT Anaphylaxis
Asthma
Asthma
Atherosclerosis
Bladder, neoplasm
Diarrhea
Glaucoma (disease)
Hypertension
Kidney, neoplasm
Lung, neoplasm
Lymphoma
Mammary gland, neoplasm
Melanoma
Neoplasm
Osteoporosis
Ovary, neoplasm
Pancreas, neoplasm
Prostate gland, neoplasm
Psoriasis
Rheumatoid arthritis
Sarcoma
Sickle cell anemia
Stomach, neoplasm
Transplant rejection
Ulcer
Urticaria
(treatment; preparation of (hetero)arylamides as chloride channel blockers)

IT Eye, disease
Inflammation
(uveoretinitis, treatment; preparation of (hetero)arylamides as chloride channel blockers)

IT 6345-04-6P 19407-53-5P 37836-95-6P 60498-39-7P 75541-86-5P
100874-12-2P 108204-33-7P 125119-24-6P 349652-73-9P 352645-21-7P
402582-89-2P 402584-79-6P 402590-25-4P 404831-43-2P 404838-46-6P
404845-64-3P 404897-09-2P 420842-07-5P 496015-33-9P 518021-60-8P
518021-61-9P 550304-87-5P 667403-90-9P 667410-02-8P 668264-76-4P
668265-59-6P 668265-79-0P 668975-70-0P 672300-01-5P 672300-02-6P

672300-03-7P 672300-04-8P 672300-05-9P 672300-06-0P 672300-07-1P
672300-08-2P 672300-09-3P 672300-10-6P 672300-11-7P
672300-12-8P 672300-13-9P 672300-14-0P **672300-15-1P**
672300-16-2P 672300-17-3P 672300-18-4P 672300-19-5P 672300-20-8P
672300-21-9P 672300-22-0P 672300-23-1P 672300-24-2P 672300-25-3P
672300-26-4P 672300-27-5P 672300-28-6P 672300-29-7P 672300-30-0P
672300-31-1P 672300-32-2P 672300-33-3P 672300-34-4P 672300-35-5P
672300-36-6P 672300-37-7P 672300-38-8P 672300-39-9P 672300-40-2P
672300-41-3P 672300-42-4P 672300-43-5P 672300-44-6P 672300-45-7P
672300-46-8P 672300-47-9P 672300-48-0P 672300-49-1P 672300-50-4P
672300-51-5P 672300-52-6P 672300-53-7P 672300-54-8P 672300-55-9P
672300-56-0P 672300-57-1P 672300-58-2P 672300-60-6P 672300-61-7P
672300-62-8P 672300-63-9P 672300-64-0P 672300-65-1P 672300-66-2P
672300-67-3P 672300-68-4P 672300-69-5P 672300-70-8P 672300-71-9P
672300-72-0P 672300-73-1P 672300-74-2P 672300-75-3P 672300-76-4P
672300-77-5P 672300-78-6P 672300-79-7P 672300-80-0P 672300-81-1P
672300-82-2P 672300-83-3P 672300-84-4P 672300-85-5P 672300-86-6P
672300-87-7P 672300-88-8P 672300-89-9P 672300-90-2P 672300-91-3P
672300-92-4P 672300-93-5P 672300-94-6P 672300-95-7P 672300-96-8P
672300-97-9P 672300-98-0P 672300-99-1P 672301-00-7P 672301-01-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (hetero)arylamides as chloride channel blockers)

IT 89-77-0, 2-Amino-4-chlorobenzoic acid 618-46-2, 3-Chlorobenzoyl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of (hetero)arylamides as chloride channel blockers)

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) American Home Prod; WO 9907669 A 1999 HCAPLUS
(2) Anon; DATABASE REGISTRY ON STN INTERN [Online] File Registry No 444077-81-0 2002
(3) Dahl, B; WO 0024707 A 2000 HCAPLUS
(4) Dahl, B; WO 0239987 A 2002 HCAPLUS
(5) Hansen, D; US 4108632 A 1978 HCAPLUS
(6) Neurosearch As; WO 9745400 A 1997 HCAPLUS
(7) Neurosearch As; WO 9847879 A 1998 HCAPLUS
(8) Nippon Zoki Pharmaceutical Co Ltd; JP 57064655 A 1982 HCAPLUS
(9) Rahalkar, S; INDIAN DRUGS 1986, V23(10), P545 HCAPLUS
(10) Raman, H; US 3100226 A 1963
(11) Sanwa Kagaku Kenkyusho Co; GB 1320484 A 1973 HCAPLUS
(12) Shiseido Co Ltd; JP 08301760 A 1996 HCAPLUS
(13) Siim, M; WO 03000245 A 2003 HCAPLUS
(14) Smith, A; CA 519684 A 1955 HCAPLUS
(15) Socibre; FR 2102170 A 1972 HCAPLUS
(16) Sumitomo Chemical Company Limited; GB 1162727 A 1969 HCAPLUS
(17) Ugine, K; FR 2143577 A 1973 HCAPLUS
(18) Victoria, A; WO 03000267 A 2003 HCAPLUS

IT **672300-08-2P 672300-15-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (hetero)arylamides as chloride channel blockers)

RN 672300-08-2 HCAPLUS
CN Benzoic acid, 4-chloro-2-[[(4-chlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 672300-15-1 HCAPLUS
CN Benzoic acid, 3,5-dibromo-2-[[(4-chlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



L61 ANSWER 13 OF 58 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:117206 HCAPLUS
DN 140:159049
ED Entered STN: 13 Feb 2004
TI Selective herbcidal compositions for maize and cereals
IN Haas, Ulrich
PA Syngenta Participations AG, Switz.
SO Eur. Pat. Appl., 36 pp.
CODEN: EPXXDW
DT **Patent**
LA English
IC ICM A01N043-40
ICS A01N061-00; A01N025-32
CC 5-3 (Agrochemical Bioregulators)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1388285	A2	20040211	EP 2003-17961	20030806 <--
EP 1388285	A3	20040317		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
ZA 2003005993	A	20040209	ZA 2003-5993	20030804 <--
CA 2436648	AA	20040207	CA 2003-2436648	20030805 <--
US 2004033897	A1	20040219	US 2003-634347	20030805 <--
BR 2003002668	A	20040824	BR 2003-2668	20030805 <--
JP 2004099602	A2	20040402	JP 2003-206257	20030806 <--
CN 1494827	A	20040512	CN 2003-127562	20030807 <--
PRAI CH 2002-1371	A	20020807 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
EP 1388285	ICM	A01N043-40
	ICS	A01N061-00; A01N025-32
EP 1388285	ECLA	A01N043/40+M <--
US 2004033897	NCL	504/255.000
	ECLA	A01N043/40+M <--
JP 2004099602	FTERM	4H011/AB01; 4H011/BA03; 4H011/BA05; 4H011/BA06; 4H011/BB04; 4H011/BB06; 4H011/BB07; 4H011/BB08; 4H011/BB09; 4H011/BB10; 4H011/BB13; 4H011/BB14; 4H011/BB17; 4H011/BC06; 4H011/BC07; 4H011/BC08; 4H011/BC09; 4H011/BC10; 4H011/BC14; 4H011/DA02;

4H011/DD04; 4H011/DF04; 4H011/DF06 <--

GI



I

AB A selective herbicidal composition, comprises: (a) a compound of formula I {3-[[2-[(acetyloxy)methyl]-6-(trifluoromethyl)-3-pyridinyl]carbonyl]-4-hydroxy-Bicyclo[3.2.1]oct-3-en-2-one} (REG 380354-68-7) or an agronomically acceptable salt of that compound; (b) a synergistically effective amount of one or more compds. selected from atrazine, simazine, terbutryn, ametryn, foramsulfuron, trifloxysulfuron, metolachlor, S-metolachlor, alachlor, acetochlor, flufenacet, dimethenamid, S-dimethenamid, pethoxamid, flumetsulam, metosulam, pyridate, pyridafol, dicamba and salts thereof, procarbazone, glufosinate, fluthiacet, imazamox, imazethapyr, nicosulfuron, primisulfuron-Me, rimsulfuron, halosulfuron, cloransulam, clomazone, diclosulam, 2,4-D, florasulam, flumiclorac, bromoxynil, sethoxydim, ioxynil, tepraloxydim, carfentrazone, clethodim, sulfentrazone, imazaquin, sulcotrione, imazapyr, mesotrione, thifensulfuron, isoxaflutole, prosulfuron, isoxachlortole, bentazone, iodosulfuron, prohexadione, diflufenzopyr, flurtamone, butylate, flumioxazin, fentrazamide, benzfendizone, isopropazol, fluazolate, aclonifen, tritosulfuron, cinidon-Et, glyphosate and the potassium, isopropylammonium, sodium, trimesium, ammonium and diammonium salts thereof, mesotrione + terbuthylazine, metolachlor + terbuthylazine, S-metolachlor + terbuthylazine, paraquat, ketospiradox, aminopyralid, amicarbazone and azafenidin; and, optionally, (c) a herbicide safener . The herbicidal compns. is especially useful for controlling weeds in maize and cereals.

ST herbicides selective maize cereal

IT Cereal (grain)
Zea mays
(selective herbcidal compns. for maize and cereals)

IT Herbicides
(selective; selective herbcidal compns. for maize and cereals)

IT 3740-92-9D, mixts. containing 31541-57-8 37764-25-3 71526-07-3 72850-64-7 79260-71-2 88485-37-4 98730-04-2 99607-70-2D, mixts. containing 103112-35-2 121776-33-8 129531-12-0 135590-91-9D, mixts. containing 143276-05-5 205121-04-6 219479-18-2 654646-57-8
RL: AGR (Agricultural use); BSU (Biological study, unclassified); BIOL (Biological study); USES (Uses)
(safener in selective herbcidal compns. for maize and cereals)

IT 94-75-7D, 2,4-D, mixts. containing 122-34-9D, Simazine, mixts. containing 834-12-8D, Ametryn, mixts. containing 886-50-0D, Terbutryn, mixts. containing 1071-83-6D, Glyphosate, mixts. containing 1689-83-4D, Ioxynil, mixts. containing 1689-84-5D, Bromoxynil, mixts. containing 1912-24-9D, Atrazine, mixts. containing 1918-00-9D, Dicamba, mixts. containing 2008-41-5D, Butylate, mixts. containing 4685-14-7D, Paraquat, mixts. containing 15972-60-8D, Alachlor, mixts. containing 25057-89-0D, Bentazone, mixts. containing 34256-82-1D, Acetochlor, mixts. containing 40020-01-7D, Pyridafol, mixts. containing 40465-66-5D, Glycine, N-(phosphonomethyl)-, monoammonium salt, mixts. containing 51218-45-2D, Metolachlor, mixts. containing 51276-47-2D, Glufosinate, mixts. containing 55512-33-9D, Pyridate, mixts. containing 68049-83-2D, Azafenidin., mixts. containing 69254-40-6D, Glycine, N-(phosphonomethyl)-, diammonium salt, mixts. containing 70901-12-1D, Glycine, N-(phosphonomethyl)-, potassium salt, mixts. containing

74051-80-2D, Sethoxydim, mixts. containing 74070-46-5D, Aclonifen, mixts. containing 79277-67-1D, Thifensulfuron, mixts. containing 81334-34-1D, Imazapyr, mixts. containing 81335-37-7D, Imazaquin, mixts. containing 81335-77-5D, Imazethapyr, mixts. containing 81591-81-3D, Glyphosate-trimesium, mixts. containing 81777-89-1D, Clomazone, mixts. containing 86209-51-0D, Primisulfuron-Methyl, mixts. containing 87392-12-9D, S-Metolachlor, mixts. containing 87547-04-4D, Flumiclorac, mixts. containing 87674-68-8D, Dimethenamid, mixts. containing 88805-35-0D, Prohexadione, mixts. containing 94125-34-5D, Prosulfuron, mixts. containing 96525-23-4D, Flurtamone, mixts. containing 98967-40-9D, Flumetsulam, mixts. containing 99105-77-8D, Sulcotrione, mixts. containing 99129-21-2D, Clethodim, mixts. containing 102413-71-8D, Glycine, N-(phosphonomethyl)-, sodium salt, mixts. containing 103361-09-7D, Flumioxazin, mixts. containing 104206-82-8D, Mesotrione, mixts. containing 106700-29-2D, Pethoxamid, mixts. containing 109293-97-2D, Diflufenzopyr, mixts. containing 111991-09-4D, Nicosulfuron, mixts. containing 114311-32-9D, Imazamox, mixts. containing 118147-37-8D, Metolachlor-terbuthylazine mixture, mixts. containing 122836-35-5D, Sulfentrazone, mixts. containing 122931-48-0D, Rimsulfuron, mixts. containing 128621-72-7D, Carfentrazone, mixts. containing 129909-90-6D, Amicarbazone, mixts. containing 135397-30-7D, Halosulfuron, mixts. containing 139528-85-1D, Metosulam, mixts. containing 141112-06-3D, Isoxachlortole, mixts. containing 141112-29-0D, Isoxaflutole, mixts. containing 142459-58-3D, Flufenacet, mixts. containing 142469-14-5D, Tritosulfuron, mixts. containing 142891-20-1D, Cinidon-Ethyl, mixts. containing 145026-81-9D, Procarbazone, mixts. containing 145099-21-4D, Trifloxysulfuron, mixts. containing 145701-21-9D, Diclosulam, mixts. containing 145701-23-1D, Florasulam, mixts. containing 149253-65-6D, Fluthiacet, mixts. containing 149979-41-9D, Tepraloxydim, mixts. containing 150114-71-9D, Aminopyralid, mixts. containing 158237-07-1D, Fentrazamide, mixts. containing 158755-95-4D, Benzfendizone, mixts. containing **159518-97-5D**, Cloransulam, mixts. containing 163515-14-8D, S-Dimethenamid, mixts. containing 173159-57-4D, Foramsulfuron, mixts. containing 174514-07-9D, Isopropazol, mixts. containing 185119-76-0D, Iodosulfuron, mixts. containing 192708-91-1D, Ketospiradox, mixts. containing 223671-72-5D, S-Metolachlor-terbuthylazine mixture, mixts. containing 380354-68-7D, mixts. containing 478164-81-7D, Mesotrione-terbuthylazine mixture, mixts. containing
RL: AGR (Agricultural use); BSU (Biological study, unclassified); BIOL (Biological study); USES (Uses)
(selective herbcidal compns. for maize and cereals containing)

IT **159518-97-5D**, Cloransulam, mixts. containing
RL: AGR (Agricultural use); BSU (Biological study, unclassified); BIOL (Biological study); USES (Uses)
(selective herbcidal compns. for maize and cereals containing)

RN 159518-97-5 HCAPLUS

CN Benzoic acid, 3-chloro-2-[[(5-ethoxy-7-fluoro[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



L61 ANSWER 14 OF 58 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:101169 HCAPLUS

DN 140:146121

ED Entered STN: 08 Feb 2004

TI Preparation of furoisoquinoline derivatives as phosphodiesterase 4 inhibitors

IN Inoue, Yoshihisa; Fujii, Nobuhiro; Gyoten, Michiyo; Matsumoto, Tatsumi

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 272 pp.
CODEN: PIXXD2
DT **Patent**
LA Japanese
IC ICM C07D491-048
ICS A61K031-4355; A61K031-444; A61K031-455; A61K031-4709; A61K031-517; A61K031-538; A61K031-5513; A61P003-10; A61P009-10; A61P011-00; A61P011-02; A61P011-06; A61P017-00; A61P019-02; A61P019-10; A61P025-24; A61P025-28; A61P029-00; A61P037-02
CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004011470	A1	20040205	WO 2003-JP9386	20030724 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2004067690	A2	20040304	JP 2003-279166	20030724 <--
EP 1541576	A1	20050615	EP 2003-741560	20030724 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI JP 2002-217496	A	20020726 <--		
WO 2003-JP9386	W	20030724		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004011470	ICM	C07D491-048
	ICS	A61K031-4355; A61K031-444; A61K031-455; A61K031-4709; A61K031-517; A61K031-538; A61K031-5513; A61P003-10; A61P009-10; A61P011-00; A61P011-02; A61P011-06; A61P017-00; A61P019-02; A61P019-10; A61P025-24; A61P025-28; A61P029-00; A61P037-02
WO 2004011470	ECLA	A61K031/4355; A61K031/444; A61K031/455; A61K031/4709; A61K031/517; A61K031/538; A61K031/5513; C07D491/04+307A+221A; C07D491/04+307A+239A <--
JP 2004067690	FTERM	4C050/AA01; 4C050/AA08; 4C050/BB07; 4C050/CC16; 4C050/EE01; 4C050/FF05; 4C050/GG03; 4C050/HH01; 4C050/HH03; 4C050/HH04; 4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/CB22; 4C086/MA01; 4C086/MA04; 4C086/MA13; 4C086/MA17; 4C086/MA22; 4C086/MA23; 4C086/MA28; 4C086/MA31; 4C086/MA35; 4C086/MA36; 4C086/MA37; 4C086/MA41; 4C086/MA43; 4C086/MA52; 4C086/MA56; 4C086/MA58; 4C086/MA59; 4C086/MA60; 4C086/MA63; 4C086/MA66; 4C086/NA14; 4C086/ZA02; 4C086/ZA12; 4C086/ZA16; 4C086/ZA22; 4C086/ZA34; 4C086/ZA45; 4C086/ZA89; 4C086/ZA96; 4C086/ZA97; 4C086/ZB07; 4C086/ZB11; 4C086/ZB13; 4C086/ZB15; 4C086/ZC20; 4C086/ZC35 <--
EP 1541576	ECLA	A61K031/4355; A61K031/444; A61K031/455; A61K031/4709; A61K031/517; A61K031/538; A61K031/5513; C07D491/04+307A+221A; C07D491/04+307A+239A <--

OS MARPAT 140:146121
GI



I

AB The title compds. I [X represents (O)n; A represents a bond, a group represented by the formula CRa:CRb (Ra and Rb each represents hydrogen or C1-6 alkyl), etc.; R1 represents cyano or optionally esterified or amidated carboxy; R2 represents hydrogen, optionally substituted hydroxy, optionally substituted amino, etc.; R3 and R4 each represents hydrogen, etc.; R5 represents hydrogen, etc.; R6 represents optionally substituted hydroxy, etc.; R7 and R8 each represents optionally substituted hydrocarbon group, etc.; R9 and R10 each represents hydrogen, etc.; Y represents optionally substituted methylene; and n is 0 or 1] are prepared The bioactivity of I was demonstrated. Formulations are given.

ST furoisoquinoline deriv phosphodiesterase inhibitor prepn

IT Allergy
Inflammation
Nose, disease
(allergic rhinitis; preparation and bioeffect of furoisoquinoline derivs. with activity against phosphodiesterase 4)

IT Dermatitis
(atopic; preparation and bioeffect of furoisoquinoline derivs. with activity against phosphodiesterase 4)

IT Lung, disease
(chronic obstructive; preparation and bioeffect of furoisoquinoline derivs. with activity against phosphodiesterase 4)

IT Rheumatoid arthritis
(chronic; preparation and bioeffect of furoisoquinoline derivs. with activity against phosphodiesterase 4)

IT Mental disorder
(depression; preparation and bioeffect of furoisoquinoline derivs. with activity against phosphodiesterase 4)

IT Memory, biological
(disorder; preparation and bioeffect of furoisoquinoline derivs. with activity against phosphodiesterase 4)

IT Mental disorder
(memory disorder; preparation and bioeffect of furoisoquinoline derivs. with activity against phosphodiesterase 4)

IT Alzheimer's disease
Anti-Alzheimer's agents
Anti-inflammatory agents
Antiarteriosclerotics
Antiasthmatics
Antidepressants
Antidiabetic agents
Antirheumatic agents
Arteriosclerosis
Asthma
Autoimmune disease
Diabetes mellitus
Inflammation
Mammalia
Osteoporosis

(preparation and bioeffect of furoisoquinoline derivs. with activity against phosphodiesterase 4)

IT 363606-35-3P
RL: BYP (Byproduct); PREP (Preparation)
(preparation and bioeffect of furoisoquinoline derivs. with activity against phosphodiesterase 4)

IT 652998-73-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and bioeffect of furoisoquinoline derivs. with activity against phosphodiesterase 4)

IT 9036-21-9, Phosphodiesterase 4
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of furoisoquinoline derivs. as phosphodiesterase 4 inhibitors)

IT 652995-77-2P 652995-78-3P 652995-79-4P 652995-80-7P 652995-81-8P
652995-82-9P 652995-83-0P 652995-84-1P 652995-85-2P 652995-87-4P
652995-89-6P 652995-91-0P 652995-93-2P 652995-95-4P 652995-97-6P
652995-98-7P 652996-00-4P 652996-05-9P 652996-07-1P 652996-11-7P
652996-12-8P 652996-13-9P 652996-14-0P 652996-16-2P 652996-21-9P
652996-28-6P 652996-31-1P 652996-33-3P 652996-34-4P 652996-38-8P
652996-42-4P 652996-52-6P 652996-63-9P 652996-65-1P 652996-84-4P
652996-96-8P 652996-98-0P 652997-34-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of furoisoquinoline derivs. as phosphodiesterase 4 inhibitors)

IT 652995-86-3P 652995-88-5P 652995-90-9P 652995-92-1P 652995-94-3P
652995-96-5P 652995-99-8P 652996-01-5P 652996-02-6P
652996-03-7P 652996-04-8P 652996-06-0P 652996-08-2P 652996-09-3P
652996-10-6P 652996-15-1P 652996-17-3P 652996-18-4P 652996-19-5P
652996-20-8P 652996-22-0P 652996-23-1P 652996-24-2P 652996-25-3P
652996-26-4P 652996-30-0P 652996-32-2P 652996-35-5P 652996-36-6P
652996-37-7P 652996-39-9P 652996-40-2P 652996-41-3P 652996-43-5P
652996-44-6P 652996-46-8P 652996-47-9P 652996-48-0P 652996-49-1P
652996-50-4P 652996-51-5P 652996-53-7P 652996-54-8P 652996-55-9P
652996-56-0P 652996-57-1P 652996-58-2P 652996-59-3P 652996-60-6P
652996-61-7P 652996-62-8P 652996-64-0P 652996-66-2P 652996-67-3P
652996-68-4P 652996-70-8P 652996-71-9P 652996-72-0P 652996-73-1P
652996-74-2P 652996-75-3P 652996-76-4P 652996-77-5P 652996-78-6P
652996-79-7P 652996-80-0P 652996-81-1P 652996-82-2P 652996-83-3P
652996-85-5P 652996-86-6P 652996-87-7P 652996-88-8P 652996-89-9P
652996-90-2P 652996-91-3P 652996-92-4P 652996-93-5P 652996-94-6P
652996-95-7P 652996-97-9P 652996-99-1P 652997-01-8P 652997-02-9P
652997-03-0P 652997-04-1P 652997-05-2P 652997-06-3P 652997-07-4P
652997-08-5P 652997-09-6P 652997-10-9P 652997-12-1P 652997-13-2P
652997-14-3P 652997-15-4P 652997-16-5P 652997-17-6P 652997-18-7P
652997-19-8P 652997-20-1P 652997-21-2P 652997-22-3P 652997-23-4P
652997-24-5P 652997-26-7P 652997-27-8P 652997-28-9P 652997-29-0P
652997-30-3P 652997-31-4P 652997-32-5P 652997-33-6P 652997-35-8P
652997-36-9P 652997-37-0P 652997-38-1P 652997-39-2P 652997-40-5P
652997-41-6P 652997-42-7P 652997-43-8P 652997-44-9P 652997-45-0P
652997-46-1P 652997-47-2P 652997-48-3P 652997-49-4P 652997-50-7P
652997-51-8P 652997-52-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of furoisoquinoline derivs. as phosphodiesterase 4 inhibitors)

IT 62-53-3, Aniline, reactions 67-56-1, Methanol, reactions 74-88-4, Iodomethane, reactions 74-89-5, Methylamine, reactions 75-03-6, Iodoethane 75-07-0, Acetaldehyde, reactions 75-30-9, 2-Iodopropane 75-36-5, Acetyl chloride 75-45-6, Chlorodifluoromethane 76-02-8, Trichloroacetyl chloride 79-04-9, Chloroacetyl chloride 86-90-8, 4-Bromophthalic anhydride 93-10-7, 2-Quinolinecarboxylic acid 96-32-2, Methyl bromoacetate 96-33-3, Methyl acrylate 98-88-4, Benzoyl chloride 100-39-0, Benzyl bromide 100-46-9, Benzylamine, reactions 105-07-7, 4-Cyanobenzaldehyde 106-96-7, 3-Bromo-1-propyne 107-08-4,

1-Iodopropane 108-24-7, Acetic anhydride 108-30-5, Succinic anhydride, reactions 108-86-1, Bromobenzene, reactions 109-90-0, Ethyl isocyanate 110-89-4, Piperidine, reactions 123-75-1, Pyrrolidine, reactions 124-40-3, Dimethylamine, reactions 124-63-0, Methanesulfonyl chloride 143-33-9, Sodium cyanide 144-48-9, 2-Iodoacetamide 149-87-1, 5-Oxopyrrolidine-2-carboxylic acid 288-32-4, Imidazole, reactions 353-83-3, 1,1,1-Trifluoro-2-iodoethane 358-23-6, Trifluoromethanesulfonic anhydride 530-62-1, N,N'-Carbonyldiimidazole 540-51-2, 2-Bromoethanol 588-63-6, 3-Phenoxypropyl bromide 593-51-1, Methylamine hydrochloride 622-95-7, p-Chlorobenzyl bromide 623-33-6, Glycine ethyl ester hydrochloride 623-51-8, Ethyl thioglycolate 624-83-9, Methyl isocyanate 696-59-3, 2,5-Dimethoxytetrahydrofuran 762-49-2, 1-Bromo-2-fluoroethane 766-80-3, m-Chlorobenzyl bromide 767-00-0, 4-Cyanophenol 824-94-2, p-Methoxybenzyl chloride 867-13-0, Ethyl diethylphosphonoacetate 873-74-5, 4-Aminobenzonitrile 874-89-5, 4-Cyanobenzyl alcohol 1001-53-2, N-Acetylethylenediamine 1013-88-3, Benzophenone imine 1067-74-9, Methyl diethylphosphonoacetate 1074-82-4, Potassium phthalimide 1443-80-7, 4-Acetylbenzonitrile 1477-50-5, Indole-2-carboxylic acid 1667-11-4, 4-(Chloromethyl)biphenyl 1668-10-6, Glycinamide hydrochloride 1877-72-1, 3-Cyanobenzoic acid 2417-72-3, Methyl 4-(bromomethyl)benzoate 2707-93-9 3272-08-0, 4-Cyano-2-nitrophenol 3303-84-2, 3-(tert-Butoxycarbonylamino)propionic acid 3699-66-9, Triethyl 2-phosphonopropionate 3747-74-8, 2-Chloromethylquinoline hydrochloride 4421-08-3, 4-Hydroxy-3-methoxybenzonitrile 4637-24-5 5292-43-3, tert-Butyl bromoacetate 5398-44-7, 2,6-Dichloro-4-pyridinecarboxylic acid 6313-54-8, 2-Chloroisonicotinic acid 6959-47-3, 2-(Chloromethyl)pyridine hydrochloride 7035-02-1, 2-Methoxybenzyl chloride 12125-02-9, Ammonium chloride, reactions 13515-93-0, Sarcosine methyl ester hydrochloride 17201-43-3, p-Cyanobenzyl bromide 17288-15-2 17704-74-4 20260-53-1, Nicotinic acid chloride hydrochloride 30525-89-4, Paraformaldehyde 34613-09-7 35092-89-8, 2-Nitroterephthalic acid 1-methyl ester 36268-62-9, 4-Cyano-N-methylbenzamide 39098-97-0, Thiophene-2-acetyl chloride 39178-35-3, Isonicotinic acid chloride hydrochloride 39901-94-5, Picolinic acid chloride hydrochloride 41963-20-6, 4-Bromo-3-methylbenzonitrile 52798-01-3, Methyl 4-cyanophenylacetate 60728-41-8, 2-Aminoterephthalic acid 1-methyl ester 62174-99-6 63307-62-0 84358-12-3 90178-58-8, 4-Cyano-2-nitrophenylacetic acid 90178-78-2, 4-Formyl-3-nitrobenzonitrile 98592-04-2 110893-37-3 188793-06-8 210962-75-7 219841-91-5, Methyl 5-cyano-2-iodobenzoate 362707-80-0 362707-90-2 362708-42-7 362709-42-0 362710-04-1 362711-04-4 362713-71-1 362714-07-6 362714-09-8 362714-19-0 362714-37-2 362715-24-0 362715-35-3 362715-41-1 363185-38-0 363185-93-7 521068-36-0 521069-13-6 652998-09-9 652998-65-7 652998-69-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of furoisoquinoline derivs. as phosphodiesterase 4 inhibitors)

IT 20132-75-6P 22240-89-7P 127267-56-5P 159847-83-3P 208457-45-8P 208457-46-9P 302571-72-8P 362716-28-7P 362716-32-3P 363606-34-2P 444807-47-0P 521069-18-1P 521069-40-9P 521069-41-0P 651747-70-5P 652997-53-0P 652997-54-1P 652997-55-2P 652997-56-3P 652997-57-4P 652997-58-5P 652997-59-6P 652997-60-9P 652997-61-0P 652997-62-1P 652997-63-2P 652997-64-3P 652997-65-4P 652997-66-5P 652997-67-6P 652997-68-7P 652997-69-8P 652997-70-1P 652997-71-2P 652997-72-3P 652997-73-4P 652997-74-5P 652997-75-6P 652997-76-7P 652997-77-8P 652997-78-9P 652997-79-0P 652997-80-3P 652997-81-4P 652997-82-5P 652997-83-6P 652997-84-7P 652997-85-8P 652997-86-9P 652997-87-0P 652997-88-1P 652997-89-2P 652997-90-5P 652997-91-6P 652997-92-7P 652997-93-8P 652997-94-9P 652997-95-0P 652997-96-1P 652997-97-2P 652997-98-3P 652997-99-4P 652998-00-0P 652998-01-1P 652998-02-2P 652998-03-3P 652998-04-4P 652998-05-5P 652998-06-6P 652998-07-7P 652998-08-8P 652998-10-2P 652998-11-3P 652998-12-4P 652998-13-5P 652998-14-6P 652998-15-7P 652998-16-8P 652998-17-9P 652998-18-0P 652998-19-1P 652998-20-4P 652998-22-6P 652998-23-7P 652998-24-8P 652998-25-9P 652998-26-0P 652998-27-1P 652998-28-2P 652998-29-3P 652998-30-6P 652998-31-7P 652998-32-8P 652998-33-9P 652998-34-0P

652998-35-1P 652998-36-2P 652998-37-3P 652998-38-4P 652998-39-5P
652998-40-8P 652998-41-9P 652998-42-0P 652998-44-2P 652998-45-3P
652998-46-4P 652998-47-5P 652998-48-6P 652998-49-7P 652998-50-0P
652998-51-1P 652998-52-2P 652998-53-3P 652998-54-4P 652998-55-5P
652998-56-6P 652998-58-8P 652998-59-9P 652998-60-2P 652998-61-3P
652998-62-4P 652998-63-5P 652998-67-9P 652998-68-0P 652998-70-4P
652998-71-5P 652998-72-6P 652999-92-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of furoisoquinoline derivs. as phosphodiesterase 4 inhibitors)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Takeda Chemical Industries Ltd; WO 0170746 A 2001 HCAPLUS
(2) Takeda Chemical Industries Ltd; EP 1270577 A 2001 HCAPLUS
(3) Takeda Chemical Industries Ltd; WO 0335650 A 2003
(4) Takeda Chemical Industries Ltd; JP 2003171381 A 2003 HCAPLUS
IT **652995-96-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of furoisoquinoline derivs. as phosphodiesterase 4 inhibitors)
RN 652995-96-5 HCAPLUS
CN Benzoic acid, 4-(6-ethoxy-3,4,8,9-tetrahydro-3,3,8,8-tetramethylfuro[2,3-h]isoquinolin-1-yl)-2-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)



L61 ANSWER 15 OF 58 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:972066 HCAPLUS
DN 140:27753
ED Entered STN: 14 Dec 2003
TI Preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders
IN Dahnke, Karl Robert; Gajewski, Robert Peter; Jones, Charles David; Linebarger, Jared Harris; Lu, Jianliang; Ma, Tianwei; Nagpal, Sunil; Simard, Todd Parker; Yee, Ying Kwong; Bunel, Emilio Enrique; Stites, Ryan Edward
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 504 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM C07D333-38
ICS C07D333-16; C07D333-18; C07D333-22; C07D409-12; C07D409-06; C07D333-34; C07D413-04; C07D409-04; A61K031-381; A61K031-401; A61K031-41; A61K031-4245; A61P019-10
CC 27-8 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI	WO 2003101978	A1	20031211	WO 2003-US14539	20030522 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2485503	AA	20031211	CA 2003-2485503	20030522 <--
	BR 2003009983	A	20050222	BR 2003-9983	20030522 <--
	EP 1511740	A1	20050309	EP 2003-728782	20030522 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-384151P	P	20020529 <--		
	WO 2003-US14539	W	20030522		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003101978	ICM	C07D333-38
	ICS	C07D333-16; C07D333-18; C07D333-22; C07D409-12; C07D409-06; C07D333-34; C07D413-04; C07D409-04; A61K031-381; A61K031-401; A61K031-41; A61K031-4245; A61P019-10
WO 2003101978	ECLA	C07D333/18; C07D333/20; C07D333/22; C07D333/24; C07D333/34; C07D333/38; C07D333/40; C07D409/06+333B+207; C07D409/12+333B+257; C07D413/04+333B+271 <--

OS MARPAT 140:27753

GI



I



II

AB The present invention relates to novel, nonsecosteroidal, phenylalkyl thiophene compds. (shown as I; variables defined below; e.g. 3'-[4-(2-oxo-3,3-dimethylbutoxy)-3-methylphenyl]-3'-[5-(methoxycarbonyl)-4-(methyl)thiophen-2-yl]pentane (II)) with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1α,25 dihydroxy vitamin D3. These compds. are useful for treating bone disease and psoriasis. For I: R and R' = C1-C5 alkyl, C1-C5 fluoroalkyl, or together

R and R' form a (un)substituted, (un)saturated carbocyclic ring having 3-8 C atoms; ring atoms Q1 and Q2 = C or S, with the proviso that one atom is S and the other atom is C; RP and RT = H, halo, C1-C5 alkyl, C1-C5 fluoroalkyl, -O-C1-C5 alkyl, -S-C1-C5 alkyl, -O-C1-C5 fluoroalkyl, -CN, -NO2, acetyl, -S-C1-C5 fluoroalkyl, C2-C5 alkenyl, C3-C5 cycloalkyl, and C3-C5 cycloalkenyl; LP and LT are divalent linking bond, -(CH2)mC(X1)- (X1 = O, S; m = 0-2), -(CH2)mCH(OH)-, etc.; ZP and ZT = H, Ph, benzyl, fluorophenyl, C1-C5 alkyl, etc.; addnl. details including provisos are given in the claims. Although the methods of preparation are not claimed, .apprx.180 example prepns. are included. For example, II was prepared in 7 steps starting from 2-hydroxy-5-bromotoluene and tert-butyldimethylsilyl chloride and involving intermediates 2-(tert-Butyldimethylsilyloxy)-5-bromotoluene, 3'-[4-(tert-Butyldimethylsilyloxy)-3-methylphenyl]pentan-3-ol, 3'-[4-(Hydroxy)-3-methylphenyl]-3'-[4-(methyl)thiophen-2-yl]pentane, 3'-[4-(Benzyloxy)-3-methylphenyl]-3'-[4-(methyl)thiophen-2-yl]pentane, 3'-[4-(Benzyloxy)-3-methylphenyl]-3'-[5-(methoxycarbonyl)-4-(methyl)thiophen-2-yl]pentane, and 3'-[4-(Hydroxy)-3-methylphenyl]-3'-[5-(methoxycarbonyl)-4-(methyl)thiophen-2-yl]pentane with yields of 97, 72, 95, 92, 54, 100 and 85, resp. Results are tabulated for many of the example I for the following assays: RXR-VDR heterodimerization (SaOS-2 cells), VDR co-transfection (Caco-2 cells), osteocalcin promotor, mouse hypercalcemia, keratinocyte proliferation, and IL-10 induction; e.g. one enantiomer of 1-[4-[1-ethyl-1-(5-hydroxymethyl-4-methylthiophen-2-yl)propyl]-2-methylphenoxy]-3,3-dimethylbutan-2-ol exhibits an EC50 = 2.8 nM in the RXR-VDR assay compared to 3 nM for the control calcipotriol.

ST phenylalkyl thiophene prepn vitamin D receptor modulator pharmaceutical compn; bone disease treatment phenylalkyl thiophene deriv prepn; psoriasis treatment phenylalkyl thiophene deriv prepn

IT Connective tissue, disease
(adhesion; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT Intestine, neoplasm
(colon; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT Kidney, disease
(failure; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT Bone, disease
(fracture, pathol. effects of healing; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT Transplant and Transplantation
(graft-vs.-host reaction; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT Retinoid X receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(heterodimers with vitamin D receptors, agonists; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT Sebum
(insufficient secretion; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT Vitamin D receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(modulators; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT Bone, disease
(pathol. effects of maintenance in zero gravity; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT Antiarthritics
Arthritis
(phoriatic; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT Abscess
Acne
Alopecia
Alzheimer's disease
Anti-Alzheimer's agents
Antidiabetic agents
Antirheumatic agents
Antitumor agents
Diabetes mellitus
Drug delivery systems
Human
Leukemia
Lupus erythematosus
Mammary gland, neoplasm
Multiple sclerosis
Neoplasm
Osteomalacia
Osteoporosis
Prostate gland, neoplasm
Psoriasis
Rheumatoid arthritis
(preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT Bone, disease
(renal osteodystrophy; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT Connective tissue, disease
(scleroderma; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT Lupus erythematosus
(systemic; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT Skin, disease
(wrinkles, insufficient dermal firmness and hydration; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT 633337-90-3P 633338-50-8P 633338-54-2P 633338-59-7P 633339-25-0P
633339-33-0P 633339-42-1P 633339-72-7P 633339-84-1P
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)
(drug candidate, chromatog. resolution; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT 633338-07-5P 633338-16-6P 633338-22-4P 633338-30-4P 633338-39-3P
633338-43-9P 633338-93-9P 633338-98-4P 633339-03-4P 633339-08-9P
633339-10-3P 633339-19-2P 633339-51-2P 633339-63-6P 633339-77-2P
633339-92-1P 633339-98-7P 633340-48-4P 633340-60-0P 633340-64-4P
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(drug candidate, chromatog. resolution; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT 633337-91-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate, chromatog. resolution; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT 633340-11-1P 633340-13-3P 633340-15-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate, enantiomer; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT 633339-31-8P 633339-40-9P 633339-47-6P 633340-12-2P 633340-14-4P
633340-16-6P 633340-35-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate, enantiomer; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT 633338-73-5P 633338-75-7P 633338-77-9P 633338-83-7P 633340-09-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate, epimer; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT 633338-74-6P 633338-76-8P 633338-78-0P 633338-84-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate, epimer; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT 633356-89-5 633356-90-8 633356-91-9 633356-92-0 633356-93-1
633356-94-2 633356-95-3 633356-96-4 633356-97-5 633356-98-6
633356-99-7 633357-00-3 633357-01-4 633357-02-5 633357-03-6
633357-04-7 633357-05-8 633357-06-9 633357-07-0 633357-08-1
633357-09-2 633357-10-5 633357-11-6 633357-12-7 633357-13-8
633357-14-9
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(drug candidate; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT 633337-98-1P 633337-99-2P 633338-00-8P 633338-01-9P 633338-31-5P
633338-32-6P 633338-44-0P 633338-45-1P 633338-60-0P 633338-61-1P
633338-94-0P 633338-95-1P 633339-64-7P 633339-65-8P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT 633338-08-6P 633338-09-7P 633338-17-7P 633338-18-8P 633338-23-5P
633338-24-6P 633338-40-6P 633338-41-7P 633338-51-9P 633338-52-0P
633338-55-3P 633338-56-4P 633338-99-5P 633339-00-1P 633339-04-5P
633339-05-6P 633339-14-7P 633339-15-8P 633339-17-0P 633339-18-1P
633339-23-8P 633339-24-9P 633339-29-4P 633339-30-7P 633339-38-5P
633339-39-6P 633339-48-7P 633339-49-8P 633339-57-8P 633339-58-9P
633339-73-8P 633339-74-9P 633339-81-8P 633339-82-9P 633339-90-9P
633339-91-0P 633339-99-8P 633340-00-8P 633340-49-5P 633340-50-8P
633340-61-1P 633340-62-2P 633340-65-5P 633340-66-6P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT 633337-84-5P 633337-96-9P 633338-02-0P 633338-12-2P 633338-21-3P
633338-25-7P 633338-27-9P 633338-29-1P 633338-35-9P 633338-42-8P
633338-58-6P 633338-63-3P 633338-67-7P 633338-69-9P 633338-71-3P
633338-79-1P 633338-81-5P 633338-85-9P 633338-87-1P 633338-91-7P

633339-06-7P 633339-83-0P 633339-97-6P 633340-05-3P 633340-17-7P
633340-22-4P 633340-26-8P 633340-36-0P 633340-44-0P 633340-45-1P
633340-47-3P 633340-58-6P 633340-63-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT 633337-92-5P 633338-19-9P 633338-28-0P 633338-33-7P 633338-34-8P
633338-46-2P 633338-47-3P 633338-48-4P 633338-49-5P 633338-53-1P
633338-57-5P 633338-62-2P 633338-68-8P 633338-70-2P 633338-72-4P
633338-80-4P 633338-82-6P 633338-86-0P 633338-88-2P 633338-89-3P
633338-90-6P 633338-92-8P 633338-96-2P 633338-97-3P 633339-01-2P
633339-02-3P 633339-59-0P 633339-66-9P 633339-67-0P 633339-68-1P
633339-75-0P 633339-76-1P 633339-93-2P 633340-01-9P 633340-02-0P
633340-06-4P 633340-07-5P **633340-08-6P** 633340-10-0P
633340-20-2P 633340-21-3P 633340-27-9P 633340-28-0P 633340-29-1P
633340-30-4P 633340-31-5P 633340-33-7P 633340-34-8P 633340-46-2P
633340-51-9P 633340-53-1P 633340-67-7P 633340-68-8P 633340-69-9P
633340-70-2P 633340-71-3P 633340-72-4P 633340-73-5P 633340-74-6P
633340-75-7P 633340-76-8P 633340-77-9P 633340-78-0P 633340-79-1P
633340-80-4P 633340-81-5P 633340-82-6P 633340-83-7P 633340-84-8P
633340-85-9P 633340-86-0P 633340-87-1P 633340-88-2P 633340-89-3P
633340-90-6P 633340-91-7P 633340-92-8P 633340-93-9P 633340-94-0P
633340-95-1P 633340-96-2P 633340-97-3P 633340-98-4P 633340-99-5P
633341-00-1P 633341-01-2P 633341-02-3P 633341-03-4P 633341-04-5P
633341-05-6P 633341-06-7P 633341-07-8P 633341-08-9P 633341-09-0P
633341-10-3P 633341-11-4P 633341-12-5P 633341-13-6P 633341-14-7P
633341-15-8P 633341-16-9P 633341-17-0P 633341-18-1P 633341-19-2P
633341-20-5P 633341-21-6P 633341-22-7P 633341-23-8P 633341-24-9P
633341-25-0P 633341-26-1P 633341-27-2P 633341-28-3P 633341-29-4P
633341-30-7P 633341-31-8P 633341-32-9P 633341-33-0P 633341-34-1P
633341-35-2P 633341-36-3P 633341-37-4P 633341-38-5P 633341-39-6P
633341-40-9P 633341-41-0P 633341-42-1P 633341-43-2P 633341-44-3P
633341-45-4P 633341-46-5P 633341-47-6P 633341-48-7P 633341-49-8P
633341-50-1P 633341-51-2P 633341-52-3P 633341-53-4P 633341-54-5P
633341-55-6P 633341-56-7P 633341-57-8P 633341-58-9P 633341-59-0P
633341-60-3P 633341-61-4P 633341-62-5P 633341-63-6P 633341-64-7P
633341-65-8P 633341-66-9P 633341-67-0P 633341-68-1P 633341-69-2P
633341-70-5P 633341-71-6P 633341-72-7P 633341-73-8P 633341-74-9P
633341-75-0P 633341-76-1P 633341-77-2P 633341-78-3P 633341-79-4P
633341-80-7P 633341-81-8P 633341-82-9P 633341-83-0P 633341-84-1P
633341-85-2P 633341-86-3P 633341-87-4P 633341-88-5P 633341-89-6P
633341-90-9P 633341-91-0P 633341-92-1P 633341-93-2P 633341-94-3P
633341-95-4P 633341-96-5P 633341-97-6P 633341-98-7P 633341-99-8P
633342-00-4P 633342-01-5P 633342-02-6P 633342-03-7P 633342-04-8P
633342-05-9P 633342-06-0P 633342-07-1P 633342-08-2P 633342-09-3P
633342-10-6P 633342-11-7P 633342-12-8P 633342-13-9P 633342-14-0P
633342-15-1P 633342-16-2P 633342-17-3P 633342-18-4P 633342-19-5P
633342-20-8P 633342-21-9P 633342-22-0P 633342-23-1P 633342-24-2P
633342-25-3P 633342-26-4P 633342-27-5P 633342-28-6P 633342-29-7P
633342-30-0P 633342-31-1P 633342-32-2P 633342-33-3P 633342-34-4P
633342-35-5P 633342-36-6P 633342-37-7P 633342-38-8P 633342-39-9P
633342-40-2P 633342-41-3P 633342-42-4P 633342-43-5P 633342-44-6P
633342-45-7P 633342-46-8P 633342-47-9P 633342-48-0P 633342-49-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT 633342-50-4P 633342-51-5P 633342-52-6P 633342-53-7P 633342-54-8P
633342-55-9P 633342-56-0P 633342-57-1P 633342-58-2P 633342-59-3P
633342-60-6P 633342-61-7P 633342-62-8P 633342-63-9P 633342-64-0P
633342-65-1P 633342-66-2P 633342-67-3P 633342-68-4P 633342-69-5P

633342-70-8P 633342-71-9P 633342-72-0P 633342-73-1P 633342-74-2P
633342-75-3P 633342-76-4P 633342-77-5P 633342-78-6P 633342-79-7P
633342-80-0P 633342-81-1P 633342-82-2P 633342-83-3P 633342-84-4P
633342-85-5P 633342-86-6P 633342-87-7P 633342-88-8P 633342-89-9P
633342-90-2P 633342-91-3P 633342-92-4P 633342-93-5P 633342-94-6P
633342-95-7P 633342-96-8P 633342-97-9P 633342-98-0P 633342-99-1P
633343-00-7P 633343-01-8P 633343-02-9P 633343-03-0P 633343-04-1P
633343-05-2P 633343-06-3P 633343-07-4P 633343-08-5P 633343-09-6P
633343-10-9P 633343-11-0P 633343-12-1P 633343-13-2P 633343-14-3P
633343-15-4P 633343-16-5P 633343-17-6P 633343-18-7P 633343-19-8P
633343-20-1P 633343-21-2P 633343-22-3P 633343-23-4P 633343-24-5P
633343-25-6P 633343-26-7P 633343-27-8P 633343-28-9P 633343-29-0P
633343-30-3P 633343-31-4P 633343-32-5P 633343-33-6P 633343-34-7P
633343-35-8P 633343-36-9P 633343-37-0P 633343-38-1P 633343-39-2P
633343-40-5P 633343-41-6P 633343-42-7P 633343-43-8P 633343-44-9P
633343-45-0P 633343-46-1P 633343-47-2P 633343-48-3P 633343-49-4P
633343-50-7P 633343-51-8P 633343-52-9P 633343-53-0P 633343-54-1P
633343-55-2P 633343-56-3P 633343-57-4P 633343-58-5P 633343-59-6P
633343-60-9P 633343-61-0P 633343-62-1P 633343-63-2P 633343-64-3P
633343-65-4P 633343-66-5P 633343-67-6P 633343-68-7P 633343-69-8P
633343-70-1P 633343-71-2P 633343-72-3P 633343-73-4P 633343-74-5P
633343-75-6P 633343-76-7P 633343-77-8P 633343-79-0P 633343-80-3P
633343-81-4P 633343-82-5P 633343-83-6P 633343-84-7P 633343-85-8P
633343-86-9P 633343-87-0P 633343-88-1P 633343-89-2P 633343-90-5P
633343-91-6P 633343-92-7P 633343-93-8P 633343-94-9P 633343-95-0P
633343-96-1P 633343-97-2P 633343-98-3P 633343-99-4P 633344-00-0P
633344-01-1P 633344-02-2P 633344-03-3P 633344-04-4P 633344-05-5P
633344-06-6P 633344-07-7P 633344-08-8P 633344-09-9P 633344-10-2P
633344-11-3P 633344-12-4P 633344-13-5P 633344-14-6P 633344-15-7P
633344-16-8P 633344-17-9P 633344-18-0P 633344-19-1P 633344-20-4P
633344-21-5P 633344-22-6P 633344-23-7P 633344-24-8P 633344-25-9P
633344-26-0P 633344-27-1P 633344-28-2P 633344-29-3P 633344-30-6P
633344-31-7P 633344-32-8P 633344-33-9P 633344-34-0P 633344-35-1P
633344-36-2P 633344-37-3P 633344-38-4P 633344-39-5P 633344-40-8P
633344-41-9P 633344-42-0P 633344-43-1P 633344-44-2P 633344-45-3P
633344-46-4P 633344-47-5P 633344-48-6P 633344-49-7P 633344-50-0P
633344-51-1P 633344-52-2P 633344-53-3P 633344-54-4P 633344-55-5P
633344-56-6P 633344-57-7P 633344-58-8P 633344-59-9P 633344-60-2P
633344-61-3P 633344-62-4P 633344-63-5P 633344-64-6P 633344-65-7P
633344-66-8P 633344-67-9P 633344-68-0P 633344-69-1P 633344-70-4P
633344-71-5P 633344-72-6P 633344-73-7P 633344-74-8P 633344-75-9P
633344-76-0P 633344-77-1P 633344-78-2P 633344-79-3P 633344-80-6P
633344-81-7P 633344-82-8P 633344-83-9P 633344-84-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT 633344-85-1P 633344-86-2P 633344-87-3P 633344-88-4P 633344-89-5P
633344-90-8P 633344-91-9P 633344-92-0P 633344-93-1P 633344-94-2P
633344-95-3P 633344-96-4P 633344-97-5P 633344-98-6P 633344-99-7P
633345-00-3P 633345-01-4P 633345-02-5P 633345-03-6P 633345-04-7P
633345-05-8P 633345-06-9P 633345-07-0P 633345-08-1P 633345-09-2P
633345-10-5P 633345-11-6P 633345-12-7P 633345-13-8P 633345-14-9P
633345-15-0P 633345-16-1P 633345-17-2P 633345-18-3P 633345-19-4P
633345-20-7P 633345-21-8P 633345-22-9P 633345-23-0P 633345-24-1P
633345-25-2P 633345-26-3P 633345-27-4P 633345-28-5P 633345-29-6P
633345-30-9P 633345-31-0P 633345-32-1P 633345-33-2P 633345-34-3P
633345-35-4P 633345-36-5P 633345-37-6P 633345-38-7P 633345-39-8P
633345-40-1P 633345-41-2P 633345-42-3P 633345-43-4P 633345-44-5P
633345-45-6P 633345-46-7P 633345-47-8P 633345-48-9P 633345-49-0P
633345-50-3P 633345-51-4P 633345-52-5P 633345-53-6P 633345-54-7P
633345-55-8P 633345-56-9P 633345-57-0P 633345-58-1P 633345-59-2P
633345-60-5P 633345-61-6P 633345-62-7P 633345-63-8P 633345-64-9P
633345-65-0P 633345-66-1P 633345-67-2P 633345-68-3P 633345-69-4P

633345-70-7P 633345-71-8P 633345-72-9P 633345-73-0P 633345-74-1P
633345-75-2P 633345-76-3P 633345-77-4P 633345-78-5P 633345-79-6P
633345-80-9P 633345-81-0P 633345-82-1P 633345-83-2P 633345-84-3P
633345-85-4P 633345-86-5P 633345-87-6P 633345-88-7P 633345-89-8P
633345-90-1P 633345-91-2P 633345-92-3P 633345-93-4P 633345-94-5P
633345-95-6P 633345-96-7P 633345-97-8P 633345-98-9P 633345-99-0P
633346-00-6P 633346-01-7P 633346-02-8P 633346-03-9P 633346-04-0P
633346-05-1P 633346-06-2P 633346-07-3P 633346-08-4P 633346-09-5P
633346-10-8P 633346-11-9P 633346-12-0P 633346-13-1P 633346-14-2P
633346-15-3P 633346-16-4P 633346-17-5P 633346-18-6P 633346-19-7P
633346-20-0P 633346-21-1P 633346-22-2P 633346-23-3P 633346-24-4P
633346-25-5P 633346-26-6P 633346-27-7P 633346-28-8P 633346-30-2P
633346-32-4P 633346-34-6P 633346-36-8P 633346-38-0P 633346-42-6P
633346-43-7P 633346-44-8P 633346-45-9P 633346-46-0P 633346-47-1P
633346-48-2P 633346-49-3P 633346-50-6P 633346-51-7P 633346-52-8P
633346-53-9P 633346-54-0P 633346-55-1P 633346-56-2P 633346-57-3P
633346-58-4P 633346-59-5P 633346-60-8P 633346-61-9P 633346-62-0P
633346-63-1P 633346-64-2P 633346-65-3P 633346-66-4P 633346-67-5P
633346-68-6P 633346-69-7P 633346-70-0P 633346-71-1P 633346-72-2P
633346-73-3P 633346-74-4P 633346-75-5P 633346-76-6P 633346-77-7P
633346-78-8P 633346-79-9P 633346-80-2P 633346-81-3P 633346-82-4P
633346-83-5P 633346-84-6P 633346-85-7P 633346-86-8P 633346-87-9P
633346-88-0P 633346-89-1P 633346-90-4P 633346-91-5P 633346-92-6P
633346-93-7P 633346-94-8P 633346-95-9P 633346-96-0P 633346-97-1P
633346-98-2P 633346-99-3P 633347-00-9P 633347-01-0P 633347-02-1P
633347-03-2P 633347-04-3P 633347-05-4P 633347-06-5P 633347-07-6P
633347-08-7P 633347-09-8P 633347-10-1P 633347-11-2P 633347-12-3P
633347-13-4P 633347-14-5P 633347-15-6P 633347-16-7P 633347-17-8P
633347-18-9P 633347-19-0P 633347-20-3P 633347-21-4P 633347-22-5P
633347-23-6P 633347-24-7P 633347-25-8P 633347-26-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT 633347-27-0P 633347-28-1P 633347-29-2P 633347-30-5P 633347-31-6P
633347-32-7P 633347-33-8P 633347-34-9P 633347-35-0P 633347-36-1P
633347-37-2P 633347-38-3P 633347-39-4P 633347-40-7P 633347-41-8P
633347-42-9P 633347-43-0P 633347-44-1P 633347-45-2P 633347-46-3P
633347-47-4P 633347-48-5P 633347-49-6P 633347-50-9P 633347-51-0P
633347-52-1P 633347-53-2P 633347-54-3P 633347-55-4P 633347-56-5P
633347-57-6P 633347-58-7P 633347-59-8P 633347-60-1P 633347-61-2P
633347-62-3P 633347-63-4P 633347-64-5P 633347-65-6P 633347-66-7P
633347-67-8P 633347-68-9P 633347-69-0P 633347-70-3P 633347-71-4P
633347-72-5P 633347-73-6P 633347-75-8P 633347-76-9P 633347-77-0P
633347-78-1P 633347-79-2P 633347-80-5P 633347-81-6P 633347-82-7P
633347-83-8P 633347-84-9P 633347-85-0P 633347-86-1P 633347-87-2P
633347-88-3P 633347-89-4P 633347-90-7P 633347-91-8P 633347-92-9P
633347-93-0P 633347-94-1P 633347-95-2P 633347-96-3P 633347-97-4P
633347-98-5P 633347-99-6P 633348-00-2P 633348-01-3P 633348-02-4P
633348-03-5P 633348-04-6P 633348-05-7P 633348-06-8P 633348-07-9P
633348-08-0P 633348-09-1P 633348-10-4P 633348-11-5P 633348-12-6P
633348-13-7P 633348-14-8P 633348-15-9P 633348-16-0P 633348-17-1P
633348-18-2P 633348-19-3P 633348-20-6P 633348-21-7P 633348-22-8P
633348-23-9P 633348-24-0P 633348-25-1P 633348-26-2P 633348-27-3P
633348-28-4P 633348-29-5P 633348-30-8P 633348-31-9P 633348-32-0P
633348-33-1P 633348-34-2P 633348-35-3P 633348-36-4P 633348-37-5P
633348-38-6P 633348-39-7P 633348-40-0P 633348-41-1P 633348-42-2P
633348-43-3P 633348-44-4P 633348-45-5P 633348-46-6P 633348-47-7P
633348-48-8P 633348-49-9P 633348-50-2P 633348-51-3P 633348-52-4P
633348-53-5P 633348-54-6P 633348-55-7P 633348-56-8P 633348-57-9P
633348-58-0P 633348-59-1P 633348-60-4P 633348-61-5P 633348-62-6P
633348-63-7P 633348-64-8P 633348-65-9P 633348-66-0P 633348-67-1P
633348-68-2P 633348-69-3P 633348-70-6P 633348-71-7P 633348-72-8P
633348-73-9P 633348-74-0P 633348-75-1P 633348-76-2P 633348-77-3P

633348-78-4P 633348-79-5P 633348-80-8P 633348-81-9P 633348-82-0P
633348-83-1P 633348-84-2P 633348-85-3P 633348-86-4P 633348-87-5P
633348-88-6P 633348-89-7P 633348-90-0P 633348-91-1P 633348-93-3P
633348-94-4P 633348-97-7P 633348-98-8P 633348-99-9P 633349-01-6P
633349-02-7P 633349-03-8P 633349-04-9P 633349-05-0P 633349-06-1P
633349-07-2P 633349-08-3P 633349-09-4P 633349-10-7P 633349-11-8P
633349-12-9P 633349-13-0P 633349-14-1P 633349-15-2P 633349-16-3P
633349-17-4P 633349-18-5P 633349-19-6P 633349-20-9P 633349-21-0P
633349-22-1P 633349-23-2P 633349-24-3P 633349-25-4P 633349-26-5P
633349-27-6P 633349-28-7P 633349-29-8P 633349-30-1P 633349-31-2P
633349-32-3P 633349-33-4P 633349-34-5P 633349-35-6P 633349-36-7P
633349-37-8P 633349-38-9P 633349-39-0P 633349-40-3P 633349-41-4P
633349-42-5P 633349-43-6P 633349-44-7P 633349-45-8P 633349-46-9P
633349-47-0P 633349-48-1P 633349-49-2P 633349-50-5P 633349-51-6P
633349-52-7P 633349-53-8P 633349-54-9P 633349-55-0P 633349-56-1P
633349-57-2P 633349-58-3P 633349-59-4P 633349-60-7P 633349-61-8P
633349-62-9P 633349-63-0P 633349-64-1P 633349-65-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT 633349-66-3P 633349-67-4P 633349-68-5P 633349-69-6P 633349-70-9P
633349-71-0P 633349-72-1P 633349-73-2P 633349-74-3P 633349-75-4P
633349-76-5P 633349-77-6P 633349-78-7P 633349-79-8P 633349-80-1P
633349-81-2P 633349-82-3P 633349-83-4P 633349-84-5P 633349-85-6P
633349-86-7P 633349-87-8P 633349-88-9P 633349-89-0P 633349-90-3P
633349-91-4P 633349-92-5P 633349-93-6P 633349-94-7P 633349-95-8P
633349-96-9P 633349-97-0P 633349-98-1P 633349-99-2P 633350-00-2P
633350-01-3P 633350-02-4P 633350-03-5P 633350-04-6P 633350-05-7P
633350-06-8P 633350-07-9P 633350-08-0P 633350-09-1P 633350-10-4P
633350-11-5P 633350-12-6P 633350-13-7P 633350-14-8P 633350-15-9P
633350-16-0P 633350-17-1P 633350-18-2P 633350-19-3P 633350-20-6P
633350-21-7P 633350-22-8P 633350-23-9P 633350-24-0P 633350-25-1P
633350-26-2P 633350-27-3P 633350-28-4P 633350-29-5P 633350-30-8P
633350-31-9P 633350-32-0P 633350-33-1P 633350-34-2P 633350-35-3P
633350-36-4P 633350-37-5P 633350-38-6P 633350-39-7P 633350-40-0P
633350-41-1P 633350-42-2P 633350-43-3P 633350-44-4P 633350-45-5P
633350-46-6P 633350-47-7P 633350-48-8P 633350-49-9P 633350-50-2P
633350-51-3P 633350-52-4P 633350-53-5P 633350-54-6P 633350-55-7P
633350-56-8P 633350-57-9P 633350-58-0P 633350-59-1P 633350-60-4P
633350-61-5P 633350-62-6P 633350-63-7P 633350-64-8P 633350-65-9P
633350-66-0P 633350-67-1P 633350-68-2P 633350-69-3P 633350-70-6P
633350-71-7P 633350-72-8P 633350-73-9P 633350-74-0P 633350-75-1P
633350-76-2P 633350-77-3P 633350-78-4P 633350-79-5P 633350-80-8P
633350-81-9P 633350-82-0P 633350-83-1P 633350-84-2P 633350-85-3P
633350-86-4P 633350-87-5P 633350-88-6P 633350-89-7P 633350-90-0P
633350-91-1P 633350-92-2P 633350-93-3P 633350-94-4P 633350-95-5P
633350-96-6P 633350-97-7P 633350-98-8P 633350-99-9P 633351-00-5P
633351-01-6P 633351-02-7P 633351-03-8P 633351-04-9P 633351-05-0P
633351-06-1P 633351-07-2P 633351-08-3P 633351-09-4P 633351-10-7P
633351-11-8P 633351-12-9P 633351-13-0P 633351-14-1P 633351-15-2P
633351-16-3P 633351-17-4P 633351-18-5P 633351-19-6P 633351-20-9P
633351-21-0P 633351-22-1P 633351-23-2P 633351-24-3P 633351-25-4P
633351-26-5P 633351-27-6P 633351-28-7P 633351-29-8P 633351-30-1P
633351-31-2P 633351-32-3P 633351-33-4P 633351-34-5P 633351-35-6P
633351-36-7P 633351-37-8P 633351-38-9P 633351-39-0P 633351-40-3P
633351-41-4P 633351-42-5P 633351-43-6P 633351-44-7P 633351-45-8P
633351-46-9P 633351-47-0P 633351-48-1P 633351-49-2P 633351-50-5P
633351-51-6P 633351-52-7P 633351-53-8P 633351-54-9P 633351-55-0P
633351-56-1P 633351-57-2P 633351-58-3P 633351-59-4P 633351-60-7P
633351-61-8P 633351-62-9P 633351-63-0P 633351-64-1P 633351-65-2P
633351-66-3P 633351-67-4P 633351-68-5P 633351-69-6P 633351-70-9P
633351-71-0P 633351-72-1P 633351-73-2P 633351-74-3P 633351-75-4P
633351-76-5P 633351-77-6P 633351-78-7P 633351-79-8P 633351-80-1P

633351-81-2P 633351-82-3P 633351-83-4P 633351-84-5P 633351-85-6P
633351-86-7P 633351-87-8P 633351-88-9P 633351-89-0P 633351-90-3P
633351-91-4P 633351-92-5P 633351-93-6P 633351-94-7P 633351-95-8P
633351-96-9P 633351-97-0P 633351-98-1P 633351-99-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT 633352-00-8P 633352-01-9P 633352-02-0P 633352-03-1P 633352-04-2P
633352-05-3P 633352-06-4P 633352-07-5P 633352-08-6P 633352-09-7P
633352-10-0P 633352-11-1P 633352-12-2P 633352-13-3P 633352-14-4P
633352-15-5P 633352-16-6P 633352-17-7P 633352-18-8P 633352-19-9P
633352-20-2P 633352-21-3P 633352-22-4P 633352-23-5P 633352-24-6P
633352-25-7P 633352-26-8P 633352-27-9P 633352-28-0P 633352-29-1P
633352-30-4P 633352-31-5P 633352-32-6P 633352-33-7P 633352-34-8P
633352-35-9P 633352-36-0P 633352-37-1P 633352-38-2P 633352-39-3P
633352-40-6P 633352-41-7P 633352-42-8P 633352-43-9P 633352-44-0P
633352-45-1P 633352-46-2P 633352-47-3P 633352-48-4P 633352-49-5P
633352-50-8P 633352-51-9P 633352-52-0P 633352-53-1P 633352-54-2P
633352-55-3P 633352-56-4P 633352-57-5P 633352-58-6P 633352-59-7P
633352-60-0P 633352-61-1P 633352-62-2P 633352-63-3P 633352-64-4P
633352-65-5P 633352-66-6P 633352-67-7P 633352-68-8P 633352-69-9P
633352-70-2P 633352-71-3P 633352-72-4P 633352-73-5P 633352-74-6P
633352-75-7P 633352-76-8P 633352-77-9P 633352-78-0P 633352-79-1P
633352-80-4P 633352-81-5P 633352-82-6P 633352-83-7P 633352-84-8P
633352-85-9P 633352-86-0P 633352-87-1P 633352-88-2P 633352-89-3P
633352-90-6P 633352-91-7P 633352-92-8P 633352-93-9P 633352-94-0P
633352-96-2P 633352-98-4P 633353-01-2P 633353-03-4P 633353-05-6P
633353-07-8P 633353-10-3P 633353-11-4P 633353-13-6P 633353-15-8P
633353-16-9P 633353-17-0P 633353-18-1P 633353-19-2P 633353-20-5P
633353-21-6P 633353-22-7P 633353-23-8P 633353-24-9P 633353-25-0P
633353-26-1P 633353-27-2P 633353-28-3P 633353-29-4P 633353-30-7P
633353-31-8P 633353-32-9P 633353-33-0P 633353-34-1P 633353-35-2P
633353-36-3P 633353-37-4P 633353-38-5P 633353-39-6P 633353-40-9P
633353-41-0P 633353-42-1P 633353-43-2P 633353-44-3P 633353-45-4P
633353-46-5P 633353-47-6P 633353-48-7P 633353-49-8P 633353-50-1P
633353-51-2P 633353-52-3P 633353-53-4P 633353-54-5P 633353-55-6P
633353-56-7P 633353-57-8P 633353-58-9P 633353-59-0P 633353-60-3P
633353-61-4P 633353-62-5P 633353-63-6P 633353-64-7P 633353-65-8P
633353-66-9P 633353-67-0P 633353-68-1P 633353-69-2P 633353-70-5P
633353-71-6P 633353-72-7P 633353-73-8P 633353-74-9P 633353-75-0P
633353-76-1P 633353-77-2P 633353-78-3P 633353-79-4P 633353-80-7P
633353-81-8P 633353-82-9P 633353-83-0P 633353-84-1P 633353-85-2P
633353-86-3P 633353-87-4P 633353-88-5P 633353-89-6P 633353-90-9P
633353-91-0P 633353-92-1P 633353-93-2P 633353-94-3P 633353-95-4P
633353-96-5P 633353-97-6P 633353-98-7P 633353-99-8P 633354-00-4P
633354-01-5P 633354-02-6P 633354-03-7P 633354-04-8P 633354-05-9P
633354-06-0P 633354-07-1P 633354-08-2P 633354-09-3P 633354-10-6P
633354-11-7P 633354-12-8P 633354-13-9P 633354-14-0P 633354-15-1P
633354-16-2P 633354-17-3P 633354-18-4P 633354-19-5P 633354-20-8P
633354-21-9P 633354-22-0P 633354-23-1P 633354-24-2P 633354-25-3P
633354-26-4P 633354-27-5P 633354-28-6P 633354-29-7P 633354-30-0P
633354-31-1P 633354-32-2P 633354-33-3P 633354-34-4P 633354-35-5P
633354-36-6P 633354-37-7P 633354-38-8P 633354-39-9P 633354-40-2P
633354-41-3P 633354-42-4P 633354-43-5P 633354-44-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT 633354-45-7P 633354-46-8P 633354-47-9P 633354-48-0P 633354-49-1P
633354-50-4P 633354-51-5P 633354-52-6P 633354-53-7P 633354-54-8P
633354-55-9P 633354-56-0P 633354-57-1P 633354-58-2P 633354-59-3P

633354-60-6P 633354-61-7P 633354-62-8P 633354-63-9P 633354-64-0P
633354-65-1P 633354-66-2P 633354-67-3P 633354-68-4P 633354-69-5P
633354-70-8P 633354-71-9P 633354-72-0P 633354-73-1P 633354-74-2P
633354-75-3P 633354-76-4P 633354-77-5P 633354-78-6P 633354-79-7P
633354-80-0P 633354-81-1P 633354-82-2P 633354-83-3P 633354-84-4P
633354-85-5P 633354-86-6P 633354-87-7P 633354-88-8P 633354-89-9P
633354-90-2P 633354-91-3P 633354-92-4P 633354-93-5P 633354-94-6P
633354-95-7P 633354-96-8P 633354-97-9P 633354-98-0P 633354-99-1P
633355-00-7P 633355-01-8P 633355-02-9P 633355-03-0P 633355-04-1P
633355-05-2P 633355-06-3P 633355-07-4P 633355-08-5P 633355-09-6P
633355-10-9P 633355-11-0P 633355-12-1P 633355-13-2P 633355-14-3P
633355-15-4P 633355-16-5P 633355-17-6P 633355-18-7P 633355-19-8P
633355-20-1P 633355-21-2P 633355-22-3P 633355-23-4P 633355-24-5P
633355-25-6P 633355-26-7P 633355-27-8P 633355-28-9P 633355-29-0P
633355-30-3P 633355-31-4P 633355-32-5P 633355-33-6P 633355-34-7P
633355-35-8P 633355-36-9P 633355-37-0P 633355-38-1P 633355-39-2P
633355-40-5P 633355-41-6P 633355-42-7P 633355-43-8P 633355-44-9P
633355-45-0P 633355-46-1P 633355-47-2P 633355-48-3P 633355-49-4P
633355-50-7P 633355-51-8P 633355-52-9P 633355-53-0P 633355-54-1P
633355-55-2P 633355-56-3P 633355-57-4P 633355-58-5P 633355-59-6P
633355-60-9P 633355-61-0P 633355-62-1P 633355-63-2P 633355-64-3P
633355-65-4P 633355-66-5P 633355-67-6P 633355-68-7P 633355-69-8P
633355-70-1P 633355-71-2P 633355-72-3P 633355-73-4P 633355-74-5P
633355-75-6P 633355-76-7P 633355-77-8P 633355-78-9P 633355-79-0P
633355-80-3P 633355-81-4P 633355-82-5P 633355-83-6P 633355-84-7P
633355-85-8P 633355-86-9P 633355-87-0P 633355-88-1P 633355-89-2P
633355-90-5P 633355-91-6P 633355-92-7P 633355-93-8P 633355-94-9P
633355-95-0P 633355-96-1P 633355-97-2P 633355-98-3P 633355-99-4P
633356-00-0P 633356-02-2P 633356-03-3P 633356-04-4P 633356-05-5P
633356-06-6P 633356-07-7P 633356-08-8P 633356-09-9P 633356-10-2P
633356-11-3P 633356-12-4P 633356-13-5P 633356-14-6P 633356-15-7P
633356-16-8P 633356-17-9P 633356-18-0P 633356-19-1P 633356-20-4P
633356-21-5P 633356-22-6P 633356-23-7P 633356-24-8P 633356-25-9P
633356-26-0P 633356-27-1P 633356-28-2P 633356-29-3P 633356-30-6P
633356-31-7P 633356-32-8P 633356-33-9P 633356-34-0P 633356-35-1P
633356-36-2P 633356-37-3P 633356-38-4P 633356-39-5P 633356-40-8P
633356-41-9P 633356-42-0P 633356-43-1P 633356-44-2P 633356-45-3P
633356-46-4P 633356-47-5P 633356-48-6P 633356-49-7P 633356-50-0P
633356-51-1P 633356-52-2P 633356-53-3P 633356-54-4P 633356-55-5P
633356-56-6P 633356-57-7P 633356-58-8P 633356-59-9P 633356-60-2P
633356-61-3P 633356-62-4P 633356-63-5P 633356-64-6P 633356-65-7P
633356-66-8P 633356-67-9P 633356-68-0P 633356-69-1P 633356-70-4P
633356-71-5P 633356-72-6P 633356-73-7P 633356-74-8P 633356-75-9P
633356-76-0P 633356-77-1P 633356-78-2P 633356-79-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT 633356-80-6P 633356-81-7P 633356-82-8P 633356-83-9P 633356-84-0P
633356-85-1P 633356-86-2P 633356-87-3P 633356-88-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT 633340-32-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(enantiomer; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

IT 633338-36-0P 633339-41-0P 633339-50-1P 633339-86-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(enantiomer; preparation of phenylalkyl thiophene-type vitamin D receptor

modulators for treating bone disease, psoriasis and other disorders)
IT 7440-70-2, Calcium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hypercalcemia, humoral; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)
IT 75-97-8, Pinacolone 79-09-4, Propionic acid, reactions 79-31-2, 2-Methylpropionic acid 88-69-7, o-Isopropylphenol 90-00-6, o-Ethylphenol 95-48-7, o-Cresol, reactions 96-22-0, 3-Pentanone 96-32-2, Methyl bromoacetate 96-34-4, Methyl chloroacetate 100-39-0, Benzyl bromide 110-02-1, Thiophene 134-20-3, 2-Aminobenzoic acid methyl ester 499-76-3, 3-Methyl-4-hydroxybenzoic acid 616-44-4, 3-Methylthiophene 623-51-8, Ethyl 2-mercaptoacetate 625-45-6, Methoxyacetic acid 636-72-6, 2-Hydroxymethylthiophene 644-35-9, o-Propylphenol 1759-53-1, Cyclopropanecarboxylic acid 2133-40-6, L-Proline methyl ester hydrochloride 2362-12-1 2491-20-5, L-Alanine methyl ester hydrochloride 2810-04-0, Ethyl thiophene-2-carboxylate 3943-74-6, Methyl 4-hydroxy-3-methoxybenzoate 4244-84-2, 3-Aminopropionic acid ethyl ester hydrochloride 4418-61-5, 5-Aminotetrazole 5469-26-1 5680-79-5, Methyl glycinate hydrochloride 5680-80-8, L-Serine methyl ester hydrochloride 6456-74-2 7146-15-8, D-Valine methyl ester hydrochloride 13515-93-0, Sarcosine methyl ester hydrochloride 13547-70-1 14316-06-4, D-Alanine methyl ester hydrochloride 15028-41-8 18162-48-6, tert-Butyldimethylsilyl chloride 18598-74-8, L-Isoleucine methyl ester hydrochloride 22934-36-7 32213-95-9, L-Aspartic acid dimethyl ester hydrochloride 58620-93-2 59531-86-1 65365-28-8, D-Proline methyl ester hydrochloride 69630-50-8, D-Aspartic acid dimethyl ester hydrochloride 69739-34-0, tert-Butyldimethylsilyl trifluoromethanesulfonate 104458-24-4 123014-68-6 193065-68-8 633338-20-2 633338-37-1 633340-04-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)
IT 22906-17-8P, 2-(Methylthiomethyl)thiophene 42113-13-3P 82732-66-9P 160083-66-9P 160083-67-0P 179636-73-8P 633337-85-6P 633337-86-7P 633337-87-8P 633337-88-9P 633337-89-0P 633337-93-6P 633337-94-7P 633337-95-8P 633337-97-0P 633338-03-1P 633338-04-2P 633338-05-3P 633338-06-4P 633338-10-0P 633338-11-1P 633338-13-3P 633338-14-4P 633338-15-5P 633338-26-8P 633338-64-4P 633338-65-5P 633338-66-6P 633339-07-8P 633339-09-0P 633339-11-4P 633339-12-5P 633339-13-6P 633339-16-9P 633339-20-5P 633339-21-6P 633339-22-7P 633339-26-1P 633339-27-2P 633339-28-3P 633339-32-9P 633339-34-1P 633339-35-2P 633339-36-3P 633339-37-4P 633339-43-2P 633339-44-3P 633339-45-4P 633339-46-5P 633339-52-3P 633339-53-4P 633339-54-5P 633339-55-6P 633339-56-7P 633339-60-3P 633339-61-4P 633339-62-5P 633339-69-2P 633339-70-5P 633339-71-6P 633339-78-3P 633339-79-4P 633339-80-7P 633339-85-2P 633339-87-4P 633339-88-5P 633339-89-6P 633339-94-3P 633339-95-4P 633339-96-5P 633340-03-1P 633340-18-8P 633340-19-9P 633340-23-5P 633340-24-6P 633340-25-7P 633340-37-1P 633340-38-2P 633340-39-3P 633340-40-6P 633340-41-7P 633340-42-8P 633340-43-9P 633340-52-0P 633340-54-2P 633340-55-3P 633340-56-4P 633340-57-5P 633340-59-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Boehm, M; CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY 1999, V6(5), P265 HCAPLUS
(2) Ligand Pharm Inc; WO 0010958 A 2000 HCAPLUS
(3) Ligand Pharm Inc; US 6218430 A 2001 HCAPLUS
(4) Michel, B; WO 0138320 A 2001 HCAPLUS
(5) Torikov, D; DOKL NEFTEKHIM SEKTS, BASHKIR RESPUB PRAVL, VSES KHIM OBSHCHEST 1971, V6, P220 HCAPLUS
IT **633340-08-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

RN 633340-08-6 HCAPLUS

CN Benzoic acid, 2-[[[5-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-3-methyl-2-thienyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



L61 ANSWER 16 OF 58 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:971725 HCAPLUS

DN 140:35893

ED Entered STN: 14 Dec 2003

TI Transcription factor modulating compounds and methods of use thereof

IN Levy, Stuart B.; Alekshun, Michael N.; Podlogar, Brent L.; Ohemeng, Kwasi; Verma, Atul K.; Warchol, Tadeusz; Bhatia, Beena

PA USA

SO U.S. Pat. Appl. Publ., 301 pp.
CODEN: USXXCO

DT **Patent**

LA English

IC ICM A61K031-555
ICS A61K031-505; A61K031-4745; A61K031-47; A61K031-415; A61K031-40; A61K031-407

INCL 514185000; 514256000; 514311000; 514303000; 514383000; 514381000; 514394000; 514410000; 514408000

CC 1-5 (Pharmacology)
Section cross-reference(s): 10, 28, 63

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 2003229065	A1	20031211	US 2002-139591	20020814	<--
	CA 2445515	AA	20021104	CA 2002-2445515	20020506	<--
	WO 2004001058	A2	20031231	WO 2002-US14255	20020506	<--
	WO 2004001058	A3	20050303			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	EP 1524974	A2	20050427	EP 2002-807554	20020506	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
	JP 2005519998	T2	20050707	JP 2004-515557	20020506	<--
	US 2005124678	A1	20050609	US 2003-700661	20031103	<--
PRAI	US 2001-288660P	P	20010504	<--		
	WO 2002-US14255	W	20020506	<--		
	US 2002-139591	A2	20020814	<--		

US 2002-423319P P 20021101 <--
US 2002-425916P P 20021113 <--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003229065	ICM	A61K031-555
	ICS	A61K031-505; A61K031-4745; A61K031-47; A61K031-415; A61K031-40; A61K031-407
	INCL	514185000; 514256000; 514311000; 514303000; 514383000; 514381000; 514394000; 514410000; 514408000
US 2003229065	NCL	514/185.000
	ECLA	A61K031/40; A61K031/407; A61K031/415; A61K031/47; A61K031/4745; A61K031/505; A61K031/555 <--
WO 2004001058	ECLA	A61K031/40; A61K031/407; A61K031/415; A61K031/47; A61K031/4745; A61K031/505; A61K031/555 <--
JP 2005519998	FTERM	2G045/AA40; 2G045/BB20; 2G045/CB21; 4B024/AA01; 4B024/AA11; 4B024/BA80; 4B024/CA04; 4B024/DA06; 4B024/EA04; 4B024/GA11; 4B024/GA19; 4B063/QA01; 4B063/QA18; 4B063/QQ06; 4B063/QQ13; 4B063/QS38; 4C037/KA09; 4C050/AA01; 4C050/BB04; 4C050/BB05; 4C050/CC04; 4C050/CC05; 4C050/DD02; 4C050/EE02; 4C050/EE05; 4C050/FF02; 4C050/FF05; 4C050/FF10; 4C050/GG01; 4C050/GG03; 4C050/HH01; 4C050/HH04; 4C056/AA01; 4C056/AB01; 4C056/AC01; 4C056/AD08; 4C056/AE03; 4C056/FA01; 4C056/FB01; 4C056/FC01; 4C062/EE50; 4C063/AA01; 4C063/BB01; 4C063/CC41; 4C063/CC47; 4C063/CC75; 4C063/DD14; 4C063/DD29; 4C063/DD41; 4C063/EE01; 4C065/AA03; 4C065/AA04; 4C065/AA18; 4C065/BB05; 4C065/CC01; 4C065/CC09; 4C065/DD02; 4C065/DD03; 4C065/EE02; 4C065/HH01; 4C065/HH05; 4C065/HH08; 4C065/JJ01; 4C065/KK01; 4C065/KK02; 4C065/KK09; 4C065/LL01; 4C065/LL03; 4C065/PP03; 4C065/PP07; 4C072/AA01; 4C072/AA06; 4C072/BB02; 4C072/BB03; 4C072/BB06; 4C072/CC02; 4C072/CC04; 4C072/CC11; 4C072/CC16; 4C072/DD06; 4C072/DD10; 4C072/EE03; 4C072/EE09; 4C072/EE13; 4C072/FF05; 4C072/FF06; 4C072/FF09; 4C072/GG01; 4C072/GG07; 4C072/HH02; 4C072/HH07; 4C072/UU01; 4C076/CC10; 4C076/CC11; 4C076/CC17; 4C076/CC34; 4C076/DD48F; 4C076/DD55F; 4C076/DD60F; 4C076/EE23F; 4C076/FF43; 4C084/AA02; 4C084/AA13; 4C084/AA17; 4C084/AA27; 4C084/BA35; 4C084/NA14; 4C084/ZA342; 4C084/ZA362; 4C084/ZA672; 4C084/ZA812; 4C084/ZA892; 4C084/ZA962; 4C084/ZB112; 4C084/ZB352; 4C086/AA01; 4C086/AA02; 4C086/EA16; 4C086/MA01; 4C086/MA04; 4C086/NA14; 4C086/ZA34; 4C086/ZA36; 4C086/ZA67; 4C086/ZA81; 4C086/ZA89; 4C086/ZA96; 4C086/ZB11; 4C086/ZB35 <--
US 2005124678	NCL	514/394.000 <--

OS MARPAT 140:35893

AB Methods for identifying compound useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. In one embodiment, the method comprises contacting a microbial cell comprising: (1) a selectable marker under the control of a transcription factor responsive element and (2) a transcription factor, with a compound under conditions which allow interaction of the compound with the microbial cell; and measuring the ability of the compound to affect the growth or survival of the microbial cell as an indication of whether the test compound modulates the activity of a transcription factor.

ST transcription factor modulator antiinfective agent resistance decrease

IT Bacteroides
(3452A; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(MarA; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT Genetic element
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MarO, transcription factor activation of; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Rob; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(SoxS; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT Genetic element
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(URA3, transcription factor modulation of; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(araC (arabinose operon regulatory protein C); transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT Infection
(bacterial, treatment; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT Acne
Cystic fibrosis
Immunodeficiency
Osteomyelitis
(biofilm infection, treatment; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT Genetic element
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(bla, transcription factor modulation of; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT Tooth, disease
(caries, biofilm infection, treatment; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT Drug delivery systems
(carriers; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT Genetic element
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cat, transcription factor modulation of; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT Medical goods
(catheters, disinfection; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and

growth identified by determining marker under control of responsive element)
IT Genetic element
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ccdB, transcription factor modulation of; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)
IT Promoter (genetic element)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(constitutive, transcription factor expression control by; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)
IT Contact lenses
(disinfection; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)
IT Heart, disease
Inflammation
(endocarditis, biofilm infection, treatment; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)
IT Disinfectants
(for biofilms; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)
IT Genetic element
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(fum, transcription factor activation of; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)
IT Genetic element
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(galT, transcription factor activation of; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)
IT Promoter (genetic element)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gene GAL1, transcription factor expression control by; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)
IT Genetic element
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(guaB, transcription factor repression of; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)
IT Prosthetic materials and Prosthetics
(implants, disinfection; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)
IT Genetic element
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inaA, transcription factor activation of; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)
IT Promoter (genetic element)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inducible, transcription factor expression control by; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under

control of responsive element)
IT Medical goods
(indwelling, disinfection; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)
IT Genetic element
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(kan, transcription factor modulation of; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)
IT Genetic element
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(micF, transcription factor activation of; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)
IT Infection
(microbial, treatment; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)
IT Ear, disease
(middle, biofilm infection, treatment; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)
IT Molecular association
(of transcription factors and modulators; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)
IT Genetic element
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(offeeA, transcription factor repression of; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)
IT Prosthetic materials and Prosthetics
(orthopedic, disinfection; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)
IT Inflammation
Prostate gland, disease
(prostatitis, biofilm infection, treatment; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)
IT Genetic element
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(purA, transcription factor repression of; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)
IT Genetic element
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(responsive, transcription factor modulation of; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)
IT Glycolipids
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rhamnose-containing, surfactants; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth and combination with surfactants)
IT Sulfonic acids, biological studies

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(salts, surfactants; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth and combination with surfactants)

IT Quaternary ammonium compounds, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surfactants; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth and combination with surfactants)

IT Promoter (genetic element)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tac, transcription factor expression control by; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT Promoter (genetic element)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tet, transcription factor expression control by; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT Drug interactions
Surfactants
(transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth and combination with surfactants)

IT Acinetobacter calcoaceticus
Acinetobacter haemolyticus
Aeromonas hydrophila
Antibacterial agents
Antibiotic resistance
Antibiotics
Antimicrobial agents
Bacteroides distasonis
Bacteroides eggerthii
Bacteroides fragilis
Bacteroides splanchnicus
Bacteroides thetaiotaomicron
Bacteroides uniformis
Bacteroides vulgatus
Bordetella bronchiseptica
Bordetella parapertussis
Bordetella pertussis
Borrelia burgdorferi
Burkholderia cepacia
Campylobacter coli
Campylobacter fetus
Campylobacter jejuni
Citrobacter freundii
Clostridium
Clostridium difficile
Comamonas acidovorans
Corynebacterium diphtheriae
Drug delivery systems
Drug design
Drug screening
Enterobacter aerogenes
Enterobacter cloacae
Enterobacteriaceae
Enterococcus
Enterococcus faecalis
Enterococcus faecium
Escherichia coli
Eubacteria

Firmicutes
Francisella tularensis
Gardnerella vaginalis
Genetic markers
Gram-negative bacteria
Haemophilus ducreyi
Haemophilus haemolyticus
Haemophilus influenzae
Haemophilus parahaemolyticus
Haemophilus parainfluenzae
Helicobacter pylori
Human
Klebsiella oxytoca
Klebsiella pneumoniae
Legionella pneumophila
Listeria monocytogenes
Mammalia
Mannheimia haemolytica
Microorganism
Moraxella catarrhalis
Morganella morganii
Mycobacterium avium
Mycobacterium intracellulare
Mycobacterium leprae
Mycobacterium tuberculosis
Neisseria gonorrhoeae
Neisseria meningitidis
Pasteurella multocida
Prevotella oralis
Proteus mirabilis
Proteus vulgaris
Providencia alcalifaciens
Providencia rettgeri
Providencia stuartii
Pseudomonas aeruginosa
Pseudomonas alcaligenes
Pseudomonas fluorescens
Pseudomonas putida
Salmonella enteritidis
Salmonella paratyphi
Salmonella typhi
Salmonella typhimurium
Serratia marcescens
Shigella dysenteriae
Shigella flexneri
Shigella sonnei
Staphylococcus
Staphylococcus aureus
Staphylococcus epidermidis
Staphylococcus hemolyticus
Staphylococcus hominis
Staphylococcus hyicus hyicus
Staphylococcus intermedius
Staphylococcus saccharolyticus
Staphylococcus saprophyticus
Stenotrophomonas maltophilia
Streptococcus
Streptococcus agalactiae
Streptococcus pneumoniae
Streptococcus pyogenes
Vibrio cholerae
Vibrio parahaemolyticus
Yersinia enterocolitica
Yersinia intermedia
Yersinia pestis
Yersinia pseudotuberculosis

(transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT Antisense oligonucleotides
Heterocyclic compounds
Nucleic acids
Oligonucleotides
Organic compounds, biological studies
Porphyrins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT Helix-turn-helix
(transcription factors containing; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT Plasmids
(transcription factors expression from; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT Prokaryota
(transcription factors of; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT Biofilms (microbial)
(treatment; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT Promoter (genetic element)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(trp, transcription factor expression control by; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT 634620-12-5, Protein (Escherichia coli gene marA) 634620-13-6
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(peptides, modulators interaction with; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT 151-21-3, Sodium Dodecyl Sulfate, biological studies 9002-93-1, Triton X-100 9004-95-9, Brij 56 9005-65-6, Tween 80 9005-70-3, Tween 85
18820-83-2D, Pyridinium iodide, alkyl derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surfactant; transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth and combination with surfactants)

IT 24730-31-2, Surfactin 496064-69-8, Visconsin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth and combination with surfactants)

IT 51-17-2D, Benzimidazole, derivs. 91-22-5D, Quinoline, derivs.
110-86-1D, Pyridine, derivs. 117-39-5 123-75-1D, Pyrrolidine, derivs.
288-94-8D, 1H-Tetrazole, derivs. 289-95-2D, Pyrimidine, derivs.

480-23-9 520-36-5 891-43-0 1218-82-2 1571-85-3 1571-90-0
1645-21-2 1772-39-0 2513-33-9 2555-29-5 3164-28-1 3283-93-0
4143-63-9 4143-74-2 5211-78-9 5346-13-4 5452-31-3 5460-84-4
10066-15-6 10420-73-2 14172-90-8 14172-91-9 14172-92-0
14244-55-4 14514-68-2 14518-23-1 16796-31-9 18384-19-5
18706-63-3 22198-48-7 22395-22-8 22697-40-1 22894-67-3
25437-73-4 31283-09-7 32396-64-8 33289-14-4 36387-84-5
37306-44-8D, Triazole, derivs. 39679-60-2 39776-53-9 41383-95-3
41383-96-4 49619-82-1 50287-25-7 50878-11-0 55736-01-1
57645-95-1 58996-65-9 62536-78-1 63046-14-0 63576-07-8
65047-30-5 67574-57-6 67574-58-7 70188-31-7 70591-05-8
71348-79-3 71720-87-1 76648-60-7 79049-98-2 84437-40-1
88379-74-2 89002-85-7 89813-65-0 91352-96-4 91486-87-2
92301-83-2 92831-11-3 92897-45-5 95356-81-3 95594-15-3
95716-70-4 96754-58-4 103855-21-6 104676-23-5 106726-42-5
107607-43-2 107792-87-0 109211-66-7 109723-54-8 110442-19-8
116718-53-7 126145-51-5 129415-03-8 129718-80-5 129886-25-5
129886-26-6 138884-21-6 138915-42-1 140410-61-3 146618-32-8
154269-13-3 154546-75-5 154678-99-6 154867-12-6 155276-97-4
156172-93-9 157428-39-2 157428-40-5 158584-21-5 159325-85-6
161466-04-2 164355-99-1 164356-03-0 167493-42-7 168209-86-7
175136-52-4 177082-78-9 177082-79-0 177082-84-7 182171-05-7
210639-69-3 210639-84-2 214140-91-7 216382-88-6D, Imidazopyridine,
derivs. 216880-62-5 221179-01-7 222715-96-0 222716-13-4
222716-32-7 231630-20-9 232927-14-9 248595-25-7 252331-98-9
253178-59-5 254980-04-6 254980-06-8 254980-08-0 255395-82-5
255714-31-9 255725-40-7 256347-92-9 256417-22-8 256488-11-6
256488-13-8 256521-48-9 257861-94-2 257869-87-7 261946-03-6
261946-04-7 261946-06-9 262856-10-0 262856-11-1 262856-14-4
262856-15-5 263016-22-4 263016-25-7 263744-91-8 263766-87-6
263766-88-7 263766-94-5 263766-96-7 264232-74-8 264626-20-2
264626-22-4 265130-20-9 266362-06-5 266362-07-6 266362-08-7
266362-72-5 271775-19-0 279691-70-2 282523-56-2 282523-61-9
285980-79-2 285985-78-6 285985-96-8 285987-31-7 286439-77-8
289651-63-4 289651-74-7 289651-75-8 292170-06-0 292640-33-6
292641-43-1 292641-59-9 292641-66-8 292641-77-1 292641-89-5
292641-94-2 292641-96-4 292870-96-3 292871-13-7 292871-19-3
292871-23-9 292871-24-0 292871-26-2 292871-48-8 292871-52-4
292871-54-6 292871-55-7 292871-65-9 292871-69-3 292871-78-4
292871-81-9 292871-86-4 292871-94-4 292871-99-9 292872-04-9
292872-05-0 292872-11-8 292872-14-1 292875-92-4 292876-62-1
292877-08-8 292877-14-6 292877-44-2 293760-39-1 293760-44-8
294873-89-5 295787-47-2 296772-03-7 296790-72-2 296790-73-3
296790-75-5 296790-77-7 296791-26-9 296791-46-3 296791-48-5
296791-57-6 296793-15-2 296885-59-1 299198-34-8 299921-77-0
299964-86-6 300360-28-5 300377-27-9 300377-30-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT 300377-54-2 300377-60-0 300590-03-8 300690-35-1 **300695-50-5**
300700-73-6 300701-30-8 300716-40-9 300723-23-3 300805-10-1
301354-45-0 302575-31-1 302935-50-8 302950-94-3 303100-86-9
303100-87-0 303121-28-0 303122-04-5 303140-78-5 303148-61-0
303148-63-2 303148-99-4 303149-18-0 303226-67-7 304878-27-1
304896-73-9 305331-86-6 305332-46-1 305332-58-5 305333-17-9
305337-60-4 305362-03-2 305859-05-6 305865-87-6 305865-91-2
305866-04-0 305866-28-8 305866-71-1 305867-31-6 306288-57-3
306308-80-5 306308-92-9 306308-94-1 306309-07-9 306309-33-1
306309-35-3 306309-36-4 306309-44-4 306309-52-4 306309-58-0
306309-74-0 306310-02-1 306310-03-2 306310-21-4 306310-22-5
306310-23-6 306310-24-7 306310-26-9 306310-35-0 306319-47-1
306764-57-8 306956-43-4 309271-93-0 309274-37-1 309289-92-7
309293-80-9 309294-15-3 309294-32-4 309735-50-0 309735-52-2
309736-48-9 309736-49-0 309736-53-6 309737-21-1 309920-59-0

309921-09-3 309928-00-5 310447-13-3 310456-50-9 311774-09-1
311785-59-8 311798-45-5 312264-89-4 312269-59-3 312278-59-4
312278-72-1 312287-95-9 312317-18-3 312495-33-3 312497-06-6
312502-43-5 312505-29-6 312506-77-7 312521-88-3 312522-33-1
312529-33-2 312531-21-8 312536-81-5 312603-44-4 312621-18-4
312621-22-0 312621-26-4 312635-81-7 312703-25-6 312703-26-7
312703-27-8 312703-28-9 312703-30-3 312703-32-5 312703-35-8
312704-86-2 312734-07-9 312758-70-6 312935-38-9 312935-46-9
313050-17-8 313068-17-6 313068-18-7 313068-39-2 313068-45-0
313068-55-2 313068-60-9 313068-62-1 313068-87-0 313068-94-9
313272-50-3 313361-39-6 313377-25-2 313381-33-8 313389-91-2
313391-70-7 313397-97-6 313400-70-3 313400-73-6 313400-84-9
313400-88-3 313400-90-7 313400-92-9 313518-30-8 313518-33-1
313518-34-2 313518-35-3 313647-42-6 313705-02-1 313955-78-1
313955-79-2 313955-80-5 313955-82-7 313955-84-9 313955-88-3
313955-91-8 313955-95-2 313957-07-2 313957-10-7 313957-11-8
313965-69-4 313965-70-7 313965-71-8 313965-79-6 313966-29-9
313966-34-6 313976-26-0 313982-23-9 313982-24-0 313982-31-9
313982-32-0 313982-33-1 313982-38-6 313982-40-0 314027-98-0
314035-11-5 314035-14-8 314035-22-8 314035-24-0 314045-76-6
314046-18-9 314054-59-6 314054-60-9 314054-61-0 314054-63-2
314054-66-5 315183-66-5 315184-13-5 315184-21-5 316360-75-5
317374-73-5 320784-76-7 321392-06-7 321392-09-0 321975-78-4
324030-86-6 324071-14-9 324071-58-1 324071-63-8 324071-66-1
324072-02-8 324072-03-9 324072-06-2 324072-21-1 324072-23-3
324073-95-2 324542-36-1 324542-97-4 324543-00-2 324543-03-5
324543-49-9 324566-54-3 324567-44-4 326612-29-7 327031-34-5
327031-45-8 327031-83-4 327032-26-8 327032-30-4 327032-47-3
327032-59-7 327032-83-7 327032-85-9 327055-09-4 327055-16-3
327055-27-6 327055-29-8 327055-30-1 327055-48-1 327055-51-6
327055-58-3 327055-59-4 327055-62-9 327055-63-0 327055-65-2
327055-66-3 327055-68-5 327055-70-9 327055-72-1 327055-96-9
327055-97-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT 327056-03-1 327056-05-3 327100-35-6 328012-23-3 328118-26-9
328264-08-0 328264-17-1 328264-18-2 328264-19-3 328264-25-1
328264-26-2 328264-27-3 328264-31-9 328264-33-1 328264-35-3
328264-60-4 328264-66-0 328264-67-1 328264-76-2 328264-77-3
328264-80-8 328264-82-0 328264-83-1 328264-85-3 328264-87-5
328271-66-5 328271-67-6 328271-69-8 328271-70-1 328271-71-2
328271-76-7 328271-77-8 328271-79-0 328271-80-3 328271-84-7
328271-85-8 328271-88-1 328271-92-7 328272-06-6 328272-07-7
328272-08-8 328272-11-3 328272-13-5 328285-97-8 328391-94-2
329689-08-9 329693-08-5 329740-08-1 330560-95-7 330571-22-7
330852-05-6 330852-85-2 330854-50-7 331002-28-9 331002-56-3
331253-46-4 331253-51-1 331260-25-4 331260-26-5 331260-28-7
331261-77-9 331261-78-0 331261-92-8 331262-03-4 331262-07-8
331262-11-4 331263-52-6 331263-58-2 331710-55-5 331711-61-6
331749-70-3 331749-72-5 331760-77-1 331852-08-5 331856-24-7
331859-20-2 331944-58-2 331976-76-2 331978-51-9 332022-52-3
332022-53-4 332030-63-4 332075-02-2 332102-86-0 332102-89-3
332102-91-7 332102-93-9 332159-11-2 332401-95-3 332412-67-6
332867-75-1 332898-49-4 333769-72-5 333770-99-3 333793-27-4
337918-76-0 337919-26-3 337921-53-6 337921-56-9 338791-19-8
338791-34-7 338791-35-8 338791-36-9 338987-62-5 339009-79-9
339009-92-6 339009-95-9 339009-96-0 339009-98-2 339010-04-7
339026-82-3 339026-84-5 339026-96-9 339104-28-8 339314-09-9
340204-12-8 340207-27-4 341538-13-4 341538-41-8 341538-50-9
341538-59-8 343591-38-8 347363-05-7 347866-94-8 348163-00-8
350503-73-0 350503-74-1 350503-75-2 350503-77-4 350503-78-5
350612-07-6 350612-82-7 350612-83-8 350612-84-9 350680-42-1
351166-54-6 351210-57-6 351210-59-8 351210-65-6 351210-67-8

351213-06-4 351213-09-7 351213-11-1 351213-13-3 351213-15-5
351213-32-6 351213-33-7 351213-48-4 351213-55-3 351213-61-1
351213-64-4 351213-71-3 351213-73-5 351213-74-6 351213-75-7
351222-84-9 351504-60-4 351509-71-2 351510-77-5 351514-75-5
351514-86-8 351514-87-9 351515-00-9 351515-09-8 351515-89-4
351516-01-3 351516-08-0 351516-12-6 351516-15-9 351516-31-9
351516-76-2 351517-40-3 351517-44-7 351517-48-1 351517-73-2
351517-92-5 351518-64-4 351518-77-9 351518-85-9 351518-93-9
351518-94-0 351518-95-1 351519-28-3 351895-44-8 351895-47-1
351895-49-3 352023-44-0 352204-86-5 352204-90-1 352226-44-9
352226-46-1 352304-59-7 352304-63-3 352455-56-2 352455-70-0
352455-85-7 352455-89-1 352455-95-9 352455-98-2 352456-00-9
352456-02-1 352456-21-4 352456-23-6 352456-31-6 352554-28-0
352639-80-6 352647-29-1 352647-46-2 352657-21-7 352663-86-6
353254-75-8 353264-13-8 353467-61-5 353467-63-7 353467-65-9
353470-55-0 353470-72-1 353470-81-2 353504-56-0 353514-57-5
353774-04-6 353776-27-9 353776-40-6 353777-01-2 353781-12-1
353781-19-8 354143-43-4 354543-27-4 354557-15-6 357162-68-6
357227-12-4 357430-14-9 357432-12-3 357432-15-6 357432-69-0
357432-74-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT 357432-77-0 357433-19-3 357434-16-3 357434-22-1 357440-09-6
357441-42-0 357441-45-3 358731-11-0 360764-84-7 360764-99-4
361178-70-3 361371-95-1 362482-78-8 363590-74-3 370074-53-6
371127-11-6 371917-60-1 372155-97-0 372157-62-5 372503-90-7
373618-99-6 374707-65-0 374708-40-4 374758-72-2 374759-01-0
375839-59-1 381223-51-4 383375-26-6 383376-13-4 383391-54-6
384822-05-3 392325-80-3 398472-83-8 400754-38-3 400821-72-9
401466-92-0 413619-86-0 414873-85-1 414886-56-9 414906-10-8
415691-91-7 415699-86-4 415928-40-4 416878-53-0 416884-40-7
416885-05-7 416885-29-5 416894-20-7 418774-87-5 418792-63-9
418801-37-3 418803-13-1 418805-97-7 418809-85-5 418810-07-8
419537-97-6 419538-24-2 419538-42-4 419538-58-2 419539-53-0
419539-99-4 419540-52-6 419540-66-2 419540-81-1 419540-97-9
419541-01-8 419541-49-4 419541-76-7 419541-79-0 419544-90-4
419544-97-1 419546-31-9 419546-75-1 419547-14-1 419550-77-9
419550-80-4 419551-35-2 419551-60-3 419551-61-4 419577-67-6
420099-12-3 420103-39-5 420104-82-1 420105-40-4 423151-53-5
445025-50-3 464155-99-5 468093-19-8 470471-35-3 470471-80-8
470687-12-8 478048-43-0 487021-77-2 500118-46-7 500864-49-3
551921-20-1 634189-24-5 634189-25-6 634189-26-7 634189-27-8
634189-28-9 634189-29-0 634189-30-3 634189-31-4 634189-32-5
634189-33-6 634189-34-7 634189-35-8 634189-36-9 634189-37-0
634189-38-1 634189-39-2 634189-40-5 634189-41-6 634189-42-7
634189-43-8 634189-44-9 634189-45-0 634189-47-2 634189-48-3
634189-49-4 634189-50-7 634189-51-8 634189-52-9 634189-53-0
634189-54-1 634189-55-2 634189-56-3 634189-58-5 634189-61-0
634189-62-1 634189-63-2 634189-64-3 634189-65-4 634189-66-5
634189-67-6 634189-68-7 634189-69-8 634189-70-1 634189-71-2
634189-72-3 634189-74-5 634189-76-7 634189-77-8 634189-78-9
634189-79-0 634189-80-3 634189-81-4 634189-82-5 634189-84-7
634189-85-8 634189-86-9 634189-87-0 634189-88-1 634189-89-2
634189-90-5 634189-91-6 634189-92-7 634189-93-8 634189-94-9
634189-95-0 634189-96-1 634189-97-2 634189-98-3 634189-99-4
634190-00-4 634190-01-5 634190-02-6 634190-03-7 634190-04-8
634190-05-9 634190-06-0 634190-07-1 634190-08-2 634190-09-3
634190-10-6 634190-11-7 634190-12-8 634190-13-9 634190-14-0
634190-15-1 634190-16-2 634190-17-3 634190-18-4 634190-19-5
634190-20-8 634190-21-9 634190-22-0 634190-23-1 634190-24-2
634190-25-3 634190-26-4 634190-27-5 634190-28-6 634190-29-7
634190-32-2 634190-34-4 634190-36-6 634190-39-9 634190-40-2
634190-44-6 634190-46-8 634190-51-5 634190-52-6 634190-69-5

634190-71-9 634190-72-0 634190-73-1 634190-74-2 634190-75-3
634190-76-4 634190-77-5 634190-78-6 634190-79-7 634190-80-0
634197-52-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT 71-36-3, n-Butanol, reactions 79-19-6, Thiosemicarbazide 91-56-5, Isatin 107-13-1, Acrylonitrile, reactions 5570-18-3, 2-Aminophenylboronic acid 35371-03-0, 4-Iodothioanisole
RL: RCT (Reactant); RACT (Reactant or reagent)
(transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT 27161-64-4P 41383-89-5P 634190-81-1P 634190-82-2P 634190-83-3P
634190-84-4P 634190-85-5P 634190-86-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT 634190-87-7P 634190-88-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

IT 634652-75-8 634652-76-9
RL: PRP (Properties)
(unclaimed nucleotide sequence; transcription factor modulating compds. and methods of use thereof)

IT **300695-50-5**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

RN 300695-50-5 HCAPLUS
CN Benzoic acid, 5-[[(2-carboxyphenyl)amino]sulfonyl]-2-hydroxy- (9CI) (CA INDEX NAME)



L61 ANSWER 17 OF 58 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:931209 HCAPLUS
DN 140:787
ED Entered STN: 28 Nov 2003
TI Agitation process for the preparation and activation of drugs and other substances, and production means
IN Whyte, Susan Kay
PA Chemstop Pty Ltd, Australia
SO PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM A61K041-00
ICS A61K031-375; A61K033-06; A61P019-02; A61P019-10; A61P019-04

```
CC   1-12 (Pharmacology)
     Section cross-reference(s): 5, 17, 18, 63
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2003097095         A1    20031127    WO 2003-AU607           20030520 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2486881             AA    20031127    CA 2003-2486881         20030520 <--
     EP 1506014             A1    20050216    EP 2003-722058          20030520 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRAI AU 2002-2400          A     20020520  <--
     AU 2002-2480          A     20020522  <--
     WO 2003-AU607         W     20030520
CLASS
 PATENT NO.       CLASS  PATENT FAMILY CLASSIFICATION CODES
 --------------   -----  ----------------------------------------------
 WO 2003097095    ICM    A61K041-00
                  ICS    A61K031-375; A61K033-06; A61P019-02; A61P019-10;
                         A61P019-04
 WO 2003097095    ECLA   A23L001/025; A23L001/30M; A61K031/00; A61K031/375;
                         A61K031/375+M; A61K041/00D; A61K045/06          <--
AB   The invention discloses a process for the preparation and activation of a
     substance and a means for producing the activated substance.  In
     particular, the invention discloses a method for treating a disease in a
     subject in need of such treatment, comprising administering a substance or
     active agent which comprises one or more components which have been
     agitated such that a harmonic of 20-50 Hz has been produced, in an amount
     effective to treat the disease, with the proviso that the disease is not
     an airway disorder.
ST   agitation drug activation therapeutic
IT   Agitation (mechanical)
     Anti-inflammatory agents
     Antiarthritics
     Antiasthmatics
     Antibacterial agents
     Antibiotics
     Anticoagulants
     Antihistamines
     Antioxidants
     Antiviral agents
     Apparatus
     Arthritis
     Asthma
     Aves
     Bakery products
     Beer
     Beverages
     Bifidobacterium
     Bifidobacterium bifidum
     Breakfast cereal
     Bronchodilators
     Butter
     Candy
     Canis familiaris
     Cheese
     Chemicals
```

Chemotherapy
Chewing gum
Chocolate
Coffea
Dairy products
Decongestants
Drug delivery systems
Drugs
Enterococcus durans
Equus caballus
Felis catus
Food
Fungicides
Gene therapy
Herbicides
Human
Ice cream
Injury
Jams and Jellies
Lactobacillus acidophilus
Lactobacillus brevis
Lactobacillus casei
Lactobacillus delbrueckii
Lactobacillus plantarum
Lactobacillus rhamnosus
Lactobacillus salivarius
Lactococcus lactis
Mammalia
Margarine
Mayonnaise
Milk
Nutrients
Osteoporosis
Oxalis
Panax
Pesticides
Potato chips
Primates
Rolls
Roton
Ruminant
Salad dressings
Shortening
Sus scrofa domestica
Therapy
Vortex (fluids)
Wine
(agitation process for preparation and activation of drugs and other substances, and production means)

IT Fertilizers
Pyrethrins
RL: AGR (Agricultural use); BIOL (Biological study); USES (Uses)
(agitation process for preparation and activation of drugs and other substances, and production means)

IT Carbohydrates, biological studies
Elements
Gene
Glycoproteins
Hormones, animal, biological studies
Lipids, biological studies
Lipoproteins
Mineral elements, biological studies
Mucoproteins
Nucleic acids
Nucleoproteins
Nucleosides, biological studies

Nucleotides, biological studies
Oligonucleotides
Peptides, biological studies
Retinoids
Steroids, biological studies
Trace elements, biological studies
Vitamins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(agitation process for preparation and activation of drugs and other substances, and production means)

IT Mixers (processing apparatus)
(agitators; agitation process for preparation and activation of drugs and other substances, and production means)

IT Bread
(and bread dough; agitation process for preparation and activation of drugs and other substances, and production means)

IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(and small mols.; agitation process for preparation and activation of drugs and other substances, and production means)

IT Cytotoxic agents
(antiproliferative agents; agitation process for preparation and activation of drugs and other substances, and production means)

IT Tea products
(beverages; agitation process for preparation and activation of drugs and other substances, and production means)

IT Bakery products
(biscuits; agitation process for preparation and activation of drugs and other substances, and production means)

IT Bronchi
(bronchoconstriction; agitation process for preparation and activation of drugs and other substances, and production means)

IT Bakery products
(cakes; agitation process for preparation and activation of drugs and other substances, and production means)

IT Beverages
(carbonated; agitation process for preparation and activation of drugs and other substances, and production means)

IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates, with small mols.; agitation process for preparation and activation of drugs and other substances, and production means)

IT Meat
(cured; agitation process for preparation and activation of drugs and other substances, and production means)

IT Food gels
(desserts; agitation process for preparation and activation of drugs and other substances, and production means)

IT Tendon
(disease, tendinitis; agitation process for preparation and activation of drugs and other substances, and production means)

IT Muscle, disease
(fibromyalgia; agitation process for preparation and activation of drugs and other substances, and production means)

IT Diptera
(fly repellent; agitation process for preparation and activation of drugs and other substances, and production means)

IT Beverages
(fruit drinks; agitation process for preparation and activation of drugs and other substances, and production means)

IT Desserts
(gels; agitation process for preparation and activation of drugs and other substances, and production means)

IT Milk substitutes
(human; agitation process for preparation and activation of drugs and other substances, and production means)
IT Drug delivery systems
(injections, i.v.; agitation process for preparation and activation of drugs and other substances, and production means)
IT Drug delivery systems
(injections, s.c.; agitation process for preparation and activation of drugs and other substances, and production means)
IT Peptides, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(melanotrophic; agitation process for preparation and activation of drugs and other substances, and production means)
IT Food
(non-dairy whiteners; agitation process for preparation and activation of drugs and other substances, and production means)
IT Anti-inflammatory agents
(nonsteroidal; agitation process for preparation and activation of drugs and other substances, and production means)
IT Skin, disease
(photoaging, anti-photoaging agents; agitation process for preparation and activation of drugs and other substances, and production means)
IT Bakery products
(pies; agitation process for preparation and activation of drugs and other substances, and production means)
IT Intestinal bacteria
(probiotic; agitation process for preparation and activation of drugs and other substances, and production means)
IT Egg white
(processed; agitation process for preparation and activation of drugs and other substances, and production means)
IT Moth
Snail
(repellent; agitation process for preparation and activation of drugs and other substances, and production means)
IT Food
(sandwich spreads; agitation process for preparation and activation of drugs and other substances, and production means)
IT Inflammation
(tendinitis; agitation process for preparation and activation of drugs and other substances, and production means)
IT Injury
(trauma; agitation process for preparation and activation of drugs and other substances, and production means)
IT Fats and Glyceridic oils, biological studies
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(vegetable; agitation process for preparation and activation of drugs and other substances, and production means)
IT Cream substitutes
(whipped, artificial whipped cream, and whipping agent; agitation process for preparation and activation of drugs and other substances, and production means)
IT Milk preparations
(yogurt; agitation process for preparation and activation of drugs and other substances, and production means)
IT 128639-02-1, Carfentrazone-ethyl
RL: AGR (Agricultural use); BIOL (Biological study); USES (Uses)
(Aim; agitation process for preparation and activation of drugs and other substances, and production means)
IT 50-29-3, DDT, biological studies 52-68-6, TRICHLORFON 55-38-9, FENthioN 56-38-2, PARAthioN 58-89-9, Lindane 60-51-5, DImethOATE 60-57-1, DIELDRIN 61-82-5, Amitrole 62-73-7, DICHLORVOS 63-25-2, CARBARYL 72-20-8, ENDRIN 72-43-5, MethoxyCHLOR 72-54-8, DDD 72-55-9, DDE, biological studies 74-81-7, OctanoATE, biological studies 74-83-9, Methyl Bromide, biological studies 75-15-0, Carbon Disulfide,

biological studies 75-60-5, DimethylARSINIC acid 76-06-2, ChloroPICRIN
76-44-8, HeptACHLOR 78-48-8, TRIBUFOS 78-87-5, 1,2-Dichloropropane
82-68-8, QUINTOZENE 83-79-4, ROTEnonE 86-50-0, AZINPHOS-methyl
86-86-2, 1-Naphthaleneacetamide 86-87-3, 1-Naphthylacetic Acid
87-86-5, Pentachlorophenol 88-85-7, DINOSEB 91-20-3, Naphthalene,
biological studies 93-65-2, MECOprop 93-71-0, CDAA 93-72-1, FENOprop
93-76-5, 2,4,5-T 93-76-5D, 2,4,5-T, esters and amine salts 94-74-6,
MCPA 94-75-7, 2,4-D, biological studies 94-81-5, MCPB 94-82-6,
2,4-DB 96-12-8, DBCP 99-30-9, DCNA 101-05-3, ANILAZINE 101-21-3,
Chloropropham 101-27-9, BARBAN 101-42-8, FENURON 106-93-4, EthylENE
DIbromide 107-02-8, ACROLEIN, biological studies 112-05-0, Pelargonic
acid 114-26-1, PropOXUR 115-29-7, Endosulfan 115-32-2, DICOFol
115-90-2, FENSULFOthioN 116-06-3, ALDICARB 117-80-6, DICHLONE
118-74-1, HexachloroBENZENE 120-36-5, DICHLORprop 121-75-5, MalAthioN
122-14-5, FEnitrothioN 122-34-9, Simazine 122-42-9, PropHAM
123-33-1, Maleic hydrazide 132-66-1, Naptalam 132-67-2, Naptalam
Sodium Salt 133-06-2, CAPTAN 133-90-4, Chloramben 137-26-8, THIRAM
137-30-4, ZIRAM 137-42-8, MethAM SODIUM 139-40-2, PropAZINE
140-56-7, FENaminoSULF 141-66-2, DICROTOPHOS 144-21-8, DSMA
145-73-3, Endothall 148-79-8, THIABENDazoLE 150-68-5, MONURON
298-00-0, Methyl Parathion 298-02-2, PHORATE 298-04-4, DISULFOTON
300-76-5, NALED 301-12-2 309-00-2, ALDRIN 314-40-9, Bromacil
315-18-4, MEXACARBATE 327-98-0, TrichloroNAT 330-54-1, Diuron
330-55-2, Linuron 333-41-5, DIAZInon 510-15-6, ChloroBENZILATE
533-74-4, DazoMET 534-52-1, DNOC 555-37-3, NEBURON 556-61-6, Methyl
isothiocyanate 650-51-1 709-98-8, Propanil 732-11-6, PHOSMET
741-58-2, Bensulide 759-94-4, EPTAM 786-19-6, CARBOphenOthioN
834-12-8, Ametryn 886-50-0, TERbutRYN 944-22-9, FONOFOS 1014-70-6,
SIMETRYN 1071-83-6, Glyphosate 1114-71-2, Pebulate 1134-23-2,
Cycloate 1194-65-6, CASORON 1563-66-2, CARBOfuran 1582-09-8,
Trifluralin 1596-84-5, DaminoZIDE 1610-18-0, PROMETON 1646-88-4,
ALDoxyCARB 1689-84-5, BromoxyNIL 1689-99-2, BUCTRIL 1698-60-8,
CHLORIDazon 1702-17-6, Clopyralid 1746-81-2, MonoLINURON 1836-75-5,
NitroFEN 1861-32-1, Dacthal 1861-40-1, Benefin 1897-45-6,
ChloroTHALONIL 1910-42-5, PARAQUAT DIchloride 1912-24-9, Atrazine
1918-00-9, Dicamba 1918-02-1, Picloram 1918-16-7, Propachlor
1929-77-7, Vernolate 1929-82-4, NITRAPYRIN 1982-47-4, ChloroXURON
1982-49-6, Siduron 2008-41-5, Butylate 2032-59-9, AminoCARB
2032-65-7, MethioCARB 2104-64-5, EPN 2163-80-6, MSMA 2164-08-1
2164-17-2, Fluometuron 2212-67-1, Molinate 2227-17-0, DIENOCHLOR
2302-17-2, ASULOX 2303-16-4, DIALLATE 2303-17-5, Triallate
2310-17-0, PHOSALONE 2312-35-8, PropARGITE 2385-85-5, MIREX
2425-06-1, CAPTAFOL 2439-01-2, QUINOmethioNATE 2439-10-3 2593-15-9,
ETRIdiazoLE 2597-03-7, PhenTHOATE 2631-37-0, PROMECARB 2675-77-6,
ChloroNEB 2758-42-1 2764-72-9, Diquat 2921-88-2, CHLORPYRIFOS
3337-71-1, Asulam 3383-96-8, TEMEPHOS 3478-94-2, PIPERALIN
3861-41-4, Bromoxynil Butyrate 4147-51-7, DIpropETRYN 4685-14-7,
Paraquat 5221-53-4, DImethIRIMol 5234-68-4, CARBOXIN 5259-88-1,
OxyCARBOXIN 5598-13-0, Chlorpyrifos-Methyl 5902-51-2, Terbacil
6164-98-3, Chlordimeform 6923-22-4, MonoCROTOPHOS 6988-21-2, DIOXACARB
7287-19-6, Prometryn 7775-09-9, SODIUM CHLORATE 7778-39-4, Arsenic
Acid; 7786-34-7, MEVINPHOS 8001-35-2, TOXAphenE 8018-01-7, MANCOZEB
8065-48-3, DEMETON 9006-42-2, METIRAM 10265-92-6, MethamidoPHOS
10453-86-8, RESmethRIN 10605-21-7, CARBENDAZIM 12122-67-7, ZINEB
12407-86-2, TRImethACARB 12427-38-2, MANEB 12771-68-5, ANCYMIDOL
12789-03-6, CHLORDANE 13071-79-9, TERBUFOS 13121-70-5, CYhexATIN
13171-21-6, PHOSPHamidoN 13194-48-4, EthOprop 13356-08-6, FENbutATIN
OXIDE 13360-45-7, CHLORBROMURON 13684-56-5, Desmedipham 13684-63-4,
Phenmedipham 14484-64-1, FERBAM 15096-52-3, CRYOLITE 15299-99-7,
Napropamide 15310-01-7, BENODANIL 15972-60-8, Alachlor 16672-87-0,
EthEPHON 16752-77-5, MethOMYL 17804-35-2, BENOMYL 19044-88-3,
Oryzalin 19666-30-9, Oxadiazon 19750-95-9, Chlordimeform hydrochloride
20354-26-1, Methazole 21087-64-9, Metribuzin 21725-46-2, Cyanazine
22224-92-6, FENAMIPHOS 22248-79-9, TETRACHLORVINPHOS 22781-23-3,
BENDIOCARB 23103-98-2, PIRIMICARB 23135-22-0, OXAMYL 23184-66-9,
ButACHLOR 23422-53-9, FORMETANATE hydrochloride 23505-41-1,

Pirimiphos-Ethyl 23564-05-8 23950-58-5, Pronamide 24307-26-4,
MEPIQUAT chloride 24691-80-3, FENfurAM 25057-89-0, Bentazon
25311-71-1, ISOFENPHOS 25606-41-1, PropAMOCARB hydrochloride
25954-13-6, FOSamineammonium 26225-79-6, Ethofumesate 26259-45-0,
SECBUMETON 26399-36-0, PROFLURALIN 26644-46-2, TRIFORINE 26648-01-1,
DESICATE 26952-23-8, Dichloropropene 27314-13-2, Norflurazon
28249-77-6, Thiobencarb 29091-05-2, DINITRamine 29091-21-2, Prodiamine
30560-19-1, ACEPHATE 32357-46-3 32809-16-8, PROCYMIDONE 33089-61-1,
AMITRAZ 33245-39-5, FLUCHLORALIN
RL: AGR (Agricultural use); BIOL (Biological study); USES (Uses)
(agitation process for preparation and activation of drugs and other
substances, and production means)

IT 33820-53-0, ISOpropALIN 34014-18-1, Tebuthiuron 34256-82-1, Acetochlor
35367-38-5, DIFLUBENZURON 35400-43-2, SULPROFOS 35554-44-0, IMAZALIL
36734-19-7, IPRODIONE 37273-91-9, METaldehyde 37764-25-3, DICHLORMID
37924-13-3, Perfluidone 38641-94-0, ROUNDUP 38725-95-0, Diethatyl
38727-55-8, ANTOR 39148-24-8, FOSETYL ALUMINUM 39300-45-3, DINOCAP
39515-41-8, FENpropATHRIN 40487-42-1, Pendimethalin 40843-25-2,
Diclofop 41198-08-7, PROFENOFOS 41814-78-2, TRICYCLazoLE 42509-80-8,
ISazoFOS 42576-02-3, BIFENOX 42874-03-3, Oxyfluorfen 43121-43-3,
TRIADIMEFON 43222-48-6, AVENGE 49866-87-7, Difenzoquat 50471-44-8,
VINCLOZOLIN 50594-66-6, Acifluorfen 51218-45-2, Metolachlor
51235-04-2, Hexazinone 51276-47-2, Glufosinate 51338-27-3, HOELON
51630-58-1, FENVALERATE 51707-55-2, THIDIAZURON 51990-04-6, ERADICANE
52315-07-8, CYPERmethRIN 52645-53-1, PERmethRIN 53780-34-0, MEFLUIDIDE
54593-83-8, CHLORethoxyFOS 55219-65-3, TRIADIMENol 55283-68-6,
Ethalfluralin 55290-64-7, DImethIPIN 55335-06-3, Triclopyr
55512-33-9, Pyridate 57018-04-9, TOLCLOFOS-methyl 57213-69-1,
GRANDSTAND 57837-19-1, METALAXYL 57966-95-7, CYMOXANIL 58138-08-2,
TRIDIPHANE 59669-26-0, ThioDICARB 59756-60-4, FLURIDONE 60168-88-9,
FENARIMol 60207-90-1, PropICONazoLE 62476-59-9, BLAZER 62924-70-3,
FLUMETRALIN 64700-56-7, RELY 64902-72-3, GLEAN 65859-56-5, ANSAR
66215-27-8, CYROMAZINE 66230-04-4, ESFENVALERATE 66441-23-4,
Fenoxaprop-ethyl 66841-25-6, TRALOmethRIN 67485-29-4, HYDRAmethylnon
67747-09-5, PROCHLORAZ 68049-83-2, Azafenidin 68085-85-8, CYHALOTHRIN
68359-37-5, CYFLUTHRIN 68694-11-1, TRIFLUMIZOLE 68924-90-3, SURPASS
69806-34-4, Haloxyfop 69806-40-2, HALoxyFOP-methyl 69806-50-4,
FLUAZIFOP-butyl 70124-77-5, FLUCYTHRINATE 71626-11-4, BENALAXYL
71751-41-2, ABAMECTIN 72178-02-0, Fomesafen 72490-01-8, FENoxyCARB
74051-80-2, Sethoxydim 74115-24-5, CLOFENTEZINE 74222-97-2, OUST
74223-56-6, Sulfometuron 74223-64-6, ALLY 76578-12-6, Quizalofop
76578-14-8, ASSURE 76738-62-0, PACLObutRazoL 77182-82-2,
GLUFOSINATE-ammonium 77501-63-4, Lactofen 79241-46-6, FUsilADE DX
79277-27-3, PINNACLE 79277-67-1, Thifensulfuron 79510-48-8,
Metsulfuron 81334-34-1, IMAZAPYR 81335-37-7, Imazaquin 81335-77-5,
Imazethapyr 81405-85-8, ASSERT 81406-37-3, STARANE 81591-81-3,
Sulfosate 81777-89-1, Clomazone 82097-50-5, Triasulfuron 82558-50-7,
Isoxaben 82657-04-3, BIFENTHRIN 83055-99-6, LONDAX 83066-88-0,
Fluazifop-P 84087-01-4, Quinclorac 84332-86-5, CHLOZOLINATE
85509-19-9, FLUsilazoLE 86209-51-0, BEACON 87546-18-7, RESOURCE
87547-04-4, Flumiclorac 87674-68-8, FRONTIER 87818-31-3, CiNmethylin
87820-88-0, Tralkoxydim 88671-89-0, MYCLObutanIL 90982-32-4,
Chlorimuron-ethyl 94125-34-5, Prosulfuron 98967-40-9, Flumetsulam
99129-21-2, Clethodim 99283-01-9, Bensulfuron 100728-84-5,
Imazamethabenz 100784-20-1, SEMPRA 101200-48-0, EXPRESS 101205-02-1,
Cycloxydim 102851-06-9, TAU-FLUVALINATE 103361-09-7, Flumioxazin
104098-48-8, Imazameth 106040-48-6, Tribenuron 109293-97-2,
Diflufenzopyr 111353-84-5, Ethametsulfuron 111991-09-4, Nicosulfuron
113036-87-6, Primisulfuron 114311-32-9, Imazamox 117718-60-2,
Thiazopyr 120162-55-2, AZIMSULfuroN 122836-35-5, Sulfentrazone
122931-48-0, Rimsulfuron 123342-93-8, Pyrithiobac 123343-16-8, STAPLE
126535-15-7, UPBEET 135397-30-7, Halosulfuron 135990-29-3,
Triflusulfuron 141112-29-0, Isoxaflutole 141776-32-1, Sulfosulfuron
142459-58-3, Flufenacet 144651-06-9, Oxasulfuron 144740-53-4,
FLUPYRSULfuroN methyl 147150-35-4, FIRST-RATE **159518-97-5**,
Cloransulam 181274-17-9, Flucarbazone-sodium 404928-85-4, SCYTHE

454182-53-7, DISTINCT 628304-14-3, Biodynamic Preparation 500
RL: AGR (Agricultural use); BIOL (Biological study); USES (Uses)
(agitation process for preparation and activation of drugs and other substances, and production means)
IT 7732-18-5, Water, miscellaneous
RL: MSC (Miscellaneous)
(agitation process for preparation and activation of drugs and other substances, and production means)
IT 50-81-7, Ascorbic acid, biological studies 144-55-8, Sodium bicarbonate, biological studies 471-34-1, Calcium carbonate, biological studies 1314-13-2, Zinc oxide, biological studies 1464-42-2, Selenomethionine 7439-95-4, Magnesium, biological studies 7440-42-8, Boron, biological studies 7440-70-2, Calcium, biological studies 7487-88-9, Magnesium sulfate, biological studies 7693-13-2, Calcium citrate 17949-65-4, Zinc picolinate 18559-94-9, Ventolin 18962-61-3, Magnesium aspartate 22454-86-0, Calcium orotate 34717-03-8, Magnesium orotate 80474-14-2, Flixotide 136112-01-1, Seretide
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(agitation process for preparation and activation of drugs and other substances, and production means)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Maa, Y; J Microencapsulation 1996, V13(4), P419 HCAPLUS
(2) Pharmaceutical Machine Sales Ltd; http://www.pmsuk.com/Stocksheets/silverson1406.htm 2003
(3) Rath, M; EP 1163904 A 2001 HCAPLUS
(4) Smithkline Beecham Plc; WO 0032591 A 2000 HCAPLUS
(5) Taki Chem Co Ltd; JP 07053411 A 1995 HCAPLUS
IT **159518-97-5**, Cloransulam
RL: AGR (Agricultural use); BIOL (Biological study); USES (Uses)
(agitation process for preparation and activation of drugs and other substances, and production means)
RN 159518-97-5 HCAPLUS
CN Benzoic acid, 3-chloro-2-[[(5-ethoxy-7-fluoro[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



L61 ANSWER 18 OF 58 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:711891 HCAPLUS
DN 139:237617
ED Entered STN: 11 Sep 2003
TI Silver halide color photographic material containing pyrazolotriazole-type magenta coupler
IN Mizukawa, Hiroki; Fukuzawa, Hiroshi; Kawakishi, Toshio; Tsukase, Masaaki
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 78 pp.
CODEN: JKXXAF
DT **Patent**
LA Japanese
IC ICM G03C007-38
CC 74-2 (Radiation Chemistry, Photochemistry, and Photographic and Other Reprographic Processes)
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI	JP 2003255499	A2	20030910	JP 2002-367186	20021218 <--
	US 2004101792	A1	20040527	US 2002-329466	20021227 <--
	US 6770431	B2	20040803		
PRAI	JP 2001-401228	A	20011228 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
JP 2003255499	ICM	G03C007-38
US 2004101792	NCL	430/551.000
	ECLA	G03C007/38H2N4; G03C007/392B7D <--

OS MARPAT 139:237617

GI





AB The photog. material contains 1H-pyrazolo[3,2-c]-1,2,5-triazole-type coupler substituted with aromatic group I (R1 = substituent; R2 = alkyl, alkenyl, aryl; m = 0-4). Alternatively, the material contains ≥1 coupler selected from pyrazolotriazole II and III (R8 = substituent; X2 = H, group leaving in reaction with oxidized developer; L2 = alkylene, aralkylene; Z1 = CO2, NRCO, NRCO2, etc; R = H, alkyl, aryl; Y1 = divalent linking group; q = 0, 1; R11, R12 = H, alkyl, aryl; A1 = aromatic group). The material shows stable magenta color image formation under change of composition of treatments, e.g., developer, etc., and retention of color-forming property in reduced amts. of high-b.p. organic solvents in development, fixing, etc.

ST photog emulsion magenta coupler pyrazolotriazole

IT Magenta couplers
Photographic emulsions
(pyrazolotriazole-type magenta coupler for photog. emulsion)

IT 98-59-9 112-92-5, 1-Octadecanol 134-20-3 501-24-6 538-93-2, Isobutylbenzene 2516-96-3 15945-07-0 291543-57-2 595585-10-7 595585-11-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(for preparation of pyrazolotriazole-type magenta coupler for photog. emulsion)

IT **6311-23-5P** 42840-02-8P 50998-74-8P 192635-45-3P 339370-45-5P 416845-49-3P 416845-50-6P 416845-51-7P 595583-81-6P 595583-84-9P 595583-90-7P 595583-96-3P **595583-98-5P** 595584-00-2P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; for preparation of pyrazolotriazole-type magenta coupler for

photog. emulsion)
IT 291543-58-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(intermediate; for preparation of pyrazolotriazole-type magenta coupler for photog. emulsion)
IT 595585-13-0
RL: MOA (Modifier or additive use); USES (Uses)
(ppyrazolotriazole-type magenta coupler for photog. emulsion)
IT 540753-76-2P 595583-52-1P 595583-53-2P
RL: IMF (Industrial manufacture); MOA (Modifier or additive use); PREP (Preparation); USES (Uses)
(pyrazolotriazole-type magenta coupler for photog. emulsion)
IT 595583-51-0 595583-54-3 595583-55-4 595583-56-5 595583-57-6
595583-58-7 595583-59-8 595583-60-1 595583-61-2 595583-62-3
595583-63-4 595583-64-5 595583-65-6 595583-66-7 595583-67-8
595583-68-9 595583-69-0 595583-70-3 595583-71-4 595583-72-5
595583-73-6 595583-74-7 595583-75-8 595583-76-9 595584-01-3
595584-02-4 595584-03-5 595584-04-6 595584-05-7 595584-06-8
595584-07-9 595585-12-9 595585-14-1
RL: MOA (Modifier or additive use); USES (Uses)
(pyrazolotriazole-type magenta coupler for photog. emulsion)
IT **6311-23-5P 595583-98-5P**
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; for preparation of pyrazolotriazole-type magenta coupler for photog. emulsion)
RN 6311-23-5 HCAPLUS
CN Benzoic acid, 2-[[(4-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 595583-98-5 HCAPLUS
CN Benzoic acid, 2-[[[4-(2-methylpropyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



L61 ANSWER 19 OF 58 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:551386 HCAPLUS
DN 139:117209
ED Entered STN: 18 Jul 2003
TI Preparation of biaryl phosphate transport inhibitors
IN Jozefiak, Thomas H.; Bastos, Cecilia M.; Papoulis, Andrew T.; Holmes-Farley, Stephen Randall
PA Genzyme Corporation, USA
SO PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM A61K031-63
ICS A61K031-166; A61K031-415; A61K031-17; A61P013-12; A61P019-10;

```
         A61P003-14
CC   25-17 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
     Section cross-reference(s): 1
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     --------------       ----   --------    -------------------      --------
PI   WO 2003057225         A2    20030717    WO 2002-US41481          20021224 <--
     WO 2003057225         A3    20040408
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2004019113         A1    20040129    US 2002-327627           20021220 <--
     EP 1465638            A2    20041013    EP 2002-806234           20021224 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
     JP 2005514413         T2    20050519    JP 2003-557583           20021224 <--
PRAI US 2001-344660P       P     20011226  <--
     US 2002-371649P       P     20020410  <--
     WO 2002-US41481       W     20021224  <--
CLASS
 PATENT NO.       CLASS  PATENT FAMILY CLASSIFICATION CODES
 --------------   -----  ----------------------------------------------
 WO 2003057225    ICM    A61K031-63
                  ICS    A61K031-166; A61K031-415; A61K031-17; A61P013-12;
                         A61P019-10; A61P003-14
 WO 2003057225    ECLA   A61K031/166; A61K031/166+M; A61K031/17; A61K031/17+M;
                         A61K031/18; A61K031/18+M; A61K031/415; A61K031/415+M;
                         A61K031/63; A61K031/63+M; A61K033/38+M; A61K045/06  <--
 US 2004019113    NCL    514/602.000
                  ECLA   A61K031/166+M; A61K031/17; A61K031/17+M; A61K031/18;
                         A61K031/18+M; A61K031/415; A61K031/415+M; A61K031/63+M;
                         A61K045/06                                          <--
 JP 2005514413    FTERM  4C031/HA07; 4C037/HA19; 4C056/AA01; 4C056/AB01;
                         4C056/AC01; 4C056/AD01; 4C056/AE03; 4C056/AF05;
                         4C063/AA01; 4C063/BB01; 4C063/CC75; 4C063/DD22;
                         4C063/DD51; 4C063/EE01; 4C086/AA01; 4C086/AA02;
                         4C086/BA03; 4C086/BB02; 4C086/BC36; 4C086/BC46;
                         4C086/BC67; 4C086/DA34; 4C086/GA02; 4C086/GA07;
                         4C086/GA09; 4C086/MA01; 4C086/NA14; 4C086/ZA81;
                         4C086/ZA96; 4C086/ZA97; 4C086/ZC06; 4C206/AA01;
                         4C206/AA02; 4C206/CB19; 4C206/GA02; 4C206/GA31;
                         4C206/HA30; 4C206/JA13; 4C206/MA01; 4C206/NA14;
                         4C206/ZA81; 4C206/ZA96; 4C206/ZA97; 4C206/ZC06      <--
OS   MARPAT 139:117209
GI
```



II

AB Disclosed are compds. Ar1-W-X-Y-Ar2 [Ar1-2 = (un)substituted aryl group or 5-6 membered non-aromatic group fused to a (un)substituted monocyclic aryl group; W, Y = covalent bond, alkylene; X = SO2, SO2-alkyl, SO2-amino, etc; I] which are inhibitors of phosphate transport. For instance, 5-bromo-2-[[(4-trifluoromethoxyphenyl)sulfonyl]amino]benzoic acid (preparation given) is converted to the acid chloride (SOCl2, reflux) and used to acylate 2-methoxybenzyl amine (THF) to give II. Example compds. inhibit phosphate transport in rabbit intestinal brush border membrane vesicles; a select group of example compds. has IC50 = 0-50 μM. I are used to treat a disease associated with hyperphosphatemia, as well as a disease mediated by phosphate-transport function.

ST phosphate transport inhibitor aryl sulfonamide prepn carboxylic acid amide

IT Kidney, disease
(failure; preparation of biaryl phosphate transport inhibitors)

IT Biological transport
(glucose; preparation of biaryl phosphate transport inhibitors)

IT Biological transport
(phosphate; preparation of biaryl phosphate transport inhibitors)

IT Human
Hyperparathyroidism
Osteoporosis
(preparation of biaryl phosphate transport inhibitors)

IT Calcification
(soft tissue; preparation of biaryl phosphate transport inhibitors)

IT Bone, disease
(uremic; preparation of biaryl phosphate transport inhibitors)

IT 52757-95-6, Sevelamer
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; preparation of biaryl phosphate transport inhibitors)

IT 562079-23-6P 562079-25-8P 562079-31-6P 562080-77-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of biaryl phosphate transport inhibitors)

IT 60-82-2P 86-19-1P 87-10-5P 403-96-3P 621-96-5P 659-22-3P
1091-57-2P 1141-60-2P 1154-59-2P 1651-12-3P 1678-25-7P
1763-78-6P 2535-77-5P 3051-11-4P 3112-88-7P 3709-43-1P
4106-18-7P 4193-55-9P 4525-91-1P 5066-65-9P 6137-36-6P
6149-62-8P 6898-97-1P 24089-96-1P 31271-90-6P 34063-53-1P
40899-71-6P 51023-76-8P 52645-14-4P 53356-76-6P 61381-64-4P
66078-31-7P 66820-85-7P 67483-13-0P **68003-38-3P**
75227-41-7P 78974-45-5P 91286-90-7P 91286-93-0P 107143-19-1P
107143-20-4P **107143-69-1P** 107635-21-2P 134897-44-2P
134897-59-9P 136402-20-5P 136402-22-7P 136402-25-0P
136427-98-0P 142920-39-6P 192049-20-0P 195452-46-1P
197513-49-8P 197800-20-7P 197800-22-9P 197800-24-1P 197800-26-3P
199583-73-8P 261962-64-5P 297178-83-7P 298187-97-0P 301683-40-9P
305859-66-9P 313495-77-1P 326007-87-8P 329937-51-1P 335334-01-5P
341021-41-8P 358656-73-2P 362016-88-4P 397245-42-0P 491861-53-1P
491861-56-4P **496015-34-0P** 505040-67-5P **562078-11-9P**
562078-12-0P **562078-13-1P** **562078-14-2P**

562078-15-3P 562078-16-4P 562078-17-5P
562078-18-6P 562078-19-7P 562078-20-0P
562078-21-1P 562078-22-2P 562078-23-3P
562078-25-5P 562078-28-8P 562078-29-9P
562078-30-2P 562078-31-3P 562078-32-4P
562078-33-5P 562078-34-6P 562078-36-8P
562078-37-9P 562078-38-0P 562078-39-1P
562078-40-4P 562078-41-5P 562078-42-6P 562078-43-7P
562078-44-8P 562078-45-9P 562078-46-0P 562078-47-1P 562078-48-2P
562078-49-3P 562078-50-6P 562078-51-7P 562078-52-8P 562078-53-9P
562078-54-0P 562078-55-1P 562078-56-2P 562078-57-3P 562078-58-4P
562078-59-5P 562078-60-8P 562078-61-9P 562078-62-0P 562078-63-1P
562078-64-2P 562078-65-3P 562078-66-4P 562078-67-5P 562078-68-6P
562078-69-7P 562078-71-1P 562078-72-2P 562078-73-3P 562078-74-4P
562078-75-5P 562078-76-6P 562078-77-7P 562078-78-8P 562078-79-9P
562078-80-2P 562078-81-3P 562078-82-4P 562078-83-5P 562078-84-6P
562078-85-7P 562078-86-8P 562078-87-9P 562078-88-0P 562078-89-1P
562078-90-4P 562078-91-5P 562078-92-6P 562078-93-7P 562078-94-8P
562078-95-9P 562078-96-0P 562078-97-1P 562078-98-2P 562078-99-3P
562079-00-9P 562079-01-0P 562079-02-1P 562079-03-2P 562079-04-3P
562079-05-4P 562079-07-6P 562079-08-7P 562079-09-8P 562079-10-1P
562079-11-2P 562079-12-3P 562079-13-4P 562079-14-5P 562079-15-6P
562079-16-7P 562079-18-9P 562079-19-0P 562079-20-3P 562079-21-4P
562079-22-5P 562079-24-7P 562079-26-9P 562079-27-0P 562079-28-1P
562079-29-2P 562079-32-7P 562079-33-8P 562079-34-9P 562079-35-0P
562079-36-1P 562079-37-2P 562079-38-3P 562079-39-4P 562079-40-7P
562079-41-8P 562079-42-9P 562079-43-0P 562079-44-1P 562079-45-2P
562079-46-3P 562079-47-4P 562079-48-5P 562079-49-6P 562079-50-9P
562079-51-0P 562079-52-1P 562079-53-2P 562079-54-3P 562079-55-4P
562079-56-5P 562079-57-6P 562079-58-7P 562079-59-8P 562079-60-1P
562079-61-2P 562079-62-3P 562079-64-5P 562079-65-6P 562079-66-7P
562079-67-8P 562079-68-9P 562079-69-0P 562079-70-3P 562079-71-4P
562079-72-5P 562079-73-6P 562079-74-7P 562079-75-8P 562079-76-9P
562079-77-0P 562079-78-1P 562079-79-2P 562079-80-5P 562079-81-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biaryl phosphate transport inhibitors)

IT 562079-82-7P 562079-83-8P 562079-84-9P 562079-85-0P 562079-86-1P
562079-87-2P 562079-88-3P 562079-89-4P 562079-90-7P 562079-91-8P
562079-92-9P 562079-93-0P 562079-94-1P 562079-96-3P 562079-97-4P
562079-98-5P 562079-99-6P 562080-00-6P 562080-01-7P 562080-02-8P
562080-03-9P 562080-04-0P 562080-05-1P 562080-06-2P 562080-07-3P
562080-08-4P 562080-09-5P 562080-10-8P 562080-11-9P 562080-13-1P
562080-15-3P 562080-21-1P 562080-23-3P 562080-25-5P 562080-26-6P
562080-27-7P 562080-28-8P 562080-29-9P 562080-30-2P 562080-31-3P
562080-32-4P 562080-34-6P 562080-35-7P 562080-36-8P 562080-37-9P
562080-39-1P 562080-40-4P 562080-41-5P 562080-46-0P 562080-48-2P
562080-51-7P 562080-54-0P 562080-57-3P 562080-60-8P 562080-61-9P
562080-62-0P **562080-63-1P 562080-64-2P**
562080-65-3P 562080-66-4P 562080-67-5P 562080-68-6P
562080-69-7P 562080-70-0P 562080-71-1P 562080-72-2P 562080-73-3P
562080-74-4P 562080-75-5P 562080-76-6P 562080-78-8P 562080-79-9P
562080-80-2P 562080-81-3P 562080-82-4P 562080-83-5P 562080-84-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biaryl phosphate transport inhibitors)

IT 60-34-4, Methylhydrazine 89-97-4 90-04-0, 2-Methoxyaniline 95-51-2, 2-Chloroaniline 95-76-1, 3,4-Dichloroaniline 95-82-9, 2,5-Dichloroaniline 97-08-5, 4-Chloro-3-nitrobenzenesulfonyl chloride 98-01-1, 2-Furancarboxaldehyde, reactions 98-16-8 99-93-4 100-01-6, reactions 100-06-1 104-84-7, 4-Methylbenzylamine 104-96-1 106-40-1 108-91-8, Cyclohexanamine, reactions 134-20-3, Methyl anthranilate 139-59-3 140-75-0, 4-Fluorobenzylamine 320-51-4 328-74-5 329-01-1 348-54-9, 2-Fluoroaniline 393-36-2 455-14-1 456-48-4 459-60-9

586-75-4 591-19-5, 3-Bromoaniline 827-99-6 837-95-6 875-51-4
2045-79-6 2251-65-2 2832-19-1 2965-07-3 3048-01-9 5031-78-7
6834-42-0, 3-Methoxyphenylacetyl chloride 6850-57-3,
2-Methoxybenzylamine 16588-74-2 18494-87-6, Benzo[b]thiophene-3-
sulfonyl chloride 18704-37-5, 8-Quinolinesulfonyl chloride 29632-74-4
36823-88-8 52727-57-8, Methyl 2-amino-5-bromobenzoate 56946-83-9
65303-82-4 73948-18-2 80466-79-1 94108-56-2, 4-
(Trifluoromethoxy)benzenesulfonyl chloride 160842-62-6 175205-64-8,
2-(Trifluoromethoxy)benzylamine 562080-85-7 562080-86-8 562080-87-9
562080-88-0 562080-89-1 562080-97-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of biaryl phosphate transport inhibitors)

IT 66416-72-6P 167865-92-1P 562080-91-5P 562080-92-6P 562080-93-7P
562080-94-8P 562080-96-0P 562080-98-2P 562080-99-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of biaryl phosphate transport inhibitors)

IT 50-99-7, D-Glucose, biological studies 14265-44-2, Phosphate, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(transport; preparation of biaryl phosphate transport inhibitors)

IT **68003-38-3P 107143-69-1P 136427-98-0P**
496015-34-0P 562078-11-9P 562078-12-0P
562078-13-1P 562078-14-2P 562078-15-3P
562078-16-4P 562078-17-5P 562078-18-6P
562078-19-7P 562078-20-0P 562078-21-1P
562078-22-2P 562078-23-3P 562078-25-5P
562078-28-8P 562078-29-9P 562078-30-2P
562078-31-3P 562078-32-4P 562078-33-5P
562078-34-6P 562078-36-8P 562078-37-9P
562078-38-0P 562078-39-1P 562078-40-4P
562078-41-5P 562080-63-1P 562080-64-2P
562080-65-3P 562080-66-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biaryl phosphate transport inhibitors)

RN 68003-38-3 HCAPLUS
CN Benzoic acid, 2-[[(4-chloro-3-nitrophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 107143-69-1 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[(4-chlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 136427-98-0 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[(4-chloro-3-nitrophenyl)sulfonyl]amino]- (9CI)

(CA INDEX NAME)



RN 496015-34-0 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[(2,5-dimethoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562078-11-9 HCAPLUS
CN Benzoic acid, 2-[([1,1'-biphenyl]-4-ylsulfonyl)amino]-5-bromo- (9CI) (CA INDEX NAME)



RN 562078-12-0 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562078-13-1 HCAPLUS
CN Benzoic acid, 2-[[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]amino]-5-bromo- (9CI) (CA INDEX NAME)



RN 562078-14-2 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[(2,4,5-trichlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562078-15-3 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[(4-nitrophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562078-16-4 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562078-17-5 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562078-18-6 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[(4-methyl-3-nitrophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562078-19-7 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[(3-chlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562078-20-0 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[(4-phenoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562078-21-1 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[(3-nitrophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562078-22-2 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562078-23-3 HCAPLUS
CN Benzoic acid, 5-bromo-2-[(1-naphthalenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 562078-25-5 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[(4-bromophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562078-28-8 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[(4-ethenylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562078-29-9 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[(4-iodophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562078-30-2 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[(2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562078-31-3 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[[2-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562078-32-4 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[(4-pentylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562078-33-5 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[(2-chlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562078-34-6 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[(3-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562078-36-8 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[(4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562078-37-9 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[(2-nitrophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562078-38-0 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[[3-nitro-4-(trifluoromethoxy)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562078-39-1 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[(4-hydroxy-3-nitrophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562078-40-4 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[(4-methoxy-3-nitrophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562078-41-5 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[(4-carboxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562080-63-1 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[(2,5-dichloro-3-thienyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 562080-64-2 HCAPLUS
CN Benzoic acid, 2-[(benzo[b]thien-3-ylsulfonyl)amino]-5-bromo- (9CI) (CA INDEX NAME)



RN 562080-65-3 HCAPLUS
CN Benzoic acid, 5-bromo-2-[(8-quinolinylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 562080-66-4 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[(3,5-dimethyl-4-isoxazolyl)sulfonyl]amino]-
(9CI) (CA INDEX NAME)



L61 ANSWER 20 OF 58 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:551370 HCAPLUS
DN 139:111679
ED Entered STN: 18 Jul 2003
TI Combination of microsomal triglyceride transfer protein (MTP) inhibitors or apoB secretion inhibitors with fibrates for use as drugs
IN Thomas, Leo; Mark, Michael
PA Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany
SO PCT Int. Appl., 220 pp.
CODEN: PIXXD2
DT **Patent**
LA German
IC ICM A61K031-167
ICS A61K031-17; A61K031-192; A61K031-216; A61K031-40; A61K031-4025; A61K031-4164; A61K031-4184; A61K031-437; A61K031-438; A61K031-4468; A61K031-454; A61K031-47; A61K031-4725; A61K031-496; A61K031-501; A61K031-519; A61P001-16; A61P001-18; A61P003-06
CC 1-10 (Pharmacology)
Section cross-reference(s): 27, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003057205	A2	20030717	WO 2003-EP57	20030107 <--
WO 2003057205	A3	20040401		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

```
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
            PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
            UG, US, UZ, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    DE 10200633          A1    20030724    DE 2002-10200633       20020110 <--
    DE 10256184          A1    20040609    DE 2002-10256184       20021202 <--
    CA 2471566           AA    20030717    CA 2003-2471566        20030107 <--
    EP 1465613           A2    20041013    EP 2003-702391         20030107 <--
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    JP 2005525309        T2    20050825    JP 2003-557563         20030107 <--
    US 2003162788        A1    20030828    US 2003-339088         20030109 <--
PRAI DE 2002-10200633    A     20020110  <--
    DE 2002-10256184     A     20021202  <--
    US 2002-353397P      P     20020201  <--
    US 2002-435386P      P     20021220  <--
    WO 2003-EP57         W     20030107
CLASS
 PATENT NO.       CLASS  PATENT FAMILY CLASSIFICATION CODES
 ---------------  -----  ----------------------------------------------
 WO 2003057205    ICM    A61K031-167
                  ICS    A61K031-17; A61K031-192; A61K031-216; A61K031-40;
                         A61K031-4025; A61K031-4164; A61K031-4184; A61K031-437;
                         A61K031-438; A61K031-4468; A61K031-454; A61K031-47;
                         A61K031-4725; A61K031-496; A61K031-501; A61K031-519;
                         A61P001-16; A61P001-18; A61P003-06
 WO 2003057205    ECLA   A61K031/167; A61K045/06; A61K031/167+M; A61K031/17;
                         A61K031/17+M; A61K031/192; A61K031/192+M; A61K031/195;
                         A61K031/216; A61K031/216+M; A61K031/40; A61K031/40+M;
                         A61K031/4025; A61K031/4025+M; A61K031/4164;
                         A61K031/4164+M; A61K031/4184; A61K031/4184+M;
                         A61K031/437; A61K031/437+M; A61K031/438; A61K031/438+M;
                         A61K031/4439; A61K031/4468; A61K031/4468+M;
                         A61K031/454; A61K031/454+M; A61K031/47; A61K031/47+M;
                         A61K031/4725; A61K031/4725+M; A61K031/496;
                         A61K031/496+M; A61K031/501; A61K031/501+M; A61K031/519;
                         A61K031/519+M                                      <--
 DE 10200633      ECLA   A61K031/167; A61K031/216; A61K031/216+M; A61K031/40;
                         A61K031/40+M; A61K031/4025; A61K031/4025+M;
                         A61K031/4164; A61K031/4164+M; A61K031/4184;
                         A61K031/4184+M; A61K031/437; A61K031/437+M;
                         A61K031/438; A61K031/438+M; A61K031/4439; A61K031/4468;
                         A61K031/4468+M; A61K031/454; A61K031/454+M; A61K031/47;
                         A61K031/47+M; A61K031/4725; A61K031/4725+M;
                         A61K031/496; A61K031/496+M; A61K031/501; A61K031/501+M;
                         A61K031/519; A61K031/519+M; A61K045/06; A61K031/167+M;
                         A61K031/17; A61K031/17+M; A61K031/192; A61K031/192+M;
                         A61K031/195                                        <--
 DE 10256184      ECLA   A61K031/167; A61K031/167+M; A61K031/17; A61K031/17+M;
                         A61K031/192; A61K031/192+M; A61K031/195; A61K031/216;
                         A61K031/216+M; A61K031/40; A61K031/40+M; A61K031/4025;
                         A61K031/4025+M; A61K031/4164; A61K031/4164+M;
                         A61K031/4184; A61K031/4184+M; A61K031/437;
                         A61K031/437+M; A61K031/438; A61K031/438+M;
                         A61K031/4439; A61K031/4468; A61K031/4468+M;
                         A61K031/454; A61K031/454+M; A61K031/47; A61K031/47+M;
                         A61K031/4725; A61K031/4725+M; A61K031/496;
                         A61K031/496+M; A61K031/501; A61K031/501+M; A61K031/519;
                         A61K031/519+M; A61K045/06                          <--
 JP 2005525309    FTERM  4C086/AA01; 4C086/AA02; 4C086/BC05; 4C086/BC07;
                         4C086/BC10; 4C086/BC13; 4C086/BC17; 4C086/BC19;
```

4C086/BC21; 4C086/BC27; 4C086/BC28; 4C086/BC30;
4C086/BC36; 4C086/BC38; 4C086/BC41; 4C086/BC42;
4C086/BC50; 4C086/BC60; 4C086/BC71; 4C086/BC73;
4C086/BC78; 4C086/BC82; 4C086/BC85; 4C086/GA03;
4C086/GA04; 4C086/GA07; 4C086/GA08; 4C086/GA09;
4C086/GA10; 4C086/MA02; 4C086/MA52; 4C086/NA06;
4C086/ZA45; 4C086/ZA66; 4C086/ZA70; 4C086/ZC33;
4C086/ZC35; 4C206/DA28; 4C206/GA08; 4C206/GA28;
4C206/MA02; 4C206/MA72; 4C206/NA06; 4C206/ZA45;
4C206/ZA66; 4C206/ZA70; 4C206/ZC33; 4C206/ZC35 <--

US 2003162788 NCL 514/252.050

ECLA A61K031/00; A61K031/167+M; A61K031/17+M; A61K031/192;
A61K031/192+M; A61K031/195; A61K031/216; A61K031/216+M;
A61K031/40; A61K031/40+M; A61K031/4025+M; A61K031/4164;
A61K031/4164+M; A61K031/4184+M; A61K031/437+M;
A61K031/438+M; A61K031/4439; A61K031/4468+M;
A61K031/454+M; A61K031/47+M; A61K031/4725+M;
A61K031/496+M; A61K031/501; A61K031/501+M;
A61K031/519+M; A61K045/06 <--

OS MARPAT 139:111679

AB The invention discloses the use of fibrates for reducing the hepatic toxicity of MTP inhibitors, as well as pharmaceutical compns. that contain an MTP inhibitor and a fibrate. Compound preparation is included.

ST triglyceride transfer protein inhibitor prepn liver toxicity redn fibrate; apoB secretion inhibitor fibrate combination pharmaceutical

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MTP (microsomal triglyceride-exchanging protein); combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)

IT Antiarteriosclerotics
(antiatherosclerotics; combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)

IT Drug delivery systems
(capsules; combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)

IT Anticholesteremic agents
Antidiabetic agents
Antiobesity agents
Atherosclerosis
Diabetes mellitus
Drug delivery systems
Drug interactions
Drug toxicity
Hepatotoxicity
Hypercholesterolemia
Hypolipemic agents
Liver
Obesity
(combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)

IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dyslipidemia; combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)

IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hyperlipidemia; combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)

IT Fatty acids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(liver; combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)

IT Drug delivery systems

(oral; combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)

IT Inflammation
Pancreas, disease
(pancreatitis; combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)

IT Glycerides, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(plasma and liver; combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)

IT Drug delivery systems
(tablets; combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)

IT 486434-87-1P 486434-91-7P 486434-97-3P 486435-30-7P 486435-66-9P
486435-74-9P 486435-98-7P 486436-00-4P 486436-20-8P 486436-66-2P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)

IT 177469-96-4 177469-96-4D, tautomers, diastereomers, and enantiomers
182429-29-4 182429-29-4D, tautomers, diastereomers, and enantiomers
186390-48-7 186390-48-7D, tautomers, diastereomers, and enantiomers
194213-64-4 194213-64-4D, tautomers, diastereomers, and enantiomers
208590-26-5 208590-26-5D, tautomers, diastereomers, and enantiomers
248584-96-5 248584-96-5D, tautomers, diastereomers, and enantiomers
256395-50-3 256395-50-3D, tautomers, diastereomers, and enantiomers
256397-05-4 256397-05-4D, tautomers, diastereomers, and enantiomers
256397-11-2 256397-11-2D, tautomers, diastereomers, and enantiomers
256397-12-3 256397-12-3D, tautomers, diastereomers, and enantiomers
256397-33-8 256397-33-8D, tautomers, diastereomers, and enantiomers
256397-39-4 256397-39-4D, tautomers, diastereomers, and enantiomers
310405-68-6 310405-68-6D, tautomers, diastereomers, and enantiomers
347374-42-9 347374-42-9D, tautomers, diastereomers, and enantiomers
347374-48-5 347374-48-5D, tautomers, diastereomers, and enantiomers
347374-56-5 347374-56-5D, tautomers, diastereomers, and enantiomers
365547-69-9 365547-69-9D, tautomers, diastereomers, and enantiomers
486435-43-2 561299-76-1 561299-76-1D, tautomers, diastereomers, and enantiomers 561299-78-3 561299-78-3D, tautomers, diastereomers, and enantiomers 561299-81-8 561299-81-8D, tautomers, diastereomers, and enantiomers 561299-84-1 561299-84-1D, tautomers, diastereomers, and enantiomers 561299-87-4 561299-87-4D, tautomers, diastereomers, and enantiomers 561300-01-4 561300-01-4D, tautomers, diastereomers, and enantiomers
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)

IT 486435-11-4P 486435-13-6P 486435-28-3P 486435-39-6P 486435-82-9P
486436-05-9P 486436-35-5P 486436-57-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)

IT 486434-51-9P 486434-53-1P 486434-55-3P 486434-58-6P 486434-60-0P
486434-64-4P 486434-66-6P 486434-68-8P 486434-70-2P 486434-73-5P
486434-74-6P 486434-76-8P 486434-78-0P 486434-80-4P 486434-82-6P
486434-84-8P 486434-85-9P 486434-89-3P 486434-93-9P 486434-95-1P
486434-98-4P 486435-00-1P 486435-01-2P 486435-03-4P 486435-05-6P
486435-07-8P 486435-09-0P 486435-15-8P 486435-17-0P 486435-19-2P
486435-20-5P 486435-22-7P 486435-24-9P 486435-26-1P 486435-32-9P
486435-34-1P 486435-35-2P 486435-37-4P 486435-41-0P 486435-45-4P
486435-46-5P 486435-48-7P 486435-50-1P 486435-52-3P 486435-54-5P
486435-56-7P 486435-58-9P 486435-59-0P 486435-61-4P 486435-63-6P

486435-65-8P 486435-68-1P 486435-70-5P 486435-72-7P 486435-76-1P
486435-78-3P 486435-80-7P 486435-84-1P 486435-88-5P 486435-90-9P
486435-92-1P 486435-94-3P 486435-96-5P 486436-04-8P 486436-07-1P
486436-09-3P 486436-11-7P 486436-12-8P 486436-14-0P 486436-16-2P
486436-18-4P 486436-24-2P 486436-26-4P 486436-28-6P 486436-30-0P
486436-33-3P 486436-37-7P 486436-39-9P 486436-41-3P 486436-43-5P
486436-45-7P 486436-47-9P 486436-49-1P 486436-51-5P 486436-53-7P
486436-58-2P 486436-60-6P 486436-62-8P 486436-64-0P 486436-68-4P
486436-70-8P 486437-67-6P 561300-72-9P 561300-75-2P 561300-76-3P
561300-77-4P 561300-78-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)

IT 637-07-0, Clofibrate 943-45-3D, Fibric acid, derivs. 25812-30-0, Gemfibrozil 41859-67-0, Bezafibrate 49562-28-9, Fenofibrate 52214-84-3, Ciprofibrate 561300-57-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)

IT 75-30-9, Isopropyl iodide 76-05-1, Trifluoroacetic acid, reactions 89-93-0, 2-Methylbenzylamine 91-21-4, 1,2,3,4-Tetrahydroisoquinoline 92-66-0, 4-Bromobiphenyl 93-91-4, Benzoylacetone 100-46-9, Benzylamine, reactions 103-67-3, N-Methylbenzylamine 104-86-9, 4-Chlorobenzylamine 110-91-8, Morpholine, reactions 496-12-8, 2,3-Dihydro-1H-isoindole 635-46-1, 1,2,3,4-Tetrahydroquinoline 712-76-5, 4-Phenylbenzylamine 947-84-2, [1,1'-Biphenyl]-2-carboxylic acid 1121-79-5, 3-Chloro-6-methylpyridazine 1194-02-1, 4-Fluorobenzonitrile 2243-42-7 2450-71-7, Propargylamine 3196-73-4, β-Alanine methyl ester hydrochloride 3218-02-8, (Aminomethyl)cyclohexane 3529-10-0 3731-51-9, 2-(Aminomethyl)pyridine 3731-53-1, 4-(Aminomethyl)pyridine 3906-16-9 4187-56-8 4393-09-3 4890-85-1 5680-79-5, Glycine methyl ester hydrochloride 5930-92-7 6091-64-1 6299-02-1, 1-(4-Chlorophenyl)ethylamine **6311-23-5** 6622-55-5, N-Benzylanthranilic acid 15996-82-4 16017-26-8 17027-51-9, [1,1'-Biphenyl]-4-ethanamine 17672-27-4, 4-Cyanophenylhydrazine 22171-15-9, 4-Benzyloxybenzylamine 22171-21-7 23199-14-6 24424-99-5, Di-tert-butyl dicarbonate 25412-55-9 26177-44-6, 4-Bromobenzylamine hydrochloride 27298-99-3 32470-52-3 39895-55-1, 4-tert-Butylbenzylamine 39978-57-9 40481-13-8, 4-Cyano-4-phenylpiperidine 46182-58-5 51089-97-5, 1-(4-Methoxyphenyl)butylamine 54398-65-1 60277-40-9 72083-62-6 84392-17-6 85487-99-6 99548-56-8 100511-78-2 108468-00-4 110931-72-1, N-Methyl-4-phenylbenzylamine 126747-14-6, 4-Cyanophenylboronic acid 128796-39-4 165736-03-8 169943-94-6 175205-49-9 175277-74-4 177976-49-7, 3-Phenylbenzylamine 178163-63-8 180340-74-3 193151-93-8 214759-73-6, 4-(Piperidino)benzylamine 214759-76-9 243863-36-7, 2-Difluoromethoxybenzylamine 263270-52-6 294647-97-5 294648-05-8 356058-18-9 389602-69-1 389602-70-4 389602-72-6 389602-83-9 389602-92-0 486436-98-0 486437-01-8 486437-06-3 486437-10-9 486437-18-7 486437-19-8 486437-22-3 486437-27-8 486437-37-0 486437-45-0 486437-47-2 486437-55-2 486437-59-6 486437-62-1 486437-64-3 486437-66-5, 4-(3-Methylpiperidino)benzylamine 486437-68-7 486437-69-8 486437-70-1 486437-76-7 486437-82-5 486437-83-6 486437-84-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)

IT 5398-36-7P 42106-48-9P 92136-39-5P 192817-79-1P 389602-54-4P 389602-55-5P 389602-89-5P 486436-75-3P 486436-77-5P 486436-80-0P 486436-83-3P 486436-85-5P 486436-88-8P 486436-90-2P 486436-94-6P 486436-96-8P 486437-13-2P 486437-15-4P 486437-51-8P 486437-53-0P 486437-71-2P 486437-72-3P 486437-73-4P 486437-74-5P 486437-77-8P 486437-78-9P 486437-79-0P 486437-80-3P 561300-74-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)

IT 57-88-5, Cholesterol, biological studies 9000-86-6, Alanine aminotransferase 9000-97-9, Aspartate aminotransferase 9029-12-3, Glutamate dehydrogenase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(plasma; combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)

IT **6311-23-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)

RN 6311-23-5 HCAPLUS

CN Benzoic acid, 2-[[(4-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



```
=> b hcao;d all l65 tot
FILE 'HCAOLD' ENTERED AT 09:29:51 ON 01 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

PRE-1967 CHEMICAL ABSTRACTS FILE WITH HOUR-BASED PRICING
FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate
substance identification.  Title keywords, authors, patent
assignees, and patent information, e.g., patent numbers, are
now searchable from 1907-1966.  TIFF images of CA abstracts
printed between 1907-1966 are available in the PAGE
display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of
all substance data from the REGISTRY file.  Enter HELP FIRST for
more information.


L65  ANSWER 1 OF 5  HCAOLD  COPYRIGHT 2005 ACS on STN
AN   CA65:7983f  CAOLD
TI   identification of organic compds. - (LXIII) paper chromatographic separation and
     identification of primary aromatic amines in aqueous solvent systems
AU   Cee, Ales; Gasparic, J.
IT     79-72-1     81-11-8     82-45-1     83-83-0     84-68-4     85-74-5
       86-45-3     86-65-7     88-21-1     88-23-3     88-43-7     88-44-8
       88-45-9     88-51-7     88-53-9     88-63-1     89-63-4     90-20-0
       90-40-4     90-41-5     92-01-3     92-28-4     92-67-1     93-05-0
       95-03-4     95-70-5     95-82-9     95-86-3     97-02-9     98-32-8
       98-33-9     98-35-1     98-36-2     98-37-3     98-42-0     98-43-1
       98-44-2     99-30-9     99-98-9    101-22-4    101-54-2    102-56-7
       103-92-4    117-42-0    117-55-5    117-79-3    118-28-5    118-33-2
       119-70-0    119-90-4    119-93-7    120-71-8    120-98-9    121-47-1
       129-91-9    130-23-4    131-27-1    133-74-4    135-10-4
       137-51-9    153-78-6    156-43-4    348-54-9    394-31-0    492-17-1
       527-76-4    554-00-7    603-40-7    609-24-5    615-05-4    615-36-1
       615-66-7    618-03-1    621-96-5    623-09-6   2130-56-5   2834-92-6
       2835-04-3   3365-88-6   3577-63-7   3899-93-2   4550-72-5   5131-60-2
       5307-00-6   5465-29-2   5805-25-4   5805-26-5   5805-27-6   5840-09-5
       5851-43-4   5851-44-5   5851-49-0   5851-50-3   5851-51-4   5857-94-3
       5857-96-5   5858-13-9   6201-85-0   6201-86-1   6201-87-2   6251-07-6
       6265-14-1   6358-15-2   6370-33-8   6387-15-1   6387-28-6   6393-01-7
       6404-70-2   6409-55-8   6470-17-3   6527-78-2   6548-34-1   6837-92-9
       6973-09-7   7218-02-2   7475-04-9  13065-83-3  13065-86-6  13065-87-7
       13065-88-8  13065-93-5  13065-94-6  13065-98-0  13065-99-1  13066-00-7
       13066-01-8  13066-09-6  13066-76-7  13066-78-9  13066-80-3  13066-81-4
       13066-82-5  13066-83-6  13066-86-9  13066-89-2  13066-93-8  13066-95-0
       13066-96-1  13066-97-2  13066-98-3  13067-00-0  13067-01-1  13238-85-2
       13239-01-5  13244-33-2  13244-34-3  13306-42-8  45742-37-8

L65  ANSWER 2 OF 5  HCAOLD  COPYRIGHT 2005 ACS on STN
AN   CA61:8229d  CAOLD
TI   synthesis of anilides of p-ethylbenzenesulfonic acid
AU   Gordinskii, B. Yu.; Khoroshun, O. V.
IT   1994-35-0   2145-42-8   7230-58-2   7230-59-3  16712-69-9  64329-90-4
     92190-07-3  92192-38-6  92192-40-0  92192-41-1  92194-12-2  92194-13-3
     92248-69-6  92248-70-9  92248-71-0  92249-30-4  92249-31-5  92249-32-6
     92253-11-7  92253-12-8  92851-55-3  92851-59-7  94252-34-3
     94880-29-2  94963-42-5  97302-40-4  97320-70-2  97320-79-1  97359-32-5
     97433-59-5 101034-71-3 101358-35-4
```

L65 ANSWER 3 OF 5 HCAOLD COPYRIGHT 2005 ACS on STN
AN CA55:25147h CAOLD
TI aminobenzoic acid derivs. as insecticides
PA Geigy, J. R., A.-G.
DT Patent

PATENT NO.	KIND	DATE
GB 865735		
CH 364248		
CH 369439		
CH 369440		
CH 369441		
DE 1157235		
DE 1159466		
FR 1224090		
FR AD80316		
FR AD80319		
US 3162684		1964
US 3178339		1965
US 2995488		1961

IT 56-72-4 671-71-6 671-72-7 671-73-8 671-96-5 672-70-8
750-86-7 751-24-6 810-24-2 810-44-6 863-98-9 915-73-1
1493-85-2 1651-75-8 1763-57-1 2355-54-6 2621-78-5 2837-55-0
2837-56-1 3792-09-4 3850-23-5 4693-00-9 27918-13-4
96460-18-3 96462-05-4 97028-48-3 101879-60-1 101881-73-6
102184-54-3 102554-45-0 102809-70-1 108124-30-7 108951-11-7 109394-08-3
109394-09-4 109395-61-1 109469-89-8 109470-55-5 109470-56-6 109470-57-7
109470-58-8 109471-70-7 109471-96-7 109496-88-0 109497-15-6 110148-60-2
110149-61-6 110492-55-2 111034-12-9 112842-43-0 112865-37-9 113012-14-9
114002-82-3

L65 ANSWER 4 OF 5 HCAOLD COPYRIGHT 2005 ACS on STN
AN CA54:24449d CAOLD
TI stereospecific Lossen rearrangements
AU Bauer, Ludwig; Miarka, S. V.
IT 5426-10-8 5433-80-7 5442-38-6 16524-13-3 21715-90-2 24147-28-2
24147-30-6 76198-36-2 92619-32-4 99419-70-2 100711-73-7
100719-04-8 101090-32-8 101090-85-1 101116-20-5 102015-41-8
106272-56-4 **106275-28-9**

L65 ANSWER 5 OF 5 HCAOLD COPYRIGHT 2005 ACS on STN
AN CA51:17190e CAOLD
TI azo dye of the pyrazolone series
AU Ruckstuhl, Hans
DT Patent
TI dyes (azo) of the pyrazolone series
PA Sandoz Ltd.
DT Patent

PATENT NO.	KIND	DATE
CH 317467		

IT **91-35-0** **135-10-4** 137-65-5 99969-26-3
104098-08-0 109688-65-5 109690-37-1 110330-80-8 112551-18-5
112842-21-4 113057-87-7 113059-05-5

=> b reg;d ide can l64 tot
FILE 'REGISTRY' ENTERED AT 09:30:02 ON 01 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 31 AUG 2005 HIGHEST RN 862246-83-1
DICTIONARY FILE UPDATES: 31 AUG 2005 HIGHEST RN 862246-83-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

L64 ANSWER 1 OF 5 REGISTRY COPYRIGHT 2005 ACS on STN
RN **106272-56-4** REGISTRY
ED Entered STN: 24 Jan 1987
CN 5-Norbornene-2-carboxylic acid, 3-benzenesulfonamido- (6CI) (CA INDEX NAME)
FS 3D CONCORD
MF **C14 H15 N O4 S**
SR CAOLD
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 54:128308

L64 ANSWER 2 OF 5 REGISTRY COPYRIGHT 2005 ACS on STN
RN **100719-04-8** REGISTRY
ED Entered STN: 08 Mar 1986
CN Bicyclo[2.2.1]heptane-2-carboxylic acid, 3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Norbornanecarboxylic acid, 3-benzenesulfonamido- (6CI)
FS 3D CONCORD

MF **C14 H17 N O4 S**
SR CAOLD
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 54:128308

L64 ANSWER 3 OF 5 REGISTRY COPYRIGHT 2005 ACS on STN
RN **96460-18-3** REGISTRY
ED Entered STN: 25 May 1985
CN Benzoic acid, 2-[[(3,4-dichlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Anthranilic acid, N-(3,4-dichlorophenylsulfonyl)- (6CI)
FS 3D CONCORD
MF **C13 H9 Cl2 N O4 S**
LC STN Files: CA, CAOLD, CAPLUS, CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 106:138093

REFERENCE 2: 55:133517

L64 ANSWER 4 OF 5 REGISTRY COPYRIGHT 2005 ACS on STN
RN **92851-55-3** REGISTRY
ED Entered STN: 17 Dec 1984
CN Anthranilic acid, N-[(p-ethylphenyl)sulfonyl]- (7CI) (CA INDEX NAME)
FS 3D CONCORD
MF **C15 H15 N O4 S**
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 61:47630

L64 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2005 ACS on STN
RN **135-10-4** REGISTRY
ED Entered STN: 16 Nov 1984
CN Benzoic acid, 2-amino-5-[[(2-carboxyphenyl)amino]sulfonyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Anthranilic acid, N,5'-sulfonyldi- (6CI, 7CI, 8CI)
OTHER NAMES:
CN N,5'-Sulfonyldianthranilic acid
FS 3D CONCORD
MF **C14 H12 N2 O6 S**
LC STN Files: CA, CAOLD, CAPLUS, CHEMLIST, TOXCENTER, USPATFULL
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 90:73288

REFERENCE 2: 89:112324

REFERENCE 3: 65:42626

REFERENCE 4: 65:42625

REFERENCE 5: 51:95039

REFERENCE 6: 43:42731

REFERENCE 7: 43:42667

=> b home

FILE 'HOME' ENTERED AT 09:30:07 ON 01 SEP 2005

=>